FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Pellicano, R
El-Serag, HB
Rizzetto, M
AF Pellicano, R.
El-Serag, H. B.
Rizzetto, M.
TI Hepatocellular carcinoma at the cutting edge of science and practice
SO MINERVA MEDICA
LA English
DT Editorial Material
ID LIVER-TRANSPLANTATION; UNITED-STATES; HEPATITIS-B; SORAFENIB;
SURVEILLANCE; THERAPY; CANCER
C1 [Pellicano, R.; Rizzetto, M.] Molinette Hosp SGAS, Dept Gastroenterol & Hepatol, Turin, Italy.
[El-Serag, H. B.] Houston Vet Affairs Med Ctr, Gastroenterol Sect, Houston, TX USA.
[El-Serag, H. B.] Houston Vet Affairs Med Ctr, Sect Hlth Serv Res, Houston, TX USA.
[El-Serag, H. B.] Baylor Coll Med, Houston, TX 77030 USA.
RP Pellicano, R (reprint author), Molinette Mauriziano Hosp, Dept Gastroenterol & Hepatol, Via Cavour 31, I-10123 Turin, Italy.
EM rinaldo_pellican@hot-mail.com
NR 20
TC 0
Z9 0
U1 0
U2 0
PU EDIZIONI MINERVA MEDICA
PI TURIN
PA CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY
SN 0026-4806
J9 MINERVA MED
JI Minerva Med.
PD DEC
PY 2010
VL 101
IS 6
BP 391
EP 393
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 711HR
UT WOS:000286578300003
PM 21196898
ER
PT J
AU Rodriguez, AL
Grier, MD
Jones, CK
Herman, EJ
Kane, AS
Smith, RL
Williams, R
Zhou, Y
Marlo, JE
Days, EL
Blatt, TN
Jadhav, S
Menon, UN
Vinson, PN
Rook, JM
Stauffer, SR
Niswender, CM
Lindsley, CW
Weaver, CD
Conn, PJ
AF Rodriguez, Alice L.
Grier, Mark D.
Jones, Carrie K.
Herman, Elizabeth J.
Kane, Alexander S.
Smith, Randy L.
Williams, Richard
Zhou, Ya
Marlo, Joy E.
Days, Emily L.
Blatt, Tasha N.
Jadhav, Satyawan
Menon, Usha N.
Vinson, Paige N.
Rook, Jerri M.
Stauffer, Shaun R.
Niswender, Colleen M.
Lindsley, Craig W.
Weaver, C. David
Conn, P. Jeffrey
TI Discovery of Novel Allosteric Modulators of Metabotropic Glutamate
Receptor Subtype 5 Reveals Chemical and Functional Diversity and In Vivo
Activity in Rat Behavioral Models of Anxiolytic and Antipsychotic
Activity
SO MOLECULAR PHARMACOLOGY
LA English
DT Article
ID MGLU5 RECEPTOR; LOCOMOTOR-ACTIVITY; BINDING-SITE; ANTAGONIST; POTENT;
2-METHYL-6-(PHENYLETHYNYL)PYRIDINE; PHARMACOLOGY; ANXIETY; FENOBAM; MPEP
AB Modulators of metabotropic glutamate receptor subtype 5 (mGluR5) may provide novel treatments for multiple central nervous system (CNS) disorders, including anxiety and schizophrenia. Although compounds have been developed to better understand the physiological roles of mGluR5 and potential usefulness for the treatment of these disorders, there are limitations in the tools available, including poor selectivity, low potency, and limited solubility. To address these issues, we developed an innovative assay that allows simultaneous screening for mGluR5 agonists, antagonists, and potentiators. We identified multiple scaffolds that possess diverse modes of activity at mGluR5, including both positive and negative allosteric modulators (PAMs and NAMs, respectively). 3-Fluoro-5-(3-(pyridine-2-yl)-1,2,4-oxadiazol-5-yl) benzonitrile (VU0285683) was developed as a novel selective mGluR5 NAM with high affinity for the 2-methyl-6-(phenyl-ethynyl)-pyridine (MPEP) binding site. VU0285683 had anxiolytic-like activity in two rodent models for anxiety but did not potentiate phen-cyclidine-induced hyperlocomotor activity. (4-Hydroxypiperidin-1-yl)(4-phenylethynyl) phenyl) methanone (VU0092273) was identified as a novel mGluR5 PAM that also binds to the MPEP site. VU0092273 was chemically optimized to an orally active analog, N-cyclobutyl-6-((3-fluorophenyl) ethynyl) nicotinamide hydrochloride (VU0360172), which is selective for mGluR5. This novel mGluR5 PAM produced a dose-dependent reversal of amphetamine-induced hyperlocomotion, a rodent model predictive of antipsychotic activity. Discovery of structurally and functionally diverse allosteric modulators of mGluR5 that demonstrate in vivo efficacy in rodent models of anxiety and antipsychotic activity provide further support for the tremendous diversity of chemical scaffolds and modes of efficacy of mGluR5 ligands. In addition, these studies provide strong support for the hypothesis that multiple structurally distinct mGluR5 modulators have robust activity in animal models that predict efficacy in the treatment of CNS disorders.
C1 [Conn, P. Jeffrey] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA.
[Jones, Carrie K.] US Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville, TN USA.
[Lindsley, Craig W.] Vanderbilt Univ, Dept Chem, Nashville, TN 37232 USA.
[Rodriguez, Alice L.; Jones, Carrie K.; Herman, Elizabeth J.; Kane, Alexander S.; Williams, Richard; Zhou, Ya; Marlo, Joy E.; Jadhav, Satyawan; Menon, Usha N.; Vinson, Paige N.; Rook, Jerri M.; Stauffer, Shaun R.; Niswender, Colleen M.; Lindsley, Craig W.; Weaver, C. David; Conn, P. Jeffrey] Vanderbilt Univ, Vanderbilt Program Drug Discovery, Nashville, TN 37232 USA.
[Days, Emily L.; Blatt, Tasha N.; Weaver, C. David] Vanderbilt Univ, Vanderbilt Inst Chem Biol, Nashville, TN 37232 USA.
RP Conn, PJ (reprint author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, 1215D Light Hall,2215 Garland Ave, Nashville, TN 37232 USA.
EM jeff.conn@vanderbilt.edu
RI Conn, Peter/D-7848-2012; Zhou, Ya/F-1220-2013
FU National Institutes of Health National Institute of Neurological
Disorders and Stroke [1F32-NS049865, R01-NS031373]; National Institutes
of Health National Institute of Mental Health [R01-MH062646,
R01-MH074953]; National Institutes of Health National Institute on Drug
Abuse [1R01-DA023947-01]; Vanderbilt is a center in the National
Institutes of Health
FX This work was supported by the National Institutes of Health National
Institute of Neurological Disorders and Stroke [Grants 1F32-NS049865,
R01-NS031373]; the National Institutes of Health National Institute of
Mental Health [Grants R01-MH062646, R01-MH074953]; and the National
Institutes of Health National Institute on Drug Abuse [Grant
1R01-DA023947-01]. Vanderbilt is a center in the National Institutes of
Health-supported Molecular Libraries Screening Centers Network.
NR 52
TC 104
Z9 106
U1 0
U2 3
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0026-895X
J9 MOL PHARMACOL
JI Mol. Pharmacol.
PD DEC
PY 2010
VL 78
IS 6
BP 1105
EP 1123
DI 10.1124/mol.110.067207
PG 19
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 680WC
UT WOS:000284267200014
PM 20923853
ER
PT J
AU Tanaka, H
Kono, E
Tran, CP
Miyazaki, H
Yamashiro, J
Shimomura, T
Fazli, L
Wada, R
Huang, JT
Vessella, RL
An, JB
Horvath, S
Gleave, M
Rettig, MB
Wainberg, ZA
Reiter, RE
AF Tanaka, Hiroshi
Kono, Evelyn
Tran, Chau P.
Miyazaki, Hideyo
Yamashiro, Joyce
Shimomura, Tatsuya
Fazli, Ladan
Wada, Robert
Huang, Jiaoti
Vessella, Robert L.
An, Jaibin
Horvath, Steven
Gleave, Martin
Rettig, Matthew B.
Wainberg, Zev A.
Reiter, Robert E.
TI Monoclonal antibody targeting of N-cadherin inhibits prostate cancer
growth, metastasis and castration resistance
SO NATURE MEDICINE
LA English
DT Article
ID MESENCHYMAL TRANSITION; ANDROGEN RECEPTOR; ANTITUMOR-ACTIVITY;
STEM-CELLS; PROGRESSION; THERAPY; INDEPENDENCE; INCREASES; PATHWAY;
BIOLOGY
AB The transition from androgen-dependent to castration-resistant prostate cancer (CRPC) is a lethal event of uncertain molecular etiology. Comparing gene expression in isogenic androgen-dependent and CRPC xenografts, we found a reproducible increase in N-cadherin expression, which was also elevated in primary and metastatic tumors of individuals with CRPC. Ectopic expression of N-cadherin in nonmetastatic, androgen-dependent prostate cancer models caused castration resistance, invasion and metastasis. Monoclonal antibodies against the ectodomain of N-cadherin reduced proliferation, adhesion and invasion of prostate cancer cells in vitro. In vivo, these antibodies slowed the growth of multiple established CRPC xenografts, blocked local invasion and metastasis and, at higher doses, led to complete regression. N-cadherin-specific antibodies markedly delayed the time to emergence of castration resistance, markedly affected tumor histology and angiogenesis, and reduced both AKT serine-threonine kinase activity and serum interleukin-8 (IL-8) secretion. These data indicate that N-cadherin is a major cause of both prostate cancer metastasis and castration resistance. Therapeutic targeting of this factor with monoclonal antibodies may have considerable clinical benefit. (C) 2010 Nature America, Inc. All rights reserved.
C1 [Tanaka, Hiroshi; Kono, Evelyn; Tran, Chau P.; Yamashiro, Joyce; Shimomura, Tatsuya; Wada, Robert; An, Jaibin; Rettig, Matthew B.; Reiter, Robert E.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA.
[Tanaka, Hiroshi; Kono, Evelyn; Tran, Chau P.; Yamashiro, Joyce; Shimomura, Tatsuya; Huang, Jiaoti; Rettig, Matthew B.; Wainberg, Zev A.; Reiter, Robert E.] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
[Miyazaki, Hideyo] Univ Tokyo, Dept Urol, Tokyo, Japan.
[Fazli, Ladan; Gleave, Martin] Univ British Columbia, Vancouver Prostate Ctr, Vancouver, BC V5Z 1M9, Canada.
[Huang, Jiaoti] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA.
[Vessella, Robert L.] Univ Washington, Med Ctr, Dept Urol, Puget Sound Vet Hlth Care Adm, Seattle, WA 98195 USA.
[An, Jaibin; Rettig, Matthew B.] Vet Affairs Greater Los Angeles Healthcare Syst W, Dept Med, Los Angeles, CA USA.
[Horvath, Steven] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA.
[Horvath, Steven] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90095 USA.
[Wainberg, Zev A.] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA.
[Reiter, Robert E.] Univ Calif Los Angeles, David Geffen Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA.
RP Reiter, RE (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA.
EM rreiter@mednet.ucla.edu
FU US National Cancer Institute Prostate Cancer SPORE at the University of
California-Los Angeles [P50CA092131-09]; US Department of Defense
[W81XWH-06-1-0324, W81XWH-09-1-0630, PC061456]; Takeda Pharmaceuticals;
Jean Perkins Foundation; American Cancer Society [RSG-07-092-01-TBE]
FX This work was supported in parts by the US National Cancer Institute
Prostate Cancer SPORE at the University of California-Los Angeles
(P50CA092131-09 to R. E. R.), US Department of Defense Prostate Cancer
Research grants (W81XWH-06-1-0324 to Z.A.W., W81XWH-09-1-0630 to R. E.
R. and M. B. R., PC061456 to J.H.), Takeda Pharmaceuticals, the Jean
Perkins Foundation and the American Cancer Society (RSG-07-092-01-TBE to
J.H.). We also thank S. and L. Resnick, the Prostate Cancer Foundation
and the Luskin Foundation for generous support and J. Said and N. Doan
for immunohistochemical assessments. LNCaP-CL1 cells were provided by C.
L. Tso (University of California-Los Angeles). Plasmid p Delta VPR was
provided by I. Chen (University of California-Los Angeles).
NR 28
TC 131
Z9 137
U1 0
U2 21
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
J9 NAT MED
JI Nat. Med.
PD DEC
PY 2010
VL 16
IS 12
BP 1414
EP U96
DI 10.1038/nm.2236
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
Medicine
GA 690ZH
UT WOS:000285048900035
PM 21057494
ER
PT J
AU McGregor, R
Siegel, JM
AF McGregor, Ronald
Siegel, Jerome M.
TI Illuminating the locus coeruleus: control of posture and arousal
SO NATURE NEUROSCIENCE
LA English
DT Editorial Material
ID IN-VIVO MICRODIALYSIS; RELEASE; NEURONS; PONTINE; CATAPLEXY; NUCLEUS;
ATONIA; CELLS
C1 [McGregor, Ronald; Siegel, Jerome M.] Vet Adm Greater Los Angeles Healthcare Syst, North Hills, CA USA.
[McGregor, Ronald; Siegel, Jerome M.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
[McGregor, Ronald; Siegel, Jerome M.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA.
RP McGregor, R (reprint author), Vet Adm Greater Los Angeles Healthcare Syst, North Hills, CA USA.
EM icelos@gmail.com; jsiegel@ucla.edu
NR 15
TC 11
Z9 11
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1097-6256
J9 NAT NEUROSCI
JI Nat. Neurosci.
PD DEC
PY 2010
VL 13
IS 12
BP 1448
EP 1449
DI 10.1038/nn1210-1448
PG 3
WC Neurosciences
SC Neurosciences & Neurology
GA 684CW
UT WOS:000284525800005
PM 21102568
ER
PT J
AU Peralta, CA
Lin, F
Shlipak, MG
Siscovick, D
Lewis, C
Jacobs, DR
Bibbins-Domingo, K
AF Peralta, Carmen A.
Lin, Feng
Shlipak, Michael G.
Siscovick, David
Lewis, Cora
Jacobs, David R., Jr.
Bibbins-Domingo, Kirsten
TI Race differences in prevalence of chronic kidney disease among young
adults using creatinine-based glomerular filtration rate-estimating
equations
SO NEPHROLOGY DIALYSIS TRANSPLANTATION
LA English
DT Article
DE chronic kidney disease; glomerular filtration rate; race
ID STAGE RENAL-DISEASE; SERUM CREATININE; GFR; PERFORMANCE; HEALTH
AB Background. Despite a higher incidence of end-stage renal disease (stage 5), blacks have been shown to have the same or lower prevalence of chronic kidney disease (CKD stages 3 and 4). Current creatinine-based glomerular filtration rate (GFR)-estimating equations may misclassify young, healthy blacks.
Methods. Among 3501 young adults (mean age 45), we compared the prevalence of CKD in blacks and whites using the Modification of Diet in Renal Disease (MDRD) and the CKD Epidemiology Collaboration (CKD-EPI) equations. In addition, we used measured creatinine excretion rates to determine the actual excretion ratio for CARDIA (race coefficient 12%) and applied this to the CKD-EPI equation. We also studied the prevalence of CKD risk factors among black and white participants near the CKD threshold cut-off (eGFR CKD-EPI 60-80 mL/min/1.73 m(2)) to estimate the relative likelihood of misclassification in blacks and whites.
Results. Using the MDRD equation, prevalence of CKD stages 4 and 5 was higher for blacks compared with whites (0.6% vs. 0.1%, P-value 0.05). In contrast, prevalence of eGFR <60 mL/min/1.73 m(2) was significantly higher for whites (3.6%) compared with blacks (1.9%), due to higher prevalence of stage 3 among whites. Prevalence of CKD was similar for blacks and whites using CKD-EPI equation (1.2%), but was higher among blacks when using the CARDIA-derived race coefficient (1.6% vs. 1.2%, P-value = 0.03). Among persons with eGFR by CKD-EPI of 60-80 mL/min/1.73 m(2), blacks had higher levels of albuminuria, uric acid, systolic blood pressure and higher diabetes prevalence.
Conclusions. CKD classification among young blacks is very sensitive to the race coefficients. Despite whites having higher rates of CKD stage 3, blacks with eGFRs just above the CKD threshold had higher rates of CKD risk factors. Current equations used to define CKD may systematically miss a high-risk group of blacks at a time in the disease course when interventions are crucial.
C1 [Peralta, Carmen A.; Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
[Peralta, Carmen A.; Shlipak, Michael G.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Lin, Feng; Shlipak, Michael G.; Bibbins-Domingo, Kirsten] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Siscovick, David] Univ Washington, Dept Med & Epidemiol, Seattle, WA 98195 USA.
[Lewis, Cora] Univ Alabama, Div Prevent Med, Birmingham, AL USA.
[Jacobs, David R., Jr.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol, Minneapolis, MN 55455 USA.
[Bibbins-Domingo, Kirsten] San Francisco Gen Hosp, Div Gen Internal Med, San Francisco, CA 94110 USA.
[Bibbins-Domingo, Kirsten] San Francisco Gen Hosp, UCSF Ctr Vulnerable Populat San Francisco, San Francisco, CA 94110 USA.
RP Peralta, CA (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
EM Carmenalicia.peralta@ucsf.edu
FU NIDDK [1K23DK082793-01]
FX C.A.P. is funded by grant 1K23DK082793-01 from NIDDK.
NR 15
TC 16
Z9 16
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0931-0509
J9 NEPHROL DIAL TRANSPL
JI Nephrol. Dial. Transplant.
PD DEC
PY 2010
VL 25
IS 12
BP 3934
EP 3939
DI 10.1093/ndt/gfq299
PG 7
WC Transplantation; Urology & Nephrology
SC Transplantation; Urology & Nephrology
GA 685PK
UT WOS:000284640400022
PM 20519233
ER
PT J
AU Wasterlain, CG
Thompson, KW
Suchomelova, L
Niquet, J
AF Wasterlain, Claude G.
Thompson, Kerry W.
Suchomelova, Lucie
Niquet, Jerome
TI Brain Energy Metabolism During Experimental Neonatal Seizures
SO NEUROCHEMICAL RESEARCH
LA English
DT Article
DE Epilepsy; Neonatal seizures; Energy metabolism; ATP; Brain development;
Hypoglycemia
ID NUCLEAR-MAGNETIC-RESONANCE; PROLONGED EPILEPTIC SEIZURES; INDUCED
NEURONAL INJURY; IMMATURE RAT-BRAIN; FEBRILE SEIZURES; CEREBRAL
METABOLISM; RECURRENT SEIZURES; COMBINED H-1; INVIVO P-31; DAMAGE
AB During flurothyl seizures in 4-day-old rats, cortical concentration of ATP, phosphocreatine and glucose fell while lactate rose. Cortical energy use rate more than doubled, while glycolytic rate increased fivefold. Calculation of the cerebral metabolic balance during sustained seizures suggests that energy balance could be maintained in hyperglycemic animals, and would decline slowly in normoglycemia, but would be compromised by concurrent hypoglycemia, hyperthermia or hypoxia. These results suggest that the metabolic challenge imposed on the brain by this model of experimental neonatal seizures is milder than that seen at older ages, but can become critical when associated with other types of metabolic stress.
C1 [Wasterlain, Claude G.; Thompson, Kerry W.; Suchomelova, Lucie; Niquet, Jerome] VA Greater Angeles Hlth Care Syst, Epilepsy Res Lab, W Los Angels, CA 90073 USA.
[Thompson, Kerry W.] Occidental Coll, Dept Biol, Los Angeles, CA 90041 USA.
[Wasterlain, Claude G.; Thompson, Kerry W.; Suchomelova, Lucie; Niquet, Jerome] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
[Wasterlain, Claude G.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA.
RP Wasterlain, CG (reprint author), VA Greater Angeles Hlth Care Syst, Epilepsy Res Lab, 11301 Wilshire Blvd, W Los Angels, CA 90073 USA.
EM wasterla@ucla.edu
FU VHA Research Service; NINDS [RO1-NS13515]
FX Supported by VHA Research Service and by research grant RO1-NS13515 from
NINDS. A large part of the credit for this work belongs to Dr. Thomas E.
Duffy, who unfortunately died before its completion. We are indebted to
Barbara Blackburn for preparation of the manuscript, and to Roger
Baldwin for superb technical help. I (CGW) am particularly indebted to
Dr Abel Lajtha for his support during my early days as a neurochemist.
He was both a mentor and an inspiration, and was always available and
generous with fresh ideas, new techniques and very wise advice. Abel and
Claude Baxter welcomed me into the Society for Neurochemistry, which was
a young and vibrant meeting place for all kinds of scientists. Abel was
a strong leader, but his style was so kind and unassuming that I always
felt like he was helping me to find my own way. There are only a few
people whose influence on the world has been exclusively positive, and
he is one of those elite few. I hope that he will continue to provide
wisdom and inspiration to present and future neurochemists.
NR 56
TC 13
Z9 15
U1 0
U2 1
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0364-3190
J9 NEUROCHEM RES
JI Neurochem. Res.
PD DEC
PY 2010
VL 35
IS 12
SI SI
BP 2193
EP 2198
DI 10.1007/s11064-010-0339-4
PG 6
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 695IX
UT WOS:000285364900037
PM 21136154
ER
PT J
AU Fabrizio, KS
Keltner, NL
AF Fabrizio, Katherine S.
Keltner, Norman L.
TI Traumatic Brain Injury in Operation Enduring Freedom/Operation Iraqi
Freedom: A Primer
SO NURSING CLINICS OF NORTH AMERICA
LA English
DT Article
DE Brain injury; Blast; Military; Veterans
ID POSTTRAUMATIC-STRESS-DISORDER; PSYCHIATRIC-DISORDERS; PART II;
AFGHANISTAN; SOLDIERS; WAR; CONSEQUENCES; DEPRESSION; RECOVERY; LONG
AB In greater numbers than in prior conflicts, service members deployed as part of Operation Enduring Freedom and Operation Iraqi Freedom have an increased risk of experiencing a traumatic brain injury (TBI). The basics of TBI are discussed, with particular attention paid to blast-related events, as this is a common mechanism of injury in this population. Particular attention is focused on the pharmacologic treatment of the sequlae of TBI and common comorbid conditions.
C1 [Fabrizio, Katherine S.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA.
[Keltner, Norman L.] Univ Alabama, Sch Nursing, Birmingham, AL 35294 USA.
RP Fabrizio, KS (reprint author), Birmingham Vet Affairs Med Ctr, Phys Med & Rehabil 117,700 S 19th St, Birmingham, AL 35233 USA.
EM Katherine.Fabrizio@va.gov
NR 39
TC 10
Z9 10
U1 1
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0029-6465
J9 NURS CLIN N AM
JI Nurs. Clin. North Am.
PD DEC
PY 2010
VL 45
IS 4
BP 569
EP +
DI 10.1016/j.cnur.2010.06.003
PG 13
WC Nursing
SC Nursing
GA 683AI
UT WOS:000284443700006
PM 20971337
ER
PT J
AU Cole, GM
Ma, QL
Frautschy, SA
AF Cole, Greg M.
Ma, Qiu-Lan
Frautschy, Sally A.
TI Dietary fatty acids and the aging brain
SO NUTRITION REVIEWS
LA English
DT Review
DE Alzheimer's disease; amyloid; dementia; docosahexaenoic acid (DHA);
omega-3 fatty acid (n-3)
ID MILD COGNITIVE IMPAIRMENT; RETINOID-X-RECEPTOR; DISEASE MOUSE MODEL;
ALZHEIMERS-DISEASE; DOCOSAHEXAENOIC ACID; AMYLOID-BETA; DENDRITIC
PATHOLOGY; MEDITERRANEAN DIET; SYNAPTIC PROTEINS; CONTROLLED-TRIAL
AB Aging contributes to physiological decline and vulnerability to disease. In the brain, even with minimal neuronal loss, aging increases oxidative damage, inflammation, demyelination, impaired processing, and metabolic deficits, particularly during pathological brain aging. In this review, the possible role of docosahexaenoic acid (DHA) in the prevention of age-related disruption of brain function is discussed. High-fat diabetogenic diets, cholesterol, and the omega-6 fatty acid arachidonate and its prostaglandin metabolites have all been implicated in promoting the pathogenesis of Alzheimer's disease. Evidence presented here shows DHA acts to oppose this, exerting a plethora of pleiotropic activities to protect against the pathogenesis of Alzheimer's disease.
C1 [Cole, Greg M.; Ma, Qiu-Lan; Frautschy, Sally A.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA.
[Cole, Greg M.; Frautschy, Sally A.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA.
[Cole, Greg M.; Ma, Qiu-Lan; Frautschy, Sally A.] Greater Los Angeles Vet Affairs Healthcare Syst, Geriatr Res Educ & Clin Ctr, VA Med Ctr, North Hills, CA USA.
RP Cole, GM (reprint author), Greater Los Angeles Healthcare Syst, GRECC Vet Affairs, Res 151,Bldg 7,Rm A101,16111 Plummer St, North Hills, CA 91343 USA.
EM gmcole@ucla.edu
FU National Center for Complementary and Alternative Medicine (NCCAM) [NIH
R01 AT3008, NIA R01AG13471, VA MERIT, AG021975]
FX Funding. This work was supported by National Center for Complementary
and Alternative Medicine (NCCAM) NIH R01 AT3008, NIA R01AG13471, VA
MERIT (SAF, GMC), AG021975 (SAF).
NR 80
TC 33
Z9 33
U1 1
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0029-6643
EI 1753-4887
J9 NUTR REV
JI Nutr. Rev.
PD DEC
PY 2010
VL 68
IS 12
SU 2
BP S102
EP S111
DI 10.1111/j.1753-4887.2010.00345.x
PG 10
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 684WZ
UT WOS:000284587300007
PM 21091943
ER
PT J
AU Ng, E
Ilsen, PF
AF Ng, Eileen
Ilsen, Pauline F.
TI Orbital Metastases
SO OPTOMETRY-JOURNAL OF THE AMERICAN OPTOMETRIC ASSOCIATION
LA English
DT Article
DE Orbital metastasis; Radiation; Palliative therapy; Proptosis; Ptosis;
Diplopia
ID RENAL-CELL CARCINOMA; RADIATION-INDUCED MENINGIOMAS; BREAST-CARCINOMA;
TUMORS; CANCER; EYE; MELANOMA; ADENOCARCINOMA; RETINOPATHY; MANAGEMENT
AB BACKGROUND: Orbital metastasis, although uncommon, is a condition optometrists should consider in a patient presenting with proptosis, ptosis, diplopia, or a lid mass with a history of cancer. However, in as many as 19% of cases, patients have no prior or concurrent history of systemic cancer when presenting with ophthalmic symptoms. If suspecting an orbital metastasis, neuroimaging is important, as well as a referral to the patient's primary care provider, oncologist, and ophthalmologist.
CASE REPORTS: Three patients with orbital metastasis are discussed. The first was a 55-year-old white man who initially presented with a left ptosis of unclear etiology. Magnetic resonance imaging of his orbits and an orbital biopsy found metastatic esophageal adenocarcinoma. Radiotherapy and chemotherapy were initiated, but the patient died shortly afterward. The second patient was a 49-year-old black man who also presented with a ptosis of the right upper eyelid. An area of the retina appeared elevated; ophthalmic B-scan and computed tomography of the orbits confirmed the presence of a mass, determined to be metastatic lung carcinoma to the right orbit. A course of radiotherapy was initiated, but the patient died 3 clays after completing therapy. The last case was a 77-year-old white man with a history of metastasis to the left orbit from non-Hodgkin's lymphoma. On examination, he had proptosis of the left eye, initially thought to be caused by a recurrence of the metastasis. However, a computed tomography scan showed a new meningioma in the same orbit, and treatment was started. The proptosis improved, and the patient continues to be followed up regularly.
CONCLUSIONS: Any patient with proptosis and/or ptosis with a history of cancer should be evaluated for orbital metastasis. Optometrists should keep in mind that an orbital metastasis may represent the initial manifestation of undiagnosed systemic cancer. Prognosis can be poor, and thus treatment is sometimes palliative in nature, intending to slow the progression of the disease instead of providing a cure. Optometry 2010;81:647-657
C1 W Los Angeles Vet Affairs Healthcare Ctr, Los Angeles, CA USA.
So Calif Coll Optometry, Los Angeles, CA USA.
RP Ng, E (reprint author), W Los Angeles Vet Affairs Healthcare, Optometry, Bldg 304,Room 2-111,11031 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM eng510@gmail.com
NR 53
TC 5
Z9 5
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1529-1839
J9 OPTOMETRY
JI Optometry
PD DEC
PY 2010
VL 81
IS 12
BP 647
EP 657
DI 10.1016/j.optm.2010.07.026
PG 11
WC Ophthalmology
SC Ophthalmology
GA 778ML
UT WOS:000291708300005
PM 21111373
ER
PT J
AU Singh, JA
Ayub, S
AF Singh, J. A.
Ayub, S.
TI Accuracy of VA databases for diagnoses of knee replacement and hip
replacement
SO OSTEOARTHRITIS AND CARTILAGE
LA English
DT Article
DE Hip replacement; Knee replacement; Validity; Databases; Veterans Affairs
ID HEALTH-CARE-SYSTEM; VETERANS; QUALITY
AB Purpose: To examine the validity of International Classification of Diseases-Ninth Revision (ICD-9) and Current Procedural Terminology (CPT) codes for knee replacement and hip replacement in Veterans Affairs (VA) databases.
Methods: From a cohort of veterans who received health care at Minneapolis VA Medical Center and/or affiliated medical facilities, we obtained four random samples of 50 patients each with: neither hip nor knee replacement code, knee replacement code only, hip replacement code only and both knee and hip replacement codes. The gold standard was documentation of knee or hip replacement surgery in patient medical records. Accuracy of ICD-9 or CPT code for knee and hip replacement was assessed by calculating sensitivity, specificity, positive and negative predictive values (PPV and NPV).
Results: Of the 200 patients, medical records were available for 166:140 (70%) had complete medical records and 26 (13%) had incomplete medical records. Knee replacement codes were accurate with excellent PPV of 95%, sensitivity of 95%, specificity of 96% and NPV of 96%. Hip replacement codes were accurate with excellent PPV of 98%, sensitivity of 96%, specificity of 99% and NPV of 96%. Sensitivity analyses that included incomplete charts had little impact on these estimates. The procedure dates found in VA databases matched exactly with medical records in 96%.
Conclusions: The ICD-9 and CPT codes for knee replacement and hip replacement in VA databases are valid. These codes may be used to identify cohorts of veterans with knee replacement and hip replacement for research studies. Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.
C1 [Singh, J. A.] Univ Alabama, Birmingham, AL 35294 USA.
[Singh, J. A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL USA.
[Singh, J. A.] Mayo Clin, Sch Med, Dept Hlth Sci Res, Rochester, MN USA.
[Singh, J. A.] Mayo Clin, Sch Med, Dept Orthoped Surg, Rochester, MN USA.
[Singh, J. A.] VA Med Ctr, Minneapolis, MN USA.
[Ayub, S.] Univ Minnesota, Div Rheumatol, Minneapolis, MN USA.
RP Singh, JA (reprint author), Univ Alabama, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.
EM Jasvinder.md@gmail.com
OI singh, jasvinder/0000-0003-3485-0006
FU Allergan; Takeda; Savient; Wyeth; Amgen; URL pharmaceuticals; NIH (Mayo
Clinic Center for Clinical and Translational Research) [KL2
RR024151-01]; Birmingham VA Medical Center, Alabama, USA
FX There are no financial conflicts related to this work. JAS has received
speaker honoraria from Abbott; research and travel grants from Allergan,
Takeda, Savient, Wyeth and Amgen; and consultant fees from Savient and
URL pharmaceuticals. SA has no financial conflicts.; JAS's time was
protected for research through a NIH CTSA Award 1 KL2 RR024151-01 (Mayo
Clinic Center for Clinical and Translational Research) grant. The
funding source had no contributions to design or conduct of study,
preparation of manuscript or decision to submit it for publication. This
material is the result of work supported by the resources and the use of
facilities at the Birmingham VA Medical Center, Alabama, USA.
NR 14
TC 20
Z9 20
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 1063-4584
J9 OSTEOARTHR CARTILAGE
JI Osteoarthritis Cartilage
PD DEC
PY 2010
VL 18
IS 12
BP 1639
EP 1642
DI 10.1016/j.joca.2010.10.003
PG 4
WC Orthopedics; Rheumatology
SC Orthopedics; Rheumatology
GA 701IT
UT WOS:000285812300012
PM 20950694
ER
PT J
AU Nazar, G
Garmendia, ML
Royer, M
McDowell, JA
Weymuller, EA
Yueh, B
AF Nazar, Gonzalo
Garmendia, Maria Luisa
Royer, Michel
McDowell, Jennifer A.
Weymuller, Ernest A., Jr.
Yueh, Bevan
TI Spanish validation of the University of Washington Quality of Life
questionnaire for head and neck cancer patients
SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY
LA English
DT Article
ID PERFORMANCE STATUS SCALE; OROPHARYNGEAL CANCER; UW-QOL; DOMAIN;
LARYNGECTOMY; DISABILITY
AB OBJECTIVE: The University of Washington Quality of Life (UW-QOL) questionnaire is one of the most widely used instruments to evaluate the quality of life of head and neck cancer patients. The aim of this study was to perform a Spanish translation and validation of the UW-QOL questionnaire.
STUDY DESIGN: A cross-sectional study.
SETTING: Three tertiary-care hospitals and a laryngectomee rehabilitation center.
SUBJECTS AND METHODS: The translation and cultural adaptation of the questionnaire were performed following accepted international guidelines. The psychometric validation was performed on a consecutive series of patients treated for squamous cell carcinoma of the upper aerodigestive tract with no signs of relapse, recruited from May 2007 to December 2008. Eligible subjects were invited to complete the Spanish version of the UW-QOL questionnaire during routine clinical consultation, and complete it again within 15 days. Subjects also completed a validated Spanish version of the Goldberg Mental Health Survey and were evaluated by the use of the Karnofsky Index.
RESULTS: A Spanish version of the questionnaire was developed in iterative fashion. In the psychometric validation process, a total of 76 patients were analyzed. Reliability was excellent, including both internal consistency (Cronbach's alpha of 0.84) and test-retest reliability (intraclass correlation coefficient between 0.91 and 0.97 with a confidence interval of 95%). Construct validity was supported by statistically significant relationships between the Karnofsky Index, the Goldberg Mental Health Survey, and the translated UW-QOL questionnaire.
CONCLUSION: The Spanish version of the UW-QOL questionnaire appears to be culturally appropriate and psychometrically valid. Copyright (C) 2010 American Academy of Otolaryngology-Head and Neck Surgery Foundation. Published by Mosby, Inc. All rights reserved.
C1 [Nazar, Gonzalo] Clin Las Condes, Dept Otolaryngol, Santiago, Chile.
[Garmendia, Maria Luisa] Univ Chile, Sch Publ Hlth, Santiago, Chile.
[Royer, Michel] Univ Chile, Hosp Clin, Dept Otolaryngol, Santiago, Chile.
[McDowell, Jennifer A.] Vet Affairs Puget Sound Healthcare Syst, Seattle, WA USA.
[Weymuller, Ernest A., Jr.] Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA.
[Yueh, Bevan] Univ Minnesota, Dept Otolaryngol Head & Neck Surg, Minneapolis, MN USA.
RP Nazar, G (reprint author), Clin Las Condes, Dept Otolaryngol, Lo Fontecilla 441, Santiago, Chile.
RI Garmendia, Maria Luisa/H-7417-2013
OI Garmendia, Maria Luisa/0000-0002-0589-6091; Yueh,
Bevan/0000-0003-1380-1053
FU Chilean Society of Otolaryngology, Head and Neck Surgery
FX This study was financially supported by the Chilean Society of
Otolaryngology, Head and Neck Surgery The funding organization had no
influence in study design, data analysis or manuscript writing The
Chilean Society of Otolaryngology only demands that the paper resulting
from the funded research must be published in a medical journal
NR 29
TC 8
Z9 8
U1 0
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0194-5998
J9 OTOLARYNG HEAD NECK
JI Otolaryngol. Head Neck Surg.
PD DEC
PY 2010
VL 143
IS 6
BP 801
EP 807
DI 10.1016/j.otohns.2010.08.008
PG 7
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA 690BF
UT WOS:000284974400012
PM 21109081
ER
PT J
AU Morasco, BJ
Duckart, JP
Carr, TP
Deyo, RA
Dobscha, SK
AF Morasco, Benjamin J.
Duckart, Jonathan P.
Carr, Thomas P.
Deyo, Richard A.
Dobscha, Steven K.
TI Clinical characteristics of veterans prescribed high doses of opioid
medications for chronic non-cancer pain
SO PAIN
LA English
DT Article
DE Chronic pain; Opioids; Epidemiology; Quality of life; Pain/drug therapy
ID PRIMARY-CARE PHYSICIANS; CHRONIC BACK-PAIN; ADMINISTRATIVE DATA;
NONMALIGNANT PAIN; ATTITUDES; PRESCRIPTIONS; THERAPY; ASSOCIATION;
MANAGEMENT; DISORDERS
AB Little is known about patients prescribed high doses of opioids to treat chronic non-cancer pain, though these patients may be at higher risk for medication-related complications. We describe the prevalence of high-dose opioid use and associated demographic and clinical characteristics among veterans treated in a VA regional healthcare network. Veterans with chronic non-cancer pain prescribed high doses of opioids (>= 180 mg/day morphine equivalent; n = 478) for 90+ consecutive days were compared to two groups with chronic pain: Traditional-dose (5-179 mg/day; n = 500) or no opioid (n = 500). High-dose opioid use occurred in 2.4% of all chronic pain patients and in 8.2% of all chronic pain patients prescribed opioids long-term. The average dose in the high-dose group was 324.9 (SD = 285.1) mg/day. The only significant demographic difference among groups was race (p = 0.03) with black veterans less likely to receive high doses. High-dose patients were more likely to have four or more pain diagnoses and the highest rates of medical, psychiatric, and substance use disorders. After controlling for demographic factors and VA facility, neuropathy, low back pain, and nicotine dependence diagnoses were associated with increased likelihood of high-dose prescriptions. High-dose patients frequently did not receive care consistent with treatment guidelines: there was frequent use of short-acting opioids, urine drug screens were administered to only 25.7% of patients in the prior year, and 32.0% received concurrent benzodiazepine prescriptions, which may increase risk for overdose and death. Further study is needed to identify better predictors of high-dose usage, as well as the efficacy and safety of such dosing. Published by Elsevier B.V. on behalf of International Association for the Study of Pain.
C1 [Morasco, Benjamin J.; Dobscha, Steven K.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, Portland, OR 97201 USA.
[Carr, Thomas P.] Oregon Hlth & Sci Univ, Div Gen Med & Geriatr, Dept Med, Primary Care Div,Portland VA Med Ctr, Portland, OR 97201 USA.
[Deyo, Richard A.] Oregon Hlth & Sci Univ, Dept Family Med, Portland, OR 97201 USA.
[Deyo, Richard A.] Oregon Hlth & Sci Univ, Dept Internal Med, Portland, OR 97201 USA.
[Duckart, Jonathan P.; Dobscha, Steven K.] Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Mental & Phys D, Portland, OR USA.
RP Morasco, BJ (reprint author), Portland VA Med Ctr R&D99, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM benjamin.morasco@va.gov
FU National Institute on Drug Abuse [K23DA023467]; VA Health Services
Research and Development service; National Center for Research
Resources, a component of the National Institutes of Health
[Ul1RR024140]; NIH Roadmap for Medical Research
FX This study was supported in part by award K23DA023467 from the National
Institute on Drug Abuse to Dr. Morasco. Jonathan Duckart, MPS, was
supported by a Research Enhancement Award Program grant from the VA
Health Services Research and Development service. The authors appreciate
assistance from Sharon Medley and for the support provided by the Oregon
Clinical and Translational Research Institute, Grant number Ul1RR024140
from the National Center for Research Resources, a component of the
National Institutes of Health and NIH Roadmap for Medical Research. The
content of this manuscript is solely the responsibility of the authors
and does not necessarily represent the official views of the National
Institutes of Health, National Institute on Drug Abuse, or the
Department of Veterans Affairs.
NR 55
TC 79
Z9 80
U1 2
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-3959
J9 PAIN
JI Pain
PD DEC
PY 2010
VL 151
IS 3
BP 625
EP 632
DI 10.1016/j.pain.2010.08.002
PG 8
WC Anesthesiology; Clinical Neurology; Neurosciences
SC Anesthesiology; Neurosciences & Neurology
GA 673KC
UT WOS:000283657300014
PM 20801580
ER
PT J
AU Meiksin, R
Chang, JC
Bhargava, T
Arnold, R
Dado, D
Frankel, R
Rodriguez, KL
Ling, B
Zickmund, S
AF Meiksin, Rebecca
Chang, Judy C.
Bhargava, Tina
Arnold, Robert
Dado, Diane
Frankel, Richard
Rodriguez, Keri L.
Ling, Bruce
Zickmund, Susan
TI Now is the chance: Patient-provider communication about unplanned
pregnancy during the first prenatal visit
SO PATIENT EDUCATION AND COUNSELING
LA English
DT Article
DE Patient-provider relationship; Communication; Prenatal care; Pregnancy;
Unplanned
ID UNINTENDED PREGNANCY; WOMEN; DEPRESSION; HEALTH
AB Objective: Unplanned pregnancy is associated with psychosocial stress, post-partum depression, and future unplanned pregnancies. Our study describes how topics related to unplanned pregnancy were addressed with patients during the first prenatal visit.
Methods: We audio-recorded and transcribed initial prenatal visits between 48 patients and 16 providers from a clinic serving racially diverse, lower-socio-economic patients. We conducted a fine-grained thematic analysis of cases in which the patient's pregnancy was unplanned.
Results: Of the 48 patients, 35 (73%) had unplanned pregnancies. Twenty-nine visits for unplanned pregnancies (83%) included discussion of the patient's feelings about the pregnancy. Approximately half (51%) of the visits touched on partner or other types of social support. Six patients (17%) were offered referrals to counseling or social services. Only four visits (11%) touched on future birth control options.
Conclusion: Most initial prenatal visits for unplanned pregnancies included discussion of patient feelings about the pregnancy. However, opportunities to discuss future birth control and for more in-depth follow-up regarding social support and psychological risks associated with unplanned pregnancy were typically missed.
Practice implications: Obstetrics care providers should be cautious about making assumptions and should consider discussing pregnancy circumstances and psychosocial issues in more depth when treating patients facing unplanned pregnancy. Published by Elsevier Ireland Ltd.
C1 [Meiksin, Rebecca] VA Puget Sound, Seattle, WA 98101 USA.
[Meiksin, Rebecca] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA.
[Chang, Judy C.; Dado, Diane] Magee Womens Hosp, Pittsburgh, PA USA.
[Bhargava, Tina] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA.
[Arnold, Robert; Rodriguez, Keri L.; Ling, Bruce; Zickmund, Susan] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA.
[Frankel, Richard] Indiana Univ Sch Med, Med & Regenstrief Inst, Bloomington, IN USA.
[Rodriguez, Keri L.; Ling, Bruce; Zickmund, Susan] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Rodriguez, Keri L.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
RP Meiksin, R (reprint author), VA Puget Sound, Metropolitan Pk W,Suite 1400,1100 Olive Way, Seattle, WA 98101 USA.
EM Rebecca.Meiksin@va.gov
FU Association of Professors of Gynecology and Obstetrics/Abbott Medical
Education; Scaife Family Foundation; NIH/NICHD [5 K12HD43441-04 PI];
Agency for Healthcare Research and Quality [1 K08 HS13913-01A1];
Veterans Affairs Health Services Research Development
FX Financial support came from an Association of Professors of Gynecology
and Obstetrics/Abbott Medical Education Program Award, the Scaife Family
Foundation, and a Building Interdisciplinary Research Careers in Women's
Health Award (NIH/NICHD 5 K12HD43441-04 PI Roberts; Scholar Chang). The
efforts of Dr. Chang were also supported by the Agency for Healthcare
Research and Quality (1 K08 HS13913-01A1). The efforts of Drs. Rodriguez
and Zickmund were respectively sponsored by the Veterans Affairs Health
Services Research & Development Merit Review Entry Program (MREP) and
Investigator-Initiative Merit Review Award Program. None of the sponsors
of this study had any role in the study design; collection, analysis and
interpretation of the data; writing of the report; or decision to submit
the paper for publication.
NR 25
TC 8
Z9 9
U1 2
U2 7
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0738-3991
J9 PATIENT EDUC COUNS
JI Patient Educ. Couns.
PD DEC
PY 2010
VL 81
IS 3
SI SI
BP 462
EP 467
DI 10.1016/j.pec.2010.09.002
PG 6
WC Public, Environmental & Occupational Health; Social Sciences,
Interdisciplinary
SC Public, Environmental & Occupational Health; Social Sciences - Other
Topics
GA 707OH
UT WOS:000286295400023
PM 20884161
ER
PT J
AU Bhargava, P
Parisi, M
AF Bhargava, Puneet
Parisi, Marguerite
TI Infected thyroglossal duct cyst
SO PEDIATRIC RADIOLOGY
LA English
DT Editorial Material
C1 [Bhargava, Puneet] Univ Washington, Dept Radiol, Seattle, WA 98108 USA.
[Bhargava, Puneet] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Parisi, Marguerite] Univ Washington, Dept Radiol, Seattle, WA 98105 USA.
[Parisi, Marguerite] Seattle Childrens Hosp, Seattle, WA 98105 USA.
RP Bhargava, P (reprint author), Univ Washington, Dept Radiol, Mailbox 358280,S-114 Radiol,1660 S Columbian Way, Seattle, WA 98108 USA.
EM bhargp@u.washington.edu
RI Bhargava, Puneet /F-1330-2011
OI Bhargava, Puneet/0000-0002-3849-9666
NR 2
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0301-0449
J9 PEDIATR RADIOL
JI Pediatr. Radiol.
PD DEC
PY 2010
VL 40
SU 1
BP 84
EP 84
DI 10.1007/s00247-010-1563-4
PG 1
WC Pediatrics; Radiology, Nuclear Medicine & Medical Imaging
SC Pediatrics; Radiology, Nuclear Medicine & Medical Imaging
GA 692KZ
UT WOS:000285153000040
ER
PT J
AU Bhargava, P
Phillips, G
AF Bhargava, Puneet
Phillips, Grace
TI Giant gastric bezoar presenting as an acute abdominal emergency
SO PEDIATRIC RADIOLOGY
LA English
DT Editorial Material
C1 [Bhargava, Puneet] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Bhargava, Puneet; Phillips, Grace] Univ Washington, Dept Radiol, Seattle, WA 98195 USA.
[Phillips, Grace] Seattle Childrens Hosp, Div Computed Tomog, Seattle, WA USA.
RP Bhargava, P (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S-114 Radiol,Mail Stop 35828, Seattle, WA 98108 USA.
EM bhargp@u.washington.edu
RI Bhargava, Puneet /F-1330-2011
OI Bhargava, Puneet/0000-0002-3849-9666
NR 2
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0301-0449
J9 PEDIATR RADIOL
JI Pediatr. Radiol.
PD DEC
PY 2010
VL 40
SU 1
BP 99
EP 99
DI 10.1007/s00247-009-1511-3
PG 1
WC Pediatrics; Radiology, Nuclear Medicine & Medical Imaging
SC Pediatrics; Radiology, Nuclear Medicine & Medical Imaging
GA 692KZ
UT WOS:000285153000049
ER
PT J
AU Boulware, DR
Meya, DB
Bergemann, TL
Wiesner, DL
Rhein, J
Musubire, A
Lee, SJ
Kambugu, A
Janoff, EN
Bohjanen, PR
AF Boulware, David R.
Meya, David B.
Bergemann, Tracy L.
Wiesner, Darin L.
Rhein, Joshua
Musubire, Abdu
Lee, Sarah J.
Kambugu, Andrew
Janoff, Edward N.
Bohjanen, Paul R.
TI Clinical Features and Serum Biomarkers in HIV Immune Reconstitution
Inflammatory Syndrome after Cryptococcal Meningitis: A Prospective
Cohort Study
SO PLOS MEDICINE
LA English
DT Article
ID COLONY-STIMULATING FACTOR; ACTIVE ANTIRETROVIRAL THERAPY;
HUMAN-IMMUNODEFICIENCY-VIRUS; ALLERGIC BRONCHOPULMONARY MYCOSIS;
ENDOTHELIAL GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; CD4(+) T-CELLS;
RESTORATION DISEASE; INFECTED PATIENTS; RISK-FACTORS
AB Background: Although antiretroviral therapy (ART) improves survival in persons with cryptococcal meningitis (CM) and AIDS, ART frequently elicits HIV immune reconstitution inflammatory syndrome (IRIS), an exaggerated and frequently deadly inflammatory reaction that complicates recovery from immunodeficiency. The pathogenesis of IRIS is poorly understood and prediction of IRIS is not possible.
Methods and Findings: We prospectively followed 101 ART-naive Ugandans with AIDS and recent CM for one year after initiating ART, and used Luminex multiplex assays to compare serum cytokine levels in participants who did or did not develop IRIS. IRIS occurred in 45% of participants with recent CM on ART, including 30% with central nervous system (CNS) manifestations. The median time to CM-IRIS was 8.8 wk on ART. Overall mortality on ART was 36% with IRIS and 21% without IRIS. CM-IRIS was independently associated with death (HR = 2.3, 95% CI 1.1-5.1, p = 0.04). Patients experiencing subsequent CM-IRIS had 4-fold higher median serum cryptococcal antigen (CRAG) levels pre-ART (p = 0.006). Higher pre-ART levels of interleukin (IL)-4 and IL-17 as well as lower tumor necrosis factor (TNF)-alpha, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and vascular endothelial growth factor (VEGF) predicted future IRIS in multivariate analyses (area under the curve [AUC] = 0.82). An algorithm based on seven pre-ART serum biomarkers was a robust tool for stratifying high (83%), moderate (48%), and low risk (23%) for IRIS in the cohort. After ART was initiated, increasing levels of C-reactive protein (CRP), D-dimer, IL-6, IL-7, IL-13, G-CSF, or IL-1RA were associated with increasing hazard of IRIS by time-to-event analysis (each p <= 0.001). At the time of IRIS onset, multiple proinflammatory cytokine responses were present, including CRP and IL-6. Mortality was predicted by pre-ART increasing IL-17, decreasing GM-CSF, and CRP level >32 mg/l (highest quartile). Pre-ART CRP level >32 mg/l alone was associated with future death (OR = 8.3, 95% CI 2.7-25.6, p<0.001).
Conclusions: Pre-ART increases in Th-17 and Th-2 responses (e.g., IL-17, IL-4) and lack of proinflammatory cytokine responses (e.g., TNF-alpha, G-CSF, GM-CSF, VEGF) predispose individuals to subsequent IRIS, perhaps as biomarkers of immune dysfunction and poor initial clearance of CRAG. Although requiring validation, these biomarkers might be an objective tool to stratify the risk of CM-IRIS and death, and could be used clinically to guide when to start ART or use prophylactic interventions.
C1 [Boulware, David R.; Meya, David B.; Rhein, Joshua; Lee, Sarah J.; Kambugu, Andrew; Bohjanen, Paul R.] Univ Minnesota, Dept Med, Div Infect Dis & Int Med, Minneapolis, MN 55455 USA.
[Boulware, David R.; Wiesner, Darin L.; Rhein, Joshua; Bohjanen, Paul R.] Univ Minnesota, Ctr Infect Dis & Microbiol Translat Res, Minneapolis, MN 55455 USA.
[Meya, David B.; Musubire, Abdu; Kambugu, Andrew] Makerere Univ, Infect Dis Inst, Kampala, Uganda.
[Bergemann, Tracy L.] Univ Minnesota, Div Biostat, Sch Publ Hlth, Minneapolis, MN 55455 USA.
[Janoff, Edward N.] Univ Colorado, Mucosal & Vaccine Res Program Colorado MAVRC, Div Infect Dis, Denver Sch Med,Denver Vet Affairs Med Ctr, Denver, CO 80202 USA.
[Bohjanen, Paul R.] Univ Minnesota, Dept Microbiol, Minneapolis, MN 55455 USA.
RP Boulware, DR (reprint author), Univ Minnesota, Dept Med, Div Infect Dis & Int Med, Box 736 UMHC, Minneapolis, MN 55455 USA.
EM boulw001@umn.edu
RI Boulware, David/B-5516-2011; Boulware, David/I-4533-2013; Bohjanen,
Paul/B-2329-2015
OI Bohjanen, Paul/0000-0002-2772-3597; Meya, David/0000-0002-4138-240X;
Bergemann, Tracy/0000-0003-3902-2605; Boulware,
David/0000-0002-4715-0060
FU University of Minnesota Academic Health Center; NIH National Institute
of Allergy and Infectious Diseases [T32AI055433-03, L30AI066779,
K12RR023247-04, K23AI073192, R03AI078750]; Minnesota Medical Foundation;
Tibotec REACH Initiative; University of Minnesota; Academic Alliance
Foundation; Mucosal and Vaccine Research Program Colorado; Veterans
Affairs Research Service
FX This work was supported by the University of Minnesota Academic Health
Center (PRB, DBM), NIH National Institute of Allergy and Infectious
Diseases (DRB: T32AI055433-03; L30AI066779; K12RR023247-04; K23AI073192.
PRB: R03AI078750), Minnesota Medical Foundation (PRB, DRB, DBM), Tibotec
REACH Initiative (PRB, DRB, DBM), University of Minnesota Dean's
Grant-in-Aid (DRB), Academic Alliance Foundation (AK, DBM), Mucosal and
Vaccine Research Program Colorado (ENJ), and the Veterans Affairs
Research Service (ENJ). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 67
TC 105
Z9 105
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1549-1676
J9 PLOS MED
JI PLos Med.
PD DEC
PY 2010
VL 7
IS 12
AR e1000384
DI 10.1371/journal.pmed.1000384
PG 14
WC Medicine, General & Internal
SC General & Internal Medicine
GA 697GA
UT WOS:000285499600010
PM 21253011
ER
PT J
AU Elder, GA
Mitsis, EM
Ahlers, ST
Cristian, A
AF Elder, Gregory A.
Mitsis, Effie M.
Ahlers, Stephen T.
Cristian, Adrian
TI Blast-induced Mild Traumatic Brain Injury
SO PSYCHIATRIC CLINICS OF NORTH AMERICA
LA English
DT Article
DE Blast-related brain injury; Improvised explosive device; Posttraumatic
stress disorder; Traumatic brain injury
ID POSTTRAUMATIC-STRESS-DISORDER; CENTRAL-NERVOUS-SYSTEM; DIFFUSE AXONAL
INJURY; ADULT-RAT BRAIN; PERSISTENT POSTCONCUSSIVE SYMPTOMS;
TYMPANIC-MEMBRANE PERFORATION; LASTING IMPULSE NOISE; NON-PENETRATIVE
BLAST; WHITE-MATTER INJURY; HEAD-INJURY
AB Traumatic brain injury (TBI) has been a major cause of mortality and morbidity in the wars in Iraq and Afghanistan Blast exposure has been the most common cause of TBI, occurring through multiple mechanisms What is less clear is whether the primary blast wave causes brain damage through mechanisms that are distinct from those common in civilian TBI and whether multiple exposures to low-level blast can lead to long-term sequelae Complicating TBI in soldiers is the high prevalence of posttraumatic stress disorder At present the relationship is unclear Resolution of these issues will affect both treatment strategies and strategies for the protection of troops in the field
C1 [Elder, Gregory A.] James J Peters Dept Vet Affairs Med Ctr, Neurol Serv, Bronx, NY 10468 USA.
[Elder, Gregory A.; Mitsis, Effie M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
[Elder, Gregory A.] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA.
[Mitsis, Effie M.; Cristian, Adrian] James J Peters Vet Affairs Med Ctr, Rehabil Med Serv, Bronx, NY 10468 USA.
[Ahlers, Stephen T.] Naval Med Res Ctr, Operat & Undersea Med Directorate, Silver Spring, MD 20910 USA.
[Cristian, Adrian] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA.
RP Elder, GA (reprint author), James J Peters Vet Affairs Med Ctr, Neurol Serv, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
NR 105
TC 73
Z9 74
U1 2
U2 15
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0193-953X
J9 PSYCHIAT CLIN N AM
JI Psychiatr. Clin. North Amer.
PD DEC
PY 2010
VL 33
IS 4
BP 757
EP +
DI 10.1016/j.psc.2010.08.001
PG 26
WC Psychiatry
SC Psychiatry
GA 694TA
UT WOS:000285320700003
PM 21093677
ER
PT J
AU Riggio, S
AF Riggio, Silvana
TI Traumatic Brain Injury and Its Neurobehavioral Sequelae
SO PSYCHIATRIC CLINICS OF NORTH AMERICA
LA English
DT Article
DE Traumatic brain injury; Postconcussive syndrome; Neuropsychiatric
disorders; Frontal lobe seizures
ID POSTTRAUMATIC-STRESS-DISORDER; HEAD-INJURY; CHRONIC PAIN;
PSYCHIATRIC-DISORDERS; SYMPTOMS; FATIGUE; ASSOCIATION; PREVALENCE;
CONCUSSION; DISABILITY
AB The neurobehavioral sequelae (NBS) of traumatic brain injury (TBI) consist of a spectrum of somatic neurological and psychiatric symptoms The challenge for clinicians lies in understanding the interface of the various symptoms and how they interrelate with other entities Specifically, the challenge is differentiating post-TBI-related symptoms from pre-existing or de novo psychiatric neurological and/or systemic disorders A comprehensive evaluation and a multidisciplinary approach to evaluating patients are essential to be able to develop the differential diagnosis needed to design a management plan that maximizes recovery
C1 [Riggio, Silvana] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
[Riggio, Silvana] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA.
[Riggio, Silvana] James J Peters VAMC, Dept Psychiat, Bronx, NY USA.
RP Riggio, S (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1 Gustave L Levy Pl,Box 1230, New York, NY 10029 USA.
NR 46
TC 15
Z9 15
U1 0
U2 6
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0193-953X
J9 PSYCHIAT CLIN N AM
JI Psychiatr. Clin. North Amer.
PD DEC
PY 2010
VL 33
IS 4
BP 807
EP +
DI 10.1016/j.psc.2010.08.004
PG 14
WC Psychiatry
SC Psychiatry
GA 694TA
UT WOS:000285320700006
PM 21093680
ER
PT J
AU Pasinetti, GM
Fivecoat, H
Ho, L
AF Pasinetti, Giulio Maria
Fivecoat, Hayley
Ho, Lap
TI Personalized Medicine in Traumatic Brain Injury
SO PSYCHIATRIC CLINICS OF NORTH AMERICA
LA English
DT Article
DE Postconscussive traumatic brain injury; MicroRNA; Biomarker;
Personalized medicine
ID AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; COGNITIVE REHABILITATION;
BREAST-CANCER; TASK-FORCE; EXPRESSION; RISK; TAU; CHEMOTHERAPY;
MECHANISMS
AB Patients who have sustained a mild traumatic brain injury (TBI) from both civilian and military populations exhibit clinical symptoms of varying severity with minimal to profound impact on their daily functioning Although most patients make a full recovery, a subgroup of mild TBI patients develop cognitive somatic, and neurobehavioral sequelae that generally resolve over 3 to 6 months a smaller subgroup develop persisting symptoms The reason why a mild TBI results in varying clinical symptoms is currently unknown Based on evidence that microRNA species in peripheral blood mononuclear cells (PBMCs) may reflect molecular alterations in neurodegenerative disorders it can be hypothesized that at early preclinical phases of the disease PBMC may provide an ideal and clinically assessable window' into the brain Thus it is conceivable that changes in the expression profile of clinically accessible biological indices (biomarkers) such as microRNA in PBMC may reflect molecular alterations
C1 [Pasinetti, Giulio Maria; Fivecoat, Hayley; Ho, Lap] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA.
[Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY 10468 USA.
RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Dept Neurol, 1 Gustave L Levy Pl,Box 1137, New York, NY 10029 USA.
NR 40
TC 5
Z9 5
U1 1
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0193-953X
J9 PSYCHIAT CLIN N AM
JI Psychiatr. Clin. North Amer.
PD DEC
PY 2010
VL 33
IS 4
BP 905
EP +
DI 10.1016/j.psc.2010.09.003
PG 11
WC Psychiatry
SC Psychiatry
GA 694TA
UT WOS:000285320700011
PM 21093685
ER
PT J
AU Goldstein, G
Luther, JF
Haas, GL
Appelt, CJ
Gordon, AJ
AF Goldstein, Gerald
Luther, James F.
Haas, Gretchen L.
Appelt, Cathleen J.
Gordon, Adam J.
TI Factor Structure and Risk Factors for the Health Status of Homeless
Veterans
SO PSYCHIATRIC QUARTERLY
LA English
DT Article
DE Homeless; Health status; Comorbidity
ID SERIOUS MENTAL-ILLNESS
AB Homeless veterans have numerous health problems that have been previously characterized as falling into four major subgroups; addiction, psychosis, vascular disorders, and generalized medical and psychiatric illness. Comorbid conditions are common, often involving a combination of psychiatric and medical disorders. Using data from the same survey of homeless veterans that was used to establish these subgroups with cluster analysis, the present study examined the structure of these subgroup patterns through the use of factor analysis. This analysis yielded a five factor solution. They were named "Cardiac", Mood, Stress, Addiction, and Psychosis factors. Factor scores were computed and an odds ratio analysis was accomplished to determine the association between obtaining a high score on a given factor with a number of sociodemographic and homelessness related variables. It was concluded that health status of homeless veterans is a complex condition, but has a clear latent structure demonstrated by factor analysis. Scoring high or low on a particular factor is associated with numerous historical and sociodemographic considerations, notably age, ethnicity, and employment status.
C1 [Goldstein, Gerald; Luther, James F.; Haas, Gretchen L.; Appelt, Cathleen J.; Gordon, Adam J.] Vet Affairs Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA.
[Goldstein, Gerald; Luther, James F.; Haas, Gretchen L.; Appelt, Cathleen J.; Gordon, Adam J.] Univ Pittsburgh, Pittsburgh, PA USA.
[Gordon, Adam J.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA.
RP Goldstein, G (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA.
EM ggold@nb.net
FU NIMH NIH HHS [T32 MH15169]
NR 16
TC 2
Z9 2
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0033-2720
J9 PSYCHIAT QUART
JI Psychiatr. Q.
PD DEC
PY 2010
VL 81
IS 4
BP 311
EP 323
DI 10.1007/s11126-010-9140-4
PG 13
WC Psychiatry
SC Psychiatry
GA 666ED
UT WOS:000283094300005
PM 20532627
ER
PT J
AU Denneson, LM
Basham, C
Dickinson, KC
Crutchfield, MC
Millet, L
Shen, X
Dobscha, SK
AF Denneson, Lauren M.
Basham, Chandra
Dickinson, Kathryn C.
Crutchfield, Megan C.
Millet, Lisa
Shen, Xun
Dobscha, Steven K.
TI Suicide Risk Assessment and Content of VA Health Care Contacts Before
Suicide Completion by Veterans in Oregon
SO PSYCHIATRIC SERVICES
LA English
DT Article
ID MENTAL-HEALTH; DEPRESSION; POPULATION; STRATEGIES; MORTALITY; VALIDITY;
SYSTEM; DEATH; IRAQ
AB Objective: This study described health care contacts at a Department of Veterans Affairs (VA) medical center in Oregon in the year before death of veterans who completed suicide. Methods: Oregon Violent Death Reporting System (OVDRS) data and VA administrative data were linked to identify the 112 veterans who completed suicide in Oregon between 2000 and 2005 and who had contact with a single VA medical center in the year before death. Medical records were reviewed to collect data on clinician assessment of suicide risk and reasons for the last contact. Results: In the year before death, 54 veterans (48%) had one or more mental health contacts and 71 (63%) had one or more primary care contacts. The mean age was 57; common diagnoses included mood disorders (38%) and cardiovascular disease (38%). The median number of days between the last contact and date of death was 42 (range=0-358). Thirty-six last contacts (32%) were patient initiated for new or exacerbated medical concerns, and 76 (68%) were follow-ups for ongoing problems. Clinicians noted that 41 patients (37%) were experiencing emotional distress at the last contact. Thirteen of the 18 patients (72%) who were assessed for suicidal ideation at their last contact denied such thoughts. Conclusions: During their last contact, most veterans were seen for routine medical care and few endorsed thoughts of suicide. Results underscore challenges that clinicians face in identifying and caring for veterans at risk of suicide in health care settings. Additional research is indicated to identify better ways to facilitate communication of suicidal thoughts when they are present. (Psychiatric Services 61:1192-1197, 2010)
C1 [Denneson, Lauren M.; Dickinson, Kathryn C.; Crutchfield, Megan C.; Dobscha, Steven K.] Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Phys & Mental D, Portland, OR 97207 USA.
[Basham, Chandra] ZoomCare PC, Hillsboro, OR USA.
[Millet, Lisa; Shen, Xun] Injury & Violence Prevent Program, Oregon Publ Hlth Div, Portland, OR USA.
RP Denneson, LM (reprint author), Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Phys & Mental D, 3710 SW US Vet Hosp Rd, Portland, OR 97207 USA.
EM lauren.denneson@va.gov
FU VA; Veterans Health Administration; VA Health Services [DHI-08-096]
FX This article is based on work supported in part by the VA, the Veterans
Health Administration, and VA Health Services Research and Development
Service Project DHI-08-096. The views expressed are those of the authors
and do not necessarily reflect the position or policy of the VA or the
U.S. government.
NR 23
TC 22
Z9 22
U1 3
U2 5
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD DEC
PY 2010
VL 61
IS 12
BP 1192
EP 1197
DI 10.1176/appi.ps.61.12.1192
PG 6
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 688DE
UT WOS:000284829200006
PM 21123402
ER
PT J
AU Hansen, RA
Chen, SY
Gaynes, BN
Maciejewski, ML
AF Hansen, Richard A.
Chen, Shih-Yin
Gaynes, Bradley N.
Maciejewski, Matthew L.
TI Relationship of Pharmaceutical Promotion to Antidepressant Switching and
Adherence: A Retrospective Cohort Study
SO PSYCHIATRIC SERVICES
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; PRESCRIPTION DRUGS; PHARMACY RECORDS;
CONSUMER; DEPRESSION; PHYSICIANS; VALIDATION; REQUESTS; THERAPY; IMPACT
AB Objective: Patient nonadherence and early discontinuation of antidepressant treatment are common. Pharmaceutical promotion to consumers and physicians may influence this behavior. The objectives of this study were to explore whether promotional spending is related to early antidepressant switching, acute-phase adherence, and continuation-phase adherence. Methods: A retrospective cohort study was conducted with national promotional expenditure data merged with medical and prescription claims data from a large national health plan affiliated with i3 Innovus. Included were records for continuously insured adults with major depression who received a new prescription for an antidepressant: 5,010 were in the cohort assessed for switching, 4,457 were in the cohort assessed for acute-phase adherence, and 1,772 were in the cohort assessed for continuation-phase adherence. National promotional efforts were estimated by examining inflation-adjusted spending on direct-to-consumer advertising (DTCA) and physician detailing. Clinical guidelines were used to create proxies for aspects of treatment outcomes, including antidepressant switching and adherence in the acute phase and adherence in the continuation phase. Logistic regression models estimated the association between promotional variables and these outcomes. Results: Patients taking medications that were more highly promoted to physicians were less likely to switch medications (odds ratio [ OR]=.61) and were more likely to be adherent during the acute phase of treatment (OR=1.13). DTCA had little effect on switching or antidepressant adherence. Conclusions: Detailing to physicians was associated with lower rates of medication switching and had a positive relationship with patient adherence during early antidepressant treatment. This finding indicates that certain aspects of promotion may have beneficial effects on antidepressant use. (Psychiatric Services 61:1232-1238, 2010)
C1 [Hansen, Richard A.] Univ N Carolina, Div Pharmaceut Outcomes & Policy, Chapel Hill, NC USA.
[Gaynes, Bradley N.] Univ N Carolina, Dept Psychiat, Chapel Hill, NC USA.
[Chen, Shih-Yin] United BioSource Corp, Ctr Hlth Econ & Sci Policy, Lexington, MA USA.
[Maciejewski, Matthew L.] Duke Univ, US Dept Vet Affairs, Ctr Hlth Serv Res Primary Care, Med Ctr, Durham, NC USA.
[Maciejewski, Matthew L.] Duke Univ, Med Ctr, Dept Med, Div Gen Internal Med, Durham, NC 27710 USA.
RP Hansen, RA (reprint author), Auburn Univ, Harrison Sch Pharm, Dept Pharm Care Syst, 207 Dunstan Hall, Auburn, AL 26849 USA.
EM rah0019@auburn.edu
OI Gaynes, Bradley/0000-0002-8283-5030; Hansen, Richard/0000-0002-4578-6698
FU American Association of Colleges of Pharmacy; National Institutes of
Health [K12RR023248]; Takeda Pharmaceuticals; GlaxoSmithKline;
Bristol-Myers Squibb; M-3 Information; Novartis
FX A portion of this work was funded by the new investigator program of the
American Association of Colleges of Pharmacy. Dr. Hansen was supported
by grant K12RR023248 from the National Institutes of Health at the time
of this work. The authors thank Emily Brouwer, Pharm.D., for her
contributions to data management; David Ridley, Ph.D., for his
contribution to study design; and Julie Donohue, Ph.D., for her
insightful comments on the manuscript.; Dr. Hansen has received
consulting fees and research support from Takeda Pharmaceuticals and
GlaxoSmithKline. Dr. Gaynes has received consulting fees and research
support from Bristol-Myers Squibb, M-3 Information, and Novartis, and he
has served as an advisor to Bristol-Myers Squibb. Dr. Maciejewski has
received consulting fees from Takeda Pharmaceuticals. Dr. Chen reports
no competing interests.
NR 35
TC 6
Z9 7
U1 3
U2 7
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD DEC
PY 2010
VL 61
IS 12
BP 1232
EP 1238
DI 10.1176/appi.ps.61.12.1232
PG 7
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 688DE
UT WOS:000284829200012
PM 21123408
ER
PT J
AU Phelan, CH
Love, GD
Ryff, CD
Brown, RL
Heidrich, SM
AF Phelan, Cynthia H.
Love, Gayle D.
Ryff, Carol D.
Brown, Roger L.
Heidrich, Susan M.
TI Psychosocial Predictors of Changing Sleep Patterns in Aging Women A
Multiple Pathway Approach
SO PSYCHOLOGY AND AGING
LA English
DT Article
DE sleep older women; psychological well being; depression; health
ID QUALITY-OF-LIFE; OLDER-ADULTS; COMPLAINTS; HEALTH; COMMUNITY;
PREVALENCE; INSOMNIA; MODEL; INDEX; INTERLEUKIN-6
AB The authors of this investigation sought to examine changes in the sleep quality of older women over time and to determine whether dimensions of psychological well being health (subjective health and number of illnesses) and psychological distress (depression and anxiety) predict these changes A secondary analysis was conducted with a longitudinal sample of aging women (Kwan Love Ryff & Essex 2003) Of 518 community dwelling older women in the parent study, 115 women (baseline M age = 67 years SD = 7 18) with data at baseline, 8 years, and 10 years were used for this investigation Participants completed self administered questionnaires and participated in in home interviews and observations Growth curve modeling was used to examine the overall linear trajectories of sleep quality Growth mixture modeling was used to examine whether there were different patterns of change in sleep quality over time and to examine baseline predictors of each pattern Sleep quality declined over time but not for all women Two distinctly different sleep patterns emerged good but declining sleep quality and disrupted sleep quality Higher psychological well being (positive relations with others environmental mastery personal growth purpose in life and self acceptance) fewer Illnesses and lower depression scores at baseline predicted reduced odds for membership in the disrupted sleep group Future research is needed to examine whether interventions focused on maintaining or enhancing psychological well being could minimize later life declines in sleep quality
C1 [Phelan, Cynthia H.] William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison, WI 53705 USA.
[Love, Gayle D.; Ryff, Carol D.] Univ Wisconsin, Inst Aging, Madrid, Spain.
[Brown, Roger L.; Heidrich, Susan M.] Univ Wisconsin, Sch Nursing, Madison, WI USA.
RP Phelan, CH (reprint author), William S Middleton Mem Vet Adm Med Ctr, GRECC, 2500 Overlook Terrace, Madison, WI 53705 USA.
FU NCRR NIH HHS [M01 RR003186, M01 RR003186-20, M01 RR03186]; NIA NIH HHS
[R01-AG0879]; NIMH NIH HHS [P50 MH061083, P50 MH061083-01, P50 MH61083]
NR 52
TC 19
Z9 20
U1 2
U2 9
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0882-7974
J9 PSYCHOL AGING
JI Psychol. Aging
PD DEC
PY 2010
VL 25
IS 4
BP 858
EP 866
DI 10.1037/a0019622
PG 9
WC Gerontology; Psychology, Developmental
SC Geriatrics & Gerontology; Psychology
GA 701IM
UT WOS:000285811600012
PM 20731498
ER
PT J
AU Lozano, BE
Stephens, RS
AF Lozano, Brian E.
Stephens, Robert S.
TI Comparison of Participatively Set and Assigned Goals in the Reduction of
Alcohol Use
SO PSYCHOLOGY OF ADDICTIVE BEHAVIORS
LA English
DT Article
DE goal setting; alcohol; college students; social cognitive theory
ID COLLEGE-STUDENT DRINKERS; SELF-EFFICACY; CONSTRUCT-VALIDITY;
TASK-PERFORMANCE; FOLLOW-UP; CONTROLLED DRINKING; SETTING PROCESS;
COMMITMENT; ABSTINENCE; ACCEPTANCE
AB The effects of setting goals on goal commitment, self-efficacy for goal achievement, and goal achievement in the context of an alcohol use intervention were examined using an experimental design in which participants were randomized to participatively set goals. assigned goals. and no goal conditions. One hundred and twenty-six heavy-drinking college students received a single cognitive-behavioral assessment/intervention session and completed measures of goal commitment. self-efficacy for goal achievement, and alcohol use. Results were consistent with, and expanded upon, previous research by demonstrating that having a goal for limiting alcohol consumption was predictive of lower quantity and frequency of alcohol use relative to not having a goal. Participation in goal setting yielded greater goal commitment and self-efficacy for goal achievement than assigned goals. but did not result in significantly greater reductions in alcohol use relative to assigned goals. Goal commitment and self-efficacy explained unique variance in the prediction of alcohol use at follow-up. Findings support the importance of goal setting in alcohol interventions and suggest areas for further research.
C1 [Lozano, Brian E.] Ralph H Johnson VAMC, Mental Hlth Serv 116, Charleston, SC 29401 USA.
[Stephens, Robert S.] Virginia Polytech Inst & State Univ, Dept Psychol, Blacksburg, VA 24061 USA.
RP Lozano, BE (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA.
EM Brian.Lozano@va.gov
NR 61
TC 11
Z9 11
U1 3
U2 8
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 0893-164X
J9 PSYCHOL ADDICT BEHAV
JI Psychol. Addict. Behav.
PD DEC
PY 2010
VL 24
IS 4
BP 581
EP 591
DI 10.1037/a0021444
PG 11
WC Substance Abuse; Psychology, Multidisciplinary
SC Substance Abuse; Psychology
GA 705WJ
UT WOS:000286171100004
PM 21198221
ER
PT J
AU Kim, HJ
Park, SH
Pickhardt, PJ
Yoon, SN
Lee, SS
Yee, J
Kim, DH
Kim, AY
Kim, JC
Yu, CS
Ha, HK
AF Kim, Hye Jin
Park, Seong Ho
Pickhardt, Perry J.
Yoon, Sang Nam
Lee, Seung Soo
Yee, Judy
Kim, David H.
Kim, Ah Young
Kim, Jin Cheon
Yu, Chang Sik
Ha, Hyun Kwon
TI CT Colonography for Combined Colonic and Extracolonic Surveillance after
Curative Resection of Colorectal Cancer
SO RADIOLOGY
LA English
DT Article
ID COMPUTED TOMOGRAPHIC COLONOGRAPHY; FOLLOW-UP; ADVANCED NEOPLASIA;
COLONOSCOPY; POPULATION; EXPERIENCE; RISK; FEASIBILITY; RECURRENCE;
ADENOMAS
AB Purpose: To determine the accuracy of contrast material-enhanced computed tomographic (CT) colonography for postoperative surveillance in colorectal cancer patients without clinical or laboratory evidence of disease recurrence.
Materials and Methods: The Institutional Review Board approved this HIPAA-compliant study and waived informed consent. Between January 2006 and December 2007, 742 consecutive patients without clinical or laboratory evidence of recurrence following curative-intent colorectal cancer surgery underwent contrast-enhanced CT colonography. Of these, 548 patients who had subsequent colonoscopy and pathologic confirmation of colonic lesions (reference standard) were included in the colonic analysis. All 742 patients were included in the extracolonic analysis. Sensitivity and specificity of CT colonography for nonanastomotic colonic lesions at least 6 mm in size and anastomotic lesions of any size, including performance according to lesion histologic type, were determined. Diagnostic yields of contrast-enhanced CT colonography for colonic cancers and for extracolonic recurrences were obtained.
Results: CT colonography depicted all six metachronous cancers and one anastomotic recurrence within the colon in six patients (0.8%; 95% confidence interval [CI]: 0.3%, 1.8%]), for per-patient and per-lesion sensitivities of 100% (95% CIs: 64.3%, 100% and 67.8%, 100%, respectively). All cancer lesions within the colon were amenable to additional curative treatment. CT colonography per-patient and per-lesion sensitivity was 81.8% (95% CI: 60.9%, 93.3%) and 80.8% (95% CI: 64.3%, 97.2%), respectively, for advanced neoplasia and 80.0% (95% CI: 68.6%, 88.1%) and 78.5% (95% CI: 68.3%, 88.7%), respectively, for all adenomatous lesions. Negative predictive values for adenocarcinoma, advanced neoplasia, and all adenomatous lesions were 100%, 99.1%, and 97.0%, respectively. CT colonography specificity was 93.1% (95% CI: 90.4%, 95.2%). Contrast-enhanced CT colonography enabled detection of extracolonic recurrences in an additional 11 patients (1.5%; 95% CI: 0.8%, 2.7%).
Conclusion: Contrast-enhanced CT colonography is an accurate and practical surveillance tool following colorectal cancer surgery in patients without clinical or laboratory evidence of recurrence, allowing for simultaneous less-invasive evaluation of both colon and extracolonic organs. (C)RSNA, 2010
C1 [Kim, Hye Jin; Park, Seong Ho; Lee, Seung Soo; Kim, Ah Young; Ha, Hyun Kwon] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiol, Seoul 138736, South Korea.
[Kim, Hye Jin; Park, Seong Ho; Lee, Seung Soo; Kim, Ah Young; Ha, Hyun Kwon] Univ Ulsan, Coll Med, Asan Med Ctr, Res Inst Radiol, Seoul 138736, South Korea.
[Yoon, Sang Nam; Kim, Jin Cheon; Yu, Chang Sik] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Surg, Seoul 138736, South Korea.
[Pickhardt, Perry J.; Kim, David H.] Univ Wisconsin, Sch Med, Dept Radiol, Madison, WI USA.
[Yee, Judy] Univ Calif San Francisco, San Francisco Vet Adm Med Ctr, Dept Radiol, San Francisco, CA 94143 USA.
RP Park, SH (reprint author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiol, Asanbyeongwon Gil 86, Seoul 138736, South Korea.
EM seonghopark@paran.com
OI Park, Seong Ho/0000-0002-1257-8315
FU NCI NIH HHS [R01 CA144835]
NR 29
TC 28
Z9 30
U1 2
U2 5
PU RADIOLOGICAL SOC NORTH AMERICA
PI OAK BROOK
PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA
SN 0033-8419
J9 RADIOLOGY
JI Radiology
PD DEC
PY 2010
VL 257
IS 3
BP 697
EP 704
DI 10.1148/radiol.10100385
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 683IL
UT WOS:000284469300014
PM 20876390
ER
PT J
AU Bespalova, IN
Durner, M
Ritter, BP
Angelo, GW
Rossy-Fullana, E
Carrion-Baralt, J
Schmeidler, J
Silverman, JM
AF Bespalova, Irina N.
Durner, Martina
Ritter, Benjamin P.
Angelo, Gary W.
Rossy-Fullana, Enrique
Carrion-Baralt, Jose
Schmeidler, James
Silverman, Jeremy M.
TI Non-synonymous variants in the AMACR gene are associated with
schizophrenia
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Schizophrenia; 5p13; AMACR; Genetic association; Case control study
ID METHYLACYL-COA-RACEMASE; 409 EUROPEAN-ANCESTRY; GENOME-WIDE SCAN;
PROSTATE-CANCER; FATTY-ACIDS; REVEALS ALTERATIONS; GENDER-DIFFERENCES;
EXPRESSION; LOCUS; RISK
AB Background The AMACR gene is located in the schizophrenia susceptibility locus on chromosome 5p13 previously identified in a large Puerto Rican pedigree of Spanish origin The AMACR-encoded protein is an enzyme involved in the metabolism of branched chain fatty and bile acids The enzyme deficiency causes structural and functional brain changes and disturbances in fatty acid and oxidative phosphorylation pathways observed in individuals with schizophrenia Therefore AMACR is both a positional and functional candidate gene for susceptibility to schizophrenia
Methods The study had a two step design we performed mutation analysis of the coding and flanking regions of AMACR in affected members of the pedigree and tested the detected sequence variants for association with schizophrenia in a Puerto Rican case-control sample (n = 383) of Spanish descent
Results and conclusion We identified three missense variants segregating with the disorder in the family rs2278008 rs2287939 and rs10941112 Two of them rs2278008 and rs2287939 demonstrated significant differences in genotype (P = 4 x 10(-4) P = 4 x 10(-4)) and allele (P = 1 x10(-4) P = 9 5 x 10(-5)) frequencies in unrelated male patients compare to controls with the odds ratios (OR) 2 24 (95% Cl 1 48-3 40) and 225 (95% Cl 1 49-3 38) respectively The G-C-G haplotype of rs2278008-rs2287939 rs10941112 revealed the most significant association with schizophrenia (P = 425 x 10(-6) OR = 2 96 95% Cl 1 85-4 76) in male subjects There were no statistically significant differences in genotype allele and haplotype frequencies between female schizophrenia subjects and controls Our results suggest that AMACR may play a significant role in susceptibility to schizophrenia in male patients (C) 2010 Elsevier B V All rights reserved
C1 [Bespalova, Irina N.; Durner, Martina; Ritter, Benjamin P.; Angelo, Gary W.; Schmeidler, James; Silverman, Jeremy M.] Mt Sinai Med Ctr, Dept Psychiat, New York, NY 10029 USA.
[Bespalova, Irina N.; Durner, Martina; Ritter, Benjamin P.; Angelo, Gary W.; Silverman, Jeremy M.] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA.
[Rossy-Fullana, Enrique] San Juan Vet Affairs Med Ctr, San Juan, PR USA.
[Carrion-Baralt, Jose] Univ Puerto Rico, San Juan, PR 00936 USA.
RP Bespalova, IN (reprint author), Mt Sinai Med Ctr, Dept Psychiat, 1 Gustave Levy Pl,Box 1230, New York, NY 10029 USA.
FU National Alliance for Research on Schizophrenia and Depression (NARSAD);
National Institute of Mental Health (NIMH) [RO3MH082134 01,
RO3MH082134]; Department of Veterans Affairs (VA); NINDC [R01NS37466]
FX Funding for this study was provided by the National Alliance for
Research on Schizophrenia and Depression (NARSAD) Young Investigator
Award to INB the National Institute of Mental Health (NIMH) Award
RO3MH082134 01 to INB and The Department of Veterans Affairs (VA) Merit
Award to JMS The funding sources had no further role in study design in
the collection analysis and interpretation of data; The authors thank
all the subjects for their participation in the study and Mount Sinai
Core Facility for sequencing our samples This study was supported by the
NIMH Award RO3MH082134 (INB) the NARSAD Young Investigator Award (INB)
the NINDC Award R01NS37466 (MD) and the Department of Veterans Affairs
Merit Award (JMS)
NR 73
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD DEC
PY 2010
VL 124
IS 1-3
BP 208
EP 215
DI 10.1016/j.schres.2010.08.040
PG 8
WC Psychiatry
SC Psychiatry
GA 694UE
UT WOS:000285323700028
PM 20875727
ER
PT J
AU Conhaim, RL
Mangino, MJ
Dovi, WF
Watson, KE
Warner, TF
Harms, BA
AF Conhaim, Robert L.
Mangino, Martin J.
Dovi, William F.
Watson, Kal E.
Warner, Thomas F.
Harms, Bruce A.
TI MICROTHROMBUS FORMATION MAY TRIGGER LUNG INJURY AFTER ACUTE BLOOD LOSS
SO SHOCK
LA English
DT Article
DE Acute lung injury; shock lung; acute respiratory distress syndrome;
pulmonary microcirculation; microcirculatory thrombosis
ID INTERALVEOLAR PERFUSION; RAT LUNGS; SEPSIS
AB We showed previously that acute blood loss, without resuscitation, caused marked maldistribution of interalveolar perfusion. Because hemorrhage is a known risk factor for the development of lung injury, the goal of our present studies was to determine if there was a correlation between perfusion maldistribution and the subsequent development of lung injury after blood loss. Specifically, we wanted to know if the perfusion maldistribution might be due to microthrombus formation and/or leukocyte sequestration within the pulmonary microcirculation. We bled rats (30% blood loss) and harvested their lungs 45 min or 24 h later. Lungs were prepared for perfusion distribution analysis, Western blot analysis to measure whole-lung fibrinogen concentrations, and for immunohistochemistry to measure fibrin deposition and leukocyte deposition (CD16 fluorescence). Perfusion was significantly maldistributed at 45 min and 24 h (P < 0.05). At 45 min, whole-lung fibrinogen concentrations were less than half that in controls (P < 0.05), whereas numbers of fibrin microthrombi were 2.5-fold greater than control by 45 min (not statistically significant) and were 4.5-fold greater by 24 h (P = 0.01). Leukocyte deposition was two-fold greater than control by 45 min (not statistically significant) and was 4-fold greater by 24 h (P = 0.02). Fibrin-to-leukocyte nearest-neighbor distances remained unchanged (18.1 [SD, 1.1] mu m) even as the numbers of both increased with time after blood loss. Our results suggest that soluble fibrinogen polymerized to insoluble fibrin within minutes after acute blood loss, which caused perfusion maldistribution and attracted leukocytes. The development of lung injury after blood loss may be a consequence of leukocyte chemoattraction to fibrin microthrombi that seem to form within minutes after blood loss.
C1 [Conhaim, Robert L.; Watson, Kal E.; Harms, Bruce A.] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI USA.
[Conhaim, Robert L.; Dovi, William F.; Warner, Thomas F.; Harms, Bruce A.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
[Mangino, Martin J.] Virginia Commonwealth Univ, Dept Surg, Richmond, VA USA.
RP Conhaim, RL (reprint author), H5-301 BX3236,600 Highland Ave, Madison, WI 53792 USA.
EM conhaim@surgery.wisc.edu
FU Department of Veterans Affairs
FX This study was supported by a grant from the Department of Veterans
Affairs.
NR 17
TC 8
Z9 8
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1073-2322
J9 SHOCK
JI Shock
PD DEC
PY 2010
VL 34
IS 6
BP 601
EP 607
DI 10.1097/SHK.0b013e3181e46e2a
PG 7
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
& Cardiology
GA 680LW
UT WOS:000284234400009
PM 20442694
ER
PT J
AU Seelig, AD
Jacobson, IG
Smith, B
Hooper, TI
Boyko, EJ
Gackstetter, GD
Gehrman, P
Macera, CA
Smith, TC
AF Seelig, Amber D.
Jacobson, Isabel G.
Smith, Besa
Hooper, Tomoko I.
Boyko, Edward J.
Gackstetter, Gary D.
Gehrman, Philip
Macera, Carol A.
Smith, Tyler C.
CA Millennium Cohort Study Team
TI Sleep Patterns Before, During, and After Deployment to Iraq and
Afghanistan
SO SLEEP
LA English
DT Article
DE Sleep; deployment; Millennium Cohort; mental health; veterans
ID POSTTRAUMATIC-STRESS-DISORDER; MILITARY DEPLOYMENT; MILLENNIUM COHORT;
GENERAL-POPULATION; COMBAT DEPLOYMENT; DECISION-MAKING; YOUNG-ADULTS;
DURATION; DEPRIVATION; HEALTH
AB Study Objectives: To determine the associations between deployment in support of the wars in Iraq and Afghanistan and sleep quantity and quality.
Design: Longitudinal cohort study
Setting: The Millennium Cohort Study survey is administered via a secure website or US mail.
Participants: Data were from 41,225 Millennium Cohort members who completed baseline (2001-2003) and follow-up (2004-2006) surveys. Participants were placed into 1 of 3 exposure groups based on their deployment status at follow-up: nondeployed, survey completed during deployment, or survey completed postdeployment.
Interventions: N/A
Measurements and Results: Study outcomes were self-reported sleep duration and trouble sleeping, defined as having trouble falling asleep or staying asleep. Adjusted mean sleep duration was significantly shorter among those in the deployed and postdeployment groups compared with those who did not deploy. Additionally, male gender and greater stress were significantly associated with shorter sleep duration. Personnel who completed their survey during deployment or postdeployment were significantly more likely to have trouble sleeping than those who had not deployed. Lower self-reported general health, female gender, and reporting of mental health symptoms at baseline were also significantly associated with increased odds of trouble sleeping.
Conclusions: Deployment significantly influenced sleep quality and quantity in this population though effect size was mediated with statistical modeling that included mental health symptoms. Personnel reporting combat exposures or mental health symptoms had increased odds of trouble sleeping. These findings merit further research to increase understanding of temporal relationships between sleep and mental health outcomes occurring during and after deployment.
C1 [Seelig, Amber D.; Jacobson, Isabel G.; Smith, Besa; Smith, Tyler C.] USN, Hlth Res Ctr, Dept Deployment Hlth Res, San Diego, CA 92106 USA.
[Hooper, Tomoko I.] Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, Bethesda, MD 20814 USA.
[Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA.
[Gackstetter, Gary D.] Analyt Serv Inc ANSER, Arlington, VA USA.
[Gehrman, Philip] Univ Penn, Dept Psychiat, Penn Sleep Ctr, Philadelphia, PA 19104 USA.
[Seelig, Amber D.; Macera, Carol A.] San Diego State Univ, Grad Sch Publ Hlth, San Diego, CA 92182 USA.
RP Seelig, AD (reprint author), USN, Hlth Res Ctr, Dept Deployment Hlth Res, 140 Sylvester Rd, San Diego, CA 92106 USA.
EM amber.seelig@med.navy.mil
OI Boyko, Edward/0000-0002-3695-192X
FU Henry M. Jackson Foundation
FX In addition to the authors, the Millennium Cohort Study Team includes
Melissa Bagnell, Lacy Farnell, Gia Gumbs, Nisara Granado, Jaime Horton,
Kelly Jones, Molly Kelton, Cynthia LeardMann, Travis Leleu, Gordon
Lynch, Jamie McGrew, Amanda Pietrucha, Teresa Powell, Donald Sandweiss,
Beverly Sheppard, Katherine Snell, Steven Spiegel, Kari Welch, Martin
White, James Whitmer, and Charlene Wong, from the Department of
Deployment Health Research, Naval Health Research Center, San Diego, CA;
Paul Amoroso, from the Madigan Army Medical Center, Tacoma, WA; Gregory
Gray, from the College of Public Health and Health Professions,
University of Florida, Gainesville, FL; James Riddle; Margaret Ryan from
the Naval Hospital Camp Pendleton, Camp Pendleton, CA; and Timothy Wells
from the US Air Force Research Laboratory, Wright-Patterson Air Force
Base, OH.; The authors thank the Millennium Cohort Study participants,
without whom these analyses would not be possible. We thank Scott
Seggerman from the Management Information Division, US Defense Manpower
Data Center, Monterey, CA; Michelle Stoia from the Naval Health Research
Center; and all the professionals from the US Army Medical Research and
Materiel Command, especially those from the Military Operational
Medicine Research Program, Fort Detrick, MD. We appreciate the support
of the Henry M. Jackson Foundation for the Advancement of Military
Medicine, Rockville, MD.
NR 41
TC 65
Z9 65
U1 1
U2 11
PU AMER ACAD SLEEP MEDICINE
PI WESTCHESTER
PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA
SN 0161-8105
J9 SLEEP
JI Sleep
PD DEC 1
PY 2010
VL 33
IS 12
BP 1615
EP 1622
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 686TZ
UT WOS:000284719900006
PM 21120123
ER
PT J
AU Leger, D
Partinen, M
Hirshkowitz, M
Chokroverty, S
Hedner, J
AF Leger, Damien
Partinen, Markku
Hirshkowitz, Max
Chokroverty, Sudhansu
Hedner, Jan
CA EQUINOX Evaluation Daytime QUality
TI Characteristics of insomnia in a primary care setting: EQUINOX survey of
5293 insomniacs from 10 countries
SO SLEEP MEDICINE
LA English
DT Article
DE Insomnia; Epidemiology; Difficulties initiating sleep; Difficulties
maintaining sleep; Nocturnal awakenings; Non restorative sleep; Primary
care
ID GENERAL-POPULATION; SLEEP; PREVALENCE; ADULTS; COMPLAINTS
AB Objective: To describe the characteristics of insomnia in primary care physicians' (PCPs') practices in 10 countries and to understand how the difficulty of maintaining sleep (DMS) was or was not associated with other insomnia symptoms such as difficulty initiating sleep (DIS), early morning awakenings (EMA) or nonrestorative sleep (NRS) in PCPs patients with insomnia.
Methods: International, noninterventional, cross-sectional, observational survey conducted in a primary care setting in subjects complaining of sleep disturbances in 10 countries. A questionnaire based on DSM-IV and ICSD criteria was administered.
Results: Thirteen thousand one hundred twenty-four subjects were enrolled by 647 physicians; 5293 of them (32.6%) had insomnia and were surveyed. The population was predominantly female (63.9%) with a mean age of 47.8 +/- 15.3 years; 39.9% of these patients have already been treated for sleep difficulties. Combination of all types of insomnia symptoms (DIS + DMS + EMA + NRS) was the most frequently reported combination (38.6% of the subjects), while the percentage of subjects presenting with only one type of insomnia symptom (DIS, DMS, EMA or NRS) was very low: 3%, 1.8%, 0.9% and 1.4% respectively. DMS was on average the most commonly reported insomnia symptom (80.2%). Multiple logistic regression showed that DMS, EMA and NRS symptoms were significantly linked with each other and also to other insomnia criteria (sleep satisfaction, sleep quality, sleep duration, number of hours of sleep, frequency of insomnia symptoms, wake up rested / unrested and non restorative sleep).
Conclusions: Patients visiting PCPs with insomnia are likely to present with severe and poly-symptomatic insomnia. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Leger, Damien] Univ Paris 05, APHP, Ctr Sommeil & Vigilance, Hotel Dieu Paris, F-75004 Paris, France.
[Partinen, Markku] Rinnekoti Res Ctr, Skogby Sleep Clin, Espoo, Finland.
[Hirshkowitz, Max] VA Med Ctr, Sleep Disorders & Res Ctr, Houston, TX USA.
[Chokroverty, Sudhansu] JFK Med Ctr, New Jersey Neurosci Inst, Edison, NJ USA.
[Hedner, Jan] Sahlgrens Univ Hosp, Dept Resp Med & Allergol, Sleep Lab Unit, Gothenburg, Sweden.
RP Leger, D (reprint author), Univ Paris 05, Pl Parvis Notre Dame, F-75181 Paris 04, France.
EM damien.leger@htd.aphp.fr
FU Sanofi Aventis
FX This survey has been supported by Sanofi Aventis. All authors have been
sponsored to design the protocol and review the data as a scientific
advisory board.
NR 29
TC 21
Z9 21
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1389-9457
J9 SLEEP MED
JI Sleep Med.
PD DEC
PY 2010
VL 11
IS 10
SI SI
BP 987
EP 998
DI 10.1016/j.sleep.2010.04.019
PG 12
WC Clinical Neurology
SC Neurosciences & Neurology
GA 704AD
UT WOS:000286022600006
PM 21093363
ER
PT J
AU Leger, D
Partinen, M
Hirshkowitz, M
Chokroverty, S
Touchette, E
Hedner, J
AF Leger, Damien
Partinen, Markku
Hirshkowitz, Max
Chokroverty, Sudhansu
Touchette, Evelyne
Hedner, Jan
CA EQUINOX Evaluation Daytime QUality
TI Daytime consequences of insomnia symptoms among outpatients in primary
care practice: EQUINOX international survey
SO SLEEP MEDICINE
LA English
DT Article
DE Insomnia; Difficulty initiating sleep; Difficulty maintaining sleep;
Early morning awakening; Non-restorative sleep; Daytime consequences;
International survey
ID QUALITY-OF-LIFE; GENERAL-POPULATION; PSYCHIATRIC-DISORDERS; SLEEP
DISTURBANCES; PREVALENCE; ADULTS; MANAGEMENT; COMPLAINTS; IMPACT
AB Objective: To assess the daytime consequences in outpatients suffering from different insomnia symptoms in primary care practice.
Methods: An international cross-sectional survey was conducted in 5293 outpatients complaining of sleep disturbances in primary care practice. A sleep questionnaire addressing daytime consequences, insomnia symptoms, socio-demographic characteristics, and other sleep variables was administered by 647 physicians in 10 countries.
Results: Overall, 20-33% of subjects reported "severe" daytime impairments associated with sleep disturbances. Approximately 45% of patients complaining of sleep disturbances in primary, care practice suffered from a combination of insomnia symptoms. Patients suffering from all insomnia symptoms reported the most severe daytime functioning impairments compared with patients suffering from initiation or maintenance insomnia only. Conversely, the majority of patients suffering from non-restorative sleep reported little daytime functioning impairments compared to the patients suffering from other combinations of insomnia symptoms. The strongest risk factor associated with "severe" daytime functioning impairments was sleep quality perception.
Conclusions: Primary insomnia disturbs subjective daytime functioning. A report of combined insomnia symptoms reflected the most damaging insomnia subtype and had a negative impact on a wide range of daytime functioning consequences. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Leger, Damien; Touchette, Evelyne] Univ Paris 05, APHP, Ctr Sommeil & Vigilance, Hotel Dieu Paris, F-75181 Paris 04, France.
[Partinen, Markku] Rinnekoti Res Ctr, Skogby Sleep Clin, Espoo, Finland.
[Hirshkowitz, Max] VA Med Ctr, Sleep Disorders & Res Ctr, Houston, TX USA.
[Chokroverty, Sudhansu] JFK Med Ctr, New Jersey Neurosci Inst, Edison, NJ USA.
[Hedner, Jan] Sahlgrens Univ Hosp, Dept Resp Med & Allergol, Sleep Lab Unit, Gothenburg, Sweden.
RP Leger, D (reprint author), Univ Paris 05, APHP, Ctr Sommeil & Vigilance, Hotel Dieu Paris, 1 Pl Parvis Notre Dame, F-75181 Paris 04, France.
EM damien.leger@htd.aphp.fr
RI Touchette, Evelyne/A-3592-2013
OI Touchette, Evelyne/0000-0002-0557-9352
FU Sanofi-Aventis
FX This survey has been supported by Sanofi-Aventis. All authors have been
sponsored to design the protocol and review the data as a scientific
advisory board.
NR 31
TC 11
Z9 14
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1389-9457
J9 SLEEP MED
JI Sleep Med.
PD DEC
PY 2010
VL 11
IS 10
SI SI
BP 999
EP 1009
DI 10.1016/j.sleep.2010.04.018
PG 11
WC Clinical Neurology
SC Neurosciences & Neurology
GA 704AD
UT WOS:000286022600007
PM 20965779
ER
PT J
AU Livingston, JD
Boyd, JE
AF Livingston, James D.
Boyd, Jennifer E.
TI Correlates and consequences of internalized stigma for people living
with mental illness: A systematic review and meta-analysis
SO SOCIAL SCIENCE & MEDICINE
LA English
DT Review
DE Stigma; Mental illness; Meta-analysis; Systematic review
ID QUALITY-OF-LIFE; SCHIZOPHRENIA SPECTRUM DISORDERS; MODIFIED LABELING
THEORY; DEPRESSION SELF-STIGMA; PRIMARY-CARE PATIENTS; STRESS-COPING
MODEL; PERCEIVED STIGMA; HEALTH-SERVICES; SOCIAL ANXIETY; PSYCHIATRIC
OUTPATIENTS
AB An expansive body of research has investigated the experiences and adverse consequences of internalized stigma for people with mental illness. This article provides a systematic review and meta-analysis of the extant research regarding the empirical relationship between internalized stigma and a range of sociodemographic, psychosocial, and psychiatric variables for people who live with mental illness. An exhaustive review of the research literature was performed on all articles published in English that assessed a statistical relationship between internalized stigma and at least one other variable for adults who live with mental illness. In total, 127 articles met the inclusion criteria for systematic review, of which, data from 45 articles were extracted for meta-analyses. None of the sociodemographic variables that were included in the study were consistently or strongly correlated with levels of internalized stigma. The review uncovered a striking and robust negative relationship between internalized stigma and a range of psychosocial variables (e.g., hope, self-esteem, and empowerment). Regarding psychiatric variables, internalized stigma was positively associated with psychiatric symptom severity and negatively associated with treatment adherence. The review draws attention to the lack of longitudinal research in this area of study which has inhibited the clinical relevance of findings related to internalized stigma. The study also highlights the need for greater attention on disentangling the true nature of the relationship between internalized stigma and other psychosocial variables. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Livingston, James D.] Prov Hlth Serv Author, BC Mental Hlth Serv, Forens Psychiat Serv Commiss, Port Coquitlam, BC V3C 5X9, Canada.
[Livingston, James D.] Prov Hlth Serv Author, Addict Serv, Forens Psychiat Serv Commiss, Port Coquitlam, BC V3C 5X9, Canada.
[Livingston, James D.] Simon Fraser Univ, Sch Criminol, Burnaby, BC V5A 1S6, Canada.
[Boyd, Jennifer E.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Boyd, Jennifer E.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
RP Livingston, JD (reprint author), Prov Hlth Serv Author, BC Mental Hlth Serv, Forens Psychiat Serv Commiss, 70 Colony Farm Rd, Port Coquitlam, BC V3C 5X9, Canada.
EM jlivingston@forensic.bc.ca
NR 171
TC 286
Z9 299
U1 16
U2 130
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0277-9536
J9 SOC SCI MED
JI Soc. Sci. Med.
PD DEC
PY 2010
VL 71
IS 12
BP 2150
EP 2161
DI 10.1016/j.socscimed.2010.09.030
PG 12
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA 702RN
UT WOS:000285912300013
PM 21051128
ER
PT J
AU Smith, MW
Chen, S
Siroka, AM
Hamlett-Berry, K
AF Smith, Mark W.
Chen, Shuo
Siroka, Andrew M.
Hamlett-Berry, Kim
TI Using policy to increase prescribing of smoking cessation medications in
the VA healthcare system
SO TOBACCO CONTROL
LA English
DT Article
ID TOBACCO-DEPENDENCE TREATMENT; SUSTAINED-RELEASE BUPROPION; NICOTINE
PATCH; SERVICES; LESSONS
AB Background Since 2002 the US Veterans Affairs (VA) healthcare system has initiated national policies and programmes to reduce smoking among its patients and to increase evidence-based treatment for smoking.
Objective To document changes in dispensing rates of cessation-related medications in VA from 2004 to 2008.
Design Retrospective analysis of VA administrative data.
Results Prescription fills for nicotine replacement therapy (NAT), and for bupropion among NAT users, each grew more than 60% in four years. The increase stemmed primarily from treating more people rather than from filling more prescriptions per person.
Conclusion The results provide strong support for the efficacy of these policies and illustrate how healthcare systems can successfully employ multiple strategies to increase evidence-based smoking-cessation treatment.
C1 [Smith, Mark W.; Chen, Shuo; Siroka, Andrew M.] Vet Affairs Palo Alto Hlth Care Syst, Hlth Econ Resource Ctr, Menlo Pk, CA USA.
[Smith, Mark W.] Stanford Med Sch, Ctr Primary Care & Outcomes Res, Stanford, CA USA.
[Hamlett-Berry, Kim] US Dept Vet Affairs, Publ Hlth Strateg Hlth Care Grp, Off Publ Hlth Policy & Prevent, Washington, DC USA.
RP Smith, MW (reprint author), VA Palo Alto Hlth Care Syst 650 617 2630, Hlth Econ Resource Ctr, 795 Willow Rd,152 MPD, Menlo Pk, CA 94025 USA.
EM mark.smith9@va.gov
RI Smith, Mark/G-1522-2012
OI Smith, Mark/0000-0002-4582-9088
FU Clinical Science Research and Development Service, US Department of
Veterans Affairs [519]
FX Funding was provided by the Cooperative Studies Program of the Clinical
Science Research and Development Service, US Department of Veterans
Affairs (CSP #519). The views expressed here are those of the authors
and riot necessarily those of the US Department of Veterans Affairs.
NR 27
TC 8
Z9 8
U1 1
U2 1
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0964-4563
J9 TOB CONTROL
JI Tob. Control
PD DEC
PY 2010
VL 19
IS 6
BP 507
EP 511
DI 10.1136/tc.2009.035147
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 681WI
UT WOS:000284353800020
PM 20870742
ER
PT J
AU Morgan, KL
Estevez, AO
Mueller, CL
Cacho-Valadez, B
Miranda-Vizuete, A
Szewczyk, NJ
Estevez, M
AF Morgan, Kathleen L.
Estevez, Annette O.
Mueller, Catherine L.
Cacho-Valadez, Briseida
Miranda-Vizuete, Antonio
Szewczyk, Nathaniel J.
Estevez, Miguel
TI The Glutaredoxin GLRX-21 Functions to Prevent Selenium-Induced Oxidative
Stress in Caenorhabditis elegans
SO TOXICOLOGICAL SCIENCES
LA English
DT Article
DE selenium; antioxidant; toxicity; glutaredoxin; glutathione; glrx-21
ID AMYOTROPHIC-LATERAL-SCLEROSIS; THIOREDOXIN REDUCTASE; REDUCED
GLUTATHIONE; CANCER PREVENTION; SODIUM SELENITE; AQUATIC BIRDS;
DNA-DAMAGE; CELL-DEATH; C-ELEGANS; TOXICITY
AB Selenium is an essential micronutrient that functions as an antioxidant. Yet, at higher concentrations, selenium is pro-oxidant and toxic. In extreme cases, exposures to excess selenium can lead to death or selenosis, a syndrome characterized by teeth, hair and nail loss, and nervous system alterations. Recent interest in selenium as an anti- tumorigenic agent has reemphasized the need to understand the mechanisms underlying the cellular consequences of increased selenium exposure. We show here, that in the nematode, Caenorhabditis elegans, selenium has a concentration range in which it functions as an antioxidant, but beyond this range it exhibits a dose- and time-dependent lethality. Oxidation-induced fluorescence emitted by the dye, carboxy-H(2)DCFDA, indicative of reactive oxygen species formation was significantly higher in animals after a brief exposure to 5mM sodium selenite. Longer-term exposures lead to a progressive selenium-induced motility impairment that could be partially prevented by coincident exposure to the cellular antioxidant-reduced glutathione. The C elegans glrx-21 gene belongs to the family of glutaredoxins (glutathione-dependent oxidoreductases) and the glrx-21(tm2921) allele is a null mutation that renders animals hypersensitive for the selenium-induced motility impairment, but not lethality. In addition, the lethality of animals with the tm2921 mutation exposed to selenium was unaffected by the addition of reduced glutathione, suggesting that GLRX-21 is required for glutathione to moderate this selenium-induced lethality. Our findings provide the first description of selenium-induced toxicity in C elegans and support its use as a model for elucidating the mechanisms of selenium toxicity.
C1 [Morgan, Kathleen L.; Estevez, Miguel] Vet Affairs Pittsburgh Healthcare Syst, Res & Dev 151U, Dept Neurol, Pittsburgh, PA 15240 USA.
[Morgan, Kathleen L.; Estevez, Annette O.; Mueller, Catherine L.; Estevez, Miguel] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA.
[Cacho-Valadez, Briseida; Miranda-Vizuete, Antonio] Univ Pablo de Olavide, CSIC, CABD, Seville 41013, Spain.
[Cacho-Valadez, Briseida; Miranda-Vizuete, Antonio] Univ Pablo de Olavide, Dept Fisiol Anat & Biol Celular, Seville 41013, Spain.
[Miranda-Vizuete, Antonio] Univ Seville, CSIC, Hosp Univ Virgen del Rocio, Inst Biomed Sevilla, Seville 41013, Spain.
[Szewczyk, Nathaniel J.] Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA.
RP Estevez, M (reprint author), Univ Arizona, Dept Neurol, 1501 N Campbell Ave, Tucson, AZ 85724 USA.
EM estevezm@email.arizona.edu
RI Miranda-Vizuete, Antonio/D-6927-2012; IBIS, FISIOLOGIA/O-9485-2015
OI Miranda-Vizuete, Antonio/0000-0002-6856-5396; Szewczyk,
Nathaniel/0000-0003-4425-9746
FU Office of Research and Development, Department of Veterans Affairs;
National Institutes of Environmental Health Sciences [R21-ES012305];
Arthritis and Musculoskeletal and Skin Diseases [R01-AR054342];
Instituto de Salud Carlos III [PI050065, PI080557]; Fondo Social
Europeo, FEDER; Junta de Andalucia, Spain [P07-CVI-02697,
P08-CVI-03629]; CONACYT, Mexico
FX This work was supported by a Career Development Award (M. E.) provided
through the Office of Research and Development, Department of Veterans
Affairs, the National Institutes of Environmental Health Sciences
(R21-ES012305 to A. E. and M. E.) and Arthritis and Musculoskeletal and
Skin Diseases (R01-AR054342 to N.J.S.), the Instituto de Salud Carlos
III (Projects PI050065 and PI080557, co-financed with the Fondo Social
Europeo, FEDER) and Junta de Andalucia (Projects P07-CVI-02697 and
P08-CVI-03629), Spain (A. M.-V.) and a predoctoral fellowship from
CONACYT, Mexico (B.C.-V.).
NR 90
TC 20
Z9 24
U1 2
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1096-6080
J9 TOXICOL SCI
JI Toxicol. Sci.
PD DEC
PY 2010
VL 118
IS 2
BP 530
EP 543
DI 10.1093/toxsci/kfq273
PG 14
WC Toxicology
SC Toxicology
GA 682WB
UT WOS:000284432600019
PM 20833709
ER
PT J
AU De Gasperi, R
Sosa, MAG
Naumowicz, Z
Hof, PR
Notterpek, L
Davis, KL
Buxbaum, JD
Elder, GA
AF De Gasperi, Rita
Sosa, Miguel A. Gama
Naumowicz, Zuzanna
Hof, Patrick R.
Notterpek, Lucia
Davis, Kenneth L.
Buxbaum, Joseph D.
Elder, Gregory A.
TI PERIPHERAL MYELIN PROTEIN-22 IS EXPRESSED IN CNS MYELIN
SO TRANSLATIONAL NEUROSCIENCE
LA English
DT Article
DE Myelin; Peripheral myelin protein-22; Schizophrenia
AB Myelin abnormalities exist in schizophrenia leading to the hypothesis that oligodendrocyte dysfunction plays a role in the pathophysiology of the disease. The expression of the mRNA for the peripheral myelin protein-22 (PMP-22) is decreased in schizophrenia and recent genetic evidence suggests a link between PMP-22 and schizophrenia. While PMP-22 mRNA is found in both rodent and human brain it has been generally thought that no protein expression occurs. Here we show that PMP-22 protein is present in myelin isolated from adult mouse and human brain. These results suggest that PMP-22 protein likely plays a role in the maintenance and function of central nervous system (CNS) myelin and provide an explanation for why altered PMP-22 expression may be pathophysiologically relevant in a CNS disorder such as schizophrenia.
C1 [De Gasperi, Rita; Elder, Gregory A.] James J Peters Dept Vet Affairs Med Ctr, Neurol Serv, Bronx, NY 10468 USA.
[De Gasperi, Rita; Sosa, Miguel A. Gama; Naumowicz, Zuzanna; Davis, Kenneth L.; Buxbaum, Joseph D.; Elder, Gregory A.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
[Hof, Patrick R.; Buxbaum, Joseph D.] Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA.
[Hof, Patrick R.] Mt Sinai Sch Med, Dept Geriatr & Palliat Care, New York, NY 10029 USA.
[Buxbaum, Joseph D.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY 10029 USA.
[Elder, Gregory A.] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA.
[Notterpek, Lucia] Univ Florida, Coll Med, McKnight Brain Inst, Dept Neurosci, Gainesville, FL 32610 USA.
RP De Gasperi, R (reprint author), James J Peters Dept Vet Affairs Med Ctr, Neurol Serv, Bronx, NY 10468 USA.
EM gregory.elder@mssm.edu
OI Buxbaum, Joseph/0000-0001-8898-8313
FU Mount Sinai Silvio Conte Neuroscience Center (NIH) [P50 MH36692]
FX This research was supported by the Mount Sinai Silvio Conte Neuroscience
Center (NIH grant P50 MH36692). We thank Dr. Vahram Haroutunian for
providing frozen samples of postmortem human brain.
NR 21
TC 5
Z9 5
U1 0
U2 3
PU VERSITA
PI WARSAW
PA SOLIPSKA 14A-1, 02-482 WARSAW, POLAND
SN 2081-3856
J9 TRANSL NEUROSCI
JI Transl. Neurosci.
PD DEC
PY 2010
VL 1
IS 4
BP 282
EP 285
DI 10.2478/v10134-010-0038-3
PG 4
WC Neurosciences
SC Neurosciences & Neurology
GA V20QA
UT WOS:000208153300004
PM 21572910
ER
PT J
AU Sun, HY
Shields, RK
Cacciarelli, TV
Muder, RR
Singh, N
AF Sun, H. -Y.
Shields, R. K.
Cacciarelli, T. V.
Muder, R. R.
Singh, N.
TI A novel combination regimen for the treatment of refractory bacteremia
due to multidrug-resistant Pseudomonas aeruginosa in a liver transplant
recipient
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article
DE multidrug resistant; Pseudomonas aeruginosa; liver transplant; biliary
cast syndrome; combination regimen
ID BILIARY CAST SYNDROME; GRAM-NEGATIVE BACILLI; BLOOD-STREAM INFECTIONS;
BETA-LACTAM MONOTHERAPY; ACINETOBACTER-BAUMANNII; INTRAVENOUS COLISTIN;
MOUSE MODEL; THERAPY; METAANALYSIS; RIFAMPIN
AB P>Both bacteremia and biliary cast syndrome are serious post-transplant complications in liver transplant recipients. In the setting of increasing drug resistance in the current era, management of infections caused by multidrug-resistant (MDR) bacteria has proven challenging. We present a case of a liver transplant recipient who developed biliary cast syndrome and intractable MDR Pseudomonas bacteremia that failed to resolve with conventional antimicrobial therapy and which was finally controlled by a novel combination regimen of colistimethate, doripenem, and tobramycin. Future studies validating the clinical efficacy of this combination strategy are warranted.
C1 [Sun, H. -Y.; Cacciarelli, T. V.; Muder, R. R.; Singh, N.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Sun, H. -Y.] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan.
[Sun, H. -Y.] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan.
[Shields, R. K.; Muder, R. R.; Singh, N.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
[Shields, R. K.] Univ Pittsburgh, Med Ctr, Antibiot Management Program, Pittsburgh, PA USA.
[Cacciarelli, T. V.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15260 USA.
RP Singh, N (reprint author), VA Med Ctr, Infect Dis Sect, Univ Dr C, Pittsburgh, PA 15240 USA.
EM nis5@pitt.edu
OI SUN, HSIN-YUN/0000-0003-0074-7721
NR 44
TC 11
Z9 11
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1398-2273
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
PD DEC
PY 2010
VL 12
IS 6
BP 555
EP 560
DI 10.1111/j.1399-3062.2010.00543.x
PG 6
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA 689BS
UT WOS:000284902900014
PM 20626709
ER
PT J
AU Schneeberger, S
Amberger, A
Mandl, J
Hautz, T
Renz, O
Obrist, P
Meusburger, H
Brandacher, G
Mark, W
Strobl, D
Troppmair, J
Pratschke, J
Margreiter, R
Kuznetsov, AV
AF Schneeberger, Stefan
Amberger, Albert
Mandl, Julia
Hautz, Theresa
Renz, Oliver
Obrist, Peter
Meusburger, Hugo
Brandacher, Gerald
Mark, Walter
Strobl, Daniela
Troppmair, Jakob
Pratschke, Johann
Margreiter, Raimund
Kuznetsov, Andrey V.
TI Cold ischemia contributes to the development of chronic rejection and
mitochondrial injury after cardiac transplantation
SO TRANSPLANT INTERNATIONAL
LA English
DT Article
DE cardiac transplantation; chronic rejection; cold ischemia; mitochondrial
function; respirometry
ID CORONARY-ARTERY-DISEASE; REAL-TIME PCR; HEART-TRANSPLANTATION;
ALLOGRAFT-REJECTION; REPERFUSION INJURY; MUSCLE-FIBERS; MINIMUM
INFORMATION; MICROARRAY DATA; RAT-HEART; MODEL
AB P>Chronic rejection (CR) remains an unsolved hurdle for long-term heart transplant survival. The effect of cold ischemia (CI) on progression of CR and the mechanisms resulting in functional deficit were investigated by studying gene expression, mitochondrial function, and enzymatic activity. Allogeneic (Lew -> F344) and syngeneic (Lew -> Lew) heart transplantations were performed with or without 10 h of CI. After evaluation of myocardial contraction, hearts were excised at 2, 10, 40, and 60 days for investigation of vasculopathy, gene expression, enzymatic activities, and mitochondrial respiration. Gene expression studies identified a gene cluster coding for subunits of the mitochondrial electron transport chain regulated in response to CI and CR. Myocardial performance, mitochondrial function, and mitochondrial marker enzyme activities declined in all allografts with time after transplantation. These declines were more rapid and severe in CI allografts (CR-CI) and correlated well with progression of vasculopathy and fibrosis. Mitochondria related gene expression and mitochondrial function are substantially compromised with the progression of CR and show that CI impacts on progression, gene profile, and mitochondrial function of CR. Monitoring mitochondrial function and enzyme activity might allow for earlier detection of CR and cardiac allograft dysfunction.
C1 [Schneeberger, Stefan; Hautz, Theresa; Renz, Oliver; Meusburger, Hugo; Brandacher, Gerald; Mark, Walter; Strobl, Daniela; Troppmair, Jakob; Pratschke, Johann; Margreiter, Raimund; Kuznetsov, Andrey V.] Innsbruck Med Univ, Daniel Swarovski Res Lab, Ctr Operat Med, Dept Visceral Transplant & Thorac Surg, A-6020 Innsbruck, Austria.
[Schneeberger, Stefan; Brandacher, Gerald] UPMC, Div Plast Surg, Dept Surg, Pittsburgh, PA USA.
[Schneeberger, Stefan] VA Univ Dr, Dept Surg, Pittsburgh, PA USA.
[Schneeberger, Stefan] VA Pittsburgh Healthcare Syst, Univ Dr Div, Dept Surg, Pittsburgh, PA USA.
[Amberger, Albert; Mandl, Julia] Innsbruck Med Univ, Tyrolean Canc Res Inst, A-6020 Innsbruck, Austria.
[Obrist, Peter] St Vinzenz Hosp Zams, Dept Pathol, Zams, Austria.
[Kuznetsov, Andrey V.] Innsbruck Med Univ, Cardiac Surg Res Lab, Dept Cardiac Surg, Ctr Operat Med, A-6020 Innsbruck, Austria.
RP Schneeberger, S (reprint author), Innsbruck Med Univ, Daniel Swarovski Res Lab, Ctr Operat Med, Dept Visceral Transplant & Thorac Surg, Anichstr 35, A-6020 Innsbruck, Austria.
EM stefan.schneeberger@i-med.ac.at
RI Brandacher, Gerald/L-7540-2016
FU Austrian Cancer Society/Tyrol; Medizinischer Forschungsfonds Tirol (MFF)
[23]; Tiroler Versicherungen; Hypo Bank Tirol
FX This work was supported by the Austrian Cancer Society/Tyrol, the
Medizinischer Forschungsfonds Tirol (MFF, grant #. 23) and unrestricted
educational grants from the 'Tiroler Versicherungen' and the 'Hypo Bank
Tirol' awarded to Stefan Schneeberger.
NR 43
TC 6
Z9 7
U1 0
U2 2
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0934-0874
J9 TRANSPL INT
JI Transpl. Int.
PD DEC
PY 2010
VL 23
IS 12
BP 1282
EP 1292
DI 10.1111/j.1432-2277.2010.01126.x
PG 11
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 678JN
UT WOS:000284070000011
PM 20561305
ER
PT J
AU Orloff, MJ
Isenberg, JI
Wheeler, HO
Haynes, KS
Jinich-Brook, H
Rapier, R
Vaida, F
Hye, RJ
Orloff, SL
AF Orloff, M. J.
Isenberg, J. I.
Wheeler, H. O.
Haynes, K. S.
Jinich-Brook, H.
Rapier, R.
Vaida, F.
Hye, R. J.
Orloff, S. L.
TI Liver Transplantation in a Randomized Controlled Trial of Emergency
Treatment of Acutely Bleeding Esophageal Varices in Cirrhosis
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 23rd International Congress of the-Transplantation-Society
CY AUG 15-19, 2010
CL Vancouver, CANADA
SP Transplantat Soc
ID PORTOSYSTEMIC STENT-SHUNT; PRIOR PORTASYSTEMIC SHUNT; PORTACAVAL-SHUNT;
PORTAL-HYPERTENSION; CONSORT STATEMENT; HEMORRHAGE; SURVIVAL;
ENCEPHALOPATHY; MANAGEMENT; SCLEROTHERAPY
AB Background. Bleeding esophageal varices (BEV) in cirrhosis has been considered an indication for liver transplantation (LT). This issue was examined in a randomized controlled trial (ROT) of unselected, consecutive patients with advanced cirrhosis and BEV that compared endoscopic sclerotherapy (EST; n = 106) to emergency direct portacaval shunt (EPCS; n = 105).
Methods. Diagnostic work-up and treatment were initiated within 8 hours. Patients were evaluated for LT on admission and repeatedly thereafter; 96% underwent over 10 years of regular follow-up. The analysis was supplemented by 1300 unrandomized cirrhotic patients who previously underwent portacaval shunt (PCS) with 100% follow-up.
Results. In the RCT long-term bleeding control was 100% following EPCS, only 20% following EST. Also, 3-, 5-, 10-, and 15-year survival rates were 75%, 73%, 46%, and 46%, respectively, following EPCS compared with 44%, 21%, 9%, and 9% following EST, respectively (P <.001). Only 13 RCT patients (6%) were ultimately referred for LT mainly because of progressive liver failure; only 7 (3%) were approved for LT and only 4 (2%) underwent LT. The 1- and 5-year LT survival rates were 0.68% and 0, respectively, compared with 81% and 73%, respectively, after EPCS. In the 1300 unrandomized PCS patients, 50 (3.8%) were referred and 19 (1.5%) underwent LT. The 5-year survival rate was 53% compared with 72% for all 1300 patients.
Conclusions. If bleeding is permanently controlled, as occurred invariably following EPCS, cirrhotic patients with BEV seldom require LT. PCS is effective first-line and long-term treatment. Should LT be required in patients with PCS, although technically more demanding, numerous studies have shown that PCS does not increase mortality or complications. EST is not effective emergency or long-term therapy.
C1 [Orloff, M. J.; Hye, R. J.] UCSD Med Ctr, Dept Surg, San Diego, CA 92103 USA.
[Isenberg, J. I.; Wheeler, H. O.; Haynes, K. S.; Jinich-Brook, H.; Rapier, R.] UCSD Med Ctr, Dept Med Gastroenterol, San Diego, CA 92103 USA.
[Vaida, F.] UCSD Med Ctr, Dept Family & Prevent Med Biostat & Bioinformat, San Diego, CA 92103 USA.
[Orloff, S. L.] Oregon Hlth & Sci Univ, Dept Surg, Div Abdominal Organ Transplantat, Portland, OR 97201 USA.
[Orloff, S. L.] Portland VA Med Ctr, Portland, OR USA.
RP Orloff, MJ (reprint author), UCSD Med Ctr, Dept Surg, 200 W Arbor Dr, San Diego, CA 92103 USA.
EM morloff@ucsd.edu
OI Hye, Robert/0000-0002-7733-6173
FU NIDDK NIH HHS [R01 DK041920, R01 DK041920-07]; PHS HHS
[234-2005-370011C]
NR 47
TC 8
Z9 8
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD DEC
PY 2010
VL 42
IS 10
BP 4101
EP 4108
DI 10.1016/j.transproceed.2010.09.035
PG 8
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 700IQ
UT WOS:000285732200054
PM 21168637
ER
PT J
AU Chen, DH
Sul, Y
Weiss, M
Hillel, A
Lipe, H
Wolff, J
Matsushita, M
Raskind, W
Bird, T
AF Chen, D. -H.
Sul, Y.
Weiss, M.
Hillel, A.
Lipe, H.
Wolff, J.
Matsushita, M.
Raskind, W.
Bird, T.
TI CMT2C with vocal cord paresis associated with short stature and
mutations in the TRPV4 gene
SO NEUROLOGY
LA English
DT Article
ID SPINAL MUSCULAR-ATROPHY; MARIE-TOOTH DISEASE; SENSORY NEUROPATHY;
HEREDITARY MOTOR; LOCALIZATION; DISORDERS; SPECTRUM; HMSN2C; TYPE-2
AB Background: Recently, mutations in the transient receptor potential cation channel, subfamily V, member 4 gene (TRPV4) have been reported in Charcot-Marie-Tooth Type 2C (CMT2C) with vocal cord paresis. Other mutations in this same gene have been described in separate families with various skeletal dysplasias. Further clarification is needed of the different phenotypes associated with this gene.
Methods: We performed clinical evaluation, electrophysiology, and genetic analysis of the TRPV4 gene in 2 families with CMT2C.
Results: Two multigenerational families had a motor greater than sensory axonal neuropathy associated with variable vocal cord paresis. The vocal cord paresis varied from absent to severe, requiring permanent tracheotomy in 2 subjects. One family with mild neuropathy also manifested pronounced short stature, more than 2 SD below the average height for white Americans. There was one instance of dolichocephaly. A novel S542Y mutation in the TRPV4 gene was identified in this family. The other family had a more severe, progressive, motor neuropathy with sensory loss, but less remarkable short stature and an R315W mutation in TRPV4. Third cranial nerve involvement and sleep apnea occurred in one subject in each family.
Conclusion: CMT2C with axonal neuropathy, vocal cord paresis, and short stature is a unique syndrome associated with mutations in the TRPV4 gene. Mutations in TRPV4 can cause abnormalities in bone, peripheral nerve, or both and may result in highly variable orthopedic and neurologic phenotypes. Neurology (R) 2010;75:1968-1975
C1 [Chen, D. -H.; Weiss, M.; Bird, T.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA.
[Sul, Y.; Matsushita, M.; Raskind, W.; Bird, T.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
[Hillel, A.] Univ Washington, Sch Med, Dept Otolaryngol, Seattle, WA 98195 USA.
[Raskind, W.; Bird, T.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Lipe, H.; Wolff, J.; Bird, T.] VA Puget Sound Hlth Care Syst, Res Educ Ctr, Geriatr, Seattle, WA USA.
[Lipe, H.; Wolff, J.; Bird, T.] VA Puget Sound Hlth Care Syst, Ctr Clin, Geriatr, Seattle, WA USA.
[Raskind, W.] VA Puget Sound Hlth Care Syst, Ctr Clin, Mental Illness, Seattle, WA USA.
[Raskind, W.] VA Puget Sound Hlth Care Syst, Res Educ Ctr, Mental Illness, Seattle, WA USA.
RP Bird, T (reprint author), 1660 S Columbian Way,S-182 GRECC, Seattle, WA 98108 USA.
EM tomnroz@uw.edu
FU Athena Diagnostics, Inc.; Department of Veterans Affairs Merit Review;
NIH [R01 NS069719, R01 HD054562, HD054562, RC1 AG035681, RC2 HG005608,
R01 AG033693, P50 HD055782, AG005136, R01 MH069867]; Seattle Puget Sound
Veterans Affairs Mental Illness Research, Education and Clinical Center;
Puget Sound Veterans Affairs Medical Center; Department of Veterans
Affairs; Springer-Verlag GmbH Biomedical Sciences
FX Dr. Chen receives licensing fees for PKCgamma in diagnosis of SCA14 from
Athena Diagnostics, Inc. Ms. Sul reports no disclosures. Dr. Weiss has
received speaker honoraria from Athena Diagnostics, Inc., and Talecris
Biotherapeutics; serves on the editorial boards of Muscle and Nerve and
the Journal of Clinical Neuromuscular Disease; has served as a
consultant for Genzyme Corporation and for Washington State Department
of Labor and Industries; and serves on the speakers' bureau for Athena
Diagnostics, Inc. Dr. Hillel reports no disclosures. Ms. Lipe receives
research support from a Department of Veterans Affairs Merit Review
Grant. Mr. Wolff reports no disclosures. Mr. Matsushita receives
research support from the NIH (R01 NS069719 [technician] and R01
HD054562 [technician]), and from the Seattle Puget Sound Veterans
Affairs Mental Illness Research, Education and Clinical Center. Dr.
Raskind serves on the editorial boards of the American Journal of
Medical Genetics (Neuropsychiatric Genetics Section); the Journal of
Learning Disabilities, The Open Genomics Journal, and
Neuropsychopharmacology; receives licensing fees for PKCgamma in
diagnosis of SCA14 from Athena Diagnostics, Inc.; receives research
support from the NIH (R01 NS069719 [PI], HD054562 [PI], RC1 AG035681
[PI], RC2 HG005608 [PI], R01 AG033693 [coinvestigator], and P50 HD055782
[coinvestigator]) and from the Puget Sound Veterans Affairs Medical
Center; and her spouse serves on the editorial boards of the Journal of
Geriatric Psychiatry and Neurology, Alzheimer Disease and Associated
Disorders: An International Journal, and the European Neurological
Journal; receives research support from the NIH (AG005136 and R01
MH069867) and from the Department of Veterans Affairs; and served as an
expert witness on behalf of Johnson & Johnson on galantamine patent
case. Dr. Bird serves on scientific advisory boards for the Association
for Frontotemporal Dementia and the CMT Association; has received
funding for travel and speaker honoraria from Athena Diagnostics, Inc.;
serves on the editorial boards of Brain and Neurology Today; is listed
as a co-inventor on and receives license fees from Athena Diagnostics,
Inc. for patents re: PKCgamma in diagnosis of SCA14 and Mutations
Associated With A Human Demyelinating Neuropathy (Charcot-Marie-Tooth
Disease Type 1C); receives royalties from the publication of Human
Genetics: Principles and Approaches, 4th ed. (Springer-Verlag GmbH
Biomedical Sciences, 2010); serves on the speakers' bureau for Athena
Diagnostics, Inc.; and receives research support from the Department of
Veterans Affairs.
NR 26
TC 33
Z9 34
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD NOV 30
PY 2010
VL 75
IS 22
BP 1968
EP 1975
DI 10.1212/WNL.0b013e3181ffe4bb
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA 686GW
UT WOS:000284685800009
PM 21115951
ER
PT J
AU Cheng, EM
Tonn, S
Swain-Eng, R
Factor, SA
Weiner, WJ
Bever, CT
AF Cheng, E. M.
Tonn, S.
Swain-Eng, R.
Factor, S. A.
Weiner, W. J.
Bever, C. T., Jr.
CA Amer Acad Neurology Parkinson Dis
TI Quality improvement in neurology: AAN Parkinson disease quality measures
Report of the Quality Measurement and Reporting Subcommittee of the
American Academy of Neurology
SO NEUROLOGY
LA English
DT Article
ID MOVEMENT-DISORDER SOCIETY; JOINT TASK-FORCE; STANDARDS SUBCOMMITTEE;
PRACTICE PARAMETER; OF-NEUROLOGY; THERAPEUTIC MANAGEMENT; PHYSICIAN
PERFORMANCE; EUROPEAN FEDERATION; INVITED ARTICLE; HEALTH
AB Background: Measuring the quality of health care is a fundamental step toward improving health care and is increasingly used in pay-for-performance initiatives and maintenance of certification requirements. Measure development to date has focused on primary care and common conditions such as diabetes; thus, the number of measures that apply to neurologic care is limited. The American Academy of Neurology (AAN) identified the need for neurologists to develop measures of neurologic care and to establish a process to accomplish this.
Objective: To adapt and test the feasibility of a process for independent development by the AAN of measures for neurologic conditions for national measurement programs.
Methods: A process that has been used nationally for measure development was adapted for use by the AAN. Topics for measure development are chosen based upon national priorities, available evidence base from a systematic literature search, gaps in care, and the potential impact for quality improvement. A panel composed of subject matter and measure development methodology experts oversees the development of the measures. Recommendation statements and their corresponding level of evidence are reviewed and considered for development into draft candidate measures. The candidate measures are refined by the expert panel during a 30-day public comment period and by review by the American Medical Association for Current Procedural Terminology (CPT) II codes. All final AAN measures are approved by the AAN Board of Directors.
Results: Parkinson disease (PD) was chosen for measure development. A review of the medical literature identified 258 relevant recommendation statements. A 28-member panel approved 10 quality measures for PD that included full specifications and CPT II codes.
Conclusion: The AAN has adapted a measure development process that is suitable for national measurement programs and has demonstrated its capability to independently develop quality measures. Neurology (R) 2010;75:2021-2027
C1 [Tonn, S.; Swain-Eng, R.] Amer Acad Neurol, St Paul, MN 55116 USA.
[Cheng, E. M.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA.
[Cheng, E. M.] VA Greater Angeles, Dept Neurol, Los Angeles, CA USA.
[Factor, S. A.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA.
[Weiner, W. J.; Bever, C. T., Jr.] Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA.
[Bever, C. T., Jr.] VA Maryland Hlth Care Syst, Res Serv, Baltimore, MD USA.
[Bever, C. T., Jr.] VA Maryland Hlth Care Syst, Dept Neurol, Baltimore, MD USA.
RP Cheng, EM (reprint author), Amer Acad Neurol, 1080 Montreal Ave, St Paul, MN 55116 USA.
EM quality@aan.com
FU NIH/NINDS [K23NS058571]; VA Parkinson's Disease Research, Education, and
Clinical Center; Department of Veterans Affairs; California Office of
Statewide Planning and Development; National Multiple Sclerosis Society;
American Heart Association; Pfizer Inc.; CDC; Parkinson's Disease
Diagnosis and Clinical Management (Demos); Drug Induced Movement
Disorders (Blackwell Futura); Teva Pharmaceutical Industries Ltd.;
Ipsen; UCB; Schering-Plough Corp.; publication of Neurology for the
Non-Neurologist; Hopkins University; Handbook of Clinical Neurology
Hyperkinetic Disorders; Novartis; Santhera Pharmaceuticals; Boehringer
Ingelheim; Abraxis BioScience, Inc.; publication of Ambulatory Medicine;
National MS Society
FX Dr. Cheng serves as a consultant for the National Parkinson Foundation
and receives research support from the NIH/NINDS (K23NS058571 [PI]), the
VA Parkinson's Disease Research, Education, and Clinical Center, the
Department of Veterans Affairs, the California Office of Statewide
Planning and Development, the National Multiple Sclerosis Society, and
the American Heart Association. Ms. Tonn is a full-time employee of the
American Academy of Neurology (AAN) and served as project director for
AAN grants from Pfizer Inc. and the CDC. Ms. Swain-Eng is a full-time
employee of the American Academy of Neurology. Dr. Factor has served on
scientific advisory boards for Lundbeck Inc., Allergan, Inc., and UCB;
serves as a section editor for Current Treatment Options in Neurology;
receives royalties from the publication of Parkinson's Disease Diagnosis
and Clinical Management (Demos, 2008) and Drug Induced Movement
Disorders (Blackwell Futura, 2005); has given expert testimony, prepared
affidavits, and served as a consultant for Boehringer Ingelheim; and
receives research support from Teva Pharmaceutical Industries Ltd.,
Ipsen, UCB, and Schering-Plough Corp. Dr. Weiner has served on
scientific advisory boards for Santhera Pharmaceuticals and Rexahn
Pharmaceuticals, Inc.; serves on the editorial boards of Parkinsonism
and Related Disorders and Neurological Reviews, and as Editor of
Treatment Options in Neurology; receives royalties from the publication
of Neurology for the Non-Neurologist (6th edition, Kluwer/Lippincott
2010), Parkinson's Disease: A Complete Guide for Patients and Family
(Hopkins University Press 2nd edition, 2007), and Handbook of Clinical
Neurology Hyperkinetic Disorders (Elsevier, 2011); has received
honoraria from Santhera Pharmaceuticals and Novartis; has received
research support from Novartis, Santhera Pharmaceuticals, Boehringer
Ingelheim, and has provided expert testimony and served as a subject
matter expert in legal proceedings. Dr. Bever serves on the editorial
board of the MS Quarterly Report; is listed as a co-inventor on and
receives royalties from Abraxis BioScience, Inc. for a pending patent
re: Use of hematogenous stem cells in neuronal replacement therapy and
gene delivery; receives royalties from the publication of Ambulatory
Medicine (Lippincott Williams & Wilkins, 7th edition, 2006); and has
received research support from the Department of Veterans Affairs and
the National MS Society.
NR 39
TC 42
Z9 43
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD NOV 30
PY 2010
VL 75
IS 22
BP 2021
EP 2027
DI 10.1212/WNL.0b013e3181ff96dd
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 686GW
UT WOS:000284685800017
PM 21115958
ER
PT J
AU Yehuda, R
Golier, JA
Bierer, LM
Mikhno, A
Pratchett, LC
Burton, CL
Makotkine, I
Devanand, DP
Pradhaban, G
Harvey, PD
Mann, JJ
AF Yehuda, Rachel
Golier, Julia A.
Bierer, Linda M.
Mikhno, Arthur
Pratchett, Laura C.
Burton, Charles L.
Makotkine, Iouri
Devanand, D. P.
Pradhaban, Gnanavalli
Harvey, Philip D.
Mann, J. John
TI Hydrocortisone responsiveness in Gulf War veterans with PTSD: Effects on
ACTH, declarative memory hippocampal [(18)F]FDG uptake on PET
SO PSYCHIATRY RESEARCH-NEUROIMAGING
LA English
DT Article
DE PTSD; Gulf War veterans; Hippocampus; Cortisol; Glucocorticoid
receptors; Episodic memory; [(18)F]FDG-PET
ID POSTTRAUMATIC-STRESS-DISORDER; MILD COGNITIVE IMPAIRMENT; CHILDHOOD
SEXUAL-ABUSE; GLUCOCORTICOID-RECEPTORS; COMBAT VETERANS;
ALZHEIMERS-DISEASE; MAJOR DEPRESSION; HOLOCAUST SURVIVORS; TRAUMA
SURVIVORS; PLASMA-CORTISOL
AB Neuroendocrine, cognitive and hippocampal alterations have been described in Gulf War (GW) veterans, but their inter-relationships and significance for posttraumatic stress disorder (PTSD) have not been described. Hydrocortisone (Hcort) was administered to GW veterans with (PTSD+ n = 12) and without (PTSD- n = 8) chronic PTSD in a randomized, placebo-controlled, double-blind challenge. Changes in plasma ACTH, memory, and hippocampal [(18)F]FDG uptake on positron emission tomography were assessed. The low-dose dexamethasone suppression test was also administered. The PTSD+ group showed greater cortisol and ACTH suppression, reflecting greater peripheral glucocorticoid receptor (GR) responsiveness, and did not show an Hcort-induced decrement in delayed recall or retention. The groups had comparable relative regional hippocampal [(18)F]FDG uptake at baseline, but only the PTSD group had an Hcort-associated decrease in hippocampal [(18)F]FDG uptake. Asymmetry in hippocampal hemispheric volumes differed between PTSD+ and PTSD- groups. This asymmetry was associated with cortisol, ACTH, retention and functional hippocampal asymmetry before, but not after, Hcort administration. Differences in brain metabolic responses between GW veterans with and without PTSD may reflect differences in peripheral and central GR responsiveness. Published by Elsevier Ireland Ltd.
C1 [Yehuda, Rachel; Golier, Julia A.; Bierer, Linda M.; Pratchett, Laura C.; Burton, Charles L.; Makotkine, Iouri] Mt Sinai Sch Med, Dept Psychiat, Traumat Stress Studies Div, New York, NY 10029 USA.
[Yehuda, Rachel; Golier, Julia A.; Bierer, Linda M.; Pratchett, Laura C.; Burton, Charles L.; Makotkine, Iouri] James J Peters Vet Affairs Med Ctr, PTSD Program, Bronx, NY USA.
[Devanand, D. P.; Pradhaban, Gnanavalli; Harvey, Philip D.] Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY USA.
[Devanand, D. P.] Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY USA.
[Mikhno, Arthur; Mann, J. John] New York State Psychiat Inst & Hosp, Dept Mol Imaging & Neuropathol, New York, NY 10032 USA.
[Devanand, D. P.; Pradhaban, Gnanavalli; Harvey, Philip D.] Columbia Univ, Coll Phys & Surg, Div Geriatr Psychiat, New York, NY USA.
[Harvey, Philip D.] Univ Miami, Miller Sch Med, Dept Psychiat & Behav Sci, Miami, FL 33136 USA.
RP Yehuda, R (reprint author), Mt Sinai Sch Med, Dept Psychiat, Traumat Stress Studies Div, New York, NY 10029 USA.
EM rachel.yehuda@va.gov
FU VA MERIT; National Center for Research Resources, National Institutes of
Health [5 MO1 RR00071]
FX This grant was primarily supported by a VA MERIT entitled
"Glucocorticoid Responsivity in Gulf War Veterans." In addition, partial
support was obtained by a grant (5 MO1 RR00071) for the Mount Sinai
General Clinical Research Center from the National Center for Research
Resources, National Institutes of Health. The authors would like to
acknowledge several colleagues for work on this project. First, thanks
to Josef Machac, M.D. and Ash Rafique, B.S. at the Mount Sinai Hospital
Clinical Neuroimaging Laboratory, to Janelle Wohltmann, B.A., Research
Coordinator, to Lisa Tischler, Ph.D., Sharon Y. Jedel, Psy.D., and Ellen
Labinsky, Ph.D. for psychological assessments of the subjects, to Ken
Belzer, Ph.D., for statistical consultation, and most of all, the Gulf
War Veterans who participated in this research.
NR 99
TC 20
Z9 20
U1 3
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0925-4927
J9 PSYCHIAT RES-NEUROIM
JI Psychiatry Res. Neuroimaging
PD NOV 30
PY 2010
VL 184
IS 2
BP 117
EP 127
DI 10.1016/j.pscychresns.2010.06.010
PG 11
WC Clinical Neurology; Neuroimaging; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 681TF
UT WOS:000284341500007
PM 20934312
ER
PT J
AU Tien, PC
Schneider, MF
Cox, C
Cohen, M
Karim, R
Lazar, J
Young, M
Glesby, MJ
AF Tien, Phyllis C.
Schneider, Michael F.
Cox, Christopher
Cohen, Mardge
Karim, Roksana
Lazar, Jason
Young, Mary
Glesby, Marshall J.
TI HIV, HAART, and lipoprotein particle concentrations in the Women's
Interagency HIV Study
SO AIDS
LA English
DT Article
DE HAART; HIV; lipids; lipoprotein particle concentrations; women
ID MAGNETIC-RESONANCE SPECTROSCOPY; REGIONAL ADIPOSE-TISSUE; ANTIRETROVIRAL
THERAPY; CARDIOVASCULAR-DISEASE; INFECTED WOMEN; HEART-DISEASE; MEN;
RISK; SIZE; HETEROGENEITY
AB Background: Changes in lipoprotein particle concentrations, especially greater small low-density lipoprotein particle (LDL-p) and lower small high-density lipoprotein particle (HDL-p) may provide information regarding cardiovascular disease (CVD) risk above and beyond that which is provided by standard lipids. We quantified the association HIV and HAART use had with LDL-p and HDL-p.
Methods: Cross-sectional study of 1077 individuals classified by HIV/HAART status (361 HIV-uninfected, 128 HIV-infected/HAART naive, 588 HIV-infected/on HAART) enrolled in the Women's Interagency HIV Study. Nuclear magnetic resonance spectroscopy estimated total and subclass lipoprotein particle concentrations. Quantile regression models were used to estimate differences in the 10th, 25th, 50th, 75th, and 90th percentiles of the distributions of lipoprotein particle concentrations between the two HIV-infected exposure groups and HIV-uninfected controls after adjustment for demographic, nonlipid metabolic factors, and standard lipids.
Results: Compared with HIV-uninfected women, those on HAART had greater 75th and 90th percentiles of small LDL-p; there was little difference between HIV-infected/HAART naive and HIV-uninfected women. After adjustment for triglycerides, the association of HAART with greater 75th and 90th percentiles of small LDL-p was attenuated and no longer significant. In contrast, after adjustment for triglycerides, HIV infection irrespective of HAART status remained associated with significantly lower 10th, 25th, 50th, 75th, and 90th percentiles of small HDL-p.
Conclusion: Our findings suggest that testing for LDL-p confers little additional information beyond triglycerides levels when assessing CVD risk. Further investigation is needed to examine the role of HDL-p in the link between HIV and CVD in women. (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
C1 [Tien, Phyllis C.] Univ Calif San Francisco, VAMC, Infect Dis Sect, Dept Med, San Francisco, CA 94121 USA.
[Tien, Phyllis C.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Schneider, Michael F.; Cox, Christopher] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Cohen, Mardge] Stroger Hosp, Dept Med, Chicago, IL USA.
[Cohen, Mardge] Rush Univ, Dept Med, Chicago, IL 60612 USA.
[Karim, Roksana] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA.
[Lazar, Jason] SUNY Hlth Sci Ctr, Dept Med, Brooklyn, NY 11203 USA.
[Young, Mary] Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20007 USA.
[Glesby, Marshall J.] Weill Cornell Med Coll, Dept Med, New York, NY USA.
RP Tien, PC (reprint author), Univ Calif San Francisco, VAMC, Infect Dis Sect, Dept Med, 111W,4150 Clement St, San Francisco, CA 94121 USA.
EM ptien@ucsf.edu
FU National Institute of Allergy and Infectious Diseases [UO1-AI-35004,
UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, UO1-AI-42590,
K23-AI-66943-04, K24-AI-078884]; Eunice Kennedy Shriver National
Institute of Child Health and Human Development [UO1-HD-32632]; National
Cancer Institute; National Institute on Drug Abuse; National Institute
on Deafness and Other Communication Disorders; National Center for
Research Resources (UCSF-CTSI ) [UL1 RR024131]
FX Data in this manuscript were collected by the WIHS Collaborative Study
Group with centers (principal investigators) at New York City/Bronx
Consortium (Kathryn Anastos); Brooklyn, New York (Howard Minkoff);
Washington DC Metropolitan Consortium (M.Y.); The Connie Wofsy Study
Consortium of Northern California (Ruth Greenblatt); Los Angeles
County/Southern California Consortium (Alexandra Levine); Chicago
Consortium (M. C.); Data Coordinating Center (Stephen Gange). The WIHS
is funded by the National Institute of Allergy and Infectious Diseases
(UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993,
and UO1-AI-42590) and by the Eunice Kennedy Shriver National Institute
of Child Health and Human Development (UO1-HD-32632). The study is
co-funded by the National Cancer Institute, the National Institute on
Drug Abuse, and the National Institute on Deafness and Other
Communication Disorders. Funding is also provided by the National Center
for Research Resources (UCSF-CTSI Grant Number UL1 RR024131). P. C. T.
and M.J.G. are supported by the National Institute of Allergy and
Infectious Diseases through K23-AI-66943-04 and K24-AI-078884,
respectively. The contents of this publication are solely the
responsibility of the authors and do not necessarily represent the
official views of the National Institutes of Health. All authors played
a role in editing the manuscript and approved the text as submitted to
AIDS. P. C. T. designed the study and wrote the manuscript. M. F. S. and
C. C. performed the data analysis and assisted in the interpretation of
statistical data. M. C., R. K., M.Y., J.L., and M.J.G. reviewed and
edited the manuscript.
NR 28
TC 9
Z9 9
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD NOV 27
PY 2010
VL 24
IS 18
BP 2809
EP 2817
DI 10.1097/QAD.0b013e32833fcb3b
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 678EU
UT WOS:000284057300007
PM 20871387
ER
PT J
AU Mandal, CC
Ghosh-Choudhury, T
Yoneda, T
Choudhury, GG
Ghosh-Choudhury, N
AF Mandal, Chandi Charan
Ghosh-Choudhury, Triparna
Yoneda, Toshi
Choudhury, Goutam Ghosh
Ghosh-Choudhury, Nandini
TI Fish oil prevents breast cancer cell metastasis to bone
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Osteolytic metastasis; DHA; EPA; Fish oil diet
ID NUDE-MICE; LUNG METASTASIS; CD44; GROWTH; PROGRESSION; EXPRESSION;
OMEGA-3-FATTY-ACIDS; HYALURONAN; TUMORS; ACID
AB The data derived from epidemiological and animal models confirm a beneficial effect of fish oil (rich in omega-3 polyunsaturated fatty acids) in the amelioration of tumor growth and progression including breast cancer The breast cancer patients often develop bone metastasis evidenced by osteolytic lesions leading to severe pain and bone fracture Using a mouse model of MDA-MB-231 human breast cancer cell metastasis to bone here we show that fish oil diet enriched in DHA (docosahexaenoic acid) and EPA (eicosapentaenoic acid) prevents the formation of osteolytic lesions in bone indicating suppression of cancer cell metastasis to bone These results are supported by our data showing both DHA and EPA significantly attenuate the migration/invasion of MDA-MB-231 breast cancer cells in culture The mechanism that limits breast cancer cells to selective metastasis to bone remains hitherto unexplored Aberrant Increased expression of CD44 is associated with generation of cancer stem cells which contribute to metastasis of breast cancer cells We demonstrate that DHA and EPA significantly inhibit the expression of CD44 protein and mRNA by a transcriptional mechanism Furthermore we show markedly reduced levels of CD44 mRNA and protein in the tumors of mice which were fed fish oil diet than those in control diet Our data provide the first evidence for a salutary effect of fish oil on breast cancer metastasis to bone Our results identify a novel function of the fish oil active components DHA and EPA which target the cell-intrinsic pro-metastatic molecule CD44 to inhibit migration/invasion Published by Elsevier Inc
C1 [Choudhury, Goutam Ghosh; Ghosh-Choudhury, Nandini] VA Res S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Mandal, Chandi Charan; Ghosh-Choudhury, Triparna; Ghosh-Choudhury, Nandini] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[Choudhury, Goutam Ghosh] S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA.
[Yoneda, Toshi; Choudhury, Goutam Ghosh] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
RP Choudhury, GG (reprint author), VA Res S Texas Vet Hlth Care Syst, San Antonio, TX USA.
FU NIH [RO1 DK50190, RO1 AR52425]; Juvenile Diabetes Research Foundation
[1-2008-185]; Cancer Therapy and Research Center University of Texas
Health Science Center at San Antonio; VA
FX NIH RO1 AR52425 VA Merit review grants and Ronald Williams Orthopedic
Award (Cancer Therapy and Research Center University of Texas Health
Science Center at San Antonio) to NGC supported this work GGC is a
recipient of VA Senior Research Career Scientist Award and is supported
by VA Research Service Merit Review grant NIH RO1 DK50190 grant and
Juvenile Diabetes Research Foundation 1-2008-185 grant
NR 34
TC 29
Z9 35
U1 5
U2 15
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD NOV 26
PY 2010
VL 402
IS 4
BP 602
EP 607
DI 10.1016/j.bbrc.2010.10.063
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 692QW
UT WOS:000285171200005
PM 20971068
ER
PT J
AU Eid, AA
Ford, BM
Block, K
Kasinath, BS
Gorin, Y
Ghosh-Choudhury, G
Barnes, JL
Abboud, HE
AF Eid, Assaad A.
Ford, Bridget M.
Block, Karen
Kasinath, Balakuntalam S.
Gorin, Yves
Ghosh-Choudhury, Goutam
Barnes, Jeffrey L.
Abboud, Hanna E.
TI AMP-activated Protein Kinase (AMPK) Negatively Regulates Nox4-dependent
Activation of p53 and Epithelial Cell Apoptosis in Diabetes
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID NADPH OXIDASES; MEMBRANE THICKNESS; PODOCYTE DEPLETION;
ENDOTHELIAL-CELLS; OXIDATIVE STRESS; SKELETAL-MUSCLE; TRANSGENIC MICE;
GLUCOSE-UPTAKE; RAT-KIDNEY; YEAST SNF1
AB Diabetes and high glucose (HG) increase the generation of NADPH oxidase-derived reactive oxygen species and induce apoptosis of glomerular epithelial cells (podocytes). Loss of podocytes contributes to albuminuria, a major risk factor for progression of kidney disease. Here, we show that HG inactivates AMP-activated protein kinase (AMPK), up-regulates Nox4, enhances NADPH oxidase activity, and induces podocyte apoptosis. Activation of AMPK blocked HG-induced expression of Nox4, NADPH oxidase activity, and apoptosis. We also identified the tumor suppressor protein p53 as a mediator of podocyte apoptosis in cells exposed to HG. Inactivation of AMPK by HG up-regulated the expression and phosphorylation of p53, and p53 acted downstream of Nox4. To investigate the mechanism of podocyte apoptosis in vivo, we used OVE26 mice, a model of type 1 diabetes. Glomeruli isolated from these mice showed decreased phosphorylation of AMPK and enhanced expression of Nox4 and p53. Pharmacologic activation of AMPK by 5-aminoimidazole-4-carboxamide-1-riboside in OVE26 mice attenuated Nox4 and p53 expression. Administration of 5-aminoimidazole-4-carboxamide-1-riboside also prevented renal hypertrophy, glomerular basement thickening, foot process effacement, and podocyte loss, resulting in marked reduction in albuminuria. Our results uncover a novel function of AMPK that integrates metabolic input to Nox4 and provide new insight for activation of p53 to induce podocyte apoptosis. The data indicate the potential therapeutic utility of AMPK activators to block Nox4 and reactive oxygen species generation and to reduce urinary albumin excretion in type 1 diabetes.
C1 [Abboud, Hanna E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, San Antonio, TX 78229 USA.
[Block, Karen; Kasinath, Balakuntalam S.; Ghosh-Choudhury, Goutam; Barnes, Jeffrey L.; Abboud, Hanna E.] Vet Affairs Res, San Antonio, TX 78229 USA.
[Ghosh-Choudhury, Goutam] S Texas Vet Healthcare Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA.
RP Abboud, HE (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, MC 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM abboud@uthscsa.edu
OI Gorin, Yves/0000-0003-4048-6925
FU National Institutes of Health [CA131272, R01 DK079996, R01 DK50190, R01
DK080106, DK-R01-078971]; George O'Brien Kidney Center [DK061597];
National Kidney Foundation; Juvenile Diabetes Research Foundation;
Veterans Affairs
FX This work was supported, in whole or in part, by National Institutes of
Health Grants CA131272 (to K. B.), R01 DK079996 (to Y. G.), R01 DK50190
(to G. G.-C.), R01 DK080106 (to J. L. B.), and DK-R01-078971 (to H. E.
A.) and George O'Brien Kidney Center-Morphology Core Grant DK061597 (to
J. L. B.). This work was also supported by a National Kidney Foundation
postdoctoral fellowship grant and a Juvenile Diabetes Research
Foundation grant (to A. A. E.), a Juvenile Diabetes Research Foundation
regular research grant (to Y. G.), and a Juvenile Diabetes Research
Foundation grant and a Veterans Affairs merit review grant (to H. E.
A.).
NR 71
TC 93
Z9 96
U1 2
U2 8
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD NOV 26
PY 2010
VL 285
IS 48
BP 37503
EP 37512
DI 10.1074/jbc.M110.136796
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 682ST
UT WOS:000284424000042
PM 20861022
ER
PT J
AU Hoang, B
Frost, P
Shi, YJ
Belanger, E
Benavides, A
Pezeshkpour, G
Cappia, S
Guglielmelli, T
Gera, J
Lichtenstein, A
AF Hoang, Bao
Frost, Patrick
Shi, Yijiang
Belanger, Eileen
Benavides, Angelica
Pezeshkpour, Gholam
Cappia, Susanna
Guglielmelli, Tommasina
Gera, Joseph
Lichtenstein, Alan
TI Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor
SO BLOOD
LA English
DT Article
ID MAMMALIAN TARGET; AKT KINASE; PHASE-I; RAPAMYCIN; CELLS;
PHOSPHORYLATION; TRANSLATION; MUTATIONS; RICTOR; DEXAMETHASONE
AB Although preclinical work with rapalogs suggests potential in treatment of multiple myeloma (MM), they have been less successful clinically. These drugs allostearically inhibit the mammalian target of rapamycin kinase primarily curtailing activity of the target of rapamycin complex (TORC)1. To assess if the mammalian target of rapamycin within the TORC2 complex could be a better target in MM, we tested a new agent, pp242, which prevents activation of TORC2 as well as TORC1. Although comparable to rapamy-cin against phosphorylation of the TORC1 substrates p70S6kinase and 4E-BP-1, pp242 could also inhibit phosphorylation of AKT on serine 473, a TORC2 substrate, while rapamycin was ineffective. pp242 was also more effective than rapamycin in achieving cytoreduction and apoptosis in MM cells. In addition, pp242 was an effective agent against primary MM cells in vitro and growth of 8226 cells in mice. Knockdown of the TORC2 complex protein, rictor, was deleterious to MM cells further supporting TORC2 as the critical target for pp242. TORC2 activation was frequently identified in primary specimens by immunostaining for AKT phosphorylation on serine 473. Potential mechanisms of up-regulated TORC2 activity in MM were stimulation with interleukin-6 or insulin-like growth factor 1, and phosphatase and tensin homolog or RAS alterations. Combining pp242 with bortezomib led to synergistic anti-MM effects. These results support TORC2 as a therapeutic target in MM. (Blood. 2010; 116(22): 4560-4568)
C1 [Hoang, Bao; Frost, Patrick; Shi, Yijiang; Belanger, Eileen; Benavides, Angelica; Gera, Joseph; Lichtenstein, Alan] Univ Calif Los Angeles, Div Hematol Oncol, Greater Los Angeles Vet Adm VA Healthcare Ctr, Los Angeles, CA USA.
[Hoang, Bao; Frost, Patrick; Shi, Yijiang; Belanger, Eileen; Benavides, Angelica; Gera, Joseph; Lichtenstein, Alan] Jonsson Comprehens Canc Ctr, Los Angeles, CA 90034 USA.
[Pezeshkpour, Gholam] Greater Los Angeles VA Healthcare Ctr, Dept Pathol, Los Angeles, CA USA.
[Pezeshkpour, Gholam] Univ So Calif, Sch Med, Los Angeles, CA USA.
[Cappia, Susanna; Guglielmelli, Tommasina] Univ Turin, Turin, Italy.
[Cappia, Susanna; Guglielmelli, Tommasina] San Luigi Hosp, Turin, Italy.
RP Lichtenstein, A (reprint author), W Los Angeles Vet Adm Hosp, W111H,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM alan.lichtenstein@med.va.gov
OI Frost, Patrick/0000-0003-3348-5983
FU National Institutes of Health [RO1 CA109312, RO1 CA111448]; Department
of Defense; Veterans Administration
FX This work was supported by National Institutes of Health grants RO1
CA109312 and RO1 CA111448 and research funds of the Department of
Defense and Veterans Administration.
NR 37
TC 61
Z9 66
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 25
PY 2010
VL 116
IS 22
BP 4560
EP 4568
DI 10.1182/blood-2010-05-285726
PG 9
WC Hematology
SC Hematology
GA 685BT
UT WOS:000284599900029
PM 20686120
ER
PT J
AU Shah, ND
Montori, VM
Krumholz, HM
Tu, K
Alexander, GC
Jackevicius, CA
AF Shah, Nilay D.
Montori, Victor M.
Krumholz, Harlan M.
Tu, Karen
Alexander, G. Caleb
Jackevicius, Cynthia A.
TI Responding to an FDA Warning - Geographic Variation in the Use of
Rosiglitazone.
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
C1 [Shah, Nilay D.; Montori, Victor M.] Mayo Clin, Knowledge & Encounter Res Unit, Rochester, MN 55905 USA.
[Krumholz, Harlan M.] Yale Univ, Sch Med, New Haven, CT USA.
[Krumholz, Harlan M.] Yale New Haven Med Ctr, New Haven, CT 06504 USA.
[Tu, Karen; Jackevicius, Cynthia A.] Univ Toronto, Toronto, ON, Canada.
[Tu, Karen] Toronto Western Hosp, Family Hlth Team, Toronto, ON M5T 2S8, Canada.
[Tu, Karen; Jackevicius, Cynthia A.] Inst Clin Evaluat Sci, Toronto, ON, Canada.
[Alexander, G. Caleb] Univ Chicago, Chicago, IL 60637 USA.
[Alexander, G. Caleb] Univ Illinois, Chicago Sch Pharm, Chicago, IL USA.
[Jackevicius, Cynthia A.] Western Univ Hlth Sci, Los Angeles, CA USA.
[Jackevicius, Cynthia A.] Vet Affairs Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA.
RP Shah, ND (reprint author), Mayo Clin, Knowledge & Encounter Res Unit, Rochester, MN 55905 USA.
OI Montori, Victor/0000-0003-0595-2898
NR 6
TC 37
Z9 37
U1 0
U2 2
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD NOV 25
PY 2010
VL 363
IS 22
BP 2081
EP 2084
DI 10.1056/NEJMp1011042
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA 684XE
UT WOS:000284587800001
PM 21083379
ER
PT J
AU Baicu, CF
Li, JY
Zhang, YH
Kasiganesan, H
Yamane, K
Zile, MR
Bradshaw, AD
AF Baicu, Catalin F.
Li, Jiayu
Zhang, Yuhua
Kasiganesan, Harinath
Yamane, Kentaro
Zile, Michael R.
Bradshaw, Amy D.
TI Increased Interstitial Collagen in Chronic Pressure Overload Hypertrophy
is Associated with a Change in Cardiac Fibroblast Phenotype and An
Increase in SPARC Expression
SO CIRCULATION
LA English
DT Meeting Abstract
DE Hypertrophy; Cells; Remodeling
C1 [Baicu, Catalin F.; Li, Jiayu; Zhang, Yuhua; Kasiganesan, Harinath; Yamane, Kentaro; Zile, Michael R.; Bradshaw, Amy D.] Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 23
PY 2010
VL 122
IS 21
SU S
MA A13030
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA V21UD
UT WOS:000208231601132
ER
PT J
AU Bradley, SM
Bryson, CL
Maynard, C
Maddox, TM
Fihn, SD
AF Bradley, Steven M.
Bryson, Chris L.
Maynard, Charles
Maddox, Thomas M.
Fihn, Stephan D.
TI Influence of Recent Hospitalization for Non-coronary Events on the Use
of Preventive Medications for Coronary Artery Disease
SO CIRCULATION
LA English
DT Meeting Abstract
DE Coronary artery disease; Prevention; Drugs; Health services research;
Patient care
C1 Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
Univ Colorado, Denver Vet Affairs Med Cntr, Denver, CO 80202 USA.
RI Maynard, Charles/N-3906-2015
OI Maynard, Charles/0000-0002-1644-7814
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 23
PY 2010
VL 122
IS 21
SU S
MA A12098
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA V21UD
UT WOS:000208231600739
ER
PT J
AU DeSantis, SM
Toole, JM
Kratz, JM
Uber, WE
Wheat, MJ
Stroud, MR
Ikonomidis, JS
Spinale, FG
AF DeSantis, Stacia M.
Toole, J. M.
Kratz, John M.
Uber, Walter E.
Wheat, Margaret J.
Stroud, Martha R.
Ikonomidis, John S.
Spinale, Francis G.
TI Early Postoperative Outcomes and Blood Product Utilization in Adult
Cardiac Surgery: The Post-Aprotinin Era
SO CIRCULATION
LA English
DT Meeting Abstract
DE Cardiac surgery; Fibrinolytic agents
C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 23
PY 2010
VL 122
IS 21
SU S
MA A9456
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA V21UD
UT WOS:000208231600410
ER
PT J
AU Dixon, JA
Gaillard, WF
Rivers, WT
Koval, CN
Stroud, RE
Mukherjee, R
Spinale, FG
AF Dixon, Jennifer A.
Gaillard, William F.
Rivers, William T.
Koval, Christine N.
Stroud, Robert E.
Mukherjee, Rupak
Spinale, Francis G.
TI Identification of a Unique Proteolytic-Profibrotic Interaction Following
Myocardial Infarction Which is Amplified Following a Second Episode of
Ischemia-Reperfusion
SO CIRCULATION
LA English
DT Meeting Abstract
DE Myocardial infarction; Ischemia reperfusion; Proteolytic enzymes
C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 23
PY 2010
VL 122
IS 21
SU S
MA A13284
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA V21UD
UT WOS:000208231601217
ER
PT J
AU Dixon, JA
Gorman, RC
Stroud, RE
Meyer, EC
O'Quinn, EC
Baker, NL
Morita, M
Hamamoto, H
Ryan, LP
Gorman, JH
Spinale, FG
AF Dixon, Jennifer A.
Gorman, Robert C.
Stroud, Robert E.
Meyer, Evan C.
O'Quinn, Elizabeth C.
Baker, Nathaniel L.
Morita, Masato
Hamamoto, Hirotsugu
Ryan, Liam P.
Gorman, Joseph H.
Spinale, Francis G.
TI Targeted Regional Injection of Biocomposite Microspheres Alters Post
Myocardial Infarction Remodeling and Matrix Proteolytic Pathways
SO CIRCULATION
LA English
DT Meeting Abstract
DE Myocardial infarction; Remodeling; Proteolytic enzymes
C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA.
Univ Penn, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 23
PY 2010
VL 122
IS 21
SU S
MA A9196
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA V21UD
UT WOS:000208231600370
ER
PT J
AU Dixon, JA
Goodman, AM
Gaillard, WF
Rivers, WT
McKinney, RA
Mukherjee, R
Baker, NL
Ikonomidis, JS
Spinale, FG
AF Dixon, Jennifer A.
Goodman, Amy M.
Gaillard, William F.
Rivers, William T.
McKinney, Richard A.
Mukherjee, Rupak
Baker, Nathaniel L.
Ikonomidis, John S.
Spinale, Francis G.
TI Hemodynamics and Myocardial Blood Flow Patterns Following Placement of a
Cardiac Passive Restraint Device in a Model of Dilated Cardiomyopathy
SO CIRCULATION
LA English
DT Meeting Abstract
DE Cardiomyopathy; Surgery; Device; Blood flow
C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA.
Paracor, Sunnyvale, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 23
PY 2010
VL 122
IS 21
SU S
MA A9037
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA V21UD
UT WOS:000208231600347
ER
PT J
AU Graham, EM
Atz, AM
Butts, RJ
Baker, NL
Stroud, RE
Deardorff, RL
Reeves, ST
Bradley, SM
Spinale, FG
AF Graham, Eric M.
Atz, Andrew M.
Butts, Ryan J.
Baker, Nathaniel L.
Stroud, Robert E.
Deardorff, Rachael L.
Reeves, Scott T.
Bradley, Scott M.
Spinale, Francis G.
TI Preoperative Steroid Treatment Does Not Improve Markers of Inflammation
or Outcomes Following Cardiac Surgery in Neonates
SO CIRCULATION
LA English
DT Meeting Abstract
DE Pediatrics; Cardiac surgery; Inflammation
C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 23
PY 2010
VL 122
IS 21
SU S
MA A10816
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA V21UD
UT WOS:000208231600550
ER
PT J
AU Graham, EM
Atz, AM
Butts, RJ
Baker, NL
Zyblewski, SC
Deardorff, RL
Reeves, ST
Bradley, SM
Spinale, FG
AF Graham, Eric M.
Atz, Andrew M.
Butts, Ryan J.
Baker, Nathaniel L.
Zyblewski, Sinai C.
Deardorff, Rachael L.
Reeves, Scott T.
Bradley, Scott M.
Spinale, Francis G.
TI Standardized Preoperative Corticosteroid Treatment in Neonates
Undergoing Cardiac Surgery-Results From a Randomized Trial
SO CIRCULATION
LA English
DT Meeting Abstract
DE Cardiac surgery; Pediatrics
C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 23
PY 2010
VL 122
IS 21
SU S
MA A10814
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA V21UD
UT WOS:000208231600549
ER
PT J
AU Greyson, CR
Ye, SY
Lu, L
Xu, Y
Schwartz, GG
Ahmad, H
AF Greyson, Clifford R.
Ye, Shuyu
Lu, Li
Xu, Ya
Schwartz, Gregory G.
Ahmad, Hasan
TI Acute Right Ventricular Pressure Overload Disrupts Organization of the
Focal Adhesion Protein Talin
SO CIRCULATION
LA English
DT Meeting Abstract
DE Pulmonary heart disease; Proteolytic enzymes; Acute heart failure;
Contractility; Pathology
C1 [Greyson, Clifford R.; Ye, Shuyu; Lu, Li; Xu, Ya; Schwartz, Gregory G.; Ahmad, Hasan] Denver VAMC, Denver, CO USA.
NR 0
TC 1
Z9 1
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 23
PY 2010
VL 122
IS 21
SU S
MA A16249
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA V21UD
UT WOS:000208231602115
ER
PT J
AU Ikonomidis, JS
Jones, JA
O'Quinn, EC
Elefteriades, JA
Stroud, RE
Bavaria, JE
Gorman, JH
Gorman, RC
Spinale, FG
AF Ikonomidis, John S.
Jones, Jeffrey A.
O'Quinn, Elizabeth C.
Elefteriades, John A.
Stroud, Robert E.
Bavaria, Joseph E.
Gorman, Joseph H.
Gorman, Robert C.
Spinale, Francis G.
TI Direct Profiling of MicroRNA in Thoracic Aortic Aneurysms: Relationship
to Aortic Expansion and Growth
SO CIRCULATION
LA English
DT Meeting Abstract
DE Aortic aneurysm; Remodeling
C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA.
Yale Univ, New Haven, CT USA.
Univ Penn, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 23
PY 2010
VL 122
IS 21
SU S
MA A15773
PG 3
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA V21UD
UT WOS:000208231601934
ER
PT J
AU Jones, JA
Bouges, S
Zavadzkas, JA
Rivers, WT
Brinsa, TA
Stroud, RE
Spinale, FG
Mukherjee, R
Ikonomidis, JS
AF Jones, Jeffrey A.
Bouges, Shenikqua
Zavadzkas, Jouzas A.
Rivers, William T.
Brinsa, Thersa A.
Stroud, Robert E.
Spinale, Francis G.
Mukherjee, Rupak
Ikonomidis, John S.
TI Membrane Type-1 Matrix Metalloproteinase Activity and in vivo Abundance
Using Targeted Microbubble Imaging, Intensify During Thoracic Aortic
Aneurysm Formation: Relationship to Change in Aortic Diameter
SO CIRCULATION
LA English
DT Meeting Abstract
DE Aortic aneurysm; Remodeling; Proteolytic enzymes
C1 [Jones, Jeffrey A.; Bouges, Shenikqua; Zavadzkas, Jouzas A.; Rivers, William T.; Brinsa, Thersa A.; Stroud, Robert E.; Spinale, Francis G.; Mukherjee, Rupak; Ikonomidis, John S.] Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 23
PY 2010
VL 122
IS 21
SU S
MA A12403
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA V21UD
UT WOS:000208231600827
ER
PT J
AU Jones, JA
Prescott, CB
Stroud, RE
Spinale, FG
Ikonomidis, JS
AF Jones, Jeffrey A.
Prescott, Corey B.
Stroud, Robert E.
Spinale, Francis G.
Ikonomidis, John S.
TI Latent Transforming Growth Factor-beta Binding Protein-1 is Cleaved by
Matrix Metalloproteinase-2 During Thoracic Aortic Aneurysm Development
SO CIRCULATION
LA English
DT Meeting Abstract
DE Aortic aneurysm; Remodeling; Proteolytic enzymes
C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 23
PY 2010
VL 122
IS 21
SU S
MA A12406
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA V21UD
UT WOS:000208231600829
ER
PT J
AU Mukherjee, R
Adams, DK
Clarke, EK
McClure, CD
Stroud, RE
McKinney, RA
Spinale, FG
Gold, MR
AF Mukherjee, Rupak
Adams, Deborah K.
Clarke, Elizabeth K.
McClure, Catherine D.
Stroud, Robert E.
McKinney, Richard A.
Spinale, Francis G.
Gold, Michael R.
TI Differential Plasma Profiles of Matrix Metalloproteinases and Tissue
Inhibitors of the Metalloproteinases with Atrial Fibrillation: Relation
to Recurrence Following Cardioversion
SO CIRCULATION
LA English
DT Meeting Abstract
DE Atrial fibrillation; Biomarkers; Proteolytic enzymes
C1 [Mukherjee, Rupak; Adams, Deborah K.; Clarke, Elizabeth K.; McClure, Catherine D.; Stroud, Robert E.; McKinney, Richard A.; Spinale, Francis G.; Gold, Michael R.] Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 23
PY 2010
VL 122
IS 21
SU S
MA A13798
PG 3
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA V21UD
UT WOS:000208231601367
ER
PT J
AU Mukherjee, R
Rivers, WT
Patel, RK
Stroud, RE
Spinale, FG
AF Mukherjee, Rupak
Rivers, William T.
Patel, Risha K.
Stroud, Robert E.
Spinale, F. G.
TI Membrane Type-1 Matrix Metalloproteinase Activity and Specific In Vivo
Quantitation Using Specific Targeted Microbubble Imaging: Relation to
Left Ventricular Remodeling Following Myocardial Infarction
SO CIRCULATION
LA English
DT Meeting Abstract
DE Myocardial infarction; Proteolytic enzymes; Imaging agents
C1 [Mukherjee, Rupak; Rivers, William T.; Patel, Risha K.; Stroud, Robert E.; Spinale, F. G.] Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 23
PY 2010
VL 122
IS 21
SU S
MA A10086
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA V21UD
UT WOS:000208231600426
ER
PT J
AU Mukherjee, R
Rivers, WT
Stroud, RE
Patel, RK
Ruddy, JM
Spinale, FG
AF Mukherjee, Rupak
Rivers, William T.
Stroud, Robert E.
Patel, Risha K.
Ruddy, Jean M.
Spinale, Francis G.
TI Chronic Localized High-Frequency Electrical Stimulation Within the
Myocardial Infarct Attenuates Infarct Expansion Through Transforming
Growth Factor-beta Signaling
SO CIRCULATION
LA English
DT Meeting Abstract
DE Myocardial infarction; Remodeling; Growth factors
C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 23
PY 2010
VL 122
IS 21
SU S
MA A10085
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA V21UD
UT WOS:000208231600425
ER
PT J
AU Reust, DL
Dixon, JA
McKinney, RA
Patel, RK
Rivers, WT
Mukherjee, R
Stroud, RE
Reeves, ST
Abernathy, JH
Spinale, FG
AF Reust, Daryl L.
Dixon, Jennifer A.
McKinney, Richard A.
Patel, Risha K.
Rivers, William T.
Mukherjee, Rupak
Stroud, Robert E.
Reeves, Scott T.
Abernathy, James H.
Spinale, Francis G.
TI Continuous Localized Monitoring of Plasmin Activity Identifies
Differential and Regional Effects of the Serine Protease Inhibitor
Aprotinin: Relevance to Antifibrinolytic Therapy
SO CIRCULATION
LA English
DT Meeting Abstract
DE Cardiac surgery; Fibrinolytic agents
C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 23
PY 2010
VL 122
IS 21
SU S
MA A12431
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA V21UD
UT WOS:000208231600839
ER
PT J
AU Spinale, FG
Toole, JM
Yarbrough, WM
Patel, RK
O'Quinn, EC
Gengler, I
Gillis, JF
Stroud, RE
Ikonomidis, JS
AF Spinale, Francis G.
Toole, John M.
Yarbrough, William M.
Patel, Risha K.
O'Quinn, Elizabeth C.
Gengler, Isabelle
Gillis, Jenna F.
Stroud, Robert E.
Ikonomidis, John S.
TI The Unique Membrane Type-1 Matrix Metalloproteinase is Constitutively
Active Within the Human Myocardial Interstitium and Dynamically Changes
with Ischemia-Reperfusion
SO CIRCULATION
LA English
DT Meeting Abstract
DE Ischemia reperfusion; Proteolytic enzymes; Myocardium
C1 [Spinale, Francis G.; Toole, John M.; Yarbrough, William M.; Patel, Risha K.; O'Quinn, Elizabeth C.; Gengler, Isabelle; Gillis, Jenna F.; Stroud, Robert E.; Ikonomidis, John S.] Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 23
PY 2010
VL 122
IS 21
SU S
MA A15925
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA V21UD
UT WOS:000208231602017
ER
PT J
AU Spinale, FG
Zavadzkas, JA
Stroud, RE
Rivers, WT
McKinney, RA
Chang, EI
Plyler, RA
Bouges, S
Mukherjee, R
AF Spinale, Francis G.
Zavadzkas, Juozas A.
Stroud, Robert E.
Rivers, William T.
McKinney, Richard A.
Chang, Eileen I.
Plyler, Rebecca A.
Bouges, Shenikqua
Mukherjee, Rupak
TI Myocardial Induction of Tissue Inhibitor of Matrix Metalloproteinase-4
Modifies Post Myocardial Infarction Left Ventricular Remodeling
SO CIRCULATION
LA English
DT Meeting Abstract
DE Myocardial infarction; Remodeling; Proteolytic enzymes
C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 23
PY 2010
VL 122
IS 21
SU S
MA A15791
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA V21UD
UT WOS:000208231601942
ER
PT J
AU Spinale, FG
Mukherjee, R
Zavadzkas, JA
Koval, CN
Stroud, RE
Rivers, WT
McKinney, RA
AF Spinale, Francis G.
Mukherjee, Rupak
Zavadzkas, Juozas A.
Koval, Christine N.
Stroud, Robert E.
Rivers, William T.
McKinney, Richard A.
TI Altering Myocardial Membrane Type-1 Following Myocardial Infarction
Directly Affects LV Remodeling and Function Through a Novel Fibrotic
Signaling Cascade
SO CIRCULATION
LA English
DT Meeting Abstract
DE Myocardial infarction; Proteolytic enzymes; Remodeling
C1 [Spinale, Francis G.; Mukherjee, Rupak; Zavadzkas, Juozas A.; Koval, Christine N.; Stroud, Robert E.; Rivers, William T.; McKinney, Richard A.] Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 23
PY 2010
VL 122
IS 21
SU S
MA A12801
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA V21UD
UT WOS:000208231601075
ER
PT J
AU Spinale, FG
Zavadzkas, JA
Koval, CN
Stroud, RE
Plyler, RA
Rivers, WT
McKinney, RA
Mukherjee, R
AF Spinale, Francis G.
Zavadzkas, Juozas A.
Koval, Christine N.
Stroud, Robert E.
Plyler, Rebecca A.
Rivers, William T.
McKinney, Richard A.
Mukherjee, Rupak
TI Direct Regulation of Myocardial Membrane Type-1 Following Myocardial
Infarction Causes Changes in Survival, Function and Remodeling
SO CIRCULATION
LA English
DT Meeting Abstract
DE Myocardial infarction; Proteolytic enzymes; Remodeling
C1 [Spinale, Francis G.; Zavadzkas, Juozas A.; Koval, Christine N.; Stroud, Robert E.; Plyler, Rebecca A.; Rivers, William T.; McKinney, Richard A.; Mukherjee, Rupak] Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 23
PY 2010
VL 122
IS 21
SU S
MA A12796
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA V21UD
UT WOS:000208231601071
ER
PT J
AU Stroud, RE
Ikonomidis, JS
Yarbrough, WM
Toole, JM
O'Quinn, EC
Gengler, I
Spinale, FG
AF Stroud, Robert E.
Ikonomidis, John S.
Yarbrough, William M.
Toole, John M.
O'Quinn, Elizabeth C.
Gengler, Isabelle
Spinale, Francis G.
TI The Human Myocardial Interstitium Contains a Specific Portfolio of
microRNAs which are Dynamically Regulated Following Ischemia-Reperfusion
SO CIRCULATION
LA English
DT Meeting Abstract
DE Ischemia reperfusion; Myocardium
C1 [Stroud, Robert E.; Ikonomidis, John S.; Yarbrough, William M.; Toole, John M.; O'Quinn, Elizabeth C.; Gengler, Isabelle; Spinale, Francis G.] Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 23
PY 2010
VL 122
IS 21
SU S
MA A13152
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA V21UD
UT WOS:000208231601168
ER
PT J
AU Tsai, TT
Messenger, JC
Brennan, JM
Patel, UD
Dai, D
Piana, R
Anstrom, KJ
Eisenstein, EL
Dokholyan, RS
Peterson, ED
Douglas, PS
AF Tsai, Thomas T.
Messenger, John C.
Brennan, J. Matthew
Patel, Uptal D.
Dai, David
Piana, Robert
Anstrom, Kevin J.
Eisenstein, Eric L.
Dokholyan, Rachel S.
Peterson, Eric D.
Douglas, Pamela S.
TI Contemporary Risk of Follow-up Adverse Events in Older Patients with
Chronic Kidney Disease and Dialysis Undergoing Percutaneous Coronary
Interventions: A Report from the Merged NCDR CMS Registry
SO CIRCULATION
LA English
DT Meeting Abstract
DE Percutaneous coronary intervention; Renal function; Aging; Health
services research
C1 Denver VAMC, Denver, CO USA.
Univ Colorado Denver, Denver, CO USA.
Duke Univ, Med Cntr, Durham, NC USA.
Vanderbilt Univ, Med Cntr, Nashville, TN USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 23
PY 2010
VL 122
IS 21
SU S
MA A19884
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA V21UD
UT WOS:000208231603306
ER
PT J
AU Yarbrough, WM
Van Laer, A
Rivers, WT
McKinney, RA
O'Quinn, EC
Black, LE
Stroud, RE
Zile, MR
Mukherjee, R
Spinale, FG
AF Yarbrough, William M.
Van Laer, An
Rivers, William T.
McKinney, Richard A.
O'Quinn, Elizabeth C.
Black, Laurel E.
Stroud, Robert E.
Zile, Michael R.
Mukherjee, Rupak
Spinale, Francis G.
TI Direct Modulation of Myocardial Tissue Inhibitor of Matrix
Metalloproteinase-4 Alters the Course of Myocardial Growth and Matrix
Remodeling with Pressure Overload
SO CIRCULATION
LA English
DT Meeting Abstract
DE Hypertrophy; Remodeling
C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 23
PY 2010
VL 122
IS 21
SU S
MA A13228
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA V21UD
UT WOS:000208231601200
ER
PT J
AU Yarbrough, WM
Van Laer, A
Rivers, WT
McKinney, RA
Black, LE
Stroud, RE
Zile, MR
Mukherjee, R
Spinale, FG
AF Yarbrough, William M.
Van Laer, An
Rivers, William T.
McKinney, Richard A.
Black, Laurel E.
Stroud, Robert E.
Zile, Michael R.
Mukherjee, Rupak
Spinale, Francis G.
TI Tissue Inhibitor of Matrix Metalloproteinase-4 Overexpression and
Deletion- Effects on Survival and Collagen Accumulation with Pressure
Overload Hypertrophy
SO CIRCULATION
LA English
DT Meeting Abstract
DE Hypertrophy; Remodeling; Proteolytic enzymes
C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 23
PY 2010
VL 122
IS 21
SU S
MA A12601
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA V21UD
UT WOS:000208231600905
ER
PT J
AU Zile, MR
Baicu, CF
Van Laer, A
Patel, RK
Black, LE
Stroud, RE
Mukherjee, R
Spinale, FG
AF Zile, Michael R.
Baicu, Catalin F.
Van Laer, An
Patel, Risha K.
Black, Laurel E.
Stroud, Robert E.
Mukherjee, Rupak
Spinale, Francis G.
TI Role of Membrane Type-1 Matrix Metalloproteinase Expression in
Pressure-Overload Induced Left Ventricular Remodeling
SO CIRCULATION
LA English
DT Meeting Abstract
DE Hypertrophy; Proteolytic enzymes; Remodeling
C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 23
PY 2010
VL 122
IS 21
SU S
MA A13207
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA V21UD
UT WOS:000208231601188
ER
PT J
AU Zile, MR
DeSantis, SM
Baicu, CF
Prescott, CB
Stroud, RE
Thompson, SB
McClure, CD
Spinale, FG
AF Zile, Michael R.
DeSantis, Stacia M.
Baicu, Catalin F.
Prescott, Corey B.
Stroud, Robert E.
Thompson, Sheila B.
McClure, Catherine D.
Spinale, Francis G.
TI Plasma Galectin-3 Levels in Patients with Structural and Clinical
Manifestations of Hypertensive Heart Disease: Relationship to
Determinants of Matrix Composition
SO CIRCULATION
LA English
DT Meeting Abstract
DE Hypertension; Heart disease
C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 23
PY 2010
VL 122
IS 21
SU S
MA A12433
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA V21UD
UT WOS:000208231600840
ER
PT J
AU Zile, MR
Baicu, CF
Stroud, RE
Van Laer, A
Mukherjee, R
Spinale, FG
AF Zile, Michael R.
Baicu, Catalin F.
Stroud, Robert E.
Van Laer, An
Mukherjee, Rupak
Spinale, Francis G.
TI Effects of Pressure-Overload Induced Left Ventricular Remodeling on
Membrane Type-1 Matrix Metalloproteinase Promoter Activation and
Expression
SO CIRCULATION
LA English
DT Meeting Abstract
DE Hypertrophy; Proteolytic enzymes
C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 23
PY 2010
VL 122
IS 21
SU S
MA A12438
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA V21UD
UT WOS:000208231600842
ER
PT J
AU Zile, MR
Mehurg, SM
O'Quinn, EC
Stroud, RE
DeSantis, SM
Spinale, FG
AF Zile, Michael R.
Mehurg, Shannon M.
O'Quinn, Elizabeth C.
Stroud, Robert E.
DeSantis, Stacia M.
Spinale, Francis G.
TI Plasma microRNA in Patients with Hypertensive Heart Disease:
Differential Expression in Left Ventricular Hypertrophy versus Diastolic
Heart Failure
SO CIRCULATION
LA English
DT Meeting Abstract
DE Hypertension; Heart failure
C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 23
PY 2010
VL 122
IS 21
SU S
MA A12427
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA V21UD
UT WOS:000208231600837
ER
PT J
AU Kullgren, JT
Galbraith, AA
Hinrichsen, VL
Miroshnik, I
Penfold, RB
Rosenthal, MB
Landon, BE
Lieu, TA
AF Kullgren, Jeffrey T.
Galbraith, Alison A.
Hinrichsen, Virginia L.
Miroshnik, Irina
Penfold, Robert B.
Rosenthal, Meredith B.
Landon, Bruce E.
Lieu, Tracy A.
TI Health Care Use and Decision Making Among Lower-Income Families in
High-Deductible Health Plans
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Article
ID BLUNT INSTRUMENT; INSURANCE; COMMUNICATION; AWARENESS; COSTS
AB Background: Lower-income families may face unique challenges in high-deductible health plans (HDHPs).
Methods: We administered a cross-sectional survey to a stratified random sample of families in a New England health plan's HDHP with at least $500 in annualized out-of-pocket expenditures. Lower-income families were defined as having incomes that were less than 300% of the federal poverty level. Primary outcomes were costrelated delayed or foregone care, difficulty understanding plans, unexpected costs, information-seeking, and likelihood of families asking their physician about hypothetical recommended services subject to the plan deductible. Multivariate logistic regression was used to control for potential confounders of associations between income group and primary outcomes.
Results: Lower-income families (n= 141) were more likely than higher-income families (n= 273) to report costrelated delayed or foregone care (57% vs 42%; adjusted odds ratio [AOR], 1.81; 95% confidence interval [CI], 1.15-2.83]). There were no differences in plan understanding, unexpected costs, or information-seeking by income. Lower-income families were more likely than others to say they would ask their physician about a $100 blood test (79% vs 63%; AOR, 1.97; 95% CI, 1.18-3.28) or a $1000 screening colonoscopy (89% vs 80%; AOR, 2.04; 95% CI, 1.06-3.93) subject to the plan deductible.
Conclusions: Lower-income families with out-of-pocket expenditures in an HDHP were more likely than higher-income families to report cost-related delayed or foregone care but did not report more difficulty understanding or using their plans, and might be more likely to question services requiring out-of-pocket expenditures. Policymakers and physicians should consider focused monitoring and benefit design modifications to support lower-income families in HDHPs.
C1 [Kullgren, Jeffrey T.] Univ Penn, Robert Wood Johnson Fdn Clin Scholars, Philadelphia, PA 19104 USA.
[Kullgren, Jeffrey T.] Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA.
[Kullgren, Jeffrey T.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Lieu, Tracy A.] Childrens Hosp, Div Gen Pediat, Boston, MA 02115 USA.
[Kullgren, Jeffrey T.] Brigham & Womens Hosp, Residency Program Primary Care & Populat Hlth, Boston, MA 02115 USA.
[Kullgren, Jeffrey T.; Galbraith, Alison A.; Hinrichsen, Virginia L.; Miroshnik, Irina; Penfold, Robert B.; Lieu, Tracy A.] Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Boston, MA USA.
[Galbraith, Alison A.; Hinrichsen, Virginia L.; Miroshnik, Irina; Penfold, Robert B.; Lieu, Tracy A.] Ctr Child Hlth Care Studies, Boston, MA USA.
[Rosenthal, Meredith B.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA.
[Landon, Bruce E.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.
RP Kullgren, JT (reprint author), Univ Penn, Robert Wood Johnson Fdn Clin Scholars, 1303B Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM kullgren@mail.med.upenn.edu
OI Rosenthal, Meredith/0000-0003-3410-0184
FU National Institute of Child Health and Human Development (NICHD),
Bethesda, Maryland [HD053440]; NICHD [HD047667, HD052742]
FX This study was supported by an R21 grant (HD053440) from the National
Institute of Child Health and Human Development (NICHD), Bethesda,
Maryland. Dr Lieu's effort was supported in part by a K24 Mid-Career
Development Award from NICHD (HD047667). Dr Galbraith's effort was
supported in part by a K23 Mentored Career Development Award from NICHD
(HD052742).
NR 28
TC 21
Z9 21
U1 0
U2 9
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9926
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD NOV 22
PY 2010
VL 170
IS 21
BP 1918
EP 1925
DI 10.1001/archinternmed.2010.428
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 683MN
UT WOS:000284480000012
PM 21098352
ER
PT J
AU Ancha, HR
Fajardo, NR
Bauman, WA
Rosman, AS
Galea, M
Creasey, G
Korsten, MA
AF Ancha, Hanumantha R.
Fajardo, Noel R.
Bauman, William A.
Rosman, Alan S.
Galea, Marinella
Creasey, Graham
Korsten, Mark A.
TI Absence of high amplitude propagating contractions in subjects with
chronic spinal cord injury
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Spinal cord injury; Neurogenic bowel; Bowel motility; High amplitude
propagating contractions; Motility index
ID COLONIC MOTOR-ACTIVITY; SLOW-TRANSIT CONSTIPATION; 24 HOUR; MOTILITY;
MANOMETRY
AB AIM: To investigate the presence or absence of high amplitude propagating contractions (HAPC), as well as the other measures of colonic motility, in persons with spinal cord injury (SCI).
METHODS: Prolonged colonic ambulatory manometric studies were performed on 14 male volunteers: 8 with SCI (mean age, 59 +/- 13 years; mean duration of injury, 13 +/- 4 years) and 6 healthy able-bodied controls (mean age, 57 +/- 10 years). A solid-state manometry catheter was endoscopically clipped to the splenic flexure. Recording was performed for > 24 h after manometric catheter placement.
RESULTS: HAPC were absent in individuals with SCI during pre-sleep, sleep, and post-sleep phases. HAPC were significantly increased after awakening in non-SCI controls (0.8 +/- 0.2 HAPC/h vs 10.5 +/- 2.0 HAPC/h, P < 0.005). The motility index was lower in those with SCI than in controls pre- and post-sleep (SCI vs non-SCI: Pre-sleep, 2.4 +/- 0.4 vs 8.8 +/- 1.9, P < 0.01; Post-sleep, 4.3 +/- 0.8 vs 16.5 +/- 4.5, P < 0.05). However; a sleep-induced depression of colonic motility was observed in both the SCI and non-SCI groups (Pre-sleep vs Sleep, non-SCI: 8.8 1.9 vs 2.1 +/- 0.9, P < 0.002; SCI: 2.4 +/- 0.4 vs 0.2 +/- 0.03, P < 0.001), with the motility index of those with SCI during sleep not significantly different than that of the controls.
CONCLUSION: HAPC were not observed in individuals with SCI pre- or post-sleep. A sleep-induced depression in general colonic motility was evident in SCI and control subjects. (C) 2010 Baishideng. All rights reserved.
C1 [Korsten, Mark A.] James J Peters VA Med Ctr, Med Serv, Bronx, NY 10468 USA.
[Ancha, Hanumantha R.; Fajardo, Noel R.; Bauman, William A.; Rosman, Alan S.; Korsten, Mark A.] James J Peters VA Med Ctr, Rehabil Res & Dev Ctr Excellence Med Consequences, Bronx, NY 10468 USA.
[Bauman, William A.; Rosman, Alan S.; Korsten, Mark A.] Mt Sinai Sch Med, Dept Med, Bronx, NY 10468 USA.
[Bauman, William A.] Mt Sinai Sch Med, Dept Rehabil Med, Bronx, NY 10468 USA.
[Galea, Marinella] James J Peters VA Med Ctr, Spinal Cord Injury Serv, Bronx, NY 10468 USA.
[Creasey, Graham] VA Med Ctr, Spinal Cord Injury Serv, Palo Alto, CA 94304 USA.
RP Korsten, MA (reprint author), James J Peters VA Med Ctr, Med Serv, Bronx, NY 10468 USA.
EM mark.korsten@va.gov
FU Department of Veterans Affairs Rehabilitation Research and Development
Service Center of Excellence for the Medical Consequences of Spinal Cord
Injury [B4162C]
FX Supported by The Department of Veterans Affairs Rehabilitation Research
and Development Service Center of Excellence for the Medical
Consequences of Spinal Cord Injury (B4162C)
NR 22
TC 1
Z9 2
U1 0
U2 0
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD NOV 21
PY 2010
VL 16
IS 43
BP 5435
EP 5439
DI 10.3748/wjg.v16.i43.5435
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 683SC
UT WOS:000284494500006
PM 21086560
ER
PT J
AU Bagby, GC
Yates, J
Anur, P
Rathbuin, K
Harrington, C
Pasquini, R
Pelz, C
AF Bagby, Grover C., Jr.
Yates, Jane
Anur, Praveen
Rathbuin, Keaney
Harrington, Christina
Pasquini, Ricardo
Pelz, Carl
TI Clonal Evolution In Fanconi Anemia; The Role of HOXA9
SO BLOOD
LA English
DT Meeting Abstract
CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH)
CY DEC 04-07, 2010
CL Orlando, FL
SP Amer Soc Hematol
C1 [Pelz, Carl] Oregon Hlth & Sci Univ, Mol & Med Genet & Stem Cell Ctr, Portland, OR 97201 USA.
[Bagby, Grover C., Jr.] Portland VA Med Ctr, Portland, OR USA.
[Yates, Jane; Rathbuin, Keaney] NW VA Canc Res Ctr, Portland, OR USA.
[Harrington, Christina] Gene Microarray Shared Resource, Portland, OR USA.
[Pasquini, Ricardo] Univ Fed Parana, Hosp Clin, BR-80060000 Curitiba, Parana, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 19
PY 2010
VL 116
IS 21
BP 61
EP 61
PG 1
WC Hematology
SC Hematology
GA 752BH
UT WOS:000289662200127
ER
PT J
AU D'Souza, S
Kurihara, N
Shiozawa, Y
Taichman, R
Galson, D
Roodman, D
AF D'Souza, Sonia
Kurihara, Noriyoshi
Shiozawa, Yusuke
Taichman, Russell
Galson, Deborah
Roodman, David
TI Annexin II Interactions with the Annexin II Receptor Enhance Multiple
Myeloma Cell Adhesion and Growth In the Bone Marrow Microenvironment
SO BLOOD
LA English
DT Meeting Abstract
CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH)
CY DEC 04-07, 2010
CL Orlando, FL
SP Amer Soc Hematol
C1 [D'Souza, Sonia; Kurihara, Noriyoshi; Galson, Deborah; Roodman, David] Univ Pittsburgh, Bone Biol Ctr, UPMC, Pittsburgh, PA USA.
[D'Souza, Sonia; Kurihara, Noriyoshi; Galson, Deborah; Roodman, David] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Shiozawa, Yusuke; Taichman, Russell] Univ Michigan, Ann Arbor, MI 48109 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 19
PY 2010
VL 116
IS 21
BP 62
EP 62
PG 1
WC Hematology
SC Hematology
GA 752BH
UT WOS:000289662200131
ER
PT J
AU Teramachi, J
Windle, JJ
Roodman, D
Kurihara, N
AF Teramachi, Jumpei
Windle, Jolene J.
Roodman, David
Kurihara, Noriyoshi
TI The ZZ Domain of Sequestosome-1/p62 Plays An Important Role In Stromal
Cell Support of Myeloma Cell Growth and Osteoclast Formation
SO BLOOD
LA English
DT Meeting Abstract
CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH)
CY DEC 04-07, 2010
CL Orlando, FL
SP Amer Soc Hematol
C1 [Teramachi, Jumpei; Roodman, David; Kurihara, Noriyoshi] Univ Pittsburgh, Pittsburgh, PA USA.
[Teramachi, Jumpei; Roodman, David; Kurihara, Noriyoshi] UPMC, Ctr Bone Biol, Pittsburgh, PA USA.
[Windle, Jolene J.] Virginia Commonwealth Univ, Richmond, VA USA.
[Roodman, David] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 19
PY 2010
VL 116
IS 21
BP 62
EP 62
PG 1
WC Hematology
SC Hematology
GA 752BH
UT WOS:000289662200129
ER
PT J
AU Li, SR
Pal, R
Monaghan, S
Schafer, P
Ouyang, H
Mapara, MY
Lentzsch, S
AF Li, Shirong
Pal, Rekha
Monaghan, Sara
Schafer, Peter
Ouyang, Hongjiao
Mapara, Markus Y.
Lentzsch, Suzanne
TI C/EBPb Is a Critical Mediator of Resistance to IMiD (R) Immunomodulatory
Compounds and Affected by IMiD Compounds Via Control of Protein
Translation
SO BLOOD
LA English
DT Meeting Abstract
CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH)
CY DEC 04-07, 2010
CL Orlando, FL
SP Amer Soc Hematol
C1 [Li, Shirong; Pal, Rekha; Mapara, Markus Y.; Lentzsch, Suzanne] Univ Pittsburgh, Inst Canc, Div Hematol Oncol, Pittsburgh, PA USA.
[Monaghan, Sara] Univ Pittsburgh, Dept Pathol, Med Ctr, Pittsburgh, PA USA.
[Schafer, Peter] Celgene Corp, Translat Dev, Summit, NJ USA.
[Ouyang, Hongjiao] VA Pittsburgh Healthcare Syst, Ctr Bone Biol, Pittsburgh, PA USA.
RI mapara, markus/A-2134-2013
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 19
PY 2010
VL 116
IS 21
BP 64
EP 65
PG 2
WC Hematology
SC Hematology
GA 752BH
UT WOS:000289662200136
ER
PT J
AU Sorror, ML
Storer, B
Sandmaier, BM
Franke, GN
Laport, GG
Chauncey, T
Agura, E
Maris, MT
Wade, J
Pulsipher, MA
Maziarz, RT
Sahebi, F
McSweeney, P
Bruno, B
Vindelov, L
Yeager, AM
Rezvani, A
Niederwieser, DW
Blume, KG
Storb, RF
Maloney, DG
AF Sorror, Mohamed L.
Storer, Barry
Sandmaier, Brenda M.
Franke, Georg N.
Laport, Ginna G.
Chauncey, Thomas
Agura, Edward
Maris, Michael T.
Wade, James
Pulsipher, Michael A.
Maziarz, Richard T.
Sahebi, Firoozeh
McSweeney, Peter
Bruno, Benedetto
Vindelov, Lars
Yeager, Andrew M.
Rezvani, Andrew
Niederwieser, Dietger W.
Blume, Karl G.
Storb, Rainer F.
Maloney, David G.
TI Outcomes Following Relapse of Non-Hodgkin Lymphoma (NHL) or Chronic
Lymphocytic Leukemia (CLL) After Nonmyeloablative Conditioning and
Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched
Related or Unrelated Donors.
SO BLOOD
LA English
DT Meeting Abstract
CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH)
CY DEC 04-07, 2010
CL Orlando, FL
SP Amer Soc Hematol
C1 [Sorror, Mohamed L.; Storer, Barry; Sandmaier, Brenda M.; Chauncey, Thomas; Rezvani, Andrew; Storb, Rainer F.; Maloney, David G.] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA.
[Franke, Georg N.; Niederwieser, Dietger W.] Univ Leipzig, Leipzig, Germany.
[Laport, Ginna G.; Blume, Karl G.] Stanford Univ, Stanford, CA 94305 USA.
[Chauncey, Thomas] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Agura, Edward] Baylor Univ, Dallas, TX USA.
[Maris, Michael T.] Rocky Mt Canc Ctr, Denver, CO USA.
[Wade, James] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Pulsipher, Michael A.] Univ Utah, Salt Lake City, UT USA.
[Maziarz, Richard T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Sahebi, Firoozeh] City Hope Natl Med Ctr, Duarte, CA 91010 USA.
[McSweeney, Peter] Univ Colorado, Boulder, CO 80309 USA.
[Bruno, Benedetto] Univ Turin, Turin, Italy.
[Vindelov, Lars] Rigshosp, DK-2100 Copenhagen, Denmark.
[Yeager, Andrew M.] Univ Arizona, Tucson, AZ USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 19
PY 2010
VL 116
IS 21
BP 553
EP 553
PG 1
WC Hematology
SC Hematology
GA 752BH
UT WOS:000289662201395
ER
PT J
AU Varadarajan, P
Toro, J
Craig, RM
Schneider, D
Chao, JH
Haile, D
Freytes, CO
AF Varadarajan, Prakash
Toro, Juan
Craig, Robert M.
Schneider, Deanna
Chao, Ju-Hsien
Haile, David
Freytes, Cesar O.
TI Does Bisphosphonate-Induced Osteonecrosis of the Jaw (BONJ) Preclude
Intensive Chemotherapy? Oral and Infectious Toxicities Associated with
Autotransplantation In Patients with BONJ
SO BLOOD
LA English
DT Meeting Abstract
CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH)
CY DEC 04-07, 2010
CL Orlando, FL
SP Amer Soc Hematol
C1 [Varadarajan, Prakash; Haile, David; Freytes, Cesar O.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Toro, Juan; Craig, Robert M.; Schneider, Deanna; Chao, Ju-Hsien] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 19
PY 2010
VL 116
IS 21
BP 562
EP 563
PG 2
WC Hematology
SC Hematology
GA 752BH
UT WOS:000289662201417
ER
PT J
AU Sorror, ML
Storer, B
Sandmaier, BM
Braunert, L
Laport, GG
Chauncey, T
Bredeson, C
Maziarz, RT
Pulsipher, MA
Agura, E
Mans, MT
Vindelov, L
Sahebi, F
McSweeney, P
Bruno, B
Langston, A
Storb, RF
Maloney, DG
AF Sorror, Mohamed L.
Storer, Barry
Sandmaier, Brenda M.
Braunert, Leanthe
Laport, Ginna G.
Chauncey, Thomas
Bredeson, Christopher
Maziarz, Richard T.
Pulsipher, Michael A.
Agura, Edward
Mans, Michael T.
Vindelov, Lars
Sahebi, Firoozeh
McSweeney, Peter
Bruno, Benedetto
Langston, Amelia
Storb, Rainer F.
Maloney, David G.
TI Impacts of Cytogenetic Abnormalities and Prior Alemtuzumab on Outcomes
of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL)
Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation
(HCT)
SO BLOOD
LA English
DT Meeting Abstract
CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH)
CY DEC 04-07, 2010
CL Orlando, FL
SP Amer Soc Hematol
C1 [Sorror, Mohamed L.; Storer, Barry; Sandmaier, Brenda M.; Chauncey, Thomas; Storb, Rainer F.; Maloney, David G.] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA.
[Braunert, Leanthe] Univ Leipzig, Leipzig, Germany.
[Laport, Ginna G.] Stanford Univ, Stanford, CA 94305 USA.
[Chauncey, Thomas] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Bredeson, Christopher] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Maziarz, Richard T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Pulsipher, Michael A.] Univ Utah, Salt Lake City, UT USA.
[Agura, Edward] Baylor Univ, Dallas, TX USA.
[Mans, Michael T.] Rocky Mt Canc Ctr, Denver, CO USA.
[Vindelov, Lars] Rigshosp, DK-2100 Copenhagen, Denmark.
[Sahebi, Firoozeh] City Hope Natl Med Ctr, Duarte, CA 91010 USA.
[McSweeney, Peter] Univ Colorado, Boulder, CO 80309 USA.
[Bruno, Benedetto] Univ Turin, Turin, Italy.
[Langston, Amelia] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 19
PY 2010
VL 116
IS 21
BP 978
EP 978
PG 1
WC Hematology
SC Hematology
GA 752BH
UT WOS:000289662202587
ER
PT J
AU Sorror, ML
Storer, B
Sandmaier, BM
Chauncey, T
Maris, MT
Storb, RF
Maloney, DG
AF Sorror, Mohamed L.
Storer, Bany
Sandmaier, Brenda M.
Chauncey, Thomas
Maris, Michael T.
Storb, Rainer F.
Maloney, David G.
TI Sequential Autologous Followed by Nonmyeloablative Allogeneic
Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or
Unrelated Donors Improves Outcomes of Patients (pts) with Bulky Lymphoma
or Chronic Lymphocytic Leukemia (CLL)
SO BLOOD
LA English
DT Meeting Abstract
CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH)
CY DEC 04-07, 2010
CL Orlando, FL
SP Amer Soc Hematol
C1 [Sorror, Mohamed L.; Storer, Bany; Sandmaier, Brenda M.; Chauncey, Thomas] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA.
[Chauncey, Thomas] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Maris, Michael T.] Rocky Mt Canc Ctr, Denver, CO USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 19
PY 2010
VL 116
IS 21
BP 979
EP 979
PG 1
WC Hematology
SC Hematology
GA 752BH
UT WOS:000289662202588
ER
PT J
AU Doolittle, ND
Kraemer, DF
Lacy, C
Tyson, RM
Neuwelt, EA
AF Doolittle, Nancy D.
Kraemer, Dale F.
Lacy, Cynthia
Tyson, Rose Marie
Neuwelt, Edward A.
TI Enhanced Delivery of Rituximab In Combination with Methotrexate-Based
Blood-Brain Barrier Disruption for patients with Newly Diagnosed Primary
CNS Lymphoma
SO BLOOD
LA English
DT Meeting Abstract
CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH)
CY DEC 04-07, 2010
CL Orlando, FL
SP Amer Soc Hematol
C1 [Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurol, Dept Neurosurg, Portland, OR 97201 USA.
[Kraemer, Dale F.] Oregon State Univ, Dept Pharm Practice, Portland, OR USA.
[Neuwelt, Edward A.] Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 1
U1 0
U2 3
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 19
PY 2010
VL 116
IS 21
BP 1151
EP 1151
PG 1
WC Hematology
SC Hematology
GA 752BH
UT WOS:000289662203124
ER
PT J
AU Scott, BL
Gooley, TA
Linenberger, ML
Sandmaier, BM
Myerson, D
Chauncey, T
Appelbaum, FR
Deeg, HJ
AF Scott, Bart Lee
Gooley, Ted A.
Linenberger, Michael L.
Sandmaier, Brenda M.
Myerson, David
Chauncey, Thomas
Appelbaum, Frederick R.
Deeg, H. Joachim
TI International Working Group Scores Predict Post-Transplant Outcomes In
Patients with Myelofibrosis
SO BLOOD
LA English
DT Meeting Abstract
CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH)
CY DEC 04-07, 2010
CL Orlando, FL
SP Amer Soc Hematol
C1 [Scott, Bart Lee; Gooley, Ted A.; Linenberger, Michael L.; Sandmaier, Brenda M.; Myerson, David; Chauncey, Thomas; Appelbaum, Frederick R.; Deeg, H. Joachim] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA.
[Chauncey, Thomas] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 19
PY 2010
VL 116
IS 21
BP 1272
EP 1272
PG 1
WC Hematology
SC Hematology
GA 752BH
UT WOS:000289662203417
ER
PT J
AU Gyurkocza, B
Storb, R
Storer, BE
Chauncey, T
Lange, T
Laport, GG
Langston, A
Pulsipher, MA
Bredeson, C
Maziarz, R
Bruno, B
Petersen, F
Maris, M
Agura, E
Yeager, AM
Bethge, WA
Sahebi, F
Appelbaum, FR
Maloney, DG
Estey, EH
Sandmaier, BM
AF Gyurkocza, Boglarka
Storb, Rainer
Storer, Barry E.
Chauncey, Thomas
Lange, Thoralf
Laport, Ginna G.
Langston, Amelia
Pulsipher, Michael A.
Bredeson, Christopher
Maziarz, Richard
Bruno, Benedetto
Petersen, Finn
Maris, Michael
Agura, Edward
Yeager, Andrew M.
Bethge, Wolfgang A.
Sahebi, Firoozeh
Appelbaum, Frederick R.
Maloney, David G.
Estey, Elihu H.
Sandmaier, Brenda M.
TI A Relapse Risk Score to Predict Acute Myeloid Leukemia Relapse After
Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Based on
Pre-Transplant Variables
SO BLOOD
LA English
DT Meeting Abstract
CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH)
CY DEC 04-07, 2010
CL Orlando, FL
SP Amer Soc Hematol
C1 [Gyurkocza, Boglarka; Storb, Rainer; Storer, Barry E.; Appelbaum, Frederick R.; Maloney, David G.; Estey, Elihu H.; Sandmaier, Brenda M.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Gyurkocza, Boglarka; Storb, Rainer; Storer, Barry E.; Appelbaum, Frederick R.; Maloney, David G.; Estey, Elihu H.; Sandmaier, Brenda M.] Univ Washington, Seattle, WA 98195 USA.
[Chauncey, Thomas] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA.
[Chauncey, Thomas] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Lange, Thoralf] Univ Leipzig, Leipzig, Germany.
[Laport, Ginna G.] Stanford Univ, Stanford, CA 94305 USA.
[Langston, Amelia] Emory Univ, Sch Med, Winship Canc Ctr, Atlanta, GA 30322 USA.
[Pulsipher, Michael A.] Univ Utah, Sch Med, Salt Lake City, UT USA.
[Bredeson, Christopher] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Maziarz, Richard] Oregon Hlth & Sci Univ, Ctr Clin Canc, Portland, WI USA.
[Bruno, Benedetto] Univ Turin, Turin, Italy.
[Petersen, Finn] LDS Hosp, Intermountain Blood & Marrow Trans Prog, Salt Lake City, UT USA.
[Maris, Michael] Rocky Mt Blood & Marrow Trans, Denver, CO USA.
[Agura, Edward] Baylor Univ, Med Ctr, BMT, Dallas, TX USA.
[Yeager, Andrew M.] Univ Arizona, Tucson, AZ USA.
[Bethge, Wolfgang A.] Univ Tubingen, Dept Med Hematol Oncol, Tubingen, Germany.
[Sahebi, Firoozeh] City Hope Natl Med Ctr, Duarte, CA 91010 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 19
PY 2010
VL 116
IS 21
BP 1415
EP 1416
PG 2
WC Hematology
SC Hematology
GA 752BH
UT WOS:000289662203781
ER
PT J
AU Hutchinson, CB
Crow, JH
Qin, H
Lu, CM
Sebastain, S
Rehder, C
Lagoo, AS
Goodman, B
Horwitz, ME
Rizzieri, DA
Datto, M
Buckley, P
Wang, E
AF Hutchinson, Charles Blake
Crow, Jennifer H.
Qin Huang
Lu, Chuanyi M.
Sebastain, Siby
Rehder, Catherine
Lagoo, Anand S.
Goodman, Barbara
Horwitz, Mitchell E.
Rizzieri, David A.
Datto, Michael
Buckley, Patrick
Wang, Endi
TI Donor Cell Leukemia: A Clinicopathological Study of 9 Cases and a
Comprehensive Review of Literature
SO BLOOD
LA English
DT Meeting Abstract
CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH)
CY DEC 04-07, 2010
CL Orlando, FL
SP Amer Soc Hematol
C1 [Hutchinson, Charles Blake; Crow, Jennifer H.; Sebastain, Siby; Rehder, Catherine; Lagoo, Anand S.; Goodman, Barbara; Datto, Michael; Buckley, Patrick; Wang, Endi] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA.
[Qin Huang] City Hope Natl Canc Ctr, Dept Pathol, Duarte, CA USA.
[Lu, Chuanyi M.] San Francisco VA Med Ctr, Lab Med Serv, San Francisco, CA USA.
[Horwitz, Mitchell E.; Rizzieri, David A.] Duke Univ, Med Ctr, Div Cellular Therapy, Durham, NC USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 19
PY 2010
VL 116
IS 21
BP 1423
EP 1424
PG 2
WC Hematology
SC Hematology
GA 752BH
UT WOS:000289662203797
ER
PT J
AU Utz, K
Neumon, B
Frye, BL
Chao, JH
Toro, J
Haile, D
Freytes, C
AF Utz, Kenneth
Neumon, Bonita
Frye, Brenda L.
Chao, Ju-Hsien
Toro, Juan
Haile, David
Freytes, Cesar
TI Have Clinicians Adopted the International Uniform Response Criteria
(IURC) for Multiple Myeloma (MM)? Adherence to the IURC for
Posttransplant Evaluations In Patients with Multiple Myeloma
SO BLOOD
LA English
DT Meeting Abstract
CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH)
CY DEC 04-07, 2010
CL Orlando, FL
SP Amer Soc Hematol
C1 [Utz, Kenneth] S Texas Vet Hlth Care Syst, Audie L Murphy Mem Hosp, Dept Pharm, San Antonio, TX USA.
[Frye, Brenda L.] Audie Murphy Vet Affairs BMT, San Antonio, TX USA.
[Freytes, Cesar] Audie L Murphy Mem Vet Adm Med Ctr, Med Serv 111 BMT, San Antonio, TX 78284 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 19
PY 2010
VL 116
IS 21
BP 43
EP 43
PG 1
WC Hematology
SC Hematology
GA 752BH
UT WOS:000289662200085
ER
PT J
AU Devine, EB
Williams, EC
Martin, DP
Sittig, DF
Tarczy-Hornoch, P
Payne, TH
Sullivan, SD
AF Devine, Emily Beth
Williams, Emily C.
Martin, Diane P.
Sittig, Dean F.
Tarczy-Hornoch, Peter
Payne, Thomas H.
Sullivan, Sean D.
TI Prescriber and staff perceptions of an electronic prescribing system in
primary care: a qualitative assessment
SO BMC MEDICAL INFORMATICS AND DECISION MAKING
LA English
DT Article
ID PHYSICIAN ORDER ENTRY; CLINICAL DECISION-SUPPORT; ADVERSE DRUG EVENTS;
MEDICATION ERRORS; INFORMATION-TECHNOLOGY; CROSS-SITE; HEALTH-CARE;
IMPLEMENTATION; EXPERIENCES; HOSPITALS
AB Background: The United States (US) Health Information Technology for Economic and Clinical Health Act of 2009 has spurred adoption of electronic health records. The corresponding meaningful use criteria proposed by the Centers for Medicare and Medicaid Services mandates use of computerized provider order entry (CPOE) systems. Yet, adoption in the US and other Western countries is low and descriptions of successful implementations are primarily from the inpatient setting; less frequently the ambulatory setting. We describe prescriber and staff perceptions of implementation of a CPOE system for medications (electronic-or e-prescribing system) in the ambulatory setting.
Methods: Using a cross-sectional study design, we conducted eight focus groups at three primary care sites in an independent medical group. Each site represented a unique stage of e-prescribing implementation - pre/transition/post. We used a theoretically based, semi-structured questionnaire to elicit physician (n = 17) and staff (n = 53) perceptions of implementation of the e-prescribing system. We conducted a thematic analysis of focus group discussions using formal qualitative analytic techniques (i.e. deductive framework and grounded theory). Two coders independently coded to theoretical saturation and resolved discrepancies through discussions.
Results: Ten themes emerged that describe perceptions of e-prescribing implementation: 1) improved availability of clinical information resulted in prescribing efficiencies and more coordinated care; 2) improved documentation resulted in safer care; 3) efficiencies were gained by using fewer paper charts; 4) organizational support facilitated adoption; 5) transition required time; resulted in workload shift to staff; 6) hardware configurations and network stability were important in facilitating workflow; 7) e-prescribing was time-neutral or time-saving; 8) changes in patient interactions enhanced patient care but required education; 9) pharmacy communications were enhanced but required education; 10) positive attitudes facilitated adoption.
Conclusions: Prescribers and staff worked through the transition to successfully adopt e-prescribing, and noted the benefits. Overall impressions were favorable. No one wished to return to paper-based prescribing.
C1 [Devine, Emily Beth; Sullivan, Sean D.] Univ Washington, Pharmaceut Outcomes Res & Policy Program, Seattle, WA 98195 USA.
[Devine, Emily Beth; Tarczy-Hornoch, Peter] Univ Washington, Dept Med Educ & Biomed Informat, Seattle, WA 98195 USA.
[Williams, Emily C.] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98101 USA.
[Williams, Emily C.; Martin, Diane P.; Sullivan, Sean D.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Sittig, Dean F.] Univ Texas Houston, Sch Hlth Informat Sci, UT Mem Hermann Ctr Healthcare Qual & Safety, Houston, TX 77030 USA.
[Payne, Thomas H.; Sullivan, Sean D.] Univ Washington, Dept Med, Seattle, WA 98195 USA.
RP Devine, EB (reprint author), Univ Washington, Pharmaceut Outcomes Res & Policy Program, Box 357630, Seattle, WA 98195 USA.
EM bdevine@uw.edu
OI Tarczy-Hornoch, Peter/0000-0003-1047-179X
FU AHRQ Health Information Technology [5-UC1 HS015319]; AHRQ Mentored
Clinical Scientist Training [5-K-08-HS014739]
FX AHRQ Health Information Technology Grant #: 5-UC1 HS015319 (PI:
Sullivan) AHRQ Mentored Clinical Scientist Training Grant #:
5-K-08-HS014739 (PI: Devine)
NR 57
TC 9
Z9 9
U1 6
U2 13
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6947
J9 BMC MED INFORM DECIS
JI BMC Med. Inform. Decis. Mak.
PD NOV 19
PY 2010
VL 10
AR 72
DI 10.1186/1472-6947-10-72
PG 12
WC Medical Informatics
SC Medical Informatics
GA 688VR
UT WOS:000284883200001
PM 21087524
ER
PT J
AU Coker, TR
Chan, LS
Newberry, SJ
Limbos, MA
Suttorp, MJ
Shekelle, PG
Takata, GS
AF Coker, Tumaini R.
Chan, Linda S.
Newberry, Sydne J.
Limbos, Mary Ann
Suttorp, Marika J.
Shekelle, Paul G.
Takata, Glenn S.
TI Diagnosis, Microbial Epidemiology, and Antibiotic Treatment of Acute
Otitis Media in Children A Systematic Review
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Review
ID PNEUMOCOCCAL CONJUGATE VACCINE; RANDOMIZED CONTROLLED-TRIAL;
DOUBLE-BLIND TRIAL; PRESCRIBING STRATEGIES; CLINICAL-EFFICACY;
GENERAL-PRACTICE; AMOXICILLIN; MANAGEMENT; CEFACLOR; PLACEBO
AB Context Acute otitis media (AOM) is the most common condition for which antibiotics are prescribed for US children; however, wide variation exists in diagnosis and treatment.
Objectives To perform a systematic review on AOM diagnosis, treatment, and the association of heptavalent pneumococcal conjugate vaccine (PCV7) use with AOM microbiology.
Data Sources PubMed, Cochrane Databases, and Web of Science, searched to identify articles published from January 1999 through July 2010.
Study Selection Diagnostic studies with a criterion standard, observational studies and randomized controlled trials comparing AOM microbiology with and without PCV7, and randomized controlled trials assessing antibiotic treatment.
Data Extraction Independent article review and study quality assessment by 2 investigators with consensus resolution of discrepancies.
Results Of 8945 citations screened, 135 were included. Meta-analysis was performed for comparisons with 3 or more trials. Few studies examined diagnosis; otoscopic findings of tympanic membrane bulging (positive likelihood ratio, 51[95% confidence interval {CI}, 36-73]) and redness (positive likelihood ratio, 8.4 [95% CI, 7-11]) were associated with accurate diagnosis. In the few available studies, prevalence of Streptococcus pneumoniae decreased (eg, 33%-48% vs 23%-31% of AOM isolates), while that of Haemophilus influenzae increased (41%-43% vs 56%-57%) pre-vs post-PCV7. Short-term clinical success was higher for immediate use of ampicillin or amoxicillin vs placebo(73% vs 60%; pooled rate difference, 12% [95% CI, 5%-18%]; number needed to treat, 9 [95% CI, 6-20]), while increasing the rate of rash or diarrhea by 3% to 5%. Two of 4 studies showed greater clinical success for immediate vs delayed antibiotics(95% vs 80%; rate difference, 15% [95% CI, 6%-24%] and 86% vs 70%; rate difference, 16% [95% CI, 6%-26%]). Data are absent on long-term effects on antimicrobial resistance. Meta-analyses in general showed no significant differences in antibiotic comparative effectiveness.
Conclusions Otoscopic findings are critical to accurate AOM diagnosis. AOM microbiology has changed with use of PCV7. Antibiotics are modestly more effective than no treatment but cause adverse effects in 4% to 10% of children. Most antibiotics have comparable clinical success. JAMA. 2010; 304(19): 2161-2169
C1 [Coker, Tumaini R.] Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Dept Pediat, Los Angeles, CA 90024 USA.
[Coker, Tumaini R.] RAND, Santa Monica, CA USA.
[Chan, Linda S.] Los Angeles Cty USC Med Ctr, Div Biostat & Outcomes Assessment, Los Angeles, CA USA.
[Chan, Linda S.; Limbos, Mary Ann; Takata, Glenn S.] USC Keck Sch Med, Los Angeles, CA USA.
[Newberry, Sydne J.; Suttorp, Marika J.; Shekelle, Paul G.] RAND Hlth, So Calif Evidence Based Practice Ctr, Santa Monica, CA USA.
[Shekelle, Paul G.] W Los Angeles VA Med Ctr, Los Angeles, CA USA.
[Takata, Glenn S.] Childrens Hosp Los Angeles, Div Gen Pediat, Los Angeles, CA 90027 USA.
RP Coker, TR (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, UCLA RAND Ctr Adolescent Hlth Promot, 10960 Wilshire Blvd,Ste 1550, Los Angeles, CA 90024 USA.
EM tcoker@mednet.ucla.edu
FU Agency for Healthcare Research and Quality (AHRQ) [290-2007-10056]; EPC
FX This article is based on research conducted by the Southern California
Evidence-based Practice Center (EPC) under contract with the Agency for
Healthcare Research and Quality (AHRQ) (contract 290-2007-10056). This
work was commissioned by AHRQ as an update to an earlier report and in
support of the update of practice guidelines.; AHRQ had a role, through
its sponsorship of the EPC program, in the general methods of EPC
systematic reviews and in development of the key questions for each
review. However, AHRQ had no role in the specific conduct of the review;
in the collection, management, analysis, and interpretation of the data;
or in the preparation, review, or approval of the manuscript.
NR 70
TC 101
Z9 104
U1 1
U2 11
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD NOV 17
PY 2010
VL 304
IS 19
BP 2161
EP 2169
DI 10.1001/jama.2010.1651
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 680XC
UT WOS:000284269800027
PM 21081729
ER
PT J
AU Nardone, DA
AF Nardone, David A.
TI Open Notes: Sharing Physician Notes With Patients
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Letter
C1 Portland VA Med Ctr, Portland, OR 97239 USA.
RP Nardone, DA (reprint author), Portland VA Med Ctr, Portland, OR 97239 USA.
NR 1
TC 0
Z9 0
U1 0
U2 1
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD NOV 16
PY 2010
VL 153
IS 10
BP 690
EP 690
DI 10.1059/0003-4819-153-10-201011160-00023
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 680ES
UT WOS:000284215800031
PM 21079235
ER
PT J
AU Turner, EH
AF Turner, Erick H.
TI Reboxetine in depression All the relevant data?
SO BRITISH MEDICAL JOURNAL
LA English
DT Letter
ID TRIALS
C1 [Turner, Erick H.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Turner, Erick H.] Portland VA Med Ctr, P3MHDC, Portland, OR 97239 USA.
RP Turner, EH (reprint author), Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
EM turnere@ohsu.edu
NR 6
TC 4
Z9 4
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1756-1833
J9 BRIT MED J
JI Br. Med. J.
PD NOV 16
PY 2010
VL 341
AR c6487
DI 10.1136/bmj.c6487
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 684WJ
UT WOS:000284585600004
PM 21081614
ER
PT J
AU Seetharaman, SV
Taylor, AB
Holloway, S
Hart, PJ
AF Seetharaman, Sai V.
Taylor, Alexander B.
Holloway, Stephen
Hart, P. John
TI Structures of mouse SOD1 and human/mouse SOD1 chimeras
SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Article
DE Copper-zinc superoxide dismutase; Amyotrophic lateral sclerosis; X-ray
crystallography; Protein aggregation
ID AMYOTROPHIC-LATERAL-SCLEROSIS; ZINC SUPEROXIDE-DISMUTASE; MOTOR-NEURON
DISEASE; WILD-TYPE; TRANSGENIC MICE; POSTTRANSLATIONAL MODIFICATIONS;
ATOMIC STRUCTURES; CRYSTAL-STRUCTURE; COPPER CHAPERONE; FAMILIAL ALS
AB Mutations in human copper-zinc superoxide dismutase (SOD1) cause an inherited form of amyotrophic lateral sclerosis (ALS). Inclusions enriched in pathogenic SOD1 accumulate in the spinal cords of transgenic mice expressing these proteins, but endogenous mouse SOD1 is not found as a component of these aggregates. In the accompanying paper, Karch and colleagues analyze aggregation propensities of human/mouse SOD1 chimeras in cell culture and identify two sequence elements in the human enzyme that seem to enhance its aggregation relative to the mouse enzyme. Here, we report the first structure of mouse SOD1 along with those of SOD1 chimeras in which residues 1-80 come from human SOD1 and residues 81-153 come from mouse SOD1 and vice versa. Taken together, the structural and cell-based data suggest a model in which residues Q42 and Q123 in mouse SOD1 modulate non-native SOD1-SOD1 intermolecular interactions at edge strands in the SOD1 Greek key beta-barrel. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Seetharaman, Sai V.; Taylor, Alexander B.; Holloway, Stephen; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA.
[Taylor, Alexander B.; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, XRay Crystallog Core Lab, San Antonio, TX 78229 USA.
[Hart, P. John] S Texas Vet Hlth Care Syst, Dept Vet Affairs, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA.
RP Hart, PJ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA.
EM pjhart@biochem.uthscsa.edu
FU NIH-NINDS [R01-NS39112, P01-NS04913]; William and Ella Owens Medical
Research Foundation; Judith and Jean Pape Adams Charitable Foundation;
X-ray Crystallography Core Laboratory; UTHSCSA
FX This work was supported by Grants from the NIH-NINDS R01-NS39112 (to
PJH), P01-NS04913 (to JSV, DRB, and PJH). SVS was supported in part by
the William and Ella Owens Medical Research Foundation and the Judith
and Jean Pape Adams Charitable Foundation. Support for the X-ray
Crystallography Core Laboratory by the UTHSCSA Executive Research
Committee and the San Antonio Cancer Institute is also gratefully
acknowledged. We thank Celeste Karch, Mercedes Prudencio, and David
Borchelt for continued collaboration and invaluable insight into the
biological aspects of aggregation of SOD1 and the SOD1 chimera
structures described in this paper.
NR 62
TC 8
Z9 11
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-9861
J9 ARCH BIOCHEM BIOPHYS
JI Arch. Biochem. Biophys.
PD NOV 15
PY 2010
VL 503
IS 2
BP 183
EP 190
DI 10.1016/j.abb.2010.08.014
PG 8
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 662JU
UT WOS:000282804400003
PM 20727846
ER
PT J
AU Porter, MP
AF Porter, Michael P.
TI Examining the Association Between Delay in Diagnosis and Decreased
Survival in Bladder Cancer
SO CANCER
LA English
DT Editorial Material
ID RADICAL CYSTECTOMY; GENDER
C1 [Porter, Michael P.] Univ Washington, Dept Urol, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
RP Porter, MP (reprint author), 1660 S Columbian Way S-112-GU, Seattle, WA 98108 USA.
EM mporter@u.washington.edu
NR 9
TC 4
Z9 4
U1 0
U2 2
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0008-543X
J9 CANCER-AM CANCER SOC
JI Cancer
PD NOV 15
PY 2010
VL 116
IS 22
BP 5122
EP 5125
DI 10.1002/cncr.25290
PG 4
WC Oncology
SC Oncology
GA 678CP
UT WOS:000284047400003
PM 20665888
ER
PT J
AU Yukl, SA
Gianella, S
Sinclair, E
Epling, L
Li, QS
Duan, LJ
Choi, ALM
Girling, V
Ho, T
Li, PL
Fujimoto, K
Lampiris, H
Hare, CB
Pandori, M
Haase, AT
Gunthard, HF
Fischer, M
Shergill, AK
McQuaid, K
Havlir, DV
Wong, JK
AF Yukl, Steven A.
Gianella, Sara
Sinclair, Elizabeth
Epling, Lorrie
Li, Qingsheng
Duan, Lijie
Choi, Alex L. M.
Girling, Valerie
Ho, Terence
Li, Peilin
Fujimoto, Katsuya
Lampiris, Harry
Hare, C. Bradley
Pandori, Mark
Haase, Ashley T.
Guenthard, Huldrych F.
Fischer, Marek
Shergill, Amandeep K.
McQuaid, Kenneth
Havlir, Diane V.
Wong, Joseph K.
TI Differences in HIV Burden and Immune Activation within the Gut of
HIV-Positive Patients Receiving Suppressive Antiretroviral Therapy
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CD38 ANTIGEN-EXPRESSION; DNA CPG
METHYLATION; T-CELL-ACTIVATION; LYMPHOID-TISSUE; HISTONE ACETYLATION;
VIRAL SUPPRESSION; TYPE-1 INFECTION; PROGNOSTIC VALUE; RECTAL MUCOSA
AB Background. The gut is a major reservoir for human immunodeficiency virus (HIV) in patients receiving antiretroviral therapy (ART). We hypothesized that distinct immune environments within the gut may support varying levels of HIV.
Methods. In 8 HIV-1-positive adults who were receiving ART and had CD4(+) T cell counts of >200 cells/mu L and plasma viral loads of <40 copies/mu L, levels of HIV and T cell activation were measured in blood samples and endoscopic biopsy specimens from the duodenum, ileum, ascending colon, and rectum.
Results. HIV DNA and RNA levels per CD4(+) T cell were higher in all 4 gut sites compared with those in the blood. HIV DNA levels increased from the duodenum to the rectum, whereas the median HIV RNA level peaked in the ileum. HIV DNA levels correlated positively with T cell activation markers in peripheral blood mononuclear cells (PBMCs) but negatively with T cell activation markers in the gut. Multiply spliced RNA was infrequently detected in gut, and ratios of unspliced RNA to DNA were lower in the colon and rectum than in PBMCs, which reflects paradoxically low HIV transcription, given the higher level of T cell activation in the gut.
Conclusions. HIV DNA and RNA are both concentrated in the gut, but the inverse relationship between HIV DNA levels and T cell activation in the gut and the paradoxically low levels of HIV expression in the large bowel suggest that different processes drive HIV persistence in the blood and gut.
C1 [Yukl, Steven A.; Choi, Alex L. M.; Li, Peilin; Fujimoto, Katsuya; Lampiris, Harry; Shergill, Amandeep K.; McQuaid, Kenneth; Wong, Joseph K.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Yukl, Steven A.; Sinclair, Elizabeth; Epling, Lorrie; Choi, Alex L. M.; Girling, Valerie; Ho, Terence; Li, Peilin; Fujimoto, Katsuya; Lampiris, Harry; Hare, C. Bradley; Shergill, Amandeep K.; McQuaid, Kenneth; Havlir, Diane V.; Wong, Joseph K.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Sinclair, Elizabeth; Epling, Lorrie; Girling, Valerie; Ho, Terence; Hare, C. Bradley; Havlir, Diane V.] San Francisco Gen Hosp, San Francisco, CA 94110 USA.
[Pandori, Mark] Dept Publ Hlth, San Francisco, CA USA.
[Li, Qingsheng; Duan, Lijie; Haase, Ashley T.] Univ Minnesota, Minneapolis, MN USA.
[Gianella, Sara; Guenthard, Huldrych F.; Fischer, Marek] Univ Zurich, Univ Zurich Hosp, Div Infect Dis & Hosp Epidemiol, Zurich, Switzerland.
RP Yukl, SA (reprint author), 4150 Clement St,111W3, San Francisco, CA 94121 USA.
EM steven.yukl@ucsf.edu
RI gunthard, huldrych/F-1724-2011; Fujimoto, Katsuya/G-2835-2012;
Infektiologie, USZ/A-6921-2011
OI gunthard, huldrych/0000-0002-1142-6723;
FU US Department of Veterans Affairs; National Institutes of Health
[P30-AI027763, NS051145, T32 AI60530]; Swiss National Science Foundation
[324730-130865, 3100A0-112670]
FX US Department of Veterans Affairs (Merit Award to J.K.W. and S.Y.);
National Institutes of Health (grant P30-AI027763 to S.Y., grant
NS051145 to J.K.W. and S.Y., and grant T32 AI60530 to D. V. H. and
S.Y.); Swiss National Science Foundation (grant to S. G., grant
324730-130865 to H. F. G., and grant 3100A0-112670 to M.F.).
NR 47
TC 135
Z9 135
U1 2
U2 10
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 15
PY 2010
VL 202
IS 10
BP 1553
EP 1561
DI 10.1086/656722
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 665SY
UT WOS:000283057000014
PM 20939732
ER
PT J
AU Montine, TJ
Shi, M
Quinn, JF
Peskind, ER
Craft, S
Ginghina, C
Chung, KA
Kim, H
Galasko, DR
Jankovic, J
Zabetian, CP
Leverenz, JB
Zhang, J
AF Montine, Thomas J.
Shi, Min
Quinn, Joseph F.
Peskind, Elaine R.
Craft, Suzanne
Ginghina, Carmen
Chung, Kathryn A.
Kim, Hojoong
Galasko, Douglas R.
Jankovic, Joseph
Zabetian, Cyrus P.
Leverenz, James B.
Zhang, Jing
TI CSF A beta(42) and tau in Parkinson's Disease with Cognitive Impairment
SO MOVEMENT DISORDERS
LA English
DT Article
DE Parkinson's disease; cognitive impairment; CSF biomarkers; A beta(42);
tau
ID CEREBROSPINAL-FLUID; ALZHEIMERS-DISEASE; BIOMARKERS; DEMENTIA; RATIO;
BETA
AB We tested the hypothesis that the CSF biomarker signature associated with Alzheimer's disease (AD) is present in a subset of individuals with Parkinson's disease and Dementia (PD-D) or with PD and Cognitive Impairment, Not Dementia (PD-CIND). We quantified CSF A beta(42), total tau (T-tau), and phospho-tau (P181-tau) using commercially available kits. Samples were from 345 individuals in seven groups (n): Controls <= 50 years (35), Controls > 50 years (115), amnestic Mild Cognitive Impairment (aMCI) (24), AD (49), PD (49), PD-CIND (62), and PD-D (11). We observed expected changes in AD or aMCI compared with age-matched or younger controls. CSF Ab42 was reduced in PD-CIND (P < 0.05) and PD-D (P < 0.01), whereas average CSF T-tau and P181-tau were unchanged or decreased. One-third of PD-CIND and one-half of PD-D patients had the biomarker signature of AD. Abnormal metabolism of Ab42 may be a common feature of PD-CIND and PD-D. (c) 2010 Movement Disorder Society
C1 [Montine, Thomas J.; Shi, Min; Ginghina, Carmen; Zhang, Jing] Univ Washington, Dept Pathol, Sch Med, Seattle, WA 98104 USA.
[Quinn, Joseph F.; Chung, Kathryn A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA.
[Peskind, Elaine R.; Craft, Suzanne] Univ Washington, Dept Psychiat & Behav Sci, Sch Med, Seattle, WA 98104 USA.
[Peskind, Elaine R.; Leverenz, James B.] VA Puget Sound Hlth Care Syst, Educ & Clin Ctr, VA NW Network Mental Illness Res, Seattle, WA USA.
[Craft, Suzanne; Kim, Hojoong; Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA.
[Kim, Hojoong; Zabetian, Cyrus P.; Leverenz, James B.] Univ Washington, Dept Neurol, Sch Med, Seattle, WA 98104 USA.
[Galasko, Douglas R.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA.
[Jankovic, Joseph] Baylor Coll Med, Parkinsons Dis Ctr, Houston, TX 77030 USA.
[Jankovic, Joseph] Baylor Coll Med, Dept Neurol, Movement Disorders Clin, Houston, TX 77030 USA.
RP Montine, TJ (reprint author), Univ Washington, Dept Pathol, Sch Med, 300 9th Ave,Room 713B, Seattle, WA 98104 USA.
EM tmontine@uw.edu
RI Shi, Min/G-6165-2012
OI Shi, Min/0000-0002-6901-2558
FU NIH [ES004696, NS057567, AG025327, AG033398, NS060252, NS062684,
AG05136, AG08017]
FX This work was supported by grants from the NIH (ES004696, NS057567,
AG025327, AG033398, NS060252, NS062684, AG05136, and AG08017), the
Michael J. Fox Foundation, the VA, and the Nancy and Buster Alvord
Endowment. This support had no role in the design and conduct of the
study; collection, management, analysis, and interpretation of the data;
and preparation, review, or approval of the manuscript. We thank Dr.
Kathleen Montine for editorial assistance.
NR 19
TC 86
Z9 89
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0885-3185
J9 MOVEMENT DISORD
JI Mov. Disord.
PD NOV 15
PY 2010
VL 25
IS 15
BP 2682
EP 2685
DI 10.1002/mds.23287
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA 678FX
UT WOS:000284060600032
PM 20818673
ER
PT J
AU Yin, MT
Shi, QH
Hoover, DR
Anastos, K
Sharma, A
Young, M
Levine, A
Cohen, MH
Shane, E
Golub, ET
Tien, PC
AF Yin, Michael T.
Shi, Qiuhu
Hoover, Donald R.
Anastos, Kathryn
Sharma, Anjali
Young, Mary
Levine, Alexandra
Cohen, Mardge H.
Shane, Elizabeth
Golub, Elizabeth T.
Tien, Phyllis C.
TI Fracture incidence in HIV-infected women: results from the Women's
Interagency HIV Study
SO AIDS
LA English
DT Article
DE fracture; fragility fracture; HIV-infected women; premenopausal
ID BONE-MINERAL DENSITY; ANTIRETROVIRAL THERAPY; AIDS PATIENTS; MEN;
OSTEOPOROSIS; PREVALENCE; OSTEOPENIA; INITIATION; DECREASES; EFAVIRENZ
AB Background: The clinical importance of the association of HIV infection and antiretroviral therapy (ART) with low bone mineral density (BMD) in premenopausal women is uncertain because BMD stabilizes on established ART and fracture data are limited.
Methods: We measured time to first new fracture at any site with median follow-up of 5.4 years in 2391 (1728 HIV-infected, 663 HIV-uninfected) participants in the Women's Interagency HIV Study (WIHS). Self-report of fracture was recorded at semiannual visits. Proportional hazard models assessed predictors of incident fracture.
Results: At baseline, HIV-infected women were older (40 +/- 9 vs. 36 +/- 10 years, P<0.0001), more likely to report postmenopausal status and be hepatitis C virus-infected, and weighed less than HIV-uninfected women. Among HIV-infected women, mean CD4(+) cell count was 482 cells/mu l; 66% were taking ART. Unadjusted incidence of fracture did not differ between HIV-infected and uninfected women (1.8 vs. 1.4/100 person-years, respectively, P - 0.18). In multivariate models, white (vs. African-American) race, hepatitis C virus infection, and higher serum creatinine, but not HIV serostatus, were statistically significant predictors of incident fracture. Among HIV-infected women, older age, white race, current cigarette use, and history of AIDS-defining illness were associated with incidence of new fracture.
Conclusion: Among predominantly premenopausal women, there was little difference in fracture incidence rates by HIV status, rather traditional risk factors were important predictors. Further research is necessary to characterize fracture risk in HIV-infected women during and after the menopausal transition. (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
C1 [Yin, Michael T.] Columbia Univ, Div Infect Dis, Med Ctr, New York, NY 10032 USA.
[Shi, Qiuhu] New York Med Coll, Valhalla, NY 10595 USA.
[Hoover, Donald R.] Rutgers State Univ, Piscataway, NJ USA.
[Anastos, Kathryn] Montefiore Med Ctr, Bronx, NY 10467 USA.
[Sharma, Anjali] SUNY Hlth Sci Ctr, Brooklyn, NY 11203 USA.
[Young, Mary] Georgetown Sch Med, Washington, DC USA.
[Levine, Alexandra] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
[Golub, Elizabeth T.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Tien, Phyllis C.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA.
[Cohen, Mardge H.] Stroger Hosp, Dept Med, Chicago, IL USA.
[Cohen, Mardge H.] Rush Univ, Dept Med, Chicago, IL 60612 USA.
RP Yin, MT (reprint author), Columbia Univ, Div Infect Dis, Med Ctr, 630 W168th St,PH8-876, New York, NY 10032 USA.
EM Mty4@columbia.edu
FU National Institute of Allergy and Infectious Diseases [UO1-AI-35004,
UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, UO1-AI-42590,
K23 AI 059884, K23 AI 066943]; Eunice Kennedy Shriver National Institute
of Child Health and Human Development [UO1-HD-32632]; National Cancer
Institute; National Institute on Drug Abuse; National Institute on
Deafness and Other Communication Disorders; National Center for Research
Resources (UCSF-CTSI) [UL1 RR024131]
FX The WIHS is funded by the National Institute of Allergy and Infectious
Diseases (UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989,
UO1-AI-34993, and UO1-AI-42590) and by the Eunice Kennedy Shriver
National Institute of Child Health and Human Development (UO1-HD-32632).
The study is cofunded by the National Cancer Institute, the National
Institute on Drug Abuse, and the National Institute on Deafness and
Other Communication Disorders. Funding is provided by the National
Center for Research Resources (UCSF-CTSI Grant Number UL1 RR024131).
Drs. Yin and Tien are supported by the National Institute of Allergy and
Infectious Diseases through K23 AI 059884 and K23 AI 066943,
respectively.
NR 36
TC 48
Z9 48
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD NOV 13
PY 2010
VL 24
IS 17
BP 2679
EP 2686
DI 10.1097/QAD.0b013e32833f6294
PG 8
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 672KV
UT WOS:000283582800010
PM 20859192
ER
PT J
AU Ducharme, N
Banks, WA
Morley, JE
Robinson, SM
Niehoff, ML
Mattern, C
Farr, SA
AF Ducharme, Nicole
Banks, William A.
Morley, John E.
Robinson, Sandra M.
Niehoff, Michael L.
Mattern, Claudia
Farr, Susan A.
TI Brain distribution and behavioral effects of progesterone and
pregnenolone after intranasal or intravenous administration (vol 641, pg
128, 2010)
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Correction
C1 [Ducharme, Nicole; Banks, William A.; Morley, John E.; Robinson, Sandra M.; Niehoff, Michael L.; Farr, Susan A.] St Louis Univ, Sch Med, Dept Internal Med, Div Geriatr, St Louis, MO 63103 USA.
[Ducharme, Nicole; Morley, John E.; Robinson, Sandra M.; Niehoff, Michael L.; Farr, Susan A.] Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, St Louis, MO USA.
[Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
[Mattern, Claudia] M&P Pharma AG, CH-6370 Stans, Switzerland.
RP Banks, WA (reprint author), St Louis Univ, Sch Med, Dept Internal Med, Div Geriatr, St Louis, MO 63103 USA.
EM wabanks1@uw.edu
RI morley, john/F-9177-2011
OI morley, john/0000-0001-6444-2965
NR 1
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-2999
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD NOV 10
PY 2010
VL 646
IS 1-3
BP 46
EP 46
DI 10.1016/j.ejphar.2010.07.021
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 662YY
UT WOS:000282851400006
ER
PT J
AU Crum-Cianflone, NF
Roediger, M
Hullsiek, KH
Ganesan, A
Landrum, M
Weintrob, A
Agan, B
Medina, S
Rahkola, J
Hale, B
Janoff, EN
AF Crum-Cianflone, Nancy F.
Roediger, Mollie
Hullsiek, Kathy Huppler
Ganesan, Anuradha
Landrum, Michael
Weintrob, Amy
Agan, Brian
Medina, Sheila
Rahkola, Jeremy
Hale, Braden
Janoff, Edward N.
CA Infect Dis Clinical Res Program HI
TI The association of ethnicity with antibody responses to pneumococcal
vaccination among adults with HIV infection
SO VACCINE
LA English
DT Article
DE Ethnicity; Antibodies; Pneumococcal vaccination; HIV
ID IMMUNODEFICIENCY-VIRUS-INFECTION; HIV-1-INFECTED UGANDAN ADULTS;
POLYSACCHARIDE VACCINE; RISK-FACTORS; RESISTANCE PATTERNS;
CLINICAL-FEATURES; CHARLESTON COUNTY; CONJUGATE VACCINE; SOUTH-CAROLINA;
DISEASE
AB Ethnicity may be associated with the incidence of pneumococcal infections and the frequency of protective vaccine responses. Earlier studies have suggested that HIV-infected persons of black ethnicity develop less robust immune responses to pneumococcal vaccination that may relate to their higher incidence of invasive disease. We evaluated the association of ethnicity with capsule-specific antibody responses to pneumococcal revaccination, with either the pneumococcal conjugate (PCV) or polysaccharide (PPV) vaccines among 188 HIV-infected adults. The proportion of the 77 African Americans (AA) and 111 Caucasians with comparable virologic and immunologic parameters who achieved a positive immune response (>= 2-fold rise in capsule-specific IgG from baseline with post-vaccination value >= 1 mu g/mL for >= 2 of 4 serotypes) at day 60 after revaccination was similar (43% vs. 49%, respectively, p = 0.65). Results were also similar when vaccine types (PPV and PCV) were examined separately. Mean changes in log(10) transformed IgG levels from baseline to days 60 and 180 post-vaccination were also not significantly different between AA and Caucasians. In summary, in this ethnically diverse cohort with equal access to care, we did not observe differential antibody responses between AA and Caucasian HIV-infected adults after pneumococcal revaccination. Published by Elsevier Ltd.
C1 [Crum-Cianflone, Nancy F.] USN, San Diego Med Ctr, Clin Invest Dept KCA, San Diego, CA 92134 USA.
[Crum-Cianflone, Nancy F.; Roediger, Mollie; Hullsiek, Kathy Huppler; Ganesan, Anuradha; Landrum, Michael; Weintrob, Amy; Agan, Brian; Medina, Sheila; Hale, Braden] Uniformed Serv Univ Hlth Sci, Infect Dis Clin Res Program, Bethesda, MD 20814 USA.
[Roediger, Mollie; Hullsiek, Kathy Huppler] Univ Minnesota, Div Biostat, Minneapolis, MN USA.
[Ganesan, Anuradha] Natl Naval Med Ctr, Bethesda, MD USA.
[Landrum, Michael] San Antonio Mil Med Ctr, San Antonio, TX USA.
[Weintrob, Amy] Walter Reed Army Med Ctr, Washington, DC 20307 USA.
[Rahkola, Jeremy; Janoff, Edward N.] Univ Colorado, Mucosal & Vaccine Res Program Colorado MAVRC, Denver, CO 80202 USA.
[Hale, Braden] USN, Hlth Res Ctr, San Diego, CA 92134 USA.
[Rahkola, Jeremy; Janoff, Edward N.] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Crum-Cianflone, NF (reprint author), USN, San Diego Med Ctr, Clin Invest Dept KCA, 34800 Bob Wilson Dr,Ste 5, San Diego, CA 92134 USA.
EM nancy.crum@med.navy.mil
OI Agan, Brian/0000-0002-5114-1669
FU Department of Defense (DoD) through the Uniformed Services University of
the Health Sciences [IDCRP RV-150]; National Institute of Allergy and
Infectious Diseases, National Institutes of Health (NIH) [Y1-AI-5072];
Veterans Affairs Research Service
FX Support for this work (IDCRP RV-150) was provided by the Infectious
Disease Clinical Research Program (IDCRP), a Department of Defense (DoD)
program executed through the Uniformed Services University of the Health
Sciences. This project has been funded in whole, or in part, with
federal funds from the National Institute of Allergy and Infectious
Diseases, National Institutes of Health (NIH), under Inter-Agency
Agreement Y1-AI-5072. Additional support was obtained from the Veterans
Affairs Research Service.
NR 27
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD NOV 10
PY 2010
VL 28
IS 48
BP 7583
EP 7588
DI 10.1016/j.vaccine.2010.09.056
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 696HN
UT WOS:000285432600002
PM 20887830
ER
PT J
AU De Sousa, M
Smith, D
Corcoran, A
Bailey, FA
Furman, C
Ritchie, C
Rosenfeld, K
Shreve, S
Casarett, D
AF De Sousa, Maysa
Smith, Dawn
Corcoran, Amy
Bailey, F. Amos
Furman, Christian
Ritchie, Christine
Rosenfeld, Kenneth
Shreve, Scott
Casarett, David
TI Families' Perceptions of Inpatient and Home Hospice Care at End-of-Life
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Letter
ID TERMINALLY-ILL
C1 [De Sousa, Maysa; Smith, Dawn; Casarett, David] Ctr Hlth Equ Res & Promot, Dept Vet Affairs Med Ctr, Philadelphia, PA USA.
[Corcoran, Amy; Casarett, David] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
[Bailey, F. Amos] Safe Harbor Palliat Care, Dept Vet Affairs Med Ctr, Birmingham, AL USA.
[Furman, Christian] Univ Louisville, Div Geriatr Med, Louisville, KY 40292 USA.
[Ritchie, Christine] Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Dept Vet Affairs Med Ctr, Birmingham, AL USA.
[Rosenfeld, Kenneth] Dept Vet Affairs Med Ctr, Greater Los Angeles, CA USA.
[Shreve, Scott] Hosp & Palliat Care, Dept Vet Affairs, Washington, DC USA.
RP Casarett, D (reprint author), Philadelphia VA Ctr Hlth Equ Res & Promot, Inst Aging, Ctr Bioeth, 3615 Chestnut St, Philadelphia, PA 19104 USA.
EM Casarett@mail.med.upenn.edu
FU PHS HHS [K01 HP00084-02]
NR 6
TC 4
Z9 4
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9926
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD NOV 8
PY 2010
VL 170
IS 20
BP 1856
EP 1857
DI 10.1001/archinternmed.2010.392
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 676SC
UT WOS:000283937600023
PM 21059980
ER
PT J
AU Pierce, A
Wei, R
Halade, D
Yoo, SE
Ran, QT
Richardson, A
AF Pierce, Anson
Wei, Rochelle
Halade, Dipti
Yoo, Si-Eun
Ran, Qitao
Richardson, Arlan
TI A Novel mouse model of enhanced proteostasis: Full-length human heat
shock factor 1 transgenic mice
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Aggresome; Chaperones; Heat shock proteins; Heat shock response;
Polyglutamine; Heat shock transcription factor 1
ID TRANSCRIPTION FACTOR; OXIDATIVE STRESS; PROTEINS; DISEASE; HSF1;
ACTIVATION; AGGRESOMES; ASSOCIATION; DEGRADATION; REPRESSION
AB The heat shock response (HSR) is controlled by the master transcriptional regulator heat shock factor 1 (HSF1). HSF1 maintains proteostasis and resistance to stress through production of heat shock proteins (HSPs). No transgenic model exists that overexpresses HSF1 in tissues of the central nervous system (CNS). We generated a transgenic mouse overexpressing full-length non-mutant HSF1 and observed a 2-4-fold increase in HSF1 mRNA and protein expression in all tissues studied of HSF1 transgenic (HSF1(+/0)) mice compared to wild type (WT) littermates, including several regions of the CNS. Basal expression of HSP70 and 90 showed only mild tissue-specific changes: however, in response to forced exercise, the skeletal muscle HSR was more elevated in HSF1(+/0) mice compared to WT littermates and in fibroblasts following heat shock, as indicated by levels of inducible HSP70 mRNA and protein. HSF1(+/0) cells elicited a significantly more robust HSR in response to expression of the 82 repeat polyglutamine-YFP fusion construct (Q82YFP) and maintained proteasome-dependent processing of Q82YFP compared to WT fibroblasts. Overexpression of HSF1 was associated with fewer, but larger Q82YFP aggregates resembling aggresomes in HSF1(+/0) cells, and increased viability. Therefore, our data demonstrate that tissues and cells from mice overexpressing full-length non-mutant HSF1 exhibit enhanced proteostasis. Published by Elsevier Inc.
C1 [Pierce, Anson; Yoo, Si-Eun; Ran, Qitao; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
[Pierce, Anson; Wei, Rochelle; Halade, Dipti; Yoo, Si-Eun; Ran, Qitao; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
[Pierce, Anson; Ran, Qitao; Richardson, Arlan] S Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX 78284 USA.
RP Pierce, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM piercea2@uthscsa.edu
RI Pierce, Anson/D-1079-2012
OI Pierce, Anson/0000-0002-1383-0180
FU VA career development award [VISN17]; Semp Russ Foundation of the San
Antonio Area Foundation
FX This work was supported by a VA career development award, VISN17 grant,
and by the Semp Russ Foundation of the San Antonio Area Foundation to
A.P.
NR 28
TC 11
Z9 11
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD NOV 5
PY 2010
VL 402
IS 1
BP 59
EP 65
DI 10.1016/j.bbrc.2010.09.111
PG 7
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 679TB
UT WOS:000284182600011
PM 20920476
ER
PT J
AU Yang, L
Hu, HM
Zielinska-Kwiatkowska, A
Chansky, HA
AF Yang, Liu
Hu, Hsien-Ming
Zielinska-Kwiatkowska, Anna
Chansky, Howard A.
TI FOXO1 is a direct target of EWS-Fli1 oncogenic fusion protein in Ewing's
sarcoma cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Ewing's sarcoma; EWS-Fli1; Oncogenic fusion protein; FOXO1; RNA
interference; Inducible siRNA; Tumor suppressor gene
ID FORKHEAD TRANSCRIPTION FACTORS; RNA INTERFERENCE; DNA-BINDING;
EXPRESSION; CANCER; RECEPTOR; GROWTH; TUMORS; TRANSLOCATION; REPRESSION
AB Ewing's family tumors are characterized by a specific t(11;22) chromosomal translocation that results in the formation of EWS-Fli1 oncogenic fusion protein. To investigate the effects of EWS-Fli1 on gene expression, we carried out DNA microarray analysis after specific knockdown of EWS-Fli1 through transfection of synthetic siRNAs. EWS-Fli1 knockdown increased expression of genes such as DKK1 and p57 that are known to be repressed by EWS-Fli1 fusion protein. Among other potential EWS-Fli1 targets identified by our microarray analysis, we have focused on the FOXO1 gene since it encodes a potential tumor suppressor and has not been previously reported in Ewing's cells. To better understand how EWS-Fli1 affects FOXO1 expression, we have established a doxycycline-inducible siRNA system to achieve stable and reversible knockdown of EWS-Fli1 in Ewing's sarcoma cells. Here we show that FOXO1 expression in Ewing's cells has an inverse relationship with EWS-Fli1 protein level, and FOXO1 promoter activity is increased after doxycycline-induced EWS-Fli1 knockdown. In addition, we have found that direct binding of EWS-Fli1 to FOXO1 promoter is attenuated after doxycycline-induced siRNA knockdown of the fusion protein. Together, these results suggest that suppression of FOXO1 function by EWS-Fli1 fusion protein may contribute to cellular transformation in Ewing's family tumors. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Yang, Liu] Univ Washington, Sch Med, Dept Orthoped, Seattle, WA 98108 USA.
VA Puget Sound Hlth Care Syst, Med Res Serv, Seattle, WA 98108 USA.
RP Yang, L (reprint author), Univ Washington, Sch Med, Dept Orthoped, 1660 S Columbian Way,GMR 151, Seattle, WA 98108 USA.
EM lyang@u.washington.edu
FU Veterans Affairs Merit Review Award; Public Health Service Grant [RO1
AR051455]
FX This work was supported by Public Health Service Grant RO1 AR051455 (to
L.Y.) and by a Veterans Affairs Merit Review Award (to H.A.C.).
NR 27
TC 9
Z9 10
U1 3
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD NOV 5
PY 2010
VL 402
IS 1
BP 129
EP 134
DI 10.1016/j.bbrc.2010.09.129
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 679TB
UT WOS:000284182600023
PM 20933505
ER
PT J
AU Weisbart, RH
Chan, G
Heinze, E
Mory, R
Nishimura, RN
Colburn, K
AF Weisbart, Richard H.
Chan, Grace
Heinze, Emil
Mory, Rachel
Nishimura, Robert N.
Colburn, Keith
TI BRAF Drives Synovial Fibroblast Transformation in Rheumatoid Arthritis
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID B-RAF; SIGNALING PATHWAY; JOINT DESTRUCTION; MUTATIONS; CANCER; GENE;
ACTIVATION; MECHANISM; MELANOMA
AB Synovial fibroblasts destroy articular cartilage and bone in rheumatoid arthritis, but the mechanism of fibroblast transformation remains elusive. Because gain-of-function mutations of BRAF can transform fibroblasts, we examined BRAF in rheumatoid synovial fibroblasts. The strong gain-of-function mutation, V600R, of BRAF found in melanomas and other cancers was identified in first passage synovial fibroblasts from two of nine rheumatoid arthritis patients and confirmed by restriction site mapping. BRAF-specific siRNA inhibited proliferation of synovial fibroblasts with V600R mutations. A BRAF aberrant splice variant with an intact kinase domain and partial loss of the N-terminal autoinhibitory domain was identified in fibroblasts from an additional patient, and fibroblast proliferation was inhibited by BRAF-specific siRNA. Our finding is the first to establish mechanisms for fibroblast transformation responsible for destruction of articular cartilage and bone in rheumatoid arthritis and establishes a new target for therapeutic intervention.
C1 [Weisbart, Richard H.; Chan, Grace] Vet Affairs Greater Los Angeles Hlth Care Syst, Dept Res, Sepulveda, CA 91343 USA.
[Heinze, Emil; Mory, Rachel] Olive View UCLA Med Ctr, Dept Med, Sylmar, CA 91342 USA.
[Nishimura, Robert N.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA.
[Colburn, Keith] Vet Affairs Med Ctr, Dept Med, Loma Linda, CA 92357 USA.
[Colburn, Keith] Loma Linda Univ, Dept Med, Loma Linda, CA 92354 USA.
RP Weisbart, RH (reprint author), 16111 Plummer St, North Hills, CA 91343 USA.
EM rweisbar@ucla.edu
NR 22
TC 4
Z9 8
U1 0
U2 1
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD NOV 5
PY 2010
VL 285
IS 45
BP 34299
EP 34303
DI 10.1074/jbc.C110.168195
PG 5
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 673KL
UT WOS:000283659100002
PM 20843808
ER
PT J
AU Abdallah, RT
Keum, JS
Lee, MH
Wang, B
Gooz, M
Luttrell, DK
Luttrell, LM
Jaffa, AA
AF Abdallah, Rany T.
Keum, Joo-Seob
Lee, Mi-Hye
Wang, Bing
Gooz, Monika
Luttrell, Deirdre K.
Luttrell, Louis M.
Jaffa, Ayad A.
TI Plasma Kallikrein Promotes Epidermal Growth Factor Receptor
Transactivation and Signaling in Vascular Smooth Muscle through Direct
Activation of Protease-activated Receptors
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID OXIDE-GENERATING VASODILATORS; MOLECULAR-WEIGHT KININOGEN; RAT
CAROTID-ARTERY; NITRIC-OXIDE; ENDOTHELIAL-CELLS; ATHEROSCLEROTIC
LESIONS; SUBSTRATE-SPECIFICITY; THROMBIN RECEPTORS; CORONARY-ARTERIES;
GENE-EXPRESSION
AB The kallikrein-kinin system, along with the interlocking reninangiotensin system, is a key regulator of vascular contractility and injury response. The principal effectors of the kallikrein-kinin system are plasma and tissue kallikreins, proteases that cleave high molecular weight kininogen to produce bradykinin. Most of the cellular actions of kallikrein (KK) are thought to be mediated by bradykinin, which acts via G protein-coupled B1 and B2 bradykinin receptors on VSMCs and endothelial cells. Here, we find that primary aortic vascular smooth muscle but not endothelial cells possess the ability to activate plasma prekallikrein. Surprisingly, exposing VSMCs to prekallikrein leads to activation of the ERK1/2 mitogen-activated protein kinase cascade via a mechanism that requires kallikrein activity but does not involve bradykinin receptors. In transfected HEK293 cells, we find that plasma kallikrein directly activates G protein-coupled protease-activated receptors (PARs) 1 and 2, which possess consensus kallikrein cleavage sites, but not PAR4. In vascular smooth muscles, KK stimulates ADAM (a disintegrin and metalloprotease) 17 activity via a PAR1/2 receptor-dependent mechanism, leading sequentially to release of the endogenous ADAM17 substrates, amphiregulin and tumor necrosis factor-alpha, metalloprotease-dependent transactivation of epidermal growth factor receptors, and metalloprotease and epidermal growth factor receptor-dependent ERK1/2 activation. These results suggest a novel mechanism of bradykinin-independent kallikrein action that may contribute to the regulation of vascular responses in pathophysiologic states, such as diabetes mellitus.
C1 [Abdallah, Rany T.; Keum, Joo-Seob; Lee, Mi-Hye; Wang, Bing; Gooz, Monika; Luttrell, Deirdre K.; Luttrell, Louis M.; Jaffa, Ayad A.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Luttrell, Louis M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
[Luttrell, Louis M.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA.
RP Jaffa, AA (reprint author), Amer Univ Beirut, Fac Med, Dept Biochem, Beirut, Lebanon.
EM aj24@aub.edu.lb
FU National Institutes of Health [HL087986, HL077192, DK55524]; South
Carolina Center for Biomedical Research Excellence in Cardiovascular
Diseases; Department of Veterans Affairs
FX This work was supported, in whole or in part, by National Institutes of
Health Grants HL087986 and HL077192 (to A. A. J.), and DK55524 (to L. M.
L.). This work was also supported by the South Carolina Center for
Biomedical Research Excellence in Cardiovascular Diseases (to D. K. L.)
and Department of Veterans Affairs Research Enhancement Award Program
awards.
NR 66
TC 24
Z9 25
U1 0
U2 5
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD NOV 5
PY 2010
VL 285
IS 45
BP 35206
EP 35215
DI 10.1074/jbc.M110.171769
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 673KL
UT WOS:000283659100094
PM 20826789
ER
PT J
AU Wong, KK
Muller, MLTM
Kuwabara, H
Studenski, SA
Bohnen, NI
AF Wong, Ka Kit
Muller, Martijn L. T. M.
Kuwabara, Hiroto
Studenski, Stephanie A.
Bohnen, Nicolaas I.
TI Olfactory loss and nigrostriatal dopaminergic denervation in the elderly
SO NEUROSCIENCE LETTERS
LA English
DT Article
DE Aging; Basal ganglia; Dopamine; Nigrostriatal; Olfaction; positron
emission tomography
ID C-11 METHYL TRIFLATE; LEWY BODY DISEASE; PARKINSONS-DISEASE;
ALZHEIMERS-DISEASE; COGNITIVE IMPAIRMENT; PET RADIOLIGANDS; IN-VIVO;
DEMENTIA; AGE; DYSFUNCTION
AB Olfactory dysfunction may precede common neurodegenerative disorders in the elderly, such as Alzheimer (AD) or Parkinson disease (PD). However, pathobiological mechanisms of olfactory loss in the elderly are poorly understood. Although nigrostriatal dopaminergic denervation is a key patholobiological feature of PD, age-associated nigrostriatal denervation (AASDD) occurs also with normal aging and can be more prominent in some elderly. We investigated the relationship between AASDD and olfactory performance in community-dwelling subjects. Community-dwelling subjects (n = 73, 44 F/29 M, mean age 64.0 +/- 16.4, range 20-85) underwent brain dopamine transporter (DAT)[C-11]2-beta-carbomethoxy-3 beta-(4-fluorophenyl) tropane (beta-CFT) positron emission tomography (PET) imaging and olfactory assessment using the 40-odor University of Pennsylvania Smell Identification Test (UPSIT). Subjects with clinical or DAT PET evidence of Parkinson disease (PD) were not eligible for the study. AASDD was defined based on normative data in young and middle-aged subjects. Compared to a mild and general linear decline in odor identification observed in most subjects (R-2 = 0.18, P = 0.0002), there were 13 subjects who deviated below the 5% confidence interval level in age-predicted UPSIT scores. Analysis limited to elderly subjects 60 years and over demonstrated a significant association between poor smell (n = 10 out of 49, 20.4%) and AASDD (chi(2) = 4.4, P<0.05). There is a significant association between olfactory dysfunction and more prominent nigrostriatal denervation in the elderly. Olfactory assessment may have potential as a screening tool to detect age-accelerated neurodegeneration in the elderly. Published by Elsevier Ireland Ltd.
C1 [Muller, Martijn L. T. M.; Bohnen, Nicolaas I.] Univ Michigan, Dept Radiol, Funct Neuroimaging Cognit & Mobil Lab, Ann Arbor, MI 48105 USA.
[Wong, Ka Kit; Bohnen, Nicolaas I.] GRECC, VA Ann Arbor Healthcare Syst, Ann Arbor, MI USA.
[Muller, Martijn L. T. M.; Bohnen, Nicolaas I.] Univ Michigan, Dept Radiol, Dept Neurol, Ann Arbor, MI 48105 USA.
[Kuwabara, Hiroto] Johns Hopkins Univ, Dept Radiol, Baltimore, MD USA.
[Studenski, Stephanie A.] GRECC, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Studenski, Stephanie A.] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr Med, Pittsburgh, PA USA.
RP Bohnen, NI (reprint author), Univ Michigan, Dept Radiol, Funct Neuroimaging Cognit & Mobil Lab, 24 Frank Lloyd Wright Dr,Box 362, Ann Arbor, MI 48105 USA.
EM nbohnen@umich.edu
RI Muller, Martijn/A-7205-2010
OI Muller, Martijn/0000-0002-1133-7202
FU Department of Veterans Affairs
FX This study was funded by the Department of Veterans Affairs.
NR 32
TC 20
Z9 21
U1 1
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0304-3940
J9 NEUROSCI LETT
JI Neurosci. Lett.
PD NOV 5
PY 2010
VL 484
IS 3
BP 163
EP 167
DI 10.1016/j.neulet.2010.08.037
PG 5
WC Neurosciences
SC Neurosciences & Neurology
GA 664XX
UT WOS:000282998400001
PM 20727944
ER
PT J
AU Maes, K
Nemeth, E
Roodman, GD
Huston, A
Esteve, F
Freytes, C
Callander, N
Katodritou, E
Tussing-Humphreys, L
Rivera, S
Vanderkerken, K
Lichtenstein, A
Ganz, T
AF Maes, Ken
Nemeth, Elizabeta
Roodman, G. David
Huston, Alissa
Esteve, Flavia
Freytes, Cesar
Callander, Natalie
Katodritou, Eirini
Tussing-Humphreys, Lisa
Rivera, Seth
Vanderkerken, Karin
Lichtenstein, Alan
Ganz, Tomas
TI In anemia of multiple myeloma, hepcidin is induced by increased bone
morphogenetic protein 2
SO BLOOD
LA English
DT Article
ID EXPRESSION; IL-6; PROMOTER; CELLS; RECEPTORS; CYTOKINES; BMP;
INFLAMMATION; INDUCTION; SURVIVAL
AB Hepcidin is the principal iron-regulatory hormone and a pathogenic factor in anemia of inflammation. Patients with multiple myeloma (MM) frequently present with anemia. We showed that MM patients had increased serum hepcidin, which inversely correlated with hemoglobin, suggesting that hepcidin contributes to MM-related anemia. Searching for hepcidin-inducing cytokines in MM, we quantified the stimulation of hepcidin promoter-luciferase activity in HuH7 cells by MM sera. MM sera activated the hepcidin promoter significantly more than did normal sera. We then examined the role of bone morphogenetic proteins (BMPs) and interleukin-6 (IL-6), the major transcriptional regulators of hepcidin. Mutations in both BMP-responsive elements abrogated the activation dramatically, while mutations in the IL-6-responsive signal transducer and activator of transcription 3-binding site (STAT3-BS) had only a minor effect. Cotreatment with anti-BMP-2/4 or noggin-Fc blocked the promoter induction with all MM sera, anti-IL-6 blocked it with a minority of sera, whereas anti-BMP-4, -6, or -9 antibodies had no effect. BMP-2-immunodepleted MM sera had decreased promoter stimulatory capacity, and BMP-2 concentrations in MM sera were significantly higher than in normal sera. Our results demonstrate that BMP-2 is a major mediator of the hepcidin stimulatory activity of MM sera. (Blood. 2010;116(18):3635-3644)
C1 [Nemeth, Elizabeta; Rivera, Seth; Ganz, Tomas] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Nemeth, Elizabeta; Rivera, Seth; Ganz, Tomas] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA.
[Maes, Ken; Vanderkerken, Karin] Vrije Univ Brussel VUB, Dept Hematol & Immunol, Brussels, Belgium.
[Roodman, G. David; Huston, Alissa; Esteve, Flavia] Univ Pittsburgh, Sch Med & Pittsburgh, VA Med Ctr, Pittsburgh, PA USA.
[Freytes, Cesar] Univ Texas Hlth Sci Ctr San Antonio, Audie L Murphy Mem Vet Hosp, San Antonio, TX 78229 USA.
[Callander, Natalie] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Div Hematol, Madison, WI USA.
[Katodritou, Eirini] Theagen Canc Ctr, Dept Hematol, Thessaloniki, Greece.
[Tussing-Humphreys, Lisa] USDA ARS, Baton Rouge, LA USA.
[Lichtenstein, Alan] W Los Angeles VA Univ Calif Los Angeles Med Ctr, Los Angeles, CA USA.
RP Ganz, T (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, 10833 Le Conte Ave,CHS 37-055, Los Angeles, CA 90095 USA.
EM tganz@mednet.ucla.edu
RI Vanderkerken, Karin/I-3513-2013
FU National Institutes of Health [RO1 DK 065029]; UCLA-Jonsson
Comprehensive Cancer Center; VA, Los Angeles, CA
FX This work was funded by National Institutes of Health grant RO1 DK
065029 (T.G. and E.N.), an Interdisciplinary Seed Grant from the
UCLA-Jonsson Comprehensive Cancer Center (E.N., A.L., and T.G.), and by
research support from the VA, Los Angeles, CA (A.L.).
NR 33
TC 68
Z9 73
U1 1
U2 8
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 4
PY 2010
VL 116
IS 18
BP 3635
EP 3644
DI 10.1182/blood-2010-03274571
PG 10
WC Hematology
SC Hematology
GA 675SM
UT WOS:000283853200034
PM 20679527
ER
PT J
AU Allen, KD
Oddone, EZ
Coffman, CJ
Datta, SK
Juntilla, KA
Lindquist, JH
Walker, TA
Weinberger, M
Bosworth, HB
AF Allen, Kelli D.
Oddone, Eugene Z.
Coffman, Cynthia J.
Datta, Santanu K.
Juntilla, Karen A.
Lindquist, Jennifer H.
Walker, Tessa A.
Weinberger, Morris
Bosworth, Hayden B.
TI Telephone-Based Self-management of Osteoarthritis A Randomized Trial
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID PHYSICAL-ACTIVITY; HEALTH-STATUS; KNEE OSTEOARTHRITIS;
EDUCATION-PROGRAMS; CLINICAL-TRIALS; CHRONIC DISEASE; ARTHRITIS;
VETERANS; INTERVENTIONS; OUTCOMES
AB Background: Osteoarthritis is a leading cause of pain and disability, and self-management behaviors for osteoarthritis are underutilized.
Objective: To examine the effectiveness of a telephone-based self-management intervention for hip or knee osteoarthritis in a primary care setting.
Design: Randomized clinical trial with equal assignment to osteoarthritis self-management, health education (attention control), and usual care control groups. (ClinicalTrials.gov registration number: NCT00288912)
Setting: Primary care clinics in a Veterans Affairs Medical Center.
Patients: 515 patients with symptomatic hip or knee osteoarthritis.
Intervention: The osteoarthritis self-management intervention involved educational materials and 12 monthly telephone calls to support individualized goals and action plans. The health education intervention involved nonosteoarthritis educational materials and 12 monthly telephone calls related to general health screening topics.
Measurements: The primary outcome was score on the Arthritis Impact Measurement Scales-2 pain subscale (range, 0 to 10). Pain was also assessed with a 10-cm visual analog scale. Measurements were collected at baseline and 12 months.
Results: 461 participants (90%) completed the 12-month assessment. The mean Arthritis Impact Measurement Scales-2 pain score in the osteoarthritis self-management group was 0.4 point lower (95% CI, -0.8 to 0.1 point; P = 0.105) than in the usual care group and 0.6 point lower (CI, -1.0 to -0.2 point; P = 0.007) than in the health education group at 12 months. The mean visual analog scale pain score in the osteoarthritis self-management group was 1.1 points lower (CI, -1.6 to -0.6 point; P < 0.001) than in the usual care group and 1.0 point lower (CI, -1.5 to -0.5 point; P < 0.001) than in the health education group. Health care use did not differ across the groups.
Limitation: The study was conducted at 1 Veterans Affairs Medical Center, and the sample consisted primarily of men.
Conclusion: A telephone-based osteoarthritis self-management program produced moderate improvements in pain, particularly compared with a health education control group.
C1 Duke Univ, Med Ctr, Durham Vet Affairs Med Ctr, Durham, NC 27706 USA.
Univ N Carolina, Chapel Hill, NC USA.
RP Allen, KD (reprint author), US Dept Vet Affairs, Hlth Serv Res & Dev Serv 152, Durham Vet Affairs Med Ctr, 508 Fulton St, Durham, NC 27705 USA.
EM kelli.allen@duke.edu
FU U.S. Department of Veterans Affairs, Veterans Health Administration,
Health Services Research and Development Service [IIR 04-016, 08-027,
91-408]
FX By the U.S. Department of Veterans Affairs, Veterans Health
Administration, Health Services Research and Development Service (IIR
04-016 and Career Scientist Awards 08-027 [Dr. Bosworth] and 91-408 [Dr.
Weinberger]).
NR 42
TC 40
Z9 41
U1 2
U2 9
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD NOV 2
PY 2010
VL 153
IS 9
BP 570
EP 579
DI 10.7326/0003-4819-153-9-201011020-00006
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 673MH
UT WOS:000283667000003
PM 21041576
ER
PT J
AU Arciniegas, DB
Beresford, TP
AF Arciniegas, David B.
Beresford, Thomas P.
TI Managing difficult interactions with patients in neurology practices A
practical approach
SO NEUROLOGY
LA English
DT Article
ID PRIMARY-CARE; DEMENTIA; PSYCHOPATHOLOGY; PREVALENCE; OUTCOMES
C1 [Arciniegas, David B.; Beresford, Thomas P.] Univ Colorado, Sch Med, Neurobehav Disorders Program, Dept Psychiat, Aurora, CO 80045 USA.
[Arciniegas, David B.] Univ Colorado, Sch Med, Behav Neurol Sect, Dept Neurol, Aurora, CO 80045 USA.
[Beresford, Thomas P.] Denver Vet Affairs Med Ctr, Psychiat Serv, Denver, CO USA.
RP Arciniegas, DB (reprint author), Univ Colorado, Sch Med, Neurobehav Disorders Program, Dept Psychiat, 13001 E 17th Pl,Campus Box F546, Aurora, CO 80045 USA.
EM David.Arciniegas@UCDenver.edu
FU Neuropsychiatry; American Psychiatric Publishing, Inc.; Demos Medical
Publishing; Orasi Medical, Inc.; National Institute of Mental Health
(NIMH) [R01 MH081920-01A1]; National Institute of Child Health and Human
Development (NICHD) [R01 HD047242-04, R01 HD047242-04S1]; Department of
Defense [W81XWH-08-2-0652, A-15306]; National Institute on Aging (NIA)
[R21 AG028609-01]; Henry M. Jackson Foundation; National Institute on
Alcohol Abuse and Alcoholism [5R21AA016294]
FX Dr. Arciniegas serves as an Associate Editor for Journal of
Neuropsychiatry and Clinical Neurosciences and Neuropsychiatric Disease
and Treatment, serves as an Editorial Board Member for The Open
Psychiatry Journal, Brain Injury, Neurotrauma Letter, serves as Guest
Editor for NeuroRehabilitation, and serves as International Editorial
Board Member for Archivos de Neurociencias; receives publishing
royalties from Neuropsychiatry: An Introductory Approach (Cambridge
University Press, 2001), Clinical Manual for the Management of Adults
with Traumatic Brain Injuries (American Psychiatric Publishing, Inc.,
2010-prepublication royalties), and Brain Injury Medicine, 2nd edition
(Demos Medical Publishing, 2010-prepublication royalties); receives
research support from Orasi Medical, Inc.; receives research support
from National Institute of Mental Health (NIMH R01 MH081920-01A1
[Coinvestigator]), National Institute of Child Health and Human
Development (NICHD R01 HD047242-04 [Site Principal Investigator], NICHD
R01 HD047242-04S1 [Site Principal Investigator]), Department of Defense
(W81XWH-08-2-0652 [Consultant]), National Institute on Aging (NIA R21
AG028609-01 [Coinvestigator]); and receives research support from Henry
M. Jackson Foundation. Dr. Beresford served as editorial board member
for Alcohol & Alcoholism; received royalties from publishing
Neuropsychiatry: An Introductory Approach, Cambridge University Press;
received honoraria from speaking engagements or educational activities
from Bristol Meyers Squibb; and receives research support from
Department of Defense [A-15306 (Principal Investigator)] and National
Institute on Alcohol Abuse and Alcoholism [5R21AA016294 (Principal
Investigator)].
NR 21
TC 4
Z9 4
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD NOV 2
PY 2010
VL 75
IS 18
SU 1
BP S39
EP S44
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 690KH
UT WOS:000285003200008
PM 21041770
ER
PT J
AU Corboy, JR
Gross, RA
AF Corboy, John R.
Gross, Robert A.
TI Clinical perspective for the practicing neurologist A new journal?
SO NEUROLOGY
LA English
DT Editorial Material
C1 [Corboy, John R.] Univ Colorado, Dept Neurol, Denver, CO 80202 USA.
[Corboy, John R.] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Gross, Robert A.] Univ Rochester, Med Ctr, Strong Epilepsy Ctr, Rochester, NY 14642 USA.
RP Corboy, JR (reprint author), Univ Colorado, 12631 E 17th Ave,B185, Aurora, CO 80045 USA.
EM john.corboy@ucdenver.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD NOV 2
PY 2010
VL 75
IS 18
SU 1
BP S1
EP S1
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA 690KH
UT WOS:000285003200001
ER
PT J
AU Miravalle, A
Corboy, JR
AF Miravalle, Augusto
Corboy, John R.
TI Therapeutic options in multiple sclerosis Five new things
SO NEUROLOGY
LA English
DT Article
ID CEREBROSPINAL VENOUS INSUFFICIENCY; STEM-CELL TRANSPLANTATION;
PLACEBO-CONTROLLED TRIAL; AUTOIMMUNE ENCEPHALOMYELITIS; ORAL FINGOLIMOD;
JC VIRUS; INTERFERON; DISEASE; FLUID; REMYELINATION
C1 [Miravalle, Augusto; Corboy, John R.] Univ Colorado, Dept Neurol, Denver, CO 80202 USA.
[Corboy, John R.] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Miravalle, A (reprint author), 12631 E 17th Ave,B185, Aurora, CO 80045 USA.
EM augusto.miravalle@ucdenver.edu
FU Novartis; BioMS Medical; Orasi Medical Inc.; NIH/NINDS
[1UO1NS4571901A1]; National MS Society
FX Dr. Miravalle serves as a consultant for Bayer Schering Pharma, EMD
Serono, Inc., Advanced Studies in Medicine (ASiM), and Novartis. Dr.
Corboy serves as Editor for Neurology (R) Clinical Practice and as
Section Editor for Neurology Today; serves as a consultant for Bayer
Schering Pharma, EMD Serono, Inc., Advanced Studies in Medicine (ASiM),
and Novartis; has received research support from Novartis, BioMS
Medical, Orasi Medical Inc., the NIH/NINDS (1UO1NS4571901A1 [PI]), and
the National MS Society; and has reviewed files and given expert
testimony in medico-legal cases. He is a part-time employee of the
Denver Veterans Medical Center.
NR 35
TC 5
Z9 5
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD NOV 2
PY 2010
VL 75
IS 18
SU 1
BP S22
EP S26
PG 5
WC Clinical Neurology
SC Neurosciences & Neurology
GA 690KH
UT WOS:000285003200005
PM 21041767
ER
PT J
AU Zhou, Y
Manka, JT
Rodriguez, AL
Weaver, CD
Days, EL
Vinson, PN
Jadhav, S
Hermann, EJ
Jones, CK
Conn, PJ
Lindsley, CW
Stauffer, SR
AF Zhou, Ya
Manka, Jason T.
Rodriguez, Alice L.
Weaver, C. David
Days, Emily L.
Vinson, Paige N.
Jadhav, Satyawan
Hermann, Elizabeth J.
Jones, Carrie K.
Conn, P. Jeffrey
Lindsley, Craig W.
Stauffer, Shaun R.
TI Discovery of N-Aryl Piperazines as Selective mGluR(5) Potentiators with
Improved In Vivo Utility
SO ACS MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE mGluR; potentiator; positive allosteric modulator; schizophrenia;
hyperlocomotion
ID POSITIVE ALLOSTERIC MODULATOR; GLUTAMATE-RECEPTOR SUBTYPE-5;
ANTIPSYCHOTIC-LIKE; SCHIZOPHRENIA; SERIES; SAR
AB This letter describes the discovery, structure-activity relationship, and in vitro and in vivo pharmacological profile of a novel non-MPEP-derived mGluR(5) positive allosteric modulator (PAM) based upon an N-aryl piperazine chemotype. This mGluR(5) chemotyper exhibits the ability to act as either a noncompetitive antagonist/negative allosteric modulator or a potentiator of the glutamate response, depending on the identity of the amide substituent, that is, a molecular switch". A rapidly optimized PAM, 10e (VU0364289), was shown to be potent and specific for the rat mGluR(5) receptor and subsequently demonstrated to be efficacious in a clinically relevant rodent model predictive of antipsychotic activity, thus providing the first example of a centrally active mGluR(5) PAM optimized from an HTS-derived mGluR(5) noncompetitive antagonist.
C1 [Zhou, Ya; Manka, Jason T.; Rodriguez, Alice L.; Weaver, C. David; Vinson, Paige N.; Jadhav, Satyawan; Hermann, Elizabeth J.; Jones, Carrie K.; Conn, P. Jeffrey; Lindsley, Craig W.; Stauffer, Shaun R.] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA.
[Lindsley, Craig W.] Vanderbilt Univ, Med Ctr, Dept Chem, Nashville, TN 37232 USA.
[Zhou, Ya; Manka, Jason T.; Rodriguez, Alice L.; Weaver, C. David; Days, Emily L.; Vinson, Paige N.; Jadhav, Satyawan; Hermann, Elizabeth J.; Jones, Carrie K.; Conn, P. Jeffrey; Lindsley, Craig W.; Stauffer, Shaun R.] Vanderbilt Univ, Med Ctr, Vanderbilt Program Drug Discovery, Nashville, TN 37232 USA.
[Jones, Carrie K.] Tennessee Valley Healthcare Syst, US Dept Vet Affairs, Nashville, TN 37212 USA.
[Weaver, C. David; Days, Emily L.] Vanderbilt Inst Chem Biol, Nashville, TN 37232 USA.
RP Stauffer, SR (reprint author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA.
EM shaun.stauffer@vanderbilt.edu
RI Conn, Peter/D-7848-2012; Zhou, Ya/F-1220-2013
FU NIH National Institute of Neurological Disorders and Stroke (NINDS)
[5R01 NS031373-15]; National Institute of Mental Health (NIMH) [R01
MH073676-04]
FX We thank the NIH National Institute of Neurological Disorders and Stroke
(NINDS #5R01 NS031373-15) and the National Institute of Mental Health
(NIMH #R01 MH073676-04) for support of this program.
NR 25
TC 29
Z9 29
U1 0
U2 2
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-5875
J9 ACS MED CHEM LETT
JI ACS Med. Chem. Lett.
PD NOV
PY 2010
VL 1
IS 8
BP 433
EP 438
DI 10.1021/ml100181a
PG 6
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 680AS
UT WOS:000284203100013
PM 23308336
ER
PT J
AU Jablecki, CK
Nuckols, TK
Sandin, KJ
Asch, SM
AF Jablecki, Charles K.
Nuckols, Teryl K.
Sandin, Karl J.
Asch, Steven M.
TI CLINICAL QUALITY MEASURES FOR ELECTRODIAGNOSIS IN SUSPECTED CTS:
COMMENTS REPLY
SO MUSCLE & NERVE
LA English
DT Letter
C1 [Jablecki, Charles K.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.
[Nuckols, Teryl K.; Asch, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA.
[Nuckols, Teryl K.; Asch, Steven M.] RAND Corp, Santa Monica, CA USA.
[Sandin, Karl J.] Sister Kenny Rehabil Inst, Minneapolis, MN USA.
[Asch, Steven M.] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA.
RP Jablecki, CK (reprint author), Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0148-639X
J9 MUSCLE NERVE
JI Muscle Nerve
PD NOV
PY 2010
VL 42
IS 5
BP 843
EP 844
DI 10.1002/21850
PG 2
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 675JW
UT WOS:000283827700029
ER
PT J
AU Grudzen, CR
Richardson, LD
Morrison, M
Cho, E
Morrison, RS
AF Grudzen, Corita R.
Richardson, Lynne D.
Morrison, Matthew
Cho, Elizabeth
Morrison, R. Sean
TI Palliative Care Needs of Seriously Ill, Older Adults Presenting to the
Emergency Department
SO ACADEMIC EMERGENCY MEDICINE
LA English
DT Article; Proceedings Paper
CT Annual Scientific Meeting of the Society-for-Academic-Emergency-Medicine
CY JUN, 2010
CL Phoenix, AZ
SP Soc Acad Emergency Med
ID OF-LIFE QUESTIONNAIRE; COGNITIVE IMPAIRMENT; VALIDATION; MORTALITY;
VALIDITY
AB Objectives: The objective was to identify the palliative care needs of seriously ill, older adults in the emergency department (ED).
Methods: The authors conducted a cross-sectional structured survey. A convenience sample of 50 functionally impaired adults 65 years or older with coexisting cancer, congestive heart failure, end-stage liver or renal disease, stroke, oxygen-dependent pulmonary disease, or dementia was recruited from an urban academic tertiary care ED. Face-to-face interviews were conducted using the Needs Near the End-of-Life Screening Tool (NEST), McGill Quality of Life Index (MQOL), and Edmonton Symptom Assessment Survey (ESAS) to assess 1) range and severity of symptoms, 2) goals of care, 3) psychological well-being, 4) health care utilization, 5) spirituality, 6) social connectedness, 7) financial burden, 8) the patient clinician relationship, and 9) overall quality of life (QOL).
Results: Mean (+/- SD) age was 74.3 (+/- 6.5) years and cancer was the most common diagnosis. Mean (+/- SD) QOL on the MQOL was 3.6 (+/- 2.9). Over half of the patients exceeded intratest severity-of-needs cutoffs in four categories of the NEST: physical symptoms (47/50, 94%), finances (36/50, 72%), mental health (31/50, 62%), and access to care (29/50, 58%). The majority of patients reported moderate to severe fatigue, pain, dyspnea, and depression on the ESAS.
Conclusions: Seriously ill, older adults in an urban ED have substantial palliative care needs. Future work should focus on the role of emergency medicine and the new specialty of palliative care in addressing these needs.
C1 [Grudzen, Corita R.; Richardson, Lynne D.; Morrison, Matthew; Cho, Elizabeth] Mt Sinai Sch Med, Dept Emergency Med, New York, NY USA.
[Grudzen, Corita R.; Morrison, R. Sean] Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Med, New York, NY USA.
[Morrison, R. Sean] James J Peters VA Hosp, Bronx, NY USA.
RP Grudzen, CR (reprint author), Mt Sinai Sch Med, Dept Emergency Med, New York, NY USA.
EM corita.grudzen@mssm.edu
OI Grudzen, Corita/0000-0003-3039-8497
FU NIA NIH HHS [K24 AG022345]
NR 21
TC 37
Z9 39
U1 3
U2 11
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1069-6563
J9 ACAD EMERG MED
JI Acad. Emerg. Med.
PD NOV
PY 2010
VL 17
IS 11
BP 1253
EP 1257
DI 10.1111/j.1553-2712.2010.00907.x
PG 5
WC Emergency Medicine
SC Emergency Medicine
GA 676UW
UT WOS:000283945100019
PM 21175525
ER
PT J
AU Henderson, C
Jackson, C
Slade, M
Young, AS
Strauss, JL
AF Henderson, Claire
Jackson, Carlos
Slade, Mike
Young, Alexander S.
Strauss, Jennifer L.
TI How Should we Implement Psychiatric Advance Directives? Views of
Consumers, Caregivers, Mental Health Providers and Researchers
SO ADMINISTRATION AND POLICY IN MENTAL HEALTH AND MENTAL HEALTH SERVICES
RESEARCH
LA English
DT Article
DE Psychiatric advance directives; Consensus study; Implementation
ID RANDOMIZED CONTROLLED-TRIAL; SERVICES; ILLNESS; CARE
AB The aim of this study was to measure expert consensus on the implementation of Psychiatric Advance Directives (PADs) within the Veterans Health Administration. We conducted a two-round Delphi study with 55 panelists including consumers, caregivers, mental health providers and researchers. For a number of items where no positive or negative consensus was reached we found differences between the views of consumers and non-consumers, reflecting consumer's preferences for nonmedical settings for completion and assistance with completion independent of the treatment team. Thus, the principle of consumer choice that applies to MHAD content should also be applied to the process of completion offered.
C1 [Henderson, Claire; Slade, Mike] Kings Coll London, Inst Psychiat, Hlth Serv, London SE5 8AF, England.
[Henderson, Claire; Jackson, Carlos] James J Peters VA Med Ctr, Bronx, NY USA.
[Young, Alexander S.] Greater Los Angeles VA, Los Angeles, CA USA.
[Young, Alexander S.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Strauss, Jennifer L.] Durham VA Med Ctr, Durham, NC USA.
[Strauss, Jennifer L.] Duke Univ, Med Ctr, Durham, NC USA.
[Henderson, Claire; Slade, Mike] Kings Coll London, Inst Psychiat, Populat Res Dept, London SE5 8AF, England.
RP Henderson, C (reprint author), Kings Coll London, Inst Psychiat, Hlth Serv, P029,Crespigny Pk, London SE5 8AF, England.
EM Claire.Henderson@iop.kcl.ac.uk
RI Henderson, Claire/E-4664-2010; Slade, Mike/C-1641-2010; Young,
Alexander/A-1523-2009
OI Henderson, Claire/0000-0002-6998-5659; Slade, Mike/0000-0001-7020-3434;
Young, Alexander/0000-0002-9367-9213
NR 30
TC 14
Z9 14
U1 3
U2 7
PU MAIK NAUKA/INTERPERIODICA/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA
SN 0894-587X
J9 ADM POLICY MENT HLTH
JI Adm. Policy. Ment. Health
PD NOV
PY 2010
VL 37
IS 6
BP 447
EP 458
DI 10.1007/s10488-010-0264-5
PG 12
WC Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 711RW
UT WOS:000286610100001
PM 20099077
ER
PT J
AU Fife, CE
Yankowsky, KW
Ayello, EA
Capitulo, KL
Fowler, E
Krasner, DL
Mulder, G
Sibbald, RG
AF Fife, Caroline E.
Yankowsky, Kevin W.
Ayello, Elizabeth A.
Capitulo, Kathleen Leask
Fowler, Evonne
Krasner, Diane L.
Mulder, Gerit
Sibbald, R. Gary
TI Legal Issues in the Care of Pressure Ulcer Patients: Key Concepts for
Healthcare Providers-A Consensus Paper from the International Expert
Wound Care Advisory Panel (c)
SO ADVANCES IN SKIN & WOUND CARE
LA English
DT Article
ID ELECTRONIC MEDICAL-RECORD; M SKIN CONDITIONS; LONG-TERM-CARE; BRADEN
SCALE; RELIABILITY
C1 [Fife, Caroline E.] Univ Texas Hlth Sci Ctr, Div Cardiol, Houston, TX USA.
[Fife, Caroline E.] Mem Hermann Ctr Wound Healing, Houston, TX USA.
[Yankowsky, Kevin W.] Fulbright & Jaworski LLP, Houston, TX USA.
[Ayello, Elizabeth A.] John A Hartford Inst Geriatr Nursing, New York, NY USA.
[Capitulo, Kathleen Leask] James J Peters VA Med Ctr, Bronx, NY USA.
[Capitulo, Kathleen Leask] Case Western Univ, Cleveland, OH USA.
[Capitulo, Kathleen Leask] Wenzhou Med Coll, Wenzhou, Peoples R China.
[Fowler, Evonne] San Gorgonio Mem Hosp, Banning, CA USA.
[Krasner, Diane L.] Rest Haven York, York, PA USA.
[Mulder, Gerit] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA.
[Sibbald, R. Gary] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON M5S 1A1, Canada.
RP Fife, CE (reprint author), Univ Texas Hlth Sci Ctr, Div Cardiol, Houston, TX USA.
NR 35
TC 4
Z9 4
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1527-7941
J9 ADV SKIN WOUND CARE
JI Adv. Skin Wound Care
PD NOV
PY 2010
VL 23
IS 11
BP 493
EP +
DI 10.1097/01.ASW.0000390494.20964.a5
PG 14
WC Dermatology; Nursing; Surgery
SC Dermatology; Nursing; Surgery
GA 832ZF
UT WOS:000295849100003
PM 20975333
ER
PT J
AU Ho, CH
Powell, HL
Collins, JF
Bauman, WA
Spungen, AM
AF Ho, Chester H.
Powell, Heather L.
Collins, Joseph F.
Bauman, William A.
Spungen, Ann M.
TI Poor Nutrition Is a Relative Contraindication to Negative Pressure Wound
Therapy for Pressure Ulcers: Preliminary Observations in Patients with
Spinal Cord Injury
SO ADVANCES IN SKIN & WOUND CARE
LA English
DT Article
ID VACUUM-ASSISTED CLOSURE; PREVALENCE
AB OBJECTIVE: To assess the efficacy of negative-pressure wound therapy (NPWT) for healing of pressure ulcers (PrUs) in individuals with spinal-cord injury (SCI).
DESIGN: Multicenter, 28-day observational study.
SETTING: Ten Veterans Affairs Medical Center SCI centers.
PATIENTS: Eighty-six SCI inpatients with Stage III/IV pelvic PrUs.
INTERVENTIONS: Standard wound care with NPWT versus standard wound care alone (NoNPWT).
MAIN OUTCOME MEASURES: Change in wound surface area (WSA) using the Verg Videometer Measurement Documentation software.
MAIN RESULTS: The proportion of patients demonstrating a decrease in WSA (healing subgroup) was not significantly different between the NPWT (n = 33) and NoNPWT (n = 53) groups (67% vs 70%, respectively). In the healing subgroup, there was no significant difference between the NPWT versus NoNPWT groups in WSA decrease (-43 +/- 22% vs -50% +/- 26%, not statistically significant). Similarly, in the nonhealing subgroup, there was no significant difference between NPWT and NoNPWT groups (31% +/- 26% vs 32% +/- 34%). In the NPWT group, the nonhealing subgroup (11/33) had significantly lower serum albumin levels than the healing subgroup (22/33) (2.9 +/- 0.4 vs 3.3 +/- 0.5 mg/dL, P < .05). In the NoNPWT group, there was no significant difference in serum albumin levels between the healing versus nonhealing subgroups (3.2 +/- 0.3 vs 3.2 +/- 0.3 mg/dL).
CONCLUSION: In SCI patients with Stage III/IV pelvic PrUs, NPWT did not significantly influence the rate of healing. Additionally, in malnourished individuals (albumin <3.0 mg/dL), NPWT was not efficacious. Healing outcomes in the NPWT group were significantly influenced by albumin levels, whereas no such disparity was noted between the healing and nonhealing PrUs for the NoNPWT group. Nutritional status appears to be important in the effectiveness of NPWT.
C1 [Ho, Chester H.; Powell, Heather L.] Louis Stokes Cleveland Dept Vet Affairs Med Ctr, Cleveland, OH USA.
[Ho, Chester H.; Powell, Heather L.] Case Western Reserve Univ, Dept Phys Med & Rehabil, Cleveland, OH 44106 USA.
[Collins, Joseph F.] VA Med Ctr, Cooperat Studies Program Coordinating Ctr, Perry Point, MD USA.
[Bauman, William A.; Spungen, Ann M.] James J Peters VA Med Ctr, RR&D Ctr Excellence Med Consequences Spinal Cord, Bronx, NY USA.
[Bauman, William A.; Spungen, Ann M.] Mt Sinai Sch Med, Dept Med, New York, NY USA.
[Bauman, William A.; Spungen, Ann M.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA.
FU Department of Veterans Affairs, VA Office of Research and Development,
Clinical Sciences Service [535]; SCI Service and Rehabilitation Research
and Development Center of Excellence for the Medical Consequences of
SCI, VA Medical Center, Bronx, New York [B4162C]
FX Funding for this study was provided by the Department of Veterans
Affairs, VA Office of Research and Development, Clinical Sciences
Service, Cooperative Studies Program, CS #535; SCI Service and
Rehabilitation Research and Development Center of Excellence for the
Medical Consequences of SCI #B4162C, James J. Peters VA Medical Center,
Bronx, New York. The authors acknowledge Dr William Krol, as well as the
following participating sites and site investigators for their effort
and participation in this project: Charlie Norwood VA Medical Center
(Augusta, Georgia)-Rose C. Trincher, MD; James J. Peters VA Medical
Center (Bronx, New York)-George A. Deitrick, MD; Louis Stokes VA Medical
Center (Cleveland, Ohio)-Chester H. Ho, MD; VA North Texas Healthcare
System: Dallas VA Medical Center-Lance L. Goetz, MD; Edward Hines Jr VA
Hospital (Hines, Illinois)-Bernard A. Nemchausky, MD; Michael E. Debakey
VA Medical Center (Houston, Texas)-Sally A. Holmes, MD; VA Palo Alto
Health Care System (Palo Alto, California)-Roy Sasaki, MD; Hunter Holmes
McGuire VA Medical Center (Richmond, Virginia)-Meena Midha, MD; James A.
Haley Veterans' Hospital (Tampa, Florida)-John L. Merritt, MD; and VA
Boston Healthcare System, West Roxbury Campus (Boston,
Massachusetts)-Sunil Sabharwal, MD.
NR 21
TC 11
Z9 13
U1 1
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1527-7941
J9 ADV SKIN WOUND CARE
JI Adv. Skin Wound Care
PD NOV
PY 2010
VL 23
IS 11
BP 508
EP 516
DI 10.1097/01.ASW.0000390493.43835.ec
PG 9
WC Dermatology; Nursing; Surgery
SC Dermatology; Nursing; Surgery
GA 832ZF
UT WOS:000295849100004
PM 20975334
ER
PT J
AU Kim, MS
Wang, TY
Ou, FS
Klein, AJ
Hudson, PA
Messenger, JC
Masoudi, FA
Rumsfeld, JS
Ho, PM
AF Kim, Michael S.
Wang, Tracy Y.
Ou, Fang-Shu
Klein, Andrew J.
Hudson, Paul A.
Messenger, John C.
Masoudi, Frederick A.
Rumsfeld, John S.
Ho, P. Michael
TI Association of prior coronary artery bypass graft surgery with quality
of care of patients with non-ST-segment elevation myocardial infarction:
A report from the National Cardiovascular Data Registry Acute Coronary
Treatment and Intervention Outcomes Network Registry-Get With the
Guidelines
SO AMERICAN HEART JOURNAL
LA English
DT Article
ID RITA-3 RANDOMIZED-TRIAL; UNSTABLE ANGINA; FOLLOW-UP; GLYCOPROTEIN
IIB/IIIA; NONINVASIVE STRATEGY; SURVIVAL; DISEASE; IMPROVEMENT
AB Background The American College of Cardiology/American Health Association guidelines recommend both an early invasive strategy and administration of antiplatelet/anticoagulant therapy for high-risk patients in the absence of contraindications. Little is known about adherence to guideline recommendations in patients with prior coronary artery bypass graft (CABG) surgery presenting with non-ST-segment elevation myocardial infarction (NSTEMI).
Methods We analyzed 47,557 patients with NSTEMI in the 2007-2008 National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines. Treatment patterns were compared between patients with and without prior CABG surgery. Multivariable regression with generalized estimating equations evaluated the association between prior CABG and in-hospital outcomes.
Results In this study, 8,790 NSTEMI patients (18.5%) had a history of CABG surgery. Prior CABG surgery was associated with a significantly lower adjusted likelihood of early cardiac catheterization (adjusted odds ratio [OR] 0.88, 95% CI 0.83-0.92), higher rates of short-term clopidogrel use (adjusted OR 1.08, 95% CI 1.02-1.14), and comparable use of anticoagulant therapy (adjusted OR 0.96, 95% CI 0.88-1.04). Adjusted risks of bleeding and in-hospital mortality did not differ significantly between the 2 groups (adjusted ORs 1.00, 95% CI 0.92-1.11 and 0.99, 95% CI 0.87-1.11, respectively).
Conclusions Patients with prior CABG surgery presenting with NSTEMI are often felt to be at high risk for adverse outcomes and therefore require aggressive treatment. Our study indicates that they are less likely to undergo guideline-recommended early cardiac catheterization but equally or more likely to receive guideline-recommended antiplatelet and anticoagulant therapy. This risk-treatment paradox, however, does not appear to negatively influence short-term clinical outcomes. (Am Heart J 2010;160:951-7.)
C1 [Kim, Michael S.] Univ Washington, Med Ctr, Sch Med, Seattle, WA 98195 USA.
[Wang, Tracy Y.; Ou, Fang-Shu] Duke Clin Res Inst, Durham, NC USA.
[Klein, Andrew J.] John Cochran VA Med Ctr, St Louis, MO USA.
[Hudson, Paul A.; Messenger, John C.] Univ Colorado Denver, Aurora, CO USA.
[Masoudi, Frederick A.] Denver Hlth Med Ctr, Denver, CO USA.
[Rumsfeld, John S.; Ho, P. Michael] Denver VA Med Ctr, Denver, CO USA.
RP Kim, MS (reprint author), Univ Washington, Med Ctr, Sch Med, 1959 NE Pacific St,Box 356116, Seattle, WA 98195 USA.
EM mshkim@u.washington.edu
NR 25
TC 9
Z9 10
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
J9 AM HEART J
JI Am. Heart J.
PD NOV
PY 2010
VL 160
IS 5
BP 951
EP 957
DI 10.1016/j.ahj.2010.07.025
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 683FX
UT WOS:000284458700025
PM 21095285
ER
PT J
AU Lawson, N
Thompson, K
Saunders, G
Saiz, J
Richardson, J
Brown, D
Ince, N
Caldwell, M
Pope, D
AF Lawson, Nancy
Thompson, Kim
Saunders, Gabrielle
Saiz, Jaya
Richardson, Jeannette
Brown, Deborah
Ince, Naomi
Caldwell, Marc
Pope, Diana
TI SOUND INTENSITY AND NOISE EVALUATION IN A CRITICAL CARE UNIT
SO AMERICAN JOURNAL OF CRITICAL CARE
LA English
DT Article
ID ENVIRONMENTAL NOISE; SLEEP DISRUPTION; HOSPITAL WARDS; ICU;
INTERVENTION; SETTINGS; NIGHT
AB Background Sound levels in intensive care units can be high. Unfortunately, high levels of sound tend to result in poor sleep quality, which leads to slower healing, poorer immune response, and decreased cognitive function.
Objectives To measure sound levels to which patients in intensive care units are typically exposed.
Methods Peak sound pressure levels of alarms on medical devices set at different output levels were measured. Additionally, ambient sound pressure levels for durations of 10 to 24 hours were measured on 12 occasions in patients' rooms in the intensive care unit.
Results Peak levels of equipment alarms measured inside a patient's room were high, and increased as the setting of the alarm level increased. The levels of these alarms when measured in an adjacent room did not increase with alarm output level. Mean sound levels inside the patient's room were generally less than 45 dB(A), but peak levels were often greater than 85 dB(C). Closing the door of the adjacent room did not decrease these peak levels. Peak and mean levels did not differ systematically during 24 hours of measurement.
Conclusions High-intensity equipment alarms disturb patients' sleep but are critical in a medical emergency. However, nurses should not assume that raising the alarm output level will ensure that the alarm is audible from an adjacent room. Ambient noise measurements indicate high peak levels during both day and night. (American Journal of Critical Care. 2010; 19:e88-e99)
C1 [Lawson, Nancy; Thompson, Kim; Saunders, Gabrielle; Brown, Deborah; Ince, Naomi] Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, Portland, OR 97239 USA.
[Caldwell, Marc] Seattle VA Med Ctr, Seattle, WA USA.
RP Saunders, G (reprint author), Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM Gabrielle.saunders@va.gov
FU Department of Veterans Affairs, Veterans Health Administration
Rehabilitation Research and Development [4844C]
FX This study was supported in part by grant 4844C from the Department of
Veterans Affairs, Veterans Health Administration Rehabilitation Research
and Development.
NR 40
TC 25
Z9 26
U1 1
U2 9
PU AMER ASSOC CRITICAL CARE NURSES
PI ALISO VIEJO
PA 101 COLUMBIA, ALISO VIEJO, CA 92656 USA
SN 1062-3264
J9 AM J CRIT CARE
JI Am. J. Crit. Care
PD NOV 1
PY 2010
VL 19
IS 6
BP E88
EP E99
DI 10.4037/ajcc2010180
PG 12
WC Critical Care Medicine; Nursing
SC General & Internal Medicine; Nursing
GA 673LB
UT WOS:000283662100003
PM 21041190
ER
PT J
AU Spiegel, BMR
AF Spiegel, Brennan M. R.
TI Treatment Strategies for Acid Reflux: EncomPASSing Practical Solutions
for Primary Care
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Editorial Material
ID DISEASE; TRIALS
AB Despite a steady diet of randomized controlled trials (RCTs) for over three decades, nearly all of our routine clinical decisions remain incompletely supported, or even totally unaddressed, by the burgeoning pile of RCT data. The biomedical literature tends to focus on explanatory RCTs that compare new agents with placebo; it is less common to find pragmatic clinical trials (PCTs) that test the risks, benefits, and costs of competing active therapies within the context of usual practice settings. In this issue of the American Journal of Gastroenterology, Moayeddi and colleagues report the results of the EncomPASS study-a novel PCT for the primary care management of reflux disease. In this editorial, the results of EncomPASS are discussed, and the study is highlighted as a model for investigators to follow as we continue to emphasize pragmatic trials that address everyday challenges in clinical care.
C1 [Spiegel, Brennan M. R.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Spiegel, Brennan M. R.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Spiegel, Brennan M. R.] CURE Digest Dis Res Ctr, Los Angeles, CA USA.
[Spiegel, Brennan M. R.] Univ Calif Los Angeles, VA Ctr Outcomes Res & Educ, Los Angeles, CA USA.
RP Spiegel, BMR (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,Bldg 115,Room 215, Los Angeles, CA 90073 USA.
EM bspiegel@mednet.ucla.edu
NR 9
TC 1
Z9 1
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD NOV
PY 2010
VL 105
IS 11
BP 2347
EP 2349
DI 10.1038/ajg.2010.378
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 674UM
UT WOS:000283775600003
PM 21048680
ER
PT J
AU Kvale, EA
Woodby, L
Williams, BR
AF Kvale, Elizabeth A.
Woodby, Lesa
Williams, Beverly Rosa
TI The Experience of Older Patients With Cancer in Phase 1 Clinical Trials:
A Qualitative Case Series
SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE
LA English
DT Article
DE aging; cancer psychosocial aspects; hope; illness and disease
experiences; older people; pain; research participation; social support;
symptom management
ID RANDOMIZED CONTROLLED-TRIAL; OF-LIFE; I TRIALS; BODY-IMAGE; HOPE;
PARTICIPATION; PERCEPTIONS; CHEMOTHERAPY; EXPECTATIONS; PERSPECTIVE
AB This article explores the experiences of older patients with cancer in phase 1 clinical trials. Conducting a case series of face-to-face, in-depth, open-ended interviews and using qualitative methods of analysis, we find that the psychosocial process of social comparison is relevant for understanding older adults' phase 1 clinical trial participation. Social comparison influences decisions to enroll in a phase 1 clinical trial, shapes perceptions of supportive care needs, and encourages the utilization of hope. Additional research should develop strategies for addressing supportive care needs among this patient cohort whose use of social comparison can inhibit articulation of pain, suffering, and symptom burden as well as use of informal support systems.
C1 [Kvale, Elizabeth A.; Woodby, Lesa; Williams, Beverly Rosa] Birmingham Atlanta Geriatr Res Educ & Clin Ctr GR, Birmingham, AL USA.
[Kvale, Elizabeth A.; Woodby, Lesa; Williams, Beverly Rosa] Birmingham VA Med Ctr, Birmingham, AL USA.
[Kvale, Elizabeth A.; Woodby, Lesa; Williams, Beverly Rosa] Univ Alabama, Ctr Aging, Birmingham, AL USA.
[Kvale, Elizabeth A.; Woodby, Lesa; Williams, Beverly Rosa] Univ Alabama, Div Gerontol Geriatr & Palliat Care, Birmingham, AL USA.
RP Kvale, EA (reprint author), CH19 Room 219R, Birmingham, AL 35205 USA.
EM ekvale@aging.uab.edu
NR 61
TC 1
Z9 1
U1 1
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1049-9091
J9 AM J HOSP PALLIAT ME
JI Am. J. Hosp. Palliat. Med.
PD NOV
PY 2010
VL 27
IS 7
BP 474
EP 481
DI 10.1177/1049909110365072
PG 8
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 669BV
UT WOS:000283322300007
PM 20388935
ER
PT J
AU Choi, A
Scherzer, R
Bacchetti, P
Tien, PC
Saag, MS
Gibert, CL
Szczech, LA
Grunfeld, C
Shlipak, MG
AF Choi, Andy
Scherzer, Rebecca
Bacchetti, Peter
Tien, Phyllis C.
Saag, Michael S.
Gibert, Cynthia L.
Szczech, Lynda A.
Grunfeld, Carl
Shlipak, Michael G.
TI Cystatin C, Albuminuria, and 5-Year All-Cause Mortality in HIV-Infected
Persons
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Article
DE Kidney disease; mortality; human immunodeficiency virus (HIV) infection
ID CHRONIC KIDNEY-DISEASE; GLOMERULAR-FILTRATION-RATE; STAGE RENAL-DISEASE;
ANTIRETROVIRAL THERAPY; CARDIOVASCULAR EVENTS; SERUM CREATININE; ELDERLY
PERSONS; RISK; OUTCOMES; DEATH
AB Background: Compared with controls, human immunodeficiency virus (HIV)-infected persons have a greater prevalence of kidney disease, assessed according to high cystatin C level and albuminuria, but not according to creatinine level. However, the clinical importance of increased cystatin C level and albuminuria in the HIV-infected population has not been studied.
Study Design: We conducted an observational cohort study to determine the association of kidney disease (measured according to albuminuria, cystatin C, and serum creatinine) with mortality.
Setting & Participants: 922 HIV-infected persons enrolled in the FRAM (Fat Redistribution and Metabolic Change in HIV Infection) Study.
Predictor: Serum cystatin C and serum creatinine levels were used to estimate glomerular filtration rates (eGFR(SCysC) and eGFR(SCr), respectively). Albuminuria was defined as a positive urine dipstick result (>= 1+) or urine albumin-creatinine ratio >30 mg/g.
Outcome: 5-Year mortality.
Results: At baseline, decreased kidney function (eGFR(SCysC) <60 mL/min/1.73 m(2)) or albuminuria was present in 28% of participants. After 5 years of follow-up, mortality was 48% in those with both eGFR(SCysC) <60 mL/min/1.73 m(2) and albuminuria, 23% in those with eGFR(SCysC) <60 mL/min/1.73 m(2) alone, 20% in those with albuminuria alone, and 9% in those with neither condition. After multivariable adjustment for demographics, cardiovascular risk factors, HIV-related factors, and inflammatory marker levels, eGFR(SCysC) <60 mL/min/1.73 m(2) and albuminuria were associated with a nearly 2-fold increase in mortality, whereas eGFR(SCr) <60 mL/min/1.73 m(2) did not appear to have a substantial association with mortality. Together, eGFR(SCysC) <60 mL/min/1.73 m(2) and albuminuria accounted for 17% of the population-level attributable risk of mortality.
Limitations: Vital status was unknown in 261 participants from the original cohort.
Conclusions: Kidney disease marked by albuminuria or increased cystatin C level appears to be an important risk factor for mortality in HIV-infected individuals. A substantial proportion of this risk may be unrecognized because of the current reliance on serum creatinine to estimate kidney function in clinical practice. Am J Kidney Dis 56: 872-882. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use.
C1 [Grunfeld, Carl] Univ Calif San Francisco, FRAM Study, Off Principal Investigator, Vet Affairs Med Ctr,Metab Sect 111F, San Francisco, CA 94121 USA.
[Choi, Andy; Scherzer, Rebecca; Tien, Phyllis C.; Grunfeld, Carl; Shlipak, Michael G.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Saag, Michael S.] Univ Alabama, Birmingham, AL USA.
[Gibert, Cynthia L.] DC VA Med Ctr, Washington, DC USA.
[Gibert, Cynthia L.] George Washington Univ, Washington, DC USA.
[Szczech, Lynda A.] Duke Univ, Med Ctr, Dept Med, Div Nephrol, Durham, NC 27710 USA.
RP Grunfeld, C (reprint author), Univ Calif San Francisco, FRAM Study, Off Principal Investigator, Vet Affairs Med Ctr,Metab Sect 111F, 4150 Clement St, San Francisco, CA 94121 USA.
EM carl.grunfeld@ucsf.edu
FU National Institutes of Health (NIH) [R01 DK57508, R01 HL74814, R01
HL53359, K23 AI66943, K23 DK080645-01A1]; NIH center [P30 AI027767, M01
RR00036, M01 RR00051, M01 RR00052, M01 RR00054, M01 RR00083, M01 RR0636,
M01 RR00865, KL2 RR024130, UL1 RR024131]
FX Support: This study was supported by National Institutes of Health (NIH)
grants R01 DK57508, R01 HL74814, R01 HL53359, K23 AI66943, and K23
DK080645-01A1 and NIH center grants P30 AI027767, M01 RR00036, M01
RR00051, M01 RR00052, M01 RR00054, M01 RR00083, M01 RR0636, M01 RR00865,
KL2 RR024130, and UL1 RR024131. The funding agency had no role in the
conduct of the study, collection of the data, management of the study,
analysis of data, interpretation of the data, or preparation of the
manuscript. A representative of the funding agent participated in
planning the protocol.
NR 45
TC 58
Z9 59
U1 0
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD NOV
PY 2010
VL 56
IS 5
BP 872
EP 882
DI 10.1053/j.ajkd.2010.05.019
PG 11
WC Urology & Nephrology
SC Urology & Nephrology
GA 668IL
UT WOS:000283261700014
PM 20709438
ER
PT J
AU Fortney, JC
Pyne, JM
Steven, CA
Williams, JS
Hedrick, RG
Lunsford, AK
Raney, WN
Ackerman, BA
Ducker, LO
Bonner, LM
Smith, JL
AF Fortney, John C.
Pyne, Jeffrey M.
Steven, Christopher A.
Williams, J. Silas
Hedrick, Richard G.
Lunsford, Amanda K.
Raney, William N.
Ackerman, Betty A.
Ducker, Loretta O.
Bonner, Laura M.
Smith, Jeffrey L.
TI A Web-Based Clinical Decision Support System for Depression Care
Management
SO AMERICAN JOURNAL OF MANAGED CARE
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL
AB Objective: To inform the design of future informatics systems that support the chronic care model.
Study Design: We describe the development and functionality of a decision support system for the chronic care model of depression treatment, known as collaborative care. Dissemination of evidence-based collaborative care models has been slow, and fidelity to the evidence base has been poor during implementation initiatives. Implementation could be facilitated by a decision support system for depression care managers, the cornerstone of the collaborative care model. The Net Decision Support System (https://www.netdss.net/) is a free Web-based system that was developed to support depression care manager activities and to facilitate the dissemination of collaborative care models that maintain high fidelity to the evidence base.
Methods: The NetDSS was based on intervention materials used for a randomized trial of depression care management that improved clinical outcomes compared with usual care. The NetDSS was developed jointly by a cross-functional design team of psychiatrists, depression care managers, information technology specialists, technical writers, and researchers.
Results: The NetDSS has the following functional capabilities: patient registry, patient encounter scheduler, trial management, clinical decision support, progress note generator, and workload and outcomes report generator. The NetDSS guides the care manager through a self-documenting patient encounter using evidence-based scripts and self-scoring instruments. The NetDSS has been used to provide evidence-based depression care management to more than 1700 primary care patients.
Conclusion: Intervention protocols can be successfully converted to Web-based decision support systems that facilitate the implementation of evidence-based chronic care models into routine care with high fidelity. (Am J Manag Care. 2070;76(17):849-854)
C1 [Fortney, John C.; Pyne, Jeffrey M.; Steven, Christopher A.; Hedrick, Richard G.; Ducker, Loretta O.; Smith, Jeffrey L.] Univ Arkansas Med Sci, Dept Psychiat, Little Rock, AR 72205 USA.
[Fortney, John C.; Pyne, Jeffrey M.; Williams, J. Silas; Lunsford, Amanda K.; Raney, William N.; Ackerman, Betty A.; Smith, Jeffrey L.] Cent Arkansas Vet Healthcare Syst, HSR&D Ctr Mental Hlth & Outcomes Res, N Little Rock, AR USA.
[Bonner, Laura M.] VA Puget Sound Healthcare Syst, NW Ctr Outcomes Res Older Adults, Seattle, WA USA.
RP Fortney, JC (reprint author), Univ Arkansas Med Sci, Dept Psychiat, 4301 W Markham St, Little Rock, AR 72205 USA.
EM fortneyjohnc@uams.edu
FU Department of Veterans Affairs [IMV 04-360, IIR 00-078-3, MNT 05-152,
MHS-03-218, MNH 98-000]; National Institute of Mental Health [R01
MH076908-01]; Department of Psychiatry, University of Arkansas for
Medical Sciences
FX This study was funded by grants IMV 04-360, IIR 00-078-3, MNT 05-152,
MHS-03-218, and MNH 98-000 from the Department of Veterans Affairs; by
grant R01 MH076908-01 from the National Institute of Mental Health; and
by a pilot grant from the Department of Psychiatry, University of
Arkansas for Medical Sciences.
NR 18
TC 10
Z9 11
U1 2
U2 7
PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC
PI PLAINSBORO
PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA
SN 1088-0224
J9 AM J MANAG CARE
JI Am. J. Manag. Care
PD NOV
PY 2010
VL 16
IS 11
BP 849
EP 854
PG 6
WC Health Care Sciences & Services; Health Policy & Services; Medicine,
General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 689GL
UT WOS:000284915400005
PM 21348556
ER
PT J
AU Tantiwong, P
Shanmugasundaram, K
Monroy, A
Ghosh, S
Li, MY
DeFronzo, RA
Cersosimo, E
Sriwijitkamol, A
Mohan, S
Musi, N
AF Tantiwong, Puntip
Shanmugasundaram, Karthigayan
Monroy, Adriana
Ghosh, Sangeeta
Li, Mengyao
DeFronzo, Ralph A.
Cersosimo, Eugenio
Sriwijitkamol, Apiradee
Mohan, Sumathy
Musi, Nicolas
TI NF-kappa B activity in muscle from obese and type 2 diabetic subjects
under basal and exercise-stimulated conditions
SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
LA English
DT Article
DE nuclear factor-kappa B; skeletal muscle; monocyte chemotactic protein-1;
interleukin-6
ID INDUCED INSULIN-RESISTANCE; SKELETAL-MUSCLE; GLUCOSE; PATHWAY
AB Tantiwong P, Shanmugasundaram K, Monroy A, Ghosh S, Li M, DeFronzo RA, Cersosimo E, Sriwijitkamol A, Mohan S, Musi N. NF-kappa B activity in muscle from obese and type 2 diabetic subjects under basal and exercise-stimulated conditions. Am J Physiol Endocrinol Metab 299: E794-E801, 2010. First published August 24, 2010; doi: 10.1152/ajpendo.00776.2009.-NF-kappa B is a transcription factor that controls the gene expression of several proinflammatory proteins. Cell culture and animal studies have implicated increased NF-kappa B activity in the pathogenesis of insulin resistance and muscle atrophy. However, it is unclear whether insulin-resistant human subjects have abnormal NF-kappa B activity in muscle. The effect that exercise has on NF-kappa B activity/signaling also is not clear. We measured NF-kappa B DNA-binding activity and the mRNA level of putative NF-kappa B-regulated myokines interleukin (IL)-6 and monocyte chemotactic protein-1 (MCP-1) in muscle samples from T2DM, obese, and lean subjects immediately before, during (40 min), and after (210 min) a bout of moderate-intensity cycle exercise. At baseline, NF-kappa B activity was elevated 2.1- and 2.7-fold in obese nondiabetic and T2DM subjects, respectively. NF-kappa B activity was increased significantly at 210 min following exercise in lean (1.9-fold) and obese (2.6-fold) subjects, but NF-kappa B activity did not change in T2DM. Exercise increased MCP-1 mRNA levels significantly in the three groups, whereas IL-6 gene expression increased significantly only in lean and obese subjects. MCP-1 and IL-6 gene expression peaked at the 40-min exercise time point. We conclude that insulin-resistant subjects have increased basal NF-kappa B activity in muscle. Acute exercise stimulates NF-kappa B in muscle from nondiabetic subjects. In T2DM subjects, exercise had no effect on NF-kappa B activity, which could be explained by the already elevated NF-kappa B activity at baseline. Exercise-induced MCP-1 and IL-6 gene expression precedes increases in NF-kappa B activity, suggesting that other factors promote gene expression of these cytokines during exercise.
C1 [Musi, Nicolas] S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA.
[Tantiwong, Puntip; Monroy, Adriana; Ghosh, Sangeeta; Li, Mengyao; DeFronzo, Ralph A.; Cersosimo, Eugenio; Sriwijitkamol, Apiradee; Musi, Nicolas] Univ Texas Hlth Sci Ctr San Antonio, Texas Diabet Inst, San Antonio, TX 78229 USA.
[Shanmugasundaram, Karthigayan; Mohan, Sumathy] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[Musi, Nicolas] Univ Texas Hlth Sci Ctr San Antonio, Ctr Healthy Aging, San Antonio, TX 78229 USA.
RP Musi, N (reprint author), S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.
FU American Diabetes Association; National Institutes of Health [AG-030979,
DK-80157, DK-24092, CA-112175]; San Antonio Nathan Shock Center; UTHSCSA
Executive Research Committee; South Texas Health Research Center; US
Department of Veterans Affairs; Faculty of Medicine Siriraj Hospital
Mahidol University of Thailand; Endocrine Fellows Foundation; Thai
Ministry of Public Health and Maharat Nakhon Ratchasima Hospital;
[T32-HL-04776]
FX This study was supported by grants from the American Diabetes
Association (N. Musi, E. Cersosimo, and R. A. DeFronzo), the National
Institutes of Health (AG-030979 and DK-80157 to N. Musi, DK-24092 to R.
A. DeFronzo, and CA-112175 to S. Mohan), the San Antonio Nathan Shock
Center (N. Musi), the UTHSCSA Executive Research Committee (N. Musi),
the South Texas Health Research Center (N. Musi), the US Department of
Veterans Affairs (R. A. DeFronzo), the Faculty of Medicine Siriraj
Hospital Mahidol University of Thailand (A. Sriwijitkamol), the
Endocrine Fellows Foundation (A. Sriwijitkamol), and the Thai Ministry
of Public Health and Maharat Nakhon Ratchasima Hospital (P. Tantiwong).
S. Ghosh was funded by T32-HL-04776.
NR 14
TC 39
Z9 42
U1 0
U2 3
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193-1849
J9 AM J PHYSIOL-ENDOC M
JI Am. J. Physiol.-Endocrinol. Metab.
PD NOV
PY 2010
VL 299
IS 5
BP E794
EP E801
DI 10.1152/ajpendo.00776.2009
PG 8
WC Endocrinology & Metabolism; Physiology
SC Endocrinology & Metabolism; Physiology
GA 673LX
UT WOS:000283665600012
PM 20739506
ER
PT J
AU Scherz, N
Labarere, J
Mean, M
Ibrahim, SA
Fine, MJ
Aujesky, D
AF Scherz, Nathalie
Labarere, Jose
Mean, Marie
Ibrahim, Said A.
Fine, Michael J.
Aujesky, Drahomir
TI Prognostic Importance of Hyponatremia in Patients with Acute Pulmonary
Embolism
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article
DE hyponatremia; prognosis; pulmonary embolism
ID ELEVATION MYOCARDIAL-INFARCTION; COMMUNITY-ACQUIRED PNEUMONIA;
HEART-FAILURE; TOTAL HIP; OUTCOMES; HYPERTENSION; ADMISSION;
HOSPITALIZATION; ARTHROPLASTY; MORTALITY
AB Rationale: Although associated with adverse outcomes in other cardiopulmonary conditions, the prognostic value of hyponatremia, a marker of neurohormonal activation, in patients with acute pulmonary embolism (PE) is unknown.
Objectives: To examine the associations between hyponatremia and mortality and hospital readmission rates for patients hospitalized with PE.
Methods: We evaluated 13,728 patient discharges with a primary diagnosis of PE from 185 hospitals in Pennsylvania (January 2000 to November 2002). We used random-intercept logistic regression to assess the independent association between serum sodium levels at the time of presentation and mortality and hospital readmission within 30 days, adjusting for patient (race, insurance, severity of illness, use of thrombolytic therapy) and hospital factors (region, size, teaching status).
Measurements and Main Results. Hyponatremia (sodium <= 135 mmol/L) was present in 2,907 patients (21.1%). Patients with a sodium level greater than 135, 130-135, and less than 130 mmol/L had a cumulative 30-day mortality of 8.0, 13.6, and 28.5% (P < 0.001), and a readmission rate of 11.8, 15.6, and 19.3% (P < 0.001), respectively. Compared with patients with a sodium greater than 135 mmol/L, the adjusted odds of dying were significantly greater for patients with a sodium 130-135 mmol/L (odds ratio [OR], 1.53; 95% confidence interval [Cl], 1.33-1.76) and a sodium less than 130 mmol/L (OR, 3.26; 95% Cl, 2.48-4.29). The adjusted odds of readmission were also increased for patients with a sodium of 130-135 mmol/L (OR, 1.28; 95% Cl, 1.12-1.46) and a sodium less than 130 mmol/L (OR, 1.44; 95% Cl, 1.02-2.02).
Conclusions: Hyponatremia is common in patients presenting with PE, and is an independent predictor of short-term mortality and hospital readmission.
C1 [Scherz, Nathalie; Mean, Marie] Univ Lausanne, Div Gen Internal Med, Lausanne, Switzerland.
[Labarere, Jose] Univ Grenoble 1, CNRS, UMR 5525, TIMC, Grenoble, France.
[Ibrahim, Said A.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
[Ibrahim, Said A.] Philadelphia Vet Affairs VA Med Ctr, Philadelphia, PA USA.
[Fine, Michael J.] VA Pittsburgh Healthcare Syst, VA Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Fine, Michael J.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA.
[Aujesky, Drahomir] Univ Bern, Div Gen Internal Med, Bern, Switzerland.
RP Aujesky, D (reprint author), Univ Hosp Bern, Klin Allgemeine Innere Med, CH-3010 Bern, Switzerland.
EM drahomir.aujesky@insel.ch
RI Labarere, Jose/N-1688-2014
OI Labarere, Jose/0000-0001-7621-6586
FU National Heart, Lung, and Blood Institute [1 R21 HL075521-01A1]; Swiss
National Science Foundation [33CSCO-122659]; National Institute of
Arthritis and Musculoskeletal and Skin Diseases; Zynx Health, Inc.;
McQuaide Blasko; Up-To-Date; National Institutes of Health
FX Supported in part by grant 1 R21 HL075521-01A1 from the National Heart,
Lung, and Blood Institute, by grant 33CSCO-122659 from the Swiss
National Science Foundation, and by a K24 career development award from
the National Institute of Arthritis and Musculoskeletal and Skin
Diseases (S.A.I.).; D.A. serves on the advisory board for Sanofi Aventis
and Bayer for $1,001-$5,000 each; M.J.F. received consultancy fees from
Zynx Health, Inc. for less than $1,000 and expert witness fees from
McQuaide Blasko for $5,001-$10,000, and also receives royalties from
Up-To-Date for less than $1,000; S.A.I. received a sponsored grant from
the National Institutes of Health for more than $100,001; J.L. does not
have a financial relationship with a commercial entity that has an
interest in the subject of this manuscript; M.M. does not have a
financial relationship with a commercial entity that has an interest in
the subject of this manuscript; N.S. does not have a financial
relationship with a commercial entity that has an interest in the
subject of this manuscript.
NR 27
TC 36
Z9 38
U1 1
U2 2
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD NOV 1
PY 2010
VL 182
IS 9
BP 1178
EP 1183
DI 10.1164/rccm.201003-0481OC
PG 6
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 677DQ
UT WOS:000283969700014
PM 20595225
ER
PT J
AU Russell, JS
Sawhney, R
Monto, A
Nanavati, S
Ben Davoren, J
Aslam, R
Corvera, CU
AF Russell, Jeffery S.
Sawhney, Rajiv
Monto, Alexander
Nanavati, Sujal
Ben Davoren, J.
Aslam, Rizwan
Corvera, Carlos U.
TI Periprocedural complications by Child-Pugh class in patients undergoing
transcatheter arterial embolization or chemoembolization to treat
unresectable hepatocellular carcinoma at a VA medical center
SO AMERICAN JOURNAL OF SURGERY
LA English
DT Article
DE Hepatitis C; Hepatocellular carcinoma; Transcatheter arterial
embolization; Chemoembolization; Surgical complications
AB BACKGROUND For patients with compensated cirrhosis transcatheter arterial embolization with and without additive chemotherapy has been shown to improve survival The aim of this study was to compare periprocedural complications in a population with hepatitis C virus related hepatocellular carcinoma to evaluate for differences in complications by severity of liver disease
METHODS Patients with unresectable hepatocellular carcinoma treated by transcatheter arterial embolization with or without additive chemotherapy procedures from 2003 to 2006 were retrospectively reviewed and compared by Child Pugh (CP) class A total of 141 embolizations were done in 76 patients
RESULTS Complication rates were seen in 27% of CP class A and 17% of CP class B patients There was no significant difference in the grade of complications between the 2 groups or between procedure types Survival rate was dependent on the degree of liver dysfunction (3-year CP class A, 49%, CP class B, 13%, P = 0048)
CONCLUSION Embolization procedures to treat hepatitis C virus related hepatocellular carcinoma can be performed safely with low morbidity and mortality rates even in patients with a compromised hepatic reserve Published by Elsevier Inc
C1 [Corvera, Carlos U.] San Francisco VA Med Ctr, Dept Surg, San Francisco, CA USA.
[Russell, Jeffery S.] Univ Calif San Francisco, Med Ctr, Dept Med, San Francisco, CA 94143 USA.
[Sawhney, Rajiv; Nanavati, Sujal; Aslam, Rizwan] San Francisco VA Med Ctr, Dept Radiol, San Francisco, CA USA.
[Monto, Alexander] San Francisco VA Med Ctr, Dept Gastroenterol, San Francisco, CA USA.
[Ben Davoren, J.] San Francisco VA Med Ctr, Dept Hematol Oncol, San Francisco, CA USA.
RP Corvera, CU (reprint author), San Francisco VA Med Ctr, Dept Surg, San Francisco, CA USA.
FU Veteran Health Administration; Northern California Institute for
Research and Education
FX Supported by a grant from the Veteran Health Administration and from the
Northern California Institute for Research and Education (CUC) This
manuscript was presented at the 2010 Association of VA Surgeons
Conference on May 10 2010
NR 12
TC 3
Z9 3
U1 0
U2 0
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9610
J9 AM J SURG
JI Am. J. Surg.
PD NOV
PY 2010
VL 200
IS 5
BP 659
EP 664
DI 10.1016/j.amjsurg.2010.07.021
PG 6
WC Surgery
SC Surgery
GA 691LS
UT WOS:000285081900021
PM 21056149
ER
PT J
AU Thirunavukarasu, P
Brewster, LP
Pecora, SM
Hall, DE
AF Thirunavukarasu, Pragatheeshwar
Brewster, Luke P.
Pecora, Stephanie M.
Hall, Daniel E.
TI Educational intervention is effective in improving knowledge and
confidence in surgical ethics-a prospective study
SO AMERICAN JOURNAL OF SURGERY
LA English
DT Article
DE Surgical ethics; Ethics education; ACGME; Core competency;
Professionalism; Resident ethics education
ID RESIDENCY PROGRAMS; RANDOMIZED-TRIAL; CLINICAL ETHICS; SURGERY; OUTCOMES
AB BACKGROUND Professionalism and ethics are Accreditation Council for Graduate Medical Education (ACGME) core competencies but there is little evidence regarding the effectiveness of ethics education
METHODS General surgery residents at the University of Pittsburgh completed questionnaires measuring attitudes and knowledge about surgical ethics before and after four 60-minute faculty-facilitated seminars implementing the American College of Surgeons ethics curriculum
RESULTS Most residents experienced ethical challenges at least once every rotation competition of Interests (75%) professional obligations (75%) confidentiality (83%) truth telling (88%), surrogate decision making (91%) and end-of life issues (100%) The educational intervention increased both knowledge about surgical ethics (P = 013) and confidence in dealing with competition of interests (P = 001) professional obligations (P = 011), truth telling (P = 013) confidentiality (P = 011), end of-life issues (P = 007) and surrogate decision making (P = 052) Most residents recommended the American College of Surgeons text for future use (84%) considering ethics education a standard part of residency training (70%)
CONCLUSIONS Focused instruction using the American College of Surgeons ethics curriculum can effectively Improve both knowledge and confidence about surgical ethics Published by Elsevier Inc
C1 [Thirunavukarasu, Pragatheeshwar; Hall, Daniel E.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15260 USA.
[Brewster, Luke P.] Emory Clin, Atlanta, GA 30322 USA.
[Pecora, Stephanie M.; Hall, Daniel E.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Hall, DE (reprint author), Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15260 USA.
RI Hall, Daniel/H-4843-2013
OI Hall, Daniel/0000-0001-6382-0522
FU Kamangar Foundation; Center for Study of Ethics and Human Values
University of Washington St Louis
FX This study was supported by funding through the Kamangar Foundation and
Award Center for Study of Ethics and Human Values University of
Washington St Louis
NR 22
TC 6
Z9 6
U1 0
U2 4
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9610
J9 AM J SURG
JI Am. J. Surg.
PD NOV
PY 2010
VL 200
IS 5
BP 665
EP 669
DI 10.1016/j.amjsurg.2010.08.002
PG 5
WC Surgery
SC Surgery
GA 691LS
UT WOS:000285081900022
PM 21056150
ER
PT J
AU Peniche, AG
Osorio, EY
Melby, PC
Travi, BL
AF Peniche, Alex G.
Osorio, Elvia Y.
Melby, Peter C.
Travi, Bruno L.
TI DEVELOPMENT OF A MEDIUM THROUGHPUT SYSTEM THAT USES LYMPH NODE EX VIVO
EXPLANT CULTURES TO IDENTIFY COMPOUNDS AGAINST CUTANEOUS LEISHMANIASIS
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 59th Annual Meeting of the
American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)
CY NOV 03-07, 2010
CL Atlanta, GA
SP Amer Soc Trop Med & Hyg (ASTMH)
C1 [Melby, Peter C.] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2010
VL 83
IS 5
SU S
MA 687
BP 205
EP 205
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 832QF
UT WOS:000295819701056
ER
PT J
AU Kelly, JX
Li, YX
Forquer, I
Melendez, V
Hickman, M
O'Neil, M
Cooper, R
Harris, E
Pybus, B
Sousa, J
Li, QG
Smilkstein, M
Winter, R
Hinrichs, D
Riscoe, M
AF Kelly, Jane X.
Li, Yuexin
Forquer, Isaac
Melendez, Victor
Hickman, Mark
O'Neil, Michael
Cooper, Roland
Harris, Erin
Pybus, Brandon
Sousa, Jason
Li, Qigui
Smilkstein, Martin
Winter, Rolf
Hinrichs, Dave
Riscoe, Mike
TI NOVEL ACRIDONES AS BROAD-SPECTRUM ANTIMALARIALS
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 59th Annual Meeting of the
American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)
CY NOV 03-07, 2010
CL Atlanta, GA
SP Amer Soc Trop Med & Hyg (ASTMH)
C1 [Kelly, Jane X.] Portland State Univ, Portland, OR 97207 USA.
[Li, Yuexin; Forquer, Isaac; Winter, Rolf; Hinrichs, Dave; Riscoe, Mike] Portland VA Med Ctr, Portland, OR USA.
[Melendez, Victor; Hickman, Mark; O'Neil, Michael; Harris, Erin; Pybus, Brandon; Sousa, Jason; Li, Qigui] Walter Reed Army Inst Res, Silver Spring, MD USA.
[Cooper, Roland] Old Dominion Univ, Norfolk, VA USA.
[Smilkstein, Martin] Oregon Translat Res & Drug Dev Inst, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2010
VL 83
IS 5
SU S
MA 716
BP 213
EP 213
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 832QF
UT WOS:000295819701084
ER
PT J
AU Wu, J
Campuzano, S
Halford, C
Haake, DA
Wang, J
AF Wu, Jie
Campuzano, Susana
Halford, Colin
Haake, David A.
Wang, Joseph
TI Ternary Surface Mono layers for Ultrasensitive (Zeptomole) Amperometric
Detection of Nucleic Acid Hybridization without Signal Amplification
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID SELF-ASSEMBLED MONOLAYERS; ELECTROCHEMICAL IMPEDANCE SPECTROSCOPY;
ESCHERICHIA-COLI O157-H7; DNA HYBRIDIZATION; GOLD ELECTRODES;
CHARGE-TRANSFER; IMMOBILIZATION; BIOSENSORS; SENSOR; DITHIOTHREITOL
AB A ternary surface monolayer, consisting of coassembled thiolated capture probe, mercaptohexanol and dithiothreitol, is shown to offer dramatic improvements in the signal-to-noise characteristics of electrochemical DNA hybridization biosensors based on common self-assembled monolayers. Remarkably low detection limits down to 40 zmol (in 4 mu L samples) as well as only 1 CFU Escherichia coli per sensor are thus obtained without any additional amplification step in connection to the commonly used horseradish peroxidase/3,3',5,5'-tetramethylbenzidine system. Such dramatic improvements in the detection limits (compared to those of common binary alkanethiol interfaces and to those of most electrochemical DNA sensing strategies without target or signal amplification) are attributed primarily to the remarkably higher resistance to nonspecific adsorption. This reflects the highly compact layer (with lower pinhole density) produced by the coupling of the cyclic- and linear-configuration "backfillers" that leads to a remarkably low background noise even in the presence of complex sample matrixes. A wide range of surface compositions have been investigated, and the ternary mixed monolayer has been systematically optimized. Detailed impedance spectroscopy and cyclic voltammetric studies shed useful insights into the surface coverage. The impressive sensitivity and high specificity of the simple developed methodology indicate great promise for a wide range of nucleic acid testing, including clinical diagnostics, biothreat detection, food safety, and forensic analysis.
C1 [Wu, Jie; Campuzano, Susana; Wang, Joseph] Univ Calif San Diego, Dept Nanoengn, La Jolla, CA 92093 USA.
[Halford, Colin; Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Halford, Colin; Haake, David A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
RP Wang, J (reprint author), Univ Calif San Diego, Dept Nanoengn, La Jolla, CA 92093 USA.
EM josephwang@ucsd.edu
RI Campuzano Ruiz, Susana/C-6448-2011; Wang, Joseph/C-6175-2011
FU National Institutes of Health [U01 AI075565]; National Science
Foundation [CHE 0506529]; University Complutense of Madrid; Programa
Becas Complutense del Amo
FX Financial support from the National Institutes of Health (Award U01
AI075565) and National Science Foundation (Award CHE 0506529) is
gratefully acknowledged. S.C. thanks the University Complutense of
Madrid and Programa Becas Complutense del Amo (2010-2011).
NR 39
TC 67
Z9 69
U1 1
U2 35
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
EI 1520-6882
J9 ANAL CHEM
JI Anal. Chem.
PD NOV 1
PY 2010
VL 82
IS 21
BP 8830
EP 8837
DI 10.1021/ac101474k
PG 8
WC Chemistry, Analytical
SC Chemistry
GA 671SS
UT WOS:000283531200014
PM 20883023
ER
PT J
AU Gaffo, AL
Roseman, JM
Jacobs, DR
Lewis, CE
Shikany, JM
Mikuls, TR
Jolly, PE
Saag, KG
AF Gaffo, Angelo L.
Roseman, Jeffrey M.
Jacobs, David R., Jr.
Lewis, Cora E.
Shikany, James M.
Mikuls, Ted R.
Jolly, Pauline E.
Saag, Kenneth G.
TI Serum urate and its relationship with alcoholic beverage intake in men
and women: findings from the Coronary Artery Risk Development in Young
Adults (CARDIA) cohort
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Article
ID NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; URIC-ACID;
PURINE-BASES; CARDIOVASCULAR MORTALITY; PLASMA-CONCENTRATIONS; METABOLIC
SYNDROME; LONG-TERM; CONSUMPTION; BEER
AB Objective To investigate if beer, liquor (spirits), wine and total alcohol intakes have different associations with serum urate (SU) concentrations at different ages in a cohort of young men and women.
Methods Data from 3123 participants at baseline and follow-up at 20 years were used, with balanced proportions of Caucasians and African Americans. The relationships of SU with categories of beer, liquor, wine and total alcohol intake referent to no intake were examined in sex-specific, cross-sectional analyses.
Results Mean age (SD) at the beginning of follow-up was 25.1 (3.6) years. Compared with non-drinkers, significant associations between higher SU concentrations and greater beer intake were observed among men and women, with more pronounced and consistent associations for women. An association between greater liquor intake and higher SU concentrations was only seen for men at the year 20 evaluation. Wine intake was not associated with SU in either sex and total alcohol was associated with higher SU concentrations in both men and women. The magnitude of the associations between alcoholic beverages intake and SU was modest (<= 0.03 mg/dl/alcoholic beverage serving).
Conclusion An association between higher SU concentrations and greater beer intake was consistent and pronounced among women, but also present in men. Despite the small magnitude of the increases in SU associated with alcohol intake, clinical implications in conditions such as cardiovascular disease and gout in young adults who are moderate and heavy drinkers cannot be ruled out.
C1 [Gaffo, Angelo L.] Univ Alabama, Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Gaffo, Angelo L.; Saag, Kenneth G.] Univ Alabama, Div Rheumatol, Birmingham, AL USA.
[Roseman, Jeffrey M.; Jolly, Pauline E.] Univ Alabama, Dept Epidemiol, Birmingham, AL USA.
[Jacobs, David R., Jr.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA.
[Jacobs, David R., Jr.] Univ Oslo, Dept Nutr, Oslo, Norway.
[Lewis, Cora E.; Shikany, James M.] Univ Alabama, Div Prevent Med, Birmingham, AL USA.
[Mikuls, Ted R.] Univ Nebraska Med Ctr, Sect Rheumatol & Clin Immunol, Omaha, NE USA.
[Mikuls, Ted R.] Omaha Vet Affairs Med Ctr, Omaha, NE USA.
RP Saag, KG (reprint author), FOT 820,1530 3rd Ave S, Birmingham, AL 35294 USA.
EM ksaag@uab.edu
FU NHLBI NIH HHS [N01 HC048047]
NR 34
TC 24
Z9 25
U1 0
U2 4
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD NOV
PY 2010
VL 69
IS 11
BP 1965
EP 1970
DI 10.1136/ard.2010.129429
PG 6
WC Rheumatology
SC Rheumatology
GA 665UI
UT WOS:000283060600013
PM 20525839
ER
PT J
AU Mata, IF
Shi, M
Agarwal, P
Chung, KA
Edwards, KL
Factor, SA
Galasko, DR
Ginghina, C
Griffith, A
Higgins, DS
Kay, DM
Kim, H
Leverenz, JB
Quinn, JF
Roberts, JW
Samii, A
Snapinn, KW
Tsuang, DW
Yearout, D
Zhang, J
Payami, H
Zabetian, CP
AF Mata, Ignacio F.
Shi, Min
Agarwal, Pinky
Chung, Kathryn A.
Edwards, Karen L.
Factor, Stewart A.
Galasko, Douglas R.
Ginghina, Carmen
Griffith, Alida
Higgins, Donald S.
Kay, Denise M.
Kim, Hojoong
Leverenz, James B.
Quinn, Joseph F.
Roberts, John W.
Samii, Ali
Snapinn, Katherine W.
Tsuang, Debby W.
Yearout, Dora
Zhang, Jing
Payami, Haydeh
Zabetian, Cyrus P.
TI SNCA Variant Associated With Parkinson Disease and Plasma
alpha-Synuclein Level
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; LOCUS TRIPLICATION; RISK-FACTORS; GENE;
SUSCEPTIBILITY; BLOOD; TRANSCRIPTION; VARIABILITY; EXPRESSION;
BIOMARKERS
AB Background: A functional repeat polymorphism in the SNCA promoter (REP1) conveys susceptibility for Parkinson disease (PD). There is also increasing evidence that single-nucleotide polymorphisms (SNPs) elsewhere in the gene are associated with PD risk.
Objectives: To further explore the association of common SNCA SNPs with PD susceptibility, to determine whether evidence of allelic heterogeneity exists, and to examine the correlation between PD-associated variants and plasma alpha-synuclein levels.
Design: Two-tiered analysis.
Setting: Academic research.
Patients: Patients and control subjects from the NeuroGenetics Research Consortium.
Main Outcome Measures: We performed a 2-tiered analysis of 1956 patients with PD and 2112 controls from the NeuroGenetics Research Consortium using a comprehensive tag SNP approach. Previously published REP1 genotypes were also included. Plasma alpha-synuclein was assayed in 86 patients with PD and 78 controls using a highly sensitive Luminex assay.
Results: Five of 15 SNPs genotyped were associated with PD under an additive model in tier 1 (alpha=.05). Of these, 4 were successfully replicated in tier 2. In the combined sample, the most significant marker was rs356219 (odds ratio, 1.41; 95% confidence interval, 1.28-1.55; P=1.6 x 10-12), located approximately 9 kilobases downstream from the gene. A regression model containing rs356219 alone best fit the data. The linkage disequilibrium correlation coefficient between this SNP and REP1 was low (r(2)=0.09). The risk-associated Callele of rs356219 was also correlated with higher transformed plasma alpha-synuclein levels in patients under an adjusted additive model (P=.005).
Conclusions: Our data suggest that 1 or more unidentified functional SNCA variants modify risk for PD and that the effect is larger than and independent of REP1. This variant(s), tagged by rs356219, might act by upregulating SNCA expression in a dose-dependent manner.
C1 [Mata, Ignacio F.; Yearout, Dora; Zabetian, Cyrus P.] Univ Washington, Geriatr Res Educ & Clin Ctr, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Leverenz, James B.; Tsuang, Debby W.] Univ Washington, Mental Illness Res Educ & Clin Ctr, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Leverenz, James B.; Samii, Ali; Zabetian, Cyrus P.] Univ Washington, Parkinsons Dis Res Educ & Clin Ctr, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Kim, Hojoong; Samii, Ali] Univ Washington, Neurol Sect, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Mata, Ignacio F.; Kim, Hojoong; Leverenz, James B.; Samii, Ali; Yearout, Dora; Zabetian, Cyrus P.] Univ Washington, Dept Neurol, Sch Med, Seattle, WA 98108 USA.
[Shi, Min; Ginghina, Carmen; Zhang, Jing] Univ Washington, Dept Pathol, Sch Med, Seattle, WA 98108 USA.
[Edwards, Karen L.; Snapinn, Katherine W.] Univ Washington, Dept Epidemiol, Sch Med, Seattle, WA 98108 USA.
[Tsuang, Debby W.] Univ Washington, Dept Psychiat & Behav Sci, Sch Med, Seattle, WA 98108 USA.
[Roberts, John W.] Virginia Mason Med Ctr, Seattle, WA 98101 USA.
[Agarwal, Pinky; Griffith, Alida] Evergreen Hosp Med Ctr, Booth Gardner Parkinsons Care Ctr, Kirkland, WA USA.
[Chung, Kathryn A.; Quinn, Joseph F.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA.
[Chung, Kathryn A.; Quinn, Joseph F.] Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Portland, OR 97201 USA.
[Factor, Stewart A.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA.
[Galasko, Douglas R.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.
[Higgins, Donald S.] Neurol Serv, Samuel Stratton Vet Affairs Med Ctr, Albany, NY USA.
[Kay, Denise M.; Payami, Haydeh] New York State Dept Hlth, Genom Inst, Wadsworth Ctr, Albany, NY 12237 USA.
RP Zabetian, CP (reprint author), Univ Washington, Geriatr Res Educ & Clin Ctr, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Mailstop S-182,1660 S Columbian Way, Seattle, WA 98108 USA.
EM zabetian@u.washington.edu
RI Shi, Min/G-6165-2012; Tsuang, Debby/L-7234-2016
OI Shi, Min/0000-0002-6901-2558; Tsuang, Debby/0000-0002-4716-1894
FU Ipsen; Schering Plough; Teva Neuroscience; Michael J. Fox Foundation;
Parkinson's Disease Foundation; American Parkinson Disease Association;
Department of Veterans Affairs [1101BX000531]; National Institutes of
Health [P30 AG008017, P42 ES004696, P50 NS062684, R01 AG033398, R01
NS065070, R01 NS036960, R01 NS057567]
FX Dr Agarwal serves on advisory boards for Ipsen and Merz Pharmaceuticals
and has received compensation as a speaker for Boehringer Ingelheim,
GlaxoSmithKline, Novartis, and Teva Neuroscience. Dr Factor has received
research grants from Ipsen, Schering Plough, and Teva Neuroscience and
is a consultant for Allergan, Boehringer Ingelheim, Lundbeck, and UCB.
Dr Samii has received compensation as a speaker for Boehringer
Ingelheim, Ipsen, and Teva Neuroscience.; This work was supported by the
Michael J. Fox Foundation, by the Parkinson's Disease Foundation, by the
American Parkinson Disease Association, by grant 1101BX000531 from the
Department of Veterans Affairs, and by grants P30 AG008017, P42
ES004696, P50 NS062684, R01 AG033398, R01 NS065070, R01 NS036960, and
R01 NS057567 from the National Institutes of Health.
NR 30
TC 70
Z9 74
U1 1
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9942
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD NOV
PY 2010
VL 67
IS 11
BP 1350
EP 1356
DI 10.1001/archneurol.2010.279
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 676RQ
UT WOS:000283935300013
PM 21060011
ER
PT J
AU Wilde, EA
Whiteneck, GG
Bogner, J
Bushnik, T
Cifu, DX
Dikmen, S
French, L
Giacino, JT
Hart, T
Malec, JF
Millis, SR
Novack, TA
Sherer, M
Tulsky, DS
Vanderploeg, RD
von Steinbuechel, N
AF Wilde, Elisabeth A.
Whiteneck, Gale G.
Bogner, Jennifer
Bushnik, Tamara
Cifu, David X.
Dikmen, Sureyya
French, Louis
Giacino, Joseph T.
Hart, Tessa
Malec, James F.
Millis, Scott R.
Novack, Thomas A.
Sherer, Mark
Tulsky, David S.
Vanderploeg, Rodney D.
von Steinbuechel, Nicole
TI Recommendations for the Use of Common Outcome Measures in Traumatic
Brain Injury Research
SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
LA English
DT Article
DE Outcome assessment; health care; Brain injuries; Neurobehavioral
manifestations; Research; Rehabilitation
ID QUALITY-OF-LIFE; PORTLAND ADAPTABILITY INVENTORY; POST-CONCUSSION
SYMPTOMS; FAMILY ASSESSMENT DEVICE; BEHAVIOR SCALE FRSBE; MINOR
HEAD-INJURY; NOS-TBI; POSTCONCUSSION SYNDROME; ALCOHOL-CONSUMPTION;
SIGNIFICANT OTHERS
AB This article summarizes the selection of outcome measures by the interagency Traumatic Brain Injury (TBI) Outcomes Workgroup to address primary clinical research objectives, including documentation of the natural course of recovery from TBI, prediction of later outcome, measurement of treatment effects, and comparison of outcomes across studies. Consistent with other Common Data Elements Workgroups, the TBI Outcomes Workgroup adopted the standard 3-tier system in its selection of measures. In the first tier, core measures included valid, robust, and widely applicable outcome measures with proven utility in TBI from each identified domain, including global level of function, neuropsychological impairment, psychological status, TBI-related symptoms, executive functions, cognitive and physical activity limitations, social role participation, and perceived health-related quality of life. In the second tier, supplemental measures were recommended for consideration in TBI research focusing on specific topics or populations. In the third tier, emerging measures included important instruments currently under development, in the process of validation, or nearing the point of published findings that have significant potential to be superior to some older ("legacy") measures in the core and supplemental lists and may eventually replace them as evidence for their utility emerges.
C1 [Wilde, Elisabeth A.; Sherer, Mark] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA.
[Wilde, Elisabeth A.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA.
[Wilde, Elisabeth A.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA.
[Sherer, Mark] TIRR Mem Hermann, Houston, TX USA.
[Wilde, Elisabeth A.] Michael E DeBakey Vet Adm Med Ctr, Houston, TX USA.
[Sherer, Mark] Univ Texas Med Sch Houston, Houston, TX USA.
[Whiteneck, Gale G.] Craig Hosp, Englewood, CO USA.
[Bogner, Jennifer] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA.
[Bushnik, Tamara] Rusk Inst Rehabil, Dept Rehabil Med, New York, NY USA.
[Cifu, David X.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, PM&R Serv, Hunter Holmes McGuire Vet Adm Med Ctr, Richmond, VA USA.
[Dikmen, Sureyya] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA.
[French, Louis] Walter Reed Army Med Ctr, Dept Orthopaed & Rehabil, Washington, DC 20307 USA.
[Giacino, Joseph T.] JFK Johnson Rehabil Inst, Edison, NJ USA.
[Giacino, Joseph T.] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Boston, MA USA.
[Hart, Tessa] Moss Rehabil Res Inst, Elkins Pk, PA USA.
[Malec, James F.] Indiana Univ Sch Med, Dept Phys Med & Rehabil, Indianapolis, IN USA.
[Malec, James F.] Rehabil Hosp Indiana, Indianapolis, IN USA.
[Millis, Scott R.] Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA.
[Millis, Scott R.] Wayne State Univ, Sch Med, Dept Emergency Med, Detroit, MI USA.
[Novack, Thomas A.] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA.
[Tulsky, David S.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA.
[Vanderploeg, Rodney D.] James A Haley Vet Hosp, Psychol Serv, Tampa, FL 33612 USA.
[Vanderploeg, Rodney D.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA.
[Vanderploeg, Rodney D.] Univ S Florida, Dept Psychiat, Tampa, FL USA.
[von Steinbuechel, Nicole] Univ Gottingen, Dept Med Psychol & Med Sociol, Univ Med Ctr, Gottingen, Germany.
RP Wilde, EA (reprint author), Baylor Coll Med, Dept Phys Med & Rehabil, 1709 Dryden Rd,Ste 1200, Houston, TX 77030 USA.
EM ewilde@bcm.edu
OI Bushnik, Tamara/0000-0003-3328-257X
FU National Institutes of Health (NIH: National Institute of Neurological
Disorders and Stroke); U.S. Department of Veterans Affairs (VA); U.S.
Department of Defense (DoD); U.S. Department of Education/National
Institute on Disability and Rehabilitation Research
FX Supported by the National Institutes of Health (NIH: National Institute
of Neurological Disorders and Stroke), U.S. Department of Veterans
Affairs (VA), U.S. Department of Defense (DoD), and U.S. Department of
Education/National Institute on Disability and Rehabilitation Research.
NR 101
TC 124
Z9 126
U1 7
U2 29
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0003-9993
EI 1532-821X
J9 ARCH PHYS MED REHAB
JI Arch. Phys. Med. Rehabil.
PD NOV
PY 2010
VL 91
IS 11
BP 1650
EP 1660
DI 10.1016/j.apmr.2010.06.033
PG 11
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 681UQ
UT WOS:000284346400004
PM 21044708
ER
PT J
AU Yang, C
Yuan, C
Canton, G
Hatsukami, T
Tang, D
AF Yang, Chun
Yuan, Chun
Canton, Gador
Hatsukami, Thomas
Tang, Dalin
TI Advanced Human Carotid Plaque Progression Correlates Positively with
Flow Shear Stress: An in Vivo MRI Multipatient 3D FSI Study
SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
LA English
DT Meeting Abstract
CT Scientific Sessions on Arteriosclerosis, Thrombosis and Vascular Biology
CY APR 08-10, 2010
CL San Francisco, CA
C1 [Yang, Chun] Beijing Normal Univ, Beijing 100875, Peoples R China.
[Yuan, Chun; Canton, Gador; Hatsukami, Thomas] Univ Washington, Seattle, WA 98195 USA.
[Hatsukami, Thomas] VA Puget Sound HCS, Seattle, WA USA.
[Tang, Dalin] Worcester Polytech Inst, Worcester, MA 01609 USA.
RI Canton, Gador/H-4227-2016
OI Canton, Gador/0000-0002-0594-2764
NR 0
TC 0
Z9 0
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1079-5642
J9 ARTERIOSCL THROM VAS
JI Arterioscler. Thromb. Vasc. Biol.
PD NOV
PY 2010
VL 30
IS 11
BP E315
EP E315
PG 1
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA 667YS
UT WOS:000283234800600
ER
PT J
AU Clancy, RM
Marion, MC
Kaufman, KM
Ramos, PS
Adler, A
Harley, JB
Langefeld, CD
Buyon, JP
AF Clancy, Robert M.
Marion, Miranda C.
Kaufman, Kenneth M.
Ramos, Paula S.
Adler, Adam
Harley, John B.
Langefeld, Carl D.
Buyon, Jill P.
CA Int Consortium Syst Lupus
TI Identification of Candidate Loci at 6p21 and 21q22 in a Genome-Wide
Association Study of Cardiac Manifestations of Neonatal Lupus
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID CONGENITAL HEART-BLOCK; PRIMARY SJOGRENS-SYNDROME; ANTI-SSA/RO;
TNF-ALPHA; ATRIOVENTRICULAR-BLOCK; ENDOTHELIAL-CELLS; SSB/LA ANTIBODIES;
RECURRENCE RATES; SS-A/RO; ERYTHEMATOSUS
AB Objective. Cardiac manifestations of neonatal lupus, comprising atrioventricular conduction defects and cardiomyopathy, occur in fetuses exposed to anti-Ro/SSA antibodies, and carry substantial mortality. There is strong evidence of a genetic contribution to the risk. This study was undertaken to evaluate single-nucleotide polymorphisms (SNPs) for associations with cardiac neonatal lupus.
Methods. Children of European ancestry with cardiac neonatal lupus (n = 116) were genotyped using the Illumina 370K SNP platform and merged with 3,351 controls. Odds ratios (ORs) and 95% confidence intervals (95% CIs) for association with cardiac neonatal lupus were determined.
Results. The 17 most significant associations with cardiac neonatal lupus were found in the HLA region. The region near the MICB gene showed the strongest variant (rs3099844; P(dom) = 4.52 x 10(-10), OR 3.34 [95% CI 2.29-4.89]), followed by a missense variant within C6orf10 (rs7775397; P(dom) = 1.35 x 10(-9), OR 3.30), which lies between NOTCH4 and BTNL2, and several SNPs near the tumor necrosis factor alpha gene, including rs2857595 (P(add) = 1.96 x 10(-9), OR 2.37), rs2230365 (P(add) = 1.00 x 10(-3), OR 0.46), and rs3128982 (P(add) = 6.40 x 10(-6), OR 1.86). Outside the HLA region, an association was detected at 21q22, upstream of the transcription regulator ets-related isoform 1 (rs743446; P = 5.45 x 10(-6), OR 2.40). HLA notwithstanding, no individual locus previously implicated in autoimmune diseases achieved genome-wide significance.
Conclusion. These results suggest that variation near genes related to inflammatory and apoptotic responses may promote cardiac injury initiated by passively acquired autoantibodies.
C1 [Clancy, Robert M.] NYU, Langone Sch Med, New York, NY 10003 USA.
[Marion, Miranda C.; Ramos, Paula S.; Langefeld, Carl D.] Wake Forest Univ, Winston Salem, NC 27109 USA.
[Harley, John B.] Univ Oklahoma, Oklahoma Med Res Fdn, Oklahoma City, OK USA.
[Harley, John B.] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA.
RP Clancy, RM (reprint author), NYU, Langone Sch Med, 301 E 17th St, New York, NY 10003 USA.
EM bobdclancy@aol.com
FU NIH [AR-42455, N01-AR-42271, P01-AI-083194-01, P20-RR-020143-06,
U19-AI-082714-01, P01-AR-049084-07, N01-AR-62277, R01-DE-018209-01A1,
R37-AI-024717-21, R01-AR-042460-15]; American Heart Association
[0655938T]; Wake Forest University Health Sciences Center for Public
Health Genomics; Alliance for Lupus Research
FX Supported by NIH grants AR-42455 and N01-AR-42271 and by American Heart
Association grant-in-aid 0655938T. Ms Marion and Drs. Ramos and
Langefeld's work was supported by the Wake Forest University Health
Sciences Center for Public Health Genomics. Drs. Kaufman and Harley are
recipients of US Department of Veterans Affairs Merit Awards. Dr.
Harley's work was also supported by NIH grants P01-AI-083194-01,
P20-RR-020143-06, U19-AI-082714-01, P01-AR-049084-07, N01-AR-62277,
R01-DE-018209-01A1, R37-AI-024717-21, and R01-AR-042460-15. The
International Consortium on Systemic Lupus Erythematosus Genetics was
funded by the Alliance for Lupus Research.
NR 50
TC 33
Z9 36
U1 0
U2 2
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0004-3591
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD NOV
PY 2010
VL 62
IS 11
BP 3415
EP 3424
DI 10.1002/art.27658
PG 10
WC Rheumatology
SC Rheumatology
GA 674UU
UT WOS:000283776400033
PM 20662065
ER
PT J
AU Grossman, JM
Gordon, R
Ranganath, VK
Deal, C
Caplan, L
Chen, WL
Curtis, JR
Furst, DE
McMahon, M
Patkar, NM
Volkmann, E
Saag, KG
AF Grossman, Jennifer M.
Gordon, Rebecca
Ranganath, Veena K.
Deal, Chad
Caplan, Liron
Chen, Weiling
Curtis, Jeffrey R.
Furst, Daniel E.
McMahon, Maureen
Patkar, Nivedita M.
Volkmann, Elizabeth
Saag, Kenneth G.
TI American College of Rheumatology 2010 Recommendations for the Prevention
and Treatment of Glucocorticoid-Induced Osteoporosis
SO ARTHRITIS CARE & RESEARCH
LA English
DT Article
ID CORTICOSTEROID-INDUCED OSTEOPOROSIS; INDUCED BONE LOSS; INTERMITTENT
CYCLICAL ETIDRONATE; SYSTEMIC-LUPUS-ERYTHEMATOSUS; RANDOMIZED
CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; VERTEBRAL FRACTURE
ASSESSMENT; INTRANASAL SALMON-CALCITONIN; CONNECTIVE-TISSUE DISEASE;
HIGH-DOSE GLUCOCORTICOIDS
AB Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient. The ACR considers adherence to these guidelines and recommendations to be voluntary, with the ultimate determination regarding their application to be made by the physician in light of each patient's individual circumstances. Guidelines and recommendations are intended to promote beneficial or desirable outcomes but cannot guarantee any specific outcome. Guidelines and recommendations developed or endorsed by the ACR are subject to periodic revision as warranted by the evolution of medical knowledge, technology, and practice.
C1 [Grossman, Jennifer M.; Gordon, Rebecca; Ranganath, Veena K.; Chen, Weiling; Furst, Daniel E.; McMahon, Maureen; Volkmann, Elizabeth] Univ Calif Los Angeles, Los Angeles, CA 90095 USA.
[Gordon, Rebecca] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Deal, Chad] Cleveland Clin, Cleveland, OH 44106 USA.
[Caplan, Liron] Univ Colorado, Denver, CO 80202 USA.
[Curtis, Jeffrey R.; Patkar, Nivedita M.; Saag, Kenneth G.] Univ Alabama, Birmingham, AL USA.
RP Grossman, JM (reprint author), Univ Calif Los Angeles, 1000 Vet Ave,Room 32-59,Rehabil Bldg, Los Angeles, CA 90095 USA.
EM jgrossman@mednet.ucla.edu
FU Lilly; Amgen; Genentech; Eli Lilly; Procter Gamble; Novartis;
Roche/Genentech; Merck; Aventis; AstraZeneca; Pfizer; Horizon
FX Dr. Deal has received consultant fees, speaking fees, and/or honoraria
(more than $10,000 each) from Lilly, Amgen, and Genentech. Dr. Curtis
has received consultant fees, speaking fees, and/or honoraria (less than
$10,000 each) from Eli Lilly and Procter & Gamble, and (more than
$10,000 each) from Novartis, Amgen, Roche/Genentech, and Merck. Dr. Saag
has received consultant fees, speaking fees, and/or honoraria (less than
$10,000 each) from Merck, Lilly, Novartis, Aventis, Genentech,
AstraZeneca, Pfizer, and Horizon.
NR 104
TC 319
Z9 346
U1 4
U2 20
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 2151-464X
J9 ARTHRIT CARE RES
JI Arthritis Care Res.
PD NOV
PY 2010
VL 62
IS 11
BP 1515
EP 1526
DI 10.1002/acr.20295
PG 12
WC Rheumatology
SC Rheumatology
GA 678BA
UT WOS:000284041200001
PM 20662044
ER
PT J
AU Davis, LA
Larson, MM
Caplan, L
AF Davis, Lisa A.
Larson, Molly M.
Caplan, Liron
TI Observational Study to Determine Predictors of Rheumatology Clinic Visit
Provider Contact Time
SO ARTHRITIS CARE & RESEARCH
LA English
DT Article
ID LENGTH
AB Objective. To address perceived inefficiencies in an academic rheumatology practice, a timing/work-flow evaluation was initiated to determine the factors that predict the provider contact time (PCT), i.e., the amount of time that attending physicians spend with patients during an outpatient encounter.
Methods. This prospective observational study was conducted at the University of Colorado Hospital Rheumatology Clinic for return patient visits in early 2008. Each patient encounter was subdivided into components, and the time for each component was recorded. Up to 20 return-visit encounters per provider were randomly selected for inclusion. Multivariate linear regression was used to predict the time, in minutes, that providers spent with patients, and logistic regression was used to determine the time intervals associated with the patient's perception that the visit ran on time.
Results. Variables associated with increased PCT were whether a procedure was performed in the clinic (P = 0.037) and whether the visit occurred in the afternoon (P < 0.025). For every minute a provider was late in beginning to see a patient, the PCT decreased by 0.32 minutes (95% confidence interval [ 95% CI] 0.15, 0.49). Variables associated with the patient's perception that the visit ran on time included the check-in to vitals delay (odds ratio [ OR] 0.95; 95% CI 0.92, 0.99) and the provider delay (OR 0.92; 95% CI 0.86, 0.99).
Conclusion. The patient's punctuality and the presence of a resident are not significantly associated with the time that a provider spends with a patient. However, the degree to which the provider runs late was associated with decreased PCT and diminishes the patient's perception that the visit is running on time.
C1 [Davis, Lisa A.; Larson, Molly M.; Caplan, Liron] Univ Colorado, Sch Med, Denver, CO 80045 USA.
[Caplan, Liron] Denver VAMC, Denver, CO USA.
RP Caplan, L (reprint author), Univ Colorado, Sch Med, POB 6511,B115, Denver, CO 80045 USA.
EM liron.caplan@ucdenver.edu
FU NIH, National Institute of Arthritis and Musculoskeletal and Skin
Diseases [T32-AR007534-24]; VA Health Services [CDP 09-388]
FX Dr. Davis's work was supported by the NIH (grant T32-AR007534-24 from
the National Institute of Arthritis and Musculoskeletal and Skin
Diseases). Dr. Caplan's work was supported by a VA Health Services
Research and Development Award (CDP 09-388).
NR 12
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 2151-464X
J9 ARTHRIT CARE RES
JI Arthritis Care Res.
PD NOV
PY 2010
VL 62
IS 11
BP 1650
EP 1654
DI 10.1002/acr.20281
PG 5
WC Rheumatology
SC Rheumatology
GA 678BA
UT WOS:000284041200017
PM 20583104
ER
PT J
AU Lee, DBN
Roberts, M
Bluchel, CG
Odell, RA
AF Lee, David B. N.
Roberts, Martin
Bluchel, Christian G.
Odell, Ross A.
TI Zirconium: Biomedical and Nephrological Applications
SO ASAIO JOURNAL
LA English
DT Article
ID OSTEOBLAST-LIKE CELLS; STAGE RENAL-FAILURE; IN-VITRO; TRACE-ELEMENT;
HEAVY-METALS; DIALYSIS OSTEOMALACIA; ORGANIC-SUBSTANCES;
ENDOTHELIAL-CELLS; URINARY-EXCRETION; CLINICAL REPORT
AB Recent years have witnessed a rapid increase in the use of zirconium (Zr)-containing compounds in artificial internal organs. Examples include dental implants and other restorative practices, total knee and hip replacement, and middle-ear ossicular chain reconstruction. In nephrological practice, Zr-containing sorbents have been used in hemofiltration, hemodialysis, peritoneal dialysis, and in the design and construction of wearable artificial kidneys. Zr compounds continue to be widely and extensively used in deodorant and antiperspirant preparations. In the public health arena, Zr compounds have been studied or used in controlling phosphorus pollution and in the reclamation of poison and bacteria-contaminated water. Experimental and clinical studies support the general consensus that Zr compounds are biocompatible and exhibit low toxicity. Reports on possible Zr-associated adverse reactions are rare and, in general, have not rigorously established a cause-and-effect relationship. Although publications on the use of Zr compounds have continued to increase in recent years, reports on Zr toxicity have virtually disappeared from the medical literature. Nevertheless, familiarity with, and continued vigilant monitoring of, the use of these compounds are warranted. This article provides an updated review on the biomedical use of Zr compounds. ASAIO Journal 2010; 56:550-556.
C1 [Lee, David B. N.; Roberts, Martin] VA Greater Healthcare Syst, Nephrol Sect, Sepulveda Ambulatory Care Ctr & Nursing Home, North Hills, CA 91343 USA.
[Lee, David B. N.; Roberts, Martin] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Lee, David B. N.; Roberts, Martin; Bluchel, Christian G.] AWAK Technol Inc, Burbank, CA USA.
[Lee, David B. N.; Roberts, Martin; Bluchel, Christian G.] AWAK Technol Inc, Singapore, Singapore.
[Bluchel, Christian G.] Temasek Polytechn, Temasek Engn Sch, Singapore, Singapore.
[Odell, Ross A.] Univ New S Wales, Grad Sch Biomed Engn, Sydney, NSW, Australia.
RP Lee, DBN (reprint author), VA Greater Healthcare Syst, Nephrol Sect, Sepulveda Ambulatory Care Ctr & Nursing Home, Room 3526,Bldg 200,16111 Plummer St, North Hills, CA 91343 USA.
EM dbnlee@ucla.edu
NR 86
TC 25
Z9 25
U1 2
U2 23
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1058-2916
J9 ASAIO J
JI Asaio J.
PD NOV-DEC
PY 2010
VL 56
IS 6
BP 550
EP 556
DI 10.1097/MAT.0b013e3181e73f20
PG 7
WC Engineering, Biomedical; Transplantation
SC Engineering; Transplantation
GA 674FH
UT WOS:000283719600012
PM 21245802
ER
PT J
AU Vaid, M
Sharma, SD
Katiyar, SK
AF Vaid, Mudit
Sharma, Som D.
Katiyar, Santosh K.
TI Honokiol, a phytochemical from the Magnolia plant, inhibits
photocarcinogenesis by targeting UVB-induced inflammatory mediators and
cell cycle regulators: development of topical formulation
SO CARCINOGENESIS
LA English
DT Article
ID FACTOR-KAPPA-B; SKIN-CANCER; MOUSE SKIN; IN-VIVO; TUMOR-DEVELOPMENT;
COX-2 EXPRESSION; HAIRLESS MICE; ACTIVATION; APOPTOSIS; CYCLOOXYGENASE-2
AB To develop newer and more effective chemopreventive agents for skin cancer, we assessed the effect of honokiol, a phytochemical from the Magnolia plant, on ultraviolet (UV) radiation-induced skin tumorigenesis using the SKH-1 hairless mouse model. Topical treatment of mice with honokiol in a hydrophilic cream-based topical formulation before or after UVB (180 mJ/cm(2)) irradiation resulted in a significant protection against photocarcinogenesis in terms of tumor multiplicity (28-60%, P < 0.05 to < 0.001) and tumor volume per tumor-bearing mouse (33-80%, P < 0.05 to 0.001, n = 20). Honokiol also inhibited and delayed the malignant progression of papillomas to carcinomas. To investigate the in vivo molecular targets of honokiol efficacy, tumors and tumor-uninvolved skin samples from the tumor-bearing mice were analyzed for inflammatory mediators, cell cycle regulators and survival signals using immunostaining, western blotting and enzyme-linked immunosorbent assay. Treatment with honokiol significantly inhibited UVB-induced expression of cyclooxygenase-2, prostaglandin E(2) (P < 0.001), proliferating cell nuclear antigen and proinflammatory cytokines, such as tumor necrosis factor-alpha (P < 0.001), interleukin (IL)-1 beta (P < 0.01) and IL-6 (P < 0.001) in the skin as well as in skin tumors. Western blot analysis revealed that honokiol: (i) inhibited the levels of cyclins D1, D2 and E and associated cyclin-dependent kinases (CDKs)2, CDK4 and CDK6, (ii) upregulated Cip/p21 and Kip/p27 and (iii) inhibited the levels of phosphatidylinositol 3-kinase and the phosphorylation of Akt at Ser(473) in UVB-induced skin tumors. Together, our results indicate that honokiol holds promise for the prevention of UVB-induced skin cancer by targeting inflammatory mediators, cell cycle regulators and cell survival signals in UVB-exposed skin.
C1 [Vaid, Mudit; Sharma, Som D.; Katiyar, Santosh K.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA.
[Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA.
RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA.
EM skatiyar@uab.edu
FU Veterans Administration
FX Veterans Administration Merit Review Award (S.K.K.).
NR 47
TC 39
Z9 39
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
J9 CARCINOGENESIS
JI Carcinogenesis
PD NOV
PY 2010
VL 31
IS 11
BP 2004
EP 2011
DI 10.1093/carcin/bgq186
PG 8
WC Oncology
SC Oncology
GA 676OS
UT WOS:000283922400014
PM 20823108
ER
PT J
AU Habib, SL
Bhandari, BK
Sadek, N
Abboud-Werner, SL
Abboud, HE
AF Habib, Samy L.
Bhandari, Besant K.
Sadek, Nahed
Abboud-Werner, Sherry L.
Abboud, Hanna E.
TI Novel mechanism of regulation of the DNA repair enzyme OGG1 in
tuberin-deficient cells
SO CARCINOGENESIS
LA English
DT Article
ID HOGG1 SER326CYS POLYMORPHISM; TUMOR-SUPPRESSOR GENE; LUNG-CANCER RISK;
EKER RAT MODEL; 3-KINASE/AKT PATHWAY; SCLEROSIS COMPLEX; DAMAGE; TSC2;
KIDNEY; PHOSPHORYLATION
AB Tuberin (protein encodes by tuberous sclerosis complex 2, Tsc2) deficiency is associated with the decrease in the DNA repair enzyme 8-oxoG-DNA glycosylase (OGG1) in tumour kidney of tuberous sclerosis complex (TSC) patients. The purpose of this study was to elucidate the mechanisms by which tuberin regulates OGG1. The partial deficiency in tuberin expression that occurs in the renal proximal tubular cells and kidney cortex of the Eker rat is associated with decreased activator protein 4 (AP4) and OGG1 expression. A complete deficiency in tuberin is associated with loss of AP4 and OGG1 expression in kidney tumour from Eker rats and the accumulation of significant levels of 8-oxo-deoxyguanosine. Knockdown of tuberin expression in human renal epithelial cells (HEK293) with small interfering RNA (siRNA) also resulted in a marked decrease in the expression of AP4 and OGG1. In contrast, overexpression of tuberin in HEK293 cells increased the expression of AP4 and OGG1 proteins. Downregulation of AP4 expression using siRNA resulted in a significant decrease in the protein expression of OGG1. Immunoprecipitation studies show that AP4 is associated with tuberin in cells. Gel shift analysis and chromatin immunoprecipitation identified the transcription factor AP4 as a positive regulator of the OGG1 promoter. AP4 DNA-binding activity is significantly reduced in Tsc2(-/-) as compared with Tsc2(+/+) cells. Transcriptional activity of the OGG1 promoter is also decreased in tuberin-null cells compared with wild-type cells. These data indicate a novel role for tuberin in the regulation of OGG1 through the transcription factor AP4. This regulation may be important in the pathogenesis of kidney tumours in patients with TSC disease.
C1 [Habib, Samy L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, San Antonio, TX 78229 USA.
[Abboud-Werner, Sherry L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[Habib, Samy L.] S Texas Vet Healthcare Syst, Dept Geriatr Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA.
RP Habib, SL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, MSC 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM habib@uthscsa.edu
FU American Diabetes Association; South Texas Veterans Healthcare System;
The National Organization for Research
FX American Diabetes Association Research Grant; Merit Review Award and New
Investigator Award from the South Texas Veterans Healthcare System to
S.L.H.; The authors would like to acknowledge Dr Daniel J.Riley and Dr
Anthony Valente for helpful discussions and for critical reading of the
manuscript, Dr P.Radicella at Radiobiologie Moleculaire et Cellulaire,
France, for providing the OGG1 promoter construct and Dr S.Mitra at the
University of Texas M. D. Anderson and Sealy Center for Molecular
Science, Galveston, TX for providing the OGG1 antibody. N.S. is a
recipient of the Research Fellowship Award from The National
Organization for Research, Egypt.
NR 44
TC 15
Z9 15
U1 1
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
J9 CARCINOGENESIS
JI Carcinogenesis
PD NOV
PY 2010
VL 31
IS 11
BP 2022
EP 2030
DI 10.1093/carcin/bgq189
PG 9
WC Oncology
SC Oncology
GA 676OS
UT WOS:000283922400016
PM 20837600
ER
PT J
AU Afessa, B
Anzueto, AR
Craven, DE
Kollef, MH
AF Afessa, Bekele
Anzueto, Antonio R.
Craven, Donald E.
Kollef, Marin H.
TI Increased Mortality in Patients Without Ventilator-Associated Pneumonia
Response
SO CHEST
LA English
DT Letter
ID COATED ENDOTRACHEAL-TUBES; BURDEN
C1 [Afessa, Bekele] Mayo Clin, Div Pulm & Crit Care Med, Coll Med, Rochester, MN 55905 USA.
[Anzueto, Antonio R.] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA.
[Anzueto, Antonio R.] Univ Texas Hlth Sci Ctr San Antonio, Univ Hosp, San Antonio, TX 78229 USA.
[Craven, Donald E.] Lahey Clin Med Ctr, Boston, MA USA.
[Craven, Donald E.] Tufts Univ, Sch Med, Boston, MA 02111 USA.
[Kollef, Marin H.] Washington Univ, Sch Med, St Louis, MO USA.
RP Afessa, B (reprint author), Mayo Clin, Div Pulm & Crit Care Med, Coll Med, 200 1st St SW, Rochester, MN 55905 USA.
EM Afessa.bekele@mayo.edu
NR 4
TC 0
Z9 0
U1 0
U2 0
PU AMER COLL CHEST PHYSICIANS
PI NORTHBROOK
PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA
SN 0012-3692
J9 CHEST
JI Chest
PD NOV
PY 2010
VL 138
IS 5
BP 1275
EP 1275
DI 10.1378/chest.10-1724
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 681TH
UT WOS:000284341700042
ER
PT J
AU Anderson, JA
Willson, P
Peterson, NJ
Murphy, C
Kent, TA
AF Anderson, Jane A.
Willson, Pamela
Peterson, Nancy J.
Murphy, Chris
Kent, Thomas A.
TI Prototype to Practice Developing and Testing a Clinical Decision Support
System for Secondary Stroke Prevention in a Veterans Healthcare Facility
SO CIN-COMPUTERS INFORMATICS NURSING
LA English
DT Article
DE Advanced practice nursing; Clinical decision support systems; Electronic
medical record; Evidence-based practice; Nursing; Secondary stroke
prevention; Usability
ID GUIDELINES
AB A clinical decision support system that guides nurse practitioners and other healthcare providers in secondary stroke prevention was developed by a multidisciplinary team with funding received from the Veterans Health Administration Office of Nursing Services. This article presents alpha-testing results obtained while using an integrated model for clinical decision support system development that emphasizes end-user perspectives throughout the development process. Before-after and descriptive methods were utilized to evaluate functionality and usability of the prototype among a sample of multidisciplinary clinicians. The predominant functionality feature of the tool is automated prompting and documentation of secondary stroke prevention guidelines in the electronic medical record. Documentation of guidelines was compared among multidisciplinary providers (N = 15) using test case scenarios and two documentation systems, standard versus the prototype. Usability was evaluated with an investigator-developed questionnaire and one open-ended question. The prototype prompted a significant increase (P < .05) in provider documentation for six of 11 guidelines as compared with baseline documentation while using the standard system. Of a possible 56 points, usability was scored high (mean, 48.9 [SD, 6.8]). These results support that guideline prompting has been successfully engineered to produce a usable and useful clinical decision support system for secondary stroke prevention.
C1 [Anderson, Jane A.; Murphy, Chris] Baylor Coll Med, Stroke Ctr, Houston, TX 77030 USA.
[Anderson, Jane A.; Peterson, Nancy J.; Murphy, Chris; Kent, Thomas A.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Anderson, Jane A.; Willson, Pamela; Peterson, Nancy J.; Murphy, Chris; Kent, Thomas A.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA.
[Anderson, Jane A.; Willson, Pamela] Prairie View A&M Univ, Coll Nursing, Houston, TX USA.
[Willson, Pamela] Elsevier, Review & Testing, Res, Houston, TX USA.
RP Anderson, JA (reprint author), Baylor Coll Med, Stroke Ctr, Houston, TX 77030 USA.
EM jane.anderson@med.va.gov
OI Kent, Thomas/0000-0002-9877-7584
FU Veterans Health Administration Office of Nursing Services
FX This project was funded by the Veterans Health Administration Office of
Nursing Services.
NR 23
TC 7
Z9 8
U1 2
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1538-2931
J9 CIN-COMPUT INFORM NU
JI CIN-Comput. Inform. Nurs.
PD NOV-DEC
PY 2010
VL 28
IS 6
BP 353
EP 363
DI 10.1097/NCN.0b013e3181f69c5b
PG 11
WC Computer Science, Interdisciplinary Applications; Medical Informatics;
Nursing
SC Computer Science; Medical Informatics; Nursing
GA 675RL
UT WOS:000283848300004
PM 20978406
ER
PT J
AU Maddox, TM
Ho, PM
Roe, M
Dai, D
Tsai, TT
Rumsfeld, JS
AF Maddox, Thomas M.
Ho, P. Michael
Roe, Matthew
Dai, David
Tsai, Thomas T.
Rumsfeld, John S.
TI Utilization of Secondary Prevention Therapies in Patients With
Nonobstructive Coronary Artery Disease Identified During Cardiac
Catheterization Insights From the National Cardiovascular Data Registry
Cath-PCI Registry
SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
LA English
DT Article
DE prevention; coronary disease; epidemiology
ID ACUTE MYOCARDIAL-INFARCTION; RISK STRATIFICATION; ANGIOGRAPHY;
GUIDELINES; MECHANISMS; OUTCOMES; SITE
AB Background-Secondary prevention therapies are indicated for patients with coronary artery disease (CAD). However, patients with nonobstructive CAD may be less likely to receive these therapies compared with patients with obstructive CAD. Therefore, we compared rates of secondary prevention medication prescription between patients with nonobstructive and obstructive CAD.
Methods and Results-We conducted a retrospective cohort study of 1 489 745 CAD patients undergoing cardiac catheterization in 786 US centers between 2004 and 2007. We measured rates of aspirin, statin, beta-blocker, and angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB) prescription at hospital discharge among eligible patients; 237 167 (15.9%) patients had nonobstructive CAD and 1 252 578 (84.1%) had obstructive CAD. Compared with obstructive CAD patients, nonobstructive CAD patients had significantly lower rates of rates of aspirin (72.7% versus 90.9%), statin (60.0% versus 80.3%), beta-blocker (57.9% versus 79.4%), and ACEI/ARB (45.9% versus 58.6%; all probability values <0.0001) prescription at hospital discharge. After multivariable adjustment, nonobstructive CAD patients remained significantly less likely to receive prescriptions for aspirin (odds ratio, 0.37; 95% confidence interval, 0.35 to 0.39), statins (odds ratio, 0.45; 95% confidence interval, 0.43 to 0.48), beta-blockers (odds ratio, 0.46; 95% CI, 0.44 to 0.47), or ACEI/ARBs (odds ratio, 0.83; 95% confidence interval, 0.8 to 0.86) compared with obstructive CAD patients. Secondary analyses of selected subgroups supported the primary findings.
Conclusions-Patients with nonobstructive CAD were significantly less likely to receive secondary prevention medication prescription at hospital discharge, as compared with patients with obstructive CAD. These findings highlight an opportunity to improve the quality of care for CAD patients with nonobstructive disease. (Circ Cardiovasc Qual Outcomes. 2010;3:632-641.)
C1 [Maddox, Thomas M.] Univ Colorado, Denver VAMC, Cardiol Sect 111B, Denver, CO 80220 USA.
[Roe, Matthew; Dai, David] Duke Clin Res Inst, Durham, NC USA.
RP Maddox, TM (reprint author), Univ Colorado, Denver VAMC, Cardiol Sect 111B, 1055 Clermont St, Denver, CO 80220 USA.
EM thomas.maddox@va.gov
FU American College of Cardiology; Society for Coronary Angiography and
Intervention; Department of Veterans Affairs Health Services Research
and Developmen
FX This study was supported by the American College of Cardiology and
Society for Coronary Angiography and Intervention. The funders had no
role in the design and conduct of the study nor collection, management,
analysis, and interpretation of the data. The Research and Publications
committee for the NCDR Cath-PCI registry reviewed and approved the final
version of the manuscript. Drs Maddox and Ho were supported by
Department of Veterans Affairs Health Services Research and Development
Career Development Awards.
NR 21
TC 29
Z9 33
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-7713
J9 CIRC-CARDIOVASC QUAL
JI Circ.-Cardiovasc. Qual. Outcomes
PD NOV
PY 2010
VL 3
IS 6
BP 632
EP 641
DI 10.1161/CIRCOUTCOMES.109.906214
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 680VB
UT WOS:000284262900011
PM 20923997
ER
PT J
AU Lambert-Kerzner, A
Havranek, EP
Plomondon, ME
Albright, K
Moore, A
Gryniewicz, K
Magid, D
Ho, PM
AF Lambert-Kerzner, Anne
Havranek, Edward P.
Plomondon, Mary E.
Albright, Karen
Moore, Ashley
Gryniewicz, Kelsey
Magid, David
Ho, P. Michael
TI Patients' Perspectives of a Multifaceted Intervention With a Focus on
Technology A Qualitative Analysis
SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
LA English
DT Article
DE hypertension; qualitative; trials
ID HEALTH-CARE; HYPERTENSION; MANAGEMENT
AB Background-Few studies have investigated the effectiveness of multifaceted interventions from the study participants' perspective. We conducted qualitative interviews to understand patients' experiences with a multifaceted blood pressure (BP) control intervention involving interactive voice response technology, home BP monitoring, and pharmacist-led BP management. In the randomized study, the intervention resulted in clinically significant decreases in BP.
Methods and Results-We used insights generated from in-depth interviews from all study participants randomly assigned to the multifaceted intervention or usual care (n = 146) to create a model explaining the observed improvements in health behavior and clinical outcomes. The data were analyzed using qualitative content analysis methods and consultative and reflexive team analysis. Six explanatory factors emerged from the patients' interviews: (1) improved relationships with medical personnel; (2) increased knowledge of hypertension; (3) increased participation in their health care and personal empowerment; (4) greater understanding of the impact of health behavior on BP; (5) high satisfaction with technology used in the intervention; and, for some patients, (6) increased health care utilization. Eighty-six percent of the intervention patients and 62% of the usual care patients stated that study participation had a positive effect on them. Of those expressing a positive effect, 68% (intervention) and 55% (usual care) reached their systolic BP goal.
Conclusions-Establishing bidirectional conversations between patients and providers is a key element of successful hypertension management. Home BP monitoring coupled with interactive voice response technology reporting facilitates such conversations. (Circ Cardiovasc Qual Outcomes. 2010;3:668-674.)
C1 [Lambert-Kerzner, Anne; Plomondon, Mary E.; Gryniewicz, Kelsey; Ho, P. Michael] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Lambert-Kerzner, Anne; Havranek, Edward P.; Plomondon, Mary E.; Albright, Karen; Moore, Ashley; Magid, David; Ho, P. Michael] Univ Colorado Denver, Aurora, CO USA.
[Lambert-Kerzner, Anne; Havranek, Edward P.; Moore, Ashley] Denver Hlth Med Ctr, Denver, CO USA.
[Magid, David] Kaiser Permanente, Inst Hlth Res, Denver, CO USA.
RP Lambert-Kerzner, A (reprint author), DVAMC, 1055 Clermont St, Denver, CO 80220 USA.
EM anne.lambert-kerzner@va.gov
FU American Heart Association [0535086N]; Colorado Department of Public
Health and Environment [99]; VA Health Services Research and Development
Award [05-026]
FX This work was funded in part by an award from the American Heart
Association (0535086N) and from the Colorado Department of Public Health
and Environment (CCPD No. 99).; Dr Ho was supported by a VA Health
Services Research and Development Award (05-026) and serves as a
consultant for Wellpoint, Inc.
NR 29
TC 7
Z9 7
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-7705
J9 CIRC-CARDIOVASC QUAL
JI Circ.-Cardiovasc. Qual. Outcomes
PD NOV
PY 2010
VL 3
IS 6
BP 668
EP 674
DI 10.1161/CIRCOUTCOMES.110.949800
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 680VB
UT WOS:000284262900015
PM 20923992
ER
PT J
AU Mathenia, J
Reyes-Cortes, E
Williams, S
Molano, I
Ruiz, P
Watson, DK
Gilkeson, GS
Zhang, XK
AF Mathenia, J.
Reyes-Cortes, E.
Williams, S.
Molano, I.
Ruiz, P.
Watson, D. K.
Gilkeson, G. S.
Zhang, X. K.
TI Impact of Fli-1 transcription factor on autoantibody and lupus nephritis
in NZM2410 mice
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE animal model; autoantibody; Fli-1 transcription factor; lupus; nephritis
ID ETS GENE FAMILY; RENAL-DISEASE; MARGINAL ZONE; MRL/LPR MICE;
CELL-PROLIFERATION; B-CELLS; EXPRESSION; ERYTHEMATOSUS; MEMBER;
GLOMERULONEPHRITIS
AB P>The transcription factor Fli-1 is implicated in the pathogenesis of both murine and human lupus. Increased levels of Fli-1 mRNA were present in the peripheral blood lymphocytes from lupus patients; furthermore, transgenic overexpression of Fli-1 in normal mice resulted in the development of a lupus-like disease. Lupus nephritis is a major cause of death in both lupus patients as well as in animal models. In this study, we generated Fli-1 heterozygous knockout (Fli-1+/-) NZM2410 mice (of which the wild-type is a widely used lupus murine model) that expressed decreased levels of Fli-1 and investigated the impact of Fli-1 expression on lupus nephritis development and survival. Ninety-three per cent of the Fli-1+/- NZM2410 mice survived to the age of 52 weeks compared to only 35% of wild-type NZM2410 mice. Autoantibodies, including anti-dsDNA and anti-glomerular basement antigen, in Fli-1+/- NZM2410 mice were statistically significantly lower when compared to wild-type NZM2410 mice at the ages of 30 and 34 weeks. Total B cell and activated B cell populations in the spleens from Fli-1+/- NZM2410 mice were decreased significantly compared to wild-type NZM2410 mice. Fli-1+/- NZM2410 mice also had remarkably diminished proteinuria and decreased renal pathological scores when compared with wild-type NZM2410 mice. Expression of early growth response 1 (Egr-1) was decreased significantly in the kidneys from Fli-1+/- NZM2410 mice when compared to wild-type littermates. Our data indicate that expression of Fli-1 plays an important role in lupus disease development in NZM2410 mice.
C1 [Mathenia, J.; Reyes-Cortes, E.; Molano, I.; Gilkeson, G. S.; Zhang, X. K.] Med Univ S Carolina, Div Rheumatol & Immunol, Dept Med, Charleston, SC 29425 USA.
[Watson, D. K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA.
[Mathenia, J.; Williams, S.; Gilkeson, G. S.; Zhang, X. K.] Ralph H Johnson Vet Affairs Med Ctr, Med Res Serv, Charleston, SC USA.
[Ruiz, P.] Univ Miami, Sch Med, Miami, FL USA.
RP Zhang, XK (reprint author), Med Univ S Carolina, Div Rheumatol & Immunol, Dept Med, Suite 912,Jonathan Lucas St MSC637, Charleston, SC 29425 USA.
EM zhangjo@musc.edu
FU National Institutes of Health [AR054546]; Department of Veterans Affairs
FX We thank Sarah Darley and William Zhang for providing excellent
technical assistance. This study was supported by National Institutes of
Health grants (AR054546 to X.K.Z.) and the Medical Research Service and
Research Enhancement Award Programs, Department of Veterans Affairs (to
X.K.Z and G. S. G.)
NR 36
TC 14
Z9 16
U1 0
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0009-9104
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD NOV
PY 2010
VL 162
IS 2
BP 362
EP 371
DI 10.1111/j.1365-2249.2010.04245.x
PG 10
WC Immunology
SC Immunology
GA 661AP
UT WOS:000282694800017
PM 20731671
ER
PT J
AU Beste, LA
Ioannou, GN
Larson, MS
Chapko, M
Dominitz, JA
AF Beste, Lauren A.
Ioannou, George N.
Larson, Meaghan S.
Chapko, Michael
Dominitz, Jason A.
TI Predictors of Early Treatment Discontinuation Among Patients With
Genotype 1 Hepatitis C and Implications for Viral Eradication
SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article
DE Hepatology; Viral Hepatitis; Treatment Duration; Treatment Attrition
ID PEGYLATED INTERFERON; VIRUS-INFECTION; ANTIVIRAL THERAPY; PLUS
RIBAVIRIN; UNITED-STATES; PREVALENCE; VETERANS; COMPLETION; SYMPTOMS;
USERS
AB BACKGROUND & AIMS A significant proportion of patients with hepatitis C virus (HCV) infection discontinue anti viral treatment prematurely Risk factors for discontinuation before 48 weeks among patients with genotype 1 HCV vary over the course of therapy We investigated the rates and risk factors for treatment discontinuation within 12 weeks, 12-24 weeks, and 24-48 weeks METHODS We retrospectively evaluated data from all Veterans Affairs (VA) patients with genotype 1 HCV who initiated pegylated interferon and ribavirin therapy from 2002-2007 (n = 11,019) We accounted for appropriate discontinuation because of viral nonresponse RESULTS Overall, 53% of patients completed at least 38 4 weeks of therapy (80% of the projected 48 weeks), 16 5% discontinued early in the setting of viral nonresponse, and 30 9% discontinued de spite viral response or in the absence of virologic data Cirrhosis, diabetes, pretreatment substance use disorder, hemoglobin, and lack of hematopoietic growth factor use independently predicted discontinuation before 12 weeks (P < 05 for all) Among patients with documented early virologic responses, higher baseline levels of creatinine, depression, and lack of growth factor use predicted discontinuation from 12-24 weeks No factors independently predicted discontinuation from 24-48 weeks among patients responding to treatment at 24 weeks CONCLUSIONS Early discontinuation of antiviral therapy is common Use of growth factors was the strongest independent predictor of treatment retention be fore 24 weeks and should be evaluated prospectively Early interventions may also be warranted for other risk factors for early discontinuation, such as pre-existing substance use, depression, cirrhosis, or diabetes
C1 VA Puget Sound Healthcare Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA.
[Beste, Lauren A.; Larson, Meaghan S.; Chapko, Michael; Dominitz, Jason A.] VA Puget Sound Healthcare Syst, NW Hepatitis Resource Ctr C, Seattle, WA USA.
[Beste, Lauren A.] VA Puget Sound Healthcare Syst, Div Gen Internal Med, Seattle, WA USA.
[Ioannou, George N.; Dominitz, Jason A.] VA Puget Sound Healthcare Syst, Div Gastroenterol, Seattle, WA USA.
[Ioannou, George N.; Dominitz, Jason A.] Univ Washington, Sch Med, Seattle, WA USA.
[Chapko, Michael] Univ Washington, Sch Publ Hlth & Community Med, Dept Hlth Serv, Seattle, WA 98195 USA.
RP Beste, LA (reprint author), 1660 S Columbian Way, Seattle, WA 98108 USA.
OI Dominitz, Jason/0000-0002-8070-7086
FU VA Puget Sound Health Care System, Seattle, Washington; Department of
Veterans Affairs Health Services Research and Development [TPM 61-032];
Northwest Hepatitis C Resource Center Study
FX This material is the result of work supported by resources from the VA
Puget Sound Health Care System, Seattle, Washington The study was
supported by Department of Veterans Affairs Health Services Research and
Development research and training funds (TPM 61-032) and the Northwest
Hepatitis C Resource Center Study sponsors had no role in the study
design, collection, analysis or interpretation of the data or in the
writing of the report
NR 24
TC 21
Z9 21
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1542-3565
J9 CLIN GASTROENTEROL H
JI Clin. Gastroenterol. Hepatol.
PD NOV
PY 2010
VL 8
IS 11
BP 972
EP 978
DI 10.1016/j.cgh.2010.07.012
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 690UU
UT WOS:000285034800018
PM 20692371
ER
PT J
AU Sun, HY
Alexander, BD
Lortholary, O
Dromer, F
Forrest, GN
Lyon, GM
Somani, J
Gupta, KL
del Busto, R
Pruett, TL
Sifri, CD
Limaye, AP
John, GT
Klintmalm, GB
Pursell, K
Stosor, V
Morris, MI
Dowdy, LA
Munoz, P
Kalil, AC
Garcia-Diaz, J
Orloff, SL
House, AA
Houston, SH
Wray, D
Huprikar, S
Johnson, LB
Humar, A
Razonable, RR
Fisher, RA
Husain, S
Wagener, MM
Singh, N
AF Sun, Hsin-Yun
Alexander, Barbara D.
Lortholary, Olivier
Dromer, Francoise
Forrest, Graeme N.
Lyon, G. Marshall
Somani, Jyoti
Gupta, Krishan L.
del Busto, Ramon
Pruett, Timothy L.
Sifri, Costi D.
Limaye, Ajit P.
John, George T.
Klintmalm, Goran B.
Pursell, Kenneth
Stosor, Valentina
Morris, Michele I.
Dowdy, Lorraine A.
Munoz, Patricia
Kalil, Andre C.
Garcia-Diaz, Julia
Orloff, Susan L.
House, Andrew A.
Houston, Sally H.
Wray, Dannah
Huprikar, Shirish
Johnson, Leonard B.
Humar, Atul
Razonable, Raymund R.
Fisher, Robert A.
Husain, Shahid
Wagener, Marilyn M.
Singh, Nina
CA Cryptococcal Collaborative
TI Unrecognized Pretransplant and Donor-Derived Cryptococcal Disease in
Organ Transplant Recipients
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID INVASIVE FUNGAL-INFECTIONS; HEMATOPOIETIC STEM-CELL; SOLID-ORGAN;
NEOFORMANS INFECTION; IRON OVERLOAD; LIVER; TRANSMISSION; MENINGITIS;
MORTALITY; VIRUS
AB Background. Cryptococcosis occurring <= 30 days after transplantation is an unusual event, and its characteristics are not known.
Methods. Patients included 175 solid-organ transplant (SOT) recipients with cryptococcosis in a multicenter cohort. Very early-onset and late-onset cryptococcosis were defined as disease occurring <= 30 days or 130 days after transplantation, respectively.
Results. Very early-onset disease developed in 9 (5%) of the 175 patients at a mean of 5.7 days after transplantation. Overall, 55.6% (5 of 9) of the patients with very early-onset disease versus 25.9% (43 of 166) of the patients with late-onset disease were liver transplant recipients (Pp. 05). Very early cases were more likely to present with disease at unusual locations, including transplanted allograft and surgical fossa/site infections (55.6% vs 7.2%; P<.001). Two very early cases with onset on day 1 after transplantation (in a liver transplant recipient with Cryptococcus isolated from the lung and a heart transplant recipient with fungemia) likely were the result of undetected pretransplant disease. An additional 5 cases involving the allograft or surgical sites were likely the result of donor-acquired infection.
Conclusions. A subset of SOT recipients with cryptococcosis present very early after transplantation with disease that appears to occur preferentially in liver transplant recipients and involves unusual sites, such as the transplanted organ or the surgical site. These patients may have unrecognized pretransplant or donor-derived cryptococcosis.
C1 [Sun, Hsin-Yun; Singh, Nina] VA Pittsburgh Healthcare Syst, Infect Dis Sect, Pittsburgh, PA 15240 USA.
[Husain, Shahid; Wagener, Marilyn M.; Singh, Nina] Univ Pittsburgh, Pittsburgh, PA USA.
[Alexander, Barbara D.] Duke Univ, Med Ctr, Durham, NC USA.
[Forrest, Graeme N.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
[Lyon, G. Marshall; Somani, Jyoti] Emory Univ, Atlanta, GA 30322 USA.
[del Busto, Ramon] Henry Ford Hosp, Detroit, MI 48202 USA.
[Johnson, Leonard B.] St Johns Hosp, Detroit, MI USA.
[Pruett, Timothy L.; Sifri, Costi D.] Univ Virginia, Charlottesville, VA USA.
[Fisher, Robert A.] Virginia Commonwealth Univ, Richmond, VA USA.
[Limaye, Ajit P.] Univ Washington, Seattle, WA 98195 USA.
[Klintmalm, Goran B.] Baylor Univ, Med Ctr, Dallas, TX USA.
[Pursell, Kenneth] Univ Chicago, Chicago, IL 60637 USA.
[Stosor, Valentina] Northwestern Univ, Chicago, IL 60611 USA.
[Morris, Michele I.; Dowdy, Lorraine A.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
[Houston, Sally H.] Tampa Gen Hosp, Tampa, FL 33606 USA.
[Kalil, Andre C.] Univ Nebraska, Omaha, NE 68182 USA.
[Garcia-Diaz, Julia] Ochsner Clin & Alton Ochsner Med Fdn, New Orleans, LA USA.
[Orloff, Susan L.] Oregon Hlth & Sci Univ, Portland, OR USA.
[Wray, Dannah] Med Univ S Carolina, Charleston, SC 29425 USA.
[Huprikar, Shirish] Mt Sinai Med Ctr, New York, NY 10029 USA.
[Razonable, Raymund R.] Mayo Clin, Rochester, MN USA.
[Sun, Hsin-Yun] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan.
[Sun, Hsin-Yun] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan.
[Lortholary, Olivier] Hop Necker Enfants Malad, Fac Med Paris Descartes, Paris, France.
[Dromer, Francoise] Inst Pasteur, Paris, France.
[Gupta, Krishan L.] Postgrad Inst Med Educ & Res, Chandigarh 160012, India.
[John, George T.] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India.
[Munoz, Patricia] Hosp Gen Univ Gregorio Maranon, Madrid, Spain.
[Munoz, Patricia] CIBER Enfermedades Resp, Madrid, Spain.
[House, Andrew A.] Univ Western Ontario, London, ON, Canada.
[Humar, Atul] Toronto Gen Hosp, Univ Hlth Network, Toronto, ON, Canada.
RP Singh, N (reprint author), VA Pittsburgh Healthcare Syst, Infect Dis Sect, Univ Dr C, Pittsburgh, PA 15240 USA.
EM nis5@pitt.edu
RI Garcia-Diaz, Julia/D-3555-2011
OI SUN, HSIN-YUN/0000-0003-0074-7721; Munoz Garcia, Patricia
Carmen/0000-0001-5706-5583
FU Astellas; Pfizer; Merck; Basilea; National Institutes of Health,
National Institute of Allergy and Infectious Diseases [R01 AI 054719-01]
FX B. D. A. has served on advisory boards for Abbott, Bristol Myers Squibb,
bioMerieux, and has received investigator initiated grants from Astellas
and Pfizer. O.L. has served on speaker's bureaus of Astellas, Gilead
Sciences, Merck, Schering-Plough, and Pfizer and as a consultant for
Astellas and Gilead Sciences. G. F. has received grant support from
Astellas. G. M. L. has served on advisory boards for and received grants
from Merck and Astellas and on speaker's bureaus of Astellas,
Schering-Plough, and Wyeth. A. P. L. has served on consultant boards for
Pfizer and Merck and has contracted research for Pfizer. M. I. M. has
served on advisory boards for Astellas, Pfizer, and Merck; has received
grants from Astellas, Basilea, and Pfizer; and has served on speaker's
bureaus of Astellas and Pfizer. P. M. has served on speaker's bureaus of
Merck and Novartis and on an advisory board for Pfizer. S. H. H. has
served on speaker's bureaus of Astellas and Pfizer. L.B.J. has served on
a speaker's bureau of Pfizer. S. H. has received grants from Pfizer,
Astellas, and Merck. N.S. has received investigator-initiated grant
support from Pfizer. All other authors: no conflicts.; National
Institutes of Health, National Institute of Allergy and Infectious
Diseases (R01 AI 054719-01 to N.S.)
NR 29
TC 27
Z9 27
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD NOV 1
PY 2010
VL 51
IS 9
BP 1062
EP 1069
DI 10.1086/656584
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 669FC
UT WOS:000283331300012
PM 20879857
ER
PT J
AU Spiegel, B
Bolus, R
Desai, AA
Zagar, P
Parker, T
Moran, J
Solomon, MD
Khawar, O
Gitlin, M
Talley, J
Nissenson, A
AF Spiegel, Brennan
Bolus, Roger
Desai, Amar A.
Zagar, Philip
Parker, Tom
Moran, John
Solomon, Matthew D.
Khawar, Osman
Gitlin, Matthew
Talley, Jennifer
Nissenson, Allen
TI Dialysis Practices That Distinguish Facilities with Below- versus
Above-Expected Mortality
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID OUTCOMES; PATIENT; CARE; PHYSICIANS; RATIO
AB Background and objectives: Mortality rates vary widely among dialysis facilities even after adjustment with standardized mortality ratios (SMRs). This variation may occur because top-performing facilities use practices not shared by others, because the SMR fails to capture key patient characteristics, or both. Practices were identified that distinguish top- from bottom-performing facilities by SMR.
Design, setting, participants, & measurements: A cross-sectional survey was performed of staff across three organizations. Staff members rated the perceived quality of their units' patient-, provider-, and facility-level practices using a six-point Likert scale. Facilities were divided into those with above- versus below-expected mortality on the basis of SMRs from U.S. Renal Data Service facility reports. Mean Likert scores were computed for each practice using t tests. Practices that were statistically significant (P <= 0.05) and achieved at least a medium effect size of >= 0.4 were reported. Significant predictors were entered into a linear regression model.
Results: Dialysis facilities with below-expected mortality reported that patients in their unit were more activated and engaged, physician communication and interpersonal relationships were stronger, dieticians were more resourceful and knowledgeable, and overall coordination and staff management were superior versus facilities with above-expected mortality. Staff ratings of these practices explained 31% of the variance in SMRs.
Conclusions: Patient-, provider-, and facility-level practices partly explain SMR variation among facilities. Improving SMRs may require processes that reflect a coordinated, multidisciplinary environment (i.e., no one group, practice, or characteristic will drive facility-level SMRs). Understanding and improving SMRs will require a holistic view of the facility. Clin J Am Soc Nephrol 5: 2024-2033, 2010. doi: 10.2215/CJN.01620210
C1 [Spiegel, Brennan; Talley, Jennifer] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA.
[Spiegel, Brennan; Bolus, Roger; Khawar, Osman] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Spiegel, Brennan; Bolus, Roger; Solomon, Matthew D.; Talley, Jennifer] Univ Calif Los Angeles, VA Ctr Outcomes Res & Educ, Los Angeles, CA USA.
[Desai, Amar A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Desai, Amar A.; Solomon, Matthew D.] Stanford Univ, Dept Med, Stanford, CA 94305 USA.
[Zagar, Philip] Dialysis Clin Inc, Albuquerque, NM USA.
[Parker, Tom] Renal Ventures Management LLC, Lakewood, CO USA.
[Moran, John] Satellite Healthcare, Mountain View, CA USA.
[Solomon, Matthew D.] Amgen Inc, Thousand Oaks, CA 91320 USA.
[Nissenson, Allen] DaVita Inc, Denver, CO USA.
RP Spiegel, B (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Med, 11301 Wilshire Blvd,Bldg 115,Room 215, Los Angeles, CA 90073 USA.
EM bspiegel@mednet.ucla.edu
FU Amgen, Inc.; Renal Physicians Association; American Nephrology Nurses
Association
FX Support for this investigator-initiated study was provided by a research
grant from Amgen, Inc. Dr. Gitlin is an employee of Amgen, Inc. The
principal investigator, Dr. Spiegel, maintained full control over all
aspects of the study design, implementation, data collection, data
analysis, data interpretation, and manuscript preparation. Dr. Spiegel
had full access to all of the data in the study and takes responsibility
for the integrity of the data and the accuracy of the data analysis. The
contributions of individual authors is as follows: AD. study design,
study implementation, data collection, data interpretation, and
manuscript preparation; R.B. study design, study implementation, data
collection, data analysis, and manuscript review; AN study design, data
interpretation, and manuscript review; P.Z. data collection/provision,
data interpretation, and manuscript review; T.P. data
collection/provision, data interpretation, and manuscript review; J.M.
data collection/provision, data interpretation, and manuscript review;
S.B. study design, data interpretation, and manuscript review; MS. study
design, data interpretation, and manuscript review; O.K. study design,
data interpretation, and manuscript review; M.G. data interpretation and
manuscript preparation; J.T. study implementation and data collection;
B.S. study design, study implementation, data collection, data analysis,
data interpretation, manuscript preparation, manuscript approval, and
guarantor of article. The opinions and assertions contained herein are
the sole views of the authors and are not to be construed as official or
as reflecting the views of the Department of Veteran Affairs. This study
endorsed and supported by the Renal Physicians Association and the
American Nephrology Nurses Association. Special thanks to the
participating dialysis organizations-DCI; Renal Ventures Management LLC,
and Satellite Healthcare.
NR 12
TC 16
Z9 16
U1 1
U2 3
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD NOV
PY 2010
VL 5
IS 11
BP 2024
EP 2033
PG 10
WC Urology & Nephrology
SC Urology & Nephrology
GA 677UX
UT WOS:000284018500018
PM 20876677
ER
PT J
AU Kutner, NG
Zhang, R
Huang, YJ
Johansen, KL
AF Kutner, Nancy G.
Zhang, Rebecca
Huang, Yijian
Johansen, Kirsten L.
TI Depressed Mood, Usual Activity Level, and Continued Employment after
Starting Dialysis
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID STAGE RENAL-DISEASE; HEMODIALYSIS-PATIENTS; END; VALIDITY; WORK
AB Background and objectives: When patients start dialysis, their employment rate declines and disability benefits are an option. With patient sociodemographic and clinical characteristics including disability income status controlled, we investigated the significance of depressed mood and usual activity level as predictors of patients' continued employment after dialysis start.
Design, setting, participants, & measurements: Incident patients from 296 randomly selected dialysis clinics were surveyed in the Comprehensive Dialysis Study (CDS). Participants provided information about employment status, disability income status, education, depressive symptoms measured by the Patient Health Questionnaire-2 (PHQ-2), and usual activity level/energy expenditure measured by the Human Activity Profile. Age, gender, race, insurance, diabetes, inability to ambulate or transfer, chronic obstructive pulmonary disease, cardiovascular conditions, and hemoglobin and serum albumin values at treatment start were obtained from US Renal Data System files. Dialysis modality was defined at time of interview.
Results: Among 585 CDS participants who worked in the previous year, 191 (32.6%) continued working after dialysis start. On the basis of the PHQ-2 cutoff score >= 3, 12.1% of patients who remained employed had possible or probable depression, compared with 32.8% of patients who were no longer employed. In adjusted analyses, higher Human Activity Profile scores were associated with increased likelihood of continued employment, and there was a borderline association between lower PHQ-2 scores and continued employment.
Conclusions: Screening and management of depressive symptoms and support for increased activity level may facilitate patients' opportunity for continued employment after dialysis start, along with generally improving their overall quality of life. Clin J Am Soc Nephrol 5: 2040-2045, 2010. doi: 10.2215/CJN.03980510
C1 [Kutner, Nancy G.] Emory Univ, Dept Rehabil Med, Rehabil Qual Life Special Studies Ctr, Atlanta, GA 30322 USA.
[Johansen, Kirsten L.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Johansen, Kirsten L.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
RP Kutner, NG (reprint author), Emory Univ, Dept Rehabil Med, Rehabil Qual Life Special Studies Ctr, Atlanta, GA 30322 USA.
EM nkutner@emory.edu
FU National Institutes of Health [HHSN267200715004C, ADB N01-DK-7-5004]
FX This study was supported by National Institutes of Health contract
HHSN267200715004C, ADB N01-DK-7-5004 (N.G.K.).
NR 37
TC 14
Z9 15
U1 0
U2 10
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD NOV
PY 2010
VL 5
IS 11
BP 2040
EP 2045
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA 677UX
UT WOS:000284018500020
PM 20884777
ER
PT J
AU Bryant, MS
Rintala, DH
Lai, EC
Protas, EJ
AF Bryant, M. S.
Rintala, D. H.
Lai, E. C.
Protas, E. J.
TI An investigation of two interventions for micrographia in individuals
with Parkinson's disease
SO CLINICAL REHABILITATION
LA English
DT Article
ID VISUAL FEEDBACK
AB Objective: This pilot study was designed to compare a change in micrographia between using grid lines and parallel horizontal lines as visual cues in individuals with Parkinson's disease.
Design: Single group pre- and post-test.
Setting: Research lab.
Participants: Eleven males with Parkinson's disease.
Interventions: Practice writing words with parallel and grid lines. The sequence of practising was randomized.
Main outcome measures: Length of words.
Results: The length of the words after practising with parallel lines was longer than in the initial free writing condition (17.83 +/- 3.93cm vs. 23.36 +/- 5.82 cm, P = 0.008). The length of the words after practising with grid lines was also longer than during free writing (17.83 +/- 3.93cm vs. 22.65 +/- 4.04 cm, P = 0.003). The length of the words after practising with parallel lines was not different from that after practising with grid lines.
Conclusion: Improvements in letter size after practising with horizontal parallel lines and grid lines were not different. The addition of vertical lines to form a grid did not appear to improve the writing more than horizontal lines alone in persons with Parkinson's disease who experienced micrographia.
C1 [Bryant, M. S.; Protas, E. J.] Univ Texas Med Branch, Sch Hlth Profess, Galveston, TX USA.
[Bryant, M. S.; Rintala, D. H.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA.
[Lai, E. C.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA.
[Lai, E. C.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
RP Bryant, MS (reprint author), 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM mon.bryant@yahoo.com
FU NICHD NIH HHS [K12 HD055929]
NR 9
TC 14
Z9 14
U1 0
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0269-2155
J9 CLIN REHABIL
JI Clin. Rehabil.
PD NOV
PY 2010
VL 24
IS 11
BP 1021
EP 1026
DI 10.1177/0269215510371420
PG 6
WC Rehabilitation
SC Rehabilitation
GA 671UU
UT WOS:000283537700006
PM 20554637
ER
PT J
AU Rubenstein, LZ
Ganz, DA
AF Rubenstein, Laurence Z.
Ganz, David A.
TI Falls and Their Prevention Preface
SO CLINICS IN GERIATRIC MEDICINE
LA English
DT Editorial Material
C1 [Rubenstein, Laurence Z.] Univ Oklahoma, Coll Med, Reynolds Dept Geriatr Med, Oklahoma City, OK 73104 USA.
[Ganz, David A.] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA 90095 USA.
RP Rubenstein, LZ (reprint author), Univ Oklahoma, Coll Med, Reynolds Dept Geriatr Med, 921 NE 13th St,VAMC 11G, Oklahoma City, OK 73104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0749-0690
J9 CLIN GERIATR MED
JI Clin. Geriatr. Med.
PD NOV
PY 2010
VL 26
IS 4
BP XIII
EP XIV
DI 10.1016/j.cger.2010.07.007
PG 2
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 678MK
UT WOS:000284079800001
PM 20934609
ER
PT J
AU Wu, SY
Keeler, EB
Rubenstein, LZ
Maglione, MA
Shekelle, PG
AF Wu, Shinyi
Keeler, Emmett B.
Rubenstein, Laurence Z.
Maglione, Margaret A.
Shekelle, Paul G.
TI A Cost-Effectiveness Analysis of a Proposed National Falls Prevention
Program
SO CLINICS IN GERIATRIC MEDICINE
LA English
DT Article
DE Falls; Fall prevention; Cost-effectiveness; Medicare; Health policy
ID DWELLING OLDER PERSONS; ELDERLY-PEOPLE; RANDOMIZED TRIAL; NURSING-HOME;
RISK-FACTORS; COMMUNITY; INJURIES; ADULTS; METAANALYSIS; POPULATION
AB Falls are a major health concern for elderly people and cause substantial health care costs The authors used meta-analytic findings on the effectiveness of fall prevention interventions to determine cost-effectiveness of a proposed Medicare fall prevention program for people who experience a recent fall Using published clinical trial data the authors constructed a population-based economic model and estimated that in the base case, the program could prevent a half million people from falling again within a year From the model under most circumstances the cost-effectiveness ratio is less than $1500 per person prevented from experiencing a recurrent fall Paying for a fall prevention program to increase the use of evidence-based interventions would be a cost-effective use of Medicare dollars
C1 [Wu, Shinyi] Univ So Calif, Epstein Dept Ind & Syst Engn, Los Angeles, CA 90089 USA.
[Wu, Shinyi; Keeler, Emmett B.; Rubenstein, Laurence Z.; Maglione, Margaret A.; Shekelle, Paul G.] RAND Corp, So Calif Evidence Based Practice Ctr, Santa Monica, CA 90401 USA.
[Rubenstein, Laurence Z.] Univ Calif Los Angeles, Div Geriatr, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Rubenstein, Laurence Z.; Shekelle, Paul G.] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Sepulveda Div, Los Angeles, CA 90073 USA.
[Rubenstein, Laurence Z.; Shekelle, Paul G.] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, W Los Angeles Div, Los Angeles, CA 90073 USA.
RP Wu, SY (reprint author), Univ So Calif, Epstein Dept Ind & Syst Engn, 3715 McClintock Ave, Los Angeles, CA 90089 USA.
FU National Institute on Aging as part of the UCLA Pepper Center [AG 10415]
FX This research was performed by the Southern California Evidence Based
Practice Center based at the RAND Corporation Santa Monica CA RAND is
under contract with the Centers for Medicare and Medicaid Services (CMS)
Dr Keeler was supported by the National Institute on Aging as part of
the UCLA Pepper Center Grant AG 10415
NR 47
TC 13
Z9 13
U1 1
U2 4
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0749-0690
J9 CLIN GERIATR MED
JI Clin. Geriatr. Med.
PD NOV
PY 2010
VL 26
IS 4
BP 751
EP +
DI 10.1016/j.cger.2010.07.005
PG 17
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 678MK
UT WOS:000284079800012
PM 20934620
ER
PT J
AU deFoneska, A
Kaunitz, JD
AF deFoneska, Arushi
Kaunitz, Jonathan D.
TI Gastroduodenal mucosal defense
SO CURRENT OPINION IN GASTROENTEROLOGY
LA English
DT Article
DE heat shock proteins; Helicobacter pylori; prostaglandins;
proteinase-activated receptors; purinergic signalling; toll-like
receptors; trefoil factors
ID INTESTINAL ALKALINE-PHOSPHATASE; HELICOBACTER-PYLORI;
GASTROINTESTINAL-DISEASES; ADAPTIVE CYTOPROTECTION; GASTRIC NECROSIS;
RATS; EXPRESSION; RECEPTOR; CELLS; LIPOPOLYSACCHARIDE
AB Purpose of review
We have summarized recent findings related to gastroduodenal mucosal defense as well as factors contributing to defensive failure, highlighting findings that illuminate new pathophysiological mechanisms.
Recent findings
Gastroduodenal bicarbonate secretion is mediated by prostaglandin E receptors and stimulated by the prostone lubiprostone. Toll-like receptor (TLR)4 signaling is protective against gastric injury. Intestinal alkaline phosphatase (IAP) is a chemosensor that regulates the duodenal mucosal surface pH. Lipopolysaccharide (LPS) increases gastric permeability; IAP secreted during fat digestion may detoxify colonic LPS. NADPH oxidase activity mediates ischemia/reperfusion-related gastric mucosal damage. Heat shock protein 70 (HSP70) protects the gastric mucosa through inhibition of apoptosis, proinflammatory cytokines, and cell adhesion molecules (CAMs). HSP90 may be a contributing factor in impaired adaptive cytoprotection. Proteinase-activated receptor-1 (PAR-1) is protective against Helicobacter-induced gastritis, mediated by the suppression of proinflammatory pathways. IKK beta/NF-kappa B signaling decreases chronic Helicobacter-induced inflammation by inhibiting cellular apoptosis and necrosis. Activation of A(2A) adenosine receptors decreases inflammation and gastritis but leads to persistent Helicobacter pylori infection.
Summary
Enhanced understanding of the mechanisms of gastroduodenal defense and injury provides new insight into potential therapeutic targets, contributing towards the development of better tolerated and more effective therapies.
C1 [deFoneska, Arushi; Kaunitz, Jonathan D.] UCLA Sch Med, W Los Angeles VA Med Ctr, Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA 90073 USA.
[Kaunitz, Jonathan D.] UCLA Sch Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90073 USA.
[Kaunitz, Jonathan D.] UCLA Sch Med, Brentwood Biomed Res Inst, Los Angeles, CA 90073 USA.
[Kaunitz, Jonathan D.] UCLA Sch Med, Dept Med, Los Angeles, CA 90073 USA.
RP Kaunitz, JD (reprint author), UCLA Sch Med, W Los Angeles VA Med Ctr, Greater Los Angeles Vet Affairs Healthcare Syst, Bldg 114,Suite 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM jake@ucla.edu
FU NIH/NIDDK [RO1 DK54221, P30 DK0413]
FX We thank Coleen Palileo for her editorial assistance. Supported by VA
Merit Review funding, NIH/NIDDK RO1 DK54221, and NIH/NIDDK P30 DK0413.
NR 40
TC 28
Z9 29
U1 2
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0267-1379
J9 CURR OPIN GASTROEN
JI Curr. Opin. Gastroenterol.
PD NOV
PY 2010
VL 26
IS 6
BP 604
EP 610
DI 10.1097/MOG.0b013e32833f1222
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 664SQ
UT WOS:000282983200011
PM 20948371
ER
PT J
AU He, WJ
Castiblanco, J
Walter, EA
Okulicz, JF
Ahuja, SK
AF He, Weijing
Castiblanco, John
Walter, Elizabeth A.
Okulicz, Jason F.
Ahuja, Sunil K.
TI Mendelian randomization: potential use of genetics to enable causal
inferences regarding HIV-associated biomarkers and outcomes
SO CURRENT OPINION IN HIV AND AIDS
LA English
DT Article
DE biomarker; chemokine; gene; HIV; Mendelian randomization
ID HUMAN-IMMUNODEFICIENCY-VIRUS; DUFFY ANTIGEN RECEPTOR; C-REACTIVE
PROTEIN; COPY-NUMBER VARIATION; CD4(+) T-CELLS; DISEASE PROGRESSION;
ANTIRETROVIRAL THERAPY; PROMOTER POLYMORPHISM; TYPE-1 INFECTION; AIDS
SUSCEPTIBILITY
AB Purpose of review
It is unknown whether biomarkers simply correlate with or are causal for HIV-associated outcomes. Mendelian randomization is a genetic epidemiologic approach used to disentangle causation from association. Here, we discuss the potential use of Mendelian randomization for differentiating whether biomarkers are correlating with or causal for HIV-associated outcomes.
Recent findings
Mendelian randomization refers to the random allocation of alleles at the time of gamete formation. In observational epidemiology, this refers to the use of genetic variants to estimate a causal effect between a modifiable risk factor and an outcome of interest. A formal Mendelian randomization study using a genetic marker as a proxy for the biomarker has not been conducted in the HIV field. However, in the postgenomic era, this approach is being used increasingly. Examples are evidence for the causal role of BMI in blood pressure and noncausal role of C-reactive protein in coronary heart disease. We discuss the conceptual framework, uses, and limitations of Mendelian randomization in the context of HIV infection as well as specific biomarkers (IL-6, C-reactive protein) and genetic determinants (e. g., in CCR5, chemokine, and DARC genes) that associate with HIV-related outcomes.
Summary
Making the distinction between correlation and causality has particular relevance when a biomarker (e. g., IL-6) is potentially modifiable, in which case a biomarker-guided targeted treatment strategy may be feasible. Although the tenets of Mendelian randomization rest on strong assumptions, and conducting a Mendelian randomization study in HIV infection presents many challenges, it may offer the potential to identify causal biomarkers for HIV-associated outcomes.
C1 [He, Weijing; Castiblanco, John; Ahuja, Sunil K.] S Texas Vet Healthcare Syst, Vet Adm Res Ctr AIDS & HIV Infect 1, San Antonio, TX USA.
[He, Weijing; Castiblanco, John; Walter, Elizabeth A.; Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol Immunol & Biochem, San Antonio, TX 78229 USA.
[Okulicz, Jason F.] Brooke Army Med Ctr, Infect Dis Serv, Ft Sam Houston, TX 78234 USA.
RP Ahuja, SK (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Vet Adm Ctr AIDS & HIV Infect, 7703 Floyd Curl Dr MC 7881,Rm 5-065R, San Antonio, TX 78229 USA.
EM ahujas@uthscsa.edu
OI CASTIBLANCO, JOHN/0000-0003-2556-3697; CASTIBLANCO,
JOHN/0000-0002-7965-9822
FU Veterans Administration HIV/AIDS Center of the South Texas Veterans
Healthcare System, NIH [R37046326]; Doris Duke Distinguished Clinical
Scientist Award; VA MERIT award; Burroughs Wellcome Clinical Scientist
Award in Translational Research
FX The present work was supported by the Veterans Administration HIV/AIDS
Center of the South Texas Veterans Healthcare System, NIH (R37046326),
and the Doris Duke Distinguished Clinical Scientist Award to S. K. A. S.
K. A. is also supported by a VA MERIT award and the Burroughs Wellcome
Clinical Scientist Award in Translational Research.
NR 137
TC 1
Z9 1
U1 3
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1746-630X
EI 1746-6318
J9 CURR OPIN HIV AIDS
JI Curr. Opin. HIV AIDS
PD NOV
PY 2010
VL 5
IS 6
BP 545
EP 559
DI 10.1097/COH.0b013e32833f2087
PG 15
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 828NX
UT WOS:000295509900014
PM 20978399
ER
PT J
AU Steven, DW
Palevsky, PM
AF Weisbord, Steven D.
Palevsky, Paul M.
TI Strategies for the prevention of contrast-induced acute kidney injury
SO CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
LA English
DT Review
DE contrast-induced acute kidney injury; prevention; risk factors
ID RANDOMIZED CONTROLLED-TRIAL; PERCUTANEOUS CORONARY INTERVENTION;
RADIOCONTRAST-INDUCED NEPHROPATHY; INTRAVENOUS N-ACETYLCYSTEINE;
ISOTONIC SODIUM-BICARBONATE; ATRIAL-NATRIURETIC-PEPTIDE; SEVERE
RENAL-INSUFFICIENCY; MEDIA-INDUCED NEPHROPATHY; DIURESIS DVD TRIAL;
HIGH-RISK PATIENTS
AB Purpose of review
The intravascular administration of iodinated contrast media for diagnostic imaging is a common cause of acute kidney injury and a leading cause of iatrogenic renal disease. The purpose of this review is to describe the principal risk factors for contrast-induced acute kidney injury and to summarize recent data describing the efficacy of various preventive interventions for this condition.
Recent findings
Whereas earlier studies suggested that certain low-osmolal contrast agents including iohexol and ioxaglate are more nephrotoxic than iso-osmolal iodixanol, recent clinical trials and meta-analyses comparing other low-osmolal contrast agents with iodixanol have found little difference in risk. The provision of prophylactic renal replacement therapy does not ameliorate the risk of contrast-induced acute kidney injury, and likely poses undue risk. Despite some research supporting a benefit of atrial natriuretic peptide, statins, and prostaglandin analogs, additional data from large, adequately powered studies are needed before these agents can be recommended. N-Acetylcysteine and isotonic intravenous bicarbonate have been investigated intensely, yet the data on these interventions are conflicting due to methodological limitations in past studies.
Summary
Prevention of contrast-induced acute kidney injury involves the identification of high-risk patients, consideration of alternative imaging procedures that do not involve the administration of iodinated contrast, and integration of the cumulative data available on preventive interventions in high-risk patients.
C1 [Palevsky, Paul M.] VA Pittsburgh Healthcare Syst, Renal Sect, Univ Drive Div, Pittsburgh, PA 15240 USA.
[Weisbord, Steven D.; Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA USA.
RP Palevsky, PM (reprint author), VA Pittsburgh Healthcare Syst, Renal Sect, Univ Drive Div, Room 7E123 111F-U, Pittsburgh, PA 15240 USA.
EM palevsky@pitt.edu
OI Palevsky, Paul/0000-0002-7334-5400
FU VA Health Services [RCD 03-176-2]
FX The views expressed in this article are those of the authors and do not
necessarily represent the views of the United States Department of
Veterans Affairs. Dr Weisbord is supported by a VA Health Services
Research and Development Career Development Transition Award (RCD
03-176-2).
NR 111
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1062-4821
J9 CURR OPIN NEPHROL HY
JI Curr. Opin. Nephrol. Hypertens.
PD NOV
PY 2010
VL 19
IS 6
BP 539
EP 549
DI 10.1097/MNH.0b013e32833d42e3
PG 11
WC Urology & Nephrology; Peripheral Vascular Disease
SC Urology & Nephrology; Cardiovascular System & Cardiology
GA 664RW
UT WOS:000282981200005
ER
PT J
AU Szymusiak, R
AF Szymusiak, Ronald
TI Hypothalamic versus neocortical control of sleep
SO CURRENT OPINION IN PULMONARY MEDICINE
LA English
DT Article
DE adenosine; cytokines; preoptic hypothalamus; sleep homeostasis; synaptic
homeostasis
ID VENTROLATERAL PREOPTIC NEURONS; SLOW-WAVE ACTIVITY; EYE-MOVEMENT SLEEP;
HORMONE-RELEASING-HORMONE; WAKING DISCHARGE PATTERNS; DORSAL RAPHE
NUCLEUS; NERVE GROWTH-FACTOR; HOMEOSTATIC REGULATION; SEROTONERGIC
NEURONS; PROSTAGLANDIN D-2
AB Purpose of review
Regions of the neocortex most strongly activated during waking exhibit increased sleep intensity during subsequent sleep. The novel concept that aspects of sleep homeostasis are determined locally in the cortex contrasts with the established views that global changes in neocortical activity during sleep are achieved through inhibition of ascending arousal systems that originate in the brainstem and hypothalamus.
Recent findings
Experiments in animals and humans document asymmetries in neocortical electroencephalogram (EEG) slow-wave activity (SWA), a marker of homeostatic sleep need, as a result of functional activity during waking. In addition to local, use-dependent augmentation of EEG SWA and evoked potentials, expression of plasticity-related genes and of sleep-regulatory cytokines and neuromodulators have been shown to be elevated in a use-dependent manner in neocortex. The functional consequences of local sleep are hypothesized to involve regulation of synaptic plasticity, synaptic homeostasis and energy balance.
Summary
The evidence for use-dependent modulation of neocortical activity during sleep is compelling and provides novel insights into sleep function. However, local changes in neocortex are generally expressed on a background of global sleep. It remains to be determined if events initiated in the cortex have global sleep-promoting effects and how neocortical and hypothalamic mechanisms of sleep control interact.
C1 [Szymusiak, Ronald] VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 91343 USA.
[Szymusiak, Ronald] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Szymusiak, Ronald] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA.
RP Szymusiak, R (reprint author), VA Greater Los Angeles Healthcare Syst, Res Serv 151A3, 16111 Plummer St,North Hills, Los Angeles, CA 91343 USA.
EM rszym@ucla.edu
FU Medical Research Service of the Department of Veterans Affairs; National
Institute of Mental Health [MH63323]
FX The author has no conflicts of interest relevant to the content of this
article. Preparation of the article was supported by the U.S. Department
of Veterans Affairs. The author has current grant support from the
Medical Research Service of the Department of Veterans Affairs and the
National Institute of Mental Health MH63323.
NR 64
TC 11
Z9 11
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1070-5287
J9 CURR OPIN PULM MED
JI Curr. Opin. Pulm. Med.
PD NOV
PY 2010
VL 16
IS 6
BP 530
EP 535
DI 10.1097/MCP.0b013e32833eec92
PG 6
WC Respiratory System
SC Respiratory System
GA 656UZ
UT WOS:000282367400002
PM 20739890
ER
PT J
AU Luxton, DD
Skopp, NA
Maguen, S
AF Luxton, David D.
Skopp, Nancy A.
Maguen, Shira
TI GENDER DIFFERENCES IN DEPRESSION AND PTSD SYMPTOMS FOLLOWING COMBAT
EXPOSURE
SO DEPRESSION AND ANXIETY
LA English
DT Article
DE depression; PTSD; combat exposure; gender; women
ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS; SCREEN PC-PTSD;
PRIMARY-CARE; SEX-DIFFERENCES; IRAQ; AFGHANISTAN; MILITARY; SELF;
PREVALENCE
AB Background: This research examined gender as a moderator of the association between combat exposure (CE) and depression as well as CE and PTSD symptoms among a nonclinical sample of Soldiers following deployment in support of operations in Afghanistan and Iraq. Methods: Cases included 6,943 (516 women, 6,427 men) active duty Soldiers that were retrospectively analyzed from a pre- and post-deployment screening database at a large Army installation. Results: Gender moderated the association between CE and depressive and PTSD symptoms such that higher levels of CE were more strongly associated with depression and PTSD symptoms in women compared to men. Female Soldiers also reported higher severity of depressive symptoms compared to male Soldiers, whereas men reported higher levels of CE and a greater number of previous deployments compared to women. Conclusions: CE was a stronger predictor of post-deployment depression and PTSD symptoms for women compared to men. These results provide evidence for gender-based differences in depression and PTSD risk. Screening for degree of CE in addition to symptoms associated with depression and PTSD can help with the care for service members who are returning from deployments to combat zones. Depression and Anxiety 27:1027-1033, 2010. Published 2010 Wiley-Liss, Inc.
C1 [Luxton, David D.; Skopp, Nancy A.] Natl Ctr Telehlth & Technol T2, Def Ctr Excellence DCoE Psychol Hlth & Traumat Br, Old Madigan Army Med Ctr, Tacoma, WA 98431 USA.
[Maguen, Shira] San Francisco VA Med Ctr, San Francisco, CA USA.
[Maguen, Shira] Univ Calif San Francisco, San Francisco, CA 94143 USA.
RP Luxton, DD (reprint author), Natl Ctr Telehlth & Technol T2, Def Ctr Excellence DCoE Psychol Hlth & Traumat Br, Old Madigan Army Med Ctr, Old Madigan Army Med Ctr Bldg 9933A, Tacoma, WA 98431 USA.
EM david.luxton@us.army.mil
NR 39
TC 52
Z9 52
U1 1
U2 11
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1091-4269
J9 DEPRESS ANXIETY
JI Depress. Anxiety
PD NOV
PY 2010
VL 27
IS 11
BP 1027
EP 1033
DI 10.1002/da.20730
PG 7
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA 676EI
UT WOS:000283892500006
PM 20721909
ER
PT J
AU Custis, T
Beynet, D
Carranza, D
Greco, J
Lask, GP
Kim, J
AF Custis, Trenton
Beynet, David
Carranza, Dafnis
Greco, Joseph
Lask, Gary P.
Kim, Jenny
TI Comparison of Treatment of Melomental Fold Rhytides with Cross-Linked
Hyaluronic Acid Combined with OnabotulinumtoxinA and Cross-Linked
Hyaluronic Acid Alone
SO DERMATOLOGIC SURGERY
LA English
DT Article
ID TOXIN TYPE-A
AB BACKGROUND
Hyaluronic acid and onabotulinumtoxinA combination therapy has been shown to have greater clinical effectiveness than hyaluronic acid alone for glabellar furrowing, but this is not well documented for melomental fold rhytides.
OBJECTIVE
To compare the efficacy of intradermal cross-linked hyaluronic acid (HA) and onabotulinumtoxinA combination therapy with the efficacy of cross-linked HA monotherapy in patients with melomental fold rhytides.
METHODS AND MATERIALS
Twenty-two patients received combination therapy to a melomental fold area while also receiving cross-linked HA and a placebo saline injection to the contralateral side. Blinded physician evaluators and patient self-evaluators clinically and photographically assessed responses during standard intervals over 12 months.
RESULTS
The melomental folds treated with combination therapy had significantly greater aesthetic improvement than the monotherapy-treated side at 2 weeks and 1 month upon physician photographic review. Furthermore, the median time for return to pretreatment rhytides was 6.5 weeks longer in the combination therapy side. Patient assessment also revealed improvement over baseline for the combination therapy at 1 month.
CONCLUSION
Cross-linked HA and onabotulinumtoxinA combination therapy to melomental fold rhytides may provide better overall aesthetic results and longer duration of aesthetic improvement than cross-linked HA monotherapy.
David Beynet, Gary P. Lask and Jenny Kim are consultants for Allergan. The authors received the cross-linked HA and onabotulinumtoxinA for the study from Allergan, Inc. (Irvine, CA). This was an investigator-initiated study and no scientific input was received from Allergan Inc.
C1 [Custis, Trenton; Beynet, David; Carranza, Dafnis; Greco, Joseph; Lask, Gary P.; Kim, Jenny] Univ Calif Los Angeles, Div Dermatol, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Beynet, David; Kim, Jenny] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Dermatol, Los Angeles, CA USA.
[Lask, Gary P.] Indianer Lask & Rosenzweig Dermatol Grp, Encino, CA USA.
RP Kim, J (reprint author), Univ Calif Los Angeles, Div Dermatol, David Geffen Sch Med, 52-121 Ctr Hlth Sci,10833 Le Conte Ave, Los Angeles, CA 90095 USA.
EM JeKim@mednet.ucla.edu
NR 9
TC 10
Z9 10
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1076-0512
J9 DERMATOL SURG
JI Dermatol. Surg.
PD NOV
PY 2010
VL 36
IS 3
SI SI
BP 1852
EP 1858
DI 10.1111/j.1524-4725.2010.01741.x
PG 7
WC Dermatology; Surgery
SC Dermatology; Surgery
GA 669UZ
UT WOS:000283377000010
PM 20969662
ER
PT J
AU Nelson, KM
Boyko, EJ
Koepsell, T
AF Nelson, Karin M.
Boyko, Edward J.
Koepsell, Thomas
TI All-Cause Mortality Risk Among a National Sample of Individuals With
Diabetes
SO DIABETES CARE
LA English
DT Article
ID CORONARY HEART-DISEASE; PHYSICAL-ACTIVITY; TIME-SCALE; FOLLOW-UP;
ADULTS; HEALTH; WOMEN; PREDICTORS; MELLITUS; CHOICE
AB OBJECTIVE- Little is known about the relative contributions of modifiable risk factors to overall diabetes mortality. The purpose of the current study is to 1) assess the association between modifiable risk factors and all-cause mortality among a nationally representative sample of individuals with diabetes and 2) determine the population-attributable risk percent (PAR%) for these factors.
RESEARCH DESIGN AND METHODS- We analyzed data from a nationally representative sample of 1,507 adults over the age of 17 years with a self-reported diagnosis of diabetes from the Third National Health and Nutrition Examination Survey (NHANES III) mortality study. Our main outcome measures were all-cause mortality and PAR%. We used the Cox proportional hazard analysis to determine hazard ratios (HRs) for known diabetes risks and calculated PAR%.
RESULTS- Among adults with diabetes, the HRs for all-cause mortality were significant for individuals who had an A1C >= 8% (HR 1.65, 95% CI 1.11-2.45) or reported no regular physical activity (1.58, 1.24-2.02) or current tobacco use (1.77, 1.15-2.73). The population-attributable risk was 15.3% for A1C value >= 8%, 16.4% for no regular physical activity, and 7.5% for current tobacco use.
CONCLUSIONS- Health systems may consider prioritizing care to include smoking cessation, increasing physical activity, and moderate glycemic control among patients with diabetes. This study suggests that focusing on these areas may result in significant reductions in mortality in individuals with diabetes.
C1 [Nelson, Karin M.; Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Gen Med Serv, Seattle, WA USA.
[Nelson, Karin M.; Boyko, Edward J.] Univ Washington, Dept Med, Seattle, WA USA.
[Nelson, Karin M.; Boyko, Edward J.; Koepsell, Thomas] VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA USA.
[Nelson, Karin M.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA.
[Koepsell, Thomas] Univ Washington, Dept Epidemiol & Hlth Serv, Seattle, WA 98195 USA.
RP Nelson, KM (reprint author), VA Puget Sound Hlth Care Syst, Gen Med Serv, Seattle, WA USA.
EM karin.nelson@va.gov
OI Boyko, Edward/0000-0002-3695-192X
FU Epidemiologic Research and Information Center VA Puget Sound Health Care
System, Seattle, Washington
FX This study was supported by the Epidemiologic Research and Information
Center, VA Puget Sound Health Care System, Seattle, Washington.
NR 24
TC 19
Z9 19
U1 0
U2 3
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD NOV
PY 2010
VL 33
IS 11
BP 2360
EP 2364
DI 10.2337/dc10-0846
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 683ZI
UT WOS:000284516400013
PM 20739687
ER
PT J
AU Osborn, CY
Bains, SS
Egede, LE
AF Osborn, Chandra Y.
Bains, Sujeev S.
Egede, Leonard E.
TI Health Literacy, Diabetes Self-Care, and Glycemic Control in Adults with
Type 2 Diabetes
SO DIABETES TECHNOLOGY & THERAPEUTICS
LA English
DT Article
ID SOCIAL SUPPORT; ELDERLY PERSONS; KNOWLEDGE; OUTCOMES; ASSOCIATION;
MORTALITY; EDUCATION
AB Background: Although limited health literacy is a barrier to disease management and has been associated with poor glycemic control, the mechanisms underlying the relationships between health literacy and diabetes outcomes are unknown. We examined the relationships between health literacy, determinants of diabetes self-care, and glycemic control in adults with type 2 diabetes.
Methods: Patients with diabetes were recruited from an outpatient primary care clinic. We collected information on demographics, health literacy, diabetes knowledge, diabetes fatalism, social support, and diabetes self-care, and hemoglobin A1c values were extracted from the medical record. Structural equation models tested the predicted pathways linking health literacy to diabetes self-care and glycemic control.
Results: No direct relationship was observed between health literacy and diabetes self-care or glycemic control. Health literacy had a direct effect on social support (r = -0.20, P < 0.05) and through social support had an indirect effect on diabetes self-care (r = -0.07) and on glycemic control (r = -0.01). More diabetes knowledge (r = 0.22, P < 0.05), less fatalism (r = -0.22, P < 0.05), and more social support (r = 0.27, P < 0.01) were independent, direct predictors of diabetes self-care and through self-care were related to glycemic control (r = -0.20, P < 0.05).
Conclusions: Our findings suggest health literacy has an indirect effect on diabetes self-care and glycemic control through its association with social support. This suggests that for patients with limited health literacy, enhancing social support would facilitate diabetes self-care and improved glycemic control.
C1 [Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA.
[Bains, Sujeev S.; Egede, Leonard E.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA.
[Osborn, Chandra Y.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA.
[Osborn, Chandra Y.] Vanderbilt Univ, Sch Med, Vanderbilt Eskind Diabet Ctr, Diabet Res & Training Ctr, Nashville, TN 37212 USA.
RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280H, Charleston, SC 29425 USA.
EM egedel@musc.edu
FU NIDDK [P60 DK020593]
FX C.Y.O. is supported by a Diversity Supplement Award (NIDDK P60
DK020593).
NR 35
TC 38
Z9 40
U1 4
U2 18
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1520-9156
J9 DIABETES TECHNOL THE
JI Diabetes Technol. Ther.
PD NOV
PY 2010
VL 12
IS 11
BP 913
EP 919
DI 10.1089/dia.2010.0058
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 682IT
UT WOS:000284395500009
PM 20879964
ER
PT J
AU Boyko, EJ
Gerstein, HC
Mohan, V
Yusuf, S
Sheridan, P
Anand, S
Shaw, JE
AF Boyko, E. J.
Gerstein, H. C.
Mohan, V.
Yusuf, S.
Sheridan, P.
Anand, S.
Shaw, J. E.
CA DREAM Trial Investigators
TI Effects of ethnicity on diabetes incidence and prevention: results of
the Diabetes REduction Assessment with ramipril and rosiglitazone
Medication (DREAM) trial
SO DIABETIC MEDICINE
LA English
DT Article
DE Asian; ethnicity; Latino; prevention; rosiglitazone; thiazolidinedione
ID IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE MODIFICATION; INSULIN-RESISTANCE;
MELLITUS; RISK; AMERICANS; ATHEROSCLEROSIS; PREVALENCE; METFORMIN;
WHITES
AB P>Aims
Risk of Type 2 diabetes varies by ethnicity, but whether ethnicity remains important among those who have impaired glucose tolerance or impaired fasting glucose is uncertain. Whether the effect of thiazolidinedione treatment on diabetes prevention in persons with non-diabetic dysglycaemia varies by ethnicity is also not known. We addressed these questions using data collected in the DREAM trial.
Methods
A 2-by-2 factorial double-blind randomized controlled trial to compare the effects of rosiglitazone and ramipril on the primary outcome of diabetes or death in persons meeting criteria for impaired glucose tolerance or impaired fasting glucose. The effect of these interventions by ethnicity was estimated using Cox regression analysis.
Results
Of 5269 adults, 2365 were randomly assigned to rosiglitzone and 2634 to placebo. South Asians showed a higher hazard for the primary outcome compared with Europeans (hazard ratio, 95% confidence interval 2.21, 1.41-3.47) adjusted for age, gender, BMI, waist-hip ratio and geographic region. A lesser increase in risk was seen in Black people (1.37, 1.04-1.81). A significant reduction in risk of the primary outcome with rosiglitazone treatment assignment was seen in all ethnic groups, but the treatment effect significantly differed by ethnicity (P = 0.0242), with South Asians experiencing a smaller, and Latinos a larger preventive effect.
Conclusions
Ethnicity is an important risk factor for Type 2 diabetes in dysglycaemic persons. All ethnic groups experienced a large significant reduction in diabetes risk because of rosiglitazone. The magnitude of this reduction differed by ethnicity. Given the post hoc nature of this analysis, further confirmation of these findings is needed.
C1 [Boyko, E. J.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Boyko, E. J.; Shaw, J. E.] Baker IDI Heart & Diabet Inst, Melbourne, Vic, Australia.
[Gerstein, H. C.; Yusuf, S.; Sheridan, P.] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada.
[Mohan, V.] Madras Diabet Res Fdn & Dr Mohans Diabet Specialt, Madras, Tamil Nadu, India.
[Anand, S.] McMaster Univ, Dept Med, Hamilton, ON, Canada.
RP Boyko, EJ (reprint author), 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA.
EM eboyko@u.washington.edu
RI Shaw, Jonathan/E-7388-2010
OI Shaw, Jonathan/0000-0002-6187-2203; Boyko, Edward/0000-0002-3695-192X
FU Canadian Institutes of Health Research [MCT41548]; Sanofi-Aventis; Glaxo
SmithKline; King Pharmaceuticals
FX Support was provided by grants from the Canadian Institutes of Health
Research (MCT41548), Sanofi-Aventis, Glaxo SmithKline and King
Pharmaceuticals. SA holds the Michael G. DeGroote and Heart and Stroke
Foundation of Ontario Chair in Population Health and the May Cohen Eli
Lilly Endowed Chair in Women's Health Research, McMaster University.
NR 22
TC 6
Z9 7
U1 0
U2 6
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0742-3071
J9 DIABETIC MED
JI Diabetic Med.
PD NOV
PY 2010
VL 27
IS 11
BP 1226
EP 1232
DI 10.1111/j.1464-5491.2010.03064.x
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 666YX
UT WOS:000283160200002
PM 20950379
ER
PT J
AU Akiba, Y
Kaunitz, JD
AF Akiba, Yasutada
Kaunitz, Jonathan D.
TI Lafutidine, a Protective H(2) Receptor Antagonist, Enhances Mucosal
Defense in Rat Esophagus
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article
DE Esophageal blood flow; Interstitial pH; Capsaicin-sensitive afferent
nerves; Pepsin; Interstitial acidification
ID SENSITIVE AFFERENT NEURONS; CARBONIC-ANHYDRASES; REFLUX ESOPHAGITIS;
ACID INJURY; BLOOD-FLOW; LOW PH; DUODENUM; MEDIATE; PEPSIN; NERVES
AB Luminal acid or CO(2) induces a hyperemic response in the esophagus, via activation of acid sensors on capsaicin-sensitive afferent nerves (CSAN). Since disruption of the hyperemic response to luminal CO(2) acidifies the interstitium of the esophageal mucosa, the hyperemic response may maintain interstitial pH (pH(int)). We hypothesized that acid-related hyperemia maintains pH(int), preventing acid-induced injury in the esophageal mucosa.
We examined the effects of capsaicin (Cap) or lafutidine (Laf), a mucosal protective H(2) antagonist, on the regulation of pH(int) and blood flow in rat esophagus using ratiometric microimaging and laser-Doppler measurements of the lower esophageal mucosa of living rats. The esophagus was topically superfused with pH 7.0 buffer, or a pH 1.0 or pH 1.0 + pepsin (1 mg/ml) solution with or without Laf.
Cap (30 or 100 A mu M) or Laf (0.1 or 1 mM) dose-dependently increased blood flow, accompanied by increased pH(int). The pH 1.0 solution increased blood flow without pH(int) change, whereas Laf (1 mM) increased blood flow and pH(int) during acid exposure. The effects of Laf were abolished by ablation of CSAN. Perfusion of the acidified pepsin solution gradually decreased pH(int), inhibited by Laf perfusion.
Activation of CSAN by Laf with or without acid, accompanied by hyperemia, increased pH(int), preventing acidified pepsin-induced interstitial acidification. Stimulation of the capsaicin pathway with compounds such as Laf enhances mucosal protection from acid-related injury in the upper gastrointestinal tract.
C1 [Akiba, Yasutada; Kaunitz, Jonathan D.] W Los Angeles Vet Affairs Med Ctr, Brentwood Biomed Res Inst, Los Angeles, CA 90073 USA.
[Akiba, Yasutada; Kaunitz, Jonathan D.] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA 90073 USA.
[Akiba, Yasutada; Kaunitz, Jonathan D.] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90073 USA.
RP Kaunitz, JD (reprint author), W Los Angeles Vet Affairs Med Ctr, Brentwood Biomed Res Inst, Bldg 114,Suite 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM jake@ucla.edu
FU Taiho Pharmaceutical Co.; NIH-NIDDK [R01 DK54221]; Veterans Affairs
FX We thank Coleen Palileo for her assistance with manuscript preparation.
This work was supported by a research grant from Taiho Pharmaceutical
Co., Veterans Affairs Merit Review Award, and NIH-NIDDK R01 DK54221 (J.
Kaunitz).
NR 25
TC 7
Z9 7
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD NOV
PY 2010
VL 55
IS 11
BP 3063
EP 3069
DI 10.1007/s10620-010-1379-y
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 668VP
UT WOS:000283300400009
PM 20824506
ER
PT J
AU Richardson, P
Henderson, L
Davila, JA
Kramer, JR
Fitton, CP
Chen, GJ
El-Serag, HB
AF Richardson, Peter
Henderson, Louise
Davila, Jessica A.
Kramer, Jennifer R.
Fitton, Conar P.
Chen, G. John
El-Serag, Hashem B.
TI Surveillance for Hepatocellular Carcinoma: Development and Validation of
an Algorithm to Classify Tests in Administrative and Laboratory Data
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article
DE Algorithm; Liver cancer; Cirrhosis; Screening; Ultrasound; Alpha
fetoprotein; VA
ID MANAGEMENT; STAGE
AB The purpose of alpha-fetoprotein (AFP) and abdominal ultrasound (US) cannot be discerned in administrative data.
We developed an algorithm to identify AFP and US used as surveillance tests for hepatocellular carcinoma (HCC).
We evaluated 300 AFP and 301 US tests from a VA database. Surveillance predictors in the administrative files (diagnoses, labs) were examined in logistic regression models. We calculated model-based probabilities of HCC surveillance status, and developed classification procedures using single and multiple imputation methods.
The predictors of surveillance intent for AFP were absence of alcoholism, abdominal pain, ascites, diabetes and high AST levels. For US, the predictors of surveillance were prior AFP testing and HIV status and absence of abdominal pain, ascites, or drug dependence. For AFP classification, single imputation compared favorably with multiple imputation, both showing robustness in discrimination and calibration. For US both approaches were less robust in discrimination and calibration which was more moderate in multiple imputation than single imputation.
Predictive algorithms in administrative files can be used to identify AFP performed for HCC surveillance, however, the intent of US is more difficult to identify.
C1 [El-Serag, Hashem B.] Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA.
[Richardson, Peter; Davila, Jessica A.; Kramer, Jennifer R.; Fitton, Conar P.; Chen, G. John; El-Serag, Hashem B.] Houston Vet Affairs Med Ctr, Sect Hlth Serv Res, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA.
[Richardson, Peter; Davila, Jessica A.; Kramer, Jennifer R.; Fitton, Conar P.; Chen, G. John; El-Serag, Hashem B.] Baylor Coll Med, Houston, TX 77030 USA.
[El-Serag, Hashem B.] Houston Vet Affairs Med Ctr, Gastroenterol Sect, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA.
[Henderson, Louise] Univ N Carolina, Dept Radiol, Chapel Hill, NC USA.
RP El-Serag, HB (reprint author), Michael E DeBakey VA Med Ctr, 2002 Holcombe Blvd 152, Houston, TX 77030 USA.
EM hasheme@bcm.tmc.edu
FU Houston VA HSR&D Center of Excellence [HFP90-020]; National Cancer
Institute [R01-CA-125487]
FX Financial support: This work was supported in part by the Houston VA
HSR&D Center of Excellence (HFP90-020) and the National Cancer Institute
(R01-CA-125487).
NR 13
TC 12
Z9 12
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
EI 1573-2568
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD NOV
PY 2010
VL 55
IS 11
BP 3241
EP 3251
DI 10.1007/s10620-010-1387-y
PG 11
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 668VP
UT WOS:000283300400033
PM 20844957
ER
PT J
AU Hiemenz, JW
Raad, II
Maertens, JA
Hachem, RY
Saah, AJ
Sable, CA
Chodakewitz, JA
Severino, ME
Saddier, P
Berman, RS
Ryan, DM
DiNubile, MJ
Patterson, TF
Denning, DW
Walsh, TJ
AF Hiemenz, J. W.
Raad, I. I.
Maertens, J. A.
Hachem, R. Y.
Saah, A. J.
Sable, C. A.
Chodakewitz, J. A.
Severino, M. E.
Saddier, P.
Berman, R. S.
Ryan, D. M.
DiNubile, M. J.
Patterson, T. F.
Denning, D. W.
Walsh, T. J.
TI Efficacy of caspofungin as salvage therapy for invasive aspergillosis
compared to standard therapy in a historical cohort
SO EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
LA English
DT Article
ID LIPOSOMAL AMPHOTERICIN-B; LIVER-TRANSPLANT RECIPIENTS; ALTERNATIVE TRIAL
DESIGNS; STEM-CELL TRANSPLANTATION; FUNGAL-INFECTIONS; HEMATOLOGIC
MALIGNANCIES; PULMONARY ASPERGILLOSIS; COLLOIDAL DISPERSION; ANTIFUNGAL
THERAPY; PROGNOSTIC-FACTORS
AB In a non-comparative study, caspofungin was effective salvage therapy for approximately half of the patients refractory to or intolerant of standard antifungal agents for invasive aspergillosis. To establish a frame of reference for these results, we compared the response to caspofungin with responses to other antifungal agents in a historical cohort of similar patients. The efficacy could be evaluated in 83 patients who received caspofungin 50 mg daily after a 70-mg loading dose. The historical control group, identified through a retrospective review of medical records, included 214 evaluable patients possibly refractory to or intolerant of a parts per thousand yen1 week of standard antifungal therapy. All patients had documented invasive aspergillosis. Favorable response was defined as a complete or partial response to therapy. Underlying diseases, baseline neutropenia, corticosteroid use, and sites of infection were similar in both studies. Most patients had received amphotericin B formulations and/or itraconazole, and were refractory to standard therapy. Favorable response rates were 45% with caspofungin and 16% with standard therapy. The unadjusted odds ratio for a favorable response (caspofungin/standard therapy) was 4.1 (95% confidence interval: 2.2, 7.5). After adjusting for potential imbalances in the frequency of disseminated infection, neutropenia, steroid use, and bone marrow transplantation between groups, the odds ratio remained at 4.1 (2.1, 7.9). Although only tentative conclusions about relative efficacy can be drawn from retrospective comparisons, caspofungin appeared to be at least as efficacious as an amphotericin B formulation and/or itraconazole for the treatment of invasive aspergillosis in patients refractory to or intolerant of their initial antifungal therapy.
C1 [Hiemenz, J. W.] Univ Florida, Coll Med, Div Hematol Oncol, Gainesville, FL 32610 USA.
[Raad, I. I.; Hachem, R. Y.] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Maertens, J. A.] Univ Hosp Gasthuisberg, Leuven, Belgium.
[Saah, A. J.; Sable, C. A.; Chodakewitz, J. A.; Severino, M. E.; Saddier, P.; Berman, R. S.; Ryan, D. M.; DiNubile, M. J.] Merck Res Labs, West Point, PA USA.
[Patterson, T. F.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA.
[Patterson, T. F.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Denning, D. W.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England.
[Walsh, T. J.] NCI, Bethesda, MD 20892 USA.
RP Hiemenz, JW (reprint author), Univ Florida, Coll Med, Div Hematol Oncol, POB 100278, Gainesville, FL 32610 USA.
EM john.hiemenz@medicine.ufl.edu
OI Denning, David/0000-0001-5626-2251
FU Merck Co., Inc.
FX Merck & Co., Inc., which markets caspofungin under the brand name
Cancidas, sponsored and funded this study. Current and former employees
of the sponsor (indicated on the title page) may own stock or stock
options in the company. All non-Merck authors have served as
investigators on Merck studies. The sponsor formally reviewed a
penultimate draft. All co-authors approved an essentially final version
of the manuscript.
NR 45
TC 13
Z9 15
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0934-9723
J9 EUR J CLIN MICROBIOL
JI Eur. J. Clin. Microbiol. Infect. Dis.
PD NOV
PY 2010
VL 29
IS 11
BP 1387
EP 1394
DI 10.1007/s10096-010-1013-0
PG 8
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA 671LL
UT WOS:000283507500009
PM 20703506
ER
PT J
AU Ponikowski, P
Mitrovic, V
O'Connor, CM
Dittrich, H
Cotter, G
Massie, BM
Givertz, MM
Chen, E
Murray, M
Weatherley, BD
Fujita, KP
Metra, M
AF Ponikowski, Piotr
Mitrovic, Veselin
O'Connor, Christopher M.
Dittrich, Howard
Cotter, Gad
Massie, Barry M.
Givertz, Michael M.
Chen, Erluo
Murray, Meredith
Weatherley, Beth D.
Fujita, Kenji P.
Metra, Marco
TI Haemodynamic effects of rolofylline in the treatment of patients with
heart failure and impaired renal function
SO EUROPEAN JOURNAL OF HEART FAILURE
LA English
DT Article
DE Haemodynamic effects; Heart failure; Renal failure
ID A(1) RECEPTOR ANTAGONIST; SYSTOLIC DYSFUNCTION; PULMONARY-ARTERY;
CONTROLLED TRIAL; KIDNEY-FUNCTION; BG9719 CVT-124; ADENOSINE; PRESSURE;
FUROSEMIDE; TOLVAPTAN
AB The direct effects of adenosine A1 receptor antagonists on haemodynamic parameters in patients with acute heart failure (HF) remain largely unknown.
We evaluated the haemodynamic effects of the AA(1)RA rolofylline in 59 HF patients with concomitant renal impairment (estimated creatinine clearance 20-80 mL/min). Placebo or rolofylline 30 mg was administered as a 4 h infusion followed by intravenous (i.v.) loop diuretic administration. Haemodynamic measurements were carried out hourly up to 8 h post-dosing by pulmonary artery catheterization. Urine output, fractional excretion of sodium, potassium, urea, and uric acid, and blood urea nitrogen (BUN) and creatinine levels were also measured. In both groups, the changes from baseline in all haemodynamic indices except mean pulmonary artery pressure (PAP) were not clinically significant. Mean [95% confidence interval (CI)] PAP showed a placebo-adjusted decrease with rolofylline of -1.5 (-4.1, 1.1)mmHg at Hour 4 and -3.5 mmHg (95% CI: -6.2, -0.2) at Hour 8. There was a significant increase with rolofylline in diuresis [placebo-corrected mean (95% CI) change of 68 (20, 116)mL/h at Hour 2-4 and 103 (21, 185)mL/h at Hour 4-8] and in fractional excretion of sodium, potassium, and uric acid. Placebo-corrected changes in plasma levels of creatinine and BUN with rolofylline were non-significant.
Single administration of rolofylline in patients with HF and impaired renal function produced a slight decrease in mean PAP and consistently increased diuresis and natriuresis without compromising renal function, both before and after administration of i.v. loop diuretics.
C1 [Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Dept Heart Dis, PL-50891 Wroclaw, Poland.
[Mitrovic, Veselin] Max Planck Inst Physiol & Clin Res, Kerckhoff Klin, D-6350 Bad Nauheim, Germany.
[O'Connor, Christopher M.] Duke Univ, Med Ctr, Durham, CA USA.
[Dittrich, Howard] NovaCardia, San Diego, CA USA.
[Cotter, Gad; Weatherley, Beth D.] Momentum Res, Durham, NC USA.
[Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Givertz, Michael M.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Chen, Erluo; Murray, Meredith] Merck & Co Inc, Upper Gwynedd, PA USA.
[Fujita, Kenji P.] Merck & Co Inc, Rahway, NJ 07065 USA.
[Metra, Marco] Univ Brescia, Div Cardiol, Dept Expt & Appl Med, Brescia, Italy.
RP Ponikowski, P (reprint author), Med Univ, Clin Mil Hosp, Dept Heart Dis, Weigla 5, PL-50891 Wroclaw, Poland.
EM piotrponikowski@4wsk.pl
RI Ponikowski, Piotr/O-6454-2015
OI Ponikowski, Piotr/0000-0002-3391-7064; Metra, Marco/0000-0001-6691-8568
FU Merck; NovaCardia/Merck; Merck Co.; NovaCardia, Inc.
FX P.P. has received honoraria from Merck and Biogen. V.M. has no
conflicts. C.M.O'.C is a consultant and has received grant support from
Merck. H.C.D. is/was a stockholder/consultant of the company
(NovaCardia/Merck) that sponsored the study. G.C. is an employee of
Momentum Research who received payments from Merck for the conduct of
the study. B.M.M. has been a consultant to NovaCardia and Merck prior to
and during the trial (payments from Merck<$ 10 000) and has received
speaking honoraria for presentations during satellite symposia (<$ 10
000). M.M.G. has received research support from Merck & Co. E.C. and M.
M. are employees of Merck and hold Merck stock options. B.D.W. is an
employee of Momentum Research Inc., which has provided consulting
services to Merck, Corthera, Celladon, Bio-heart, and Nile Therapeutics.
K.P.F. is an employee of Merck & Co. M.M. has received honoraria for
participation to meetings and as a member of the executive board from
Cardiokine, Corthera, Merck, and Servier.; This study was funded by
NovaCardia, Inc. As of September 2007, NovaCardia is a wholly owned
subsidiary of Merck & Co, Inc.
NR 35
TC 7
Z9 7
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1388-9842
J9 EUR J HEART FAIL
JI Eur. J. Heart Fail.
PD NOV
PY 2010
VL 12
IS 11
BP 1238
EP 1246
DI 10.1093/eurjhf/hfq137
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 673PB
UT WOS:000283674300014
PM 20823097
ER
PT J
AU Solomon, VR
Haq, W
Smilkstein, M
Srivastava, K
Puri, SK
Katti, SB
AF Solomon, V. R.
Haq, W.
Smilkstein, M.
Srivastava, Kumkum
Puri, Sunil K.
Katti, S. B.
TI 4-Aminoquinoline derived antimalarials: Synthesis, antiplasmodial
activity and heme polymerization inhibition studies
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE 4-Aminoquinoline; Thiourea; Antimalarial agents; Heme polymerization
ID HEMATIN POLYMERIZATION; PLASMODIUM-FALCIPARUM; RETAIN ACTIVITY;
IN-VITRO; CHLOROQUINE; DESIGN; DERIVATIVES; MECHANISM; BINDING; DRUGS
AB A new series of 4-aminoquinoline derivatives have been synthesized and found to be active against both susceptible and resistant strains of Plasmodium falciparum in vitro. Compound 1-[3-(7-chloro-quinolin-4-ylamino)-propyl]-3-cyclopropyl-thiourea (7) exhibited superior in vitro activity against resistant strains of P. falciparum as compared to chloroquine (CQ). All the compounds showed resistance factor between 0.59 and 4.31 as against 5.05 for CQ. Spectroscopic studies suggested that this class of compounds act on heme polymerization target. (C) 2010 Elsevier Masson SAS. All rights reserved.
C1 [Solomon, V. R.; Haq, W.; Katti, S. B.] Cent Drug Res Inst, Med & Proc Chem Div, Lucknow 226001, Uttar Pradesh, India.
[Srivastava, Kumkum; Puri, Sunil K.] Cent Drug Res Inst, Div Parasitol, Lucknow 226001, Uttar Pradesh, India.
[Smilkstein, M.] Portland VA Med Ctr, Portland, OR 97239 USA.
RP Katti, SB (reprint author), Cent Drug Res Inst, Med & Proc Chem Div, MG Rd, Lucknow 226001, Uttar Pradesh, India.
EM setu_katti@yahoo.com
RI Viswas, V. Raja Solomon/F-6654-2011
OI Viswas, V. Raja Solomon/0000-0002-9863-4452
FU CDRI; CSIR, New Delhi
FX The authors thank the Director, CDRI for the support and the SAIF for
the spectral data. One of the authors (V. R. Solomon) thanks the CSIR,
New Delhi for Senior Research Fellowship. CDRI communication no. 7912
NR 31
TC 19
Z9 19
U1 0
U2 4
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0223-5234
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD NOV
PY 2010
VL 45
IS 11
BP 4990
EP 4996
DI 10.1016/j.ejmech.2010.07.068
PG 7
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 676KZ
UT WOS:000283911300035
PM 20805010
ER
PT J
AU Kosinski, MA
Lipsky, BA
AF Kosinski, Mark A.
Lipsky, Benjamin A.
TI Current medical management of diabetic foot infections
SO EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
LA English
DT Review
DE empiric therapy; foot infections; multidrug-resistant organisms;
osteomyelitis polymicrobial infections; severity of infection;
soft-tissue infections
ID RESISTANT-STAPHYLOCOCCUS-AUREUS; SKIN-STRUCTURE INFECTIONS; IN-VITRO
ACTIVITY; GRAM-POSITIVE ORGANISMS; SOFT-TISSUE INFECTIONS;
LENGTH-OF-STAY; COMPLICATED SKIN; RISK-FACTORS; LOWER-EXTREMITY;
LINEZOLID THERAPY
AB Foot infections are a serious complication of diabetes associated with substantial morbidity and occasional mortality. Antibiotic therapy for mild infections in patients who have not recently received antibiotic therapy can often be directed at just staphylococci and streptococci. Empiric therapy for infections that are chronic, moderate or severe, or that occur in patients who have failed previous antibiotic treatment, should usually be more broad spectrum. Bone infection also complicates a substantial percentage of diabetic foot wounds and increases the likelihood of treatment failure, requiring lower extremity amputation. An increasing body of evidence supports the effectiveness of nonsurgical treatment of diabetic foot osteomyelitis in selected patients, although the optimal choice of agent, route of administration and duration of therapy have yet to be defined. This article examines the potential role of standard and newer antibiotics that may be appropriate for treating diabetic foot infections, including ertapenem, vancomycin, moxifloxacin, daptomycin, telavancin and tigecycline, as well as several investigational agents, such as dalbavancin, ceftobiprole and nemonoxacin.
C1 [Kosinski, Mark A.] New York Coll Podiatr Med, Div Med Sci, New York, NY 10035 USA.
[Lipsky, Benjamin A.] VA Puget Sound Hlth Care Syst, Primary Care Clin & Antibiot Res, Seattle, WA 98108 USA.
[Lipsky, Benjamin A.] Univ Washington, Sch Med, Seattle, WA 98108 USA.
RP Kosinski, MA (reprint author), New York Coll Podiatr Med, Div Med Sci, 53 E 124th St, New York, NY 10035 USA.
EM mkosins@nycpm.edu
OI Lipsky, Benjamin A./0000-0001-9886-5114
FU Merck; Pfizer; Schering-Plough/Bayer; Cubist; Wyeth; TaiGen; Innocoll
FX Mark Kosinski has received speaker fees from Merck. Benjamin Lipsky has
received research funding consultant or speaker fees from Merck, Pfizer,
Schering-Plough/Bayer, Cubist, Wyeth, TaiGen and Innocoll. The authors
have no other relevant affiliations or financial involvement with any
organization or entity with a financial interest in or financial
conflict with the subject matter or materials discussed in the
manuscript apart from those disclosed.
NR 113
TC 14
Z9 15
U1 0
U2 11
PU EXPERT REVIEWS
PI LONDON
PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
ENGLAND
SN 1478-7210
J9 EXPERT REV ANTI-INFE
JI Expert Rev. Anti-Infect. Ther.
PD NOV
PY 2010
VL 8
IS 11
BP 1293
EP 1305
DI 10.1586/ERI.10.122
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 686GG
UT WOS:000284684200016
PM 21073293
ER
PT J
AU Sano, M
AF Sano, Mary
TI ICAD 2010: detection may hold the key to treatment
SO EXPERT REVIEW OF NEUROTHERAPEUTICS
LA English
DT Review
AB The Alzheimer's Association International Conference on Alzheimer's Disease was held on July 10-15 in Honolulu (HI, USA). Over 3800 attendees participated, attending sessions that included more than 1700 posters and 200 oral presentations. The meeting, first organized in 1988 by Khalid Iqbal and Bengt Winblad, became an annual event in 2009, and under the current design includes not only well-established themes of interest, but investigator-initiated sessions also. The Alzheimer's Association started managing the conference in 2000 in partnership with the founders, and abstracts for the meeting are published in the association's journal, Alzheimer's & Dementia. Key themes of this year's conference included validation of biomarkers, drug development, the value of screening for cognitive loss and dementia and the proposal of a new criteria for Alzheimer's disease.
C1 Mt Sinai Sch Med, James J Peters Vet Adm Med Ctr, Dept Psychiat, Alzheimer Dis Res Ctr, Bronx, NY 10468 USA.
RP Sano, M (reprint author), Mt Sinai Sch Med, James J Peters Vet Adm Med Ctr, Dept Psychiat, Alzheimer Dis Res Ctr, 130 W Kingsbridge Rd,Code 150,Rm 1F01, Bronx, NY 10468 USA.
EM mary.sano@mssm.edu
NR 9
TC 1
Z9 1
U1 0
U2 0
PU EXPERT REVIEWS
PI LONDON
PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
ENGLAND
SN 1473-7175
J9 EXPERT REV NEUROTHER
JI Expert Rev. Neurother.
PD NOV
PY 2010
VL 10
IS 11
BP 1659
EP 1661
DI 10.1586/ERN.10.150
PG 3
WC Clinical Neurology; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 686GJ
UT WOS:000284684500010
PM 20977323
ER
PT J
AU George, MS
AF George, Mark S.
TI Transcranial magnetic stimulation for the treatment of depression
SO EXPERT REVIEW OF NEUROTHERAPEUTICS
LA English
DT Review
DE depression; TMS; transcranial magnetic stimulation; treatment-resistant
ID TREATMENT-RESISTANT DEPRESSION; MOTOR CORTEX STIMULATION; HEALTHY-YOUNG
MEN; RANDOMIZED CONTROLLED-TRIAL; DEEP BRAIN-REGIONS; MAJOR DEPRESSION;
ELECTROCONVULSIVE-THERAPY; PREFRONTAL CORTEX; CORTICAL EXCITABILITY;
BIPOLAR DEPRESSION
AB Repeated daily left prefrontal transcranial magnetic stimulation (TMS) was first proposed as a potential treatment for depression in 1993. Multiple studies from researchers around the world since then have repeatedly demonstrated that TMS has antidepressant effects greater than sham treatment, and that these effects are clinically meaningful. A large industry-sponsored trial, published in 2007, resulted in US FDA approval in October 2008. Most recently, a large NIH-sponsored trial, with a more rigorous sham technique, found that a course of treatment (3-5 weeks) was statistically and clinically significant in reducing depression. However, consistently showing statistically and clinically significant antidepressant effects, and gaining regulatory approval, is merely the beginning for this new treatment. As with any new treatment involving a radically different approach, there are many unanswered questions about TMS, and the field is still rapidly evolving. These unanswered questions include the appropriate scalp location, understanding the mechanisms of action, refining the 'dose' (frequency, train, number of stimuli/day and pattern of delivery), understanding whether and how TMS can be combined with medications or talking/exposure therapy, or both, and how to deliver maintenance TMS. This article summarizes the available clinical information, and discusses key areas where more research is needed. TMS reflects a paradigm shift in treating depression. It is a safe, relatively noninvasive, focal brain stimulation treatment that does not involve seizures or implanted wires, and does not have drug-drug interactions or systemic side effects.
C1 [George, Mark S.] Med Univ S Carolina, Inst Psychiat, Charleston, SC 29425 USA.
[George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP George, MS (reprint author), Med Univ S Carolina, Inst Psychiat, 502 N,67 President St, Charleston, SC 29425 USA.
EM georgem@musc.edu
FU Glaxo-Smith-Kline; Jazz Pharmaceuticals; Brainsway
FX Mark George reports no equity or other direct financial investment in
any device or pharmaceutical firm. Within the past 3 years he has:
served as a paid consultant to Glaxo-Smith-Kline, Jazz Pharmaceuticals,
Cyberonics and Neuropace; received research grants from
Glaxo-Smith-Kline, Jazz Pharmaceuticals and Brainsway; served as an
unpaid consultant to Brainsonix, Brainsway, Neuronetics and NeoStim; and
been the editor-in-chief of a journal published by Elsevier, entitled
Brain Stimulation. The Medical University of South Carolina holds
patents in the area of combining TMS with functional brain imaging. The
total compensation from any company in a single year has been less than
US$10,000. The total combined compensation from all consulting
activities is less than 10% of his university salary. The author has no
other relevant affiliations or financial involvement with any
organization or entity with a financial interest in or financial
conflict with the subject matter or materials discussed in the
manuscript apart from those disclosed.
NR 124
TC 38
Z9 39
U1 7
U2 21
PU EXPERT REVIEWS
PI LONDON
PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
ENGLAND
SN 1473-7175
J9 EXPERT REV NEUROTHER
JI Expert Rev. Neurother.
PD NOV
PY 2010
VL 10
IS 11
BP 1761
EP 1772
DI 10.1586/ERN.10.95
PG 12
WC Clinical Neurology; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 686GJ
UT WOS:000284684500020
PM 20977332
ER
PT J
AU Patel, SM
Iqbal, N
Kaul, S
Ratcliffe, SJ
Rickels, MR
Reilly, MP
Scattergood, T
Basu, A
Fuller, C
Cappola, AR
AF Patel, Shrita M.
Iqbal, Nayyar
Kaul, Shailja
Ratcliffe, Sarah J.
Rickels, Michael R.
Reilly, Muredach P.
Scattergood, Theresa
Basu, Arpita
Fuller, Carissa
Cappola, Anne R.
TI Effects of metformin and leuprolide acetate on insulin resistance and
testosterone levels in nondiabetic postmenopausal women: a randomized,
placebo-controlled trial
SO FERTILITY AND STERILITY
LA English
DT Article
DE Testosterone; insulin resistance; polycystic ovary syndrome; metabolic
syndrome; aging; elderly; women
ID POLYCYSTIC-OVARY-SYNDROME; CORONARY-ARTERY-DISEASE; METABOLIC SYNDROME;
GLUCOSE DISPOSAL; ENDOGENOUS ANDROGENS; HORMONE AGONIST; HEART-DISEASE;
SERUM; SUPPRESSION; SECRETION
AB Objective: To determine whether insulin sensitizers lower androgen levels and whether androgen suppression improves insulin resistance in nondiabetic postmenopausal women.
Design: Randomized, double-blind, placebo-controlled study.
Setting: Clinical and Translational Research Center of a university hospital.
Patient(s): Thirty-five postmenopausal women aged 50-79 years with insulin resistance and higher T levels.
Intervention(s): Subjects were randomized to metformin plus leuprolide acetate (LA) placebo, LA plus metformin placebo, or LA placebo plus metformin placebo in a 1: 1: 1 fashion during a 12-week period.
Main Outcome Measure(s): Insulin sensitivity (M) assessed by euglycemic hyperinsulinemic clamp and free T by equilibrium dialysis.
Result(s): In those randomized to metformin, free T decreased by 19% compared with placebo, along with an expected improvement in M. Total Talso decreased significantly, whereas sex hormone-binding globulin (SHBG) did not change. In those randomized to LA, the percent change in M was not different from placebo, despite a 48% relative decrease in free T levels.
Conclusion(s): These data are the first to establish a causal link between insulin resistance and T in postmenopausal women. They confirm that treatment of insulin resistance decreases T production in this population and demonstrate that pharmacologic lowering of T does not affect insulin resistance. (Fertil Steril (R) 2010; 94: 2161-6. (C) 2010 by American Society for Reproductive Medicine.)
C1 [Patel, Shrita M.; Kaul, Shailja; Rickels, Michael R.; Scattergood, Theresa; Basu, Arpita; Fuller, Carissa; Cappola, Anne R.] Univ Penn, Sch Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA.
[Patel, Shrita M.; Ratcliffe, Sarah J.; Cappola, Anne R.] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Iqbal, Nayyar] Univ Penn, Sch Med, Sect Endocrinol Diabet & Metab, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA.
[Reilly, Muredach P.] Univ Penn, Sch Med, Cardiovasc Inst, Philadelphia, PA 19104 USA.
RP Cappola, AR (reprint author), Univ Penn, Sch Med, Div Endocrinol Diabet & Metab, 764 CRB,415 Curie Blvd, Philadelphia, PA 19104 USA.
EM acappola@mail.med.upenn.edu
RI Perez , Claudio Alejandro/F-8310-2010
OI Perez , Claudio Alejandro/0000-0001-9688-184X; Ratcliffe,
Sarah/0000-0002-6644-8284
FU National Institute on Aging [K23 AG19161]; National Center for Research
Resources [UL1RR024134]; National Institute of Diabetes and Digestive
and Kidney Diseases [P30 DK19525]; John A. Hartford Foundation;
University of Pennsylvania Institute for Diabetes, Obesity, and
Metabolism
FX Supported by K23 AG19161 from the National Institute on Aging,
UL1RR024134 from the National Center for Research Resources, P30 DK19525
from the National Institute of Diabetes and Digestive and Kidney
Diseases, the John A. Hartford Foundation, and the University of
Pennsylvania Institute for Diabetes, Obesity, and Metabolism. The views
expressed are those of the authors and do not necessarily represent the
official views of the National Institutes of Health.
NR 31
TC 12
Z9 12
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
EI 1556-5653
J9 FERTIL STERIL
JI Fertil. Steril.
PD NOV
PY 2010
VL 94
IS 6
BP 2161
EP 2166
DI 10.1016/j.fertnstert.2010.01.064
PG 6
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 670QC
UT WOS:000283441400042
PM 20226444
ER
PT J
AU Zhang, YQ
Zhang, HM
Shi, Y
Lustgarten, M
Li, Y
Qi, WB
Zhang, BX
Van Remmen, H
AF Zhang, Yiqiang
Zhang, Hong-Mei
Shi, Yun
Lustgarten, Michael
Li, Yan
Qi, Wenbo
Zhang, Bin-Xian
Van Remmen, Holly
TI Loss of manganese superoxide dismutase leads to abnormal growth and
signal transduction in mouse embryonic fibroblasts
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE MnSOD; Oxidative stress; ROS; Signal transduction; Free radicals
ID REACTIVE OXYGEN; OXIDATIVE STRESS; MITOCHONDRIAL-FUNCTION; KNOCKOUT
MICE; MUTANT MICE; LIFE-SPAN; MAMMALIAN TARGET; FREE-RADICALS; CELLS;
CA2+
AB Manganese superoxide dismutase (MnSOD) in the mitochondria plays an important role in cellular defense against oxidative damage. Homozygous MnSOD knockout (Sod2(-/-)) mice are neonatal lethal, indicating the essential role of MnSOD in early development. To investigate the potential cellular abnormalities underlying the aborted development of Sod2(-/-) mice, we examined the growth of isolated mouse embryonic fibroblasts (MEFs) from Sod2(-/-) mice. We found that the proliferation of Sod2(-/-) MEFs was significantly decreased compared with wild-type MEFs despite the absence of morphological differences. The Sod2(-/-) MEFs produced less cellular ATP, had lower O(2) consumption, generated more superoxide, and expressed less Prdx3 protein. Furthermore, the loss of MnSOD dramatically altered several markers involved in cell proliferation and growth, including decreased growth stimulatory function of mTOR signaling and enhanced growth inhibitory function of GSK-3 beta signaling. Interestingly, the G-protein-coupled receptor-mediated intracellular Ca(2+) signal transduction was also severely suppressed in Sod2(-/-) MEFs. Finally, the ratio of microtubule-associated protein light chain 3 (LC3)-II/LC3-I, an index of autophagic activity, was increased in Sod2(-/-)MEFs, consistent with a reduction in mTOR signal transduction. These data demonstrate that MnSOD deficiency results in alterations in several key signaling pathways, which may contribute to the lethal phenotype of Sod2(-/-) mice. Published by Elsevier Inc.
C1 [Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
[Zhang, Yiqiang; Shi, Yun; Lustgarten, Michael; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA.
[Zhang, Yiqiang; Li, Yan; Qi, Wenbo; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
[Zhang, Yiqiang; Van Remmen, Holly] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
[Zhang, Hong-Mei; Zhang, Bin-Xian] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Zhang, Hong-Mei] Fourth Mil Med Univ, Dept Clin Oncol, Xijing Hosp, Xian 710032, Peoples R China.
RP Van Remmen, H (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
EM vanremmen@uthscsa.edu
FU Department of Veterans Affairs
FX The authors thank Corinne Price for help in editing the manuscript. This
study was supported by a Department of Veterans Affairs Merit Grant to
H.V.R.
NR 65
TC 30
Z9 31
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0891-5849
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD NOV 1
PY 2010
VL 49
IS 8
BP 1255
EP 1262
DI 10.1016/j.freeradbiomed.2010.07.006
PG 8
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 654YN
UT WOS:000282207300001
PM 20638473
ER
PT J
AU Schreiner, MA
Weiss, DG
Lieberman, DA
AF Schreiner, Mitchal A.
Weiss, David G.
Lieberman, David A.
TI Proximal and Large Hyperplastic and Nondysplastic Serrated Polyps
Detected by Colonoscopy Are Associated With Neoplasia
SO GASTROENTEROLOGY
LA English
DT Article
DE Serrated Polyps; Hyperplastic Polyps; Colon Surveillance; Advanced
Neoplasia
ID CPG ISLAND METHYLATION; COLORECTAL-CANCER; MICROSATELLITE INSTABILITY;
KRAS MUTATIONS; RISK-FACTORS; ADENOMAS; BRAF; SURVEILLANCE; PREVALENCE;
PATHWAYS
AB BACKGROUND & AIMS: The family of serrated lesions includes hyperplastic polyps and sessile serrated adenomas without dysplasia, as well as traditional serrated adenoma with dysplasia. We investigated whether detection of proximal nondysplastic serrated polyps (ND-SP) at screening and surveillance colonoscopies is associated with advanced neoplasia. METHODS: The study included 3121 asymptomatic patients (aged 50-75 years) who had screening colonoscopies; 1371 had subsequent surveillance. The proximal colon was defined as segments proximal to the descending colon. Large ND-SP were defined as > 10 mm. We compared rates of detection of any neoplasia and advanced neoplasia at screening and surveillance colonoscopies (within 5.5 years) in patients with and without proximal or large ND-SP. RESULTS: At baseline screening, 248 patients (7.9%) had at least 1 proximal ND-SP. They were more likely than patients with no proximal ND-SP to have advanced neoplasia (17.3% vs 10.0%; odds ratio [OR], 1.90; 95% confidence interval [CI], 1.33-2.70). Patients with large ND-SP (n = 44) were also more likely to have synchronous advanced neoplasia (OR, 3.37; 95% CI, 1.71-6.65). During surveillance, 39 patients with baseline proximal ND-SP and no neoplasia were more likely to have neoplasia compared with subjects who did not have polyps (OR, 3.14; 95% CI, 1.59-6.20). Among patients with advanced neoplasia at baseline, those with proximal ND-SP (n = 43) were more likely to have advanced neoplasia during surveillance (OR, 2.17; 95% CI, 1.03-4.59). CONCLUSIONS: Detection of proximal and large ND-SP at a screening colonoscopy is associated with an increased risk for synchronous advanced neoplasia. Detection of proximal ND-SP in a baseline colonoscopy is associated with an increased risk for interval neoplasia during surveillance.
C1 [Schreiner, Mitchal A.; Lieberman, David A.] Portland VA Med Ctr, Portland, OR 97239 USA.
[Schreiner, Mitchal A.; Lieberman, David A.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Weiss, David G.] Perry Point VA Med Ctr, Perry Point, MD USA.
RP Lieberman, DA (reprint author), Portland VA Med Ctr, P3 GI,1037 SW Vet Hosp Rd, Portland, OR 97239 USA.
EM lieberma@ohsu.edu
FU Department of Veterans Affairs [380]
FX Supported by the Department of Veterans Affairs Cooperative Study
Program (#380) and the Department of Veterans Affairs with statistical
support for the study (DGW).
NR 29
TC 116
Z9 117
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD NOV
PY 2010
VL 139
IS 5
BP 1497
EP 1502
DI 10.1053/j.gastro.2010.06.074
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 673HW
UT WOS:000283651100024
PM 20633561
ER
PT J
AU Egede, LE
Grubaugh, AL
Ellis, C
AF Egede, Leonard E.
Grubaugh, Anouk L.
Ellis, Charles
TI The effect of major depression on preventive care and quality of life
among adults with diabetes
SO GENERAL HOSPITAL PSYCHIATRY
LA English
DT Article
DE Major depression; Preventive care; Quality of life; Adults with diabetes
ID RISK-FACTOR SURVEY; SELF-CARE; MEDICATION ADHERENCE; COMORBID
DEPRESSION; GLYCEMIC CONTROL; US ADULTS; TYPE-2; METAANALYSIS;
INDIVIDUALS; SYMPTOMS
AB Objective: To examine the association between major depression and preventive care practices and quality-of-life indices among adults with diabetes.
Methods: Data from 16,754 participants with diabetes in the 2006 Behavioral Risk Factor Surveillance Survey were examined. Multiple logistic regression was used to assess the independent association between the presence of major depression and a range of (1) preventive care behaviors and (2) quality-of-life indices, after accounting for relevant covariates.
Results: With regard to preventive care practices, women with major depression were less likely to have received a mammogram in the past 2 years [OR 0.60 (95% Cl 0.45-0.79) for women age 40 years and older and OR 0.52 (95% Cl 0.37-0.71) for women age 50 and older] relative to their counterparts without major depression. With regard to quality-of-life indices, individuals with major depression were less likely to perceive their health as good [OR 0.24 (95% Cl 0.19-0.31)], to report being satisfied with life [OR 0.10 (95% Cl 0.07-0.14)] and to report receiving needed social support [OR 0.29 (95% Cl 0.22-0.38)] relative to individuals without major depression. Individuals with major depression were also more likely to report one or more poor physical and poor mental health days in the past 30 days [OR 4.36 (95% Cl 3.33-5.72) and OR 9.77 (95% Cl 7.81-12.22), respectively] than those without major depression.
Conclusions: Major depression in adults with diabetes is associated with decreases in a wide range of quality-of-life indices as well as preventive self-care practices that were not entirely limited to diabetes-specific disease management. (c) 2010 Elsevier Inc. All rights reserved.
C1 [Egede, Leonard E.] Med Univ S Carolina, Dept Med, Ctr Hlth Dispar Res, Charleston, SC 29425 USA.
[Grubaugh, Anouk L.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Ellis, Charles] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA.
[Egede, Leonard E.; Grubaugh, Anouk L.; Ellis, Charles] Ralph H Johnson VA Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA.
RP Egede, LE (reprint author), Med Univ S Carolina, Dept Med, Ctr Hlth Dispar Res, Charleston, SC 29425 USA.
EM egedel@musc.edu
FU SC HSRD [REA 08-261]; Veterans Health Administration Health Services
Research and Development program [07-015-2, 07-012-3]
FX This work represents work supported by the use of facilities at the
Charleston, SC HSR&D Funded Center for Disease Prevention and Health
Interventions for Diverse Populations (REA 08-261).; Dr. Grubaugh and
Dr. Ellis are both supported by a career development award (CDA2
#07-015-2 and CDA #07-012-3, respectively) from the Veterans Health
Administration Health Services Research and Development program.
NR 42
TC 22
Z9 23
U1 3
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0163-8343
J9 GEN HOSP PSYCHIAT
JI Gen. Hosp. Psych.
PD NOV-DEC
PY 2010
VL 32
IS 6
BP 563
EP 569
DI 10.1016/j.genhosppsych.2010.08.002
PG 7
WC Psychiatry
SC Psychiatry
GA 693PC
UT WOS:000285235000001
PM 21112446
ER
PT J
AU Scheuner, MT
McNeel, TS
Freedman, AN
AF Scheuner, Maren T.
McNeel, Timothy S.
Freedman, Andrew N.
TI Population prevalence of familial cancer and common hereditary cancer
syndromes. The 2005 California Health Interview Survey
SO GENETICS IN MEDICINE
LA English
DT Article
DE family history; cancer; hereditary cancer syndrome; prevalence of
familial risk
ID NONPOLYPOSIS COLORECTAL-CANCER; LYNCH-SYNDROME; OVARIAN-CANCER; HISTORY;
RISK; PREVENTION; REGISTRIES; CRITERIA
AB Purpose: Family history guides cancer prevention and genetic testing. We sought to estimate the population prevalence of increased familial risk for breast, ovarian, endometrial, prostate, and colorectal cancers and hereditary cancer syndromes that include these cancers. Methods: Using the 2005 California Health Interview Survey data, a weak, moderate, or strong familial cancer risk was assigned to 33,187 respondents. Guidelines were applied to identify individuals with hereditary breast-ovarian cancer and hereditary nonpolyposis colon cancer. Results: Among respondents without a personal history of cancer, familial breast cancer was most prevalent; 7% had a moderate and 5% a strong familial risk. Older individuals and women were more likely to report family history of cancer. Generally, whites had the highest prevalence, and Asians and Latinos had the lowest prevalence. Among women without a personal history of breast or ovarian cancer, 2.5% met criteria for hereditary breast-ovarian cancer, and among individuals without a personal history of colorectal, endometrial or ovarian cancer, 1.1% met criteria for hereditary nonpolyposis colon cancer. Conclusions: We provide population-based prevalence estimates for moderate and strong familial risk for five common cancers and hereditary breast-ovarian cancer and hereditary nonpolyposis colon cancer. Such estimates are helpful in planning and evaluation of genetic services and prevention programs, and assessment of cancer surveillance and prevention strategies. Genet Med 2010:12(11):726-735.
C1 [Scheuner, Maren T.] RAND Corp, Santa Monica, CA USA.
[Scheuner, Maren T.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Scheuner, Maren T.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[McNeel, Timothy S.] Informat Management Serv Inc, Silver Spring, MD USA.
[Freedman, Andrew N.] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA.
RP Scheuner, MT (reprint author), 1776 Main St,POB 2138, Santa Monica, CA 90407 USA.
EM scheuner@rand.org
FU National Cancer Institute at the National Institutes of Health
FX This work was supported by a contract from the National Cancer Institute
at the National Institutes of Health.
NR 25
TC 31
Z9 31
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1098-3600
J9 GENET MED
JI Genet. Med.
PD NOV
PY 2010
VL 12
IS 11
BP 726
EP 735
DI 10.1097/GIM.0b013e3181f30e9e
PG 10
WC Genetics & Heredity
SC Genetics & Heredity
GA 678UD
UT WOS:000284105800010
PM 20921897
ER
PT J
AU Paintlia, AS
Paintlia, MK
Singh, AK
Orak, JK
Singh, I
AF Paintlia, Ajaib S.
Paintlia, Manjeet K.
Singh, Avtar K.
Orak, John K.
Singh, Inderjit
TI Activation of PPAR-gamma and PTEN Cascade Participates in
Lovastatin-Mediated Accelerated Differentiation of Oligodendrocyte
Progenitor Cells
SO GLIA
LA English
DT Article
DE lovastatin; EAE/MS; oligodendrocyte progenitors; PPAR-gamma/PTEN;
RhoA-ROCK; differentiation; remyelination
ID CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; COA
REDUCTASE INHIBITOR; MULTIPLE-SCLEROSIS; GENE-EXPRESSION;
PROTEIN-KINASE; IN-VITRO; CYCLE PROGRESSION; GROWTH-ARREST; GLIAL-CELLS
AB Previously, we and others documented that statins including-lovastatin (LOV) promote the differentiation of oligodendrocyte progenitor cells (OPCs) and remyelination in experimental autoimmune encephalomyelitis (EAE), an multiple sclerosis (MS) model. Conversely, some recent studies demonstrated that statins negatively influence oligodendrocyte (OL) differentiation in vitro and remyelination in a cuprizone-CNS demyelinating model. Therefore, herein, we first investigated the cause of impaired differentiation of OLs by statins in vitro settings. Our observations indicated that the depletion of cholesterol was detrimental to LOV treated OPCs under cholesterol/serum-deprived culture conditions similar to that were used in conflicting studies. However, the depletion of geranylgeranyl-pp under normal cholesterol homeostasis conditions enhanced the phenotypic commitment and differentiation of LOV-treated OPCs ascribed to inhibition of RhoA-Rho kinase. Interestingly, this effect of LOV was associated with increased activation and expression of both PPAR-g and PTEN in OPCs as confirmed by various pharmacological and molecular based approaches. Furthermore, PTEN was involved in an inhibition of OPCs proliferation via PI3K-Akt inhibition and induction of cell cycle arrest at G1 phase, but without affecting their cell survival. These effects of LOV on OPCs in vitro were absent in the CNS of normal rats chronically treated with LOV concentrations used in EAE indicating that PPAR-g induction in normal brain may be tightly regulated-providing evidences that statins are therapeutically safe for humans. Collectively, these data provide initial evidence that statin-mediated activation of the PPAR-gamma-PTEN cascade participates in OL differentiation, thus suggesting new therapeutic-interventions for MS or related CNS-demyelinating diseases. (C) 2010 Wiley-Liss, Inc.
C1 [Paintlia, Ajaib S.; Paintlia, Manjeet K.; Orak, John K.; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Darby Childrens Res Inst, Charleston, SC 29425 USA.
[Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Dept Pathol & Lab Med, Charleston, SC 29425 USA.
RP Singh, I (reprint author), Med Univ S Carolina, Dept Pediat, Darby Childrens Res Inst, 173 Ashley Ave, Charleston, SC 29425 USA.
EM singhi@musc.edu
OI Paintlia, Ajaib/0000-0003-4525-5333
FU NIH [NS-22576, NS-34741, NS-37766, NS-038236]; Dialysis Clinic Inc.
[C06-RR015455, C06-RR018823]
FX Grant sponsor: NIH; Grant numbers: NS-22576, NS-34741, NS-37766, and
NS-038236; Contract grant sponsor: Dialysis Clinic Inc.; Contract grant
numbers: C06-RR015455 and C06-RR018823.
NR 57
TC 24
Z9 25
U1 0
U2 2
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0894-1491
J9 GLIA
JI Glia
PD NOV
PY 2010
VL 58
IS 14
BP 1669
EP 1685
DI 10.1002/glia.21039
PG 17
WC Neurosciences
SC Neurosciences & Neurology
GA 664VH
UT WOS:000282990600003
PM 20578043
ER
PT J
AU Peterson, ED
Roe, MT
Chen, AY
Fonarow, GC
Lytle, BL
Cannon, CP
Rumsfeld, JS
AF Peterson, Eric D.
Roe, Matthew T.
Chen, Anita Y.
Fonarow, Gregg C.
Lytle, Barbara L.
Cannon, Christopher P.
Rumsfeld, John S.
TI The NCDR ACTION Registry-GWTG: transforming contemporary acute
myocardial infarction clinical care
SO HEART
LA English
DT Database Review
ID ACUTE CORONARY SYNDROMES; INTERVENTION OUTCOMES NETWORK; RAPID RISK
STRATIFICATION; QUALITY IMPROVEMENT; ST-ELEVATION; EARLY IMPLEMENTATION;
ACC/AHA GUIDELINES; WRITING COMMITTEE; AMERICAN-COLLEGE; ADVERSE
OUTCOMES
AB Aims The NCDR ACTION Registry-GWTG collects detailed in-hospital clinical, process-of-care and outcomes data for patients admitted with acute myocardial infarction (AMI) in the USA. The registry is a national AMI surveillance system that contributes to the scientific enquiry process of AMI care through the facilitation of local and national quality improvement efforts.
Interventions No treatments are mandated, participating centres receive routine quality-of-care and outcomes performance feedback reports and access to quality of care tools, such as dosing algorithms and standing orders.
Population AMI patients are retrospectively identified. No informed consent is required, as data are anonymised. From January 2007 to date, 147 165 records have been submitted from 383 participating US hospitals. Patients with a primary diagnosis of ST-segment elevation myocardial infarction or non-ST-segment elevation myocardial infarction are eligible for enrolment in the registry. These patients must have ischemic symptoms and electrocardiogram changes, and/or positive cardiac markers within 24 hours of initial presentation.
Baseline data Approximately 350 fields encompassing patient demographics, medical history and risk factors, hospital presentation, initial cardiac status, medications and associated doses, reperfusion strategy, procedures, laboratory values, and outcomes. Data are manually entered by study personnel; there are non-financial incentives at the hospital level. Completeness within the registry is noteworthy with most fields at less than 5% missing.
Endpoints Main outcome measures include American College of Cardiology/American Heart Association myocardial infarction performance indicators, as well as in-hospital patient outcomes. Data are available for research by application to: http://www.ncdr.com.
C1 [Peterson, Eric D.; Roe, Matthew T.; Chen, Anita Y.; Lytle, Barbara L.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27705 USA.
[Fonarow, Gregg C.] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA.
[Cannon, Christopher P.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Rumsfeld, John S.] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Peterson, ED (reprint author), Duke Univ, Med Ctr, Duke Clin Res Inst, 2400 Pratt St, Durham, NC 27705 USA.
EM peter016@mc.duke.edu
FU Society of Chest Pain Centers; Society of Hospital Medicine; American
College of Emergency Physicians; Bristol-Myers Squibb/Sanofi
Pharmaceuticals; Schering-Plough Corporation; Agency for Healthcare
Research and Quality (AHRQ) [U18HS016964]
FX The ACTION Registry-GWTG is an initiative of the American College of
Cardiology Foundation and the American Heart Association, with
partnering support from the Society of Chest Pain Centers, the Society
of Hospital Medicine and the American College of Emergency Physicians.
The registry is sponsored by the Bristol-Myers Squibb/Sanofi
Pharmaceuticals Partnership and Schering-Plough Corporation. This
project was supported by grant number U18HS016964 from the Agency for
Healthcare Research and Quality (AHRQ). The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the AHRQ. The funding source had no role in the design
or implementation of the study, or in the decision to seek publication.
NR 17
TC 57
Z9 61
U1 0
U2 1
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1355-6037
J9 HEART
JI Heart
PD NOV
PY 2010
VL 96
IS 22
BP 1798
EP 1802
DI 10.1136/hrt.2010.200261
PG 5
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 668VC
UT WOS:000283298700004
PM 20736202
ER
PT J
AU Golden-Mason, L
Cox, AL
Randall, JA
Cheng, LL
Rosen, HR
AF Golden-Mason, Lucy
Cox, Andrea L.
Randall, Jessica A.
Cheng, Linling
Rosen, Hugo R.
TI Increased Natural Killer Cell Cytotoxicity and NKp30 Expression Protects
Against Hepatitis C Virus Infection in High-Risk Individuals and
Inhibits Replication In Vitro
SO HEPATOLOGY
LA English
DT Article
ID CD56(+) T-CELLS; NK CELLS; ACTIVATING RECEPTOR; CYTOLYTIC FUNCTION;
HUMAN HEPATOCYTES; PERIPHERAL-BLOOD; ENVELOPE PROTEIN; HCV INFECTION;
CORE PROTEIN; FREQUENCY
AB CD56(pos) natural killer (NK)/natural T (NT) cells are important innate effectors providing the first line of defense against viral infection. Enhanced NK activity has been shown to protect from human immunodeficiency virus-1 infection. However, the role played by these innate effectors in protection against or development of hepatitis C virus (HCV) infection is unknown. We characterized CD56(pos) populations in 11 injection drug users (IDUs) who remained uninfected despite being repeatedly exposed to HCV. NK profiles in exposed but uninfected (EU) individuals were compared with preinfection samples (median 90 days prior to HCV seroconversion) collected from 14 IDUs who were exposed and subsequently became infected (EI) and unexposed normal control subjects (n = 8). Flow cytometric analysis of CD56(pos) populations demonstrated that EUs had a higher proportion of CD56(low) mature (P = 0.0011) NK cells compared with El subjects. Bead-isolated NKs (>90% purity) from EUs had significantly higher interleukin-2 (IL-2) induced cytolytic activity against the NK-sensitive cell line K562 at an effector-to-target ratio of 10:1 (P < 0.0001). NKp30, a natural cytotoxicity receptor involved in NK activation, is highest on NK/NT cells in EUs relative to infected subjects. Using the JFH-1 infection system, we demonstrated that NKp30(high) cells in the absence of exogenous stimulation significantly reduce infection of hepatocytes. Conclusion: CD56(pos) populations in EUs are enriched for effector NKs displaying enhanced IL-2 induced cytolytic activity and higher levels of the natural cytotoxicity receptor NKp30-activating receptor. In addition, NKp30(high) cells are more effective in preventing infection of Huh-7.5 cells than their NKp30(low/neg) counterparts. These data support the hypothesis that NK cells contribute to anti-HCV defense in vivo in the earliest stages of infection, providing innate protection from HCV acquisition. (HEPATOLOGY 2010;52:1581-1589)
C1 [Golden-Mason, Lucy; Randall, Jessica A.; Cheng, Linling; Rosen, Hugo R.] Univ Colorado, Dept Med, Div GI Hepatol, Aurora, CO 80045 USA.
[Golden-Mason, Lucy; Rosen, Hugo R.] Univ Colorado, Integrated Dept Immunol, Denver, CO 80202 USA.
[Golden-Mason, Lucy; Rosen, Hugo R.] Natl Jewish Hosp, Denver, CO USA.
[Cox, Andrea L.] Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21205 USA.
[Rosen, Hugo R.] Denver VA Med Ctr, Denver, CO USA.
RP Rosen, HR (reprint author), Univ Colorado, Dept Med, Div GI Hepatol, Acad Off Bldg 1,12631 E 17th Ave B-158, Aurora, CO 80045 USA.
EM hugo.rosen@ucdenver.edu
FU National Institutes of Health [U19 AI40035, RO1 DK060590, U19 A 1066328]
FX Supported by National Institutes of Health Grants U19 AI40035 (to A. L.
C.) and RO1 DK060590 and U19 A 1066328 (HCV center grant; to H. R. R.).
NR 43
TC 58
Z9 60
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD NOV
PY 2010
VL 52
IS 5
BP 1581
EP 1589
DI 10.1002/hep.23896
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 674RH
UT WOS:000283764800008
PM 20812318
ER
PT J
AU Lo, M
Murray, GL
Khoo, CA
Haake, DA
Zuerner, RL
Adler, B
AF Lo, Miranda
Murray, Gerald L.
Khoo, Chen Ai
Haake, David A.
Zuerner, Richard L.
Adler, Ben
TI Transcriptional Response of Leptospira interrogans to Iron Limitation
and Characterization of a PerR Homolog
SO INFECTION AND IMMUNITY
LA English
DT Article
ID FERRIC CITRATE TRANSPORT; OUTER-MEMBRANE PROTEINS; ESCHERICHIA-COLI;
PATHOGENIC LEPTOSPIRA; BACILLUS-SUBTILIS; FUR HOMOLOGS; SEROVAR LAI;
NEISSERIA-MENINGITIDIS; BINDING PROTEIN; VIRULENCE GENES
AB Leptospirosis is a globally significant zoonosis caused by Leptospira spp. Iron is essential for growth of most bacterial species. Since iron availability is low in the host, pathogens have evolved complex iron acquisition mechanisms to survive and establish infection. In many bacteria, expression of iron uptake and storage proteins is regulated by Fur. L. interrogans encodes four predicted Fur homologs; we have constructed a mutation in one of these, la1857. We conducted microarray analysis to identify iron-responsive genes and to study the effects of la1857 mutation on gene expression. Under iron-limiting conditions, 43 genes were upregulated and 49 genes were downregulated in the wild type. Genes encoding proteins with predicted involvement in inorganic ion transport and metabolism (including TonB-dependent proteins and outer membrane transport proteins) were overrepresented in the upregulated list, while 54% of differentially expressed genes had no known function. There were 16 upregulated genes of unknown function which are absent from the saprophyte L. biflexa and which therefore may encode virulence-associated factors. Expression of iron-responsive genes was not significantly affected by mutagenesis of la1857, indicating that LA1857 is not a global regulator of iron homeostasis. Upregulation of heme biosynthetic genes and a putative catalase in the mutant suggested that LA1857 is more similar to PerR, a regulator of the oxidative stress response. Indeed, the la1857 mutant was more resistant to peroxide stress than the wild type. Our results provide insights into the role of iron in leptospiral metabolism and regulation of the oxidative stress response, including genes likely to be important for virulence.
C1 [Lo, Miranda; Murray, Gerald L.; Khoo, Chen Ai; Adler, Ben] Monash Univ, Dept Microbiol, Clayton, Vic 3800, Australia.
[Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Haake, David A.] Vet Affairs Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA 90073 USA.
[Zuerner, Richard L.] USDA ARS, Infect Bacterial Dis Res Unit, Natl Anim Dis Ctr, Ames, IA 50010 USA.
[Adler, Ben] Monash Univ, Australian Res Council, Ctr Excellence Struct & Funct Microbial Genom, Clayton, Vic 3800, Australia.
[Adler, Ben] Monash Univ, Victorian Bioinformat Consortium, Clayton, Vic 3800, Australia.
RP Adler, B (reprint author), Monash Univ, Dept Microbiol, Clayton, Vic 3800, Australia.
EM Ben.Adler@med.monash.edu.au
FU National Health and Medical Research Council; Australian Research
Council, Canberra, Australia; National Institute of Allergy and
Infectious Diseases [AI-34431]; VA Medical Research Funds
FX This work was supported by the National Health and Medical Research
Council and the Australian Research Council, Canberra, Australia (to
B.A.), by Public Health Service grant AI-34431 from the National
Institute of Allergy and Infectious Diseases (to D.A.H.), and by VA
Medical Research Funds (to D.A.H.). G.L.M. is the recipient of a NHMRC
Peter Doherty Fellowship.
NR 73
TC 30
Z9 31
U1 0
U2 6
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD NOV
PY 2010
VL 78
IS 11
BP 4850
EP 4859
DI 10.1128/IAI.00435-10
PG 10
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 665RB
UT WOS:000283052100044
PM 20805337
ER
PT J
AU Lee, BY
Wiringa, AE
Bailey, RR
Goyal, V
Tsui, B
Lewis, GJ
Muder, RR
Harrison, LM
AF Lee, Bruce Y.
Wiringa, Ann E.
Bailey, Rachel R.
Goyal, Vishal
Tsui, Becky
Lewis, G. Jonathan
Muder, Robert R.
Harrison, Lee M.
TI The Economic Effect of Screening Orthopedic Surgery Patients
Preoperatively for Methicillin-Resistant Staphylococcus aureus
SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
LA English
DT Article
ID HOSPITAL-ACQUIRED INFECTION; JOINT-REPLACEMENT SURGERY; NASAL CARRIAGE;
COLONIZATION; MRSA; PNEUMONIA; MUPIROCIN; MORTALITY; EPIDEMIOLOGY;
SURVEILLANCE
AB BACKGROUND AND OBJECTIVE. Patients undergoing orthopedic surgery are susceptible to methicillin-resistant Staphylococcus aureus (MRSA) infections, which can result in increased morbidity, hospital lengths of stay, and medical costs. We sought to estimate the economic value of routine preoperative MRSA screening and decolonization of orthopedic surgery patients.
METHODS. A stochastic decision-analytic computer simulation model was used to evaluate the economic value of implementing this strategy (compared with no preoperative screening or decolonization) among orthopedic surgery patients from both the third-party payer and hospital perspectives. Sensitivity analyses explored the effects of varying MRSA colonization prevalence, the cost of screening and decolonization, and the probability of decolonization success.
RESULTS. Preoperative MRSA screening and decolonization was strongly cost-effective (incremental cost-effectiveness ratio less than $6,000 per quality-adjusted life year) from the third-party payer perspective even when MRSA prevalence was as low as 1%, decolonization success was as low as 25%, and decolonization costs were as high as $300 per patient. In most scenarios this strategy was economically dominant (ie, less costly and more effective than no screening). From the hospital perspective, preoperative MRSA screening and decolonization was the economically dominant strategy for all scenarios explored.
CONCLUSIONS. Routine preoperative screening and decolonization of orthopedic surgery patients may under many circumstances save hospitals and third-party payers money while providing health benefits. Infect Control Hosp Epidemiol 2010; 31(11): 1130-1138
C1 [Lee, Bruce Y.] Univ Pittsburgh, Publ Hlth Computat & Operat Res PHICOR Grp, Publ Hlth Computat & Operat Res PHICOR, Pittsburgh, PA 15213 USA.
[Lee, Bruce Y.; Wiringa, Ann E.; Bailey, Rachel R.; Goyal, Vishal; Tsui, Becky; Lewis, G. Jonathan] Univ Pittsburgh, Dept Biomed Informat, Pittsburgh, PA 15213 USA.
[Lee, Bruce Y.; Wiringa, Ann E.; Bailey, Rachel R.; Goyal, Vishal; Tsui, Becky; Lewis, G. Jonathan] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15213 USA.
[Harrison, Lee M.] Univ Pittsburgh, Infect Dis Epidemiol Res Unit, Sch Med, Pittsburgh, PA 15213 USA.
[Muder, Robert R.] Vet Affairs Pittsburgh Hlth Syst, Div Infect Dis, Pittsburgh, PA USA.
RP Lee, BY (reprint author), Univ Pittsburgh, Publ Hlth Computat & Operat Res PHICOR Grp, Publ Hlth Computat & Operat Res PHICOR, 200 Meyran Ave,Suite 200, Pittsburgh, PA 15213 USA.
EM byl1@pitt.edu
OI Slayton, Rachel/0000-0003-4699-8040
FU National Institute of General Medical Sciences Models of Infectious
Disease Agent Study (MIDAS) [U01-GM070708-05]; Pennsylvania Department
of Health
FX National Institute of General Medical Sciences Models of Infectious
Disease Agent Study (MIDAS) through grant U01-GM070708-05 and the
Pennsylvania Department of Health.
NR 62
TC 17
Z9 19
U1 0
U2 3
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0899-823X
J9 INFECT CONT HOSP EP
JI Infect. Control Hosp. Epidemiol.
PD NOV
PY 2010
VL 31
IS 11
BP 1130
EP 1138
DI 10.1086/656591
PG 9
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 675OV
UT WOS:000283840900006
PM 20923285
ER
PT J
AU Shi, Y
Buffenstein, R
Pulliam, DA
Van Remmen, H
AF Shi, Yun
Buffenstein, Rochelle
Pulliam, Daniel A.
Van Remmen, Holly
TI Comparative Studies of Oxidative Stress and Mitochondrial Function in
Aging
SO INTEGRATIVE AND COMPARATIVE BIOLOGY
LA English
DT Article; Proceedings Paper
CT Annual Meeting of the Society-for-Integrative-and-Comparative-Biology
CY JAN 03-07, 2010
CL Seattle, WA
SP Soc Integrat & Comparat Biol
ID HYDROGEN-PEROXIDE PRODUCTION; FREE-RADICAL PRODUCTION; LONGEST-LIVING
RODENT; MAXIMUM LIFE-SPAN; NAKED MOLE-RAT; BUTYL-ALPHA-PHENYLNITRONE;
HUMAN SKELETAL-MUSCLE; AGE-RELATED-CHANGES; SHORT-LIVED RAT; PROTEIN
OXIDATION
AB The oxidative stress theory and its correlate the mitochondrial theory of aging are among the most studied and widely accepted of all hypotheses of the mechanism of aging. To date, most of the supporting evidence for these theories has come from investigations using common model organisms such as Caenorhabditis elegans, Drosophila melanogaster, and laboratory rodents. However, comparative data from a wide range of endotherms provide equivocal support as to whether oxidative stress is merely a correlate, rather than a determinant, of species' maximum lifespan. The great majority of studies in this area have been devoted to the relationship between reactive oxygen species and maximal longevity in young adult organisms, with little emphasis on mitochondrial respiratory efficiency, age-related alterations in mitochondrial physiology or oxidative damage. The advantage of studying a broader spectrum of species is the broad range of virtually every biological phenotype/ trait, such as lifespan, body weight and metabolic rate. Here we summarize the results from a number of comparative studies in an effort to correlate oxidant production and oxidative damage among many species with their maximal lifespan and briefly discuss the pitfalls and limitations. Based on current information, it is not possible to accept or dispute the oxidative stress theory of aging, nor can we exclude the possibility that private mechanisms might offer an explanation for the longevity of exceptionally long-lived animal models. Thus, there is need for more thorough and controlled investigations with more unconventional animal models for a deeper understanding of the role of oxidative stress in longevity.
C1 [Shi, Yun; Buffenstein, Rochelle; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA.
[Shi, Yun; Buffenstein, Rochelle; Pulliam, Daniel A.; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
[Buffenstein, Rochelle; Pulliam, Daniel A.; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
[Van Remmen, Holly] S Texas Vet Hlth Care Syst, Audie Murphy Div, San Antonio, TX USA.
RP Shi, Y (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA.
EM vanremmen@uthscsa.edu
NR 71
TC 10
Z9 10
U1 1
U2 12
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1540-7063
J9 INTEGR COMP BIOL
JI Integr. Comp. Biol.
PD NOV
PY 2010
VL 50
IS 5
BP 869
EP 879
DI 10.1093/icb/icq079
PG 11
WC Zoology
SC Zoology
GA 673QM
UT WOS:000283678100016
PM 21558246
ER
PT J
AU Zhao, SJ
Wang, YB
Cao, L
Ouellette, MM
Freeman, JW
AF Zhao, Shujie
Wang, Yubao
Cao, Lin
Ouellette, Michel M.
Freeman, James W.
TI Expression of oncogenic K-ras and loss of Smad4 cooperate to induce the
expression of EGFR and to promote invasion of immortalized human
pancreas ductal cells
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE pancreatic cancer; cell signaling; K-ras; EGFR; TGF-beta; Smad4
ID EPIDERMAL-GROWTH-FACTOR; TGF-BETA; CANCER CELLS; ADENOCARCINOMA;
PROGRESSION; METASTASIS; MUTATIONS; PATHWAYS; TRANSFORMATION;
INACTIVATION
AB Activating mutation of K-ras and inactivation of DPC4 are two common genetic alterations that occur in the development and progression of pancreatic ductal adenocarcinomas (PDAC). A separate common event in PDAC progression is increased expression of phosphotyrosine kinase receptors (PTKRs). In our study, we examined whether activating mutations of K-ras and loss of Smad4 play a role in causing the aberrant expression of PTKRs. Immortalized human pancreas ductal cells (HPNE) were genetically modified by expressing oncogenic K-ras and/or by shRNA knockdown of Smad4. EGFR and erbB2 protein levels but not Ron or IGF-1R were substantially upregulated in HPNE cells that express K-ras((GD12)). The increased expression of EGFR in HPNE cells that expressed K-ras((GD12)) was mediated by both stabilizing EGFR protein and by increasing EGFR transcription. TGF-beta signaling partially suppressed K-ras((GD12)) induced EGFR transcription in Smad4 intact HPNE cells; whereas knockdown of Smad4 in cells expressing K-ras((GD12)) further enhanced expression of EGFR and erbB2. The upregulation of EGFR and erbB2 was associated with an increase of invasion, which was blocked by a kinase inhibitor of EGFR. Our study indicates for the first time, that oncogenic ras and loss of Smad signaling cooperate to upregulate EGFR and erbB2, which plays a role in promoting invasion.
C1 [Zhao, Shujie; Wang, Yubao; Cao, Lin; Freeman, James W.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Hematol & Oncol, San Antonio, TX 78229 USA.
[Zhao, Shujie; Cao, Lin; Freeman, James W.] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX USA.
[Ouellette, Michel M.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Eppley Inst, Omaha, NE USA.
RP Freeman, JW (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Hematol & Oncol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM freemanjw@uthscsa.edu
FU NIH [R21CA125713, RO1CA069122]; VA Merit Award
FX Grant sponsor: NIH; Grant numbers: R21CA125713, RO1CA069122; Grant
sponsor: VA Merit Award
NR 38
TC 17
Z9 17
U1 0
U2 4
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD NOV 1
PY 2010
VL 127
IS 9
BP 2076
EP 2087
DI 10.1002/ijc.25412
PG 12
WC Oncology
SC Oncology
GA 659AO
UT WOS:000282539600009
PM 20473902
ER
PT J
AU Woo, BKP
Harwood, DG
Melrose, RJ
Mandelkern, MA
Campa, OM
Walston, A
Sultzer, DL
AF Woo, Benjamin K. P.
Harwood, Dylan G.
Melrose, Rebecca J.
Mandelkern, Mark A.
Campa, Olivia M.
Walston, Amy
Sultzer, David L.
TI Executive deficits and regional brain metabolism in Alzheimer's disease
SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE Alzheimer's disease; positron emission tomography; executive function
ID AMERICAN-NEUROPSYCHIATRIC-ASSOCIATION; FUNCTIONAL IMPAIRMENT; PREFRONTAL
CORTEX; FDG-PET; DYSFUNCTION; HYPOMETABOLISM; INVOLVEMENT; COMMITTEE;
MEMORY; APATHY
AB Objective: Executive deficits are common in patients with Alzheimer's disease (AD), contribute prominently to clinical disability, and may be associated with frontal lobe pathology. This study examined regional brain hypometabolism associated with executive dysfunction in patients with AD.
Methods: Forty-one patients with probable AD underwent [(18)F] fluorodeoxyglucose positron emission tomography (FDG-PET) imaging at rest. Neuropsychological measures of executive control included the Conceptualization (Conc) and Initiation/Perseveration (TIP) subscales of the Mattis Dementia Rating Scale (DRS), the Wechsler Adult Intelligence Scale (WAIS) Similarities subtest, the Tower test, and the Ruff Figural Fluency test (Ruff). Voxel-based analyses were conducted using statistical parametric mapping (SPM2) to measure the correlation between regional cerebral metabolism and executive measures. Correlations independent of global cognitive impairment were identified by including Mini-Mental State Examination (MMSE) score as a covariate in the model.
Results: Executive deficits, as measured by poor performances on the DRS I/P and Conc subscales, were associated with hypometabolism in the bilateral mid-dorsolateral frontal region. Activity in posterior cortical regions also contributed uniquely to some aspects of executive functioning, as lower resting metabolism in parietal or temporal cortex was correlated with poor performance on four of the five executive measures. After controlling for global cognitive score, there were significant extra-frontal correlations with hypometabolism in insula, occipital lobe, and temporal cortex.
Conclusions: Some but not all executive deficits in AD are associated with neural activity in the dorsolateral frontal cortex. Activities in distributed neural systems that include parietal and temporal cortex also contribute to some executive abilities. The pathophysiology of executive dysfunction is complex and includes abnormalities not limited to a single region. Copyright (C) 2010 John Wiley & Sons, Ltd.
C1 [Woo, Benjamin K. P.; Harwood, Dylan G.; Melrose, Rebecca J.; Walston, Amy; Sultzer, David L.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
[Woo, Benjamin K. P.; Harwood, Dylan G.; Melrose, Rebecca J.; Campa, Olivia M.; Walston, Amy; Sultzer, David L.] Vet Affairs Greater Los Angeles Healthcare Syst, Psychiat Serv, Los Angeles, CA USA.
[Mandelkern, Mark A.] Vet Affairs Greater Los Angeles Healthcare Syst, Nucl Med Serv, Los Angeles, CA USA.
[Mandelkern, Mark A.] Univ Calif Irvine, Dept Phys, Irvine, CA 92717 USA.
RP Woo, BKP (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
EM bkpwoo@gmail.com
OI Woo, Benjamin/0000-0002-0127-4850
FU National Institute of Mental Health [R01 MH56031]; Department of
Veterans Affairs
FX This work was supported by the National Institute of Mental Health (R01
MH56031) and by the Department of Veterans Affairs.
NR 43
TC 15
Z9 16
U1 2
U2 7
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 0885-6230
J9 INT J GERIATR PSYCH
JI Int. J. Geriatr. Psychiatr.
PD NOV
PY 2010
VL 25
IS 11
BP 1150
EP 1158
DI 10.1002/gps.2452
PG 9
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 674RM
UT WOS:000283765300008
PM 20069587
ER
PT J
AU Li, HK
Hubbard, LD
Danis, RP
Esquivel, A
Florez-Arango, JF
Ferrier, NJ
Krupinski, EA
AF Li, Helen K.
Hubbard, Larry D.
Danis, Ronald P.
Esquivel, Adol
Florez-Arango, Jose F.
Ferrier, Nicola J.
Krupinski, Elizabeth A.
TI Digital versus Film Fundus Photography for Research Grading of Diabetic
Retinopathy Severity
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article; Proceedings Paper
CT Annual Meeting of the
Association-for-Research-in-Vision-and-Ophthalmology
CY MAY, 2008
CL Ft Lauderdale, FL
SP Assoc Res Vision & Opthalmol
ID DIAGNOSIS; PROGRAM; SYSTEM; CAMERA
AB PURPOSE. To assess agreement between digital and film photography for research classification of diabetic retinopathy severity.
METHODS. Digital and film photographs from a 152-eye cohort with a full spectrum of Early Treatment Diabetic Retinopathy Study (ETDRS) severity levels were assessed for repeatability of grading within each image medium and for agreement on ETDRS discrete severity levels, ascending severity thresholds, and presence or absence of diabetic retinopathy index lesions, between digital and 35-mm slides (film). Digital photographs were color balanced to match film.
RESULTS. There was substantial agreement (kappa = 0.61, kappa(w) [linear weighted] = 0.87) in classification of ETDRS diabetic retinopathy severity levels between digital images and film. Marginal homogeneity analyses found no significant difference in frequency distributions on the severity scale (P = 0.21, Bhapkar test). The kappa results ranged from 0.72 to 0.95 for presence or absence of eight ascending diabetic retinopathy severity thresholds. Repeatability of grading between readers viewing digital images was equal to or better than that obtained with film (pair-wise interreader kappa for digital images ranged from 0.47 to 0.57 and for film from 0.43 to 0.57. The kappa results for identifying diabetic retinopathy lesions ranged from moderate to almost perfect. Moderate agreement of intraretinal microvascular abnormalities and venous beading between digital images and film accounted for slightly lower concordance for severity thresholds >= 47 and for slightly lower interreader agreement within digital and film images at severity thresholds >= 43 and >= 47.
CONCLUSIONS. Under controlled circumstances, digital photography can equal the reliability of 35-mm slides for research classification of ETDRS severity level. (Invest Ophthalmol Vis Sci. 2010;51:5846-5852) DOI:10.1167/iovs.09-4803
C1 [Li, Helen K.; Florez-Arango, Jose F.] Univ Texas Hlth Sci Ctr, Sch Biomed Informat, Houston, TX USA.
[Li, Helen K.] Thomas Jefferson Univ, Dept Ophthalmol, Philadelphia, PA 19107 USA.
[Hubbard, Larry D.; Danis, Ronald P.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA.
[Ferrier, Nicola J.] Univ Wisconsin, Dept Mech Engn, Madison, WI 53706 USA.
[Ferrier, Nicola J.] Univ Wisconsin, Dept Biomed Engn, Madison, WI 53706 USA.
[Esquivel, Adol] Houston Vet Affairs Med Ctr, Houston, TX USA.
[Esquivel, Adol] Baylor Coll Med, Houston, TX 77030 USA.
[Florez-Arango, Jose F.] Univ De Antioquia, Medellin, Colombia.
[Krupinski, Elizabeth A.] Univ Arizona, Dept Radiol, Tucson, AZ 85724 USA.
RP Li, HK (reprint author), Community Retina Grp, 1400 Hermann Dr, Houston, TX 77004 USA.
EM hlimed@mac.com
OI Florez-Arango, Jose F/0000-0001-9083-0195
NR 31
TC 9
Z9 9
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2010
VL 51
IS 11
BP 5846
EP 5852
DI 10.1167/iovs.09-4803
PG 7
WC Ophthalmology
SC Ophthalmology
GA 672BQ
UT WOS:000283558400057
PM 20484593
ER
PT J
AU Tien, PC
Choi, AI
Zolopa, AR
Benson, C
Tracy, R
Scherzer, R
Bacchetti, P
Shlipak, M
Grunfeld, C
AF Tien, Phyllis C.
Choi, Andy I.
Zolopa, Andrew R.
Benson, Constance
Tracy, Russell
Scherzer, Rebecca
Bacchetti, Peter
Shlipak, Michael
Grunfeld, Carl
TI Inflammation and Mortality in HIV-Infected Adults: Analysis of the FRAM
Study Cohort
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE HIV; inflammation; C-reactive protein; fibrinogen; mortality
ID HUMAN-IMMUNODEFICIENCY-VIRUS; C-REACTIVE PROTEIN; ANTIRETROVIRAL
THERAPY; CARDIOVASCULAR-DISEASE; GENERAL-POPULATION; FAT REDISTRIBUTION;
METABOLIC-CHANGE; DEATH; ASSOCIATION; SURVIVAL
AB Objective: To determine the association of inflammatory markers, fibrinogen, and C-reactive protein (CRP), with 5-year mortality risk.
Methods: Vital status was ascertained in 922 HIV-infected participants from the Study of Fat Redistribution and Metabolic Change in HIV infection. Multivariable logistic regression estimated odds ratios after adjustment for demographic, cardiovascular, and HIV-related factors.
Results: Over a 5-year period, HIV-infected participants with fibrinogen levels in the highest tertile (>406 mg/dL) had 2.6-fold higher adjusted odds of death than those with fibrinogen in the lowest tertile (<319 mg/dL). Those with high CRP (>3 mg/L) had 2.7-fold higher adjusted odds of death than those with CRP <1 mg/L. When stratified by CD4 count category, fibrinogen (as a linear variable) remained independently associated [odds ratio (95% confidence intervals)] per 100 mg/dL increase in fibrinogen: 1.93 (1.57 to 2.37); 1.43 (1.14 to 1.79); 1.43 (1.14 to 1.81); and 1.30 (1.04 to 1.63) for CD4 <200, 200-350, >350 to 500, and >500 cells per microliter, respectively. Higher CRP also remained associated with higher odds of death overall and within each CD4 subgroup.
Conclusions: Fibrinogen and CRP are strong and independent predictors of mortality in HIV-infected adults. Our findings suggest that even in those with relatively preserved CD4 counts >500 cells per microliter, inflammation remains an important risk factor for mortality. Further investigation should determine whether interventions to reduce inflammation might decrease mortality risk in HIV-infected individuals.
C1 [Tien, Phyllis C.] Univ Calif San Francisco, VAMC, Infect Dis Sect, Dept Med, San Francisco, CA 94121 USA.
[Tien, Phyllis C.; Choi, Andy I.; Scherzer, Rebecca; Shlipak, Michael; Grunfeld, Carl] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA.
[Zolopa, Andrew R.] Stanford Univ, Dept Med, Stanford, CA 94305 USA.
[Benson, Constance] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA.
[Tracy, Russell] Univ Vermont, Dept Pathol & Biochem, Colchester, VT USA.
[Bacchetti, Peter] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA.
RP Tien, PC (reprint author), Univ Calif San Francisco, VAMC, Infect Dis Sect, Dept Med, 111W,4150 Clement St, San Francisco, CA 94121 USA.
EM ptien@ucsf.edu
FU National Institutes of Health (NIH) [R01-DK57508, HL74814, HL53359,
K23-AI66943, DK080645]; NIH center [M01-RR00036, RR00051, RR00052,
RR00054, RR00083, RR0636, RR00865, UL1 RR024131]
FX Supported by National Institutes of Health (NIH) grants R01-DK57508,
HL74814, and HL53359; K23-AI66943 and DK080645, and NIH center grants
M01-RR00036, RR00051, RR00052, RR00054, RR00083, RR0636, RR00865, and
UL1 RR024131. The funding agency had no role in the collection or
analysis of the data.
NR 26
TC 127
Z9 129
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD NOV 1
PY 2010
VL 55
IS 3
BP 316
EP 322
DI 10.1097/QAI.0b013e3181e66216
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 675RE
UT WOS:000283847400007
PM 20581689
ER
PT J
AU Chen, D
Lei, L
Lu, CX
Galaleldeen, A
Hart, PJ
Zhong, GM
AF Chen, Ding
Lei, Lei
Lu, Chunxue
Galaleldeen, Ahmad
Hart, P. John
Zhong, Guangming
TI Characterization of Pgp3, a Chlamydia trachomatis Plasmid-Encoded
Immunodominant Antigen
SO JOURNAL OF BACTERIOLOGY
LA English
DT Article
ID SEXUALLY-TRANSMITTED-DISEASES; HUMAN-ANTIBODY RESPONSES; OUTER-MEMBRANE
PROTEIN; SECRETED PROTEASE; INFECTED CELLS; INHIBITION; ACTIVATION;
DIFFERENTIATION; IDENTIFICATION; PURIFICATION
AB Human antibody recognition of Chlamydia trachomatis plasmid-encoded Pgp3 protein is dependent on the native conformation of Pgp3. The structural basis for the conformation dependence and the function of Pgp3 remain unknown. Here, we report that Pgp3 trimerization is required for the recognition of Pgp3 by human antibodies. In a native polyacrylamide gel, Pgp3 purified from a bacterial expression system migrated as stable trimers that were dissociated into monomers only by treatment with urea or sodium dodecyl sulfate (SDS) but not nonionic detergents. Human antibodies recognized trimeric but not monomeric Pgp3, suggesting that Pgp3 is presented to the human immune system as trimers during C. trachomatis infection. The endogenous Pgp3 secreted into the chlamydial outer membrane complex or host cell cytosol is always trimerized. Intact Pgp3 trimers were eluted from the outer membrane complex by a combination of nonionic detergents with reducing agents but not by the presence of either alone. These observations have provided important information for further understanding the role of Pgp3 in chlamydial pathogenesis and potentially optimizing Pgp3 as a subunit vaccine candidate antigen.
C1 [Chen, Ding; Lei, Lei; Lu, Chunxue; Zhong, Guangming] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA.
[Galaleldeen, Ahmad; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA.
[Hart, P. John] US Dept Vet Affairs, Ctr Geriatr Res Educ & Clin, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
RP Zhong, GM (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM Zhongg@UTHSCSA.EDU
RI Lei, Lei/I-3002-2013
FU U.S. National Institutes of Health; Robert A. Welch Foundation
[AQ-1399]; Office of the Vice President for Research at the University
of Texas Health Science Center
FX This work was supported in part by grants (to G. Zhong) from the U.S.
National Institutes of Health and from the Robert A. Welch Foundation
(grant AQ-1399 to P. J. Hart). Support for the Center for Analytical
Ultracentrifugation of Macromolecular Assemblies by the Office of the
Vice President for Research at the University of Texas Health Science
Center is also gratefully acknowledged.
NR 47
TC 12
Z9 18
U1 0
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0021-9193
J9 J BACTERIOL
JI J. Bacteriol.
PD NOV
PY 2010
VL 192
IS 22
BP 6017
EP 6024
DI 10.1128/JB.00847-10
PG 8
WC Microbiology
SC Microbiology
GA 672BZ
UT WOS:000283559300018
PM 20851898
ER
PT J
AU Wijelath, E
Kohler, TR
Murray, J
Namekata, M
Yagi, M
Sobel, M
AF Wijelath, Errol
Kohler, Ted R.
Murray, Jacqueline
Namekata, Mayumi
Yagi, Mayumi
Sobel, Michael
TI Enhancement of capillary and cellular ingrowth in ePTFE implants with a
proangiogenic recombinant construct derived from fibronectin
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE expanded polytetrafluoroethylene; fibronectin; neovascularization;
vascular endothelial growth factor; prostheses and implants; rats
ID POLYTETRAFLUOROETHYLENE ARTERIAL GRAFTS; BIOLOGICAL-ACTIVITY; POROUS
IMPLANTS; VASCULAR GRAFTS; ADIPOSE-TISSUE; SMALL-CALIBER; POROSITY;
NEOVASCULARIZATION; GROWTH; VEGF
AB Based on our discoveries of a unique, synergistic interplay between vascular endothelial growth factor (VEGF) and specific domains of the matrix protein fibronectin (FN), we used recombinant technology to create a new protein construct derived from the cell-binding and VEGF-binding domains of FN. We wished to test the hypothesis that this prototype recombinant FN (rFN) protein would enhance cellular and capillary ingrowth in vivo into expanded polytetrafluoroethylene (ePTFE) implants. ePTFE disks of high porosity (60 micron internodal distance) were embedded with fibrin gel and heparin, with/without mixtures of VEGF and rFN and were implanted subcutaneously in rats. Control implants embedded with fibrin glue and heparin alone showed an average of 8.5% (+/- 0.51% standard error mean (SEM)) cellular ingrowth. The addition of either VEGF or rFN caused a mod-est but significant increase in cellular ingrowth (12.7 +/- 1% and 11.8 +/- 0.98%, respectively, p < 0.004). However, the combination of rFN/VEGF/heparin dramatically increased cellular ingrowth (27.6 +/- 1.62%, p < 0.001), compared with all other treatments. Quantification of capillary ingrowth yielded the same pattern. These results suggest that the incorporation of such biological modulators into cardiovascular implants could offer new strategies for the design of a ready-made small diameter prosthetic graft with enhanced capacity for neovascularization and endothelialization. (C) 2010 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 95A: 641-648, 2010.
C1 [Wijelath, Errol; Kohler, Ted R.; Murray, Jacqueline; Namekata, Mayumi; Yagi, Mayumi; Sobel, Michael] Univ Washington, Sch Med, Dept Surg, Div Vasc Surg,VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
RP Wijelath, E (reprint author), Univ Washington, Sch Med, Dept Surg, Div Vasc Surg,VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
EM errolw@u.washington.edu
FU NHLBI, National Institutes of Health [R01 HL079182]; Research Service of
the Department of Veterans Affairs
FX Contract grant sponsor: NHLBI, National Institutes of Health; contract
grant number: R01 HL079182; Contract grant sponsor: Research Service of
the Department of Veterans Affairs
NR 26
TC 2
Z9 3
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1549-3296
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD NOV
PY 2010
VL 95A
IS 2
BP 641
EP 648
DI 10.1002/jbm.a.32871
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 660TF
UT WOS:000282666600033
PM 20725965
ER
PT J
AU Ortqvist, E
Brooks-Worrell, B
Lynch, K
Radtke, J
Bekris, LM
Kockum, I
Agardh, CD
Cilio, CM
Lethagen, AL
Persson, B
Lernmark, A
Reichow, J
Oak, S
Palmer, JP
Hampe, CS
AF Ortqvist, E.
Brooks-Worrell, B.
Lynch, K.
Radtke, J.
Bekris, L. M.
Kockum, I.
Agardh, C. -D.
Cilio, C. M.
Lethagen, A. L.
Persson, B.
Lernmark, A.
Reichow, J.
Oak, S.
Palmer, J. P.
Hampe, C. S.
TI Changes in GAD65Ab-Specific Antiidiotypic Antibody Levels Correlate with
Changes in C-Peptide Levels and Progression to Islet Cell Autoimmunity
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; JUVENILE DIABETES-MELLITUS; DNA
ANTIBODIES; DISEASE-ACTIVITY; T-CELLS; ONSET; AUTOANTIBODIES; GAD65;
DECARBOXYLASE; EPITOPE
AB Context: The previously reported absence of 65-kDa glutamate decarboxylase antibody (GAD65Ab)-specific antiidiotypic antibodies (anti-Id) in type 1 diabetes (T1D) patients at clinical onset could be due to an inability to mount an antibody response to GAD65Ab or a longitudinal decline in anti-Id levels.
Objective and Design: We investigated anti-Id levels in longitudinal samples obtained from T1D patients (n = 41) (clinical diagnosis- 12 months), and latent autoimmune diabetes in adults (LADA) patients (n = 32) who received alum-formulated human recombinant GAD65 (baseline -12 months). We also determined anti-Id levels in a small cohort of Type 2 diabetes patients during their development of autoimmune T cell responses.
Results: At clinical onset T1D patients presented no or low anti-Id levels. However, 22/41 T1D patients showed >= 50% increase in GAD65Ab-specific anti-Id levels during follow-up; peaking at 3 (n = 1), 6 (n = 10), 9 (n = 10), or 12 (n = 1) months. Increasing anti-Id levels marked patients who experienced a temporary increase in C-peptide levels. Anti-Id levels correlated significantly with glycated hemoglobin and C-peptide levels at 6 and 9 months (P values ranged from < 0.001 to < 0.05). In LADA patients receiving placebo, anti-Id levels declined in seven of nine patients, whereas four of five patients receiving 20 mu g alum-formulated human recombinant GAD65 showed increasing anti-Id levels. Changes in anti-Id and C-peptide levels closely correlated (P < 0.0001). The significant decline in anti-Id levels (P = 0.03) in T2D patients developing T cell autoimmune responses supports our hypothesis that declining anti-Id levels are associated with developing islet autoimmunity.
Conclusions: The close association between GAD65Ab-specific anti-Id levels and beta-cell function may provide a novel marker for the progression of autoimmune diabetes. (J Clin Endocrinol Metab 95: E310-E318, 2010)
C1 [Reichow, J.; Palmer, J. P.; Hampe, C. S.] Univ Washington, Dept Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98109 USA.
[Ortqvist, E.; Persson, B.] Karolinska Inst, Dept Woman & Child Hlth, SE-17177 Stockholm, Sweden.
[Kockum, I.] Karolinska Inst, Dept Mol Med, SE-17177 Stockholm, Sweden.
[Lynch, K.] Univ S Florida, Dept Pediat, Pediat Epidemiol Ctr, Tampa, FL 33620 USA.
[Agardh, C. -D.; Cilio, C. M.; Lethagen, A. L.; Lernmark, A.] Lund Univ, Dept Clin Sci, Univ Hosp, SE-20502 Malmo, Sweden.
[Reichow, J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Inst Biomed & Clin Res, Seattle, WA 98108 USA.
RP Hampe, CS (reprint author), Univ Washington, Dept Med, Vet Affairs Puget Sound Hlth Care Syst, SLU S-276,815 Mercer St, Seattle, WA 98109 USA.
EM champe@u.washington.edu
FU National Institutes of Health [DK26190, DK17047]; Swedish Diabetes
Foundation; Swedish Diabetes Association; Swedish Child Diabetes
Foundation; Jerring Foundation; Foundation of Queen Silvia's Jubilee
Fund for Research on Children and Handicaps; American Diabetes
Association; Medical Research Service of the Department of Veterans
Affairs
FX The study was performed as independent research sponsored by the
National Institutes of Health (DK26190 and DK17047), the Swedish
Diabetes Foundation, Swedish Diabetes Association, Swedish Child
Diabetes Foundation, the Jerring Foundation, the Foundation of Queen
Silvia's Jubilee Fund for Research on Children and Handicaps, and a
Basic Science Award from the American Diabetes Association to (C.S.H.).
The study also received support through the Medical Research Service of
the Department of Veterans Affairs.
NR 43
TC 4
Z9 6
U1 0
U2 3
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD NOV
PY 2010
VL 95
IS 11
BP E310
EP E318
DI 10.1210/jc.2010-0785
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 675QB
UT WOS:000283844400004
PM 20685858
ER
PT J
AU Fiorentino, L
Martin, JL
AF Fiorentino, Lavinia
Martin, Jennifer L.
TI Awake at 4 a.m.: Treatment of Insomnia With Early Morning Awakenings
Among Older Adults
SO JOURNAL OF CLINICAL PSYCHOLOGY
LA English
DT Article
DE insomnia; circadian rhythms; advanced sleep phase syndrome; aging;
cognitive-behavioral therapy; light therapy
ID SLEEP DISORDERS; INTERVENTIONS; METAANALYSIS; EFFICACY
AB Insomnia is a common problem among older adults. In particular, older adults experience insomnia coupled with early morning awakenings due to an interaction between age-related changes in circadian rhythm timing coupled with behavior changes that contribute to sustained poor sleep. Cognitive behavioral therapy for insomnia (CBT-I), at times coupled with circadian interventions (e.g., timed light exposure), are likely to be most successful in optimizing sleep quality. In delivering CBT-I to older adults, modifications are sometimes necessary to accommodate for medical problems, lifestyle, social factors, and patient preferences. Addition of circadian interventions can ameliorate the negative effects of inappropriately timed sleep as well. These treatment methods can be highly effective and benefits can be long-standing. A case example is used to illustrate these points. (C) 2010 Wiley Periodicals, Inc. J Clin Psychol: In Session 66:1161-1174, 2010.
C1 [Fiorentino, Lavinia; Martin, Jennifer L.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Martin, Jennifer L.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Martin, JL (reprint author), VA Greater Los Angeles Healthcare Syst Geriatr Re, Educ & Clin Ctr 11E, 16111 Plummer St, North Hills, CA 91343 USA.
EM jennifer.martin@va.gov
FU NIA NIH HHS [K23 AG028452-03, K23 AG028452, R01 AG026364]; NIMH NIH HHS
[T32 MH 019925-1, T32 MH019925-10, T32 MH019925]
NR 12
TC 2
Z9 3
U1 1
U2 12
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0021-9762
J9 J CLIN PSYCHOL
JI J. Clin. Psychol.
PD NOV
PY 2010
VL 66
IS 11
BP 1161
EP 1174
DI 10.1002/jclp.20734
PG 14
WC Psychology, Clinical
SC Psychology
GA 679TF
UT WOS:000284183000004
PM 20845423
ER
PT J
AU Gehrman, PR
Harb, GC
AF Gehrman, Philip R.
Harb, Gerlinde C.
TI Treatment of Nightmares in the Context of Posttraumatic Stress Disorder
SO JOURNAL OF CLINICAL PSYCHOLOGY
LA English
DT Article
DE nightmares; sleep; PTSD; cognitive-behavioral therapy; REM; prazosin;
imagery rehearsal
ID SLEEP DISTURBANCE; COMBAT VETERANS; PRAZOSIN; SYMPTOMS; THERAPY; TRIAL;
PTSD
AB Nightmares are a common feature of posttraumatic stress disorder (PTSD) and are frequently resistant to treatment. Two emerging treatments for nightmares are pharmacotherapy with prazosin and psychotherapy using imagery rehearsal (IR). A case illustration demonstrates the application of these treatments with a client suffering from chronic, severe PTSD. The case illustrates the use of these strategies for managing PTSD-related nightmares, as well as the novel approach of scheduled awakenings following relapse. (C) 2010 Wiley Periodicals, Inc. J Clin Psychol: In Session 66:1185-1194, 2010.
C1 [Gehrman, Philip R.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Gehrman, Philip R.; Harb, Gerlinde C.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
RP Gehrman, PR (reprint author), Univ Penn, Dept Psychiat, 3535 Market St,Suite 670, Philadelphia, PA 19104 USA.
EM gehrman@exchange.upenn.edu
NR 17
TC 10
Z9 10
U1 1
U2 12
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0021-9762
J9 J CLIN PSYCHOL
JI J. Clin. Psychol.
PD NOV
PY 2010
VL 66
IS 11
BP 1185
EP 1194
DI 10.1002/jclp.20730
PG 10
WC Psychology, Clinical
SC Psychology
GA 679TF
UT WOS:000284183000006
PM 20865767
ER
PT J
AU Bell, JF
Johnson, ML
Myers, K
Patrick, DL
AF Bell, Janice F.
Johnson, M. Laura
Myers, Kathleen
Patrick, Donald L.
TI Primary Health Care Quality in a National Sample of Children and Youth
with Mental Health Impairment
SO JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS
LA English
DT Article
DE quality of care; mental health impairment; Medical Expenditures Panel
Survey; children; adolescents
ID MEDICAL HOME; PSYCHIATRIC-DISORDERS; UNMET NEED; CENTERED CARE;
SERVICES; ADOLESCENTS; DEPRESSION; PERFORMANCE; PREVALENCE; BARRIERS
AB Objective: To examine the general pediatric health care quality experiences of children and youth with mental health impairment. Methods: We conducted a cross-sectional analysis of 2006 Medical Expenditures Panel Survey data for children and youth aged 5 to 17 years (n = 7263). Mental health impairment was defined using the recommended cut-point (score >= 16) on the parent version of the Columbia Impairment Scale. Health care quality was measured with the Consumer Assessment of Healthcare Providers and Systems including parent ratings in 3 domains: provider communication, getting needed care, and getting care quickly. Logistic regression was used to test associations between mental health impairment and dichotomized Consumer Assessment of Healthcare Providers and Systems measures (poor vs good quality) adjusted for demographic characteristics, health insurance, and socioeconomic status. Analysis was conducted with Stata, Version 10.1 SE, and all estimates accounted for the Medical Expenditures Panel Survey complex sampling design. Results: In multivariable analysis, health care experiences of children with mental health impairment (versus those without) were consistently rated less favorably by parents, with greater odds of inferior quality of care ratings in all domains: getting needed care (odds ratio [OR] = 2.35), getting care quickly (OR = 1.41), physician communication (OR = 1.72), and overall health care quality (OR = 1.63). Conclusions: Further research is needed to identify specific aspects of care that families find problematic in relation to the organization and delivery of care within each quality domain. Interventions are needed to improve service systems for children and youth with mental health impairment, especially to support access to needed care.
C1 [Bell, Janice F.] Univ Washington, Dept Hlth Serv, Maternal & Child Hlth Program, Seattle, WA 98195 USA.
[Bell, Janice F.; Patrick, Donald L.] Seattle Qual Life Grp, Dept Hlth Serv, Seattle, WA USA.
[Johnson, M. Laura] Vet Affairs Puget Sound Hlth Care Syst, NW Ctr Excellence Hlth Serv Res & Dev, Seattle, WA USA.
[Myers, Kathleen] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Myers, Kathleen] Childrens Hosp, Med Ctr, Seattle, WA USA.
RP Bell, JF (reprint author), Univ Washington, Dept Hlth Serv, Maternal & Child Hlth Program, Box 357230, Seattle, WA 98195 USA.
EM jfbell@u.washington.edu
NR 51
TC 4
Z9 4
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0196-206X
J9 J DEV BEHAV PEDIATR
JI J. Dev. Behav. Pediatr.
PD NOV-DEC
PY 2010
VL 31
IS 9
BP 694
EP 704
DI 10.1097/DBP.0b013e3181f17b09
PG 11
WC Behavioral Sciences; Psychology, Developmental; Pediatrics
SC Behavioral Sciences; Psychology; Pediatrics
GA 675NV
UT WOS:000283838300002
PM 21057254
ER
PT J
AU Finley, EP
Baker, M
Pugh, MJ
Peterson, A
AF Finley, Erin P.
Baker, Monty
Pugh, Mary Jo
Peterson, Alan
TI Patterns and Perceptions of Intimate Partner Violence Committed by
Returning Veterans with Post-Traumatic Stress Disorder
SO JOURNAL OF FAMILY VIOLENCE
LA English
DT Article
DE Partner violence; Veterans; PTSD; Patterns of abuse; Trauma
ID MENTAL-HEALTH PROBLEMS; PERITRAUMATIC DISSOCIATION; MILITARY VETERANS;
VIETNAM VETERANS; COMBAT VETERANS; TRAUMA; IRAQ; WAR; AFGHANISTAN; SLEEP
AB Data from a recent mixed-methods study conducted among Veterans of Iraq and Afghanistan diagnosed with Post-Traumatic Stress Disorder (PTSD) raise important questions regarding the occurrence of Intimate Partner Violence (IPV) in this population. Three case studies illustrate two main findings. First, Veterans and family members participating in the study described three patterns of partner violence-violence committed in anger; dissociative violence; and parasomniac/hypnopompic violence-suggesting that distinct patterns of IPV may emerge in relation to PTSD symptoms. Second, participants' descriptions suggest that common ideas about PTSD and war-related suffering can play an important role in influencing how Veterans and their partners respond to episodes of partner violence. It is important for those providing care to PTSD-diagnosed Veterans and their partners to understand when and how partner violence may occur, and how both parties may perceive and respond to it, in order to aid in developing appropriate plans for coping and safety-seeking.
C1 [Finley, Erin P.] S Texas Vet Hlth Care Syst, Audie L Murphy Mem Vet Hosp Div, VERDICT Res Unit 1IC6, San Antonio, TX 78229 USA.
[Peterson, Alan] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, Div Behav Med, STRONG STAR Multidisciplinary PTSD Res Consortium, San Antonio, TX 78229 USA.
[Pugh, Mary Jo] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, Dept Med Geriatr & Gerontol, San Antonio, TX 78229 USA.
[Finley, Erin P.] Univ Texas Hlth Sci Ctr San Antonio, Div Clin Epidemiol, Dept Med, San Antonio, TX 78229 USA.
[Finley, Erin P.; Pugh, Mary Jo] S Texas Vet Hlth Care Syst, Vet Evidence Based Res Disseminat & Implementat C, San Antonio, TX 78229 USA.
RP Finley, EP (reprint author), S Texas Vet Hlth Care Syst, Audie L Murphy Mem Vet Hosp Div, VERDICT Res Unit 1IC6, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.
EM finleye@uthscsa.edu
OI Pugh, Mary Jo/0000-0003-4196-7763; Finley, Erin/0000-0003-4497-7721
NR 39
TC 18
Z9 18
U1 4
U2 20
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0885-7482
J9 J FAM VIOLENCE
JI J. Fam. Violence
PD NOV
PY 2010
VL 25
IS 8
BP 737
EP 743
DI 10.1007/s10896-010-9331-7
PG 7
WC Psychology, Clinical; Family Studies
SC Psychology; Family Studies
GA 679SR
UT WOS:000284181600004
ER
PT J
AU Gordon, WJ
Polansky, JM
Boscardin, WJ
Fung, KZ
Steinman, MA
AF Gordon, William J.
Polansky, Jesse M.
Boscardin, W. John
Fung, Kathy Z.
Steinman, Michael A.
TI Coronary Risk Assessment by Point-Based vs. Equation-Based Framingham
Models: Significant Implications for Clinical Care
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article; Proceedings Paper
CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine
CY MAY 13-16, 2009
CL Miami, FL
SP Soc Gen Internal Med
DE risk assessment; cholesterol; heart diseases; practice guidelines as
topic; prognosis
ID ISCHEMIC-HEART-DISEASE; TREATMENT PANEL-III; CARDIOVASCULAR RISK;
PRIMARY PREVENTION; CHOLESTEROL; GUIDELINES; PREDICTION; STATINS; SCORE;
RECLASSIFICATION
AB BACKGROUND: US cholesterol guidelines use original and simplified versions of the Framingham model to estimate future coronary risk and thereby classify patients into risk groups with different treatment strategies. We sought to compare risk estimates and risk group classification generated by the original, complex Framingham model and the simplified, point-based version.
METHODS: We assessed 2,543 subjects age 20-79 from the 2001-2006 National Health and Nutrition Examination Surveys (NHANES) for whom Adult Treatment Panel III (ATP-III) guidelines recommend formal risk stratification. For each subject, we calculated the 10-year risk of major coronary events using the original and point-based Framingham models, and then compared differences in these risk estimates and whether these differences would place subjects into different ATP-III risk groups (<10% risk, 10-20% risk. or >20% risk). Using standard procedures, all analyses were adjusted for survey weights, clustering, and stratification to make our results nationally representative.
RESULTS: Among 39 million eligible adults, the original Framingham model categorized 71% of subjects as having "moderate" risk (<10% risk of a major coronary event in the next 10 years), 22% as having "moderately high" (10-20%) risk, and 7% as having "high" (>20%) risk. Estimates of coronary risk by the original and point-based models often differed substantially. The point-based system classified 15% of adults (5.7 million) into different risk groups than the original model, with 10% (3.9 million) misclassified into higher risk groups and 5% (1.8 million) into lower risk groups, for a net impact of classifying 2.1 million adults into higher risk groups. These risk group misclassifications would impact guideline-recommended drug treatment strategies for 25-46% of affected subjects. Patterns of misclassifications varied significantly by gender. age. and underlying CHD risk.
CONCLUSIONS: Compared to the original Framingham model, the point-based version misclassifies millions of Americans into risk groups for which guidelines recommend different treatment strategies.
C1 [Fung, Kathy Z.; Steinman, Michael A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Gordon, William J.] Weill Cornell Med Coll, New York, NY USA.
[Gordon, William J.; Steinman, Michael A.] Med Student Training Aging Res Program, San Francisco, CA USA.
[Polansky, Jesse M.] Ctr Medicare & Medicaid Serv, Baltimore, MD USA.
[Boscardin, W. John; Fung, Kathy Z.; Steinman, Michael A.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.
[Boscardin, W. John] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
RP Steinman, MA (reprint author), San Francisco VA Med Ctr, 4150 Clement St,Box 181G, San Francisco, CA 94121 USA.
EM mike.steinman@ucsf.edu
FU NIA NIH HHS [K23-AG030999, K23 AG030999]
NR 38
TC 7
Z9 7
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD NOV
PY 2010
VL 25
IS 11
BP 1145
EP 1151
DI 10.1007/s11606-010-1454-2
PG 7
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 672YN
UT WOS:000283624000005
PM 20824362
ER
PT J
AU Rosman, AS
Korsten, MA
AF Rosman, Alan S.
Korsten, Mark A.
TI Effect of Verification Bias on the Sensitivity of Fecal Occult Blood
Testing: a Meta-Analysis
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Review
DE fecal occult blood; guaiac; colorectal cancer; summary receiver
operating characteristic curve: meta-analysis
ID DIAGNOSTIC-TEST ACCURACY; AVERAGE-RISK POPULATION; COLORECTAL-CANCER;
SYSTEMATIC REVIEWS; PROSPECTIVE MULTICENTER; SYMPTOMATIC PATIENTS;
IMMUNOCHEMICAL TEST; HEMOCCULT TEST; TOTAL COLONOSCOPY; AMERICAN-COLLEGE
AB OBJECTIVES: There is controversy regarding the sensitivity of fecal occult blood tests (FOBT) for detecting colorectal cancer. Many of the published studies failed to correct for verification bias which may have increased the sensitivity.
METHODS: A meta-analysis of published studies evaluating the sensitivity and specificity of chemical-based FOBT for colorectal cancer was performed. Studies were included if both cancer and control subjects underwent confirmatory testing. We also included studies that attempted to correct for verification bias by either performing colonoscopy on all subjects regardless of the FOBT result or by using longitudinal follow-up. We then compared the sensitivity, specificity, and other diagnostic characteristics of the studies that attempted to correct for verification (n=10) vs. those that did not correct for this bias (n=19).
RESULTS: The pooled sensitivity of guaiac-based FOBT for colorectal cancer of studies without verification bias was significantly lower than those studies with this bias [0.36 (95% CI 0.25-0.47) vs. 0.70 (95% CI 0.60-0.80), p=0.0011. The pooled specificity of the studies without verification bias was higher [0.96 (95% CI 0.94-0.97) vs. 0.88 (95% CI 0.84-0.91), p<0.005]. There was no significant difference in the area under the summary receiver operating characteristic curves. More sensitive chemical-based FOBT methods (e.g., Hemoccult (R) SENSA (R)) had a higher sensitivity but a lower specificity than standard guaiac methods.
CONCLUSIONS: The sensitivity of guaiac-based FOBT for colorectal cancer has been overestimated as a result of verification bias. This test may not be sensitive enough to serve as an effective screening option for colorectal cancer.
C1 [Rosman, Alan S.; Korsten, Mark A.] James J Peters Vet Affairs Med Ctr, Gastroenterol Sect, Bronx, NY 10468 USA.
[Rosman, Alan S.; Korsten, Mark A.] James J Peters Vet Affairs Med Ctr, Program Med, Bronx, NY 10468 USA.
[Rosman, Alan S.; Korsten, Mark A.] Mt Sinai Sch Med NYU, New York, NY USA.
RP Rosman, AS (reprint author), James J Peters Vet Affairs Med Ctr, Gastroenterol Sect, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM Alan.Rosman@VA.Gov
FU Department of Veterans Affairs
FX Funding Source: Department of Veterans Affairs.
NR 74
TC 12
Z9 12
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD NOV
PY 2010
VL 25
IS 11
BP 1211
EP 1221
DI 10.1007/s11606-010-1375-0
PG 11
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 672YN
UT WOS:000283624000015
PM 20499198
ER
PT J
AU Widera, E
Chang, A
Chen, HL
AF Widera, Eric
Chang, Anna
Chen, Helen L.
TI Presenteeism: A Public Health Hazard
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Editorial Material
DE presenteeism; infection control; norovirus; long-term care; outbreak
ID SICKNESS PRESENTEEISM; CARE WORKERS; INFLUENZA VACCINE; OUTBREAK;
INFECTION; NOROVIRUS; IMPACT; STAFF; COST; GASTROENTERITIS
AB "Presenteeism" occurs when an employee goes to work despite a medical illness that will prevent him or her from fully functioning at work. This problem has been well studied in the business and social science literature, and carries increased importance in the health care setting due to the risk of infectious disease transmission in vulnerable patient populations. In this manuscript, we discuss an outbreak of viral gastroenteritis in a long-term care facility and the role presenteeism played in disease transmission and extension of the outbreak. We use existing literature to point out the hazards of presenteeism in the health care sector. We will also discuss factors that may be involved in the decision to work while ill and propose policy changes that may reduce the incidence of presenteeism in health care organizations.
C1 [Widera, Eric] VA Med Ctr 181G, San Francisco, CA 94121 USA.
[Widera, Eric; Chang, Anna; Chen, Helen L.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.
[Widera, Eric; Chang, Anna] San Francisco VA Med Ctr, San Francisco, CA USA.
[Chen, Helen L.] Ctr Elders Independence, Oakland, CA USA.
RP Widera, E (reprint author), VA Med Ctr 181G, 4150 Clement St, San Francisco, CA 94121 USA.
EM Eric.Widera@ucsf.edu
FU Health Resources and Services Administration
FX Dr. Widera has received funding support from a Geriatrics Academic
Career Award from the Health Resources and Services Administration. Dr.
Chen has received funding support from a Geriatrics Education Center
Grant from the Health Resources and Services Administration.
NR 40
TC 34
Z9 38
U1 3
U2 23
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD NOV
PY 2010
VL 25
IS 11
BP 1244
EP 1247
DI 10.1007/s11606-010-1422-x
PG 4
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 672YN
UT WOS:000283624000021
PM 20549378
ER
PT J
AU Osborn, CY
Amico, KR
Fisher, WA
Egede, LE
Fisher, JD
AF Osborn, Chandra Y.
Amico, K. Rivet
Fisher, William A.
Egede, Leonard E.
Fisher, Jeffrey D.
TI An Information-Motivation-Behavioral Skills Analysis of Diet and
Exercise Behavior in Puerto Ricans with Diabetes
SO JOURNAL OF HEALTH PSYCHOLOGY
LA English
DT Article
DE behavior; diabetes; glycemic control; Information-Motivation-Behavioral
Skills (IMB) model; Puerto Rican
ID AIDS-PREVENTIVE BEHAVIOR; PHYSICAL-ACTIVITY; ANTIRETROVIRAL THERAPY;
GLYCEMIC CONTROL; HEALTH-BEHAVIOR; RISK BEHAVIOR; MODEL; INTERVENTION;
CARE; ADHERENCE
AB Frameworks are needed to inform diabetes self-care programs for diverse populations. We tested the Information-Motivation-Behavioral Skills (IMB) model in a sample of Puerto Ricans with Type 2 diabetes (N = 118). Structural equation models evaluated model fit and interrelations between IMB constructs. For diet behavior, information and motivation related to behavioral skills (r = 0.19, p < .05 and r = 0.39, p < .01, respectively); behavioral skills related to behavior (r = 0.42, p < .01 and r = 0.32, p < .05); and behavior related to glycemic control (r = -0.26, p < .05). For exercise, personal motivation related to behavioral skills (r = 0.53, p < .001), and behavioral skills related to behavior (r = 0.45, p < .001). The IMB model could inform interventions targeting these behaviors in diabetes.
C1 [Osborn, Chandra Y.] Vanderbilt Univ, Sch Med, Vanderbilt Ctr Hlth Serv Res, Div Gen Internal Med & Publ Hlth, Nashville, TN 37232 USA.
[Amico, K. Rivet; Fisher, Jeffrey D.] Univ Connecticut, Ctr Hlth Intervent & Prevent, Storrs, CT 06269 USA.
[Fisher, William A.] Univ Western Ontario, Dept Psychol, London, ON N6A 3K7, Canada.
[Fisher, William A.] Univ Western Ontario, Dept Obstet & Gynecol, London, ON N6A 3K7, Canada.
[Egede, Leonard E.] Med Univ S Carolina, Div Gen Internal Med & Geriatr, Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Osborn, CY (reprint author), Vanderbilt Univ, Sch Med, Vanderbilt Ctr Hlth Serv Res, Div Gen Internal Med & Publ Hlth, 1215 21st Ave S,Suite 6000,MCE N Tower, Nashville, TN 37232 USA.
EM chandra.osborn@vanderbilt.edu
FU NIDDK NIH HHS [P60 DK020593, F31 DK067022, F31 DK067022-01, F31
DK067022-02, P60 DK020593-30S2]
NR 48
TC 13
Z9 13
U1 5
U2 16
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1359-1053
J9 J HEALTH PSYCHOL
JI J. Health Psychol.
PD NOV
PY 2010
VL 15
IS 8
BP 1201
EP 1213
DI 10.1177/1359105310364173
PG 13
WC Psychology, Clinical
SC Psychology
GA 675RG
UT WOS:000283847600008
PM 20453056
ER
PT J
AU Zorzi, P
Aplin, AC
Smith, KD
Nicosia, RF
AF Zorzi, Penelope
Aplin, Alfred C.
Smith, Kelly D.
Nicosia, Roberto F.
TI The rat aorta contains resident mononuclear phagocytes with
proliferative capacity and proangiogenic properties
SO JOURNAL OF LEUKOCYTE BIOLOGY
LA English
DT Article
DE M-CSF; GM-CSF; IL-4; MHC II; dendritic cells; aortic ring; collagen
ID MULTINUCLEATED GIANT-CELLS; ENDOTHELIAL GROWTH-FACTOR;
SMOOTH-MUSCLE-CELLS; MACROPHAGE ACCUMULATION; INFLAMMATORY CYTOKINES;
VESSEL FORMATION; DENDRITIC CELLS; ADIPOSE-TISSUE; IN-VITRO;
ANGIOGENESIS
AB Angiogenesis in the aortic ring model is preceded by activation of the immune system and impaired by ablation of adventitial macrophages. Treatment of aortic cultures with M-CSF induced extensive periaortic outgrowth of CD45(+) CD68(+) mononuclear cells with ultrastructural features of macrophages and DCs. Periaortic lysis of collagen caused many CD45(+) CD68(+) cells to attach to the bottom of the culture dish. Lifting the collagen gels left behind patches of CD45(+) CD68(+) cells, which focally organized into branching cords. These cells also expressed CD14, CD169, F4/80, and alpha-SMA but not CD31, vWF, desmin, or CD163. DNA synthesis studies showed that M-CSF-stimulated cells were actively proliferating. Aortic patch cells showed phagocytic properties and responded to IL-4 and GM-CSF by expressing MHC II, differentiating into DCs, and forming multinucleated giant cells. They also stimulated angiogenesis and VEGF production in aortic ring cultures. This study demonstrates that the rat aorta contains a distinct subset of immature immunocytes capable of proliferating, differentiating into macrophages and DCs, and stimulating angiogenesis. Isolation of these cells in patches from M-CSF-stimulated aortic rings provides a reproducible system to study the biology and angiogenic role of the resident immune system of the aortic wall. J. Leukoc. Biol. 88: 1051-1059; 2010.
C1 [Nicosia, Roberto F.] Vet Adm Puget Sound Hlth Care syst, Pathol & Lab Med Serv, Seattle, WA USA.
[Zorzi, Penelope; Aplin, Alfred C.; Smith, Kelly D.; Nicosia, Roberto F.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
RP Nicosia, RF (reprint author), VA Puget Sound Hlth Care Syst, Pathol & Lab Med Serv S 113, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM roberto.nicosia@va.gov
FU National Heart Lung and Blood Institute [HL-52585]; Department of
Veterans Affairs Medical Research Services
FX This study was supported by the National Heart Lung and Blood Institute
grant HL-52585 and a Merit Review grant from the Department of Veterans
Affairs Medical Research Services. We gratefully acknowledge Ms. Debbie
Jones for her excellent technical assistance with the electron
microscopy studies.
NR 41
TC 12
Z9 12
U1 0
U2 2
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0741-5400
J9 J LEUKOCYTE BIOL
JI J. Leukoc. Biol.
PD NOV
PY 2010
VL 88
IS 5
BP 1051
EP 1059
DI 10.1189/jlb.0310178
PG 9
WC Cell Biology; Hematology; Immunology
SC Cell Biology; Hematology; Immunology
GA 692YG
UT WOS:000285191200024
PM 20628067
ER
PT J
AU Shugarman, LR
Goebel, JR
Lanto, A
Asch, SM
Sherbourne, CD
Lee, ML
Rubenstein, LV
Wen, L
Meredith, L
Lorenz, KA
AF Shugarman, Lisa R.
Goebel, Joy R.
Lanto, Andy
Asch, Steven M.
Sherbourne, Cathy D.
Lee, Martin L.
Rubenstein, Lisa V.
Wen, Li
Meredith, Lisa
Lorenz, Karl A.
TI Nursing Staff, Patient, and Environmental Factors Associated with
Accurate Pain Assessment
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Article
DE Pain measurement; veterans; outpatients
ID CANCER PAIN; NURSES ASSESSMENT; PRIMARY-CARE; REPRESENTATIVE SAMPLE;
ANXIETY DISORDERS; DECISION-MAKING; MANAGEMENT; QUESTIONNAIRE;
DEPRESSION; IMPAIRMENT
AB Context Although pain ranks highly among reasons for seeking care, routine pain assessment is often inaccurate
Objectives This study evaluated factors associated with nurses (e g, registered) and other nursing support staff (e g, licensed vocational nurses and health technicians) discordance with patients in estimates of pain in a health system where routine pain screening using a 0-10 numeric rating scale (NRS) is mandated
Methods This was a cross-sectional, visit-based, cohort study that included surveys of clinic outpatients (n = 465) and nursing staff (n = 94) who screened for pain as part of routine vital sign measurement during intake These data were supplemented by chart review We compared patient pain levels documented by the nursing staff (N-NRS) with those reported by the patient during the study survey (S-NRS)
Results Pain underestimation (N-NRS < S-NRS) occurred in 25% and overestimation (N-NRS > S-NRS) in 7% of the cases Nursing staff used informal pain-screening techniques that did not follow established NRS protocols in half of the encounters Pain underestimation was positively associated with more years of nursing staff work experience and patient anxiety or post-traumatic stress disorder and negatively associated with better patient-reported health status Pain overestimation was positively associated with nursing staffs use of the full NRS protocol and with a distracting environment in which patient vitals were taken
Conclusion Despite a long-standing mandate, pain-screening implementation falls short, and informal screening is common J Pain Symptom Manage 2010,40 723-733 (C) 2010 US Cancer Pain Relief Committee Published by Elsevier Inc All rights reserved
C1 [Lanto, Andy; Asch, Steven M.; Lee, Martin L.; Rubenstein, Lisa V.; Lorenz, Karl A.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Asch, Steven M.; Rubenstein, Lisa V.; Lorenz, Karl A.] Univ Calif Los Angeles, Geffen Sch Med, Los Angeles, CA USA.
[Wen, Li] Vet Adm Long Beach Healthcare Syst, Long Beach, CA USA.
[Goebel, Joy R.] Calif State Univ Long Beach, Sch Nursing, Dept Nursing, Long Beach, CA 90840 USA.
[Shugarman, Lisa R.; Asch, Steven M.; Sherbourne, Cathy D.; Rubenstein, Lisa V.; Meredith, Lisa; Lorenz, Karl A.] RAND Corp, Santa Monica, CA USA.
RP Lorenz, KA (reprint author), Vet Adm Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,Code 111 G, Los Angeles, CA 90073 USA.
FU Veterans Administration [IIR-030150]
FX Dr Karl Lorenz was supported by a VA HSR&D Career Development Award This
study was funded by The Veterans Administration (IIR-030150) The funder
was not involved in the conduct of the study or development of the
submission The authors declare no conflicts of interest
NR 45
TC 11
Z9 12
U1 2
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD NOV
PY 2010
VL 40
IS 5
BP 723
EP 733
DI 10.1016/j.jpainsymman.2010.02.024
PG 11
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 686BI
UT WOS:000284671400009
PM 20692807
ER
PT J
AU Anderson, WG
Goldstein, NE
AF Anderson, Wendy G.
Goldstein, Nathan E.
TI Update in Hospice and Palliative Care
SO JOURNAL OF PALLIATIVE MEDICINE
LA English
DT Article
ID ADVANCED CANCER; ASSOCIATION; DIALYSIS; DEATH
C1 [Anderson, Wendy G.] Univ Calif San Francisco, Div Hosp Med, San Francisco, CA 94143 USA.
[Anderson, Wendy G.] Univ Calif San Francisco, Palliat Care Program, San Francisco, CA 94143 USA.
[Goldstein, Nathan E.] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY USA.
[Goldstein, Nathan E.] James J Peters VA Med Ctr, Bronx, NY USA.
RP Anderson, WG (reprint author), Univ Calif San Francisco, Div Hosp Med, 521 Parnassus Ave,Box 0903, San Francisco, CA 94143 USA.
EM anderson.wg@gmail.com
FU University of California San Francisco Clinical and Translational
Science Institute by National Institutes of Health [5KL2 RR024130-04];
National Institute of Aging [K23 AG025933]
FX Dr. Anderson was supported by the University of California San Francisco
Clinical and Translational Science Institute Career Development Program,
which is supported by National Institutes of Health grant number 5KL2
RR024130-04. Dr. Goldstein was supported by a Mentored Patient-Oriented
Research Career Development Award from the National Institute of Aging
(K23 AG025933). Drs. Anderson and Goldstein presented these articles for
the State of the Science Plenary Session at the Annual Assembly of the
American Academy of Hospice and Palliative Medicine and the Hospice and
Palliative Nurses Association on March 6, 2010 in Boston, Massachusetts.
NR 16
TC 1
Z9 1
U1 1
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-6218
J9 J PALLIAT MED
JI J. Palliat. Med.
PD NOV
PY 2010
VL 13
IS 11
BP 1305
EP 1310
DI 10.1089/jpm.2010.0253
PG 6
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 682JD
UT WOS:000284397000002
ER
PT J
AU Carlson, MDA
Bradley, EH
Du, QL
Morrison, RS
AF Carlson, Melissa D. A.
Bradley, Elizabeth H.
Du, Qingling
Morrison, R. Sean
TI Geographic Access to Hospice in the United States
SO JOURNAL OF PALLIATIVE MEDICINE
LA English
DT Article
ID FOR-PROFIT; CARE; NONPROFIT; HOSPITALS; PATTERNS; CANCER; LIFE; HOME
AB Background: Despite a 41% increase in the number of hospices since 2000, more than 60% of Americans die without hospice care. Given that hospice care is predominantly home based, proximity to a hospice is important in ensuring access to hospice services. We estimated the proportion of the population living in communities within 30 and 60 minutes driving time of a hospice.
Methods: We conducted a cross-sectional study of geographic access to U. S. hospices using the 2008 Medicare Provider of Services data, U. S. Census data, and ArcGIS software. We used multivariate logistic regression to identify gaps in hospice availability by community characteristics.
Results: As of 2008, 88% of the population lived in communities within 30 minutes and 98% lived in communities within 60 minutes of a hospice. Mean time to the nearest hospice was 15 minutes and the range was 0 to 403 minutes. Community characteristics independently associated with greater geographic access to hospice included higher population density, higher median income, higher educational attainment, higher percentage of black residents, and the state not having a Certificate of Need policy. The percentage of each state's population living in communities more than 30 minutes from a hospice ranged from 0% to 48%.
Conclusions: Recent growth in the hospice industry has resulted in widespread geographic access to hospice care in the United States, although state and community level variation exists. Future research regarding variation and disparities in hospice use should focus on barriers other than geographic proximity to a hospice.
C1 [Carlson, Melissa D. A.; Du, Qingling; Morrison, R. Sean] Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Med, New York, NY 10029 USA.
[Bradley, Elizabeth H.] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA.
[Morrison, R. Sean] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
RP Carlson, MDA (reprint author), Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Med, 1 Gustave L Levy Pl,Box 1070, New York, NY 10029 USA.
EM melissa.carlson@mssm.edu
FU National Institute of Nursing Research [1K99NR010495-01]; Patrick and
Catherine Weldon Donaghue Medical Research Foundation [02-102]; National
Institute on Aging [K24 AG022345]
FX Funding sources: Brookdale Leadership in Aging Fellowship, National
Institute of Nursing Research Career Development Award
(1K99NR010495-01); Patrick and Catherine Weldon Donaghue Medical
Research Foundation Investigator Award (Grant #02-102); National
Institute on Aging Mid-Career Investigator Award in Patient Oriented
Research (K24 AG022345).
NR 30
TC 26
Z9 26
U1 3
U2 11
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-6218
J9 J PALLIAT MED
JI J. Palliat. Med.
PD NOV
PY 2010
VL 13
IS 11
BP 1331
EP 1338
DI 10.1089/jpm.2010.0209
PG 8
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 682JD
UT WOS:000284397000007
PM 20979524
ER
PT J
AU Pierre, JM
AF Pierre, Joseph M.
TI The Borders of Mental Disorder in Psychiatry and the DSM: Past, Present,
and Future
SO JOURNAL OF PSYCHIATRIC PRACTICE
LA English
DT Article
DE Diagnostic and Statistical Manual of Mental Disorders (DSM); DSM-5;
diagnosis; normality; spectrum; categorical diagnosis; dimensional
diagnosis; personality disorders; neuroethics; neuroenhancement
ID NATIONAL COMORBIDITY SURVEY; HARMFUL DYSFUNCTION ANALYSIS; RANDOMIZED
CONTROLLED-TRIAL; PLACEBO-CONTROLLED-TRIAL; BIPOLAR DISORDER;
PERSONALITY-DISORDERS; DIAGNOSTIC CRITERIA; LIFETIME PREVALENCE;
COGNITIVE DEFICITS; SURVEY REPLICATION
AB Over the past 60 years, the Diagnostic and Statistical Manual of Mental Disorders (DSM) has evolved from early efforts to collect statistical information to a modern compendium of mental disorders that can be reliably diagnosed, but have not been validated. Throughout this history, DSM architects have struggled with the seemingly fundamental, but complex question of how to define a mental disorder. Current proposals indicate that a spectrum model of mental illness will be embraced in DSM-5, prompting renewed concern and debate about pathologizing normal existence. While a spectrum view of mental illness may reflect biologic reality and help pave the path towards validated models of psychiatric disorder, diagnostic expansion does have important practical implications and could give rise to problems in clinical work and society at large, including the further sanctioning of a shift from psychiatric treatment to neuroenhancement. Debates about what should or should not be considered a mental illness in DSM-5 are likely to remain unresolved and, in the future, must be framed according to contextual utility. Diagnosis and thresholds of pathology are ultimately value-based so that careful analysis and perhaps even different definitions of disorder may be required to guide decision-making in research, clinical work, and public policy. (Journal of Psychiatric Practice 2010;16:375-386)
C1 [Pierre, Joseph M.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Pierre, Joseph M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Pierre, JM (reprint author), 11301 Wilshire Blvd,Bldg 210,Room 15, Los Angeles, CA 90073 USA.
EM joseph.pierre2@va.gov
NR 117
TC 7
Z9 7
U1 4
U2 18
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1527-4160
J9 J PSYCHIATR PRACT
JI J. Psychiatr. Pract.
PD NOV
PY 2010
VL 16
IS 6
BP 375
EP 386
DI 10.1097/01.pra.0000390756.37754.68
PG 12
WC Psychiatry
SC Psychiatry
GA 685CC
UT WOS:000284601000002
PM 21107142
ER
PT J
AU Perez-Rodriguez, MM
Weinstein, S
New, AS
Bevilacqua, L
Yuan, QP
Zhou, ZF
Hodgkinson, C
Goodman, M
Koenigsberg, HW
Goldman, D
Siever, LJ
AF Perez-Rodriguez, M. Mercedes
Weinstein, Shauna
New, Antonia S.
Bevilacqua, Laura
Yuan, Qiaoping
Zhou, Zhifeng
Hodgkinson, Colin
Goodman, Marianne
Koenigsberg, Harold W.
Goldman, David
Siever, Larry J.
TI Tryptophan-hydroxylase 2 haplotype association with borderline
personality disorder and aggression in a sample of patients with
personality disorders and healthy controls
SO JOURNAL OF PSYCHIATRIC RESEARCH
LA English
DT Article
DE Borderline personality disorder; TPH2; Suicidal behavior; Affective
instability; Impulsive aggression
ID CENTRAL SEROTONERGIC FUNCTION; ISOFORM TPH2 GENE; IMPULSIVE-AGGRESSION;
PROLACTIN RESPONSE; D-FENFLURAMINE; CEREBROSPINAL-FLUID; VIOLENT
OFFENDERS; MAJOR DEPRESSION; TRANSMISSION DISEQUILIBRIUM; POLYMORPHIC
VARIANTS
AB Background There is a decreased serotonergic function in impulsive aggression and borderline personality disorder (BPD) and genetic association studies suggest a role of serotonergic genes in impulsive aggression and BPD Only one study has analyzed the association between the tryptophan-hydroxylase 2 (TPH2) gene and BPD A TPH2 "risk" haplotype has been described that is associated with anxiety depression and suicidal behavior
Methods We assessed the relationship between the previously identified risk" haplotype at the TPH2 locus and BPD diagnosis impulsive aggression affective lability and suicidal/parasuicidal behaviors in a well-characterized clinical sample of 103 healthy controls (HCs) and 251 patients with personality disorders (109 with BPD) A logistic regression including measures of depression affective lability and aggression scores in predicting risk" haplotype was conducted
Results The prevalence of the "risk" haplotype was significantly higher in patients with BPD compared to HCs Those with the "risk" haplotype have higher aggression and affect lability scores and more suicidal/parasuicidal behaviors than those without it In the logistic regression model affect lability was the only significant predictor and it correctly classified 83 1% of the subjects as risk or non-risk haplotype carriers
Conclusions We found an association between the previously described TPH2 risk haplotype and BPD diagnosis affective lability suicidal/parasuicidal behavior and aggression scores (C) 2010 Elsevier Ltd All rights reserved
C1 [Perez-Rodriguez, M. Mercedes; Weinstein, Shauna; New, Antonia S.; Goodman, Marianne; Koenigsberg, Harold W.; Siever, Larry J.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
[Weinstein, Shauna; New, Antonia S.; Goodman, Marianne; Koenigsberg, Harold W.; Siever, Larry J.] James J Peters Vet Affairs Med Ctr, Mental Hlth Patient Care Ctr, Bronx, NY 10468 USA.
[Bevilacqua, Laura; Yuan, Qiaoping; Zhou, Zhifeng; Hodgkinson, Colin; Goldman, David] NIAAA, Neurogenet Lab, NIH, Bethesda, MD 20892 USA.
RP Siever, LJ (reprint author), James J Peters Vet Adm Med Ctr, 3rd Floor,Room 3B,20 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
RI Perez Rodriguez, Maria/B-9410-2013; Goldman, David/F-9772-2010
OI Perez Rodriguez, Maria/0000-0001-5137-1993; Goldman,
David/0000-0002-1724-5405
FU National Institute of Mental Health [MH56140, MH63875]; Veterans Affairs
[7609-028, 9001-03-0051]; Veterans Affairs VISN 3 Mental Illness
Research Education & Clinical Center; National Center for Research
Resources (NCRR) [MO1-RR-00071]
FX This research was supported by Grants MH56140 & MH63875 from the
National Institute of Mental Health to Larry J Siever by a Veterans
Affairs Merit Review Grant (7609-028) to Larry J Siever and by the
Veterans Affairs VISN 3 Mental Illness Research Education & Clinical
Center; This publication was made possible by Grant Number MO1-RR-00071
from the National Center for Research Resources (NCRR) a component of
the National Institutes of Health (NIH) Its contents are solely the
responsibility of the authors and do not necessarily represent the
official views of NCRR or NIH; This work was supported in part by a VA
Merit award to Dr New (9001-03-0051) New (PI)- Intermediate Phenotypes
for Borderline Personality Disorder and a VA Career Development Award to
Dr Goodman
NR 78
TC 30
Z9 34
U1 1
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3956
J9 J PSYCHIATR RES
JI J. Psychiatr. Res.
PD NOV
PY 2010
VL 44
IS 15
BP 1075
EP 1081
DI 10.1016/j.jpsychires.2010.03.014
PG 7
WC Psychiatry
SC Psychiatry
GA 684RJ
UT WOS:000284566700013
PM 20451217
ER
PT J
AU Chen, DC
Xiu, MH
Liu, H
Zhang, BS
Wang, Y
Kosten, TR
Zhang, XY
AF Chen, Da Chun
Xiu, Mei Hong
Liu, Hong
Zhang, Ben Shu
Wang, Yu
Kosten, Thomas R.
Zhang, Xiang Yang
TI Reduced status of plasma total antioxidant capacity in schizophrenia
with tardive dyskinesia
SO JOURNAL OF PSYCHIATRIC RESEARCH
LA English
DT Letter
C1 [Zhang, Xiang Yang] Baylor Coll Med, VA Med Ctr, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
[Chen, Da Chun; Xiu, Mei Hong; Zhang, Xiang Yang] Beijing HuiLongGuan Hosp, Ctr Biol Psychiat, Beijing, Peoples R China.
[Liu, Hong; Zhang, Ben Shu; Wang, Yu] TianJin Med Univ, Dept Neurol, Tianjin, Peoples R China.
RP Zhang, XY (reprint author), Baylor Coll Med, VA Med Ctr, Menninger Dept Psychiat & Behav Sci, Res Bldg 109,Room 130,2002 Holcombe Blvd, Houston, TX 77030 USA.
NR 11
TC 5
Z9 5
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3956
J9 J PSYCHIATR RES
JI J. Psychiatr. Res.
PD NOV
PY 2010
VL 44
IS 15
BP 1111
EP 1112
DI 10.1016/j.jpsychires.2010.03.008
PG 2
WC Psychiatry
SC Psychiatry
GA 684RJ
UT WOS:000284566700019
PM 20398909
ER
PT J
AU Singh, JA
Mahowald, ML
Noorbaloochi, S
AF Singh, Jasvinder A.
Mahowald, Maren L.
Noorbaloochi, Siamak
TI Intraarticular Botulinum Toxin A for Refractory Painful Total Knee
Arthroplasty: A Randomized Controlled Trial
SO JOURNAL OF RHEUMATOLOGY
LA English
DT Article
DE TOTAL KNEE ARTHROPLASTY; INTRAARTICULAR; BOTULINUM TOXIN A; RANDOMIZED
CONTROLLED TRIAL; PAIN; FUNCTION
ID DOUBLE-BLIND; RHEUMATOID-ARTHRITIS; NEUROPATHIC PAIN; OUTCOME MEASURES;
CLINICAL-TRIAL; SUBSTANCE-P; RAT BLADDER; JOINT PAIN; OSTEOARTHRITIS;
INJECTIONS
AB Objective. To assess short-term efficacy of single intraarticular botulinum toxin (IA-BoNT/A) injection in patients with chronically painful total knee arthroplasty (TKA) in a randomized, placebo-controlled, triple-blind study.
Methods. Patients with chronic TKA pain (pain > 6 on 0-10 scale and > 6 months post-TKA) evaluated in and referred from orthopedic surgery clinics were recruited. The primary outcome, proportion of patients with clinically meaningful decrease of at least 2 points on 0-10 visual analog scale (VAS) for pain, was compared between treatment groups at 2 months using comparison of proportions test and for all efficacy timepoints (2, 3, and 4 months) using generalized estimating equations (GEE). Secondary outcomes of global assessment, function, and quality of life were compared using GEE, duration of pain relief by t-test, and adverse events by chi-square test.
Results. In total, 54 patients with 60 painful TKA were randomized, with main analyses restricted to one TKA per patient (49 TKA in 49 patients). Mean age was 67 years, 84% were men, and mean duration of TKA pain was 4.5 years. A significantly greater proportion of patients (71%) in the IA-BoNT/A group compared to IA-placebo (35%) achieved clinically meaningful reduction in VAS pain at 2 months (p = 0.028) and at all efficacy timepoints (p = 0.019). Duration of meaningful pain relief was significantly greater after IA-BoNT/A, 39.6 days (SD 50.4) compared to IA-placebo, 15.7 days (SD 22.6; p = 0.045). Statistically significantly better scores were seen in IA-BoNT/A vs IA-placebo for all efficacy timepoints for the following outcomes: "very much improved" on physician global assessment of change (p = 0.003); Western Ontario McMaster Osteoarthritis Index physical function (p = 0.026), stiffness (p = 0.004), and total scores (p = 0.024); and Short-Form 36 pain subscale score (p = 0.049). Number of total and serious adverse events was similar between groups, with no patients in either group with new objective motor or sensory deficits during followup.
Conclusion. In this single-center randomized trial, single IA-BoNT/A injection provided clinically meaningful short-term improvements in pain, global assessment, and function in patients with chronic painful TKA. A multicenter trial is needed to confirm these findings. (First Release September I 2010; J Rheumatol 2010;37:2377-86; doi:10.3899/jrheum.100336)
C1 [Singh, Jasvinder A.; Mahowald, Maren L.] Univ Minnesota, Vet Affairs Med Ctr, Rheumatol Sect, Med Serv, Minneapolis, MN USA.
Univ Minnesota, Vet Affairs Med Ctr, Div Rheumatol, Dept Med, Minneapolis, MN USA.
Univ Minnesota, Vet Affairs Med Ctr, Dept Med, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA.
[Singh, Jasvinder A.] Mayo Clin, Sch Med, Dept Hlth Sci Res, Rochester, MN USA.
[Singh, Jasvinder A.] Mayo Clin, Sch Med, Dept Orthoped, Rochester, MN USA.
[Singh, Jasvinder A.] Birmingham Vet Affairs Med Ctr, Birmingham, MN USA.
[Singh, Jasvinder A.] Univ Alabama, Fac Off Tower 805B, Birmingham, AL 35294 USA.
RP Singh, JA (reprint author), Univ Alabama, Fac Off Tower 805B, 510 20th St S, Birmingham, AL 35294 USA.
EM Jasvinder.md@gmail.com
RI teng, yj/C-4440-2011
OI singh, jasvinder/0000-0003-3485-0006
FU NIH CTSA [1 KL2 RR024151-01]; Arthritis Foundation North Central Chapter
Grant; University of Minnesota Academic Health Center; Minnesota Medical
Foundation; Allergan Pharmaceuticals, Irvine, CA
FX Supported by the NIH CTSA Award 1 KL2 RR024151-01 (Mayo Clinic Center
for Clinical and Thanslational Research), Arthritis Foundation North
Central Chapter Grant, University of Minnesota Academic Health Center
Seed Grant, and Minnesota Medical Foundation Grant. Dr. Singh and Dr
Mahowald have received research and travel grants from Allergan
Pharmaceuticals, Irvine, CA, for other research projects. Dr. Mahowald
served as a consultant to Allergan Pharmaceuticals.
NR 57
TC 17
Z9 18
U1 1
U2 5
PU J RHEUMATOL PUBL CO
PI TORONTO
PA 920 YONGE ST, SUITE 115, TORONTO, ONTARIO M4W 3C7, CANADA
SN 0315-162X
J9 J RHEUMATOL
JI J. Rheumatol.
PD NOV
PY 2010
VL 37
IS 11
BP 2377
EP 2386
DI 10.3899/jrheum.100336
PG 10
WC Rheumatology
SC Rheumatology
GA 681HL
UT WOS:000284301900030
PM 20810509
ER
PT J
AU Raval, MV
Bilimoria, KY
Bentrem, DJ
Stewart, AK
Ko, CY
Reynolds, M
Wayne, JD
AF Raval, Mehul V.
Bilimoria, Karl Y.
Bentrem, David J.
Stewart, Andrew K.
Ko, Clifford Y.
Reynolds, Marleta
Wayne, Jeffrey D.
TI Use of Sentinel Lymph Node Biopsy for Melanoma in Children and
Adolescents
SO JOURNAL OF SURGICAL ONCOLOGY
LA English
DT Article
DE melanoma; sentinel lymph node biopsy; pediatric oncology; pediatric
surgery; National Cancer Data Base
ID CANCER-DATA-BASE; UNITED-STATES; PEDIATRIC MELANOMA; MELANOCYTIC
LESIONS; MALIGNANT-MELANOMA; SINGLE-INSTITUTION; POPULATION;
EPIDEMIOLOGY; EXPERIENCE; SURVIVAL
AB Background: Though sentinel lymph node biopsy (SLNB) is an integral component of melanoma staging, little is known about its use in children
Methods: Patients (0-18 years) with melanoma diagnosed from 2003 to 2007 in the National Cancer Data Base were assessed Logistic regression models were used to identify clinicopathologic, socioeconomic, and hospital factors associated with SLNB use and lymph node metastases (LNM)
Results: 01 671 children, 68 7% underwent SLNB SLNB utilization rates were 39 9% for T1a patients and 87 6% for T1b-T3 patients T1b-T3 patients were more likely to undergo SLNB if they were older (OR 4 86 95% Cl 1 88-12 59) or cared for at Children's hospitals (OR 2 43 95% CI 1 09-5 40) T1b-T3 patients were less likely to undergo SLNB if uninsured (OR 0 25 95% CI 0 08-0 76) Of those with SLNB, 1 I 8 (25 6%) had pathologically confirmed LNM Patients were more likely to have LNM if younger (OR 3 19 95% Cl 1 20-8 51) or having higher T stage. (OR 10 38 95% CI 4 59-23 47)
Conclusions: SI,NB use for children with melanoma was associated with clinicopathologic. socioeconomic, and hospital factors Younger patients have a higher likelihood of LNM but are the least likely to undergo SLNB Though overall adherence appears high. there remains an opportunity for improved care for children with melanoma J. Surg Oncol 2010,102 634-639 (C) 2010 Wiley-Liss, Inc
C1 [Raval, Mehul V.; Bilimoria, Karl Y.; Stewart, Andrew K.; Ko, Clifford Y.] Amer Coll Surg, Canc Programs, Div Res & Optimal Patient Care, Chicago, IL USA.
[Raval, Mehul V.; Reynolds, Marleta] Childrens Mem Hosp, Div Pediat Surg, Chicago, IL 60614 USA.
[Raval, Mehul V.; Bilimoria, Karl Y.; Bentrem, David J.; Wayne, Jeffrey D.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Div Gastrointestinal & Oncol Surg, Chicago, IL 60611 USA.
[Bentrem, David J.] Jesse Brown VA Med Ctr, Chicago, IL USA.
[Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA.
[Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Raval, MV (reprint author), 633 N St Clair St,22nd Floor, Chicago, IL 60611 USA.
OI Raval, Mehul/0000-0002-1527-2661
FU John Gray Research Fellowship; Daniel F and Ada L Rice Foundation;
Northwestern University; Department of Veterans Affairs, Veterans Health
Administration, Health Services Research and Development Service;
American College of Surgeons, Commission on Cancer; American Cancer
Society
FX M V R participates in the American College of Surgeons Clinical Scholars
in Residence Program M V R is supported by the John Gray Research
Fellowship and the Daniel F and Ada L Rice Foundation. K Y B is
supported by a Priority Grant from Northwestern University D J B is
supported by a Career Development Award from the Department of Veterans
Affairs, Veterans Health Administration, Health Services Research and
Development Service The National Cancer Data Base is supported by the
American College of Surgeons, Commission on Cancer, and the American
Cancer Society
NR 43
TC 3
Z9 3
U1 0
U2 3
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0022-4790
J9 J SURG ONCOL
JI J. Surg. Oncol.
PD NOV 1
PY 2010
VL 102
IS 6
BP 634
EP 639
DI 10.1002/jso.21683
PG 6
WC Oncology; Surgery
SC Oncology; Surgery
GA 674OZ
UT WOS:000283758300018
PM 20721965
ER
PT J
AU Friedlander, AH
AF Friedlander, Arthur H.
TI Untitled
SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION
LA English
DT Letter
ID DENTAL PROCEDURES; ARTHROPLASTY
C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Friedlander, AH (reprint author), VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
NR 3
TC 0
Z9 0
U1 0
U2 0
PU AMER DENTAL ASSOC
PI CHICAGO
PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA
SN 0002-8177
J9 J AM DENT ASSOC
JI J. Am. Dent. Assoc.
PD NOV
PY 2010
VL 141
IS 11
BP 1295
EP 1296
PG 2
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 680OK
UT WOS:000284244100002
PM 21037183
ER
PT J
AU Alley, DE
Koster, A
Mackey, D
Cawthon, P
Ferrucci, L
Simonsick, EM
Yu, BB
Hardy, S
Goodpaster, B
Sarkisian, C
Houston, DK
Kritchevsky, SB
Cummings, S
Lee, JS
Tylavsky, FA
Newman, A
Harris, T
AF Alley, Dawn E.
Koster, Annemarie
Mackey, Dawn
Cawthon, Peggy
Ferrucci, Luigi
Simonsick, Eleanor M.
Yu, Binbing
Hardy, Susan
Goodpaster, Bret
Sarkisian, Catherine
Houston, Denise K.
Kritchevsky, Stephen B.
Cummings, Steven
Lee, Jung-Sun
Tylavsky, Frances A.
Newman, Anne
Harris, Tamara
CA Hlth Aging & Body Composition Stud
TI Hospitalization and Change in Body Composition and Strength in a
Population-Based Cohort of Older Persons
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE lean mass; weight loss; function; hospitalization; strength
ID BED REST; WEIGHT CHANGE; MUSCLE MASS; ADULTS; FRAILTY; HEALTH; WOMEN;
DISABILITY; MORTALITY; RECOVERY
AB OBJECTIVES: To examine the association between hospitalization and annual changes in body composition and strength in older adults.
DESIGN: Cohort study.
SETTING: Clinic examinations in Pittsburgh, Pennsylvania, or Memphis, Tennessee.
PARTICIPANTS: Well-functioning adults aged 70 to 79 who participated in the Health, Aging and Body Composition Study.
MEASUREMENTS: Hospitalizations were reported at annual clinic visits and in semiannual phone interviews. In the event of death or reported hospitalization, hospitalizations were adjudicated according to medical record review. Dual X-ray absorptiometry (DXA) assessments of total, lean, and fat mass were conducted in six annual examinations, and measures of knee extensor strength were conducted in two annual examinations.
RESULTS: DXA assessments followed 2,309 hospitalizations. In men and women, hospitalization in the previous year was associated with greater declines in total mass (- 0.76 and -0.81 kg, respectively), fat mass (-0.41 and -0.54 kg), and lean mass (-0.33 and -0.25 kg) (P < .001 for all) than in nonhospitalized participants, after adjustment for demographics and baseline values. Hospitalization was associated with strength declines in men (-4.02 Nm, P = .046) but not in women. Relationships were similar after adjusting for health behaviors and chronic conditions, although the association between hospitalization and strength was attenuated. Associations increased with number of days hospitalized; hospitalizations totaling 8 days or more in the previous year were associated with significantly greater loss of total, lean, and fat mass and loss of strength in both sexes than in nonhospitalized participants.
CONCLUSION: Hospitalization is associated with significant changes in body composition and strength in older persons. These effects appear particularly important in persons hospitalized for 8 or more days per year. J Am Geriatr Soc 58:2085-2091, 2010.
C1 [Alley, Dawn E.] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA.
[Koster, Annemarie; Yu, Binbing; Harris, Tamara] NIA, Lab Epidemiol Demog & Biometry, Bethesda, MD 20892 USA.
[Mackey, Dawn; Cawthon, Peggy; Cummings, Steven] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA.
[Ferrucci, Luigi; Simonsick, Eleanor M.] NIA, Longitudinal Studies Sect, Baltimore, MD 21224 USA.
[Hardy, Susan; Goodpaster, Bret; Newman, Anne] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
[Newman, Anne] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA USA.
[Sarkisian, Catherine] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA.
[Houston, Denise K.; Kritchevsky, Stephen B.] Wake Forest Univ, Bowman Gray Sch Med, Sticht Ctr Aging, Winston Salem, NC USA.
[Lee, Jung-Sun] Univ Georgia, Coll Publ Hlth, Athens, GA 30602 USA.
[Tylavsky, Frances A.] Univ Tennessee, Dept Epidemiol, Memphis, TN USA.
RP Alley, DE (reprint author), Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA.
EM dalley@epi.umaryland.edu
RI Koster, Annemarie/E-7438-2010; Newman, Anne/C-6408-2013
OI Newman, Anne/0000-0002-0106-1150; Kritchevsky,
Stephen/0000-0003-3336-6781
FU National Institutes of Health, National Institute on Aging (NIA);
Organized Research Center on Aging at the University of Maryland,
Baltimore; NIA [N01-AG-6-2101, N01-AG-6-2103, N01-AG-2106]
FX D. Houston received a speaker honorarium from Abbott Nutrition Health
Institute. All other authors have no financial disclosure to report.
This research was supported in part by the Intramural Research Program
of the National Institutes of Health, National Institute on Aging (NIA)
and by the Organized Research Center on Aging at the University of
Maryland, Baltimore. The Health ABC Study is funded under NIA Contracts
N01-AG-6-2101, N01-AG-6-2103, and N01-AG-2106.
NR 25
TC 22
Z9 23
U1 4
U2 9
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD NOV
PY 2010
VL 58
IS 11
BP 2085
EP 2091
DI 10.1111/j.1532-5415.2010.03144.x
PG 7
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 676WT
UT WOS:000283950100005
PM 21054288
ER
PT J
AU Hwang, U
Richardson, LD
Harris, B
Morrison, RS
AF Hwang, Ula
Richardson, Lynne D.
Harris, Ben
Morrison, R. Sean
TI The Quality of Emergency Department Pain Care for Older Adult Patients
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE emergency department; pain; quality of care; geriatrics
ID ELDERLY-PATIENTS; MEDICAL-RECORD; CANCER PAIN; MANAGEMENT; ANALGESIA;
DEMENTIA; FRACTURE
AB OBJECTIVES: To determine whether there are differences in emergency department (ED) pain assessment and treatment for older and younger adults.
DESIGN: Retrospective observational cohort.
SETTING: Urban, academic tertiary care ED during July and December 2005.
PARTICIPANTS: Adult patients with conditions warranting ED pain care.
MEASUREMENTS: Age, Charlson comorbidity score, number of prior medications, sex, race and ethnicity, triage severity, degree of pain, treating clinician, and final ED diagnosis. Pain care process measures were pain assessment and treatment and time of activities.
RESULTS: One thousand thirty-one ED visits met inclusion criteria; 92% of these had a documented pain assessment. Of those reporting pain, 41% had follow-up pain assessments, and 59% received analgesic medication (58% of these as opioids, 24% as nonsteroidal anti-inflammatory drugs (NSAIDs)). In adjusted analyses, there were no differences according to age in pain assessment and receiving any analgesic. Older patients (65-84) were less likely than younger patients (18-64) to receive opioid analgesics for moderate to severe (odds ratio (OR) 50.44, 95% confidence interval (CI) 50.22-0.88) and were more likely to more likely to receive NSAIDs for mild pain (OR = 3.72, 95% CI = 0.97-14.24). Older adults had a lower reduction of initial to final recorded pain scores (P = .002).
CONCLUSION: There appear to be differences in acute ED pain care for older and younger adults. Lower overall reduction of pain scores and less opioid use for the treatment of painful conditions in older patients highlight disparities of concern. Future studies should determine whether these differences represent inadequate ED pain care. J Am Geriatr Soc 58:2122-2128, 2010.
C1 [Hwang, Ula; Richardson, Lynne D.] Mt Sinai Sch Med, Dept Emergency Med, New York, NY 10029 USA.
[Hwang, Ula; Morrison, R. Sean] Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Med, New York, NY 10029 USA.
[Hwang, Ula; Morrison, R. Sean] James J Peters Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA.
[Harris, Ben] Univ Illinois, Dept Emergency Med, Advocate Christ Med Ctr, Oak Lawn, IL USA.
RP Hwang, U (reprint author), Mt Sinai Sch Med, Dept Emergency Med, 1 Gustave L Levy Pl,Box 1620, New York, NY 10029 USA.
EM ula.hwang@mountsinai.org
FU National Institute on Aging [K24 AG022345]; Jahnigen Career Development
Award
FX Ula Hwang was a recipient of a Jahnigen Career Development Award
administered by the American Geriatrics Society. R. Sean Morrison is a
recipient of a Mid-Career Investigator Award in Patient-Oriented
Research (K24 AG022345) from the National Institute on Aging.
NR 31
TC 33
Z9 33
U1 3
U2 8
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD NOV
PY 2010
VL 58
IS 11
BP 2122
EP 2128
DI 10.1111/j.1532-5415.2010.03152.x
PG 7
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 676WT
UT WOS:000283950100010
PM 21054293
ER
PT J
AU Espinoza, SE
Jung, I
Hazuda, H
AF Espinoza, Sara E.
Jung, Inkyung
Hazuda, Helen
TI Lower Frailty Incidence in Older Mexican Americans than in Older
European Americans: The San Antonio Longitudinal Study of Aging
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE frailty; ethnic differences; older adults
ID MINI-MENTAL-STATE; WOMENS HEALTH; ADULTS; ASSOCIATION; PHENOTYPE;
MORTALITY; PARADOX; INDEX; ADL
AB OBJECTIVES: To directly compare frailty incidence of older Mexican American (MA) and European American (EA) adults.
DESIGN: Longitudinal, observational cohort study.
SETTING: Socioeconomically diverse neighborhoods in San Antonio, Texas.
PARTICIPANTS: Three hundred one older MA and 305 older EA adults in the San Antonio Longitudinal Study of Aging (SALSA) who were nonfrail at baseline.
MEASUREMENTS: Frailty was assessed at baseline, and three follow-ups conducted over an average of 9.9 years using well-established criteria from the Cardiovascular Health Study. Covariates were baseline age, sex, socioeconomic status (SES), prefrailty status, diabetes mellitus, and comorbidity. The adjusted ethnic odds (MA vs EA) of incident frailty were estimated using generalized estimating equations.
RESULTS: There was no ethnic difference in the unadjusted incidence of frailty over the three follow-up examinations (odds ratio (OR) 50.97, 95% confidence interval (CI) 50.62-1.52), even though baseline SES was significantly lower in MAs than EAs. After covariate adjustment, the odds of incident frailty were significantly lower for MAs than EAs (OR = 0.40, 95% CI = 0.23-0.72). Other significant predictors of frailty in the adjusted model were prefrailty (present vs absent OR = 3.19, 95% CI = 1.86-5.47), education (1-year increment OR = 0.89, 95% CI = 0.83-0.96), and income (1-year increment OR = 0.88, 95% CI = 0.79-2.04).
CONCLUSION: These findings lend support to the Hispanic Paradox and suggest that MAs who live to older ages are less likely than similarly aged EAs to become frail. Further research is needed to identify the underlying biological and social mechanisms that explain this finding to enhance the development of interventions for the prevention and treatment of this clinical geriatric syndrome. J Am Geriatr Soc 58:2142-2148, 2010.
C1 [Espinoza, Sara E.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, Div Geriatr Gerontol & Palliat Med, San Antonio, TX 78229 USA.
[Espinoza, Sara E.; Hazuda, Helen] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Jung, Inkyung] Yonsei Univ, Coll Med, Dept Biostat, Seoul, South Korea.
[Espinoza, Sara E.; Hazuda, Helen] S Texas Vet Healthcare Syst, San Antonio, TX USA.
RP Espinoza, SE (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, Div Geriatr Gerontol & Palliat Med, 7703 Floyd Curl Dr,Mail Code 7875, San Antonio, TX 78229 USA.
EM espinozas2@uthscsa.edu
FU National Institute on Aging [R01-AG10444, R01-AG16518]; National Center
for Research Resources (NCRR) [M01-RR01345, KL2 RR025766]
FX Research support was received from National Institute on Aging Grants
R01-AG10444 and R01-AG16518 and National Center for Research Resources
(NCRR) Grant M01-RR01345. This work was also supported by Clinical and
Translational Science Awards Award KL2 RR025766 from NCRR.
NR 29
TC 18
Z9 21
U1 3
U2 7
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD NOV
PY 2010
VL 58
IS 11
BP 2142
EP 2148
DI 10.1111/j.1532-5415.2010.03153.x
PG 7
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 676WT
UT WOS:000283950100013
PM 21054295
ER
PT J
AU Al-Aly, Z
Zeringue, A
Fu, J
Rauchman, MI
McDonald, JR
El-Achkar, TM
Balasubramanian, S
Nurutdinova, D
Xian, H
Stroupe, K
Abbott, KC
Eisen, S
AF Al-Aly, Ziyad
Zeringue, Angelique
Fu, John
Rauchman, Michael I.
McDonald, Jay R.
El-Achkar, Tarek M.
Balasubramanian, Sumitra
Nurutdinova, Diaria
Xian, Hong
Stroupe, Kevin
Abbott, Kevin C.
Eisen, Seth
TI Rate of Kidney Function Decline Associates with Mortality
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID GLOMERULAR-FILTRATION-RATE; NONTRADITIONAL RISK-FACTORS;
CORONARY-HEART-DISEASE; REVERSE EPIDEMIOLOGY; RENAL-DISEASE;
UNITED-STATES; CARDIOVASCULAR OUTCOMES; VASCULAR CALCIFICATION;
DIABETES-MELLITUS; SERUM CREATININE
AB The effect of rate of decline of kidney function on risk for death is not well understood Using the Department of Veterans Affairs national databases, we retrospectively studied a cohort of 4171 patients who had rheumatoid arthritis and early stage 3 chronic kidney disease (CKD, estimated GFR 45 to 60 ml/min) and followed them longitudinally to characterize predictors of disease progression and the effect of rate of kidney function decline on mortality After a median of 2 6 years, 1604 (38%) maintained stable kidney function, 426 (10%), 1147 (28%), and 994 (24%) experienced mild moderate, and severe progression of CKD, respectively (defined as estimated GFR decline of 0 to 1, 1 to 4, and >4 ml/min per yr) Peripheral artery disease predicted moderate progression of CKD progression Black race, hypertension, diabetes, cardiovascular disease, and peripheral artery disease predicted severe progression of CKD After a median of 5 7 years, patients with severe progression had a significantly increased risk for mortality (hazard ratio 1 54 95% confidence interval 1 30 to 1 82) compared with those with mild progression, patients with moderate progression exhibited a similar trend (hazard ratio 1 10 95% confidence interval 0 98 to 1 30) Our results demonstrate an independent and graded association between the rate of kidney function decline and mortality Incorporating the rate of decline into the definition of CKD may transform a static definition into a dynamic one that more accurately describes the potential consequences of the disease for an individual
C1 [Al-Aly, Ziyad; Rauchman, Michael I.; El-Achkar, Tarek M.] St Louis Vet Affairs Med Ctr, Div Nephrol, St Louis, MO 63106 USA.
[Al-Aly, Ziyad; Zeringue, Angelique; Fu, John; McDonald, Jay R.; Balasubramanian, Sumitra; Nurutdinova, Diaria; Xian, Hong; Eisen, Seth] St Louis Vet Affairs Clin Res & Epidemiol Ctr, St Louis, MO USA.
[Fu, John] St Louis Univ, Div Biostat, Sch Publ Hlth, St Louis, MO 63103 USA.
[McDonald, Jay R.; Nurutdinova, Diaria] Washington Univ, Sch Med, Div Infect Dis, St Louis, MO 63110 USA.
[Stroupe, Kevin] Edward Hines Vet Affairs Med Ctr, Ctr Management Complex Chron Care, Hines, IL USA.
[Abbott, Kevin C.] Walter Reed Army Med Ctr, Div Nephrol, Washington, DC 20307 USA.
[Eisen, Seth] US Dept Vet Affairs, Washington, DC USA.
RP Al-Aly, Z (reprint author), St Louis Vet Affairs Med Ctr, Div Nephrol, 915 N Grand Blvd,111B JC, St Louis, MO 63106 USA.
RI Zeringue, Angelique/I-1755-2012; Al-Aly, Ziyad/S-4439-2016
OI Al-Aly, Ziyad/0000-0002-2600-0434; Abbott, Kevin/0000-0003-2111-7112
FU Department of Veterans Affairs [VISN 15]
FX This work was funded by a Department of Veterans Affairs VISN 15 Career
Development Award to Ziyad Al-Aly, M D
NR 48
TC 88
Z9 89
U1 1
U2 5
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD NOV
PY 2010
VL 21
IS 11
BP 1961
EP 1969
DI 10.1681/ASN.2009121210
PG 9
WC Urology & Nephrology
SC Urology & Nephrology
GA 689ZL
UT WOS:000284969500020
PM 20947634
ER
PT J
AU Victor, TL
Boone, KB
Kulick, AD
AF Victor, Tara L.
Boone, Kyle B.
Kulick, Alexis D.
TI My head hurts just thinking about it
SO JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY
LA English
DT Letter
ID EXAGGERATION
C1 [Victor, Tara L.] Calif State Univ Dominguez Hills, Dept Psychol, Carson, CA 90747 USA.
[Victor, Tara L.; Boone, Kyle B.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
[Boone, Kyle B.] Alliant Int Univ, Calif Sch Forens Studies, Alhambra, CA USA.
[Victor, Tara L.; Kulick, Alexis D.] Greater Los Angeles Vet Healthcare Syst, Dept Phys Med & Rehabil, Los Angeles, CA USA.
RP Victor, TL (reprint author), Calif State Univ Dominguez Hills, Dept Psychol, 1000 E Victoria St,SBS G305, Carson, CA 90747 USA.
NR 6
TC 3
Z9 3
U1 1
U2 2
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1355-6177
J9 J INT NEUROPSYCH SOC
JI J. Int. Neuropsychol. Soc.
PD NOV
PY 2010
VL 16
IS 6
BP 1151
EP 1152
DI 10.1017/S1355617710000858
PG 2
WC Clinical Neurology; Neurosciences; Psychiatry; Psychology
SC Neurosciences & Neurology; Psychiatry; Psychology
GA 690RL
UT WOS:000285023200023
PM 20673382
ER
PT J
AU Stelzner, F
Stelzner, M
AF Stelzner, Friedrich
Stelzner, Matthias
TI Manometry data support a novel concept of the lower esophageal sphincter
system
SO LANGENBECKS ARCHIVES OF SURGERY
LA English
DT Article
DE Esophagus; Sphincter; Manometry; Anatomy
ID IMPEDANCE CHARACTERISTICS; PARTIAL FUNDOPLICATION; ANTIREFLUX PROCEDURE;
MOTOR FUNCTION; ACHALASIA; NISSEN; DISTENSION; DIAPHRAGM; CARDIA; REFLUX
AB Purpose Detailed understanding of the functional anatomy of the lower esophageal sphincter (LES) is germane to successful surgical treatment of esophageal disorders. However, a comprehensive concept of the structure-function relationship of the LES is currently lacking.
Methods We reviewed published anatomic evidence, medical imaging, and impedance manometry data sets and developed a novel functional concept of the LES.
Results Morphologic evidence accumulated over the past three decades indicates that the LES is an anatomic structure that differs markedly from typical ring sphincters of the gastrointestinal tract (e.g., upper esophageal sphincter or anal sphincters). Recent impedance manometry investigations shed new light on the functional anatomy of the LES. These data corroborate a concept of this sphincter as a double-layer, twisted stretch sphincter. This sphincter requires tissue tension for optimal function. Retightening of the longitudinal stretch of the esophagus provides an effective therapy if this tension is lost, e.g., for patients with hiatal hernias. Paralysis of the muscle fibers of this sphincter system results in functional obstruction, and this explains the pathophysiology of "achalasia".
Conclusions Based on available data, we propose a novel concept that better explains the structure-function relationship of the LES. Improved knowledge of the biomechanical factors of esophageal disorders can be expected to advance surgical treatment for these diseases.
C1 [Stelzner, Friedrich] Univ Klinikum Bonn, Zentrum Chirurg, D-53105 Bonn, Germany.
[Stelzner, Friedrich] Univ Bonn, Med Ctr, Dept Surg, D-5300 Bonn, Germany.
[Stelzner, Matthias] Univ Calif Los Angeles, Surg Serv, VA Greater Angeles Healthcare Syst, Los Angeles, CA USA.
[Stelzner, Matthias] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA.
RP Stelzner, F (reprint author), Univ Klinikum Bonn, Zentrum Chirurg, Sigmund Freud Str 25, D-53105 Bonn, Germany.
EM Stel33345@aol.com
NR 32
TC 5
Z9 5
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1435-2443
J9 LANGENBECK ARCH SURG
JI Langenbecks Arch. Surg.
PD NOV
PY 2010
VL 395
IS 8
BP 1083
EP 1091
DI 10.1007/s00423-010-0662-x
PG 9
WC Surgery
SC Surgery
GA 679ZW
UT WOS:000284200300013
PM 20614132
ER
PT J
AU Marzo, SJ
Moeller, CW
Sharma, N
Cunningham, K
Jones, KJ
Foecking, EM
AF Marzo, Sam J.
Moeller, Carl W.
Sharma, Nijee
Cunningham, Kelly
Jones, Kathryn J.
Foecking, Eileen M.
TI Facial Motor Nuclei Cell Loss With Intratemporal Facial Nerve Crush
Injuries in Rats
SO LARYNGOSCOPE
LA English
DT Article
DE Facial nerve; facial motor nucleus; facial injury; facial crush injury;
rat facial nerve
ID POOR FUNCTIONAL RECOVERY; QUALITY-OF-LIFE; PERIPHERAL-NERVE;
ELECTRICAL-STIMULATION; CONTRIBUTING FACTORS; GONADAL-STEROIDS;
ADULT-RAT; REPAIR; MOTONEURONS; TRANSECTION
AB Objectives/Hypothesis: Injuries of cranial nerves that are distal to but near the motor nucleus might result in retrograde motoneuron cell death. The hypothesis of this article is that an intratemporal crush injury of the facial nerve in rats can cause facial motor nuclei cell death.
Study Design: Prospective, randomized, controlled animal study.
Methods: Sprague-Dawley rats were randomly divided into four groups: intratemporal sham, intratemporal crush injury, extratemporal crush injury, and extratemporal sham. The intratemporal (n = 9) and extratemporal crush injury (n = 4) groups underwent a 60-second crush of the nerve at the facial nerve tympanic segment or main facial nerve trunk distal to the stylomastoid foramen, respectively. The intratemporal sham group (n = 4) underwent identical exposure to the intratemporal crush without subsequent injury. Both sham groups and the extratemporal crush group were sacrificed at 4 weeks. The intratemporal crush group was subdivided into 4(n = 4) and 8-week (n = 5) postinjury groups. Brain sections were stained with thionin and facial motor nuclei were counted under magnification. The contralateral uninjured facial motor nucleus was used to compare motor nucleus cell survival.
Results: Intratemporal crush injury resulted in increased cell loss at 4 (89.43% +/- 8.57% standard error of mean) and 8 weeks (85.78% +/- 3.15%) after injury compared to sham injury (119.09% +/- 13.35%) (P < .05). No significant change in cell survival was noted between the distal crush (103.29% +/- 6.34%) and sham group (111.71% +/- 3.24%) (P > .05).
Conclusions: A rat intratemporal crush injury resulted in approximately 15% facial motor nuclei cell loss compared to an intratemporal sham injury. An extratemporal crush injury did not lead to any significant facial motor nuclei cell loss. This might have future translational implications in humans with intratemporal facial nerve injuries.
C1 [Marzo, Sam J.; Moeller, Carl W.; Cunningham, Kelly; Jones, Kathryn J.; Foecking, Eileen M.] Loyola Univ Chicago, Stritch Sch Med, Dept Otolaryngol Head & Neck Surg, Maywood, IL USA.
[Sharma, Nijee] Loyola Univ Chicago, Stritch Sch Med, Dept Neurosci, Maywood, IL USA.
[Jones, Kathryn J.] Loyola Univ Chicago, Stritch Sch Med, Dept Cell Biol Neurobiol & Anat, Maywood, IL USA.
[Jones, Kathryn J.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res & Dev Serv, Hines, IL 60141 USA.
RP Marzo, SJ (reprint author), Loyola Univ Hlth Syst, Div Otol Neurotol & Skull Base Surg, Dept Otolaryngol Head & Neck Surg, 2160 S 1st Ave, Maywood, IL 60153 USA.
EM smarzo@lumc.edu
FU Loyola Otolaryngology Research Fund [B6175R]
FX The work was supported by the VA Pilot Grant (No. B6175R), Loyola
Otolaryngology Research Fund. The authors have no other funding,
financial relationships, or conflicts of interest to disclose.
NR 50
TC 4
Z9 4
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0023-852X
J9 LARYNGOSCOPE
JI Laryngoscope
PD NOV
PY 2010
VL 120
IS 11
BP 2264
EP 2269
DI 10.1002/lary.21077
PG 6
WC Medicine, Research & Experimental; Otorhinolaryngology
SC Research & Experimental Medicine; Otorhinolaryngology
GA 673FI
UT WOS:000283644100024
PM 20830757
ER
PT J
AU Maciejewski, ML
Smith, VA
Livingston, EH
Kavee, AL
Kahwati, LC
Henderson, WG
Arterburn, DE
AF Maciejewski, Matthew L.
Smith, Valerie A.
Livingston, Edward H.
Kavee, Andrew L.
Kahwati, Leila C.
Henderson, William G.
Arterburn, David E.
TI Health Care Utilization and Expenditure Changes Associated With
Bariatric Surgery
SO MEDICAL CARE
LA English
DT Article
DE bariatric; surgery; expenditures; cost; utilization; veterans; weight
loss
ID LONG-TERM MORTALITY; MORBIDLY OBESE-PATIENTS; GASTRIC BYPASS-SURGERY;
OF-VETERANS-AFFAIRS; RISK ADJUSTMENT; SURGICAL CARE; COSTS; OUTCOMES;
QUALITY; IMPACT
AB Context: Bariatric surgery provides significant reductions in weight and comorbidity, and has the potential to reduce health care utilization. It is unknown whether health care utilization and expenditures are reduced for veterans after bariatric surgery.
Objectives: To examine health care utilization and expenditures of severely obese individuals before and after bariatric surgery within the Veterans Health Administration.
Design, Setting, and Patients: We conducted a retrospective, longitudinal cohort study of health care use and expenditures among all veterans who underwent bariatric surgery in 1 of 12 approved Department of Veterans Affairs bariatric centers from 2000 to 2006. Bariatric patients were identified via Current Procedural Terminology-4 codes from a database of major surgical procedures maintained by the National Surgical Quality Improvement Program.
Main Outcome Measure: The main outcomes of interest for our analysis were multivariable adjusted inpatient and outpatient health care utilization and expenditures in the 3 years prior to surgery and in the 3 years after surgery.
Results: Between 2000 and 2006, 846 veterans had bariatric surgery, 25% of whom underwent a laparoscopic procedure. The mean initial body mass index was 48.5, the mean age was 51; and 73% were male. In multivariable models including all years of data, outpatient, inpatient, and overall expenditures significantly decreased in the years after surgery because of higher clinical resources required in the months before and during surgery. When excluding the 6 months leading up to surgery and the 6 months just after surgery, outpatient expenditures remained lower in the post-surgical period, but inpatient and overall expenditures were significantly higher.
Conclusion: Our analyses indicate that this cohort of older, male bariatric surgery patients does not achieve a reduction in health care expenditures 3 years after their procedure. These results are at variance from other, similar published studies and may reflect differences in study populations or systems of care.
C1 [Maciejewski, Matthew L.; Smith, Valerie A.; Kavee, Andrew L.] Durham VA Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC 27705 USA.
[Maciejewski, Matthew L.] Duke Univ, Med Ctr, Div Gen Internal Med, Durham, NC 27710 USA.
[Livingston, Edward H.] Univ Texas SW Med Ctr Dallas, Div Gastrointestinal & Endocrine Surg, Dallas, TX 75390 USA.
[Livingston, Edward H.] Vet Adm N Texas Hlth Care Syst, Dallas, TX USA.
[Livingston, Edward H.] Univ Texas Arlington, Arlington, TX 76019 USA.
[Kahwati, Leila C.] Natl Ctr Hlth Promot & Dis Prevent, Dept Vet Affairs, Off Patient Care Serv, Durham, NC USA.
[Henderson, William G.] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Henderson, William G.] Univ Colorado, Sch Publ Hlth, Dept Biostat, Aurora, CO USA.
[Henderson, William G.] Univ Colorado, Colorado Hlth Outcomes Program, Aurora, CO USA.
[Arterburn, David E.] Grp Hlth Res Inst Seattle, Seattle, WA USA.
[Arterburn, David E.] Univ Washington, Dept Med, Div Gen Internal Med, Seattle, WA USA.
RP Maciejewski, ML (reprint author), Durham VA Med Ctr, Ctr Hlth Serv Res Primary Care 152, 411 W Chapel Hill St,Suite 600, Durham, NC 27705 USA.
EM matthew.maciejewski@va.gov
FU Office of Research and Development, Health Services Research and
Development Service, Department of Veterans Affairs [IIR 05-201]; Takeda
Pharmaceuticals; Surgical Review Corporation; Amgen; Texas Instruments
FX Supported by the Office of Research and Development, Health Services
Research and Development Service, Department of Veterans Affairs,
project number IIR 05-201. Supported by Takeda Pharmaceuticals and the
Surgical Review Corporation, and owns stock in Amgen (to M. L. M.) and
from Texas Instruments, and he serves as a contributing editor to JAMA
(to E. H. L.).
NR 34
TC 15
Z9 15
U1 4
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
J9 MED CARE
JI Med. Care
PD NOV
PY 2010
VL 48
IS 11
BP 989
EP 998
DI 10.1097/MLR.0b013e3181ef9cf7
PG 10
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 671HB
UT WOS:000283490600007
PM 20940651
ER
PT J
AU Stallard, E
Kinosian, B
Zbrozek, AS
Yashin, AI
Glick, HA
Stern, Y
AF Stallard, Eric
Kinosian, Bruce
Zbrozek, Arthur S.
Yashin, Anatoliy I.
Glick, Henry A.
Stern, Yaakov
TI Estimation and Validation of a Multiattribute Model of Alzheimer Disease
Progression
SO MEDICAL DECISION MAKING
LA English
DT Article
DE clinical assessment; outcomes; staging of dementia
ID GLOBAL DETERIORATION SCALE; COST-EFFECTIVENESS; DEMENTIA; PREDICTORS;
MEMBERSHIP; SELECTION; FEATURES; GRADE; TIME; CARE
AB Objectives. To estimate and validate a multiattribute model of the clinical course of Alzheimer disease (AD) from mild AD to death in a high-quality prospective cohort study, and to estimate the impact of hypothetical modifications to AD progression rates on costs associated with Medicare and Medicaid services. Data and Methods. The authors estimated sex-specific longitudinal Grade of Membership (GoM) models for AD patients (103 men, 149 women) in the initial cohort of the Predictors Study (1989-2001) based on 80 individual measures obtained every 6 mo for 10 y. These models were replicated for AD patients (106 men, 148 women) in the 2nd Predictors Study cohort (1997-2007). Model validation required that the disease-specific transition parameters be identical for both Predictors Study cohorts. Medicare costs were estimated from the National Long Term Care Survey. Results. Sex-specific models were validated using the 2nd Predictors Study cohort with the GoM transition parameters constrained to the values estimated for the 1st Predictors Study cohort; 57 to 61 of the 80 individual measures contributed significantly to the GoM models. Simulated, cost-free interventions in the rate of progression of AD indicated that large potential cost offsets could occur for patients at the earliest stages of AD. Conclusions. AD progression is characterized by a small number of parameters governing changes in large numbers of correlated indicators of AD severity. The analysis confirmed that the progression of AD represents a complex multidimensional physiological process that is similar across different study cohorts. The estimates suggested that there could be large cost offsets to Medicare and Medicaid from the slowing of AD progression among patients with mild AD. The methodology appears generally applicable in AD modeling.
C1 [Stallard, Eric; Yashin, Anatoliy I.] Duke Univ, Dept Sociol, Durham, NC 27706 USA.
[Stallard, Eric; Yashin, Anatoliy I.] Duke Univ, Ctr Populat Hlth & Aging, Durham, NC USA.
[Kinosian, Bruce; Glick, Henry A.] Univ Penn Hlth Syst, Div Gen Internal Med, Philadelphia, PA USA.
[Kinosian, Bruce] Philadelphia VA Med Ctr, CHERP, Philadelphia, PA USA.
[Zbrozek, Arthur S.] Wyeth Pharmaceut, Global Hlth Outcomes Assessment, Collegeville, PA USA.
[Stern, Yaakov] Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA.
[Stern, Yaakov] Columbia Univ Coll Phys & Surg, Gertrude H Sergievsky Ctr, New York, NY 10032 USA.
[Stern, Yaakov] Columbia Univ Coll Phys & Surg, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY 10032 USA.
RP Kinosian, B (reprint author), Ralston House,Rm226,3615 Chestnut St, Philadelphia, PA 19104 USA.
EM brucek@mail.med.upenn.edu
FU Elan Pharmaceuticals; Wyeth Pharmaceuticals; National Institute on Aging
[R01-AG028259, R01-AG030612, R01-AG07370]
FX The primary financial support for this study was provided by a grant
jointly funded by Elan Pharmaceuticals and Wyeth Pharmaceuticals.
Funding for supplemental analysis of the National Long Term Care Survey
was provided by the National Institute on Aging through grants
R01-AG028259 and R01-AG030612. The Predictors Study is supported by a
grant to Dr. Stern from the National Institute on Aging, grant
R01-AG07370. The funding agreements ensured the authors' independence in
designing the study, interpreting the data, and writing and publishing
the report. The following author is employed by a primary sponsor:
Arthur S. Zbrozek, Wyeth Pharmaceuticals. The helpful comments of Trent
McLaughlin, PhD, Elan Pharmaceuticals, on this article are acknowledged.
David L. Straley provided programming support at Duke University.
Revision accepted for publication 6 January 2010.
NR 35
TC 9
Z9 9
U1 0
U2 5
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0272-989X
J9 MED DECIS MAKING
JI Med. Decis. Mak.
PD NOV-DEC
PY 2010
VL 30
IS 6
BP 625
EP 638
DI 10.1177/0272989X10363479
PG 14
WC Health Care Sciences & Services; Medical Informatics
SC Health Care Sciences & Services; Medical Informatics
GA 698FU
UT WOS:000285580100001
PM 21183754
ER
PT J
AU Hickam, DH
AF Hickam, David H.
TI Decision Aids: Evolving From Novelties to Effective Communication Tools
SO MEDICAL DECISION MAKING
LA English
DT Editorial Material
ID CHRONIC ILLNESS; MANAGEMENT
C1 Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97239 USA.
RP Hickam, DH (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM hickam@ohsu.edu
NR 8
TC 0
Z9 0
U1 0
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0272-989X
J9 MED DECIS MAKING
JI Med. Decis. Mak.
PD NOV-DEC
PY 2010
VL 30
IS 6
BP 699
EP 700
DI 10.1177/0272989X10387782
PG 2
WC Health Care Sciences & Services; Medical Informatics
SC Health Care Sciences & Services; Medical Informatics
GA 698FU
UT WOS:000285580100009
PM 21183757
ER
PT J
AU Naik, AD
Singh, H
AF Naik, Aanand D.
Singh, Hardeep
TI Electronic Health Records to Coordinate Decision Making for Complex
Patients: What Can We Learn from Wiki?
SO MEDICAL DECISION MAKING
LA English
DT Article
DE decision making; communication; electronic health records; disease
management; reviews; quality and safety
ID PRIMARY-CARE; EFFECTIVE COMMUNICATION; INFORMATION-TECHNOLOGY;
SURVIVORSHIP CARE; MANAGEMENT; OUTCOMES; TRIALS; ERRORS
AB Background. Processes of communication that guide decision making among clinicians collaboratively caring for complex patients are poorly understood and vary based on local contexts. In this paper, the authors characterize these processes and propose a wiki-style communication model to improve coordination of decision making among clinicians using an integrated electronic health record (EHR). Methods. A narrative review of current patterns of communication among clinicians sharing medical decisions focusing on the emerging and potential roles of EHRs to enhance communication among clinicians caring for complex patients. Results. The authors present the taxonomy of decision making and communication among clinicians caring for complex patients. They then adapt wiki-style communication to propose a novel model of communication among clinicians for decision making within multidisciplinary disease management programs. Future innovations using wiki-style communication among clinicians are also described and placed in the context of medical decisions by clinicians working together in disease management programs. Conclusions. EHR-based wiki-style applications may have the potential to improve communication and care coordination among clinicians caring for complex patients. This could lead to improved quality and safety within multidisciplinary disease management programs.
C1 [Naik, Aanand D.] Baylor Coll Med, Hlth Decis Making & Commun Program, Houston Hlth Serv Res & Dev Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Naik, Aanand D.; Singh, Hardeep] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA.
[Singh, Hardeep] Baylor Coll Med, Hlth Policy & Qual Program, Houston Hlth Serv Res & Dev Ctr Excellence, Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA.
[Naik, Aanand D.; Singh, Hardeep] Baylor Coll Med, John M Eisenberg Ctr Clin Decis & Commun Sci, Houston, TX 77030 USA.
RP Naik, AD (reprint author), Houston HSR& Ctr Excellence, Michael E DeBakey VA 152,2002 Holcombe Blvd, Houston, TX 77030 USA.
EM anaik@bcm.tmc.edu
FU NCI NIH HHS [K23CA125585]; NIA NIH HHS [K23AG027144]
NR 36
TC 16
Z9 16
U1 4
U2 8
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0272-989X
J9 MED DECIS MAKING
JI Med. Decis. Mak.
PD NOV-DEC
PY 2010
VL 30
IS 6
BP 722
EP 731
DI 10.1177/0272989X10385846
PG 10
WC Health Care Sciences & Services; Medical Informatics
SC Health Care Sciences & Services; Medical Informatics
GA 698FU
UT WOS:000285580100012
PM 21183759
ER
PT J
AU Weisbord, SD
Palevsky, PM
AF Weisbord, Steven D.
Palevsky, Paul M.
TI ACUTE KIDNEY INJURY Kidney injury after contrast media: marker or
mediator?
SO NATURE REVIEWS NEPHROLOGY
LA English
DT News Item
ID ACUTE-RENAL-FAILURE; CORONARY INTERVENTION; INDUCED NEPHROPATHY;
CYSTATIN-C; MORTALITY
C1 [Weisbord, Steven D.; Palevsky, Paul M.] Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15240 USA.
RP Weisbord, SD (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Univ Dr, Pittsburgh, PA 15240 USA.
EM weisbordsd@upmc.edu
OI Palevsky, Paul/0000-0002-7334-5400
NR 10
TC 6
Z9 6
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-5061
J9 NAT REV NEPHROL
JI Nat. Rev. Nephrol.
PD NOV
PY 2010
VL 6
IS 11
BP 634
EP 636
DI 10.1038/nrneph.2010.129
PG 4
WC Urology & Nephrology
SC Urology & Nephrology
GA 671VQ
UT WOS:000283539900002
PM 20981117
ER
PT J
AU Handforth, A
Homanics, GE
Covey, DF
Krishnan, K
Lee, JY
Sakimura, K
Martin, FC
Quesada, A
AF Handforth, Adrian
Homanics, Gregg E.
Covey, Douglas F.
Krishnan, Kathiresan
Lee, Jae Yeol
Sakimura, Kenji
Martin, Fredricka C.
Quesada, Arnulfo
TI T-type calcium channel antagonists suppress tremor in two mouse models
of essential tremor
SO NEUROPHARMACOLOGY
LA English
DT Article
DE Essential tremor; Harmaline; Ethosuximide; Zonisamide; Calcium channel;
Cerebellum; Inferior olive
ID HARMALINE-INDUCED TREMOR; RAT SENSORY NEURONS; ABSENCE SEIZURES; GABA(A)
RECEPTOR; CEREBELLAR NEURONS; CA2+ CURRENT; ZONISAMIDE; ANTICONVULSANT;
BLOCKADE; MICE
AB Essential tremor is a common disorder that lacks molecular targets for therapeutic development. 1-type calcium channel activation has been postulated to underlie rhythmicity in the olivo-cerebellar system that is implicated in essential tremor. We therefore tested whether compounds that antagonize T-type calcium channel currents suppress tremor in two mouse models that possess an essential tremor-like pharmacological response profile. Tremor was measured using digitized spectral motion power analysis with harmaline-induced tremor and in the GABA(A) receptor alpha 1 subunit-null model. Mice were given ethosuximide, zonisamide, the neuroactive steroid (3 beta,5 alpha,17 beta)-17-hydroxyestrane-3-carbonitrile (ECN), the 3,4-dihydroquinazoline derivative KYS05064, the mibefradil derivative NNC 55-0396, or vehicle. In non-sedating doses, each compound reduced harmaline-induced tremor by at least 50% (range of maximal suppression: 53-81%), and in the GABA(A) alpha 1-null model by at least 70% (range 70-93%). Because the 1-type calcium channel Cav3.1 is the dominant subtype expressed in the inferior olive, we assessed the tremor response of Cav3.1-deficient mice to harmaline, and found that null and heterozygote mice exhibit as much tremor as wild-type mice. In addition, ECN and NNC 55-0396 suppressed harmaline tremor as well in Cav3.1-null mice as in wild-type mice. The finding that five 1-type calcium antagonists suppress tremor in two animal tremor models suggests that 1-type calcium channels may be an appropriate target for essential tremor therapy development. It is uncertain whether medications developed to block only the Cav3.1 subtype would exhibit efficacy. Published by Elsevier Ltd.
C1 [Handforth, Adrian] Vet Affairs Greater Los Angeles Healthcare Syst, Neurol Serv W127, Los Angeles, CA 90073 USA.
[Homanics, Gregg E.] Univ Pittsburgh, Dept Anesthesiol & Pharmacol, Pittsburgh, PA USA.
[Homanics, Gregg E.] Univ Pittsburgh, Dept Biol Chem, Pittsburgh, PA USA.
[Covey, Douglas F.; Krishnan, Kathiresan] Washington Univ, Sch Med, Dept Dev Biol, St Louis, MO USA.
[Lee, Jae Yeol] Kyung Hee Univ, Coll Sci, Res Inst Basic Sci, Seoul, South Korea.
[Lee, Jae Yeol] Kyung Hee Univ, Coll Sci, Dept Chem, Seoul, South Korea.
[Sakimura, Kenji] Niigata Univ, Brain Res Inst, Dept Cellular Neurobiol, Niigata, Japan.
[Martin, Fredricka C.; Quesada, Arnulfo] Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA.
[Quesada, Arnulfo] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA.
RP Handforth, A (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Neurol Serv W127, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM charles.handforth@va.gov
OI Homanics, Gregg/0000-0003-3641-8153; Lee, Jae Yeol/0000-0001-6622-6692
FU International Essential Tremor Foundation; Ralph M. Parsons Foundation;
Veterans Affairs; NIH [AA10422, GM47969]; Korea Institute of Science and
Technology
FX Cav3.1 mice embryos were provided by the Riken BRC through the National
Bio-Resource Project of the MEXT, Japan. This work was supported by the
International Essential Tremor Foundation (AQ), The Ralph M. Parsons
Foundation, Veterans Affairs (AH), NIH AA10422 (GEH), NIH GM47969 (DFC),
and Vision 21 Program, Korea Institute of Science and Technology (JYL).
We are grateful for the technical assistance of Brandon Bunker, Ana
Artero, and Christopher Shin.
NR 42
TC 21
Z9 21
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0028-3908
J9 NEUROPHARMACOLOGY
JI Neuropharmacology
PD NOV
PY 2010
VL 59
IS 6
BP 380
EP 387
DI 10.1016/j.neuropharm.2010.05.012
PG 8
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 670UR
UT WOS:000283453300003
PM 20547167
ER
PT J
AU Harner, H
Hanlon, AL
Garfinkel, M
AF Harner, Holly
Hanlon, Alexandra L.
Garfinkel, Marian
TI Effect of Iyengar Yoga on Mental Health of Incarcerated Women: A
Feasibility Study
SO NURSING RESEARCH
LA English
DT Article
DE incarcerated women; mental health; prison; yoga
ID PSYCHIATRIC-DISORDERS; STRESS REDUCTION; DEPRESSION; OSTEOARTHRITIS;
INTERVENTION; PREVALENCE; INVENTORY; SYMPTOMS
AB Background: Incarcerated women share a disproportionate burden of mental illness. Although psychotropic medications are available to women in prison, adjunctive treatment modalities, such as Iyengar yoga, may increase psychological well-being.
Objectives: The purposes of this study were (a) to address the feasibility of providing a gender-responsive exercise intervention within a correctional institution and (b) to observe the effect of a group-format Iyengar yoga program that met two sessions a week for 12 weeks on levels of depression symptoms, anxiety symptoms, and perceived stress among incarcerated women.
Methods: A repeated measures design, in which each participant served as her own control, was used. Participants completed three self-administered instruments: the Beck Depression Inventory, the Beck Anxiety Inventory, and the Perceived Stress Scale before treatment (baseline) and during treatment (Weeks 4, 8, and 12). Linear mixed effects models were used to examine statistically significant changes in mental health measures over time, taking advantage of all available data.
Results: Although 21 women initially participated in the intervention, 6 women completed the 12-week intervention. A significant linear decrease was demonstrated in symptoms of depression over time, with mean values changing from 24.90 at baseline to 5.67 at Week 12. There was a marginally significant decrease in anxiety over time (12.00 at baseline to 7.33 at Week 12) and a nonlinear change in stress over time, with decreases from baseline to Week 4 and subsequent increases to Week 12.
Discussion: Women who participated in this program experienced fewer symptoms of depression and anxiety over time. Findings from this study may be used to improve future interventions focusing on the health outcomes of incarcerated women.
C1 [Harner, Holly] Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA.
[Garfinkel, Marian] Temple Sch Med, Philadelphia, PA USA.
[Garfinkel, Marian] Temple Univ, Sch Podiatr Med, Philadelphia, PA 19122 USA.
RP Harner, H (reprint author), La Salle Univ, Sch Nursing & Hlth Sci, Philadelphia, PA 19141 USA.
EM harner@lasalle.edu
FU Boston College; Center for Health Equity Research at the University of
Pennsylvania School of Nursing
FX This research was supported by a research incentive grant from Boston
College. The authors acknowledge the guidance of Iyengar yoga instructor
Ms. Louise Colby and the research assistance from Angela Hou Liang, MSN,
WHCNP-BC, and Meggie Gavin Galligan RN, BSN. The authors also thank the
Center for Health Equity Research at the University of Pennsylvania
School of Nursing for supporting the preparation of this manuscript.
NR 35
TC 12
Z9 13
U1 3
U2 16
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0029-6562
J9 NURS RES
JI Nurs. Res.
PD NOV-DEC
PY 2010
VL 59
IS 6
BP 389
EP 399
DI 10.1097/NNR.0b013e3181f2e6ff
PG 11
WC Nursing
SC Nursing
GA 675CH
UT WOS:000283802200004
PM 20842067
ER
PT J
AU Madison, DL
Lundblad, JR
AF Madison, D. L.
Lundblad, J. R.
TI C-terminal binding protein and poly(ADP)ribose polymerase 1 contribute
to repression of the p21(waf1/cip1) promoter
SO ONCOGENE
LA English
DT Article
DE Poly(ADP)ribose Polymerase; p21; CtBP; PARP inhibitor
ID POLY(ADP-RIBOSE) POLYMERASE-1; GENE-EXPRESSION; ADENOVIRUS E1A; CELLULAR
PHOSPHOPROTEIN; COREPRESSOR FUNCTION; NEGATIVE MODULATION;
IONIZING-RADIATION; CANCER-CELLS; DNA-DAMAGE; TRANSCRIPTION
AB Transcriptional repression by the C-terminal binding protein (CtBP) is proposed to require nicotinamide adenine dinucleotide dehydrogenase (NAD(H). Previous studies have implicated CtBP in transcriptional repression of the p21(waf1/cip1) gene. Similarly, the NAD-dependent poly(adenosine diphosphate) ribose polymerase 1 (PARP1) may affect p21 expression via its NAD-dependent enzymatic activity; we therefore asked if PARP1 and CtBP were functionally linked in regulating p21 transcription. We found that restraint of basal p21 transcription requires both CtBP and PARP1. PARP inhibition attenuated activation of p21 transcription by both p53-independent and p53-dependent processes, in a CtBP-dependent manner. CtBP1 + 2 or PARP1 + 2 knockdown partially activated p21 gene expression, suggesting relief of a corepressor function dependent on both proteins. We localized CtBP-responsive repression elements to the proximal promoter region, and found ZBRK1 overexpression could also overcome DNA damage-dependent, but not p53-dependent activation through this region. By chromatin immunoprecipitation we find dismissal of CtBP from the proximal promoter following DNA-damage, and that PARP1 associates with a CtBP corepressor complex in nuclear extracts. We propose a model in which both CtBP and PARP functionally interact in a corepressor complex as components of a molecular switch necessary for p21 repression, and following DNA damage signals activation of p21 transcription by corepressor dismissal and coactivator recruitment. Oncogene (2010) 29, 6027-6039; doi:10.1038/onc.2010.338; published online 16 August 2010
C1 [Madison, D. L.; Lundblad, J. R.] Oregon Hlth & Sci Univ, Div Endocrinol, Dept Med, Portland, OR 97239 USA.
[Madison, D. L.] Portland VA Med Ctr, Endocrine Sect, Dept Hosp & Specialty Med, Portland, OR USA.
RP Madison, DL (reprint author), Oregon Hlth & Sci Univ, Div Endocrinol, Dept Med, L-604,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM Madisond@ohsu.edu
FU [NIDDK R01DK060133]; [NCI K08CA109158]
FX This work as supported by Grants (NIDDK R01DK060133) to JRL and DLM (NCI
K08CA109158). We thank J Hildebrand (University of Pittsburgh) for the
CtBP MEFs, R Klein (OHSU) for access to and assistance with real time
PCR, R Kwok (University of Michigan) for the p53 expression construct
and Madeleine Pham and Loren Brown for technical assistance.
NR 52
TC 10
Z9 10
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD NOV
PY 2010
VL 29
IS 45
BP 6027
EP 6039
DI 10.1038/onc.2010.338
PG 13
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
GA 678VA
UT WOS:000284108700005
PM 20711239
ER
PT J
AU George, M
Margolis, ML
AF George, Maureen
Margolis, Mitchell L.
TI Race and Lung Cancer Surgery-A Qualitative Analysis of Relevant Beliefs
and Management Preferences
SO ONCOLOGY NURSING FORUM
LA English
DT Article
ID ALTERNATIVE MEDICINE USE; AFRICAN-AMERICAN ADULTS; FOCUS GROUPS;
LOW-INCOME; BREAST-CANCER; COMPLEMENTARY THERAPIES; RACIAL DISPARITIES;
PROSTATE-CANCER; ASTHMA; WOMEN
AB Purpose/Objectives: To gain a better understanding of beliefs about the utility of lung cancer resection surgery and preferences for lung cancer management among African American and Caucasian adults.
Research Approach: Qualitative.
Setting: The Philadelphia Veterans Affairs Medical Center.
Participants: 21 participants (9 African Americans and 12 Caucasians; 11 with chronic obstructive pulmonary disease and 10 with lung-cancer).
Methodologic Approach: Three focus groups were conducted. Transcripts and field notes were coded, grouped into thematic categories, and explored in later focus groups.
Main Research Variables: Beliefs about lung cancer resection surgery and management preferences.
Findings: African Americans doubted that surgery was needed, questioned its efficacy, and preferred complementary and alternative medicine (CAM). African Americans and Caucasians believed that exposure to air during surgery could cause tumor spread and were skeptical that smoking caused lung cancer. Therefore, they had a sense of treatment futility. Conversely, Caucasians were impatient with forced waiting for surgery. Both groups believed that surgery would be better accepted if current patients met past surgical patients, obtained second opinions, and had trusting patient-provider relationships.
Conclusions: Suspicion about surgeons' motives and perceived ineffectiveness of surgery, as well as support for CAM among African Americans, may contribute to key racial disparities in lung cancer care.
Interpretation: If providers understand more clearly the beliefs and preferences that impede acceptance of surgical resection, then they can formulate educational interventions directed at overcoming patient resistance. The clinical utility of such individualized interventions could be evaluated in future studies.
C1 [George, Maureen] Univ Penn, Sch Nursing, Ctr Hlth Dispar Res, Family & Community Hlth Div, Philadelphia, PA 19104 USA.
[Margolis, Mitchell L.] Univ Penn, Med Ctr, Philadelphia Vet Affairs Med Ctr, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104 USA.
RP George, M (reprint author), Univ Penn, Sch Nursing, Ctr Hlth Dispar Res, Family & Community Hlth Div, Philadelphia, PA 19104 USA.
EM mgeorge@nursing.upenn.edu
FU Center for Health Equity Research and Promotion [LIP 72-011]
FX Maureen George, PhD, RN, AE-C, is an assistant professor in the Family
and Community Health Division, Center for Health Disparities Research,
in the School of Nursing at the University of Pennsylvania, and Mitchell
L. Margolis, MD, is a clinical associate professor of medicine in the
Pulmonary, Allergy, and Critical Care Division of the Philadelphia
Veterans Affairs Medical Center at the University of Pennsylvania
Medical Center, both in Philadelphia. This study was supported by a
grant from the Center for Health Equity Research and Promotion [LIP
72-011]. George can be reached at mgeorge@nursing.upenn.edu, with copy
to editor at ONEEditor@ons.org. (Submitted August 2009. Accepted for
publication October, 21, 2009.)
NR 46
TC 14
Z9 14
U1 2
U2 6
PU ONCOLOGY NURSING SOC
PI PITTSBURGH
PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA
SN 0190-535X
J9 ONCOL NURS FORUM
JI Oncol. Nurs. Forum
PD NOV
PY 2010
VL 37
IS 6
BP 740
EP 748
DI 10.1188/10.ONF.740-748
PG 9
WC Oncology; Nursing
SC Oncology; Nursing
GA 680SR
UT WOS:000284255200009
PM 21059585
ER
PT J
AU Mukherjee, R
Huang, W
Tepikin, AV
Gukovskaya, A
Criddle, DN
Sutton, R
AF Mukherjee, R.
Huang, W.
Tepikin, A. V.
Gukovskaya, A.
Criddle, D. N.
Sutton, R.
TI Alisporivir (Deb025) Prevents Necrosis in and Decreases the Severity of
Experimental Pancreatitis
SO PANCREAS
LA English
DT Meeting Abstract
C1 [Mukherjee, R.; Huang, W.; Tepikin, A. V.; Criddle, D. N.] Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England.
[Mukherjee, R.; Huang, W.; Sutton, R.] Royal Liverpool Univ Hosp, NIHR Pancreas Biomed Res Unit, Liverpool, Merseyside, England.
[Gukovskaya, A.] Univ Calif Los Angeles, Los Angeles, CA 90024 USA.
[Gukovskaya, A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0885-3177
J9 PANCREAS
JI Pancreas
PD NOV
PY 2010
VL 39
IS 8
BP 1335
EP 1335
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 664FU
UT WOS:000282946600160
ER
PT J
AU Rakonczay, Z
Biczo, G
Dosa, S
Shalbuyeva, N
Hracsko, Z
Kukor, Z
Venglovecz, V
Varga, IS
Ivanyi, B
Wittmann, T
Gukovskaya, A
Takacs, T
Hegyi, P
AF Rakonczay, Z., Jr.
Biczo, G.
Dosa, S.
Shalbuyeva, N.
Hracsko, Z.
Kukor, Z.
Venglovecz, V.
Varga, I. S.
Ivanyi, B.
Wittmann, T.
Gukovskaya, A.
Takacs, T.
Hegyi, P.
TI Mitochondial Injury Precedes NF-kappa B and Premature Trypsinogen
Activation in L-lysine-induced Acute Pancreatitis in Rats
SO PANCREAS
LA English
DT Meeting Abstract
C1 [Rakonczay, Z., Jr.; Biczo, G.; Wittmann, T.; Takacs, T.; Hegyi, P.] Univ Szeged, Dept Med 1, Szeged, Hungary.
[Dosa, S.; Ivanyi, B.] Univ Szeged, Dept Pathol, Szeged, Hungary.
[Hracsko, Z.; Varga, I. S.] Univ Szeged, Dept Biochem & Mol Biol, Szeged, Hungary.
[Venglovecz, V.] Univ Szeged, Dept Pharmacol & Pharmacotherapy, Szeged, Hungary.
[Shalbuyeva, N.; Gukovskaya, A.] Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Kukor, Z.] Semmelweis Univ, Dept Med Chem Mol Biol & Pathobiochem, H-1085 Budapest, Hungary.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0885-3177
J9 PANCREAS
JI Pancreas
PD NOV
PY 2010
VL 39
IS 8
BP 1342
EP 1342
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 664FU
UT WOS:000282946600188
ER
PT J
AU Mukherjee, R
McQuinn, TC
Dugan, MA
Saul, JP
Spinale, FG
AF Mukherjee, Rupak
McQuinn, Tim C.
Dugan, Melissa A.
Saul, J. Philip
Spinale, Francis G.
TI Cardiac Function and Circulating Cytokines After Endotoxin Exposure in
Neonatal Mice
SO PEDIATRIC RESEARCH
LA English
DT Article
ID FLOW CARDIOPULMONARY BYPASS; ARTERIAL SWITCH OPERATION; INDUCED ORGAN
DAMAGE; N-ACETYLCYSTEINE; OXIDATIVE STRESS; INFLAMMATORY RESPONSE;
CARDIOPLEGIC ARREST; INNATE IMMUNITY; CONSCIOUS RATS; SHOCK
AB Complications after cardiac surgery in neonates can occur because of activation of the inflammatory system. This study used lipopolysaccharide (LPS) endotoxin exposure to cause cytokine activation in neonatal mice and examine left ventricular (LV) function and the effects of antioxidant treatment on cytokine levels. Neonatal mice (6 d old) were injected with either 25 mg/kg LPS (n = 13) or PBS (n = 14), and LV function (echocardiography) was measured at 4 h. Plasma levels of TNF-alpha, IL-4, IL-6, and IL-10 were measured at 30 min, I, 2, and 4 h after injection (a = 5 mice per group). Effects of pretreatment with N-acetylcysteine (NAC, 50 mg/kg) on cytokine levels were examined at 2 and 4 h after PBS or LPS (n = 5 mice per group). Four hours after LPS, heart rate was increased (434 +/- 14 versus 405 +/- 14 bpm, p < 0.05). LV end-diastolic dimension and ejection time were reduced with LPS (both p < 0.05). LPS exposure increased plasma TNF-alpha IL-6, and IL-10 levels. NAC pretreatment attenuated the increases in TNF-alpha and IL-6 levels, but augmented IL-10 levels at 2 h post-LPS. LPS exposure altered cardiac performance and activated cytokines in neonatal mice, which may be ameliorated using antioxidants. (Pediatr Res 68: 381-386, 2010)
C1 [Mukherjee, Rupak; Spinale, Francis G.] Med Univ S Carolina, Div Cardiothorac Surg, Charleston, SC 29425 USA.
[Mukherjee, Rupak; McQuinn, Tim C.; Dugan, Melissa A.; Saul, J. Philip] Med Univ S Carolina, Div Pediat Cardiol, Charleston, SC 29425 USA.
[Spinale, Francis G.] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA.
RP Mukherjee, R (reprint author), Med Univ S Carolina, Div Cardiothorac Surg, Strom Thurmond Res Bldg,770 MUSC Complex,Suite 62, Charleston, SC 29425 USA.
EM mukherr@musc.edu
FU National Heart, Lung, and Blood Institute [HL-45024, HL-97012,
PO1-48788]; VA; Division of Pediatric Cardiology
FX Supported, in part, by Grants HL-45024, HL-97012, and PO1-48788 from
National Heart, Lung, and Blood Institute, a VA Merit Award [to F.G.S.],
and departmental funds from the Division of Pediatric Cardiology.
NR 40
TC 9
Z9 10
U1 0
U2 1
PU INT PEDIATRIC RESEARCH FOUNDATION, INC
PI BALTIMORE
PA 351 W CAMDEN ST, BALTIMORE, MD 21201-2436 USA
SN 0031-3998
J9 PEDIATR RES
JI Pediatr. Res.
PD NOV
PY 2010
VL 68
IS 5
BP 381
EP 386
PG 6
WC Pediatrics
SC Pediatrics
GA 670GR
UT WOS:000283409700003
PM 20613681
ER
PT J
AU Figlewicz, DP
Sipols, AJ
AF Figlewicz, Dianne P.
Sipols, Alfred J.
TI Energy regulatory signals and food reward
SO PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
LA English
DT Review
DE Insulin; Leptin; Ghrelin; Motivation; Food intake; Reward; Dopamine
ID VENTRAL TEGMENTAL AREA; BLOOD-BRAIN-BARRIER; MELANIN-CONCENTRATING
HORMONE; HYPOTHALAMIC NEUROPEPTIDE-Y; CENTRAL-NERVOUS-SYSTEM; HIGH-FAT
DIET; LEPTIN-RESPONSIVE NEURONS; OPIOID RECEPTOR-BINDING;
NUCLEUS-ACCUMBENS SHELL; AGOUTI-RELATED PEPTIDE
AB The hormones insulin leptin and ghrelin have been demonstrated to act in the central nervous system (CNS) as regulators of energy homeostasis acting at medial hypothalamic sites Here we summarize research demonstrating that in addition to direct homeostatic actions at the hypothalamus CNS circuitry that subserves reward and is also a direct and indirect target for the action of these endocrine regulator, of energy homeostasis Specifically insulin and leptin can decrease food reward behaviors and modulate the function of neurotransmitter systems and neural circuitry that mediate food reward the midbrain dopamine (DA) and opioidergic pathways Ghrelin can increase food reward behaviors and support midbrain DA neuronal function We summarize discussion of behavioral systems and cellular evidence in support of the contributions of reward circuitry to the homeostatic roles of these hormones in the CNS The understanding of neuroendocrine modulation of food reward as well as food reward modulation by diet and obesity may point to new directions for therapeutic approaches to overeating or eating disorders Published by Elsevier Inc
C1 [Figlewicz, Dianne P.] VA Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA 98108 USA.
[Figlewicz, Dianne P.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Sipols, Alfred J.] Univ Latvia, Fac Med, LV-1586 Riga, Latvia.
[Sipols, Alfred J.] Univ Latvia, Inst Expt & Clin Med, LV-1586 Riga, Latvia.
RP Figlewicz, DP (reprint author), VA Puget Sound Hlth Care Syst, Seattle Div, 1660 S Columbian Way, Seattle, WA 98108 USA.
FU Dept of Veterans Affairs; NIH [DK40963]; University of Latvia
[Y2-ZP84-003]
FX This work is supported by a Career Scientist Award from the Dept of
Veterans Affairs and NIH Grant DK40963 (DPF) and a University of Latvia
Grant Y2-ZP84-003 (AJS)
NR 249
TC 64
Z9 65
U1 2
U2 16
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0091-3057
J9 PHARMACOL BIOCHEM BE
JI Pharmacol. Biochem. Behav.
PD NOV
PY 2010
VL 97
IS 1
SI SI
BP 15
EP 24
DI 10.1016/j.pbb.2010.03.002
PG 10
WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy
SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy
GA 689YA
UT WOS:000284965800003
PM 20230849
ER
PT J
AU Lee, TJ
AF Lee, Timothy J.
TI Pharmacologic Treatment for Low Back Pain: One Component of Pain Care
SO PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA
LA English
DT Article
DE Low back pain; Acetaminophen; Nonsteroidal anti-inflammatory drugs;
Muscle relaxants; Antidepressants; Antiepileptics; Opioids
ID OPIOID PRESCRIPTIONS; PROGNOSIS; THERAPY; TRIAL; COST
AB Analgesic medications are commonly used for low back pain (LBP) Evidence on the efficacy of pharmacologic therapy for LBP comes from clinical trials that have many limitations including short-term studies and selective trial populations Evidence currently supports the use of short-term pharmacologic treatment for LBP However the safety and efficacy of long-term pharmacologic therapy for LBP is uncertain and therefore best used with caution monitoring and as one component of a comprehensive paincare approach emphasizing rehabilitation
C1 VA Puget Sound, Seattle, WA 98108 USA.
RP Lee, TJ (reprint author), VA Puget Sound, 1660 S Columbian Way, Seattle, WA 98108 USA.
NR 20
TC 5
Z9 5
U1 1
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1047-9651
J9 PHYS MED REH CLIN N
JI Phys. Med. Rehabil. Clin. N. Am.
PD NOV
PY 2010
VL 21
IS 4
BP 793
EP +
DI 10.1016/j.pmr.2010.06.013
PG 9
WC Rehabilitation
SC Rehabilitation
GA 687PJ
UT WOS:000284790100009
PM 20977961
ER
PT J
AU Stout, A
AF Stout, Alison
TI Interventions for Low Back Pain Conclusions
SO PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA
LA English
DT Editorial Material
C1 [Stout, Alison] Univ Washington, Dept Rehabil, Spine & Musculoskeletal Med Rehabil Care Serv, Vet Adm Puget Sound, Seattle, WA 98195 USA.
[Stout, Alison] VA Puget Sound HCS, Dept Rehabil, Seattle, WA 98108 USA.
RP Stout, A (reprint author), Univ Washington, Dept Rehabil, Spine & Musculoskeletal Med Rehabil Care Serv, Vet Adm Puget Sound, Seattle, WA 98195 USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1047-9651
J9 PHYS MED REH CLIN N
JI Phys. Med. Rehabil. Clin. N. Am.
PD NOV
PY 2010
VL 21
IS 4
BP 817
EP 817
DI 10.1016/j.pmr.2010.08.003
PG 1
WC Rehabilitation
SC Rehabilitation
GA 687PJ
UT WOS:000284790100011
PM 20977963
ER
PT J
AU Stout, A
AF Stout, Alison
TI Epidural Steroid Injections for Low Back Pain
SO PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA
LA English
DT Article
DE Epidural steroid; Spine intervention; Lumbar; Transforaminal;
Interlaminar; Caudal; Low back pain; Low back pain treatment
ID SPINAL STENOSIS; RADICULAR PAIN; LUMBOSACRAL RADICULOPATHY;
NITRIC-OXIDE; DOUBLE-BLIND; SCIATICA; INTERLAMINAR; EFFICACY; DISC;
HERNIATIONS
AB Epidural steroid injection (ESI) has been used as a treatment for low back pain for over 50 years In the last 10 to 15 years, there has been a significant increase in the use of ESIs for the treatment of low back pain and radicular pain without clear improvements in outcomes Recent literature has focused on the use of ESIs as treatment for radicular pain associated with low back pain with some studies showing benefit over control groups for limb symptoms There is a lack of literature, however, to support the use of ESIs for the treatment of axial low back pain The theoretical basis for their use technical considerations and the literature available for different approaches of access to the epidural space as pertaining to the treatment for low back pain without radiculopathy are reviewed
C1 [Stout, Alison] Univ Washington, Dept Rehabil, Seattle, WA 98195 USA.
RP Stout, A (reprint author), VA Puget Sound HCS, Rehabil Care Serv, 117 RCS,1660 S Columbian Way, Seattle, WA 98108 USA.
NR 51
TC 10
Z9 12
U1 0
U2 4
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1047-9651
J9 PHYS MED REH CLIN N
JI Phys. Med. Rehabil. Clin. N. Am.
PD NOV
PY 2010
VL 21
IS 4
BP 825
EP +
DI 10.1016/j.pmr.2010.08.001
PG 11
WC Rehabilitation
SC Rehabilitation
GA 687PJ
UT WOS:000284790100013
PM 20977965
ER
PT J
AU Stout, A
AF Stout, Alison
TI Discography
SO PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA
LA English
DT Article
DE Discography; Spine intervention; Lumbar disc; Low back pain; Low back
pain treatment
ID LOW-BACK-PAIN; LUMBAR DISCOGRAPHY; ASYMPTOMATIC SUBJECTS; PROVOCATIVE
DISCOGRAPHY; INTERVERTEBRAL DISC; SYMPTOMS; SPINE; DEGENERATION; FUSION;
RATES
AB Discography is a purely diagnostic interventional procedure performed to confirm or refute the hypothesis that a specific lumbar disc is the predominant source of a patient's low back pain In patients with severe low back pain, unresponsive to conservative care discography is used when clinical evaluation suggests that the pain is emanating from the intervertebral disc and other sources of pain have been ruled out The evidence for its use remains controversial There is variability and subjectivity in discography techniques and diagnostic criteria making some investigators question its validity When standardized diagnostic criteria are used, however, the specificity of discography improves dramatically Recently long-term side effects have been studied and lumbar discography seems to increase disc degeneration and herniation as detected on magnetic resonance imaging Although the clinical significance is unclear it is an important risk to consider prior to performing discography and changes in discography techniques may be indicated Discography remains the only technique, however that can be used to determine whether a patient's low back pain is emanating from the intervertebral disc and is a valid test when coupled with careful patient selection strict adherence to standardized technique and diagnostic criteria and consideration of possible long-term sequelae
C1 [Stout, Alison] Vet Affairs Puget Sound Hlth Care Syst, Dept Rehabil, Rehabil Care Serv, Seattle, WA 98108 USA.
[Stout, Alison] Univ Washington, Dept Rehabil, Seattle, WA 98195 USA.
[Stout, Alison] Univ Washington, Spine & Musculoskeletal Med Rehabil Care Serv, Vet Adm Puget Sound, Dept Rehabil, Seattle, WA 98195 USA.
RP Stout, A (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Dept Rehabil, Rehabil Care Serv, 117 RCS,1660 S Columbian Way, Seattle, WA 98108 USA.
NR 29
TC 7
Z9 8
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1047-9651
J9 PHYS MED REH CLIN N
JI Phys. Med. Rehabil. Clin. N. Am.
PD NOV
PY 2010
VL 21
IS 4
BP 859
EP +
DI 10.1016/j.pmr.2010.07.002
PG 10
WC Rehabilitation
SC Rehabilitation
GA 687PJ
UT WOS:000284790100017
PM 20977969
ER
PT J
AU Stineman, MG
Streim, JE
AF Stineman, Margaret Grace
Streim, Joel E.
TI The Biopsycho-ecological Paradigm: A Foundational Theory for Medicine
SO PM&R
LA English
DT Review
AB The current biomedical and psychosocial frameworks that form the conceptual basis of medicine today are insufficient to address the needs of the medically complex and environmentally challenged populations of patients often cared for by physical medicine and rehabilitation specialists. The expanded biopsycho-ecological model of health, illness, injury, and disability operating through mechanisms of Health Environmental Integration (HEI) encourages a more complete understanding of illness, injury, activity limitation, and participation restriction as arising at the interface between the person and the environment. HEI recognizes complex interacting multilevel functional hierarchies beginning at the cellular level and ending at the individual's experience of the environment. Although the foci of illness and injury are within the body and mind, the physical and social environments contain elements that can cause or exacerbate disease and barriers that interact in ways that lead to injuries and disabilities. Furthermore, these environments hold the elements from which treating agents, facilitators, and social supports must be fashioned. The highly integrative biopsycho-ecological framework provides an expanded basis for understanding the objective causes and subjective meanings of disabilities. Disabilities are reduced through HEI by seeking to maximally integrate the body and mind (the self) with both the surrounding physical environment and other people in society. HEI offers mechanisms for interdisciplinary research, an expanded framework for education and empowerment, and a blueprint for optimizing day-to-day clinical care at both the individual patient and treatment population levels in the ever-changing scientific, political, and policy environments. PM R 2010;2:1035-1045
C1 [Stineman, Margaret Grace] Ctr Clin Epidemiol & Biostat, Dept Phys Med & Rehabil, Philadelphia, PA 19104 USA.
[Streim, Joel E.] Univ Penn, Geriatr Psychiat Sect, Philadelphia, PA 19104 USA.
[Streim, Joel E.] Philadelphia Vet Affairs Med Ctr, VISN Mental Illness Res Clin & Educ Ctr 4, Philadelphia, PA USA.
RP Stineman, MG (reprint author), Ctr Clin Epidemiol & Biostat, Dept Phys Med & Rehabil, 904 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM mstinema@mail.med.upenn.edu
FU NIH [R01-AG032420]
FX This work was supported in part by grant R01-AG032420 from the NIH.
NR 93
TC 19
Z9 20
U1 2
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1934-1482
J9 PM&R
JI PM&R
PD NOV
PY 2010
VL 2
IS 11
BP 1035
EP 1045
DI 10.1016/j.pmrj.2010.06.013
PG 11
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA V24LS
UT WOS:000208412500008
PM 21093839
ER
PT J
AU Rotondi, AJ
Anderson, CM
Haas, GL
Eack, SM
Spring, MB
Ganguli, R
Newhill, C
Rosenstock, J
AF Rotondi, Armando J.
Anderson, Carol M.
Haas, Gretchen L.
Eack, Shaun M.
Spring, Michael B.
Ganguli, Rohan
Newhill, Christina
Rosenstock, Jason
TI Web-Based Psychoeducational Intervention for Persons With Schizophrenia
and Their Supporters: One-Year Outcomes
SO PSYCHIATRIC SERVICES
LA English
DT Article
ID PSYCHIATRIC-INPATIENTS; FAMILY MANAGEMENT; FEASIBILITY; RELAPSE;
METAANALYSIS; PREVENTION; ILLNESS; CARE
AB Objective: This study examined the use of a uniquely designed Web site and home computers to deliver online multifamily psychoeducational therapy to persons with schizophrenia and their informal supports (family and friends). Web site usage and outcome benefits are reported. Methods: Thirty-one persons with schizophrenia or schizoaffective disorder and 24 support persons were randomly assigned to the online intervention (telehealth) or treatment as usual (usual care) condition. At three, six, and 12 months, interviewer-administered assessments were conducted with participants. Intention-to-treat analyses compared persons with schizophrenia in the two study conditions on severity of positive symptoms and knowledge of schizophrenia. Support persons in the two study conditions were compared on knowledge of schizophrenia. Each participant's usage of the Web site was logged. Results: Persons with schizophrenia in the telehealth condition had a large and significant reduction in positive symptoms (p=.042, d=-.88) and a large and significant increase in knowledge of schizophrenia compared with their counterparts in the usual care condition. Support persons in the telehealth condition showed a large and significant increase in knowledge about prognosis compared with those in the usual care condition (p=.036, d=1.94). Persons with schizophrenia used the Web site to a much greater extent (pages viewed and time spent) than support persons. Conclusions: These findings suggest that online delivery of psychotherapeutic treatment and educational resources to consumers' homes has considerable potential to improve consumer well-being and offers several advantages over standard clinic-based delivery models. (Psychiatric Services 61: 1099-1105, 2010)
C1 [Rotondi, Armando J.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15260 USA.
[Eack, Shaun M.; Newhill, Christina] Univ Pittsburgh, Dept Social Work, Pittsburgh, PA 15260 USA.
[Spring, Michael B.] Univ Pittsburgh, Dept Informat Sci, Pittsburgh, PA 15260 USA.
[Anderson, Carol M.; Haas, Gretchen L.; Ganguli, Rohan; Rosenstock, Jason] Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA 15260 USA.
[Rotondi, Armando J.; Haas, Gretchen L.] Vet Affairs Pittsburgh Healthcare Syst, Vet Integrated Serv Network 4, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA.
RP Rotondi, AJ (reprint author), Univ Pittsburgh, Dept Crit Care Med, 644 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15260 USA.
EM rotondi@pitt.edu
RI lyp, maggie/G-1471-2011
FU National Institute of Mental Health [R01 MH63484]; Abbott Laboratories;
Bristol Myers-Squibb
FX This project was supported by grant R01 MH63484 from the National
Institute of Mental Health.; Dr. Eack receives consulting fees from
Abbott Laboratories. Dr. Ganguli is a consultant for Janssen
Pharmaceuticals, Johnson & Johnson, and Eli Lilly and Company, and he
works under a research grant funded by Bristol MyersSquibb. The other
authors report no competing interests.
NR 38
TC 57
Z9 57
U1 6
U2 25
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD NOV
PY 2010
VL 61
IS 11
BP 1099
EP 1105
PG 7
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 673IA
UT WOS:000283651500010
PM 21041348
ER
PT J
AU Herbst, E
Metzler, TJ
Lenoci, M
McCaslin, SE
Inslicht, S
Marmar, CR
Neylan, TC
AF Herbst, Ellen
Metzler, Thomas J.
Lenoci, Maryann
McCaslin, Shannon E.
Inslicht, Sabra
Marmar, Charles R.
Neylan, Thomas C.
TI Adaptation effects to sleep studies in participants with and without
chronic posttraumatic stress disorder
SO PSYCHOPHYSIOLOGY
LA English
DT Article
DE Posttraumatic stress disorder; Adaptation effects; First night effect;
Ambulatory polysomnography
ID ADMINISTERED PTSD SCALE; PITUITARY-ADRENAL AXIS; LABORATORY ADAPTATION;
VIETNAM VETERANS; NIGHT; HOME; DISTURBANCES; VARIABILITY; PARAMETERS;
INSOMNIACS
AB The "first night effect" (FNE) is the alteration of sleep architecture observed on the first night of polysomnographic (PSG) studies. It is unclear whether the FNE reflects adaptation to the equipment, sleeping environment, or both. Moreover, it is possible that certain patient populations, such as those with posttraumatic stress disorder (PTSD), demonstrate greater adaptation effects that are highly context dependent. We assessed FNE in participants with PTSD and healthy controls in a cross-sectional study consisting of PSG testing at home and in the hospital. Contrary to our expectations, the PTSD group showed no adaptation effects in either setting. Only the control group assigned to the "hospital first" condition showed significant decreases in total sleep time on night 1 versus night 2 of the study. The results suggest that the FNE is related to adaptation to the combination of the hospital environment and the recording equipment.
C1 [Herbst, Ellen; Metzler, Thomas J.; McCaslin, Shannon E.; Inslicht, Sabra; Marmar, Charles R.; Neylan, Thomas C.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Herbst, Ellen; Metzler, Thomas J.; Lenoci, Maryann; McCaslin, Shannon E.; Inslicht, Sabra; Marmar, Charles R.; Neylan, Thomas C.] San Francisco VA Med Ctr, Psychiat Serv, San Francisco, CA USA.
RP Neylan, TC (reprint author), VA Med Ctr, Psychiat Serv 116P, PTSD Program, 4150 Clement St, San Francisco, CA 94121 USA.
EM Thomas.Neylan@ucsf.edu
FU National Institutes of Health [MH057157, MH73978]; Sierra Pacific Mental
Illness and Education Clinical Center (MIRECC); NIH/NCRRUCSF-CTSI [UL1
RR024131]
FX This work was supported by the National Institutes of Health (TCN:
MH057157 & MH73978), the Sierra Pacific Mental Illness and Education
Clinical Center (MIRECC), and from the NIH/NCRRUCSF-CTSI Grant Number
UL1 RR024131. Its contents are solely the responsibility of the authors
and do not necessarily represent the official views of the NIH.
NR 36
TC 11
Z9 12
U1 1
U2 4
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0048-5772
J9 PSYCHOPHYSIOLOGY
JI Psychophysiology
PD NOV
PY 2010
VL 47
IS 6
BP 1127
EP 1133
DI 10.1111/j.1469-8986.2010.01030.x
PG 7
WC Psychology, Biological; Neurosciences; Physiology; Psychology;
Psychology, Experimental
SC Psychology; Neurosciences & Neurology; Physiology
GA 663HU
UT WOS:000282874800016
PM 20456661
ER
PT J
AU Li, HK
Florez-Arango, JF
Hubbard, LD
Esquivel, A
Danis, RP
Krupinski, EA
AF Li, Helen K.
Florez-Arango, Jose F.
Hubbard, Larry D.
Esquivel, Adol
Danis, Ronald P.
Krupinski, Elizabeth A.
TI GRADING DIABETIC RETINOPATHY SEVERITY FROM COMPRESSED DIGITAL RETINAL
IMAGES COMPARED WITH UNCOMPRESSED IMAGES AND FILM
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE classification; diabetic retinopathy; digital; film; fundus photography;
image compression; JND; JPEG2000; just-noticeable difference;
reproducibility; telemedicine
ID VISUAL-SYSTEM MODEL; COPY MAMMOGRAPHY DISPLAY; OBSERVER PERFORMANCE;
PHOTOGRAPHY; DIAGNOSIS; JPEG; TELEOPHTHALMOLOGY; TELEMEDICINE; CRT
AB Purpose: To compare research grading of diabetic retinopathy (DR) severity level from compressed digital images versus uncompressed images and film.
Methods: Compressed (JPEG2000, 37:1) digital images (C) were compared with uncompressed digital (U) and film (F) stereoscopic photographs from a 152-eye cohort with full-spectrum Early Treatment Diabetic Retinopathy Study severity levels for agreement on severity level, DR presence with ascending severity threshold, presence of DR index lesions, and repeatability of grading.
Results: Classification of Early Treatment Diabetic Retinopathy Study severity levels from C images agreed substantially with results from F images (kappa = 0.60, kappa(w) [linear weighted] = 0.86) and uncompressed digital images (kappa = 0.76, kappa(w) = 0.92). For agreement of uncompressed digital versus F images, kappa = 0.62 and kappa(w) = 0.86. Distribution of Early Treatment Diabetic Retinopathy Study levels was not significantly different between C and F images (P = 0.09, Bhapkar's test for marginal homogeneity). For presence/absence of DR at 8 ascending severity thresholds, agreement between C and F was "almost perfect'' (kappa >= 0.8). Agreement on severity level between readers with C images was at least as good as that with uncompressed digital image or F. Repeatability of severity threshold grading between readers was similar using C or F images. For identifying individual DR lesions, agreement between C and F ranged from "moderate'' to "perfect.'' Agreement of grading venous beading from C was slightly lower than from F.
Conclusion: Full Early Treatment Diabetic Retinopathy Study scale DR severity level grading using C images is comparable to that using U images or film. RETINA 30:1651-1661, 2010
C1 [Li, Helen K.] Thomas Jefferson Univ, Dept Ophthalmol, Philadelphia, PA 19107 USA.
[Li, Helen K.; Florez-Arango, Jose F.] Univ Texas Hlth Sci Ctr, Sch Biomed Informat, Houston, TX USA.
[Florez-Arango, Jose F.] Univ Antioquia, Sch Med, Medellin, Colombia.
[Hubbard, Larry D.; Danis, Ronald P.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA.
[Esquivel, Adol] Baylor Coll Med, Houston Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Krupinski, Elizabeth A.] Univ Arizona, Dept Radiol, Tucson, AZ 85724 USA.
RP Li, HK (reprint author), Univ Texas Med Branch, Dept Ophthalmol & Visual Sci, 301 Univ Blvd, Galveston, TX 77555 USA.
EM hlimed@mac.com
OI Florez-Arango, Jose F/0000-0001-9083-0195
FU Juvenile Diabetes Foundation Research International, New York, NY;
Research to Prevent Blindness
FX Supported by a grant from Juvenile Diabetes Foundation Research
International, New York, NY (H.K.L.) and by unrestricted grants from the
Research to Prevent Blindness (Department of Ophthalmology and Visual
Sciences, The University of Texas Medical Branch and the Department of
Ophthalmology and Visual Sciences, University of Wisconsin School of
Medicine and Public Health).
NR 42
TC 5
Z9 5
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV-DEC
PY 2010
VL 30
IS 10
BP 1651
EP 1661
DI 10.1097/IAE.0b013e3181e3790b
PG 11
WC Ophthalmology
SC Ophthalmology
GA 678HL
UT WOS:000284064600014
PM 20921928
ER
PT J
AU Wylie, KP
Tregellas, JR
AF Wylie, Korey P.
Tregellas, Jason R.
TI The role of the insula in schizophrenia
SO SCHIZOPHRENIA RESEARCH
LA English
DT Review
DE Insula; Schizophrenia; Neuroimaging; Faces; Prosody; Acetylcholine
ID AUDITORY-VERBAL HALLUCINATIONS; FUNCTIONAL MAGNETIC-RESONANCE; MATTER
VOLUME ABNORMALITIES; FACIAL AFFECT RECOGNITION; VOXEL-BASED
MORPHOMETRY; SELF-FACE RECOGNITION; COMMON NEURAL BASIS; OLD-WORLD
MONKEY; HUMAN BRAIN; EMOTIONAL PROSODY
AB Involvement of the insular cortex is a common finding in neuroanatomical studies of schizophrenia, yet its contribution to disease pathology remains unknown. This review describes the normal function of the insula and examines pathology of this region in schizophrenia. The insula is a cortical structure with extensive connections to many areas of the cortex and limbic system. It integrates external sensory input with the limbic system and is integral to the awareness of the body's state (interoception). Many deficits observed in schizophrenia involve these functions and may relate to insula pathology. Furthermore, reports describing deficits caused by lesions of the insula parallel deficits observed in schizophrenia. Examples of insula-related functions that are altered in schizophrenia include the processing of both visual and auditory emotional information, pain, and neuronal representations of the self. The last of these functions, processing representations of the self, plays a key role in discriminating between self-generated and external information, suggesting that insula dysfunction may contribute to hallucinations, a cardinal feature of schizophrenia. Published by Elsevier B.V.
C1 [Wylie, Korey P.; Tregellas, Jason R.] Univ Colorado, Dept Psychiat, Aurora, CO 80045 USA.
[Tregellas, Jason R.] Denver VA Med Ctr, Res Serv, Denver, CO 80220 USA.
RP Tregellas, JR (reprint author), Univ Colorado Denver, Dept Psychiat, Mail Stop F546,13001 E 17th Pl, Aurora, CO 80045 USA.
EM Jason.Tregellas@ucdenver.edu
RI Tregellas, Jason/J-3637-2015
FU NIMH NIH HHS [P50 MH086383]
NR 166
TC 95
Z9 96
U1 6
U2 25
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD NOV
PY 2010
VL 123
IS 2-3
BP 93
EP 104
DI 10.1016/j.schres.2010.08.027
PG 12
WC Psychiatry
SC Psychiatry
GA 687RN
UT WOS:000284795700001
PM 20832997
ER
PT J
AU Iyer, RS
Bhargava, P
Medverd, JR
AF Iyer, Ramesh S.
Bhargava, Puneet
Medverd, Jonathan R.
TI A 65-year-old man presents with pelvic pain
SO SKELETAL RADIOLOGY
LA English
DT Editorial Material
C1 [Bhargava, Puneet; Medverd, Jonathan R.] Univ Washington, Dept Radiol, Body Imaging Sect, Seattle, WA 98108 USA.
[Bhargava, Puneet; Medverd, Jonathan R.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Iyer, Ramesh S.] Univ Washington, Med Ctr, Dept Radiol, Seattle, WA 98195 USA.
RP Bhargava, P (reprint author), Univ Washington, Dept Radiol, Body Imaging Sect, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM bhargp@uw.edu
RI Bhargava, Puneet /F-1330-2011
OI Bhargava, Puneet/0000-0002-3849-9666
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0364-2348
J9 SKELETAL RADIOL
JI Skeletal Radiol.
PD NOV
PY 2010
VL 39
IS 11
BP 1129
EP 1129
DI 10.1007/s00256-010-0898-0
PG 1
WC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging
SC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging
GA 650PF
UT WOS:000281861100011
ER
PT J
AU Iyer, R
Bhargava, P
Medverd, J
AF Iyer, Ramesh S.
Bhargava, Puneet
Medverd, Jonathan R.
TI A 65-year-old man presents with pelvic pain
SO SKELETAL RADIOLOGY
LA English
DT Editorial Material
DE Tophaceous gout; Symphysis pubis
ID TOPHACEOUS GOUT; SYMPHYSIS
C1 [Bhargava, Puneet; Medverd, Jonathan R.] Univ Washington, Dept Radiol, Seattle, WA 98195 USA.
[Bhargava, Puneet; Medverd, Jonathan R.] VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
[Iyer, Ramesh S.] Univ Washington, Med Ctr, Dept Radiol, Seattle, WA 98195 USA.
RP Bhargava, P (reprint author), Univ Washington, Dept Radiol, 1660 S Columbian Way, Seattle, WA 98195 USA.
EM bhargp@uw.edu
RI Bhargava, Puneet /F-1330-2011
NR 9
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0364-2348
J9 SKELETAL RADIOL
JI Skeletal Radiol.
PD NOV
PY 2010
VL 39
IS 11
BP 1151
EP 1152
DI 10.1007/s00256-010-0899-z
PG 2
WC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging
SC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging
GA 650PF
UT WOS:000281861100015
PM 20405125
ER
PT J
AU Boyd, JE
Katz, EP
Link, BG
Phelan, JC
AF Boyd, Jennifer E.
Katz, Emerald P.
Link, Bruce G.
Phelan, Jo C.
TI The relationship of multiple aspects of stigma and personal contact with
someone hospitalized for mental illness, in a nationally representative
sample
SO SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY
LA English
DT Article
DE Stigma; Mental illness; Survey; Personal experience; Contact
ID SOCIAL DISTANCE; PERCEIVED STIGMA; PEOPLE; ILL; DISCRIMINATION;
CONSEQUENCES; SEVERITY
AB The stigma of mental illness has been shown to be affected by personal contact with mental illness and by a belief in the genetic heritability of mental illness. We use data from a nationally representative survey to test whether the relationship of stigma with contact remains after taking into account the effects of genetic beliefs and other background characteristics. Contact was defined as a history of psychiatric hospitalization among respondents themselves, their family members, or their friends. Respondents answered questions about a vignette character with a mental illness. We found that respondents with contact felt less anger and blame toward the character, thought that the character had a more serious problem, and would want less social distance from the character, including both casual and intimate aspects of social distance. Respondents with contact were not significantly different from the general population in the degree to which they expressed sympathy, thought the problem would last a lifetime, or wanted to restrict reproduction. Thus, contact is associated with having a less ostracizing, critical attitude toward a stranger with mental illness. The results underscore the importance of this experienced group as a resource in fighting stigma in society. Since many people who have had a psychiatric hospitalization have not told their friends or family members about it, this lower-stigma group could be enlarged.
C1 [Boyd, Jennifer E.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA.
[Katz, Emerald P.] San Francisco VA Med Ctr, Psychosocial Rehabil & Recovery Ctr, San Francisco, CA 94121 USA.
[Link, Bruce G.] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY USA.
[Link, Bruce G.; Phelan, Jo C.] Columbia Univ, Dept Sociomed Sci, Mailman Sch Publ Hlth, New York, NY USA.
[Link, Bruce G.] New York State Psychiat Inst & Hosp, New York, NY 10032 USA.
RP Boyd, JE (reprint author), Univ Calif San Francisco, Dept Psychiat, 4150 Clement St 116A, San Francisco, CA 94121 USA.
EM jennifer.boyd@ucsf.edu
RI Link, Bruce/N-9087-2013
OI Link, Bruce/0000-0001-9980-7450
NR 29
TC 30
Z9 31
U1 4
U2 13
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0933-7954
J9 SOC PSYCH PSYCH EPID
JI Soc. Psychiatry Psychiatr. Epidemiol.
PD NOV
PY 2010
VL 45
IS 11
BP 1063
EP 1070
DI 10.1007/s00127-009-0147-9
PG 8
WC Psychiatry
SC Psychiatry
GA 666LY
UT WOS:000283117900005
PM 19823756
ER
PT J
AU Taghavi, CE
Lee, KB
He, WB
Keorochana, G
Murray, SS
Brochmann, EJ
Uludag, H
Behnam, K
Wang, JC
AF Taghavi, Cyrus E.
Lee, Kwang-Bok
He, Wubing
Keorochana, Gun
Murray, Samuel S.
Brochmann, Elsa J.
Uludag, Hasan
Behnam, Keyvan
Wang, Jeffrey C.
TI Bone Morphogenetic Protein Binding Peptide Mechanism and Enhancement of
Osteogenic Protein-1 Induced Bone Healing
SO SPINE
LA English
DT Article
DE bone morphogenetic protein; bone morphogenetic protein binding peptide;
osteogenic protein; bone graft alternative
ID ANTERIOR CERVICAL DISKECTOMY; LUMBAR SPINE FUSION; ILIAC-CREST
AUTOGRAFT; POLYETHERETHERKETONE SPACER; LIGAMENTUM-FLAVUM; SAFETY
PROFILE; MARROW-CELLS; GRAFT; RHBMP-2; MODEL
AB Study Design. In vitro and in vivo evaluation of BBP interactions with BMP.
Objective. To explore bone morphogenetic protein-binding peptide (BBP)'s mechanism of action, investigate an extended repertoire for BBP applications, and evaluate the usefulness of BBP as a surgical adjuvant when used with recombinant human osteogenic protein-1 (rhOP-1).
Summary of Background Data. Bone morphogenetic proteins (BMPs) are osteoinductive proteins that provide a potential alternative to autograft. Their utility is limited by cost, and potential dose-dependent risks, such as local inflammatory reactions and ectopic bone formation. BBP, a cyclized synthetic peptide, avidly binds recombinant human BMP-2 (rhBMP-2) and has been shown to accelerate and enhance its osteogenic qualities.
Methods. BBP binding with 4 growth factors from the transforming growth factor -beta family were assessed using surface plasmon resonance. The in vivo retention of rhBMP-2 was quantified by comparing the percentage of retained [(125)I]-labeled rhBMP-2 in absorbable collagen sponge implants with or without BBP at 1, 3, and 7 days postimplantation. The adjunctive effect of BBP with rhOP-1-induced bone growth was evaluated by comparing time to fusion and fusion rates in a rodent posterolateral fusion model with 2 different doses of rhOP-1 with or without BBP.
Results. BBP bound all 4 growth factors with an intermediate affinity. The in vivo retention of rhBMP-2 alone ranged from about 40% on day 1 to about 30% on day 7, whereas, the retention of rhBMP-2 in the presence of BBP was about 85% on day 1 and about 55% on day 7. The addition of BBP to rhOP-1 resulted in significantly earlier and greater fusion rates than achieved with rhOP-1 alone.
Conclusion. The mechanism of the BBP enhanced osteoinductive properties of BMPs involves the binding and retention of the growth factor, resulting in a prolonged exposure of BMP to the desired fusion site. The use of BBP in conjunction with BMPs may prove to provide satisfactory fusion outcomes, while reducing the costs and side effects associated with BMP use.
C1 [Taghavi, Cyrus E.; Lee, Kwang-Bok; He, Wubing; Keorochana, Gun; Wang, Jeffrey C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Orthopaed Surg, Los Angeles, CA 90095 USA.
[Murray, Samuel S.; Brochmann, Elsa J.] VA Greater Los Angeles Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Sepulveda, CA USA.
[Murray, Samuel S.; Brochmann, Elsa J.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA.
[Murray, Samuel S.] Univ Calif Los Angeles, Interdept Program Biomed Engn, Los Angeles, CA 90024 USA.
[Uludag, Hasan] Univ Alberta, Edmonton, AB, Canada.
[Behnam, Keyvan] VA Greater Los Angeles Hlth Care Syst, Res Serv, Sepulveda, CA USA.
[Behnam, Keyvan] Lanx Inc, Broomfield, CO USA.
RP Wang, JC (reprint author), UCLA Comprehens Spine Ctr, Orthopaed Spine Serv, 1250 16th St,Suite 745, Santa Monica, CA 90404 USA.
EM jwang@mednet.ucla.edu
FU Department of Veterans Affairs, Lanx Inc.; Canadian Institutes of Health
Research
FX Department of Veterans Affairs, Lanx Inc., and Canadian Institutes of
Health Research funds were received in support of this work. Although
one or more of the author(s) has/have received or will receive benefits
for personal or professional use from a commercial party related
directly or indirectly to the subject of this manuscript, benefits will
be directed solely to a research fund, foundation, educational
institution, or other nonprofit organization which the author(s)
has/have been associated.
NR 51
TC 17
Z9 18
U1 3
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0362-2436
J9 SPINE
JI SPINE
PD NOV 1
PY 2010
VL 35
IS 23
BP 2049
EP 2056
DI 10.1097/BRS.0b013e3181cc0220
PG 8
WC Clinical Neurology; Orthopedics
SC Neurosciences & Neurology; Orthopedics
GA 671GX
UT WOS:000283490100023
PM 20581758
ER
PT J
AU Stetler, RA
Chen, J
Cao, GD
AF Stetler, R. Anne
Chen, Jun
Cao, Guodong
TI White Matter Protection by Erythropoietin: An Emerging Matter in the
Treatment of Neonatal Hypoxic-Ischemic Brain Injury Response
SO STROKE
LA English
DT Letter
ID STROKE
C1 [Stetler, R. Anne; Chen, Jun; Cao, Guodong] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
[Stetler, R. Anne; Chen, Jun; Cao, Guodong] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA.
RP Stetler, RA (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
NR 9
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0039-2499
J9 STROKE
JI Stroke
PD NOV
PY 2010
VL 41
IS 11
BP E596
EP E596
DI 10.1161/STROKEAHA.110.593574
PG 1
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 670QX
UT WOS:000283443500014
ER
PT J
AU Pollak, KI
Arnold, R
Alexander, SC
Jeffreys, AS
Olsen, MK
Abernethy, AP
Rodriguez, KL
Tulsky, JA
AF Pollak, Kathryn I.
Arnold, Robert
Alexander, Stewart C.
Jeffreys, Amy S.
Olsen, Maren K.
Abernethy, Amy P.
Rodriguez, Kari L.
Tulsky, James A.
TI Do patient attributes predict oncologist empathic responses and patient
perceptions of empathy?
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Empathy; Oncologist; Advanced cancer; Socioeconomic status; Negative
emotion
ID QUALITY-OF-LIFE; PSYCHOLOGICAL ADJUSTMENT; PHYSICIAN COMMUNICATION;
CANCER COMMUNICATION; RACIAL-DIFFERENCES; SCOPE TRIAL; INTERVENTION;
DISTRUST; PATTERNS; ANXIETY
AB Purpose Most patients with advanced cancer experience negative emotion. When patients express emotions, oncologists rarely respond empathically. Oncologists may respond more empathically to some patients, and patients may perceive different levels of empathy and trust given past documentation of disparities in cancer care.
Methods We audio-recorded 264 outpatient encounters between oncologists and patients with advanced cancer at three sites. We examined whether patient gender, age, race, marital status, education, economic security, and length of relationship with oncologist were related to oncologist empathic responses to patient's negative emotion and patient's perceptions of oncologist empathy and trust.
Results Half (51%) of the patients expressed a negative emotion. Oncologists sometimes responded with empathy (29%). Oncologists were equally empathic with all patients, except they were more empathic with patients with low economic security compared with those reporting high economic security (p=.002). Patients with low economic security viewed oncologists as more empathic (p=.06) compared with those with moderate security. Married patients also viewed oncologists as more empathic (p=.04). Patients who knew their oncologist for more than a year had more trust than patients who knew their oncologists for less time (p=.02). Conclusions Oncologists, in general, did not respond empathically to patient's negative emotion, and did this equally for most patients. Oncologists responded more empathically to patients who were less economically advantaged. In turn, patients with lower economic security perceived more empathy. Although oncologists need more education in responding empathically, they may not need to correct many biases in care.
C1 [Pollak, Kathryn I.] Duke Univ, Med Ctr, Dept Community & Family Med, Durham, NC 27710 USA.
[Pollak, Kathryn I.; Abernethy, Amy P.; Tulsky, James A.] Duke Univ, Med Ctr, Duke Comprehens Canc Ctr, Canc Prevent Detect & Control Res Program, Durham, NC 27710 USA.
[Arnold, Robert; Rodriguez, Kari L.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA.
[Arnold, Robert; Rodriguez, Kari L.] Univ Pittsburgh, Sch Med, Inst Doctor Patient Commun, Pittsburgh, PA USA.
[Arnold, Robert] Univ Pittsburgh, Sch Med, Inst Enhance Palliat Care, Pittsburgh, PA USA.
[Alexander, Stewart C.; Abernethy, Amy P.; Tulsky, James A.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
[Alexander, Stewart C.; Abernethy, Amy P.; Tulsky, James A.] Duke Univ, Med Ctr, Ctr Palliat Care, Durham, NC 27710 USA.
[Alexander, Stewart C.; Jeffreys, Amy S.; Olsen, Maren K.; Tulsky, James A.] Durham VA Med Ctr, Ctr Hlth Serv Res, Durham, NC USA.
[Olsen, Maren K.] Duke Univ, Med Ctr, Dept Biostat & Bioinformat, Durham, NC 27710 USA.
[Rodriguez, Kari L.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Rodriguez, Kari L.] VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA.
RP Pollak, KI (reprint author), Duke Univ, Med Ctr, Dept Community & Family Med, Durham, NC 27710 USA.
EM kathryn.pollak@duke.edu
OI Abernethy, Amy/0000-0001-6930-8722
FU [R01CA100387]
FX This work was supported by R01CA100387. The authors have no financial
disclosures.
NR 29
TC 7
Z9 7
U1 3
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0941-4355
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD NOV
PY 2010
VL 18
IS 11
BP 1405
EP 1411
DI 10.1007/s00520-009-0762-8
PG 7
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA 654QG
UT WOS:000282182500006
PM 19838742
ER
PT J
AU Maciejewski, ML
Livingston, EH
Kahwati, LC
Henderson, WG
Kavee, AL
Arterburn, DE
AF Maciejewski, Matthew L.
Livingston, Edward H.
Kahwati, Leila C.
Henderson, William G.
Kavee, Andrew L.
Arterburn, David E.
TI Discontinuation of diabetes and lipid-lowering medications after
bariatric surgery at Veterans Affairs medical centers
SO SURGERY FOR OBESITY AND RELATED DISEASES
LA English
DT Article
DE Bariatric; Medication; Discontinuation; Diabetes; Dyslipidemia; Veterans
ID LAPAROSCOPIC GASTRIC BYPASS; RISK ADJUSTMENT; SURGICAL CARE; OBESITY;
COSTS; IMPROVEMENT; QUALITY; EXPENDITURES; METAANALYSIS; PERFORMANCE
AB Background: Bariatric surgery has largely been performed on middle-age female populations and been associated with significant medication discontinuation; however, it is unknown whether similar medication discontinuation rates could be achieved in men. The purpose of the present analysis was to examine the discontinuation rate of diabetes or lipid-lowering medications and the patient factors associated with medication discontinuation among veterans undergoing bariatric surgery.
Methods: We identified the demographic and health status information for 284 veterans with diabetes and 298 veterans with hyperlipidemia who had undergone bariatric surgery at 1 of 12 Veterans Affairs bariatric centers in 2000 to 2006 from the Veterans Affairs National Surgical Quality Improvement Program data. We also identified the medications that had been prescribed and discontinued using the Veterans Affairs administrative data. Medication discontinuation was estimated using a logistic regression model.
Results: Of the 284 veterans with diabetes and 298 with hyperlipidemia, 52% and 40% had discontinued their medications at 1 year, respectively. The veterans with diabetes were more likely to discontinue medication if they had been taking oral hypoglycemic agents alone (odds ratio 2.77, P < .001) than were those taking insulin or oral hypoglycemic agents and insulin. The veterans with hyperlipidemia were more likely to discontinue medication if they had only been taking fibrates (odds ratio 6.15, P < .01) than were those veterans taking statins and fibrates.
Conclusion: Bariatric surgery led to significant medication discontinuation within 1 year for high-risk veterans with diabetes or hyperlipidemia. (Surg Obes Relat Dis 2010;6:601-607.) Published by Elsevier Inc.
C1 [Maciejewski, Matthew L.; Kavee, Andrew L.] Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC 27705 USA.
[Maciejewski, Matthew L.] Duke Univ, Dept Med, Div Gen Internal Med, Durham, NC USA.
[Livingston, Edward H.] Univ Texas SW Med Ctr Dallas, Div Gastrointestinal & Endocrine Surg, Dallas, TX 75390 USA.
[Livingston, Edward H.] Vet Affairs N Texas Hlth Care Syst, Dallas, TX USA.
[Livingston, Edward H.] Univ Texas Arlington, Arlington, TX 76019 USA.
[Kahwati, Leila C.] Natl Ctr Hlth Promot & Dis Prevent, Off Patient Care Serv, Vet Hlth Adm, Dept Vet Affairs, Durham, NC USA.
[Henderson, William G.] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Henderson, William G.] Univ Colorado, Dept Biostat, Sch Publ Hlth, Aurora, CO USA.
[Henderson, William G.] Univ Colorado, Colorado Hlth Outcomes Program, Aurora, CO USA.
[Arterburn, David E.] Grp Hlth Res Inst, Seattle, WA USA.
[Arterburn, David E.] Univ Washington, Dept Med, Div Gen Internal Med, Seattle, WA USA.
RP Maciejewski, ML (reprint author), Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, 508 Fulton St,Mail Stop 152, Durham, NC 27705 USA.
EM matthew.maciejewski@va.gov
FU Office of Research and Development, Health Services Research and
Development Service, Department of Veterans Affairs [IIR 05-201]; Takeda
Pharmaceuticals; Surgical Review Corporation
FX Supported by the Office of Research and Development, Health Services
Research and Development Service, Department of Veterans Affairs (IIR
05-201) and has been reviewed and approved by the Surgical Quality Data
Use Group (SQDUG), Office of Patient Care Services.; Dr. Maciejewski has
received consultation funds from Takeda Pharmaceuticals and the Surgical
Review Corporation, and owns stock in Amgen.
NR 25
TC 12
Z9 12
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1550-7289
J9 SURG OBES RELAT DIS
JI Surg. Obes. Relat. Dis.
PD NOV-DEC
PY 2010
VL 6
IS 6
BP 601
EP 607
DI 10.1016/j.soard.2010.07.005
PG 7
WC Surgery
SC Surgery
GA 694UG
UT WOS:000285323900003
PM 20965791
ER
PT J
AU Beer, TM
Benavides, M
Emmons, SL
Hayes, M
Liu, GH
Garzotto, M
Donovan, D
Katovic, N
Reeder, C
Eilers, K
AF Beer, Tomasz M.
Benavides, Maria
Emmons, Sandra L.
Hayes, Margaret
Liu, Guohui
Garzotto, Mark
Donovan, Deirdre
Katovic, Nina
Reeder, Caron
Eilers, Kristine
TI Acupuncture for Hot Flashes in Patients With Prostate Cancer
SO UROLOGY
LA English
DT Article
ID GENE-RELATED PEPTIDE; RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE;
BREAST-CANCER; VASOMOTOR SYMPTOMS; POSTMENOPAUSAL WOMEN;
LUTEINIZING-HORMONE; MEGESTROL-ACETATE; PILOT EVALUATION; BLOOD-FLOW
AB OBJECTIVES To determine the effect of acupuncture on hot flash frequency and intensity, quality of life, and sleep quality in patients undergoing hormonal therapy for prostate cancer. Hot flashes are a common adverse effect of hormonal therapy for prostate cancer.
METHODS Men who had a hot flash score > 4 who were receiving androgen deprivation therapy for prostate cancer underwent acupuncture with electrostimulation biweekly for 4 weeks, then weekly for 6 weeks, using a predefined treatment plan. The primary endpoint was a 50% reduction in the hot flash score after 4 weeks of therapy, calculated from the patients' daily hot flash diaries. The hot flash-related quality of life and sleep quality and biomarkers potentially related to hot flashes, including serotonin, calcitonin gene-related peptide, and urinary 5-hydroxyindoleacetic acid, were examined.
RESULTS A total of 25 men were enrolled from September 2003 to April 2007. Of these, 22 were eligible and evaluable. After 4 weeks, 9 (41%, 95% confidence interval 21%-64%) of 22 patients had had a > 50% reduction in the hot flash score. Of the 22 patients, 12 (55%, 95% confidence interval 32%-76%) met this response definition at any point during the therapy course. No patient had a significant increase in hot flash score during therapy. A reduced hot flash score was associated with improvement in the hot flash-related quality of life and sleep quality.
CONCLUSIONS Multiple placebo-controlled trials have demonstrated a 25% response rate to placebo treatment for hot flashes. Of the 22 patients, 41% had responded by week 4 and 55% overall in the present pilot study, providing evidence of a potentially meaningful benefit. Additional studies of acupuncture for hot flashes in this population are warranted. UROLOGY 76: 1182-1188, 2010. (C) 2010 Elsevier Inc.
C1 [Beer, Tomasz M.] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97201 USA.
Oregon Hlth & Sci Univ, Div Urol, Portland, OR 97201 USA.
Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97201 USA.
Oregon Hlth & Sci Univ, Dept Family Med, Portland, OR 97201 USA.
Goodlife Acupuncture, Bend, OR USA.
Oregon Coll Oriental Med, Portland, OR USA.
Portland VA Med Ctr, Portland, OR USA.
RP Beer, TM (reprint author), Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, 3303 SW Bond Ave,CII14R, Portland, OR 97201 USA.
EM beert@ohsu.edu
FU Oregon Health and Science University General Clinical Research Center
[M01 RR000334]; Oregon Clinical and Translational Research Institute
[UL1RR024140]; National Institutes of Health, Bethesda, Maryland [R21
CA098406]
FX This study was supported in part by grant M01 RR000334 from the Oregon
Health and Science University General Clinical Research Center, grant
UL1RR024140 from the Oregon Clinical and Translational Research
Institute, and grant R21 CA098406 from the National Institutes of
Health, Bethesda, Maryland.
NR 41
TC 14
Z9 15
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0090-4295
EI 1527-9995
J9 UROLOGY
JI Urology
PD NOV
PY 2010
VL 76
IS 5
BP 1182
EP 1188
DI 10.1016/j.urology.2010.03.033
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA 675QD
UT WOS:000283844600043
PM 20494414
ER
PT J
AU Federman, AD
Woodward, M
Keyhani, S
AF Federman, Alex D.
Woodward, Mark
Keyhani, Salomeh
TI Physicians' Opinions About Reforming Reimbursement Results of a National
Survey
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Article
ID PAY-FOR-PERFORMANCE; CARE-SPECIALTY INCOME; HEALTH-CARE; PAYMENT POLICY;
US PHYSICIANS; INSURANCE; VIEWS; PERSPECTIVE; QUALITY; OPTIONS
AB Background: Several strategies have been proposed to reform physician reimbursement while improving quality of care. Despite much debate, physicians' opinions regarding reimbursement reform proposals have not been objectively assessed.
Methods: We conducted a national survey of randomly selected physicians between June 25 and October 31, 2009. Physicians rated their support for several reimbursement reform proposals: rewarding quality with financial incentives, bundling payments for episodes of care, shifting payments from procedures to management and counseling services, increasing pay to generalists, and offsetting increased pay to generalists with a reduction in pay for other specialties. Support for the different reform options was compared with physician practice characteristics.
Results: The response rate was 48.5% (n = 1222). Four of 5 physicians (78.4%) indicated that under Medicare, some procedures are compensated too highly and others are compensated at rates insufficient to cover costs. Incentives were the most frequently supported reform option (49.1%), followed by shifting payments (41.6%) and bundling (17.2%). Shifting payments and bundling were more commonly supported by generalists than by other specialists. There was broad support for increasing pay for generalists (79.8%), but a proposal to offset the increase with a 3% reduction in specialist reimbursement was supported by only 39.1% of physicians.
Conclusions: Physicians are dissatisfied with Medicare reimbursement and show little consensus for major proposals to reform reimbursement. The successful adoption of payment reform proposals may require a better understanding of physicians' concerns and their willingness to make tradeoffs. Arch Intern Med. 2010;170(19):1735-1742
C1 [Federman, Alex D.; Woodward, Mark; Keyhani, Salomeh] Mt Sinai Sch Med, Div Gen Internal Med, New York, NY 10029 USA.
[Keyhani, Salomeh] Mt Sinai Sch Med, Dept Hlth Policy, New York, NY 10029 USA.
[Keyhani, Salomeh] James J Peters Vet Adm Med Ctr, Bronx, NY USA.
RP Federman, AD (reprint author), Mt Sinai Sch Med, Div Gen Internal Med, POB 1087,1 Gustave L Levy Pl, New York, NY 10029 USA.
EM alex.federman@mssm.edu
FU Robert Wood Johnson Foundation; National Institute on Aging; National
Heart, Lung, and Blood Institute; Veterans Administration Health
Services Research and Development Service
FX This project was supported by a grant from the Robert Wood Johnson
Foundation and also by grants from the National Institute on Aging; the
National Heart, Lung, and Blood Institute; and the Veterans
Administration Health Services Research and Development Service (Drs
Federman and Keyhani).
NR 33
TC 4
Z9 4
U1 1
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9926
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD OCT 25
PY 2010
VL 170
IS 19
BP 1735
EP 1742
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 670PT
UT WOS:000283440500009
PM 20975020
ER
PT J
AU Saban, KL
Bryant, FB
Reda, DJ
Stroupe, KT
Hynes, DM
AF Saban, Karen L.
Bryant, Fred B.
Reda, Domenic J.
Stroupe, Kevin T.
Hynes, Denise M.
TI Measurement invariance of the kidney disease and quality of life
instrument (KDQOL-SF) across Veterans and non-Veterans
SO HEALTH AND QUALITY OF LIFE OUTCOMES
LA English
DT Article
ID STAGE RENAL-DISEASE; HEMODIALYSIS-PATIENTS; DIALYSIS OUTCOMES; PRACTICE
PATTERNS; FIT INDEXES; FACTORIAL INVARIANCE; PSYCHOMETRIC PROPERTIES;
COVARIANCE-STRUCTURES; PERITONEAL-DIALYSIS; HEALTH
AB Background: Studies have demonstrated that perceived health-related quality of life (HRQOL) of patients receiving hemodialysis is significantly impaired. Since HRQOL outcome data are often used to compare groups to determine health care effectiveness it is imperative that measures of HRQOL are valid. However, valid HRQOL comparisons between groups can only be made if instrument invariance is demonstrated. The Kidney Disease Quality of Life Short Form (KDQOL-SF) is a widely used HRQOL measure for patients with chronic kidney disease (CKD) however, it has not been validated in the Veteran population. Therefore, the purpose of this study was to examine the measurement invariance of the KDQOL-SF across Veterans and non-Veterans with CKD.
Methods: Data for this study were from two large prospective observational studies of patients receiving hemodialysis: 1) Veteran End-Stage Renal Disease Study (VETERAN) (N = 314) and 2) Dialysis Outcomes and Practice Patterns Study (DOPPS) (N = 3,300). Health-related quality of life was measured with the KDQOL-SF, which consists of the SF-36 and the Kidney Disease Component Summary (KDCS). Single-group confirmatory factor analysis was used to evaluate the goodness-of-fit of the hypothesized measurement model for responses to the subscales of the KDCS and SF-36 instruments when analyzed together; and given acceptable goodness-of-fit in each group, multigroup CFA was used to compare the structure of this factor model in the two samples. Pattern of factor loadings (configural invariance), the magnitude of factor loadings (metric invariance), and the magnitude of item intercepts (scalar invariance) were assessed as well as the degree to which factors have the same variances, covariances, and means across groups (structural invariance).
Results: CFA demonstrated that the hypothesized two-factor model (KDCS and SF-36) fit the data of both the Veteran and DOPPS samples well, supporting configural invariance. Multigroup CFA results concerning metric and scalar invariance suggested partial strict invariance for the SF-36, but only weak invariance for the KDCS. Structural invariance was not supported.
Conclusions: Results suggest that Veterans may interpret the KDQOL-SF differently than non-Veterans. Further evaluation of measurement invariance of the KDQOL-SF between Veterans and non-Veterans is needed using large, randomly selected samples before comparisons between these two groups using the KDQOL-SF can be done reliably.
C1 [Saban, Karen L.; Stroupe, Kevin T.; Hynes, Denise M.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Ctr Management Chron Complex Care, Hines, IL 60141 USA.
[Saban, Karen L.] Loyola Univ Chicago, Marcella Niehoff Sch Nursing, Maywood, IL USA.
[Bryant, Fred B.] Loyola Univ Chicago, Dept Psychol, Chicago, IL USA.
[Reda, Domenic J.] Vet Affairs Cooperat Studies Program Coordinating, Hines, IL USA.
[Stroupe, Kevin T.; Hynes, Denise M.] Vet Affairs Informat Resource Ctr, Hines, IL USA.
[Stroupe, Kevin T.] Loyola Univ, Stritch Sch Med, Maywood, IL 60153 USA.
[Hynes, Denise M.] Univ Illinois, Coll Med, Chicago, IL USA.
RP Saban, KL (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Ctr Management Chron Complex Care, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA.
EM Ksaban@luc.edu
OI Saban, Karen/0000-0001-5767-5453
FU U.S. Department of Veterans Affairs; Veterans Health Administration;
Health Services Research and Development Service - "Cost and
Effectiveness of End-Stage Renal Disease Care" [ECI 20 016]; Veterans
Affairs Health Services Research and Development Service [TPN 42-001];
Amgen; Kyowa Hakko Kirin, Japan; Genzyme; Abbott
FX This research was supported by the U.S. Department of Veterans Affairs,
Veterans Health Administration, Health Services Research and Development
Service - "Cost and Effectiveness of End-Stage Renal Disease Care" (D.
Hynes, Principal Investigator) (ECI 20 016). Dr. Hynes is supported by a
five-year Veterans Affairs Health Services Research and Development
Service Research Career Scientist Award. Dr. Saban is supported by a
three-year Veterans Affairs Health Services Research and Development
Service Postdoctoral Fellowship (TPN 42-001). DOPPS data were provided
by Arbor Research Collaborative for Health which administers and
coordinates the Dialysis Outcomes and Practice Study. DOPPS is supported
by scientific research from Amgen (since 1996), Kyowa Hakko Kirin (since
1999, in Japan), Genzyme (since 2009), and Abbott (since 2009), without
restrictions on publications. We would like to thank Jenny Huo for her
statistical assistance in performing multiple imputations. In addition,
we would like to express our sincere gratitude to Dr. Albert Satorra
(Departament d'Economia i Empresa, Universitat Pompeu Fabra) for his
expert statistical guidance. Finally, we would like to acknowledge the
anonymous reviewers for their insightful comments and suggestions
concerning an earlier draft of this manuscript.
NR 89
TC 9
Z9 9
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1477-7525
J9 HEALTH QUAL LIFE OUT
JI Health Qual. Life Outcomes
PD OCT 25
PY 2010
VL 8
AR 120
DI 10.1186/1477-7525-8-120
PG 16
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 724QC
UT WOS:000287590300001
PM 20973987
ER
PT J
AU Helfrich, CD
Damschroder, LJ
Hagedorn, HJ
Daggett, GS
Sahay, A
Ritchie, M
Damush, T
Guihan, M
Ullrich, PM
Stetler, CB
AF Helfrich, Christian D.
Damschroder, Laura J.
Hagedorn, Hildi J.
Daggett, Ginger S.
Sahay, Anju
Ritchie, Mona
Damush, Teresa
Guihan, Marylou
Ullrich, Philip M.
Stetler, Cheryl B.
TI A critical synthesis of literature on the promoting action on research
implementation in health services (PARIHS) framework
SO IMPLEMENTATION SCIENCE
LA English
DT Review
ID CONCEPTUAL-FRAMEWORK; PRACTICE GUIDELINES; CARE; CONTEXT; BEHAVIOR;
FACILITATION; EXPLORATION; IMPROVEMENT; MANAGEMENT; OUTCOMES
AB Background: The Promoting Action on Research Implementation in Health Services framework, or PARIHS, is a conceptual framework that posits key, interacting elements that influence successful implementation of evidence-based practices. It has been widely cited and used as the basis for empirical work; however, there has not yet been a literature review to examine how the framework has been used in implementation projects and research. The purpose of the present article was to critically review and synthesize the literature on PARIHS to understand how it has been used and operationalized, and to highlight its strengths and limitations.
Methods: We conducted a qualitative, critical synthesis of peer-reviewed PARIHS literature published through March 2009. We synthesized findings through a three-step process using semi-structured data abstraction tools and group consensus.
Results: Twenty-four articles met our inclusion criteria: six core concept articles from original PARIHS authors, and eighteen empirical articles ranging from case reports to quantitative studies. Empirical articles generally used PARIHS as an organizing framework for analyses. No studies used PARIHS prospectively to design implementation strategies, and there was generally a lack of detail about how variables were measured or mapped, or how conclusions were derived. Several studies used findings to comment on the framework in ways that could help refine or validate it. The primary issue identified with the framework was a need for greater conceptual clarity regarding the definition of sub-elements and the nature of dynamic relationships. Strengths identified included its flexibility, intuitive appeal, explicit acknowledgement of the outcome of 'successful implementation,' and a more expansive view of what can and should constitute 'evidence.'
Conclusions: While we found studies reporting empirical support for PARIHS, the single greatest need for this and other implementation models is rigorous, prospective use of the framework to guide implementation projects. There is also need to better explain derived findings and how interventions or measures are mapped to specific PARIHS elements; greater conceptual discrimination among sub-elements may be necessary first. In general, it may be time for the implementation science community to develop consensus guidelines for reporting the use and usefulness of theoretical frameworks within implementation studies.
C1 [Helfrich, Christian D.] VA Puget Sound Healthcare Syst, NW HSR&D Ctr Excellence, Seattle, WA USA.
[Helfrich, Christian D.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA.
[Damschroder, Laura J.] VA Ann Arbor Healthcare Syst, HSR&D Ctr Clin Management Res & Diabet QUERI, Ann Arbor, MI USA.
[Hagedorn, Hildi J.] Minneapolis VA Med Ctr, VA Substance Use Disorders Qual Enhancement Res I, Minneapolis, MN USA.
[Hagedorn, Hildi J.] Univ Minnesota, Sch Med, Dept Psychiat, Minneapolis, MN 55455 USA.
[Daggett, Ginger S.; Damush, Teresa] Richard L Roudebush VA Med Ctr, VA Stroke QUERI, HSR&D Ctr Excellence, Indianapolis, IN USA.
[Sahay, Anju] VA Palo Alto Hlth Care Syst, Chron Heart Failure QUERI Ctr, Palo Alto, CA USA.
[Ritchie, Mona] Cent Arkansas Vet Healthcare Syst, Mental Hlth Qual Enhancement Res Initiat, N Little Rock, AR USA.
[Damush, Teresa] Indiana Univ, Ctr Aging Res, Regenstrief Inc, Indianapolis, IN 46204 USA.
[Guihan, Marylou] Jr VA Hosp, Spinal Cord Injury QUERI Res Coordinating Ctr, Ctr Management Complex Chron Care CMC3, Hines, IL USA.
[Ullrich, Philip M.] VA Puget Sound Hlth Care Syst, Spinal Cord Injury QUERI, Seattle, WA USA.
[Stetler, Cheryl B.] Boston Univ, Sch Publ Hlth, Dept Hlth Serv, Boston, MA USA.
RP Helfrich, CD (reprint author), VA Puget Sound Healthcare Syst, NW HSR&D Ctr Excellence, Seattle, WA USA.
EM christian.helfrich@va.gov
RI Helfrich, Christian/D-2382-2016
OI Helfrich, Christian/0000-0002-9827-4768; Damschroder,
Laura/0000-0002-3657-8459
FU U.S. Department of Veterans Affairs, Office of Research and Development
Health Services
FX This material is based upon work supported by the U.S. Department of
Veterans Affairs, Office of Research and Development Health Services R&D
Program. We wish to acknowledge the important contributions of Jeffrey
Smith to the paper, and the important administrative assistance of Jared
LeClerc and Rachel Smith. Also, our thanks to Corrine Voils for
providing invaluable feedback on a draft of the paper, and to Lars
Wallin and Jacqueline Tetroe for their excellent reviews and
suggestions. The views expressed in this article are the authors' and do
not necessarily reflect the position or policy of the Department of
Veterans Affairs.
NR 61
TC 89
Z9 91
U1 3
U2 42
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1748-5908
J9 IMPLEMENT SCI
JI Implement. Sci.
PD OCT 25
PY 2010
VL 5
AR 82
DI 10.1186/1748-5908-5-82
PG 20
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 680KT
UT WOS:000284231500001
PM 20973988
ER
PT J
AU Qin, WP
Pan, JP
Bauman, WA
Cardozo, CP
AF Qin, Weiping
Pan, Jiangping
Bauman, William A.
Cardozo, Christopher P.
TI Differential alterations in gene expression profiles contribute to
time-dependent effects of nandrolone to prevent denervation atrophy
SO BMC GENOMICS
LA English
DT Article
ID SKELETAL-MUSCLE ATROPHY; FOXO TRANSCRIPTION FACTORS; ANDROGEN RECEPTOR;
MAMMALIAN TARGET; CARDIAC-HYPERTROPHY; RAPAMYCIN PATHWAY; UBIQUITIN
LIGASES; KNOCKOUT MICE; FIBER-TYPE; F-BOX
AB Background: Anabolic steroids, such as nandrolone, slow muscle atrophy, but the mechanisms responsible for this effect are largely unknown. Their effects on muscle size and gene expression depend upon time, and the cause of muscle atrophy. Administration of nandrolone for 7 days beginning either concomitantly with sciatic nerve transection (7 days) or 29 days later (35 days) attenuated denervation atrophy at 35 but not 7 days. We reasoned that this model could be used to identify genes that are regulated by nandrolone and slow denervation atrophy, as well as genes that might explain the time-dependence of nandrolone effects on such atrophy. Affymetrix microarrays were used to profile gene expression changes due to nandrolone at 7 and 35 days and to identify major gene expression changes in denervated muscle between 7 and 35 days.
Results: Nandrolone selectively altered expression of 124 genes at 7 days and 122 genes at 35 days, with only 20 genes being regulated at both time points. Marked differences in biological function of genes regulated by nandrolone at 7 and 35 days were observed. At 35, but not 7 days, nandrolone reduced mRNA and protein levels for FOXO1, the mTOR inhibitor REDD2, and the calcineurin inhibitor RCAN2 and increased those for ApoD. At 35 days, correlations between mRNA levels and the size of denervated muscle were negative for RCAN2, and positive for ApoD. Nandrolone also regulated genes for Wnt signaling molecules. Comparison of gene expression at 7 and 35 days after denervation revealed marked alterations in the expression of 9 transcriptional coregulators, including Ankrd1 and 2, and many transcription factors and kinases.
Conclusions: Genes regulated in denervated muscle after 7 days administration of nandrolone are almost entirely different at 7 versus 35 days. Alterations in levels of FOXO1, and of genes involved in signaling through calcineurin, mTOR and Wnt may be linked to the favorable action of nandrolone on denervated muscle. Marked changes in the expression of genes regulating transcription and intracellular signaling may contribute to the time-dependent effects of nandrolone on gene expression.
C1 [Qin, Weiping; Pan, Jiangping; Bauman, William A.; Cardozo, Christopher P.] James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Bronx, NY 10468 USA.
[Qin, Weiping; Bauman, William A.; Cardozo, Christopher P.] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA.
[Bauman, William A.; Cardozo, Christopher P.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA.
RP Cardozo, CP (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Room 1E-02,130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM chris.cardozo@mssm.edu
FU Veterans Health Administration, Rehabilitation Research and Development
Service [B4162C, B3347K, B3522R]
FX The research reported here was supported by the Veterans Health
Administration, Rehabilitation Research and Development Service (B4162C,
B3347K, B3522R), which had no role in study design, data collection and
interpretation, manuscript preparation or decisions to submit the
manuscript. Microarray analysis was performed by the Microarray Core at
the Mount Sinai School of Medicine.
NR 78
TC 13
Z9 13
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD OCT 22
PY 2010
VL 11
AR 596
DI 10.1186/1471-2164-11-596
PG 17
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 679PG
UT WOS:000284172700001
PM 20969782
ER
PT J
AU Neily, J
Mills, PD
Young-Xu, YN
Carney, BT
West, P
Berger, DH
Mazzia, LM
Paull, DE
Bagian, JP
AF Neily, Julia
Mills, Peter D.
Young-Xu, Yinong
Carney, Brian T.
West, Priscilla
Berger, David H.
Mazzia, Lisa M.
Paull, Douglas E.
Bagian, James P.
TI Association Between Implementation of a Medical Team Training Program
and Surgical Mortality
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID PROPENSITY SCORE; OPERATING-ROOM; RISK ADJUSTMENT; CARE; COMMUNICATION;
MORBIDITY; SURGERY; QUALITY; SAFETY; BRIEFINGS
AB Context There is insufficient information about the effectiveness of medical team training on surgical outcomes. The Veterans Health Administration (VHA) implemented a formalized medical team training program for operating room personnel on a national level.
Objective To determine whether an association existed between the VHA Medical Team Training program and surgical outcomes.
Design, Setting, and Participants A retrospective health services study with a contemporaneous control group was conducted. Outcome data were obtained from the VHA Surgical Quality Improvement Program (VASQIP) and from structured interviews in fiscal years 2006 to 2008. The analysis included 182 409 sampled procedures from 108 VHA facilities that provided care to veterans. The VHA's nationwide training program required briefings and debriefings in the operating room and included checklists as an integral part of this process. The training included 2 months of preparation, a 1-day conference, and 1 year of quarterly coaching interviews
Main Outcome Measure The rate of change in the mortality rate 1 year after facilities enrolled in the training program compared with the year before and with non-training sites.
Results The 74 facilities in the training program experienced an 18% reduction in annual mortality (rate ratio [RR], 0.82; 95% confidence interval [CI], 0.76-0.91; P=.01) compared with a 7% decrease among the 34 facilities that had not yet undergone training (RR, 0.93; 95% CI, 0.80-1.06; P=.59). The risk-adjusted mortality rates at baseline were 17 per 1000 procedures per year for the trained facilities and 15 per 1000 procedures per year for the nontrained facilities. At the end of the study, the rates were 14 per 1000 procedures per year for both groups. Propensity matching of the trained and nontrained groups demonstrated that the decline in the risk-adjusted surgical mortality rate was about 50% greater in the training group (RR, 1.49; 95% CI, 1.10-2.07; P=.01) than in the nontraining group. A dose-response relationship for additional quarters of the training program was also demonstrated: for every quarter of the training program, a reduction of 0.5 deaths per 1000 procedures occurred (95% CI, 0.2-1.0; P=.001).
Conclusion Participation in the VHA Medical Team Training program was associated with lower surgical mortality. JAMA. 2010; 304(15): 1693-1700
C1 [Neily, Julia; Mills, Peter D.; Young-Xu, Yinong; Carney, Brian T.; West, Priscilla; Mazzia, Lisa M.; Paull, Douglas E.; Bagian, James P.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Vet Affairs,Natl Ctr Patient Safety, Hanover, NH 03756 USA.
[Mills, Peter D.; Young-Xu, Yinong] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Psychiat, Hanover, NH 03756 USA.
[Berger, David H.] Baylor Coll Med, Dept Surg, Houston, TX 77030 USA.
[Berger, David H.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Bagian, James P.] Univ Texas Med Branch, Galveston, TX USA.
[Bagian, James P.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Bethesda, MD 20814 USA.
RP Neily, J (reprint author), 215 N Main St, White River Jct, VT 05009 USA.
EM Julia.Neily@va.gov
NR 32
TC 330
Z9 336
U1 3
U2 19
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD OCT 20
PY 2010
VL 304
IS 15
BP 1693
EP 1700
DI 10.1001/jama.2010.1506
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 666PZ
UT WOS:000283129700023
PM 20959579
ER
PT J
AU Keyhani, S
Woodward, M
Federman, AD
AF Keyhani, Salomeh
Woodward, Mark
Federman, Alex D.
TI Physician Views on the Use of Comparative Effectiveness Research: A
National Survey
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Letter
C1 [Keyhani, Salomeh] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA.
[Woodward, Mark] George Inst, Camperdown, NSW 2050, Australia.
[Federman, Alex D.] Mt Sinai Sch Med, New York, NY 10029 USA.
RP Keyhani, S (reprint author), James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA.
RI Woodward, Mark/D-8492-2015
NR 4
TC 6
Z9 7
U1 0
U2 1
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD OCT 19
PY 2010
VL 153
IS 8
BP 551
EP 552
DI 10.7326/0003-4819-153-8-201010190-00023
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 665SA
UT WOS:000283054600016
PM 20956718
ER
PT J
AU Chan, ED
Keane, J
Iseman, MD
AF Chan, Edward D.
Keane, Joseph
Iseman, Michael D.
TI Should Cigarette Smoke Exposure Be a Criterion to Treat Latent
Tuberculous Infection?
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Editorial Material
ID TOBACCO SMOKING; PULMONARY TUBERCULOSIS; COLLIDING EPIDEMICS; PASSIVE
SMOKING; RISK-FACTOR; ASSOCIATION; METAANALYSIS; MORTALITY; COPD
C1 [Chan, Edward D.] Univ Colorado, Denver Vet Affairs Med Ctr, Natl Jewish Hlth, Denver, CO 80202 USA.
[Keane, Joseph] Trinity Coll Dublin, Dublin, Ireland.
[Keane, Joseph] St James Hosp, Dublin 8, Ireland.
RP Chan, ED (reprint author), Univ Colorado, Denver Vet Affairs Med Ctr, Natl Jewish Hlth, Anschutz Med Campus, Denver, CO 80202 USA.
OI Keane, Joseph/0000-0001-5313-385X
NR 23
TC 5
Z9 5
U1 0
U2 6
PU AMER THORACIC SOC
PI NEW YORK
PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD OCT 15
PY 2010
VL 182
IS 8
BP 990
EP 992
DI 10.1164/rccm.201006-0861ED
PG 3
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 669XR
UT WOS:000283384000002
PM 20947905
ER
PT J
AU Wu, X
Chen, KW
Yao, L
Ayutyanont, N
Langbaum, JBS
Fleisher, A
Reschke, C
Lee, W
Liu, XF
Alexander, GE
Bandy, D
Foster, NL
Thompson, PM
Harvey, DJ
Weiner, MW
Koeppe, RA
Jagust, WJ
Reiman, EM
AF Wu, Xia
Chen, Kewei
Yao, Li
Ayutyanont, Napatkamon
Langbaum, Jessica B. S.
Fleisher, Adam
Reschke, Cole
Lee, Wendy
Liu, Xiaofen
Alexander, Gene E.
Bandy, Dan
Foster, Norman L.
Thompson, Paul M.
Harvey, Danielle J.
Weiner, Michael W.
Koeppe, Robert A.
Jagust, William J.
Reiman, Eric M.
CA Alzheimer's Dis Neuroimaging Initi
TI Assessing the reliability to detect cerebral hypometabolism in probable
Alzheimer's disease and amnestic mild cognitive impairment
SO JOURNAL OF NEUROSCIENCE METHODS
LA English
DT Article
DE Alzheimer's disease; MCI; FDG-PET; Reproducibility of results;
Reliability; Bootstrap resampling; Family-wise error; SPM
ID POSITRON-EMISSION-TOMOGRAPHY; APOLIPOPROTEIN-E; DEMENTIA; ABNORMALITIES
AB Fluorodeoxyglucose positron emission tomography (FDG-PET) studies report characteristic patterns of cerebral hypometabolism in probable Alzheimer's disease (pAD) and amnestic mild cognitive impairment (aMCI). This study aims to characterize the consistency of regional hypometabolism in pAD and aMCI patients enrolled in the AD neuroimaging initiative (ADNI) using statistical parametric mapping (SPM) and bootstrap resampling, and to compare bootstrap-based reliability index to the commonly used type-I error approach with or without correction for multiple comparisons. Batched SPM5 was run for each of 1000 bootstrap iterations to compare FDG-PET images from 74 pAD and 142 aMCI patients, respectively, to 82 normal controls. Maps of the hypometabolic voxels detected for at least a specific percentage of times over the 1000 runs were examined and compared to an overlap of the hypometabolic maps obtained from 3 randomly partitioned independent sub-datasets. The results from the bootstrap derived reliability of regional hypometabolism in the overall data set were similar to that observed in each of the three non-overlapping sub-sets using family-wise error. Strong but non-linear association was found between the bootstrap-based reliability index and the type-I error. For threshold p = 0.0005, pAD was associated with extensive hypometabolic voxels in the posterior cingulate/precuneus and parietotemporal regions with reliability between 90% and 100%. Bootstrap analysis provides an alternative to the parametric family-wise error approach used to examine consistency of hypometabolic brain voxels in pAD and aMCI patients. These results provide a foundation for the use of bootstrap analysis characterize statistical ROIs or search regions in both cross-sectional and longitudinal FDG-PET studies. This approach offers promise in the early detection and tracking of AD, the evaluation of AD-modifying treatments, and other biologically or clinical important measurements using brain images and voxel-based data analysis techniques. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Chen, Kewei; Ayutyanont, Napatkamon; Langbaum, Jessica B. S.; Fleisher, Adam; Reschke, Cole; Lee, Wendy; Liu, Xiaofen; Bandy, Dan; Reiman, Eric M.] Banner Alzheimers Inst, Phoenix, AZ USA.
[Wu, Xia; Yao, Li] Beijing Normal Univ, Sch Informat Sci & Technol, Beijing 100875, Peoples R China.
[Chen, Kewei] Univ Arizona, Dept Radiol, Tucson, AZ 85724 USA.
[Chen, Kewei] Arizona State Univ, Sch Math & Stat, Tempe, AZ USA.
[Fleisher, Adam] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA.
[Thompson, Paul M.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA.
[Alexander, Gene E.] Univ Arizona, Dept Psychol, Phoenix, AZ USA.
[Alexander, Gene E.] Univ Arizona, Evelyn F McKnight Brain Inst, Phoenix, AZ USA.
[Foster, Norman L.] Univ Utah, Ctr Alzheimers Care Imaging & Res, Salt Lake City, UT 84112 USA.
[Foster, Norman L.] Univ Utah, Dept Neurol, Salt Lake City, UT 84112 USA.
[Weiner, Michael W.] Univ Calif San Francisco, Dept Med Radiol Psychiat & Neurol, San Francisco, CA 94143 USA.
[Weiner, Michael W.] San Francisco VA Med Ctr, Ctr Imaging & Neurodegenerat Dis, San Francisco, CA USA.
[Koeppe, Robert A.] Univ Michigan, Dept Radiol, Div Nucl Med, Ann Arbor, MI 48109 USA.
[Jagust, William J.] Univ Calif Berkeley, Sch Publ Hlth, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA.
[Chen, Kewei; Yao, Li] Beijing Normal Univ, State Key Lab Cognit Neurosci & Learning, Beijing 100875, Peoples R China.
[Harvey, Danielle J.] Univ Calif Davis, Davis, CA 95616 USA.
[Chen, Kewei; Ayutyanont, Napatkamon; Langbaum, Jessica B. S.; Fleisher, Adam; Reschke, Cole; Lee, Wendy; Liu, Xiaofen; Alexander, Gene E.; Bandy, Dan; Reiman, Eric M.] Arizona Alzheimers Consortium, Phoenix, AZ USA.
RP Chen, KW (reprint author), Banner Alzheimers Inst, Phoenix, AZ USA.
EM kewei.chen@bannerhealth.com
RI Scharre, Douglas/E-4030-2011; Chen, kewei/P-6304-2015
OI Chen, kewei/0000-0001-8497-3069
FU National Natural Science Foundation of China [60931003, 60905063,
60805040, 90820019]; National Institute of Mental Health, US [R01
MH57899]; National Institute on Aging, US [9R01AG031581-10, P30 AG19610,
k23 AG24062]; State of Arizona; Alzheimer's Disease Neuroimaging
Initiative (ADNI; National Institutes of Health) [U01 AG024904];
National Institute on Aging; National Institute of Biomedical Imaging
and Bioengineering; NIH [P30 AG010129, K01 AG030514]; Dana Foundation
FX This work was supported by the Key Program of National Natural Science
Foundation of China (60931003) and National Natural Science Foundation
of China (60905063, 60805040, and 90820019). It is also supported by the
National Institute of Mental Health, US (R01 MH57899), the National
Institute on Aging, US (9R01AG031581-10 and P30 AG19610, k23 AG24062)
and the state of Arizona.; Data collection and sharing for this project
was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI;
National Institutes of Health Grant U01 AG024904). ADNI is funded by the
National Institute on Aging, the National Institute of Biomedical
Imaging and Bioengineering, and through generous contributions from the
following: Abbott, AstraZeneca AB, Bayer Schering Pharma AG,
Bristol-Myers Squibb, Eisai Global Clinical Development, Elan
Corporation, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics,
Johnson and Johnson, Eli Lilly and Co., Medpace, Inc., Merck and Co.,
Inc., Novartis AG, Pfizer Inc, F. Hoffman-La Roche, Schering-Plough,
Synarc, Inc., and Wyeth, as well as non-profit partners the Alzheimer's
Association and Alzheimer's Drug Discovery Foundation, with
participation from the U.S. Food and Drug Administration. Private sector
contributions to ADNI are facilitated by the Foundation for the National
Institutes of Health (www.fnih.org). The grantee organization is the
Northern California Institute for Research and Education, and the study
is coordinated by the Alzheimer's Disease Cooperative Study at the
University of California, San Diego. ADNI data are disseminated by the
Laboratory for NeuroImaging at the University of California, Los
Angeles. This research was also supported by NIH grants P30 AG010129,
K01 AG030514, and the Dana Foundation.
NR 14
TC 8
Z9 8
U1 2
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-0270
J9 J NEUROSCI METH
JI J. Neurosci. Methods
PD OCT 15
PY 2010
VL 192
IS 2
BP 277
EP 285
DI 10.1016/j.jneumeth.2010.07.030
PG 9
WC Biochemical Research Methods; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 663YK
UT WOS:000282925900014
PM 20678521
ER
PT J
AU Heinrich, MC
Corless, CL
AF Heinrich, Michael C.
Corless, Christopher L.
TI CANCER Oncogenes in context
SO NATURE
LA English
DT Editorial Material
ID GASTROINTESTINAL STROMAL TUMORS
C1 [Heinrich, Michael C.] Portland VA Med Ctr, Dept Med, Portland, OR 97239 USA.
[Corless, Christopher L.] Portland VA Med Ctr, Dept Pathol, Portland, OR 97239 USA.
OHSU Knight Canc Inst, Portland, OR 97239 USA.
RP Heinrich, MC (reprint author), Portland VA Med Ctr, Dept Med, Portland, OR 97239 USA.
EM heinrich@ohsu.edu
NR 11
TC 5
Z9 5
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD OCT 14
PY 2010
VL 467
IS 7317
BP 796
EP 797
PG 2
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 663PB
UT WOS:000282898700053
PM 20944735
ER
PT J
AU Steinman, MA
Hanlon, JT
AF Steinman, Michael A.
Hanlon, Joseph T.
TI Managing Medications in Clinically Complex Elders "There's Got to Be a
Happy Medium"
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID ADVERSE DRUG EVENTS; RANDOMIZED-CONTROLLED-TRIALS; EMERGENCY-DEPARTMENT
VISITS; OLDER-ADULTS; PRIMARY-CARE; AMBULATORY-CARE; RISK-FACTORS;
DISCONTINUING MEDICATIONS; PHARMACIST INTERVENTION;
GENERAL-PRACTITIONERS
AB Multiple medication use is common in older adults and may ameliorate symptoms, improve and extend quality of life, and occasionally cure disease. Unfortunately, multiple medication use is also a major risk factor for prescribing and adherence problems, adverse drug events, and other adverse health outcomes. Using the case of an older patient taking multiple medications, this article summarizes the evidence-based literature about improving medication use and withdrawing specific drugs and drug classes. It also describes a systematic approach for how health professionals can assess and improve medication regimens to benefit patients and their caregivers and families. JAMA. 2010;304(14):1592-1601 www.jama.com
C1 [Steinman, Michael A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Steinman, Michael A.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.
[Hanlon, Joseph T.] Univ Pittsburgh, Dept Epidemiol, Dept Med, Div Geriatr Med, Pittsburgh, PA 15261 USA.
[Hanlon, Joseph T.] Univ Pittsburgh, Dept Pharm & Therapeut, Pittsburgh, PA USA.
[Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
[Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA.
RP Steinman, MA (reprint author), San Francisco VA Med Ctr, 4150 Clement St,Box 181G, San Francisco, CA 94121 USA.
EM mike.steinman@ucsf.edu
FU National Institute on Aging and the American Federation for Aging
Research [K23 AG030999]; Department of Veterans Affairs [IIR 06-080];
National Institute of Aging [R01AG027017, P30AG024827, T32 AG021885,
K07AG033174, R01AG034056]; National Institute of Mental Health [R34
MH082682]; National Institute of Nursing Research [R01 NR010135]; Agency
for Healthcare Research and Quality [HS017695, HS018721]; Veterans
Administration Health Services [IIR06-062]; SCAN Foundation
FX Dr Steinman was supported by the National Institute on Aging and the
American Federation for Aging Research (K23 AG030999) and by the
Department of Veterans Affairs (IIR 06-080). Dr Hanlon was supported by
grants from the National Institute of Aging (R01AG027017, P30AG024827,
T32 AG021885, K07AG033174, and R01AG034056), the National Institute of
Mental Health (R34 MH082682), the National Institute of Nursing Research
(R01 NR010135), the Agency for Healthcare Research and Quality (HS017695
and HS018721), and a Veterans Administration Health Services research
grant (IIR06-062). The Care of the Aging Patient series is made possible
by funding from The SCAN Foundation.
NR 97
TC 134
Z9 137
U1 3
U2 10
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD OCT 13
PY 2010
VL 304
IS 14
BP 1592
EP 1601
DI 10.1001/jama.2010.1482
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 662OE
UT WOS:000282816500024
PM 20940385
ER
PT J
AU Shabani, S
Foster, R
Gubner, N
Phillips, TJ
Mark, GP
AF Shabani, S.
Foster, R.
Gubner, N.
Phillips, T. J.
Mark, G. P.
TI MUSCARINIC TYPE 2 RECEPTORS IN THE LATERAL DORSAL TEGMENTAL AREA
MODULATE COCAINE AND FOOD SEEKING BEHAVIOR IN RATS
SO NEUROSCIENCE
LA English
DT Article
DE cocaine; addiction; acetylcholine; muscarinic; self-administration;
motivation
ID ACCUMBAL DOPAMINE RELEASE; NUCLEUS-ACCUMBENS; CHOLINERGIC NEURONS;
ACETYLCHOLINE-RECEPTORS; GLUTAMATE RECEPTORS; RETICULAR-FORMATION;
GABAERGIC NEURONS; IN-VITRO; STIMULATION; LATERODORSAL
AB The cholinergic input from the lateral dorsal tegmental area (LDTg) modulates the dopamine cells of the ventral tegmental area (VTA) and plays an important role in cocaine taking. Specific pharmacological agents that block or stimulate muscarinic receptors in the LDTg change acetylcholine (ACh) levels in the VTA. Furthermore, manipulations of cholinergic input in the VTA can change cocaine taking. In the current study, the ACh output from the LDTg was attenuated by treatment with the selective muscarinic type 2 (M2) autoreceptor agonist oxotremorine . sesquifumarate (OxoSQ). We hypothesized that OxoSQ would reduce the motivation of rats to self-administer both natural and drug rewards. Animals were tested on progressive ratio (PR) schedules of reinforcement for food pellets and cocaine. On test days, animals on food and on cocaine schedules were bilaterally microinjected prior to the test. Rats received either LDTg OxoSQ infusions or LDTg artificial cerebrospinal fluid (aCSF) infusions in a within-subjects design. In addition, infusions were delivered into a dorsal brain area above the LDTg as an anatomical control region. OxoSQ microinjection in the LDTg, compared to aCSF, significantly reduced both the number of self-administered pellets and cocaine infusions during the initial half of the session; this reduction was dose-dependent. OxoSQ microinjections into the area just dorsal to the LDTg had no significant effect on self-administration of food pellets or cocaine. Animals were also tested in locomotor activity chambers for motor effects following the above microinjections. Locomotor activity was mildly increased by OxoSQ microinjection into the LDTg during the initial half of the session. Overall, these data suggest that LDTg cholinergic neurons play an important role in modifying the reinforcing value of natural and drug rewards. These effects cannot be attributed to significant alterations of locomotor behavior and are likely accomplished through LDTg muscarinic autoreceptors. Published by Elsevier Ltd on behalf of IBRO.
C1 [Shabani, S.; Foster, R.; Gubner, N.; Phillips, T. J.; Mark, G. P.] Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
[Phillips, T. J.] Portland VA Med Ctr, Portland, OR 97239 USA.
RP Shabani, S (reprint author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk,Rd L470, Portland, OR 97239 USA.
EM shabanis@ohsu.edu
FU NIH [RO1 DA14639, T32 DA07262, P50 DA018165]; Department of Veterans
Affairs
FX We would like to thank Dr. Stephen T. Hansen for providing training on
all the surgical procedures mentioned in this study, Dr. Ted Benice for
his help with Med Associates software, and Tamie Painter for her
technical support. We would also like to thank Dr. Suzanne Mitchell for
her advice and generous support with lab space and equipment during the
locomotor activity experiment. This work was supported by NIH grants RO1
DA14639 and T32 DA07262, and P50 DA018165, and by the Department of
Veterans Affairs.
NR 59
TC 8
Z9 10
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
EI 1873-7544
J9 NEUROSCIENCE
JI Neuroscience
PD OCT 13
PY 2010
VL 170
IS 2
BP 559
EP 569
DI 10.1016/j.neuroscience.2010.07.028
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA 651PH
UT WOS:000281939100018
PM 20667466
ER
PT J
AU Reite, M
Reite, E
Collins, D
Teale, P
Rojas, DC
Sandberg, E
AF Reite, Martin
Reite, Erik
Collins, Dan
Teale, Peter
Rojas, Donald C.
Sandberg, Elliot
TI Brain size and brain/intracranial volume ratio in major mental illness
SO BMC PSYCHIATRY
LA English
DT Article
ID SCHIZOAFFECTIVE DISORDER; BIPOLAR DISORDER; SCHIZOPHRENIA; METAANALYSIS;
ENDOPHENOTYPES; MRI; CSF; AGE
AB Background: This paper summarizes the findings of a long term study addressing the question of how several brain volume measure are related to three major mental illnesses in a Colorado subject group. It reports results obtained from a large N, collected and analyzed by the same laboratory over a multiyear period, with visually guided MRI segmentation being the primary initial analytic tool.
Methods: Intracerebral volume (ICV), total brain volume (TBV), ventricular volume (W), ventricular/brain ratio (VBR), and TBV/ICV ratios were calculated from a total of 224 subject MRIs collected over a period of 13 years. Subject groups included controls (C, N = 89), and patients with schizophrenia (SZ, N = 58), bipolar disorder (BD, N = 51), and schizoaffective disorder (SAD, N = 26).
Results: ICV, TBV, and W measures compared favorably with values obtained by other research groups, but in this study did not differ significantly between groups. TBV/ICV ratios were significantly decreased, and VBR increased, in the SZ and BD groups compared to the C group. The SAD group did not differ from C on any measure.
Conclusions: In this study TBV/ICV and VBR ratios separated SZ and BD patients from controls. Of interest however, SAD patients did not differ from controls on these measures. The findings suggest that the gross measure of TBV may not reliably differ in the major mental illnesses to a degree useful in diagnosis, likely due to the intrinsic variability of the measures in question; the differences in VBR appear more robust across studies. Differences in some of these findings compared to earlier reports from several laboratories finding significant differences between groups in W and TBV may relate to phenomenological drift, differences in analytic techniques, and possibly the "file drawer problem".
C1 [Reite, Martin; Collins, Dan; Teale, Peter; Rojas, Donald C.] Univ Colorado Denver, Dept Psychiat, Aurora, CO USA.
[Reite, Erik] Eglin AFB Hosp, Ft Walton Beach, FL USA.
[Sandberg, Elliot] Denver VAMC, Dept Radiol, Denver, CO USA.
RP Reite, M (reprint author), Univ Colorado Denver, Dept Psychiat, Aurora, CO USA.
EM martin.reite@ucdenver.edu
RI Rojas, Don/F-4296-2012
OI Rojas, Don/0000-0001-6560-9616
FU USPHS [MH47476, MH64502, MH 088623]; NIH
FX This research was supported by USPHS grants No. MH47476, MH64502, and
088623; MR was Principal Investigator on the NIH grants that funded this
research, and was responsible for the overall design and interpretation
of the findings. ER personally segmented all MRI structures over the
course of the study, and contributed to the literature review and
discussion of how these findings relate to previously published findings
by other laboratories. DC initiated and performed those computer
analytic techniques used to clarify and improve resolution of several of
the brain volume variable, and maintained the final data base
contributing to the manuscript. PT supervised overall accuracy and
comparability of imaging across the several MRI laboratories, and
contributed to the final data analysis and manuscript preparation. DR
was responsible for supervision of experimental design and final data
analysis. ES was responsible for training in neuroanatomy and monitoring
accuracy of image outlines. All authors have read and approved the final
manuscript..
NR 36
TC 6
Z9 6
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-244X
J9 BMC PSYCHIATRY
JI BMC Psychiatry
PD OCT 11
PY 2010
VL 10
AR 79
DI 10.1186/1471-244X-10-79
PG 9
WC Psychiatry
SC Psychiatry
GA 668ZJ
UT WOS:000283315400001
PM 20937136
ER
PT J
AU Das, F
Ghosh-Choudhury, N
Kasinath, BS
Choudhury, GG
AF Das, Falguni
Ghosh-Choudhury, Nandini
Kasinath, Balakuntalam S.
Choudhury, Goutam Ghosh
TI TGF beta enforces activation of eukaryotic elongation factor-2 (eEF2)
via inactivation of eEF2 kinase by p90 ribosomal S6 kinase (p90Rsk) to
induce mesangial cell hypertrophy
SO FEBS LETTERS
LA English
DT Article
DE Diabetic nephropathy; Receptor serine/threonine kinase; mRNA translation
ID MESSENGER-RNA TRANSLATION; DIABETIC-NEPHROPATHY; HIGH GLUCOSE;
FIBRONECTIN EXPRESSION; PROTEIN-SYNTHESIS; PROGRESSION; MECHANISMS;
SIGNAL; ROLES; MAPK
AB eEF2 phosphorylation is under tight control to maintain mRNA translation elongation. We report that TGF beta activates eEF2 by decreasing eEF2 phosphorylation and simultaneously increasing eEF2 kinase phosphorylation. Remarkably, inhibition of Erk1/2 blocked the TGF beta-induced dephosphorylation and phosphorylation of eEF2 and eEF2 kinase. TGF beta increased phosphorylation of p90Rsk in an Erk1/2-dependent manner. Inactive p90Rsk reversed TGF beta-inhibited phosphorylation of eEF2 and suppressed eEF2 kinase activity. Finally, inactive p90Rsk significantly attenuated TGF beta-induced protein synthesis and hypertrophy of mesangial cells. These results present the first evidence that TGF beta utilizes the two layered kinase module Erk/p90Rsk to activate eEF2 for increased protein synthesis during cellular hypertrophy. Published by Elsevier B. V. on behalf of the Federation of European Biochemical Societies.
C1 [Das, Falguni; Kasinath, Balakuntalam S.; Choudhury, Goutam Ghosh] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Ghosh-Choudhury, Nandini; Kasinath, Balakuntalam S.; Choudhury, Goutam Ghosh] S Texas Vet Hlth Care Syst, VA Res, San Antonio, TX USA.
[Choudhury, Goutam Ghosh] S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Res, San Antonio, TX USA.
[Ghosh-Choudhury, Nandini] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
RP Choudhury, GG (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Mail Code 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM choudhuryg@uthscsa.edu
FU NIH [RO1 DK50190, RO1 AR52425, DK 077295, RC2A 036613]; Juvenile
Diabetes Research Foundation [1-2008-185]; VA; VA Research Service
FX NIH RO1 DK50190 and The Juvenile Diabetes Research Foundation 1-2008-185
Grants to GGC supported this work. GGC is a recipient of VA Senior
Research Career Scientist Award and is supported by VA Research Service
Merit Review grant. NGC is supported by VA Merit Review and NIH RO1
AR52425 Grants. BSK is supported by Grants from NIH (DK 077295 and RC2A
036613) and VA Research Service.
NR 27
TC 10
Z9 10
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-5793
J9 FEBS LETT
JI FEBS Lett.
PD OCT 8
PY 2010
VL 584
IS 19
BP 4268
EP 4272
DI 10.1016/j.febslet.2010.09.010
PG 5
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 656TU
UT WOS:000282360800025
PM 20837011
ER
PT J
AU Massie, BM
O'Connor, CM
Metra, M
Ponikowski, P
Teerlink, JR
Cotter, G
Weatherley, BD
Cleland, JGF
Givertz, MM
Voors, AA
DeLucca, P
Mansoor, GA
Salerno, CM
Bloomfield, DM
Dittrich, HC
AF Massie, Barry M.
O'Connor, Christopher M.
Metra, Marco
Ponikowski, Piotr
Teerlink, John R.
Cotter, Gad
Weatherley, Beth Davison
Cleland, John G. F.
Givertz, Michael M.
Voors, Adriaan A.
DeLucca, Paul
Mansoor, George A.
Salerno, Christina M.
Bloomfield, Daniel M.
Dittrich, Howard C.
CA PROTECT Investigators Comm
TI Rolofylline, an Adenosine A(sub 1)-Receptor Antagonist, in Acute Heart
Failure.
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID WORSENING RENAL-FUNCTION; A(1) RECEPTOR ANTAGONIST; RISK STRATIFICATION;
CLINICAL-TRIALS; KIDNEY-FUNCTION; IMPAIRMENT; OUTCOMES; DIAGNOSIS;
KW-3902; IMPACT
AB Background: Worsening renal function, which is associated with adverse outcomes, often develops in patients with acute heart failure. Experimental and clinical studies suggest that counterregulatory responses mediated by adenosine may be involved. We tested the hypothesis that the use of rolofylline, an adenosine A(sub 1)-receptor antagonist, would improve dyspnea, reduce the risk of worsening renal function, and lead to a more favorable clinical course in patients with acute heart failure.
Methods: We conducted a multicenter, double-blind, placebo-controlled trial involving patients hospitalized for acute heart failure with impaired renal function. Within 24 hours after presentation, 2033 patients were randomly assigned, in a 2:1 ratio, to receive daily intravenous rolofylline (30 mg) or placebo for up to 3 days. The primary end point was treatment success, treatment failure, or no change in the patient's clinical condition; this end point was defined according to survival, heart-failure status, and changes in renal function. Secondary end points were the post-treatment development of persistent renal impairment and the 60-day rate of death or readmission for cardiovascular or renal causes.
Results: Rolofylline, as compared with placebo, did not provide a benefit with respect to the primary end point (odds ratio, 0.92; 95% confidence interval, 0.78 to 1.09; P=0.35). Persistent renal impairment developed in 15.0% of patients in the rolofylline group and in 13.7% of patients in the placebo group (P=0.44). By 60 days, death or readmission for cardiovascular or renal causes had occurred in similar proportions of patients assigned to rolofylline and placebo (30.7% and 31.9%, respectively; P=0.86). Adverse-event rates were similar overall; however, only patients in the rolofylline group had seizures, a known potential adverse effect of A(sub 1)-receptor antagonists.
Conclusions: Rolofylline did not have a favorable effect with respect to the primary clinical composite end point, nor did it improve renal function or 60-day outcomes. It does not show promise in the treatment of acute heart failure with renal dysfunction. (Funded by NovaCardia, a subsidiary of Merck; ClinicalTrials.gov numbers, NCT00328692 and NCT00354458.)
N Engl J Med 2010;363:1419-28.
C1 [Massie, Barry M.; Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Massie, Barry M.; Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA.
[O'Connor, Christopher M.] Duke Univ, Med Ctr, Durham, NC USA.
[Cotter, Gad; Weatherley, Beth Davison] Momentum Res, Durham, NC USA.
[Metra, Marco] Univ Brescia, Brescia, Italy.
[Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland.
[Cleland, John G. F.] Univ Hull, Kingston Upon Hull, Yorks, England.
[Givertz, Michael M.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Voors, Adriaan A.] Univ Groningen, Groningen, Netherlands.
[DeLucca, Paul; Salerno, Christina M.] Merck Res Labs, N Wales, PA USA.
[Mansoor, George A.; Bloomfield, Daniel M.] Merck Res Labs, Rahway, NJ USA.
[Dittrich, Howard C.] NovaCardia, San Diego, CA USA.
RP Massie, BM (reprint author), San Francisco VA Med Ctr 111C, Div Cardiol, 4150 Clement St, San Francisco, CA 94121 USA.
EM barry.massie@va.gov
RI ; Teerlink, John/D-2986-2012; Zateyshchikov, Dmitry/D-6575-2012;
Vasilieva, Elena/B-2137-2016; Zadionchenko, Vladimir/A-7445-2016;
Ponikowski, Piotr/O-6454-2015
OI Cleland, John/0000-0002-1471-7016; Zateyshchikov,
Dmitry/0000-0001-7065-2045; Metra, Marco/0000-0001-6691-8568;
Zadionchenko, Vladimir/0000-0003-2377-5266; Ponikowski,
Piotr/0000-0002-3391-7064
FU NovaCardia, a subsidiary of Merck
FX Supported by NovaCardia, a subsidiary of Merck.
NR 28
TC 244
Z9 250
U1 2
U2 17
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 7
PY 2010
VL 363
IS 15
BP 1419
EP 1428
DI 10.1056/NEJMoa0912613
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 659NV
UT WOS:000282575100007
PM 20925544
ER
PT J
AU Chung, KA
Lobb, BM
Nutt, JG
Horak, FB
AF Chung, Kathryn A.
Lobb, Brenna M.
Nutt, John G.
Horak, Fay B.
TI Effects of a central cholinesterase inhibitor on reducing falls in
Parkinson disease
SO NEUROLOGY
LA English
DT Article
ID PEDUNCULOPONTINE TEGMENTAL NUCLEUS; NURSING-HOME RESIDENTS; BASALIS
MAGNOCELLULARIS; POSTURAL CONTROL; DEMENTIA; RISK; ATTENTION; BALANCE;
ANTIDEPRESSANTS; NEURONS
AB Objective: To investigate if a central cholinesterase inhibitor will reduce falling frequency in subjects with Parkinson disease (PD) with advanced postural instability.
Background: Falling due to postural instability is a significant problem in advancing PD, and is minimally impacted by dopaminergic therapy. Anticholinergic medications increase falling in the elderly. Further, CNS cholinergic neuron loss occurs in PD. We hypothesized that acetylcholine augmentation may reduce frequent falling in subjects with PD.
Methods: We enrolled 23 subjects with PD who reported falling or nearly falling more than 2 times per week. In a randomized, placebo-controlled, crossover design, subjects were given 6 weeks of donepezil or placebo with a 3-week washout between phases. The primary outcomes were daily falls and near falls reported on postcards. Secondary outcomes included scores on the Activities of Balance Confidence Scale, Berg Balance Scale, Clinical Global Impression of Change, Folstein Mini-Mental State Examination, and the motor section of the Unified Parkinson's Disease Rating Scale.
Results: Fall frequency per day on placebo was 0.25 +/- 0.08 (SEM) compared with 0.13 +/- 0.03 on donepezil (p < 0.05). The frequency of near falls was not significantly different between phases. The secondary outcomes did not differ; however, there was a trend to improvement on the subject-completed Global Impression of Change scale.
Conclusions: Subjects with PD fell approximately half as often during the 6 weeks on donepezil than on placebo. Larger trials of cholinergic augmentation are warranted in subjects with PD with frequent falls.
Classification of evidence: This study provides Class II evidence that donepezil (maximum 10 mg per day) significantly reduced the number of falls in patients with PD (0.13 falls/day, SEM = 0.03) than when taking placebo (0.25 falls/day, SEM = 0.08, p = 0.049). Neurology (R) 2010;75:1263-1269
C1 [Chung, Kathryn A.; Nutt, John G.; Horak, Fay B.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA.
[Lobb, Brenna M.] Portland VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Portland, OR USA.
RP Chung, KA (reprint author), OP 32,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM chungka@ohsu.edu
FU Veterans Administration; US Public Health Service [ULIRR024140-02]; NIH
[R01-NS21062, NIA AG006457, NINDS R01 NS 21062, UL1-RR024140, NIDCD R01
DC004082-07, NIA R37 AG006457, RC1 NS068678]; Pfizer Inc.; Department of
Veterans Affairs; Novartis; Teva Pharmaceutical Industries Ltd.;
Schering-Plough Corp; National Parkinson Foundation; National MS
Society; Parkinson's Alliance; Kinetics Foundation
FX This was an investigator-initiated project funded with an unrestricted
grant from Pfizer Inc., who did not design or monitor the study or
receive the data or influence the writing of the manuscript. Supported
by a Veterans Administration Career Development Award, US Public Health
Service Grant (ULIRR024140-02), and the NIH (R01-NS21062 and NIA
AG006457). Pfizer Inc. provided drug and matched placebo.; Dr. Chung has
received research support from a VA Career Development Award. B. M. Lobb
receives support from the Department of Veterans Affairs. Dr. Nutt has
received funding for travel from Novartis and Teva Pharmaceutical
Industries Ltd.; has received speaker honoraria from Novartis; has
served as a consultant for XenoPort Inc., IMPAX Laboratories, Inc.,
Neurogen Inc., Synosia Therapeutics, and NeuroDerm, Ltd.; and has
received research support from Schering-Plough Corp, the NIH (NINDS R01
NS 21062 [PI] and UL1-RR024140 [PI]), the Veterans Administration
(PADRECC [Co-PI]), and the National Parkinson Foundation. Dr. Horak
serves on scientific advisory boards for the Movement Disorders Society,
Novartis, and the MS Society; serves as an Associate Editor for
Cerebellum and on the editorial boards of Gait and Posture and the
Journal of Biomechanics; holds/has filed patents re: Device for
conditioning balance and motor coordination and instrumented mobility
system to objectively measure balance and gait; serves as Chief
Scientific Officer and member of the board of APDM, Inc.; and receives
research support from the NIH (NIDCD R01 DC004082-07 [PI], NIA R37
AG006457 [PI], and RC1 NS068678 [PI]), the National MS Society,
Parkinson's Alliance, and the Kinetics Foundation.
NR 39
TC 89
Z9 92
U1 2
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD OCT 5
PY 2010
VL 75
IS 14
BP 1263
EP 1269
DI 10.1212/WNL.0b013e3181f6128c
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 663JW
UT WOS:000282883900011
PM 20810998
ER
PT J
AU Canolty, RT
Ganguly, K
Kennerley, SW
Cadieu, CF
Koepsell, K
Wallis, JD
Carmena, JM
AF Canolty, Ryan T.
Ganguly, Karunesh
Kennerley, Steven W.
Cadieu, Charles F.
Koepsell, Kilian
Wallis, Jonathan D.
Carmena, Jose M.
TI Oscillatory phase coupling coordinates anatomically dispersed functional
cell assemblies
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE neuronal oscillations; neuronal ensembles; spike timing; local field
potentials; brain rhythms
ID NEURONAL OSCILLATIONS; NEOCORTICAL NEURONS; THETA-OSCILLATIONS;
AUDITORY-CORTEX; MOTOR CORTEX; BEHAVING RAT; IN-VITRO; GAMMA; NETWORK;
SYNCHRONIZATION
AB Hebb proposed that neuronal cell assemblies are critical for effective perception, cognition, and action. However, evidence for brain mechanisms that coordinate multiple coactive assemblies remains lacking. Neuronal oscillations have been suggested as one possible mechanism for cell assembly coordination. Prior studies have shown that spike timing depends upon local field potential (LFP) phase proximal to the cell body, but few studies have examined the dependence of spiking on distal LFP phases in other brain areas far from the neuron or the influence of LFP-LFP phase coupling between distal areas on spiking. We investigated these interactions by recording LFPs and single-unit activity using multiple microelectrode arrays in several brain areas and then used a unique probabilistic multivariate phase distribution to model the dependence of spike timing on the full pattern of proximal LFP phases, distal LFP phases, and LFP-LFP phase coupling between electrodes. Here we show that spiking activity in single neurons and neuronal ensembles depends on dynamic patterns of oscillatory phase coupling between multiple brain areas, in addition to the effects of proximal LFP phase. Neurons that prefer similar patterns of phase coupling exhibit similar changes in spike rates, whereas neurons with different preferences show divergent responses, providing a basic mechanism to bind different neurons together into coordinated cell assemblies. Surprisingly, phase-coupling-based rate correlations are independent of interneuron distance. Phase-coupling preferences correlate with behavior and neural function and remain stable over multiple days. These findings suggest that neuronal oscillations enable selective and dynamic control of distributed functional cell assemblies.
C1 [Canolty, Ryan T.; Ganguly, Karunesh; Kennerley, Steven W.; Cadieu, Charles F.; Koepsell, Kilian; Wallis, Jonathan D.; Carmena, Jose M.] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA.
[Ganguly, Karunesh] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Ganguly, Karunesh] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.
[Cadieu, Charles F.; Koepsell, Kilian] Univ Calif Berkeley, Redwood Ctr Theoret Neurosci, Berkeley, CA 94720 USA.
[Wallis, Jonathan D.] Univ Calif Berkeley, Dept Psychol, Berkeley, CA 94720 USA.
[Carmena, Jose M.] Univ Calif Berkeley, Program Cognit Sci, Berkeley, CA 94720 USA.
RP Carmena, JM (reprint author), Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA.
EM carmena@eecs.berkeley.edu
OI Wallis, Joni/0000-0001-7262-7417
FU National Institutes of Health [R01DA-19028, P01NS-040813, F32MH-081521];
National Science Foundation [IIS-0941343, IIS-0917342, IIS-1010239]; US
Department of Veterans Affairs and American Heart Association; Defense
Advanced Research Projects Agency [N66001-10-C-2008]; Multiscale Systems
Center
FX This work was funded by National Institutes of Health Grants R01DA-19028
and P01NS-040813 (to J.D.W.), National Institutes of Health Grant
F32MH-081521 (to S.W.K.), National Science Foundation Grants IIS-0941343
(to J.M.C.), IIS-0917342 (to K.K.) and IIS-1010239 (to C.F.C. and K.K.),
the US Department of Veterans Affairs and American Heart Association (to
K.G.), the Defense Advanced Research Projects Agency Contract
N66001-10-C-2008, and the Multiscale Systems Center (to J.M.C.).
NR 48
TC 115
Z9 116
U1 0
U2 17
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 5
PY 2010
VL 107
IS 40
BP 17356
EP 17361
DI 10.1073/pnas.1008306107
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 658TJ
UT WOS:000282512000056
PM 20855620
ER
PT J
AU Lomonaco, R
Ortiz-Lopez, C
Orsak, B
Finch, J
King, J
Cusi, K
AF Lomonaco, Romina
Ortiz-Lopez, Carolina
Orsak, Beverly
Finch, Joan
King, James
Cusi, Kenneth
TI PREVALENCE OF NAFLD BY MRS AND ROLE OF INSULIN RESISTANCE AND T2DM IN
THE DEVELOPMENT OF NASH IN A PREDOMINANTLY HISPANIC POPULATION
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 61st Annual Meeting of the
American-Association-for-the-Study-of-Liver-Diseases
CY OCT 29-NOV 02, 2010
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Lomonaco, Romina; Ortiz-Lopez, Carolina; Orsak, Beverly; King, James; Cusi, Kenneth] Univ Texas Hlth Sci Ctr San Antonio, Diabet Div, San Antonio, TX 78229 USA.
[Finch, Joan; Cusi, Kenneth] Vet Adm Med Ctr, Diabet Div, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2010
VL 52
IS 4
SU S
MA 624
BP 619A
EP 620A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 740EY
UT WOS:000288775600623
ER
PT J
AU Ortiz-Lopez, C
Webb, A
Lomonaco, R
Orsak, B
Darland, CM
Finch, J
Diaz, N
Cusi, K
AF Ortiz-Lopez, Carolina
Webb, Amy
Lomonaco, Romina
Orsak, Beverly
Darland, Celia M.
Finch, Joan
Diaz, Norma
Cusi, Kenneth
TI ABNORMAL GLUCOSE METABOLISM IS FREQUENTLY OVERLOOKED IN PATIENTS WITH
NASH AND ASSOCIATED WITH SEVERE HEPATIC AND ADIPOSE TISSUE INSULIN
RESISTANCE
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 61st Annual Meeting of the
American-Association-for-the-Study-of-Liver-Diseases
CY OCT 29-NOV 02, 2010
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Ortiz-Lopez, Carolina; Webb, Amy; Lomonaco, Romina; Orsak, Beverly; Finch, Joan; Cusi, Kenneth] Univ Texas Hlth Sci Ctr San Antonio, Diabet Div, San Antonio, TX 78229 USA.
[Webb, Amy; Darland, Celia M.; Finch, Joan; Diaz, Norma; Cusi, Kenneth] Audie L Murphy Vet Affairs Hosp, Diabet Div, San Antonio, TX USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2010
VL 52
IS 4
SU S
MA 628
BP 621A
EP 622A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 740EY
UT WOS:000288775600627
ER
PT J
AU Vermehren, J
Yu, ML
Monto, A
Yao, JD
Anderson, C
Bertuzis, R
Schneider, G
Sarrazin, C
AF Vermehren, Johannes
Yu, Ming-Lung
Monto, Alexander
Yao, Joseph D.
Anderson, Christopher
Bertuzis, Rasa
Schneider, George
Sarrazin, Christoph
TI CLINICAL UTILITY OF THE REALTIME HCV ASSAY (ABBOTT MOLECULAR) FOR
RESPONSE-GUIDED THERAPY IN PATIENTS INFECTED WITH HCV GENOTYPES 1, 2, OR
3 AND TREATED WITH PEGINTERFERON-ALFA PLUS RIBAVIRIN (PEGIFN/RBV)
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 61st Annual Meeting of the
American-Association-for-the-Study-of-Liver-Diseases
CY OCT 29-NOV 02, 2010
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Vermehren, Johannes; Sarrazin, Christoph] Klinikum JW Goethe Univ, Med Klin 1, Frankfurt, Germany.
[Yu, Ming-Lung] Kaohsiung Med Univ Hosp, Kaohsiung, Taiwan.
[Monto, Alexander] San Francisco VA Med Ctr, San Francisco, CA USA.
[Yao, Joseph D.] Mayo Med Labs, Rochester, MN USA.
[Anderson, Christopher; Bertuzis, Rasa; Schneider, George] Abbott Mol, Des Plaines, IL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2010
VL 52
IS 4
SU S
MA 972
BP 789A
EP 790A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 740EY
UT WOS:000288775601290
ER
PT J
AU Enestvedt, B
Enestvedt, CK
Faigel, DO
Orloff, SL
AF Enestvedt, Brintha
Enestvedt, C. Kristian
Faigel, Douglas O.
Orloff, Susan L.
TI RISK FACTORS FOR BILIARY STRICTURE POST ORTHOTOPIC LIVER
TRANSPLANTATION: A SINGLE CENTER EXPERIENCE
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 61st Annual Meeting of the
American-Association-for-the-Study-of-Liver-Diseases
CY OCT 29-NOV 02, 2010
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Enestvedt, Brintha; Enestvedt, C. Kristian; Faigel, Douglas O.; Orloff, Susan L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Orloff, Susan L.] Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2010
VL 52
IS 4
SU S
MA 1073
BP 838A
EP 838A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 740EY
UT WOS:000288775601391
ER
PT J
AU Kim, CW
Torrey, K
Valiga, ME
Cho, H
Lee, CD
Chang, KM
AF Kim, Chang Wook
Torrey, Keith
Valiga, Mary E.
Cho, Hyosun
Lee, Chang Don
Chang, Kyong-Mi
TI HBV-SPECIFIC T CELL RESPONSE OF HCV-INFECTED PATIENTS WITH ISOLATED
ANTI-HBC AND COMBINED ANTI-HBC/ANTI-HBS ANTIBODY RESPONSE
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 61st Annual Meeting of the
American-Association-for-the-Study-of-Liver-Diseases
CY OCT 29-NOV 02, 2010
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Torrey, Keith; Valiga, Mary E.; Cho, Hyosun; Chang, Kyong-Mi] Philadelphia VA Med Ctr, GI Hepatol Res Ctr, Philadelphia, PA USA.
[Kim, Chang Wook; Torrey, Keith; Valiga, Mary E.; Cho, Hyosun; Chang, Kyong-Mi] Univ Penn, Philadelphia, PA 19104 USA.
[Kim, Chang Wook; Lee, Chang Don] Catholic Univ Korea, Seoul, South Korea.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2010
VL 52
IS 4
SU S
MA 1372
BP 980A
EP 981A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 740EY
UT WOS:000288775601702
ER
PT J
AU Kaplan, DE
Daruich, J
Jalali, Z
Rafiullah
Nunez, M
Vogel, M
Vispo, E
Barreiro, P
Rockstroh, JK
Mauss, S
Brau, N
AF Kaplan, David E.
Daruich, Jorge
Jalali, Ziba
Rafiullah
Nunez, Marina
Vogel, Martin
Vispo, Eugenia
Barreiro, Pablo
Rockstroh, Juergen K.
Mauss, Stefan
Braeu, Norbert
TI AGE AND HEPATOCELLULAR CARCINOMA IN HIV-INFECTED PATIENTS
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 61st Annual Meeting of the
American-Association-for-the-Study-of-Liver-Diseases
CY OCT 29-NOV 02, 2010
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Kaplan, David E.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Kaplan, David E.] Univ Penn, Sch Med, Div Gastroenterol, Philadelphia, PA 19104 USA.
[Daruich, Jorge] Univ Buenos Aires, Secc Hepatol, Buenos Aires, DF, Argentina.
[Jalali, Ziba] Univ Nebraska Med Ctr, Div Infect Dis, Omaha, NE USA.
[Rafiullah; Braeu, Norbert] Bronx VA Med Ctr, Bronx, NY USA.
[Nunez, Marina] Wake Forest Univ, Div Infect Dis, Winston Salem, NC 27109 USA.
[Vogel, Martin; Rockstroh, Juergen K.] Univ Klinikum Bonn, Bonn, Germany.
[Vispo, Eugenia; Barreiro, Pablo] Hosp Carlos III, Madrid, Spain.
[Mauss, Stefan] Dusseldorf Ctr HIV & HepatoGastroenterol, Dusseldorf, Germany.
[Braeu, Norbert] Mt Sinai Sch Med, Div Infect Dis, New York, NY USA.
[Braeu, Norbert] Mt Sinai Sch Med, Div Liver Dis, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2010
VL 52
IS 4
SU S
MA 1795
BP 1174A
EP 1175A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 740EY
UT WOS:000288775602413
ER
PT J
AU Kramer, B
Jouldjian, S
Wang, M
Mitchell, M
Finke, B
AF Kramer, B.
Jouldjian, S.
Wang, M.
Mitchell, M.
Finke, B.
TI A MODEL FOR THE USE OF VETERANS HEALTH AFFAIRS AND/OR INDIAN HEALTH
SERVICE BY OLDER AMERICAN INDIAN AND ALASKA NATIVE VETERANS
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Kramer, B.; Jouldjian, S.; Wang, M.; Mitchell, M.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA.
[Kramer, B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Finke, B.] Indian Hlth Serv, Nashville, TN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD OCT
PY 2010
VL 50
SU 1
BP 16
EP 16
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 703UL
UT WOS:000286006701076
ER
PT J
AU Spira, AP
Stone, KL
Redline, S
Ensrud, K
Yaffe, K
AF Spira, A. P.
Stone, K. L.
Redline, S.
Ensrud, K.
Yaffe, K.
TI ACTIGRAPHIC SLEEP AND NEUROPSYCHOLOGICAL TEST PERFORMANCE IN VERY OLD
WOMEN
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Spira, A. P.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA.
[Stone, K. L.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA.
[Redline, S.] Case Western Reserve Univ, Cleveland, OH 44106 USA.
[Ensrud, K.] Univ Minnesota, Minneapolis, MN USA.
[Ensrud, K.] Minnepolis VA Med Ctr, Minneapolis, MN USA.
[Yaffe, K.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Yaffe, K.] San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD OCT
PY 2010
VL 50
SU 1
BP 37
EP 37
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 703UL
UT WOS:000286006701178
ER
PT J
AU Yaffe, K
Laffan, A
Harrison, SL
Spira, AP
Ensrud, K
Ancoli-Israel, S
Redline, S
Stone, KL
AF Yaffe, K.
Laffan, A.
Harrison, S. Litwack
Spira, A. P.
Ensrud, K.
Ancoli-Israel, S.
Redline, S.
Stone, K. L.
TI SLEEP DISORDERED BREATHING, HYPOXIA, AND RISK OF MILD COGNITIVE
IMPAIRMENT & DEMENTIA IN OLDER WOMEN
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Yaffe, K.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Yaffe, K.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Laffan, A.; Harrison, S. Litwack; Stone, K. L.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA.
[Spira, A. P.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Ensrud, K.] Univ Minnesota, Minneapolis, MN USA.
[Ensrud, K.] Minneapolis VA Med Ctr, Minneapolis, MN USA.
[Ancoli-Israel, S.] Univ Calif San Diego, San Diego, CA 92103 USA.
[Redline, S.] Case Western Reserve Univ, Cleveland, OH 44106 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD OCT
PY 2010
VL 50
SU 1
BP 37
EP 37
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 703UL
UT WOS:000286006701179
ER
PT J
AU Laffan, A
Stone, KL
Blackwell, T
Ancoli-Israel, S
Ensrud, K
Redline, S
Slinin, Y
Yaffe, K
AF Laffan, A.
Stone, K. L.
Blackwell, T.
Ancoli-Israel, S.
Ensrud, K.
Redline, S.
Slinin, Y.
Yaffe, K.
TI SLEEP DURATION AND DISRUPTION: ASSOCIATIONS WITH COGNITIVE DECLINE IN
OLDER MEN
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Laffan, A.; Stone, K. L.; Blackwell, T.] Calif Pacific Med Ctr, San Francisco, CA USA.
[Yaffe, K.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Ancoli-Israel, S.] Univ Calif San Diego, San Diego, CA 92103 USA.
[Yaffe, K.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Ensrud, K.; Slinin, Y.] Vet Affairs Med Ctr, Minneapolis, MN USA.
[Redline, S.] Case Western Reserve Univ, Cleveland, OH 44106 USA.
[Ensrud, K.; Slinin, Y.] Univ Minnesota, Minneapolis, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD OCT
PY 2010
VL 50
SU 1
BP 38
EP 38
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 703UL
UT WOS:000286006701181
ER
PT J
AU Lee, CG
Boyko, EJ
Strotmeyer, ES
Cawthon, PM
Hoffman, AR
Everson-Rose, S
Barrett-Connor, E
Orwoll, E
AF Lee, C. G.
Boyko, E. J.
Strotmeyer, E. S.
Cawthon, P. M.
Hoffman, A. R.
Everson-Rose, S.
Barrett-Connor, E.
Orwoll, E.
TI INCREASED RISK OF LEAN MASS LOSS ASSOCIATED WITH INSULIN RESISTANCE IN
OLDER MEN
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Lee, C. G.; Orwoll, E.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Boyko, E. J.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Strotmeyer, E. S.] Univ Pittsburgh, Pittsburgh, PA USA.
[Cawthon, P. M.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA.
[Hoffman, A. R.] Stanford Sch Med, Palo Alto, CA USA.
[Everson-Rose, S.] Univ Minnesota, Minneapolis, MN USA.
[Barrett-Connor, E.] Univ Calif San Diego, San Diego, CA 92103 USA.
RI Strotmeyer, Elsa/F-3015-2014
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD OCT
PY 2010
VL 50
SU 1
BP 41
EP 41
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 703UL
UT WOS:000286006701195
ER
PT J
AU Shrestha, S
Bradford, A
Snow, A
Wilson, N
Stanley, M
Kunik, ME
AF Shrestha, S.
Bradford, A.
Snow, A.
Wilson, N.
Stanley, M.
Kunik, M. E.
TI PREVENTING AGGRESSION IN VETERANS WITH DEMENTIA
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Shrestha, S.; Bradford, A.; Wilson, N.; Stanley, M.; Kunik, M. E.] Baylor Coll Med, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA.
[Stanley, M.; Kunik, M. E.] Michael E Debakey Vet Affair Med Ctr, Houston, TX USA.
[Snow, A.] Univ Alabama, Tuscaloosa, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD OCT
PY 2010
VL 50
SU 1
BP 66
EP 66
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 703UL
UT WOS:000286006701315
ER
PT J
AU Ahluwalia, S
Leos, R
Goebel, JR
Lorenz, K
AF Ahluwalia, S.
Leos, R.
Goebel, J. R.
Lorenz, K.
TI A USER-CENTERED DESIGN APPROACH TO THE DEVELOPMENT OF A CLINICAL
INFORMATICS SYMPTOM ASSESSMENT TOOL
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Ahluwalia, S.; Leos, R.; Goebel, J. R.; Lorenz, K.] Vet Adm Greater Los Angeles, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD OCT
PY 2010
VL 50
SU 1
BP 132
EP 132
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 703UL
UT WOS:000286006701630
ER
PT J
AU Tsukuda, R
AF Tsukuda, R.
TI INTERDISCIPLINARY TEAMWORK: LESSONS HISTORY CAN TEACH US FOR THE FUTURE
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Tsukuda, R.] Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD OCT
PY 2010
VL 50
SU 1
BP 141
EP 141
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 703UL
UT WOS:000286006701674
ER
PT J
AU Menon, S
McCullough, LB
Espadas, D
Braun, U
AF Menon, S.
McCullough, L. B.
Espadas, D.
Braun, U.
TI FEASIBILITY OF USING A VALUES INVENTORY AS A DISCUSSION AID ABOUT
END-OF-LIFE CARE
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Menon, S.; McCullough, L. B.; Espadas, D.; Braun, U.] VA Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA.
[Braun, U.] Baylor Coll Med, Dept Med, Sect Geriatr, Houston, TX 77030 USA.
[McCullough, L. B.; Braun, U.] Baylor Coll Med, Ctr Eth & Hlth Policy, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD OCT
PY 2010
VL 50
SU 1
BP 211
EP 211
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 703UL
UT WOS:000286006702131
ER
PT J
AU Espinoza, SE
Hazuda, HP
AF Espinoza, S. E.
Hazuda, H. P.
TI FRAILTY IN MEXICAN AMERICANS: WHERE THEY LIVE MAKES A DIFFERENCE
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Espinoza, S. E.] Univ Texas Hlth Sci Ctr San Antonio, Div Geriatr & Gerontol, San Antonio, TX 78229 USA.
[Hazuda, H. P.] Univ Texas Hlth Sci Ctr San Antonio Med, Div Clin Epidemiol, San Antonio, TX USA.
[Espinoza, S. E.; Hazuda, H. P.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD OCT
PY 2010
VL 50
SU 1
BP 212
EP 213
PG 2
WC Gerontology
SC Geriatrics & Gerontology
GA 703UL
UT WOS:000286006702137
ER
PT J
AU Espinoza, SE
Pierce, A
Halade, D
Richardson, A
AF Espinoza, S. E.
Pierce, A.
Halade, D.
Richardson, A.
TI PLASMA HAPTOGLOBIN IN PRE-FRAIL OLDER ADULTS: A PILOT STUDY
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Espinoza, S. E.; Pierce, A.; Halade, D.; Richardson, A.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
[Espinoza, S. E.; Pierce, A.; Halade, D.; Richardson, A.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD OCT
PY 2010
VL 50
SU 1
BP 213
EP 213
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 703UL
UT WOS:000286006702138
ER
PT J
AU Ahluwalia, S
Gross, CP
Chaudhry, S
Fried, TR
AF Ahluwalia, S.
Gross, C. P.
Chaudhry, S.
Fried, T. R.
TI THE IMPACT OF COMORBIDITY ON MORTALITY AMONG OLDER PERSONS WITH ADVANCED
HEART FAILURE
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Ahluwalia, S.] Vet Adm Greater Los Angeles, Los Angeles, CA USA.
[Gross, C. P.; Chaudhry, S.; Fried, T. R.] Yale Univ, New Haven, CT USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD OCT
PY 2010
VL 50
SU 1
BP 215
EP 215
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 703UL
UT WOS:000286006702147
ER
PT J
AU Hutt, E
Ho, M
Pointer, L
Shahan, E
AF Hutt, E.
Ho, M.
Pointer, L.
Shahan, E.
TI EFFECTIVENESS OF ACEI/ARBS IN VA NURSING HOME RESIDENTS WITH HEART
FAILURE
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Hutt, E.; Ho, M.; Pointer, L.; Shahan, E.] Univ Colorado, Denver VAMC, Denver, CO 80202 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD OCT
PY 2010
VL 50
SU 1
BP 215
EP 215
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 703UL
UT WOS:000286006702148
ER
PT J
AU Ahluwalia, S
Gross, CP
Chaudhry, S
Fried, TR
AF Ahluwalia, S.
Gross, C. P.
Chaudhry, S.
Fried, T. R.
TI A LONGITUDINAL ANALYSIS OF COMORBIDITY BURDEN AMONG OLDER ADULTS WITH
HEART FAILURE
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Ahluwalia, S.] Vet Adm Greater Los Angeles, Los Angeles, CA USA.
[Gross, C. P.; Chaudhry, S.; Fried, T. R.] Yale Univ, New Haven, CT USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD OCT
PY 2010
VL 50
SU 1
BP 216
EP 216
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 703UL
UT WOS:000286006702150
ER
PT J
AU Griffith, JL
AF Griffith, J. L.
TI SOCIAL SUPPORT AND SEXUAL INTEREST IN OLDER ADULTHOOD: A PROFILE FROM
THE NATIONAL SOCIAL LIFE, HEALTH AND AGING PROJECT (NSHAP)
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY USA.
Ctr Geriatr Res Educ & Clin, James J Peters VA Med Ctr, Bronx, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD OCT
PY 2010
VL 50
SU 1
BP 240
EP 241
PG 2
WC Gerontology
SC Geriatrics & Gerontology
GA 703UL
UT WOS:000286006702273
ER
PT J
AU Lane, D
AF Lane, D.
TI "POINTS TO CONSIDER IN PLANNING FOR A SUCCESSFUL CAREER PROVIDING
PSYCHOLOGICAL CARE TO OLDER ADULTS"
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Lane, D.] VA Puget Sound Healthcare Syst, Geriatr & Extended Care Serv, Tacoma, WA USA.
[Lane, D.] Univ Washington, Sch Med, Dept Psychiat, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD OCT
PY 2010
VL 50
SU 1
BP 243
EP 243
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 703UL
UT WOS:000286006702285
ER
PT J
AU Bass, DM
Looman, WJ
McCarthy, C
Walder, A
Morgan, RO
AF Bass, D. M.
Looman, W. J.
McCarthy, C.
Walder, A.
Morgan, R. O.
TI OUTCOMES FOR CAREGIVERS AFTER SIX-MONTHS IN PARTNERS IN DEMENTIA CARE
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Bass, D. M.; Looman, W. J.; McCarthy, C.] Benjamin Rose Inst, Margaret Blenkner Res Inst, Cleveland, OH USA.
[Walder, A.] Michael E DeBakey Vet Med Ctr, Houston, TX USA.
[Morgan, R. O.] Univ Texas Houston, Sch Publ Hlth, Houston, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD OCT
PY 2010
VL 50
SU 1
BP 322
EP 323
PG 2
WC Gerontology
SC Geriatrics & Gerontology
GA 703UL
UT WOS:000286006702661
ER
PT J
AU Kramer, B
AF Kramer, B.
TI THE GERIATRIC SCHOLARS PROGRAM: AN OVERVIEW
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Kramer, B.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Kramer, B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD OCT
PY 2010
VL 50
SU 1
BP 341
EP 341
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 703UL
UT WOS:000286006702747
ER
PT J
AU Adamson, MM
Weinstein, H
Cherrier, M
Diep, H
Taylor, J
AF Adamson, M. M.
Weinstein, H.
Cherrier, M.
Diep, H.
Taylor, J.
TI SPATIAL NAVIGATION ABILITIES IN OLDER PILOTS AND NON-PILOTS
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Adamson, M. M.; Weinstein, H.; Diep, H.; Taylor, J.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA.
[Cherrier, M.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD OCT
PY 2010
VL 50
SU 1
BP 355
EP 355
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 703UL
UT WOS:000286006702813
ER
PT J
AU Alessi, C
AF Alessi, C.
TI HS PRESIDENTIAL SYMPOSIUM: CHANGES IN LATITUDES, CHANGES IN ATTITUDES:
TRANSITIONS OF CARE IN TIMES OF DISASTER AND POVERTY
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Alessi, C.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Alessi, C.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD OCT
PY 2010
VL 50
SU 1
BP 368
EP 368
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 703UL
UT WOS:000286006703003
ER
PT J
AU Bates-Jensen, B
AF Bates-Jensen, B.
TI WOUND CARE IN HAITI 1 MONTH POST EARTHQUAKE: INFECTION, REPAIR, AND
REHABILITATION
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Bates-Jensen, B.] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA.
[Bates-Jensen, B.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD OCT
PY 2010
VL 50
SU 1
BP 368
EP 368
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 703UL
UT WOS:000286006703005
ER
PT J
AU Kramer, B
AF Kramer, B.
TI INSTEP (INCREASING STABILITY THROUGH EVALUATION AND PRACTICE): PROCESS
EVALUATION
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Kramer, B.] VA Greater Los Angeles Healthcare Syst, GRECC, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD OCT
PY 2010
VL 50
SU 1
BP 385
EP 385
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 703UL
UT WOS:000286006703083
ER
PT J
AU Rubenstein, L
Kramer, B
Vivrette, R
AF Rubenstein, L.
Kramer, B.
Vivrette, R.
TI STAYING INDEPENDENT: VALIDATING A FALL RISK SCREENER
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Rubenstein, L.; Kramer, B.; Vivrette, R.] VA Greater Los Angeles Healthcare Syst, GRECC, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD OCT
PY 2010
VL 50
SU 1
BP 385
EP 385
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 703UL
UT WOS:000286006703085
ER
PT J
AU Rubenstein, L
AF Rubenstein, L.
TI INSTEP (INCREASING STABILITY THROUGH EVALUATION AND PRACTICE): OUTCOME
ANALYSIS
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Rubenstein, L.] VA Greater Los Angeles Healthcare Syst, GRECC, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD OCT
PY 2010
VL 50
SU 1
BP 385
EP 385
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 703UL
UT WOS:000286006703084
ER
PT J
AU Payne, KL
AF Payne, K. L.
TI TIPS, TRICKS, AND ADVICE FOR LANDING A POSTDOCTORAL FELLOWSHIP IN
GEROPSYCHOLOGY
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Payne, K. L.] Milwaukee VA, Milwaukee, WI USA.
[Payne, K. L.] Portland VA Med Ctr, Portland, OR USA.
[Payne, K. L.] Univ Alabama, Tuscaloosa, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD OCT
PY 2010
VL 50
SU 1
BP 394
EP 394
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 703UL
UT WOS:000286006703129
ER
PT J
AU Alessi, C
Martin, J
Fiorentino, L
Chung, C
Josephson, K
Jouldjian, S
AF Alessi, C.
Martin, J.
Fiorentino, L.
Chung, C.
Josephson, K.
Jouldjian, S.
TI DEVELOPMENT OF A NONPHARMACOLOGICAL INTERVENTION TO IMPROVE SLEEP
PATTERNS AMONG OLDER ADULTS UNDERGOING INPATIENT POST-ACUTE
REHABILITATION
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Alessi, C.; Martin, J.; Josephson, K.; Jouldjian, S.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA.
[Alessi, C.; Martin, J.; Fiorentino, L.; Chung, C.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD OCT
PY 2010
VL 50
SU 1
BP 482
EP 482
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 703UL
UT WOS:000286006703551
ER
PT J
AU Byers, AL
Arean, PA
Yaffe, K
AF Byers, A. L.
Arean, P. A.
Yaffe, K.
TI PREVALENCE AND CHARACTERISTICS OF MENTAL HEALTH SERVICES USE IN OLDER
AMERICANS WITH AND WITHOUT MOOD AND ANXIETY DISORDERS
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Byers, A. L.; Arean, P. A.; Yaffe, K.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Byers, A. L.; Yaffe, K.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Yaffe, K.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.
[Yaffe, K.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD OCT
PY 2010
VL 50
SU 1
BP 496
EP 496
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 703UL
UT WOS:000286006703619
ER
PT J
AU Moreno, G
Mangione, CM
Wang, P
Trejo, L
Butch, A
Sarkisian, C
AF Moreno, G.
Mangione, C. M.
Wang, P.
Trejo, L.
Butch, A.
Sarkisian, C.
TI ARE PHYSICAL ACTIVITY AND PHYSICAL PERFORMANCE ASSOCIATED WITH
BIO-MARKERS AMONG ELDERLY LATINOS?
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Moreno, G.] UCLA Dept Family Med, Los Angeles, CA USA.
[Mangione, C. M.] UCLA Dept Med, Div Gen Internal Med & Hlth Serv, Los Angeles, CA USA.
[Mangione, C. M.; Wang, P.; Sarkisian, C.] UCLA Dept Med, Div Geriatr, Los Angeles, CA USA.
[Trejo, L.] Dept Aging, Los Angeles, CA USA.
[Butch, A.] UCLA Pathol Lab Med, Los Angeles, CA USA.
[Sarkisian, C.] VA Greater Healthcare Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD OCT
PY 2010
VL 50
SU 1
BP 517
EP 517
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 703UL
UT WOS:000286006703711
ER
PT J
AU Chodosh, J
Miller-Martinez, D
Aneshensel, C
Wight, RG
Karlamangla, AS
AF Chodosh, J.
Miller-Martinez, D.
Aneshensel, C.
Wight, R. G.
Karlamangla, A. S.
TI DEPRESSIVE SYMPTOMS, CHRONIC DISEASE, AND PHYSICAL DISABILITY AS
PREDICTORS OF COGNITIVE FUNCTIONING
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Chodosh, J.; Miller-Martinez, D.; Karlamangla, A. S.] UCLA Div Geriatr, Los Angeles, CA USA.
[Chodosh, J.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Aneshensel, C.; Wight, R. G.] Community Hlth Sci UCLA, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD OCT
PY 2010
VL 50
SU 1
BP 525
EP 526
PG 2
WC Gerontology
SC Geriatrics & Gerontology
GA 703UL
UT WOS:000286006703747
ER
PT J
AU Gallun, FJ
Saunders, GH
AF Gallun, Frederick J.
Saunders, Gabrielle H.
TI The Ear-Brain System: Approaches to the Study and Treatment of Hearing
Loss
SO JOURNAL OF THE AMERICAN ACADEMY OF AUDIOLOGY
LA English
DT Editorial Material
ID SPECTRAL SHAPE-DISCRIMINATION; LISTENERS; ADULTS; SPEECH; NOISE
C1 [Gallun, Frederick J.; Saunders, Gabrielle H.] Rehabil Res & Dev Serv RR&D, US Dept Vet Affairs, Natl Ctr Rehabil Auditory Res, Portland, OR 97239 USA.
RP Gallun, FJ (reprint author), Rehabil Res & Dev Serv RR&D, US Dept Vet Affairs, Natl Ctr Rehabil Auditory Res, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
RI Gallun, Frederick/G-3792-2012
OI Gallun, Frederick/0000-0002-4145-2199
NR 12
TC 0
Z9 0
U1 2
U2 3
PU AMER ACAD AUDIOLOGY
PI RESTON
PA 11730 PLAZA DR, STE 300, RESTON, VA 20190 USA
SN 1050-0545
J9 J AM ACAD AUDIOL
JI J. Am. Acad. Audiol.
PD OCT
PY 2010
VL 21
IS 9
SI SI
DI 10.3766/jaaa.21.9.1
PG 3
WC Audiology & Speech-Language Pathology; Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Otorhinolaryngology
GA 704YF
UT WOS:000286090900001
ER
PT J
AU Zuleger, CL
Macklin, MD
Newton, MA
Albertini, MR
AF Zuleger, Cindy L.
Macklin, Michael D.
Newton, Michael A.
Albertini, Mark R.
TI In Vivo 6-thioguanine-resistant T Cells from Melanoma Patients Contain T
Cells with Melanoma Specificity as well as T Cells with Suppressive
Function
SO JOURNAL OF IMMUNOTHERAPY
LA English
DT Meeting Abstract
C1 [Zuleger, Cindy L.; Macklin, Michael D.; Newton, Michael A.; Albertini, Mark R.] Univ Wisconsin, Sch Med & Publ Hlth, Carbone Comprehens Canc Ctr, Madison, WI 53706 USA.
[Albertini, Mark R.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1524-9557
J9 J IMMUNOTHER
JI J. Immunother.
PD OCT
PY 2010
VL 33
IS 8
BP 889
EP 889
PG 1
WC Oncology; Immunology; Medicine, Research & Experimental
SC Oncology; Immunology; Research & Experimental Medicine
GA 653XQ
UT WOS:000282131800107
ER
PT J
AU Campbell, J
Prochazka, AV
Yamashita, T
Gopal, R
AF Campbell, Jessica
Prochazka, Allan V.
Yamashita, Traci
Gopal, Ravi
TI Predictors of Persistent Burnout in Internal Medicine Residents: A
Prospective Cohort Study
SO ACADEMIC MEDICINE
LA English
DT Article
ID PATIENT-CARE; PROGRAM
AB Purpose Resident burnout continues to be a major problem despite work hours restrictions. The authors conducted a longitudinal study to determine whether burnout in internal medicine residents is persistent and what factors predispose residents to persistent burnout.
Method The authors mailed a survey to internal medicine residents at the University of Colorado Denver Health Science Center each May, from 2003 through 2008. The survey measures included the Maslach Burnout Inventory organized into three subscales: emotional exhaustion (EE), depersonalization (DP), and personal accomplishment. The authors defined burned-out residents as having a high EE or DP score and persistent burnout as being burned out during all three years of residency.
Results Of the 179 eligible residents, 86 (48%) responded to the survey during all three years of their residency. Sixty-seven residents (78%) were burned out at least once: 58 residents (67%) were burned out during their internship, 58 (67%) during their second year, and 50 (58%) during their third year (P <.08). Of the 58 burned-out interns, 42 (72%) continued to be burned out through their three years of training. Persistent burnout was more likely to occur in men (OR = 3.31, P <.01) and was associated with screening positive for depression as an intern (OR = 4.4, P <.002).
Conclusions Once present, burnout tends to persist through residency. Men and residents who screened positive for depression as interns are at the highest risk for persistent burnout. Interventions to prevent burnout during internship may significantly decrease burnout throughout residency.
C1 [Campbell, Jessica; Prochazka, Allan V.; Gopal, Ravi] Univ Colorado Denver, Sch Med, Dept Med, Aurora, CO USA.
[Campbell, Jessica] Denver Hlth Med Ctr, Div Hosp Med, Denver, CO USA.
[Prochazka, Allan V.; Gopal, Ravi] Denver VA Med Ctr, Denver, CO USA.
[Yamashita, Traci] Univ Colorado Denver, Sch Med, Div Gen Internal Med, Aurora, CO USA.
RP Campbell, J (reprint author), 660 Bannock St,MC 4000, Denver, CO 80204 USA.
EM jessica.campbell@dhha.org
FU University of Colorado
FX This study was funded in part by the University of Colorado Denver
Division of General Internal Medicine Small Grant Program.
NR 15
TC 34
Z9 37
U1 0
U2 15
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-2446
J9 ACAD MED
JI Acad. Med.
PD OCT
PY 2010
VL 85
IS 10
BP 1630
EP 1634
DI 10.1097/ACM.0b013e3181f0c4e7
PG 5
WC Education, Scientific Disciplines; Health Care Sciences & Services
SC Education & Educational Research; Health Care Sciences & Services
GA 656UN
UT WOS:000282365000021
PM 20881685
ER
PT J
AU Lugea, A
Gong, J
Nguyen, J
Nieto, J
French, SW
Pandol, SJ
AF Lugea, Aurelia
Gong, Jun
Nguyen, Janie
Nieto, Jose
French, Samuel W.
Pandol, Stephen J.
TI Cholinergic Mediation of Alcohol-Induced Experimental Pancreatitis
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE Pancreas; Alcohol Feeding; Cerulein; Cholinergic Pathways;
Acetylcholinesterase
ID CERULEIN-INDUCED PANCREATITIS; KAPPA-B ACTIVATION; ACINAR-CELLS;
ACETYLCHOLINESTERASE ACTIVITY; EXOCRINE SECRETION; ETHANOL; RATS;
CHOLECYSTOKININ; KINASE; INJURY
AB Objectives:
The mechanisms initiating pancreatitis in patients with chronic alcohol abuse are poorly understood. Although alcohol feeding has been previously suggested to alter cholinergic pathways, the effects of these cholinergic alterations in promoting pancreatitis have not been characterized. For this study, we determined the role of the cholinergic system in ethanol-induced sensitizing effects on cerulein pancreatitis.
Methods:
Rats were pair-fed control and ethanol-containing Lieber-DeCarli diets for 6 weeks followed by parenteral administration of 4 hourly intraperitoneal injections of the cholecystokinin analog, cerulein at 0.5 mu g/kg. This dose of cerulein was selected because it caused pancreatic injury in ethanol-fed but not in control-fed rats. Pancreatitis was preceded by treatment with the muscarinic receptor antagonist atropine or by bilateral subdiaphragmatic vagotomy. Measurement of pancreatic pathology included serum lipase activity, pancreatic trypsin, and caspase-3 activities, and markers of pancreatic necrosis, apoptosis, and autophagy. In addition, we measured the effects of ethanol feeding on pancreatic acetylcholinesterase activity and pancreatic levels of the muscarinic acetylcholine receptors m1 and m3. Finally, we examined the synergistic effects of ethanol and carbachol on inducing acinar cell damage.
Results:
We found that atropine blocked almost completely pancreatic pathology caused by cerulein administration in ethanol-fed rats, while vagotomy was less effective. Ethanol feeding did not alter expression levels of cholinergic muscarinic receptors in the pancreas but significantly decreased pancreatic acetylcholinesterase activity, suggesting that acetylcholine levels and cholinergic input within the pancreas can be higher in ethanol-fed rats. We further found that ethanol treatment of pancreatic acinar cells augmented pancreatic injury responses caused by the cholinergic agonist, carbachol.
Conclusion:
These results demonstrate key roles for the cholinergic system in the mechanisms of alcoholic pancreatitis.
C1 [Lugea, Aurelia; Gong, Jun; Nguyen, Janie; Nieto, Jose; Pandol, Stephen J.] Vet Affairs Greater Los Angeles Healthcare Syst, USC UCLA Res Ctr Alcohol Liver & Pancreat Dis, Los Angeles, CA 90073 USA.
Univ Calif Los Angeles, Los Angeles, CA USA.
[French, Samuel W.] Harbor UCLA Med Ctr, Dept Pathol, Torrance, CA 90509 USA.
RP Lugea, A (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, USC UCLA Res Ctr Alcohol Liver & Pancreat Dis, Bldg 258,Room 339,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM alugea@ucla.edu
FU National Institute on Alcohol Abuse and Alcoholism (NIAAA) [P50-A11999,
08,116]
FX This work was supported by the Department of Veterans Affairs and
Research Center for Alcoholic Liver and Pancreatic Diseases (NIAAA
P50-A11999) funded by the National Institute on Alcohol Abuse and
Alcoholism. We also acknowledge the Animal Core and Morphology Core
facilities of the NIAAA-supported Research Center for Alcoholic Liver
and Pancreatic Diseases (NIAAA P50-A11999 and NIAAA 08,116 to SW French)
for providing assistance with animal alcohol feeding and morphological
analyses of pancreatic tissues.
NR 66
TC 8
Z9 8
U1 1
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD OCT
PY 2010
VL 34
IS 10
BP 1768
EP 1781
DI 10.1111/j.1530-0277.2010.01264.x
PG 14
WC Substance Abuse
SC Substance Abuse
GA 656FW
UT WOS:000282313600014
PM 20626730
ER
PT J
AU Teng, E
Becker, BW
Woo, E
Knopman, DS
Cummings, JL
Lu, PH
AF Teng, Edmond
Becker, Brian W.
Woo, Ellen
Knopman, David S.
Cummings, Jeffrey L.
Lu, Po H.
TI Utility of the Functional Activities Questionnaire for Distinguishing
Mild Cognitive Impairment From Very Mild Alzheimer Disease
SO ALZHEIMER DISEASE & ASSOCIATED DISORDERS
LA English
DT Article
DE mild cognitive impairment; dementia; Alzheimer disease; activities of
daily living; standardized assessment
ID UNIFORM DATA SET; INSTRUMENTAL ACTIVITIES; OLDER-ADULTS; DEMENTIA;
DIAGNOSIS; MCI; INDIVIDUALS; COMMUNITY; DEFICITS; SUBTYPES
AB Current criteria for mild cognitive impairment (MCI) require "essentially intact" performance of activities of daily living (ADLs), which has proven difficult to operationalize. We sought to determine how well the Functional Activities Questionnaire (FAQ), a standardized assessment of instrumental ADLs, delineates the clinical distinction between MCI and very mild Alzheimer disease (AD). We identified 1801 individuals in the National Alzheimer's Coordinating Center Uniform Data Set with MCI (n = 1108) or very mild AD (n = 693) assessed with the FAQ and randomized them to the development or test sets. Receiver-operator curve (ROC) analysis of the development set identified optimal cut-points that maximized the sensitivity and specificity of FAQ measures for differentiating AD from MCI and were validated with the test set. ROC analysis of total FAQ scores in the development set produced an area under the curve of 0.903 and an optimal cut-point of 5/6, which yielded 80.3% sensitivity, 87.0% specificity, and 84.7% classification accuracy in the test set. Bill paying, tracking current events, and transportation (P's < 0.005) were the FAQ items of greatest diagnostic utility. These data suggest that the FAQ exhibits adequate sensitivity and specificity when used as a standardized assessment of instrumental ADLs in the diagnosis of AD versus MCI.
C1 [Teng, Edmond] Vet Affairs Greater Los Angeles Healthcare Syst, Neurobehav Unit, Los Angeles, CA USA.
[Teng, Edmond; Becker, Brian W.] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA.
[Teng, Edmond; Woo, Ellen; Cummings, Jeffrey L.; Lu, Po H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
[Cummings, Jeffrey L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Knopman, David S.] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA.
RP Teng, E (reprint author), W Los Angeles VA Healthcare Ctr, Neurobehav Unit, Bldg 500 116AF,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM eteng@ucla.edu
FU National Institute on Aging [P50 AG16570, U01 AG016976]; National
Alzheimer's Coordinating Center; Alzheimer's Disease Research Centers of
California; Sidell-Kagan Foundation
FX This research was supported by the National Institute on Aging (P50
AG16570 U01 AG016976), the National Alzheimer's Coordinating Center, the
Alzheimer's Disease Research Centers of California, and the Sidell-Kagan
Foundation.
NR 33
TC 26
Z9 27
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0893-0341
J9 ALZ DIS ASSOC DIS
JI Alzheimer Dis. Assoc. Dis.
PD OCT-DEC
PY 2010
VL 24
IS 4
BP 348
EP 353
DI 10.1097/WAD.0b013e3181e2fc84
PG 6
WC Clinical Neurology; Pathology
SC Neurosciences & Neurology; Pathology
GA 681JN
UT WOS:000284308100007
PM 20592580
ER
PT J
AU Al-Khatib, SM
Calkins, H
Eloff, BC
Kowey, P
Hammill, SC
Ellenbogen, KA
Marinac-Dabic, D
Waldo, AL
Brindis, RG
Wilbur, DJ
Jackman, WM
Yaross, MS
Russo, AM
Prystowsky, E
Varosy, PD
Gross, T
Pinnow, E
Turakhia, MP
Krucoff, MW
AF Al-Khatib, Sana M.
Calkins, Hugh
Eloff, Benjamin C.
Kowey, Peter
Hammill, Stephen C.
Ellenbogen, Kenneth A.
Marinac-Dabic, Danica
Waldo, Albert L.
Brindis, Ralph G.
Wilbur, David J.
Jackman, Warren M.
Yaross, Marcia S.
Russo, Andrea M.
Prystowsky, Eric
Varosy, Paul D.
Gross, Thomas
Pinnow, Ellen
Turakhia, Mintu P.
Krucoff, Mitchell W.
TI Developing the Safety of Atrial Fibrillation Ablation Registry
Initiative (SAFARI) as a collaborative pan-stakeholder critical path
registry model: A Cardiac Safety Research Consortium "Incubator" Think
Tank
SO AMERICAN HEART JOURNAL
LA English
DT Article
ID ANTIARRHYTHMIC-DRUG THERAPY; PULMONARY-VEIN ABLATION; RADIOFREQUENCY
ABLATION; CATHETER ABLATION; RANDOMIZED-TRIAL
AB Although several randomized clinical trials have demonstrated the safety and efficacy of catheter ablation of atrial fibrillation (AF) in experienced centers, the outcomes of this procedure in routine clinical practice and in patients with persistent and long-standing persistent AF remain uncertain. Brisk adoption of this therapy by physicians with diverse training and experience highlights potential concerns regarding the safety and effectiveness of this procedure. Some of these concerns could be addressed by a national registry of AF ablation procedures such as the Safety of Atrial Fibrillation Ablation Registry Initiative that was initially proposed at a Cardiac Safety Research Consortium Think Tank meeting in April 2009. In January 2010, the Cardiac Safety Research Consortium, in collaboration with the Duke Clinical Research Institute, the US Food and Drug Administration, the American College of Cardiology, and the Heart Rhythm Society, held a follow-up meeting of experts in the field to review the construct and progress to date. Other participants included the National Heart, Lung, and Blood Institute; the Centers for Medicare and Medicaid Services; the Agency for Healthcare Research and Quality; the AdvaMed AF working group; and additional industry representatives. This article summarizes the discussions that occurred at the meeting of the state of the Safety of Atrial Fibrillation Ablation Registry Initiative, the identification of a clear pathway for its implementation, and the exploration of solutions to potential issues in the execution of this registry. (Am Heart J 2010; 160: 619-626.e1.)
C1 [Al-Khatib, Sana M.; Krucoff, Mitchell W.] Duke Univ, Duke Clin Res Inst, Med Ctr, Durham, NC 27715 USA.
[Calkins, Hugh] Johns Hopkins Univ, Baltimore, MD USA.
[Eloff, Benjamin C.; Marinac-Dabic, Danica; Gross, Thomas; Pinnow, Ellen] US FDA, Silver Spring, MD USA.
[Kowey, Peter] Main Line Hlth Heart Ctr, Philadelphia, PA USA.
[Hammill, Stephen C.] Mayo Clin, Rochester, MN USA.
[Ellenbogen, Kenneth A.] Virginia Commonwealth Univ, Sch Med, Richmond, VA USA.
[Waldo, Albert L.] Case Western Reserve Univ, Cleveland, OH 44106 USA.
[Brindis, Ralph G.] Amer Coll Cardiol, Washington, DC USA.
[Brindis, Ralph G.] Oakland Kaiser Permanente, Oakland, CA USA.
[Wilbur, David J.] Loyola Univ, Med Ctr, Chicago, IL 60611 USA.
[Jackman, Warren M.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA.
[Yaross, Marcia S.] Biosense Webster, Diamond Bar, CA USA.
[Russo, Andrea M.] Cooper Univ Hosp, Robert Wood Johnson Med Sch, Camden, NJ USA.
[Prystowsky, Eric] Care Grp, Indianapolis, IN USA.
[Varosy, Paul D.] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Varosy, Paul D.] Univ Colorado, Denver, CO 80202 USA.
[Turakhia, Mintu P.] Palo Alto VA Hlth Care Syst, Palo Alto, CA USA.
[Turakhia, Mintu P.] Stanford Univ, Stanford, CA 94305 USA.
RP Al-Khatib, SM (reprint author), Duke Univ, Duke Clin Res Inst, Med Ctr, POB 17969, Durham, NC 27715 USA.
EM alkha001@mc.duke.edu
FU CSRC, DCRI, ACC, HRS; FDA; AdvaMed
FX This conference was funded by the CSRC, DCRI, ACC, HRS; registration
fees and in-kind support from the FDA and AdvaMed.
NR 16
TC 10
Z9 10
U1 1
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
J9 AM HEART J
JI Am. Heart J.
PD OCT
PY 2010
VL 160
IS 4
BP 619
EP U249
DI 10.1016/j.ahj.2010.06.044
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 660WN
UT WOS:000282677300010
PM 20934554
ER
PT J
AU Samlowski, WE
Moon, J
Tuthill, RJ
Heinrich, MC
Balzer-Haas, NS
Merl, SA
DeConti, RC
Thompson, JA
Witter, MT
Flaherty, LE
Sondak, VK
AF Samlowski, Wolfram E.
Moon, James
Tuthill, Ralph J.
Heinrich, Michael C.
Balzer-Haas, Naomi S.
Merl, Stuart A.
DeConti, Ronald C.
Thompson, John A.
Witter, Merle T.
Flaherty, Lawrence E.
Sondak, Vernon K.
TI A Phase II Trial of Imatinib Mesylate in Merkel Cell Carcinoma
(Neuroendocrine Carcinoma of the Skin) A Southwest Oncology Group Study
(S0331)
SO AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
LA English
DT Article
DE Merkel cell carcinoma; neuroendocrine carcinoma of the skin; imatinib
mesylate; c-KIT
ID CHRONIC MYELOID-LEUKEMIA; ABL TYROSINE KINASE; CLINICAL BEHAVIOR; CD117
EXPRESSION; KIT; CHEMOTHERAPY; TUMORS; 5-FLUOROURACIL; POLYOMAVIRUS;
INHIBITOR
AB Background: Imatinib mesylate (Gleevec) was evaluated as a treatment for Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) based on the identification of strong c-KIT staining of these neoplasms.
Methods: Eligibility included patients with measurable metastatic or unresectable MCC, c-KIT (CD117) expression and a Zubrod performance status of 0 to 2. Imatinib 400 mg daily was administered orally in 28-day cycles to 23 patients.
Results: Overall, imatinib was well tolerated with grade 1 or 2 nausea, diarrhea, and hematologic toxicity as the most frequent side effects. A partial response was seen in 1 patient (4%; 95% CI: 0%-22%). Median progression-free survival was 1 month (95% CI: 1-2 months). Median overall survival was 5 months (95% CI: 2-8 months). One patient achieved a partial response and another had prolonged disease stabilization while receiving treatment.
Conclusions: The majority of patients progressed rapidly within 1 to 2 cycles of treatment. The observed progression-free survival and overall survival were not adequate to conclude that this agent was active in advanced MCC, and thus the planned second stage of patient accrual was not opened.
C1 [Samlowski, Wolfram E.; Witter, Merle T.; Sondak, Vernon K.] Nevada Canc Inst, Las Vegas, NV USA.
[Moon, James] SW Oncol Grp, Ctr Stat, Seattle, WA USA.
[Tuthill, Ralph J.] Cleveland Clin Fdn, Cleveland, OH 44195 USA.
[Heinrich, Michael C.] Portland VA Med Ctr, Portland, OR USA.
[Heinrich, Michael C.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Balzer-Haas, Naomi S.] Univ Penn ECOG, Abramson Canc Ctr, Philadelphia, PA USA.
[Merl, Stuart A.] Dayton Clin Oncol Program, Dayton, OH USA.
[DeConti, Ronald C.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
[Thompson, John A.] Puget Sound Oncol Consortium, Seattle, WA USA.
[Flaherty, Lawrence E.] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
RP Samlowski, WE (reprint author), SW Oncol Grp, Chairs Off S0331, 24 Frank Lloyd Wright Dr,POB 483, Ann Arbor, MI 48106 USA.
EM arlauska@med.umich.edu
OI Samlowski, Wolfram/0000-0002-0713-914X
FU National Cancer Institute, DHHS [CA32102, CA38926, CA35090, CA073590,
CA20319), CA45377, A35178, CA35176, CA46113, CA46441, CA42777, CA86780,
CA58861, CA46282, CA35119, CA15488, CA21115]
FX Supported, in part, by the following PHS Cooperative Agreement grant
numbers awarded by the National Cancer Institute, DHHS: CA32102,
CA38926, CA35090, CA073590, CA20319), CA45377, CA35178, CA35176,
CA46113, CA46441, CA42777, CA86780, CA58861, CA46282, CA35119, CA15488,
CA21115.
NR 35
TC 32
Z9 32
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0277-3732
J9 AM J CLIN ONCOL-CANC
JI Am. J. Clin. Oncol.-Cancer Clin. Trials
PD OCT
PY 2010
VL 33
IS 5
BP 495
EP 499
DI 10.1097/COC.0b013e3181b9cf04
PG 5
WC Oncology
SC Oncology
GA 659WT
UT WOS:000282598700013
PM 20019577
ER
PT J
AU Kessler, C
Chen, J
Dill, C
Tyndall, G
Olszyk, MD
AF Kessler, Chad
Chen, Jennifer
Dill, Curt
Tyndall, Gary
Olszyk, Mark D.
TI State of affairs of emergency medicine in the Veterans Health
Administration
SO AMERICAN JOURNAL OF EMERGENCY MEDICINE
LA English
DT Article
ID QUALITY-OF-CARE; CENTERS; SYSTEM
AB Background: The Veterans Health Administration (VHA) has reformed its emergency medical services.
Objectives: This study updates an overview of emergency medicine within VHA.
Methods: This is a cross-sectional survey of VHA medical facilities offering emergency medical care.
Results: Sixty-eight percent (95/140) of facilities had emergency departments (EDs) only, 12% (16/140) had both ED and urgent care centers (UCCs), and 16% (23/140) had only UCCs. The mean (SD) ED/UCC census was 13 371 (7664). A mean (SD) of 53% (27%) of facility admissions were admitted through ED/UCCs. The median of all ED/UCC admissions admitted to intensive care unit level care was 11% (interquartile range, 7-16). Of physicians with any board certification, 16% (209/1331) of physicians had emergency medicine board certification.
Conclusions: Emergency medical care is now available at most VHA facilities. The specialty of emergency medicine has an important but minority presence within clinical emergency medical care at VHA. Published by Elsevier Inc.
C1 [Chen, Jennifer] W Los Angeles VA Med Ctr, David Geffen UCLA Sch Med, Dept Med, Los Angeles, CA 90073 USA.
[Kessler, Chad] Univ Illinois, Jesse Brown VA Hosp, Dept Internal Med, Chicago, IL 60612 USA.
[Kessler, Chad] Univ Illinois, Jesse Brown VA Hosp, Dept Emergency Med, Chicago, IL 60612 USA.
[Dill, Curt] NYU, Sch Med, VA New York Harbor Healthcare Ctr, Dept Emergency Serv, Brooklyn, NY 11209 USA.
[Tyndall, Gary] Syracuse VAMC, Emergency Serv, Syracuse, NY 13210 USA.
[Olszyk, Mark D.] VA Maryland Healthcare Syst, Emergency Serv, Baltimore, MD 21201 USA.
RP Chen, J (reprint author), W Los Angeles VA Med Ctr, David Geffen UCLA Sch Med, Dept Med, Los Angeles, CA 90073 USA.
EM jen.chencn@gmail.com
OI Chen, Jennifer/0000-0002-4801-5397; Tyndall, Gary/0000-0001-9984-4809
NR 10
TC 8
Z9 8
U1 1
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0735-6757
J9 AM J EMERG MED
JI Am. J. Emerg. Med.
PD OCT
PY 2010
VL 28
IS 8
BP 947
EP 951
DI 10.1016/j.ajem.2009.08.008
PG 5
WC Emergency Medicine
SC Emergency Medicine
GA 660TV
UT WOS:000282669300019
PM 20887913
ER
PT J
AU Whitcomb, DC
Muddana, V
Langmead, CJ
Houghton, FD
Guenther, A
Eagon, PK
Mayerle, J
Aghdassi, AA
Weiss, FU
Evans, A
Lamb, J
Clermont, G
Lerch, MM
Papachristou, GI
AF Whitcomb, David C.
Muddana, Venkata
Langmead, Christopher J.
Houghton, Frank D., Jr.
Guenther, Annett
Eagon, Patricia K.
Mayerle, Julia
Aghdassi, Ali A.
Weiss, F. Ulrich
Evans, Anna
Lamb, Janette
Clermont, Gilles
Lerch, Markus M.
Papachristou, Georgios I.
TI Angiopoietin-2, a Regulator of Vascular Permeability in Inflammation, Is
Associated With Persistent Organ Failure in Patients With Acute
Pancreatitis From the United States and Germany
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
ID CIRCULATING ANGIOPOIETIN-2; SEPSIS; MULTICENTER; POPULATION; MORTALITY;
SEVERITY; MEDIATOR; INJURY; SCORE; LEAK
AB OBJECTIVES: Patients with severe acute pancreatitis (AP) typically develop vascular leak syndrome, resulting in hemoconcentration, hypotension, pulmonary edema, and renal insufficiency. Angiopoietin-1 (Ang-1) and 2 (Ang-2) are autocrine peptides that reduce or increase endothelial permeability, respectively. The aim of this study was to determine whether Ang-1 and/or Ang-2 levels are predictive biomarkers of persistent organ failure (>48h) and prolonged hospital course.
METHODS: Banked serum from 28 patients enrolled in the Severity of Acute Pancreatitis Study at the University of Pittsburgh Medical Center (UPMC) and 58 controls was analyzed for Ang-1 and Ang-2 levels. Separately, serum from 123 patients and 103 controls at Greifswald University (GU), Germany was analyzed for Ang-2 levels. Angiopoietin levels were measured by enzyme-linked immunosorbent assay.
RESULTS: In all, 6 out of 28 UPMC patients (21%) and 14 out of 123 GU patients (13%) developed persistent organ failure and were classified as severe AP. Ang-2 was significantly higher on admission in patients who developed persistent organ failure compared with those who did not in UPMC (3,698 pg/ml vs. 1,001 pg/ml; P=0.001) and GU (4,945 pg/ml vs. 2,631 pg/ml; P=0.0004) cohorts. After data scaling, admission Ang-2 levels showed a receiver-operator curve of 0.81, sensitivity 90%, and specificity 67% in predicting persistent organ failure. In addition, Ang-2 levels remained significantly higher in severe AP compared with mild AP patients until day 7 (days 2-4: P<0.005; day 7: P<0.02). Ang-1 levels were not significantly different between mild and severe AP patients on admission.
CONCLUSIONS: Elevated serum Ang-2 levels on admission are associated with and may be a useful biomarker of predicting persistent organ failure and ongoing endothelial cell activation in AP.
C1 [Whitcomb, David C.; Muddana, Venkata; Houghton, Frank D., Jr.; Eagon, Patricia K.; Evans, Anna; Lamb, Janette; Papachristou, Georgios I.] Univ Pittsburgh, Dept Med, Div Gastroenterol Hepatol & Nutr, Med Ctr, Pittsburgh, PA 15213 USA.
[Whitcomb, David C.] Univ Pittsburgh, Sch Med, Dept Cell Biol, Pittsburgh, PA 15213 USA.
[Whitcomb, David C.] Univ Pittsburgh, Sch Med, Dept Physiol, Pittsburgh, PA 15213 USA.
[Whitcomb, David C.] Univ Pittsburgh, Sch Med, Dept Human Genet, Pittsburgh, PA 15213 USA.
[Langmead, Christopher J.] Carnegie Mellon Univ, Dept Comp Sci, Pittsburgh, PA 15213 USA.
[Guenther, Annett; Mayerle, Julia; Aghdassi, Ali A.; Weiss, F. Ulrich; Lerch, Markus M.] Ernst Moritz Arndt Univ Greifswald, Dept Med A, Greifswald, Germany.
[Clermont, Gilles] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15213 USA.
[Clermont, Gilles; Papachristou, Georgios I.] Vet Affairs Pittsburgh Hlth Syst, Pittsburgh, PA USA.
RP Whitcomb, DC (reprint author), Univ Pittsburgh, Dept Med, Div Gastroenterol Hepatol & Nutr, Med Ctr, Room 401-4,3708 5th Ave, Pittsburgh, PA 15213 USA.
EM whitcomb@pitt.edu
RI Lerch, Markus M./E-2206-2016; Weiss, Frank/A-6386-2009
OI Lerch, Markus M./0000-0002-9643-8263; Weiss, Frank
Ulrich/0000-0003-3369-6369
FU National Pancreas Foundation; VA Stars Competitive Pilot Project Fund
(CPPF); DFG [LE 625/8-1, 9-1, GRK 840 E3, E4]; Alfried-Krupp Foundation;
[BMBF-NBL3 01 ZZ 0403]
FX This study was funded by the National Pancreas Foundation (D. C. W.),
the VA Stars Competitive Pilot Project Fund (CPPF), DFG LE 625/8-1 and
9-1, the Alfried-Krupp Foundation, DFG GRK 840 E3 and E4, and BMBF-NBL3
01 ZZ 0403.
NR 20
TC 28
Z9 29
U1 1
U2 6
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2010
VL 105
IS 10
BP 2287
EP 2292
DI 10.1038/ajg.2010.183
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 659US
UT WOS:000282593000023
PM 20461065
ER
PT J
AU Chavalitdhamrong, D
Giri, B
Luthra, M
AF Chavalitdhamrong, Disaya
Giri, Badri
Luthra, Munish
TI Acute Autoimmune Hepatitis Mimicking an Acute Abdomen
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 75th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 15-20, 2010
CL San Antonio, TX
SP Amer Coll Gastroenterol
C1 [Chavalitdhamrong, Disaya; Giri, Badri; Luthra, Munish] Mt Sinai Sch Med Bronx Program, James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2010
VL 105
SU 1
MA 731
BP S264
EP S264
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 663VG
UT WOS:000282917700725
ER
PT J
AU Cheifetz, A
Melmed, G
Spiegel, B
Talley, J
Devlin, S
Harrell, L
Irving, P
Jones, J
Kaplan, G
Kozuch, P
Sparrow, M
Velayos, F
Baidoo, L
Bressler, B
Siegel, C
AF Cheifetz, Adam
Melmed, Gil
Spiegel, Brennan
Talley, Jennifer
Devlin, Shane
Harrell, Laura
Irving, Peter
Jones, Jennifer
Kaplan, Gil
Kozuch, Patricia
Sparrow, Miles
Velayos, Fernando
Baidoo, Leonard
Bressler, Brian
Siegel, Corey
TI Setting Priorities for Comparative Effectiveness Research in
Inflammatory Bowel Disease: Results of an International Provider Survey,
Expert RAND Panel, and Patient Focus Groups
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 75th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 15-20, 2010
CL San Antonio, TX
SP Amer Coll Gastroenterol
C1 [Cheifetz, Adam] Beth Israel Deaconess Med Ctr, Med GI, Boston, MA 02215 USA.
[Melmed, Gil] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
[Spiegel, Brennan] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Talley, Jennifer] CURE Digest Dis Res Ctr, Los Angeles, CA USA.
[Devlin, Shane; Kaplan, Gil] Univ Calgary, Calgary, AB, Canada.
[Harrell, Laura] Univ Chicago, Chicago, IL 60637 USA.
[Irving, Peter] Guys & St Thomas Hosp, London SE1 9RT, England.
[Jones, Jennifer] Univ Saskatchewan, Saskatoon, SK, Canada.
[Kozuch, Patricia] Thomas Jefferson Univ, Philadelphia, PA 19107 USA.
[Sparrow, Miles] Alfred Hosp, Melbourne, Vic, Australia.
[Velayos, Fernando] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Baidoo, Leonard] Univ Pittsburgh, Pittsburgh, PA USA.
[Bressler, Brian] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
[Siegel, Corey] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2010
VL 105
SU 1
MA 1147
BP S415
EP S416
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 663VG
UT WOS:000282917701337
ER
PT J
AU Sun, S
Spiegel, B
Mody, R
Dabbous, F
Dabbous, O
Chey, W
AF Sun, Shawn
Spiegel, Brennan
Mody, Reema
Dabbous, Firas
Dabbous, Omar
Chey, William
TI Economic and Humanistic Burden of Chronic Constipation
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 75th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 15-20, 2010
CL San Antonio, TX
SP Amer Coll Gastroenterol
C1 [Sun, Shawn; Mody, Reema; Dabbous, Firas; Dabbous, Omar] Takeda Pharmaceut N Amer, Deerfield, IL USA.
[Spiegel, Brennan] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Chey, William] Univ Michigan Hlth Syst, Ann Arbor, MI USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2010
VL 105
SU 1
MA 1081
BP S391
EP S391
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 663VG
UT WOS:000282917701271
ER
PT J
AU Copeland, LA
Parchman, ML
Zeber, JE
Lawrence, VA
Downs, JR
Miller, AL
AF Copeland, Laurel A.
Parchman, Michael L.
Zeber, John E.
Lawrence, Valerie A.
Downs, John R.
Miller, Alexander L.
TI Prediabetes Assessment and Follow-up in Older Veterans With
Schizophrenia
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE Mortality; prediabetes; schizophrenia; veterans
ID ANTIPSYCHOTIC-DRUGS; DIABETES-MELLITUS; CARDIOVASCULAR-DISEASE;
METABOLIC SYNDROME; GLUCOSE-TOLERANCE; EXCESS MORTALITY;
HEALTH-SERVICES; PRIMARY-CARE; RISK; WEIGHT
AB Objectives: Assess glycemic monitoring and follow-up. Design: Retrospective study using administrative data (October 2001-September 2005). Setting: Veterans Health Administration. Participants: A nationwide sample of 39,226 outpatients aged 50 years or older with schizophrenia. Patients had no diagnosis or medications for diabetes at baseline. Measurements: Hemoglobin A1c tests; blood glucose tests with same-day low-density lipoprotein to approximate fasting glucose. Glycemic tests were combined to indicate a) prediabetic dysglycemia (100-125 mg/dL proxy fasting glucose or 5.8%-6.4% hemoglobin A1c) and b) diabetic dysglycemia (>= 126 proxy fasting glucose or >= 6.5% A1c). Results: Approximately one-third of patients (32%; 12,587) had proxy fasting blood glucose or A1c tests in 2002; multiple tests were rare. The proportion tested increased to 40% by 2005. Test results suggested prediabetic dysglycemia for 5,345 tested patients (42% of those tested) and diabetic dysglycemia for 1,287 tested patients (10%) at baseline. In multivariate regression models, glycemic testing was associated with dyslipidemia, hypertension, and younger age. Dysglycemia was associated with hypertension, dyslipidemia, and older age. Follow-up treatment/diagnosis of diabetes occurred for 8% of patients (11% of those tested) and was associated with baseline dysglycemia, hypertension, and younger age. Mortality (15% during the 4-year study) was higher among untested and untreated patients. Conclusions: Dysglycemia was prevalent among older patients with schizophrenia, although monitoring and follow-up were uncommon. Follow-up treatment correlated with survival. Despite evident utility of testing, few at-risk patients with schizophrenia were adequately monitored, diagnosed, or treated for dysglycemia. (Am J Geriatr Psychiatry 2010; 18:887-896)
C1 [Copeland, Laurel A.; Zeber, John E.; Miller, Alexander L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA.
[Parchman, Michael L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, San Antonio, TX 78229 USA.
[Lawrence, Valerie A.; Downs, John R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
RP Copeland, LA (reprint author), VERDICT Res, S Texas Vet HCS, 7400 Merton Minter 11C6, San Antonio, TX 78229 USA.
EM LaurelACopeland@gmail.com
OI Parchman, Michael/0000-0001-7129-2889; Copeland,
Laurel/0000-0002-9478-0209
FU Department of Veterans Affairs [IIR-05-326]; VERDICT Research Center;
University of Texas Health Science Center at San Antonio; Copeland as
PI: VA HSRD; Hogg Fndn/UT-Austin; Copeland as co-I: VA HSRD; VA VISN 17;
NIH; Dept of Defense; Parchman as PI: VA/HSRD; NIDDK; Parchman as co-I:
VA HSRD; Lawrence as PI: VA/HSRD; Lawrence as co-I: VHA; Zeber as PI: VA
HSRD; PhRMA Fndn; UTHSCSA Training Pgm; Zeber as co-I: VA HSRD; Downs as
PI: none Downs as co-I: VA/HSRD; NINR; Miller as PI: AstraZeneca; Pfizer
Organon; UNC/NIMH; Glaxo Smith Kline; Pfizer; Sanofi Aventis; Janssen;
Miller as co-I: VA HSRD; Research Foundation for Mental Hygiene New
York; CME, Inc. Orlando, FL; France Foundation Atlanta, GA; Organon
(Advisory Board) Parsippany, NJ; Dainippon Sumitomo (Advisory Board)
Chicago; Eli Lilly (Advisory Board) Scottsdale, AZ; AstraZeneca
(Advisory Board) Baltimore; CME Outfitters Washington, DC; Research
Foundation for Mental Hygiene; VA San Antonio, TX; Comprehensive
Neuroscience online survey; NCME, Inc. French Camp, CA; State of
Maryland Baltimore; NCME, Inc. Smithville, TX; NCME, Inc. Reno, NV;
International Congress on Schizophrenia Research San Diego, CA; VA HSRD
FX This work was supported by the Department of Veterans Affairs (Grant #
IIR-05-326; PI: Copeland) with additional support from VERDICT Research
Center and the University of Texas Health Science Center at San
Antonio.; Funding Details: Copeland as PI: VA HSR&D 2009-2010 $50,300;
VA HSR&D 2006-2008 $300,000; VA HSR&D 2006-2009 $273,200; VA HSR&D 2008
$35,600; Hogg Fndn/UT-Austin 2009-2010 $14,995; Copeland as co-I: VA
HSR&D 2009-2010 $223,600; VA HSR&D 2006-2010 $725,500; VA HSR&D
2003-2008 $735,400; VA VISN 17 2005-2008 $586,422; VA VISN 17 20052008
$736,990; VA HSR&D 2006-2009 $518,100; NIH 2007-2010 $323,538; Dept of
Defense 2008-2013 $25,000,000.; Parchman as PI: VA/HSR&D 2009-2012
$834,600; NIH 2007-2012 $2,050,750; NIDDK 2004-2007 $301,500; Parchman
as co-I: VA HSR&D 2008 to 2009 $146,500; VA/HSR&D 2006-2009 $271,300;
VA/HSR&D 2003-2008 $735,400; NIH 2008-2013 $1,500,000; VA/HSR&D
2007-2008 $74,500; NIH 2006-2011 400,000; Lawrence as PI: VA/HSR&D
2007-2012 $734,050; VA/HSR&D 2003-2008 $735,400; Lawrence as co-I: VHA
2007-2009 $90,000; VA/HSR&D 2006-2009 $273,200; VA/HSR&D 2008-2008
$84,800; VA/HSR&D 2008-2008 $35,600; Zeber as PI: VA HSR&D 2009 $50,000;
VA VISN 17 2008-2009 $100,000; PhRMA Fndn 2007-2008 $60,000; UTHSCSA
Training Pgm 50% salary support 2006-2008; Zeber as co-I: VA HSR&D 2008
$35,600; VA HSR&D 2009-2010 $141,000; VA HSR&D 2009-2010 $50,300; VA
HSR&D 2009-2010 $223,600; VA HSR&D 2006-2010 $725,500; VA HSR&D
2003-2008 $735,400; VA HSR&D 2006-2009 $273,200.; Downs as PI: none
Downs as co-I: VA/HSR&D 2007-2010 $468,300; VA/HSR&D 2008-2008 $84,800;
NINR 2007-2010 $788,497; Miller as PI: AstraZeneca 2007-2009 $35,256;
Pfizer Organon 2007-2009 $36,988; UNC/NIMH 2007-2009 $150,030; UNC/NIMH
2007-2009 $33,750; UNC/NIMH 2007-2009 $80,360; UNC/NIMH 2009 $20,090;
Glaxo Smith Kline 2007 $9,582; Pfizer 2007-2009 $160,000; Sanofi Aventis
2009 $89,916; Janssen 2008 $9,036; NIMH 2006-2011 $2,297,435; Miller as
co-I: VA HSR&D 20062009 $273,200; Janssen 2008 $35,000; NIMH 2006-2011
$2,251,596; NIMH 2008-2013 $2,523,247; Miller Honoraria: Research
Foundation for Mental Hygiene New York 08-30-07 $1,000; CME, Inc.
Orlando, FL 10-12-07 $2,500; France Foundation Atlanta, GA 10-09-07
$1,500; Organon (Advisory Board) Parsippany, NJ 10-25-07 $3,000;
Dainippon Sumitomo (Advisory Board) Chicago 10-26-07 $3,000; Eli Lilly
(Advisory Board) Scottsdale, AZ 11-01-07$1,500; AstraZeneca (Advisory
Board) Baltimore 11-02-07 $2,750 CME Outfitters Washington, DC 11-07-07
$5,000; Research Foundation for Mental Hygiene 09-07-08 to 10-21-08
$2,500; VA San Antonio, TX 03-18-08 $300; Comprehensive Neuroscience
online survey 05-30-08 $250; NCME, Inc. French Camp, CA 10-22-08 $2,000;
State of Maryland Baltimore 11-12-08 $200; NCME, Inc. Smithville, TX
11-18-08 $2,000; NCME, Inc. Reno, NV 12-17-08 $2,000; International
Congress on Schizophrenia Research San Diego, CA 03-31-09 $1,000.
NR 36
TC 14
Z9 14
U1 2
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD OCT
PY 2010
VL 18
IS 10
BP 887
EP 896
DI 10.1097/JGP.0b013e3181e56cdc
PG 10
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 653WP
UT WOS:000282128900004
PM 20808110
ER
PT J
AU Gellad, WF
Good, CB
Lowe, JC
Donohue, JM
AF Gellad, Walid F.
Good, Chester B.
Lowe, John C.
Donohue, Julie M.
TI Variation in Prescription Use and Spending for Lipid-Lowering and
Diabetes Medications in the Veterans Affairs Healthcare System
SO AMERICAN JOURNAL OF MANAGED CARE
LA English
DT Article
ID GEOGRAPHIC-VARIATION; UNITED-STATES; DRUG PRICES; QUALITY; PREVALENCE;
HOSPITALS; DECISION; TRIALS; SAFETY; SAMPLE
AB Objectives: To examine variation in outpatient prescription use and spending for hyperlipidemia and diabetes mellitus in the Veterans Affairs Healthcare System (VA) and its association with quality measures for these conditions.
Study Design: Cross-sectional.
Methods: We compared outpatient prescription use, spending, and quality of care across 135 VA medical centers (VAMCs) in fiscal year 2008, including 2.3 million patients dispensed lipid-lowering medications and 981,031 patients dispensed diabetes medications. At each facility, we calculated VAMC-level cost per patient for these medications, the proportion of patients taking brand-name drugs, and Healthcare Effectiveness Data and Information Set (HEDIS) scores for hyperlipidemia (low-density lipoprotein cholesterol level <100 mg/dL) and for diabetes (glycosylated hemoglobin level >9% or not measured).
Results: The median cost per patient for lipid-lowering agents in fiscal year 2008 was $49.60 and varied from $39.68 in the least expensive quartile of VAMCs to $69.57 in the most expensive quartile (P < .001). For diabetes agents, the median cost per patient was $158.34 and varied from $123.34 in the least expensive quartile to $198.31 in the most expensive quartile (P < .001). The proportion of patients dispensed brand-name oral drugs among these classes in the most expensive quartile of VAMCs was twice that in the least expensive quartile (P < .001). There was no correlation between VAMC-level prescription spending and performance on HEDIS measures for lipid-lowering drugs (r = 0.12 and r = 0.07) or for diabetes agents (r = -0.10).
Conclusions: Despite the existence of a closely managed formulary, significant variation in prescription spending and use of brand-name drugs exists in the VA. Although we could not explicitly risk-adjust, there appears to be no relationship between prescription spending and quality of care. (Am J Manag Care. 2010;16(10):741-750)
C1 [Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Dept Vet Affairs Med Ctr, Pittsburgh, PA 15206 USA.
[Good, Chester B.] VA Pittsburgh Healthcare Syst, Ctr Medicat Safety, Pittsburgh, PA 15206 USA.
[Gellad, Walid F.; Good, Chester B.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
[Lowe, John C.] Univ Pittsburgh, Dept Pharm, Pittsburgh, PA USA.
[Donohue, Julie M.] Univ Pittsburgh, Dept Hlth Policy & Management, Pittsburgh, PA USA.
[Gellad, Walid F.] RAND Corp, Pittsburgh, PA USA.
[Lowe, John C.] Vet Hlth Adm, Pharm Benefits Mangement Serv, Washington, DC USA.
RP Gellad, WF (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Dept Vet Affairs Med Ctr, 7180 Highland Dr, Pittsburgh, PA 15206 USA.
EM walid.gellad@va.gov
OI Donohue, Julie/0000-0003-2418-6017
FU VA Pittsburgh Healthcare System; National Center for Research Resources,
National Institutes of Health Roadmap for Medical Research [KL2
RR024154]
FX This study is the result of work supported by resources from the VA
Pittsburgh Healthcare System. Dr Donohue was supported by grant KL2
RR024154 from the National Center for Research Resources, a component of
the National Institutes of Health Roadmap for Medical Research.
NR 38
TC 7
Z9 7
U1 0
U2 5
PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC
PI PLAINSBORO
PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA
SN 1088-0224
J9 AM J MANAG CARE
JI Am. J. Manag. Care
PD OCT
PY 2010
VL 16
IS 10
BP 741
EP 750
PG 10
WC Health Care Sciences & Services; Health Policy & Services; Medicine,
General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 678SO
UT WOS:000284100900006
PM 20964470
ER
PT J
AU Kim, H
Ross, JS
Melkus, GD
Zhao, ZL
Boockvar, K
AF Kim, Hongsoo
Ross, Joseph S.
Melkus, Gail D.
Zhao, Zhonglin
Boockvar, Kenneth
TI Scheduled and Unscheduled Hospital Readmissions Among Patients With
Diabetes
SO AMERICAN JOURNAL OF MANAGED CARE
LA English
DT Article
ID REHOSPITALIZATIONS; MEDICINE; QUALITY; RATES; CARE
AB Objectives: To describe rates of scheduled and unscheduled readmissions among midlife and older patients with diabetes and to examine associated socioeconomic and clinical factors.
Study Design: Population-based data set study.
Methods: Using the 2006 California State Inpatient Dataset, we identified 124,967 patients 50 years or older with diabetes who were discharged from acute care hospitals between April and September 2006 and examined readmissions in the 3 months following their index hospitalizations.
Results: About 26.3% of patients were readmitted within the 3-month period following their index hospitalizations, 87.2% of which were unscheduled readmissions. Patients with unscheduled readmissions were more likely to have a higher comorbidity burden, be members of racial/ethnic minority groups with public insurance, and live in lower-income neighborhoods. Having a history of hospitalization in the 3 months preceding the index hospitalization was also a strong predictor of unscheduled readmissions. Almost one-fifth of unscheduled readmissions (constituting approximately 27,500 inpatient days and costing almost $72.7 million) were potentially preventable based on definitions of Prevention Quality Indicators by the Agency for Healthcare Research and Quality. Scheduled readmissions were less likely to occur among patients 80 years or older, the uninsured, and those with an unscheduled index hospitalization.
Conclusions: The predictors of scheduled and unscheduled readmissions are different. Transition care to prevent unscheduled readmissions in acutely ill patients with diabetes may help reduce rates, improving care. Further studies are needed on potential disparities in scheduled readmissions. (Am J Manag Care. 2010;16(10):760-767)
C1 [Kim, Hongsoo] Seoul Natl Univ, Grad Sch Publ Hlth, Seoul 151742, South Korea.
[Kim, Hongsoo] Seoul Natl Univ, Inst Hlth & Environm, Seoul 151742, South Korea.
[Ross, Joseph S.; Boockvar, Kenneth] James J Peters VA Med Ctr, Bronx, NY USA.
[Ross, Joseph S.; Boockvar, Kenneth] Mt Sinai Sch Med, New York, NY USA.
[Melkus, Gail D.] NYU, Coll Nursing, New York, NY USA.
[Zhao, Zhonglin] NYU, Coll Dent, New York, NY USA.
RP Kim, H (reprint author), Seoul Natl Univ, Grad Sch Publ Hlth, 599 Kwanak Ro, Seoul 151742, South Korea.
EM hk65.snu@gmail.com
OI Boockvar, Kenneth/0000-0003-1165-5558
FU NIA NIH HHS [K08 AG032886]
NR 24
TC 23
Z9 23
U1 1
U2 4
PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC
PI PLAINSBORO
PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA
SN 1088-0224
J9 AM J MANAG CARE
JI Am. J. Manag. Care
PD OCT
PY 2010
VL 16
IS 10
BP 760
EP 767
PG 8
WC Health Care Sciences & Services; Health Policy & Services; Medicine,
General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 678SO
UT WOS:000284100900008
PM 20964472
ER
PT J
AU Singh, H
Petersen, LA
Thomas, EJ
Wilson, L
Sittig, DF
AF Singh, Hardeep
Petersen, Laura A.
Thomas, Eric J.
Wilson, Lindsey
Sittig, Dean F.
TI Notification of Abnormal and Critical Values: The Road Ahead Reply
SO AMERICAN JOURNAL OF MEDICINE
LA English
DT Letter
C1 [Singh, Hardeep; Petersen, Laura A.; Wilson, Lindsey] Baylor Coll Med, Houston VA Hlth Serv Res & Dev Ctr Excellence, Houston, TX 77030 USA.
[Singh, Hardeep; Petersen, Laura A.; Wilson, Lindsey] Baylor Coll Med, Ctr Inquiry Improve Outpatient Safety Effect Elec, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Singh, Hardeep; Petersen, Laura A.; Wilson, Lindsey] Baylor Coll Med, Sect Hlth Serv Res, Dept Med, Houston, TX 77030 USA.
[Thomas, Eric J.] Univ Texas Houston, Mem Hermann Ctr Healthcare Qual & Safety, Div Gen Med, Univ Texas Med Sch Houston,Dept Med, Houston, TX USA.
[Sittig, Dean F.] Univ Texas Sch Biomed Informat, Houston, TX USA.
[Sittig, Dean F.] UT Mem Hermann Ctr Healthcare Qual & Safety, Houston, TX USA.
RP Singh, H (reprint author), Baylor Coll Med, Houston VA Hlth Serv Res & Dev Ctr Excellence, Houston, TX 77030 USA.
NR 2
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9343
J9 AM J MED
JI Am. J. Med.
PD OCT
PY 2010
VL 123
IS 10
BP E21
EP E21
DI 10.1016/j.amjmed.2010.06.008
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 656WR
UT WOS:000282372300014
ER
PT J
AU Hua, P
Feng, WG
Ji, SN
Raij, L
Jaimes, EA
AF Hua, Ping
Feng, Wenguang
Ji, Shaonin
Raij, Leopoldo
Jaimes, Edgar A.
TI Nicotine worsens the severity of nephropathy in diabetic mice:
implications for the progression of kidney disease in smokers
SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY
LA English
DT Article
DE reactive oxygen species; tobacco
ID SMOOTH-MUSCLE-CELLS; STAGE RENAL-FAILURE; NADPH OXIDASE; NAD(P)H
OXIDASE; ACETYLCHOLINE-RECEPTORS; ENDOTHELIAL-CELLS; CIGARETTE-SMOKING;
ANGIOTENSIN-II; FIBRONECTIN EXPRESSION; ESSENTIAL-HYPERTENSION
AB Hua P, Feng W, Ji S, Raij L, Jaimes EA. Nicotine worsens the severity of nephropathy in diabetic mice: implications for the progression of kidney disease in smokers. Am J Physiol Renal Physiol 299: F732-F739, 2010. First published August 4, 2010; doi:10.1152/ajprenal.00293.2010.-Epidemiological studies have established the role of cigarette smoking as a risk factor in the progression of chronic kidney disease, including diabetic nephropathy. We have previously reported that nicotine promotes mesangial cell proliferation and hypertrophy via activation of non-neuronal nicotinic acetylcholine receptors and that nicotine worsens renal injury in a model of acute glomerulonephritis (Jaimes E, Tian RX, Raij L. Am J Physiol Heart Circ Physiol 292: H76-H82, 2007; Jaimes EA, Tian RX, Joshi M, Raij L. Am J Nephrol 29: 319-326, 2009). These studies were designed to test the hypothesis that nicotine worsens renal injury in db/db mice, a well-established model of diabetic nephropathy, and that reactive oxygen species play an important as mediators of these effects. For these studies, nicotine (100 mu g/ml) was administered in the drinking water to control and db/db mice for 10 wk. Blood pressure was measured by the tail-cuff method, and urine was collected for proteinuria. At death, kidneys were collected for histology and molecular biology. The administration of nicotine did not result in significant changes in blood pressure or blood glucose and resulted in cotinine levels similar to those found in the plasma of smokers. In diabetic mice, the administration of nicotine significantly increased urinary protein excretion (1-fold), glomerular hypertrophy, and mesangial area (similar to 20%). These changes were accompanied by significant increases in NADPH oxidase 4 (similar to 30%) and increased nitrotyrosine and Akt expression. In vitro, we determined that nicotine has additive effects to high glucose on reactive oxygen species generation and Akt phosphorylation in human mesangial cells. These findings unveil novel mechanisms that may result in the development of novel strategies in the treatment and prevention of diabetic nephropathy in smokers.
C1 [Hua, Ping; Feng, Wenguang; Ji, Shaonin; Jaimes, Edgar A.] Univ Alabama, Div Nephrol, Birmingham, AL USA.
[Jaimes, Edgar A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Raij, Leopoldo] Univ Miami, Div Renal, Miami, FL USA.
[Raij, Leopoldo] Miami Vet Affairs Med Ctr, Miami, FL USA.
RP Jaimes, EA (reprint author), ZRB 637,1530 3rd Ave S, Birmingham, AL 35294 USA.
EM ejaimes@uab.edu
FU National Institutes of Health [ES014948]; Flight Attendants Research
Institute; Florida Department of Health
FX These studies were funded by National Institutes of Health Grant
ES014948 (to E. A. Jaimes), a Clinical Investigator Award from the
Flight Attendants Research Institute (to E. A. Jaimes), and a Team
Science Project of the Florida Department of Health (to E. A. Jaimes and
L. Raij.)
NR 48
TC 30
Z9 30
U1 0
U2 7
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1931-857X
J9 AM J PHYSIOL-RENAL
JI Am. J. Physiol.-Renal Physiol.
PD OCT
PY 2010
VL 299
IS 4
BP F732
EP F739
DI 10.1152/ajprenal.00293.2010
PG 8
WC Physiology; Urology & Nephrology
SC Physiology; Urology & Nephrology
GA 658IP
UT WOS:000282484000006
PM 20685820
ER
PT J
AU Soneji, S
Lyer, SS
Armstrong, K
Asch, DA
AF Soneji, Samir
Lyer, Shally Shalini
Armstrong, Katrina
Asch, David A.
TI Racial Disparities in Stage-Specific Colorectal Cancer Mortality:
1960-2005
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID UNITED-STATES; COLON-CANCER; WHITES; SURVIVAL; BLACKS; HEALTH; CARE;
RACE; CONSEQUENCES; CARCINOMA
AB Objectives. We examined whether racial disparities in stage-specific colorectal cancer survival changed between 1960 and 2005.
Methods. We used US Mortality Multiple-Cause-of-Death Data Files and intercensal estimates to calculate standardized mortality rates by gender and race from 1960 to 2005. We used Surveillance, Epidemiology, and End Results (SEER) data to estimate stage-specific colorectal cancer survival. To account for SEER sampling uncertainty, we used a bootstrap resampling procedure and fit a Cox proportional hazards model.
Results. Between 1960-2005, patterns of decline in mortality rate as a result of colorectal cancer differed greatly by gender and race: 54% reduction for White women, 14% reduction for Black women, 39% reduction for White men, and 28% increase for Black men. Blacks consistently experienced worse rates of stage-specific survival and life expectancy than did Whites for both genders, across all age groups, and for localized, regional, and distant stages of the disease.
Conclusions. The rates of stage-specific colorectal cancer survival differed among Blacks when compared with Whites during the 4-decade study period. Differences in stage-specific life expectancy were the result of differences in access to care or quality of care. More attention should be given to racial disparities in colorectal cancer management. (Am J Public Health. 2010;100: 1912-1916. doi:10.2105/AJPH.2009.184192)
C1 [Soneji, Samir; Asch, David A.] Univ Penn, Robert Wood Johnson Hlth & Soc Scholars Program, Philadelphia, PA 19104 USA.
[Lyer, Shally Shalini] Univ Penn, Grad Program Publ Hlth Studies, Div Gen Internal Med, Philadelphia, PA 19104 USA.
[Armstrong, Katrina; Asch, David A.] Univ Penn, Leonard Davis Inst Hlth Econ, Div Gen Internal Med, Philadelphia, PA 19104 USA.
[Asch, David A.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
RP Soneji, S (reprint author), Univ Penn, Robert Wood Johnson Hlth & Soc Scholars Program, 3641 Locust Walk, Philadelphia, PA 19104 USA.
EM soneji@wharton.upenn.edu
OI Asch, David/0000-0002-7970-286X
FU Robert Wood Johnson Foundation
FX We thank the Robert Wood Johnson Foundation Health & Society Scholars
and Robert Wood Johnson Clinical Scholars programs for their financial
support.
NR 34
TC 48
Z9 48
U1 1
U2 2
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD OCT
PY 2010
VL 100
IS 10
BP 1912
EP 1916
DI 10.2105/AJPH.2009.184192
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 656SC
UT WOS:000282355900022
PM 20724684
ER
PT J
AU Mehta, KM
Fung, KZ
Kistler, CE
Chang, A
Walter, LC
AF Mehta, Kala M.
Fung, Kathy Z.
Kistler, Christine E.
Chang, Anna
Walter, Louise C.
TI Impact of Cognitive Impairment on Screening Mammography Use in Older US
Women
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID ALZHEIMERS-DISEASE; HEALTH-STATUS; SURVIVAL; DEMENTIA; PREVALENCE;
PREDICTORS; DIAGNOSIS; MORTALITY; PEOPLE
AB Objectives. We evaluated mammography rates for cognitively impaired women in the context of their life expectancies, given that guidelines do not recommend screening mammography in women with limited life expectancies because harms outweigh benefits.
Methods. We evaluated Medicare claims for women aged 70 years or older from the 2002 wave of the Health and Retirement Study to determine which women had screening mammography. We calculated population-based estimates of 2-year screening mammography prevalence and 4-year survival by cognitive status and age.
Results. Women with severe cognitive impairment had lower rates of mammography (18%) compared with women with normal cognition (45%). Nationally, an estimated 120000 screening mammograms were performed among women with severe cognitive impairment despite this group's median survival of 3.3 years (95% confidence interval=2.8, 3.7). Cognitively impaired women who had high net worth and were married had screening rates approaching 50%.
Conclusions. Although severe cognitive impairment is associated with lower screening mammography rates, certain subgroups with cognitive impairment are often screened despite lack of probable benefit. Given the limited life expectancy of women with severe cognitive impairment, guidelines should explicitly recommend against screening these women. (Am J Public Health. 2010;100:1917-1923. doi:10.2105/AJPH.2008.158485)
C1 [Mehta, Kala M.; Kistler, Christine E.; Chang, Anna; Walter, Louise C.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94121 USA.
[Fung, Kathy Z.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Mehta, KM (reprint author), Univ Calif San Francisco, Div Geriatr, 4150 Clement St,Box 181G, San Francisco, CA 94121 USA.
EM kala.mehta@ucsf.edu
FU National Institute on Aging [NIA-K-01AG025444-01A1, NIA U01AG009740];
Department of Veterans Affairs Merit Review grant [IIR 04-427]; Robert
Wood Johnson Physician Faculty Scholar; University of Michigan
FX K M. Mehta is currently supported by a Research Career Scientist Award
from the National Institute on Aging (NIA-K-01AG025444-01A1). She is
currently an affiliate of the Center for Aging in Diverse Communities at
University of California, San Francisco, a part of the P30 AG 15272 350
Resource Centers for Minority Aging Research Program (NIA, National
Institute of Nursing Research, and the National Center for Minority
Health and Health Disparities). L.C. Walter was supported by a
Department of Veterans Affairs Merit Review grant (IIR 04-427) and is a
Robert Wood Johnson Physician Faculty Scholar. The Health and Retirement
Study is sponsored by the MA (grant NIA U01AG009740) and is conducted by
the University of Michigan.
NR 37
TC 20
Z9 21
U1 1
U2 3
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD OCT
PY 2010
VL 100
IS 10
BP 1917
EP 1923
DI 10.2105/AJPH.2008.158485
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 656SC
UT WOS:000282355900023
PM 20075325
ER
PT J
AU Chan, ED
Bai, XY
Kartalija, M
Ormes, IM
Ordways, DJ
AF Chan, Edward D.
Bai, Xiyuan
Kartalija, Marinka
Ormes, Ian M.
Ordways, Diane J.
TI Host Immune Response to Rapidly Growing Mycobacteria, an Emerging Cause
of Chronic Lung Disease
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Review
DE Mycobacterium abscessus; immune responses; rapidly growing mycobacteria;
host defense
ID TUMOR-NECROSIS-FACTOR; MACROPHAGE TNF-ALPHA; GROWTH-FACTOR-BETA;
NONTUBERCULOUS MYCOBACTERIA; PULMONARY-DISEASE; AVIUM COMPLEX;
INTERFERON-GAMMA; TGF-BETA; TUBERCULOSIS INFECTION; ABSCESSUS INFECTION
AB Rapidly growing mycobacteria (RGM) are environmental organisms classified under the broader category of nontuberculous mycobacteria. The most common RGM to cause human diseases are Mycobacterium abscessus, Mycobacterium chelonae, Mycobacterium fortuitum, and Mycobacterium massiliense. Infections due to the RGM are an emerging health problem in the United States. Chronic pulmonary disease and skin/soft-tissue infections are the two most common disorders due to these organisms. Clinical outcomes in the treatment of M. abscessus infections are generally disappointing. Because less is known about the nature of the immune response to M. abscessus than for tuberculosis, we herein highlight the major clinical features associated with infections due to M. abscessus and other RGM, and review the known host immune response to RGM, drawing from experimental animal and clinical studies. Based on in vitro and in vivo murine models, Toll-like receptor 2, dectin-1, tumor necrosis factor (TNF)-alpha, IFN-gamma, leptin, T cells, and possibly neutrophils are important components in the host defense against RGM infections. However, excessive induction of TNF-alpha by the R morphotype of M. abscessus may allow it to be more pathogenic than the S morphotype. Clinical observations and/or genetic studies in humans corroborate many of the findings in animals in that those with cell-mediated immunodeficiency, genetic defects in IFN-gamma-IL-12 axis, and those individuals on TNF-alpha blockers are at increased risk for nontuberculous mycobacteria infections, including the RGM. However, much remains to be discovered on why seemingly healthy individuals, particularly slender postmenopausal women with thoracic cage anomalies, appear to be at increased risk.
C1 [Chan, Edward D.; Bai, Xiyuan] Natl Jewish Hlth, Div Mycobacterial & Resp Infect, Denver, CO 80206 USA.
[Chan, Edward D.] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Chan, Edward D.; Bai, Xiyuan] Univ Colorado Denver, Div Pulm Sci & Crit Care Med, Denver, CO USA.
[Kartalija, Marinka] Univ Colorado Denver, Div Infect Dis, Denver, CO USA.
[Ormes, Ian M.; Ordways, Diane J.] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA.
RP Chan, ED (reprint author), Natl Jewish Hlth, Div Mycobacterial & Resp Infect, D509,Neustadt Bldg,1400 Jackson St, Denver, CO 80206 USA.
EM chane@njhealth.org
FU Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development
FX This work was supported by the Department of Veterans Affairs, Veterans
Health Administration, Office of Research and Development (E.D.C.).
NR 73
TC 33
Z9 33
U1 1
U2 3
PU AMER THORACIC SOC
PI NEW YORK
PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA
SN 1044-1549
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD OCT
PY 2010
VL 43
IS 4
BP 387
EP 393
DI 10.1165/rcmb.2009-0276TR
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA 660UY
UT WOS:000282673100001
PM 20081053
ER
PT J
AU Livhits, M
Mercado, C
Yermilov, I
Parikh, JA
Dutson, E
Mehran, A
Ko, CY
Gibbons, MM
AF Livhits, Masha
Mercado, Cheryl
Yermilov, Irina
Parikh, Janak A.
Dutson, Erik
Mehran, Amir
Ko, Clifford Y.
Gibbons, Melinda Maggard
TI Behavioral Factors Associated with Successful Weight Loss after Gastric
Bypass
SO AMERICAN SURGEON
LA English
DT Article
ID BARIATRIC SURGERY; FOLLOW-UP; QUESTIONNAIRE; ATTENDANCE; OBESITY
AB Patients undergoing bariatric surgery lose substantial weight (>= 50% excess weight loss [EWL]), but an estimated 20 per cent fail to achieve this goal. Our objective was to identify behavioral predictors of weight loss after laparoscopic Roux-en-Y gastric bypass. We retrospectively surveyed 148 patients using validated instruments for factors predictive of weight loss. Success was defined as >= 50 per cent EWL and failure as <50 per cent EWL. Mean follow-up after laparoscopic Roux-en-Y gastric bypass was 40.1 +/- 15.3 months, with 52.7 per cent of patients achieving successful weight loss. After controlling for age, gender, and preoperative body mass index, predictors of successful weight loss included surgeon follow-up (odds ratio [OR] 8.2, P < 0.01), attendance of postoperative support groups (OR 3.7, P = 0.02), physical activity (OR 3.5, P < 0.01), single or divorced marital status (OR 3.2, P = 0.03), self-esteem (OR 0.3, P = 0.02), and binge eating (OR 0.9, P < 0.01). These factors should be addressed in prospective studies of weight loss after bariatric surgery, as they may identify patients at risk for weight loss failure who may benefit from early tailored interventions.
C1 [Livhits, Masha; Mercado, Cheryl; Yermilov, Irina; Parikh, Janak A.; Dutson, Erik; Mehran, Amir; Ko, Clifford Y.; Gibbons, Melinda Maggard] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA.
[Livhits, Masha; Yermilov, Irina; Parikh, Janak A.; Ko, Clifford Y.; Gibbons, Melinda Maggard] VA Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA.
[Gibbons, Melinda Maggard] Olive View Univ Calif, Dept Surg, Sylmar, CA USA.
RP Livhits, M (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 10833 LeConte Ave,72 215 CHS, Los Angeles, CA 90095 USA.
EM mlivhits@mednet.ucla.edu
FU VA Department of Surgery; Robert Wood Johnson Physician Faculty
FX We would like to acknowledge the generous contribution of Paul G.
Shekelle to the design of our project and critical review of the
analysis. The VA Department of Surgery provided support for Dr. Livhits
and Dr. Maggard Gibbons. Dr. Maggard Gibbons's time was supported in
part by a grant from the Robert Wood Johnson Physician Faculty Scholars
program.
NR 15
TC 44
Z9 45
U1 0
U2 7
PU SOUTHEASTERN SURGICAL CONGRESS
PI ATLANTA
PA 141 WEST WIEUCA RD, STE B100, ATLANTA, GA 30342 USA
SN 0003-1348
J9 AM SURGEON
JI Am. Surg.
PD OCT
PY 2010
VL 76
IS 10
BP 1139
EP 1142
PG 4
WC Surgery
SC Surgery
GA 663AO
UT WOS:000282855600027
PM 21105629
ER
PT J
AU Raval, MV
Bentrem, DJ
Stewart, AK
Ko, CY
Reynolds, M
AF Raval, Mehul V.
Bentrem, David J.
Stewart, Andrew K.
Ko, Clifford Y.
Reynolds, Marleta
TI Utilization of Total Thyroidectomy for Differentiated Thyroid Cancer in
Children
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Article
ID TERM-FOLLOW-UP; DATA-BASE; UNITED-STATES; YOUNG-ADULTS; CARCINOMA;
DISEASE; ADOLESCENTS; RECURRENCE; MANAGEMENT; CHILDHOOD
AB Purpose. Recent recommendations suggest that total thyroidectomy (TT) is the surgical management of choice for differentiated thyroid cancer in children. The objective of this study is to assess trends in extent of surgical resection for differentiated thyroid cancer in children over the past two decades and to identify patient, tumor or hospital factors associated with use of TT.
Patients and Methods. Of 8,013 patients (aged 0-21 years) with differentiated thyroid cancer from the National Cancer Data Base (1985-2007), 5,933(74%) underwent TT. Trends in extent of surgery were examined. Logistic regression was used to identify factors that predict use of TT.
Results. Use of TT increased from 50.6% in 1985 to 84% in 2007 (P < 0.001). Patients were more likely to undergo TT if they had higher household income or had private insurance (P = 0.002 and P = 0.037). Patients were more likely to undergo TT if they had larger tumors or if there were nodal metastases present at time of resection (both P < 0.001). After adjusting for patient and tumor factors, patients treated at high-volume or Children's Oncology Group hospitals were more likely to undergo TT than patients treated at low-volume or non-Children's Oncology Group hospitals (P < 0.001).
Conclusions. Overall utilization of TT in children with differentiated thyroid cancer has steadily increased over the past 23 years in the USA. Variations in use of TT are not only related to tumor factors including size and nodal involvement, but also are also related to socioeconomic and hospital factors, demonstrating disparities in care.
C1 [Raval, Mehul V.; Stewart, Andrew K.; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Canc Programs, Chicago, IL USA.
[Raval, Mehul V.; Reynolds, Marleta] Childrens Mem Hosp, Div Pediat Surg, Chicago, IL 60614 USA.
[Raval, Mehul V.; Bentrem, David J.] Northwestern Univ, Div Gastrointestinal & Oncol Surg, Dept Surg, Feinberg Sch Med, Chicago, IL 60611 USA.
[Bentrem, David J.] Jesse Brown VA Med Ctr, Chicago, IL USA.
[Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA.
[Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Raval, MV (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, Canc Programs, Chicago, IL USA.
EM mehulvraval@gmail.com
OI Raval, Mehul/0000-0002-1527-2661
FU John Gray Research Fellowship; Daniel F. and Ada L. Rice Foundation;
Department of Veterans Affairs, Veterans Health Administration, Health
Services Research and Development Service; American College of Surgeons
Commission on Cancer; American Cancer Society
FX M.V.R. participates in the American College of Surgeons Clinical
Scholars in Residence Program. M.V.R. is supported by the John Gray
Research Fellowship and the Daniel F. and Ada L. Rice Foundation. D.J.B.
is supported by a career development award from the Department of
Veterans Affairs, Veterans Health Administration, Health Services
Research and Development Service. The National Cancer Data Base is
supported by the American College of Surgeons, Commission on Cancer, and
the American Cancer Society.
NR 53
TC 10
Z9 11
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD OCT
PY 2010
VL 17
IS 10
BP 2545
EP 2553
DI 10.1245/s10434-010-1083-3
PG 9
WC Oncology; Surgery
SC Oncology; Surgery
GA 669ZP
UT WOS:000283389200003
PM 20429037
ER
PT J
AU Ge, PS
Ishaque, BM
Bonilla, J
de Virgilio, C
AF Ge, Phillip S.
Ishaque, Brandon M.
Bonilla, Janet
de Virgilio, Christian
TI Popliteal Artery Pseudoaneurysm After Isolated Hyperextension of the
Knee
SO ANNALS OF VASCULAR SURGERY
LA English
DT Article
ID VASCULAR INJURIES; ARTERIOGRAPHY ALWAYS; DISLOCATIONS; REPAIR
AB We report an unusual case of a traumatic pseudoaneurysm of the popliteal artery after an isolated blunt hyperextension injury to the knee. A 56-year-old man presented with a 1-month history of left knee pain that occurred after a fall onto his buttocks with hyperextension of the knee while transferring a relative out of a wheelchair. A large pulsatile mass in the posterior aspect of the left knee was palpated on physical examination, although he had warm distal extremities and 2+ distal pulses bilaterally. Magnetic resonance angiography revealed a 7.6 x 6.2 x 4.9 cm left popliteral artery pseudoaneurysm, which was subsequently treated with aneurysm exclusion with end to end reverse saphenous vein graft bypass. The development of a popliteal artery pseudoaneurysm after blunt knee injury without dislocation, fracture, or ligament injury is extremely unusual, but requires prompt treatment to avoid the potential complications of permanent functional impairment and limb loss.
C1 [Ge, Phillip S.; Ishaque, Brandon M.; Bonilla, Janet] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[de Virgilio, Christian] W Los Angeles VA Med Ctr, Dept Surg, Los Angeles, CA USA.
RP de Virgilio, C (reprint author), Harbor UCLA Med Ctr, Dept Surg, 1000 W Carson St, Torrance, CA 90309 USA.
EM cdevirgilio@labiomed.org
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0890-5096
J9 ANN VASC SURG
JI Ann. Vasc. Surg.
PD OCT
PY 2010
VL 24
IS 7
AR 950.e7
DI 10.1016/j.avsg.2010.01.014
PG 5
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 647YC
UT WOS:000281655700018
PM 20471789
ER
PT J
AU Weiner, M
Peloquin, C
Burman, W
Luo, CC
Engle, M
Prihoda, TJ
Mac Kenzie, WR
Bliven-Sizemore, E
Johnson, JL
Vernon, A
AF Weiner, Marc
Peloquin, Charles
Burman, William
Luo, Chi-Cheng
Engle, Melissa
Prihoda, Thomas J.
Mac Kenzie, William R.
Bliven-Sizemore, Erin
Johnson, John L.
Vernon, Andrew
TI Effects of Tuberculosis, Race, and Human Gene SLCO1B1 Polymorphisms on
Rifampin Concentrations
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID PULMONARY TUBERCULOSIS; ANTIMYCOBACTERIAL DRUGS; PHARMACOKINETICS;
RIFABUTIN; BIOAVAILABILITY; MOXIFLOXACIN; RESISTANCE; REGIMENS;
ATORVASTATIN; RIFAPENTINE
AB Rifampin has concentration-dependent activity against Mycobacterium tuberculosis. However, marked intersubject variation of rifampin concentrations occurs. In this study, we evaluated rifampin pharmacokinetics in relation to tuberculosis, geographic region, race, and single nucleotide polymorphisms of the human transporter genes SLCO1B1, SLCO1B3, and MDR1. Seventy-two adults with pulmonary tuberculosis from Africa, North America, and Spain were evaluated during multidrug intensive-phase therapy, and their results were compared to those from 16 healthy controls from North America. Rifampin pharmacokinetic values were similar between tuberculosis patients and controls (geometric mean [GM] area under the concentration-time curve from 0 to 24 h [AUC(0-24)] of 40.2 versus 40.9 mu g . h/ml; P = 0.9). However, in multivariable analyses, the rifampin AUC(0-24) was significantly affected by rifampin dosage (in mg/kg of body weight), polymorphisms in the SLCO1B1 gene, and the presence of tuberculosis by geographic region. The adjusted rifampin AUC(0-24) was lowest in patients with tuberculosis from Africa compared to that in non-African patients or control subjects. The adjusted rifampin AUC(0-24) was also 36% lower among participants with SLCO1B1 genotype c.463CA than that among participants with SLCO1B1 genotype c.463CC (adjusted GM, 29.8 versus 46.7 mu g . h/ml; P = 0.001). Polymorphisms in the SLCO1B1 gene associated with lower rifampin exposure were more frequent among black subjects. In conclusion, marked intersubject variation of the rifampin AUC(0-24) values was observed, but the mean values of the AUC(0-24) did not significantly vary between patients with tuberculosis and healthy controls. Lower rifampin exposure was associated with the polymorphism of the SLCO1B1 c. 463C>A gene. When adjusted for the patient mg/kg dosage and transporter gene polymorphisms, rifampin exposure was lower in patients with tuberculosis, which suggests that additional absorption or metabolic processes affect rifampin exposure with tuberculosis disease.
C1 [Weiner, Marc] S Texas Vet Hlth Care Syst, Div Infect Dis 111, San Antonio, TX 78229 USA.
[Weiner, Marc; Engle, Melissa; Prihoda, Thomas J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Peloquin, Charles] Univ Florida, Coll Pharm, Gainesville, FL 32610 USA.
[Burman, William] Denver Publ Hlth, Denver, CO 80204 USA.
[Luo, Chi-Cheng; Mac Kenzie, William R.; Bliven-Sizemore, Erin; Vernon, Andrew] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA.
[Johnson, John L.] Uganda Case Western Reserve Univ Res Collaborat, Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA.
RP Weiner, M (reprint author), S Texas Vet Hlth Care Syst, Div Infect Dis 111, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.
EM weiner@uthscsa.edu
RI Mac Kenzie, William /F-1528-2013
OI Mac Kenzie, William /0000-0001-7723-0339
FU Centers for Disease Control and Prevention; Global Alliance for TB Drug
Development; Veterans Administration; NIH [MO1-RR-01346]; Tuberculosis
Trials Consortium
FX This work was supported by the Centers for Disease Control and
Prevention, the Global Alliance for TB Drug Development, and the
Veterans Administration. Assistance in evaluation of patients was
provided by the Frederic C. Bartter General Clinical Research Center at
the VAMC San Antonio (supported by NIH grant MO1-RR-01346). This study
was sponsored by the Tuberculosis Trials Consortium.
NR 33
TC 51
Z9 54
U1 0
U2 8
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD OCT
PY 2010
VL 54
IS 10
BP 4192
EP 4200
DI 10.1128/AAC.00353-10
PG 9
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 651EI
UT WOS:000281907200021
PM 20660695
ER
PT J
AU Morganroth, PA
Kreider, ME
Werth, VP
AF Morganroth, Pamela A.
Kreider, Mary Elizabeth
Werth, Victoria P.
TI Mycophenolate Mofetil for Interstitial Lung Disease in Dermatomyositis
SO ARTHRITIS CARE & RESEARCH
LA English
DT Article
ID RHEUMATOID-ARTHRITIS; PULMONARY-FUNCTION; METHOTREXATE
AB Objective. To report our experience using mycophenolate mofetil as first-line treatment for dermatomyositis-associated interstitial lung disease.
Methods. We examined the medical records of all 16 dermatomyositis patients with interstitial lung disease seen in our outpatient university hospital dermatology clinic between May 26, 2006, and May 25, 2009. In this retrospective case series, we describe the clinical course of the 4 patients with definitive evidence of interstitial lung disease on radiologic imaging who were treated with mycophenolate mofetil and had pulmonary data available to document their outcome. All of the patients also received prednisone.
Results. All 3 patients with at least 1 year of followup receiving mycophenolate mofetil experienced complete normalization of pulmonary function tests (including diffusing capacity for carbon monoxide) and resolution of dyspnea. They were also able to reduce their prednisone doses. The only patient with pre- and posttreatment chest computed tomography imaging had total resolution of her interstitial opacities. The patient with only 5 months of posttreatment followup experienced an improvement in diffusing capacity for carbon monoxide from 44% to 77% predicted, but no change in dyspnea.
Conclusion. These promising data indicate that mycophenolate mofetil may be a useful therapy for interstitial lung disease in patients with dermatomyositis, but larger studies are needed to more definitively evaluate the role of this medication in therapy.
C1 [Morganroth, Pamela A.; Werth, Victoria P.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Morganroth, Pamela A.; Kreider, Mary Elizabeth; Werth, Victoria P.] Univ Penn, Philadelphia, PA 19104 USA.
RP Werth, VP (reprint author), Hosp Univ Penn, Dept Dermatol, PCAM Suite 1-330S,3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA.
EM werth@mail.med.upenn.edu
FU NIH [K24-AR-02207]; Department of the VA, Veterans Health
Administration, Office of Research and Development, Biomedical
Laboratory Research and Development
FX Based on work supported by the NIH and by a Merit Review Grant from the
Department of the VA, Veterans Health Administration, Office of Research
and Development, Biomedical Laboratory Research and Development. Dr.
Werth's work was supported by grants from the NIH (K24-AR-02207).
NR 15
TC 37
Z9 39
U1 0
U2 0
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 2151-464X
J9 ARTHRIT CARE RES
JI Arthritis Care Res.
PD OCT
PY 2010
VL 62
IS 10
BP 1496
EP 1501
DI 10.1002/acr.20212
PG 6
WC Rheumatology
SC Rheumatology
GA 667IA
UT WOS:000283185300019
PM 20506189
ER
PT J
AU Wu, Y
Bauman, WA
Blitzer, RD
Cardozo, C
AF Wu, Yong
Bauman, William A.
Blitzer, Robert D.
Cardozo, Christopher
TI Testosterone-induced hypertrophy of L6 myoblasts is dependent upon Erk
and mTOR
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Muscle; Hypertrophy; Testosterone; mTOR; Erk
ID ACTIVATED PROTEIN-KINASE; SKELETAL-MUSCLE; YOUNG MEN; MAMMALIAN TARGET;
PATHWAY; STRENGTH; RECEPTOR; CELLS; TRANSLATION; MACHINERY
AB Testosterone increases the size and strength of skeletal muscle. This study further characterized the molecular mechanisms of the anabolic actions of testosterone on a rat myoblast cell line (L6 cells). Testosterone did not induce hypertrophy in L6 cells lacking the androgen receptor (AR). Hypertrophy was prevented by the AR antagonist bicalutamide and the mTOR inhibitor rapamycin. Testosterone induced Erk phosphorylation by 2 h, and mTOR autophosphorylation was elevated within 20 min; phosphorylation of p70S6 kinase was increased by 2 h. Inhibitors of Erk or PI3K blocked tesotosterone-induced hypertrophy. Erk phosphorylation returned to baseline when media containing testosterone was replaced at 16 h with fresh media lacking testosterone; when bicalutamide was added to testosterone-enriched media at 16 h, Erk phosphorylation remained elevated. Autophosphorylation of the IGF-1 receptor was minimally altered by testosterone at 20 min and unaffected at later time points; PI3K/PDK1-dependent phosphorylation of Akt was not altered by testosterone. These findings indicate that testosterone stimulates hypertrophy of L6 myoblasts through a mechanism that requires its binding to the AR and involves a signaling cascade dependent upon Erk and mTOR which is likely activated by substances released into the extracellular space which are not IGF-1 or other ligands for receptor tyrosine kinases. Published by Elsevier Inc.
C1 [Wu, Yong; Bauman, William A.; Cardozo, Christopher] James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Dept Vet Affairs, Bronx, NY 10468 USA.
[Bauman, William A.; Cardozo, Christopher] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA.
[Bauman, William A.; Cardozo, Christopher] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA.
[Blitzer, Robert D.] Mt Sinai Sch Med, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA.
RP Cardozo, C (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Dept Vet Affairs, Room 1E-02,W Kingsbridge Rd, Bronx, NY 10468 USA.
EM Chris.Cardozo@mssm.edu
FU VA RRD [B4162C, B3347K, B4616R]; NIH [R01-GM054508, R21-DA029298]
FX Supported by VA RR&D Grants B4162C to W.A.B. and B3347K and B4616R to
C.C., respectively. R.D.B. is supported by NIH Grants R01-GM054508 and
R21-DA029298. The study sponsors had no role in the design of the
studies, collection, analysis or interpretation of the data, writing the
manuscript or the decision to submit the manuscript for publication.
NR 21
TC 23
Z9 24
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD OCT 1
PY 2010
VL 400
IS 4
BP 679
EP 683
DI 10.1016/j.bbrc.2010.08.127
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 662YP
UT WOS:000282850500039
PM 20816664
ER
PT J
AU Cowart, LA
Gandy, JL
Tholanikunnel, B
Hannun, YA
AF Cowart, L. Ashley
Gandy, Jason L.
Tholanikunnel, Baby
Hannun, Yusuf A.
TI Sphingolipids mediate formation of mRNA processing bodies during the
heat-stress response of Saccharomyces cerevisiae
SO BIOCHEMICAL JOURNAL
LA English
DT Article
DE heat-stress response; phytosphingosine; processing body; Saccharomyces
cerevisiae; sphingolipid; translation
ID BUDDING YEAST; DE-NOVO; SPHINGOID BASE; P-BODIES; CERAMIDE; GRANULES;
BIOSYNTHESIS; TRANSLATION; METABOLISM; PROGRAMS
AB Recent work, especially in the yeast Saccharomyces cerevisiae, has demonstrated that mRNA movement from active translation to cytoplasmic granules, termed mRNA'p-bodies' (processing bodies), occurs in concert with the regulation of translation during cell stress. However, the signals regulating p-body formation are poorly defined. Recent results have demonstrated a function for sphingolipids in regulating translation during heat stress, which led to the current hypothesis that p-bodies may form during heat stress in a sphingolipid-dependent manner. In the present study, we demonstrate that mild-heat-stress-induced formation of p-bodies, as determined by localization of a GFP (green fluorescent protein)-tagged Dcp2p and RFP (red fluorescent protein)-tagged Edc3p to discrete cytoplasmic foci. Sphingoid base synthesis was required for this effect, as inhibition of sphingoid base synthesis attenuated formation of these foci during heat stress. Moreover, treatment of yeast with the exogenous sphingoid bases phyto- and dihydro-sphingosine promoted formation of p-bodies in the absence of heat stress, and the lcb4/lcb5 double-deletion yeast, which accumulates high intracellular levels of sphingoid bases, had large clearly defined p-bodies under non-stress conditions. Functionally, inhibition of sphingolipid synthesis during heat stress did not prevent translation stalling, but extended translation arrest, indicating that sphingolipids mediate translation initiation. These results are consistent with the notion that p-bodies serve not only in mRNA degradation, but also for re-routing transcripts back to active translation, and that sphingolipids play a role in this facet of the heat-stress response. Together, these results demonstrate a critical and novel role for sphingolipids in mediating p-body formation during heat stress.
C1 [Cowart, L. Ashley; Gandy, Jason L.; Tholanikunnel, Baby; Hannun, Yusuf A.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29423 USA.
[Cowart, L. Ashley] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC 29401 USA.
RP Hannun, YA (reprint author), Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29423 USA.
EM hannun@musc.edu
FU National Institutes of Health [GM63625]; American Heart Association
[0555470U]; Center of Biomedical Research Excellence in Lipidomics and
Pathobiology; VA Merit Award
FX This work was supported by the National Institutes of Health [grant
number GM63625 (to Y.A.H.)]; the American Heart Association [grant
number 0555470U (to B.G.T.)]; the Center of Biomedical Research
Excellence in Lipidomics and Pathobiology (to L.A.C.); and by a VA Merit
Award (to L.A.C).
NR 35
TC 18
Z9 18
U1 0
U2 4
PU PORTLAND PRESS LTD
PI LONDON
PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND
SN 0264-6021
J9 BIOCHEM J
JI Biochem. J.
PD OCT 1
PY 2010
VL 431
BP 31
EP 38
DI 10.1042/BJ20100307
PN 1
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 662ZM
UT WOS:000282852800004
PM 20629639
ER
PT J
AU Morley, JF
Duda, JE
AF Morley, James F.
Duda, John E.
TI Olfaction as a biomarker in Parkinson's disease
SO BIOMARKERS IN MEDICINE
LA English
DT Review
DE diagnosis; dopaminergic functional imaging; neuropathology; olfaction;
olfactory bulb; Parkinson's disease; parkinsonian disorders;
pathophysiology; smell
ID SLEEP BEHAVIOR DISORDER; PROGRESSIVE SUPRANUCLEAR PALSY; SMELL
IDENTIFICATION TEST; LEWY BODY DISORDERS; ODOR IDENTIFICATION;
TRANSCRANIAL SONOGRAPHY; ALPHA-SYNUCLEINOPATHY; COGNITIVE IMPAIRMENT;
CLINICAL-DIAGNOSIS; AUTONOMIC FAILURE
AB Olfactory dysfunction in Parkinson's disease is common and of interest, both as a clinical finding and potential biomarker. In this article, we discuss studies characterizing the olfactory deficit in Parkinson's disease and pathological analysis that suggests the olfactory system is a likely induction site of the neurodegenerative process. These studies have enabled research to explore the potential of olfactory dysfunction as a key component in early diagnostic strategies, as a biomarker for diagnostic purposes, a predictor of clinical outcomes and a potential therapy-independent marker of disease progression.
C1 [Morley, James F.; Duda, John E.] Univ Penn, Sch Med, Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA 19104 USA.
[Morley, James F.; Duda, John E.] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA.
RP Duda, JE (reprint author), Univ Penn, Sch Med, Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA 19104 USA.
EM john.duda@va.gov
NR 95
TC 19
Z9 19
U1 2
U2 9
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
1QB, ENGLAND
SN 1752-0363
J9 BIOMARK MED
JI Biomark. Med.
PD OCT
PY 2010
VL 4
IS 5
BP 661
EP 670
DI 10.2217/BMM.10.95
PG 10
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 673DD
UT WOS:000283638000003
PM 20945979
ER
PT J
AU Vedeniapin, A
Cheng, L
George, MS
AF Vedeniapin, Andrei
Cheng, Laura
George, Mark S.
TI Feasibility of simultaneous cognitive behavioral therapy and left
prefrontal rTMS for treatment resistant depression
SO BRAIN STIMULATION
LA English
DT Article
ID TRANSCRANIAL MAGNETIC STIMULATION; CORTEX
C1 [Vedeniapin, Andrei] Med Univ S Carolina, IOP, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Cheng, Laura] Med Univ S Carolina, Coll Med, Charleston, SC 29425 USA.
[George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Vedeniapin, A (reprint author), Med Univ S Carolina, IOP, Dept Psychiat & Behav Sci, 519 N,67 President St, Charleston, SC 29425 USA.
EM vedeniap@musc.edu
FU National Institute on Drug Abuse [R25 DA020537]; Neuronetics; Brainsway;
Principal Investigator for a Veterans Affairs [VA CSP 556]
FX Partial funding to Dr. Vedeniapin was provided by National Institute on
Drug Abuse grant R25 DA020537.; Mark George is an unpaid consultant to
several TMS manufacturers (Neuronetics. Brainsway, Neostim, Neosync).
Neuronetics loaned the TMS equipment for a recent National Institutes of
Health-sponsored TMS trial in depression that Dr. George chaired. The
brain stimulation laboratory is conducting a depression clinical trial
funded by Brainsway. Dr. George is on the executive committee and is a
site Principal Investigator for a Veterans Affairs funded multisite
cooperative studies trial of TMS to treat depressed veterans (VA CSP
556).
NR 14
TC 11
Z9 12
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1935-861X
J9 BRAIN STIMUL
JI Brain Stimul.
PD OCT
PY 2010
VL 3
IS 4
BP 207
EP 210
DI 10.1016/j.brs.2010.03.005
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 675GG
UT WOS:000283814200004
PM 20965449
ER
PT J
AU Morrow, PK
Divers, S
Provencher, L
Luoh, SW
Petrella, TM
Giurescu, M
Schmelter, T
Wang, Y
Hortobagyi, GN
Vahdat, LT
AF Morrow, Phuong K.
Divers, Stephen
Provencher, Louise
Luoh, Shiuh-Wen
Petrella, Teresa M.
Giurescu, Marius
Schmelter, Thomas
Wang, Yao
Hortobagyi, Gabriel N.
Vahdat, Linda T.
TI Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO)
in patients with metastatic breast cancer that has progressed following
chemotherapy
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Phase II; Sagopilone; Epothilones; Breast cancer; Metastatic
ID IXABEPILONE BMS-247550; OVARIAN-CANCER; SOLID TUMORS; NEUROPATHY;
TAXANE; ANTHRACYCLINE; CAPECITABINE; CISPLATIN; RESISTANT; AGENT
AB Sagopilone is a novel, fully synthetic epothilone that has shown promising preclinical activity in a range of tumor models, including platinum-resistant ovarian cancer and metastatic breast cancer (MBC). This open-label, multicenter, Phase II study investigated the efficacy, safety, and tolerability of sagopilone administered to patients with MBC. Women with MBC whose previous chemotherapy regimen included a taxane and an anthracycline received sagopilone 16 or 22 mg/m(2) as a 3-h intravenous infusion every 21 days. Efficacy (using modified Response Evaluation Criteria in Solid Tumors), safety, and tolerability were assessed in this population. A total of 65 patients received sagopilone at either 16 mg/m(2) (N = 39) or 22 mg/m(2) (N = 26). Patients received a median of two cycles of sagopilone. Among the 65 patients who were evaluable for efficacy, there were three confirmed tumor responses over both treatment arms; however, the primary target of the study was not reached. The main treatment-related adverse events were sensory neuropathy (81.5%) and fatigue (44.6%). There were no deaths related to the study drug. Sagopilone was moderately tolerated in both treatment arms and showed limited activity in heavily pre-treated patients with MBC.
C1 [Morrow, Phuong K.; Hortobagyi, Gabriel N.] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA.
[Divers, Stephen] Genesis Canc Ctr, Hot Springs, AR USA.
[Provencher, Louise] CHA Laval Univ, Ctr Malad Sein Deschenes Fabia, Quebec City, PQ, Canada.
[Luoh, Shiuh-Wen] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Luoh, Shiuh-Wen] Portland VA Med Ctr, Portland, OR USA.
[Petrella, Teresa M.] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada.
[Giurescu, Marius; Schmelter, Thomas] Bayer Schering Pharma AG, Berlin, Germany.
[Wang, Yao] Bayer HealthCare Pharmaceut, Wayne, NJ USA.
[Vahdat, Linda T.] Weill Cornell Med Coll, New York, NY USA.
RP Morrow, PK (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, 1515 Holcombe,Box 1354, Houston, TX 77030 USA.
EM pmorrow@mdanderson.org
OI Vahdat, Linda/0000-0002-3522-7382
FU Bayer HealthCare Pharmaceuticals; Glaxo Smith Kline; Pfizer; Novartis
FX The authors would like to thank Tanya Chaudry, Ph.D., at Complete
HealthVizion for assistance in the preparation and revision of the draft
manuscript, based on detailed discussion and feedback from the authors.
Editorial assistance was supported by a grant from Bayer HealthCare
Pharmaceuticals. We would also like to thank all investigators who
participated in this study.; Dr. Shiuh-Wen Luoh receives research
support from Glaxo Smith Kline and serves as an Institute PA for
clinical trials sponsored by Glaxo Smith Kline. Dr. Teresa M. Petrella
is a consultant for Glaxo Smith Kline, Merck, and Pfizer. She has
received research funds from Pfizer. Dr. Marius Giurescu is an employee
of Bayer Schering Pharma. Dr. Thomas Schmelter is an employee of Bayer
Schering Pharma. Dr. Yao Wang is an employee of Bayer HealthCare
Pharmaceuticals and owns company stocks in Bayer HealthCare
Pharmaceuticals Dr. Gabriel N. Hortobagyi is a consultant for Novartis,
Merck and Sanofi Aventis; he has received research support from
Novartis. Dr. Linda T. Vahdat is a consultant for Bayer.
NR 22
TC 10
Z9 10
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD OCT
PY 2010
VL 123
IS 3
BP 837
EP 842
DI 10.1007/s10549-010-1102-x
PG 6
WC Oncology
SC Oncology
GA 651BQ
UT WOS:000281900000023
PM 20697802
ER
PT J
AU Tsai, TT
AF Tsai, Thomas T.
TI No Free Lunch: Transradial Access in Patients on Coumadin
SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
LA English
DT Editorial Material
ID PERCUTANEOUS CORONARY INTERVENTION
C1 [Tsai, Thomas T.] Univ Colorado, Denver VA Med Ctr, Denver, CO 80202 USA.
RP Tsai, TT (reprint author), 1055 Clermont St, Denver, CO 80220 USA.
EM thomas.tsai@ucdenver.edu
NR 7
TC 0
Z9 0
U1 0
U2 2
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1522-1946
J9 CATHETER CARDIO INTE
JI Catheter. Cardiovasc. Interv.
PD OCT 1
PY 2010
VL 76
IS 4
BP 500
EP 501
DI 10.1002/ccd.22785
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 658FN
UT WOS:000282476000008
PM 20882652
ER
PT J
AU Tsai, TT
Maddox, TM
Rumsfeld, JS
Ho, PM
Magid, DJ
Xu, S
Powers, JD
Carroll, NM
Shetterly, SM
Margolis, K
Go, AS
AF Tsai, Thomas T.
Maddox, Thomas M.
Rumsfeld, John S.
Ho, P. Michael
Magid, David J.
Xu, Stanley
Powers, J. David
Carroll, Nikki M.
Shetterly, Susan M.
Margolis, Karen
Go, Alan S.
TI Response to Letter Regarding Article, "Increased Risk of Bleeding in
Patients on Clopidogrel Therapy After Drug-Eluting Stents Implantation:
Insights From the HMO Research Network-Stent Registry (HMORN-Stent)"
SO CIRCULATION-CARDIOVASCULAR INTERVENTIONS
LA English
DT Letter
ID LONG-TERM OUTCOMES; THROMBOSIS
C1 [Tsai, Thomas T.; Maddox, Thomas M.; Rumsfeld, John S.; Ho, P. Michael; Magid, David J.] Univ Colorado, Denver VA Med Ctr, Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO 80202 USA.
[Margolis, Karen] HealthPartners Res Fdn, Minneapolis, MN USA.
[Go, Alan S.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA.
[Go, Alan S.] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA.
[Go, Alan S.] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA.
[Go, Alan S.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
RP Tsai, TT (reprint author), Univ Colorado, Denver VA Med Ctr, Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO 80202 USA.
NR 8
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-7640
J9 CIRC-CARDIOVASC INTE
JI Circ.-Cardiovasc. Interv.
PD OCT
PY 2010
VL 3
IS 5
BP E25
EP E25
DI 10.1161/CIRCINTERVENTIONS.110.958587
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 666ZA
UT WOS:000283160500005
ER
PT J
AU Eickhoff, JC
Kim, K
Beach, J
Kolesar, JM
Gee, JR
AF Eickhoff, Jens C.
Kim, KyungMann
Beach, Jason
Kolesar, Jill M.
Gee, Jason R.
TI A Bayesian adaptive design with biomarkers for targeted therapies
SO CLINICAL TRIALS
LA English
DT Article; Proceedings Paper
CT Annual Conference on Statistical Issues on Clinical Trials - Statistical
Issues in Developing Targeted Therapies
CY APR 29, 2009
CL Univ Pennsylvania, Philadelphia, PA
SP Amer Stat Assoc, Soc Clinical Trials
HO Univ Pennsylvania
ID CLINICAL-TRIAL DESIGNS; PARTIAL LEAST-SQUARES; CANCER; CLASSIFICATION;
RANDOMIZATION; VALIDATION; REGRESSION; EFFICIENCY
AB Background Targeted therapies are becoming increasingly important for the treatment of various diseases. Biomarkers are a critical component of a targeted therapy as they can be used to identify patients who are more likely to benefit from a treatment. Targeted therapies, however, have created major challenges in the design, conduct, and analysis of clinical trials. In traditional clinical trials, treatment effects for various biomarkers are typically evaluated in an exploratory fashion and only limited information about the predictive values of biomarkers obtained.
Purpose New study designs are required, which effectively evaluate both the diagnostic and the therapeutic implication of biomarkers.
Methods The Bayesian approach provides a useful framework for optimizing the clinical trial design by directly integrating information about biomarkers and clinical outcomes as they become available. We propose a Bayesian covariate-adjusted response-adaptive randomization design, which utilizes individual biomarker profiles and patient's clinical outcomes as they become available during the course of the trial, to assign the most efficacious treatment to individual patients. Predictive biomarker subgroups are determined adaptively using a partial least squares regression approach.
Results A series of simulation studies were conducted to examine the operating characteristics of the proposed study design. The simulation studies show that the proposed design efficiently identifies patients who benefit most from a targeted therapy and that there are substantial savings in the sample size requirements when compared to alternative designs.
Limitations The design does not control for the type I error in the traditional sense and a positive result should be confirmed by conducting an independent phase III study focusing on the selected biomarker profile groups.
Conclusions We conclude that the proposed design may serve a useful role in the early efficacy phase of targeted therapy development. Clinical Trials 2010; 7: 546-556. http://ctj.sagepub.com
C1 [Eickhoff, Jens C.; Kim, KyungMann; Beach, Jason] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53706 USA.
[Eickhoff, Jens C.; Kim, KyungMann; Kolesar, Jill M.] Univ Wisconsin, Paul P Carbone Comprehens Canc Ctr, Madison, WI USA.
[Gee, Jason R.] William S Middleton Mem Vet Adm Med Ctr, Urol Sect, Madison, WI USA.
[Gee, Jason R.] Lahey Clin Med Ctr, Sophia Gordon Canc Ctr, Inst Urol, Burlington, MA 01803 USA.
RP Eickhoff, JC (reprint author), Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53706 USA.
EM eickhoff@biostat.wisc.edu
FU NCI NIH HHS [P30 CA14520, P30 CA014520]
NR 27
TC 13
Z9 14
U1 0
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1740-7745
J9 CLIN TRIALS
JI Clin. Trials
PD OCT
PY 2010
VL 7
IS 5
BP 546
EP 556
DI 10.1177/1740774510372657
PG 11
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 653KK
UT WOS:000282089800005
PM 20571131
ER
PT J
AU Young, KY
Laird, A
Zhou, XH
AF Young, K. Y.
Laird, A.
Zhou, X. H.
TI The efficiency of clinical trial designs for predictive biomarker
validation
SO CLINICAL TRIALS
LA English
DT Article; Proceedings Paper
CT Annual Conference on Statistical Issues on Clinical Trials - Statistical
Issues in Developing Targeted Therapies
CY APR 29, 2009
CL Univ Pennsylvania, Philadelphia, PA
SP Amer Stat Assoc, Soc Clinical Trials
HO Univ Pennsylvania
ID BREAST-CANCER; CHEMOTHERAPY
AB Background The rapid advance of molecular genetic technology and of molecular diagnostics companies have set the stage for a new era in personalized treatments. Biomarkers such as gene expressions may be integrated into the anatomically based tumor-node-metastasis staging system to provide information for risk stratification and treatment selection. With the assumption that preliminary results show evidence that a biomarker has predictive value, the marker-based designs are geared to assess the purported predictive value in a clinical trial.
Purpose In this article, we compared the efficiency of the traditional design, which does not involve a biomarker, to several alternative designs in terms of the sample size required in each trial.
Methods We first derived the variance formulas for the two-sample t-tests under the various designs when the biomarker assay is imperfect, and then conducted numerical and simulation studies to evaluate the performance of the various designs.
Results Based on numerical and simulation studies, we conclude that the marker-based strategy designs are less efficient than the traditional design in general. Since the biomarker assay is imperfect in a realistic setting, the estimated sample size for each alternative design is influenced by the sensitivity and specificity of the assay and the prevalence of the biomarker in the population of interest as well as the parameters involved in a standard sample size calculation.
Limitations Due to limitations of a simulation study, it is not clear whether our results can be generalized to other parameter settings that are different from the ones used in the simulation study.
Conclusions The marker-based strategy designs are less efficient than the traditional design in general. If there is no treatment effect among marker-negative patients, it is still feasible to use the marker-based strategy design I if the assay sensitivity is high. If the treatment effect among marker-negative patients is half of the effect among marker-positive patients, the marker prevalence must be relatively high and the sensitivity of the assay must be very high for the marker-based strategy design I to approximate the efficiency of the traditional design. The efficiency of the marker-based strategy design II relative to the traditional design is low in all scenarios considered under the current study. Clinical Trials 2010; 7: 557-566. http://ctj.sagepub.com
C1 [Young, K. Y.; Laird, A.; Zhou, X. H.] Univ Washington, Dept Biostat, Seattle, WA 98198 USA.
[Zhou, X. H.] VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Seattle, WA 98101 USA.
RP Zhou, XH (reprint author), Univ Washington, Dept Biostat, HSB Box 357232, Seattle, WA 98198 USA.
EM azhou@u.washington.edu
NR 12
TC 14
Z9 14
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1740-7745
J9 CLIN TRIALS
JI Clin. Trials
PD OCT
PY 2010
VL 7
IS 5
BP 557
EP 566
DI 10.1177/1740774510370497
PG 10
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 653KK
UT WOS:000282089800006
PM 20571132
ER
PT J
AU Kalapatapu, RK
Patil, U
Goodman, MS
AF Kalapatapu, Raj K.
Patil, Uday
Goodman, Marianne S.
TI Using the Internet to Assess Perceptions of Patients with Borderline
Personality Disorder: What Do Patients Want in the DSM-V?
SO CYBERPSYCHOLOGY BEHAVIOR AND SOCIAL NETWORKING
LA English
DT Article
ID CLASSIFICATION; FAMILIES; STIGMA
AB Objectives: This study was an anonymous Internet survey of individuals currently diagnosed with borderline personality disorder (BPD), where participants gave opinions about BPD criteria in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Text Revision (DSM-IV-TR), and suggested modifications for BPD criteria to appear in the DSM-V (5th edition). Methods: Survey links were posted on 24 websites/Internet blogs that offered advice, education, or treatment of BPD. Demographic and clinical data pertaining to each participant were collected. Free-text responses were analyzed by frequencies of keywords and key phrases. Results: A total of 1,832 responses were downloaded between March 7 and June 6, 2009, and 646 responses were analyzable. Results indicated that the majority of the DSM-IV-TR criteria appeared to capture what participants were experiencing, even though a significant percentage of participants felt that something was missing from the current criteria. A significant percentage of participants felt that BPD should be renamed in the DSM-V; some combination of "emotion(al)'' and "(dys)regulation'' was most commonly suggested to include in an alternative name. Conclusions: This Internet study highlighted the enthusiasm of individuals diagnosed with BPD to share their opinions on the DSM criteria with mental-health professionals. A significant percentage of participants in this study felt that BPD should be renamed in the DSM-V. Patient involvement during the DSM-V revision process remains controversial.
C1 [Kalapatapu, Raj K.] Columbia Univ, New York State Psychiat Inst, Subst Use Res Ctr, Unit 120, New York, NY 10032 USA.
[Patil, Uday] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
[Goodman, Marianne S.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
[Goodman, Marianne S.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
RP Kalapatapu, RK (reprint author), Columbia Univ, New York State Psychiat Inst, Subst Use Res Ctr, Unit 120, 1051 Riverside Dr, New York, NY 10032 USA.
EM kalapat@pi.cpmc.columbia.edu
NR 33
TC 2
Z9 2
U1 1
U2 6
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2152-2715
EI 2152-2723
J9 CYBERPSYCH BEH SOC N
JI Cyberpsychology Behav. Soc. Netw.
PD OCT
PY 2010
VL 13
IS 5
BP 483
EP 494
DI 10.1089/cyber.2009.0351
PG 12
WC Psychology, Social
SC Psychology
GA 665PR
UT WOS:000283048400001
PM 20950172
ER
PT J
AU Lazo, M
Solga, SF
Horska, A
Bonekamp, S
Diehl, AM
Brancati, FL
Wagenknecht, LE
Pi-Sunyer, FX
Kahn, SE
Clark, JM
AF Lazo, Mariana
Solga, Steven F.
Horska, Alena
Bonekamp, Susanne
Diehl, Anna Mae
Brancati, Frederick L.
Wagenknecht, Lynne E.
Pi-Sunyer, F. Xavier
Kahn, Steven E.
Clark, Jeanne M.
CA Fatty Liver Subgrp Look AHEAD Res
TI Effect of a 12-Month Intensive Lifestyle Intervention on Hepatic
Steatosis in Adults With Type 2 Diabetes
SO DIABETES CARE
LA English
DT Article
ID NONALCOHOLIC FATTY LIVER; WEIGHT-LOSS; CARDIOVASCULAR-DISEASE;
INSULIN-RESISTANCE; CRYPTOGENIC CIRRHOSIS; CALORIE RESTRICTION;
NATURAL-HISTORY; RISK-FACTORS; STEATOHEPATITIS; EXERCISE
AB OBJECTIVE - Weight loss through lifestyle changes is recommended for nonalcoholic fatty liver disease (NAFLD). However, its efficacy in patients with type 2 diabetes is unproven.
RESEARCH DESIGN AND METHODS - Look AHEAD (Action for Health in Diabetes) is a 16-center clinical trial with 5,145 overweight or obese adults with type 2 diabetes, who were randomly assigned to an intensive lifestyle intervention (ILI) to induce a minimum weight loss of 7% or a control group who received diabetes support and education (DSE). In the Fatty Liver Ancillary Study, 96 participants completed proton magnetic resonance spectroscopy to quantify hepatic steatosis and tests to exclude other causes of liver disease at baseline and 12 months. We defined steatosis >5.5% as NAFLD.
RESULTS - Participants were 49% women and 68% white. The mean age was 61 years, mean BMI was 35 kg/m(2), mean steatosis was 8.0%, and mean aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were 20.5 and 24.2 units/l, respectively. After 12 months, participants assigned to ILI (n = 46) lost more weight (-8.5 vs. -0.05%; P<0.01) than those assigned to DSE and had a greater decline in steatosis (-50.8 vs. -22.8%, P=0.04) and in AI C (-0.7 vs. -0.2%, P=0.04). There were no significant 12-month changes in AST or ALT levels. At 12 months, 26% of DSE participants and 3% (1 of 31) of ILI participants without NAFLD at baseline developed NAFLD (P<0.05).
CONCLUSIONS - A 12-month intensive lifestyle intervention in patients with type 2 diabetes reduces steatosis and incident NAFLD.
C1 [Lazo, Mariana; Brancati, Frederick L.; Clark, Jeanne M.] Welch Ctr Prevent Epidemiol & Clin Res, Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Horska, Alena] Johns Hopkins Univ, Sch Med, Dept Radiol & Radiol Sci, Baltimore, MD USA.
[Diehl, Anna Mae] Duke Univ, Med Ctr, Durham, NC USA.
[Wagenknecht, Lynne E.] Wake Forest Univ, Div Publ Hlth Sci, Winston Salem, NC 27109 USA.
[Pi-Sunyer, F. Xavier] Columbia Univ, St Lukes Roosevelt Hosp Ctr, Coll Phys & Surg, Div Endocrinol Diabet & Nutr, New York, NY USA.
[Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA.
[Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA.
RP Lazo, M (reprint author), Welch Ctr Prevent Epidemiol & Clin Res, Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
EM mlazo@jhsph.edu
OI Bonekamp, Susanne/0000-0001-5847-5656; Kahn, Steven/0000-0001-7307-9002
FU National Institutes of Health National Institute of Diabetes and
Digestive and Kidney Diseases [R01-DK-060427, U01-DK-57149]; Johns
Hopkins University School of Medicine General Clinical Research Center
[M01-RR-00052]; Department of Veterans Affairs
FX The study was supported by the National Institutes of Health National
Institute of Diabetes and Digestive and Kidney Diseases (grants
R01-DK-060427 and U01-DK-57149), The Johns Hopkins University School of
Medicine General Clinical Research Center (grant M01-RR-00052), and the
Department of Veterans Affairs.
NR 24
TC 104
Z9 110
U1 0
U2 3
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD OCT
PY 2010
VL 33
IS 10
BP 2156
EP 2163
DI 10.2337/dc10-0856
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 667PD
UT WOS:000283205100005
PM 20664019
ER
PT J
AU Kahn, SE
AF Kahn, S. E.
TI Beta-cell loss in type 2 diabetes
SO DIABETES OBESITY & METABOLISM
LA English
DT Meeting Abstract
C1 [Kahn, S. E.] Univ Washington, Seattle, WA 98195 USA.
[Kahn, S. E.] VA Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1462-8902
J9 DIABETES OBES METAB
JI Diabetes Obes. Metab.
PD OCT
PY 2010
VL 12
SU 1
BP 12
EP 12
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 656XE
UT WOS:000282373600017
ER
PT J
AU Lynch, CP
Strom, JL
Egede, LE
AF Lynch, Cheryl P.
Strom, Joni L.
Egede, Leonard E.
TI Variation in Quality of Care Indicators for Diabetes in a National
Sample of Veterans and Non-Veterans
SO DIABETES TECHNOLOGY & THERAPEUTICS
LA English
DT Article
ID AFFAIRS HEALTH-CARE; PREVALENCE; ADULTS; SYSTEM
AB Background: Veterans have a disproportionately higher burden of type 2 diabetes. It is unclear whether veterans with diabetes have better self-care behaviors or receive better quality of care than non-veterans. The objective was to examine differences in diabetes care between veterans and non-veterans.
Methods: Data analysis was performed with respondents from the 2003 Behavioral Risk Factor Surveillance Survey (n-21,111 with diabetes). Veterans were those who reported U. S. military service and no longer on active duty. Self-care behaviors included daily fruit and vegetable intake, physical activity level, self-foot checks, and home glucose testing. Quality of care indicators included provider actions over the past 12 months (2+ office visits, 2+ glycosylated hemoglobin checks, 1+ foot exams, 1+ dilated eye exams, daily aspirin use, receiving flu or pneumonia vaccine). Multiple logistic regression using STATA version 10 (Stata Corp., College Station, TX) analyzed differences by veteran status on each quality indicator, controlling for sociodemographics and diabetes education.
Results: Veterans comprised 14.2% of the sample, and 12.4% had diabetes compared to 6.7% of non-veterans. In final adjusted models, veterans were significantly more likely to check their feet (odds ratio [OR] 1.33, 95% confidence interval [CI] 1.09, 1.64), get a dilated eye exam (OR 1.36, 95% CI 1.11, 1.66), receive aspirin (OR 1.31, 95% CI 1.04, 1.65), get a flu shot (OR 1.32, 95% CI 1.09, 1.61), and ever get a pneumonia shot (OR 1.38, 95% CI 1.12, 1.70).
Conclusions: Veterans appear to have better self-care behaviors and receive better preventive care than non-veterans. However, future efforts need to focus on boosting self-care to improve diabetes outcomes.
C1 [Lynch, Cheryl P.; Strom, Joni L.; Egede, Leonard E.] Med Univ S Carolina, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Ctr Hlth Dispar Res, Charleston, SC 29425 USA.
[Lynch, Cheryl P.; Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC 29425 USA.
RP Lynch, CP (reprint author), Med Univ S Carolina, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Ctr Hlth Dispar Res, 135 Rutledge Ave,MSC 250593, Charleston, SC 29425 USA.
EM lynchcp@musc.edu
FU Center for Disease Prevention and Health Interventions for Diverse
Populations [REA 08-261]
FX This work was supported by the use of facilities at the Charleston VA
Health Services Research & Development-funded Center for Disease
Prevention and Health Interventions for Diverse Populations (REA
08-261).
NR 25
TC 5
Z9 5
U1 0
U2 2
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1520-9156
J9 DIABETES TECHNOL THE
JI Diabetes Technol. Ther.
PD OCT
PY 2010
VL 12
IS 10
BP 785
EP 790
DI 10.1089/dia.2010.0040
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 659UC
UT WOS:000282591400006
PM 20809677
ER
PT J
AU Amorosa, V
MacNeil, A
McConnell, R
Patel, A
Dillon, KE
Hamilton, K
Erickson, BR
Campbell, S
Knust, B
Cannon, D
Miller, D
Manning, C
Rollin, PE
Nichol, ST
AF Amorosa, Valerianna
MacNeil, Adam
McConnell, Ryan
Patel, Ami
Dillon, Katherine E.
Hamilton, Keith
Erickson, Bobbie Rae
Campbell, Shelley
Knust, Barbara
Cannon, Deborah
Miller, David
Manning, Craig
Rollin, Pierre E.
Nichol, Stuart T.
TI Imported Lassa Fever, Pennsylvania, USA, 2010
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID EPIDEMIC; LIBERIA
AB We report a case of Lassa fever in a US traveler who visited rural Liberia, became ill while in country, sought medical care upon return to the United States, and subsequently had his illness laboratory confirmed. The patient recovered with supportive therapy. No secondary cases occurred.
C1 [Amorosa, Valerianna; McConnell, Ryan; Dillon, Katherine E.; Hamilton, Keith] Univ Penn, Philadelphia, PA 19104 USA.
[Amorosa, Valerianna] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[MacNeil, Adam; Patel, Ami; Erickson, Bobbie Rae; Campbell, Shelley; Knust, Barbara; Cannon, Deborah; Miller, David; Manning, Craig; Rollin, Pierre E.; Nichol, Stuart T.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Patel, Ami] Philadelphia Dept Hlth, Philadelphia, PA USA.
RP Amorosa, V (reprint author), Philadelphia VAMC Med, Philadelphia, PA 19104 USA.
EM valerianna.amorosa@uphs.upenn.edu
OI Cameron, Katherine/0000-0002-0859-0741
NR 14
TC 25
Z9 27
U1 0
U2 2
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD OCT
PY 2010
VL 16
IS 10
BP 1598
EP 1600
DI 10.3201/eid1610.100774
PG 3
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 657EA
UT WOS:000282394800014
PM 20875288
ER
PT J
AU Ramsay, E
Faught, E
Krumholz, A
Naritoku, D
Privitera, M
Schwarzman, L
Mao, L
Wiegand, F
Hulihan, J
AF Ramsay, Eugene
Faught, Edward
Krumholz, Allan
Naritoku, Dean
Privitera, Michael
Schwarzman, Lesley
Mao, Lian
Wiegand, Frank
Hulihan, Joseph
CA Capss-272 Study Group
TI Efficacy, tolerability, and safety of rapid initiation of topiramate
versus phenytoin in patients with new-onset epilepsy: A randomized
double-blind clinical trial
SO EPILEPSIA
LA English
DT Article
DE Complex partial seizures; Epilepsy; Generalized tonic-clonic seizures;
Phenytoin; Rapid-initiation; Topiramate
ID NEWLY-DIAGNOSED EPILEPSY; 1ST UNPROVOKED SEIZURE; TONIC CLONIC SEIZURES;
UNTREATED EPILEPSY; CARBAMAZEPINE; LAMOTRIGINE; MONOTHERAPY; RISK;
VALPROATE; ADULTS
AB P>Purpose:
To evaluate topiramate (TPM) and phenytoin (PHT) monotherapy following rapid oral initiation in new-onset epilepsy.
Methods:
Randomized, double-blind, 28-day trial of TPM (100 mg/day beginning on day 1) versus PHT (1,000 mg on day 1 followed by 300 mg/day maintenance dosing) in 261 patients with new-onset epilepsy. The primary end point was time to seizure, and the primary objective was to establish noninferiority of TPM to PHT in the risk of seizure.
Results:
At day 28, the estimated seizure-free rate was 81.1% for TPM treatment in comparison with 90.3% for PHT treatment. Noninferiority of TPM to PHT (primary objective) could not be established [hazard ratio (HR) 2.0, 95% confidence interval (CI), 0.98 to 4.12, p = 0.366), and PHT could not be shown to be superior to TPM. A higher percentage discontinued with PHT compared to TPM for all reasons (21.1 vs. 12.8%) and due to adverse events (13.4 vs. 6.8%). The most common treatment-related adverse events in both groups were dizziness, paresthesia, and somnolence. A post hoc analysis showed that TPM was superior to PHT in time to discontinuation (retention rate) for all causes (89.4% vs. 80.3%, p = 0.047).
Conclusion:
This study was inconclusive in establishing noninferiority of TPM 100 mg/day compared to a standard regimen of oral PHT in seizure risk in this population of patients with new-onset epilepsy. Given the superiority of TPM in overall retention and favorable tolerability without titration, it may nonetheless be an appropriate option in some patients with new-onset epilepsy requiring rapid treatment initiation.
C1 [Ramsay, Eugene] Ochsner Baptist Med Ctr, Epilepsy Inst, New Orleans, LA 70115 USA.
[Faught, Edward] Univ Alabama, Sch Med, Birmingham, AL USA.
[Faught, Edward] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Krumholz, Allan] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
[Naritoku, Dean] So Illinois Univ, Springfield, IL USA.
[Privitera, Michael] Univ Cincinnati, Coll Med, Cincinnati, OH USA.
[Schwarzman, Lesley; Mao, Lian; Wiegand, Frank; Hulihan, Joseph] LLC, Ortho McNeil Janssen Sci Affairs, Titusville, NJ USA.
RP Ramsay, E (reprint author), Ochsner Baptist Med Ctr, Epilepsy Inst, 4299 Clara St,MacFarland Bldg,Suite 440, New Orleans, LA 70115 USA.
EM eramsay@epiworld.com
RI Ramsay, R. Eugene/D-4491-2011
FU Ortho-McNeil Janssen Scientific Affairs, LLC.; Abbott Laboratories;
Bertex; Carter-Wallace; Cephalon; Cyberonics; Eisai; GlaxoSmithKline;
IVAX; Marion Merrell Dow; Novartis; Ortho-McNeil Pharmaceuticals;
Ovation Pharmaceuticals; Pfizer; RW Johnson; Schwarz Pharma; SmithKline
Beecham; UCB Pharma; X-cel Pharma; Ortho-McNeil/JohnsonJohnson; Schwarz
Pharma/UCB; American Epilepsy Society; EpiFellows Foundation;
Janssen-Cilag; National Institutes of Health; Pfizer Inc
FX Funding for this study was provided by Ortho-McNeil Janssen Scientific
Affairs, LLC.; Eugene Ramsay has received support from, and/or has
served as a paid consultant for Abbott Laboratories, Bertex,
Carter-Wallace, Cephalon, Cyberonics, Eisai, GlaxoSmithKline, IVAX,
Marion Merrell Dow, Novartis, Ortho-McNeil Pharmaceuticals, Ovation
Pharmaceuticals, Pfizer, RW Johnson, Schwarz Pharma, SmithKline Beecham,
UCB Pharma, and X-cel Pharma.; Edward Faught has received support from,
and/or has served as a paid consultant for
Ortho-McNeil/Johnson&Johnson.; Allan Krumholz has received support from,
and/or has served as a paid consultant for Ortho-McNeil Pharmaceuticals,
Ovation Pharmaceuticals, and UCB Pharma.; Dean Naritoku has received
support from, and/or has served as a paid consultant for Abbott
Laboratories, Eisai, GlaxoSmithKline, Ortho-McNeil Pharmaceuticals, and
Schwarz Pharma/UCB.; Michael Privitera has received support from, and/or
has served as a paid consultant for the American Epilepsy Society,
epiFellows Foundation, GlaxoSmithKline, Janssen-Cilag, National
Institutes of Health, Ortho-McNeil Pharmaceuticals, Pfizer Inc, and UCB
Pharma.
NR 35
TC 17
Z9 17
U1 0
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0013-9580
J9 EPILEPSIA
JI Epilepsia
PD OCT
PY 2010
VL 51
IS 10
BP 1970
EP 1977
DI 10.1111/j.1528-1167.2010.02670.x
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA 660KE
UT WOS:000282639700006
PM 20633037
ER
PT J
AU de Molina, RM
Mortensen, EM
Restrepo, MI
Copeland, LA
Pugh, MJV
Anzueto, A
AF de Molina, R. Malo
Mortensen, E. M.
Restrepo, M. I.
Copeland, L. A.
Pugh, M. J. V.
Anzueto, A.
TI Inhaled corticosteroid use is associated with lower mortality for
subjects with COPD and hospitalised with pneumonia
SO EUROPEAN RESPIRATORY JOURNAL
LA English
DT Article
DE Chronic obstructive pulmonary disease; inhaled corticosteroids;
mortality; pneumonia
ID OBSTRUCTIVE PULMONARY-DISEASE; COMMUNITY-ACQUIRED PNEUMONIA;
SALMETEROL/FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE;
UNITED-STATES; RISK-FACTORS; PROPENSITY SCORE; LUNG-DISEASE; SALMETEROL;
EXACERBATIONS
AB Recent studies suggest that use of inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease (COPD) may be associated with a higher incidence of pneumonia. However, it is unclear whether COPD subjects on ICS who develop pneumonia have worse outcomes. Therefore, our aim was to examine the association of prior outpatient ICS therapy with mortality in hospitalised COPD subjects with pneumonia.
We included subjects >= 64 yrs of age, hospitalised with pneumonia in US Veterans Affairs hospitals, and assessed the association of ICS exposure with mortality for hospitalised COPD subjects with pneumonia in a covariate-adjusted regression model.
We identified 6,353 subjects with a diagnosis of pneumonia and prior COPD, of whom 38% were on ICS. Mortality was 9% at 30 days and 16% at 90 days. In regression analyses, outpatient ICS therapy was associated with lower mortality at both 30 days (OR 0.76, 95% CI 0.70-0.83), and 90 days (OR 0.80, 95% CI 0.75-0.86).
Outpatient therapy with ICS was associated with a significantly lower 30- and 90-day mortality in hospitalised COPD patients with pneumonia.
C1 [Restrepo, M. I.] UTHSCSA, ALMD, VERDICT Res Programme,S Texas Vet Hlth Care Syst, Vet Evidence Based Res Disseminat & Implementat C, San Antonio, TX 78229 USA.
[de Molina, R. Malo; Restrepo, M. I.; Anzueto, A.] UTHSCSA, Div Pulm & Crit Care Med, Dept Med, San Antonio, TX 78229 USA.
[Mortensen, E. M.] UTHSCSA, Div Gen Internal Med, Dept Med, San Antonio, TX 78229 USA.
[Copeland, L. A.] UTHSCSA, Dept Psychiat, San Antonio, TX 78229 USA.
[Pugh, M. J. V.] UTHSCSA, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA.
RP Restrepo, MI (reprint author), UTHSCSA, ALMD, VERDICT Res Programme,S Texas Vet Hlth Care Syst, Vet Evidence Based Res Disseminat & Implementat C, 11C6,7400 Merton Minter Blvd, San Antonio, TX 78229 USA.
EM restrepom@uthscsa.edu
OI Mortensen, Eric/0000-0002-3880-5563; Copeland,
Laurel/0000-0002-9478-0209
FU Spanish Pulmonary Society (SEPAR) [757]; Dept of Veterans Affairs [IIR
02-076, MREP 02-267]
FX R. Malo de Molina received funding from the Spanish Pulmonary Society
(SEPAR), project 757. M.J. Pugh received funding from the Dept of
Veterans Affairs IIR 02-076 and MREP 02-267. L. A. Copeland was
supported by the Dept of Veterans Affairs MREP 05-145. M. I. Restrepo is
supported by a Dept of Veteran Affairs Veterans Integrated Service
Network 17 new faculty grant and National Health Institute KL2 Grant
9CTSA Award Number (KL2 RR025766). This material is the result of work
supported with resources and the use of facilities at the South Texas
Veterans Health Care System. The funding agencies had no role in
conducting the study, or role in the preparation, review, or approval of
the manuscript. The views expressed in this article are those of the
authors and do not necessarily represent the views of the Department of
Veterans Affairs.
NR 52
TC 39
Z9 39
U1 0
U2 0
PU EUROPEAN RESPIRATORY SOC JOURNALS LTD
PI SHEFFIELD
PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND
SN 0903-1936
J9 EUR RESPIR J
JI Eur. Resp. J.
PD OCT
PY 2010
VL 36
IS 4
BP 751
EP 757
DI 10.1183/09031936.00077509
PG 7
WC Respiratory System
SC Respiratory System
GA 658ER
UT WOS:000282473700014
ER
PT J
AU Stengel, A
Tache, Y
AF Stengel, Andreas
Tache, Yvette
TI Corticotropin-releasing factor signaling and visceral response to stress
SO EXPERIMENTAL BIOLOGY AND MEDICINE
LA English
DT Article; Proceedings Paper
CT Annual FASEB Experimental Biology Meeting
CY APR 21, 2009
CL San Diego, CA
DE cardiovascular system; corticotropin-releasing factor (CRF); irritable
bowel syndrome (IBS); stress; urocortin (Ucn)
ID IRRITABLE-BOWEL-SYNDROME; ENTERIC NERVOUS-SYSTEM; EXPERIMENTAL
HEART-FAILURE; MESSENGER-RNA EXPRESSION; FUNCTIONAL GASTROINTESTINAL
DISORDERS; HORMONE-RECEPTOR ANTAGONIST; WATER-AVOIDANCE STRESS; COLONIC
MOTOR RESPONSE; TYPE-2 CRF RECEPTORS; ISOLATED RAT-HEART
AB Stress may cause behavioral and/or psychiatric manifestations such as anxiety and depression and also impact on the function of different visceral organs, namely the gastrointestinal and cardiovascular systems. During the past years substantial progress has been made in the understanding of the underlying mechanisms recruited by stressors. Activation of the corticotropin-releasing factor (CRF) signaling system is recognized to be involved in a large number of stress-related behavioral and somatic disorders. This review will outline the present knowledge on the distribution of the CRF system (ligands and receptors) expressed in the brain and peripheral viscera and its relevance in stress-induced alterations of gastrointestinal and cardiovascular functions and the therapeutic potential of CRF(1) receptor antagonists.
C1 [Tache, Yvette] VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr, Ctr Neurobiol Stress, Los Angeles, CA 90073 USA.
Univ Calif Los Angeles, CURE Digest Dis Res Ctr, Los Angeles, CA USA.
Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress, Div Digest Dis, Los Angeles, CA 90095 USA.
RP Tache, Y (reprint author), VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr, Ctr Neurobiol Stress, Bldg 115,Room 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM ytache@mednet.ucla.edu
FU NIDDK NIH HHS [R01 DK033061, R01 DK 33061, R01 DK 57238, R01 DK057238,
R37 DK033061]
NR 171
TC 54
Z9 59
U1 0
U2 7
PU SOC EXPERIMENTAL BIOLOGY MEDICINE
PI MAYWOOD
PA 195 WEST SPRING VALLEY AVE, MAYWOOD, NJ 07607-1727 USA
SN 1535-3702
J9 EXP BIOL MED
JI Exp. Biol. Med.
PD OCT
PY 2010
VL 235
IS 10
BP 1168
EP 1178
DI 10.1258/ebm.2010.009347
PG 11
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 670VN
UT WOS:000283455500005
PM 20881321
ER
PT J
AU Mukherjee, R
Colbath, GP
Justus, CD
Bruce, JA
Allen, CM
Hewett, KW
Saul, JP
Gourdie, RG
Spinale, FG
AF Mukherjee, Rupak
Colbath, Gregory P.
Justus, Charles D.
Bruce, James A.
Allen, Claire M.
Hewett, Kenneth W.
Saul, J. Philip
Gourdie, Robert G.
Spinale, Francis G.
TI Spatiotemporal induction of matrix metalloproteinase-9 transcription
after discrete myocardial injury
SO FASEB JOURNAL
LA English
DT Article
DE myocardial injury; structure; remodeling
ID MATRIX-METALLOPROTEINASE INHIBITION; LEFT-VENTRICULAR ENLARGEMENT;
GAP-JUNCTION; HEART-FAILURE; ATRIAL-FIBRILLATION; TARGETED DELETION;
TISSUE INHIBITOR; CARDIAC-FUNCTION; INFARCTION; EXPRESSION
AB Radiofrequency (RF) ablation of the myocardium causes discrete sites of injury. RF scars can expand, altering the extracellular matrix (ECM) structure and the continuity of the electrical syncytium of the adjacent myocardium. Matrix metalloproteinases (MMPs), such as MMP-9, contribute to ECM remodeling. However, whether and to what degree transcriptional induction of MMP-9 occurs after myocardial RF injury and the association with electrical conduction patterns after RF injury remains unexplored. This study examined MMP-9 gene promoter (M9PROM) activation after myocardial RF injury using mice in which the M9PROM was fused to a beta-galactosidase (beta-gal) reporter. RF lesions (0.5-mm probe, 80 degrees C, 30 s) were created on the left ventricular (LV) epicardium of M9PROM mice (n=62) and terminally studied at 1 h, 1 d, 3 d, 7 d, 14 d, and 28 d after RF injury. M9PROM activation was localized through beta-gal staining. The RF scar area and the area of beta-gal staining were measured and normalized to LV area (planimetry). RF scar size increased from 1 h post-RF-injury values by 7 d and remained higher at 28 d. M9PROM activation became evident at 3 d and peaked at 7 d. Electrical conduction was measured (potentiometric dye mapping) at 7 d after RF injury. Heterogeneities in action potentials and electrical impulse propagation coincident with M9PROM activation were observed after RF injury. For example, conduction proximal to the RF site was slower than that in the remote myocardium (0.15+/-0.02 vs. 0.83+/-0.08 mm/ms, P<0.05). Thus, a unique spatiotemporal pattern of MMP-9 transcriptional activation occurred after discrete myocardial injury, which was associated with the development of electrical heterogeneity. Therefore, these findings suggest that changes in a key determinant of extracellular matrix remodeling, in addition to changes in myocardial structure, can contribute to arrhythmogenesis around the region of myocardial injury.-Mukherjee, R., Colbath, G. P., Justus, C. D., Bruce, J. A., Allen, C. M., Hewett, K. W., Saul, J. P., Gourdie, R. G., Spinale, F. G. Spatiotemporal induction of matrix metalloproteinase-9 transcription following discrete myocardial injury. FASEB J. 24, 3819-3828 (2010). www.fasebj.org
C1 [Mukherjee, Rupak; Colbath, Gregory P.; Spinale, Francis G.] Med Univ S Carolina, Div Cardiothorac Surg, Charleston, SC 29425 USA.
[Mukherjee, Rupak; Bruce, James A.; Allen, Claire M.; Saul, J. Philip; Spinale, Francis G.] Med Univ S Carolina, Div Pediat Cardiol, Charleston, SC 29425 USA.
[Justus, Charles D.; Hewett, Kenneth W.; Gourdie, Robert G.] Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA.
[Spinale, Francis G.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
RP Mukherjee, R (reprint author), Med Univ S Carolina, Div Cardiothorac Surg, Strom Thurmond Res Bldg,770 MUSC Complex,Ste 625, Charleston, SC 29425 USA.
EM mukherr@musc.edu
FU U.S. National Institutes of Health [HL-66029, HL-45024, HL-97012,
P01-48788, HL-56728]
FX This study was supported by U.S. National Institutes of Health grants
HL-66029 (to R.M.), HL-45024, HL-97012, and P01-48788 (to F.G.S.), and
HL-56728 (to R.G.G.).
NR 41
TC 6
Z9 6
U1 0
U2 2
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD OCT
PY 2010
VL 24
IS 10
BP 3819
EP 3828
DI 10.1096/fj.10-155531
PG 10
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 690LI
UT WOS:000285005900020
PM 20530752
ER
PT J
AU Leung, FW
Harker, JO
Jackson, G
Okamoto, KE
Behbahani, OM
Jamgotchian, NJ
Aharonian, HS
Guth, PH
Mann, SK
Leung, JW
AF Leung, Felix W.
Harker, Judith O.
Jackson, Guy
Okamoto, Kate E.
Behbahani, Omid M.
Jamgotchian, Nora J.
Aharonian, H. Steven
Guth, Paul H.
Mann, Surinder K.
Leung, Joseph W.
TI A proof-of-principle, prospective, randomized, controlled trial
demonstrating improved outcomes in scheduled unsedated colonoscopy by
the water method
SO GASTROINTESTINAL ENDOSCOPY
LA English
DT Article; Proceedings Paper
CT Digestive Disease Week/111th Annual Meeting of the
American-Gastroenterological-Association
CY MAY 01-06, 2010
CL New Orleans, LA
SP Amer Gastroenterol Assoc
ID SEDATION-FREE COLONOSCOPY; SCREENING COLONOSCOPY; COLORECTAL-CANCER;
PATIENT; VETERANS; PERFORMANCE; POPULATION; DISCOMFORT; ENDOSCOPY; TIME
AB Background: An observational study in veterans showed that a novel water method (water infusion in lieu of air insufflation) enhanced cecal intubation and willingness to undergo a repeat scheduled unsedated colonoscopy.
Objective: To confirm these beneficial effects and significant attenuation of discomfort in a randomized, controlled trial (RCT).
Design: Prospective RCT, intent-to-treat analysis.
Setting: Veterans Affairs ambulatory care facility.
Patients: Veterans undergoing scheduled unsedated colonoscopy.
Interventions: During insertion, the water and traditional air methods were compared.
Main Outcome Measurements: Discomfort and procedure-related outcomes.
Results: Eighty-two veterans were randomized to the air (n = 40) or water (n = 42) method. Cecal intubation (78% vs 98%) and willingness to repeat (78% vs 93%) were significantly better with the water method (P < .05; Fisher exact test). The mean (standard deviation) of maximum discomfort (0 = none, 10 = most severe) during colonoscopy was 5.5 (3.0) versus 3.6 (2.1) P = .002 (Student t test), and the median overall discomfort after colonoscopy was 3 versus 2, P = .052 (Mann-Whitney U test), respectively. The method, but not patient characteristics, was a predictor of discomfort (t = -1.998, P = .049, R(2) = 0.074). The odds ratio for failed cecal intubation was 2.09 (95% CI, 1.49-2.93) for the air group. Fair/poor previous experience increased the risk of failed cecal intubation in the air group only. The water method numerically increased adenoma yield.
Limitations: Single site, small number of elderly men, unblinded examiner, possibility of unblinded subjects, restricted generalizability.
Conclusions: The RCT data confirmed that the water method significantly enhanced cecal intubation and willingness to undergo a repeat colonoscopy. The decrease in maximum discomfort was significant; the decrease in overall discomfort approached significance. The method, but not patient characteristics, was a predictor of discomfort. (Clinical trial registration number NCT00747084). (Gastrointest Endosc 2010;72:693-700.)
C1 [Leung, Felix W.] Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, David Geffen Sch Med,Div Gastroenterol 111G, Res Serv,Sepulveda Ambulatory Care Ctr, North Hills, CA 91343 USA.
[Leung, Felix W.; Aharonian, H. Steven; Guth, Paul H.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Mann, Surinder K.; Leung, Joseph W.] Vet Affairs No Calif Healthcare Syst, Sacramento VAMC, Mather, CA USA.
[Mann, Surinder K.; Leung, Joseph W.] UC Davis Med Ctr, Sacramento, CA USA.
[Leung, Felix W.; Harker, Judith O.; Jackson, Guy; Okamoto, Kate E.; Behbahani, Omid M.; Jamgotchian, Nora J.; Aharonian, H. Steven; Guth, Paul H.] Vet Affairs Greater Los Angeles Healthcare Syst, Med Serv, Sepulveda Ambulatory Care Ctr, North Hills, CA USA.
RP Leung, FW (reprint author), Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, David Geffen Sch Med,Div Gastroenterol 111G, Res Serv,Sepulveda Ambulatory Care Ctr, 16111 Plummer St, North Hills, CA 91343 USA.
EM felix.leung@va.gov
NR 42
TC 50
Z9 51
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0016-5107
J9 GASTROINTEST ENDOSC
JI Gastrointest. Endosc.
PD OCT
PY 2010
VL 72
IS 4
BP 693
EP 700
DI 10.1016/j.gie.2010.05.020
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 663ZB
UT WOS:000282927600004
PM 20619405
ER
PT J
AU Becker, PS
Taylor, JA
Trobridge, GD
Zhao, X
Beard, BC
Chien, S
Adair, J
Kohn, DB
Wagner, JE
Shimamura, A
Kiem, HP
AF Becker, P. S.
Taylor, J. A.
Trobridge, G. D.
Zhao, X.
Beard, B. C.
Chien, S.
Adair, J.
Kohn, D. B.
Wagner, J. E.
Shimamura, A.
Kiem, H-P
TI Preclinical correction of human Fanconi anemia complementation group A
bone marrow cells using a safety-modified lentiviral vector
SO GENE THERAPY
LA English
DT Article
DE gene therapy; mitomycin C; reducing agent; hypoxia
ID HEMATOPOIETIC STEM-CELLS; NATURAL GENE-THERAPY; FUNCTIONAL CORRECTION;
REPOPULATING CELLS; REVERSE MOSAICISM; PROGENITOR CELLS; ENGRAFTMENT;
VIRUS
AB One of the major hurdles for the development of gene therapy for Fanconi anemia (FA) is the increased sensitivity of FA stem cells to free radical-induced DNA damage during ex vivo culture and manipulation. To minimize this damage, we have developed a brief transduction procedure for lentivirus vector-mediated transduction of hematopoietic progenitor cells from patients with Fanconi anemia complementation group A (FANCA). The lentiviral vector FancA-sW contains the phosphoglycerate kinase promoter, the FANCA cDNA, and a synthetic, safety-modified woodchuck post transcriptional regulatory element (sW). Bone marrow mononuclear cells or purified CD34(+) cells from patients with FANCA were transduced in an overnight culture on recombinant fibronectin peptide CH-296, in low (5%) oxygen, with the reducing agent, N-acetyl-L-cysteine (NAC), and a combination of growth factors, granulocyte colony-stimulating factor (G-CSF), Flt3 ligand, stem cell factor, and thrombopoietin. Transduced cells plated in methylcellulose in hypoxia with NAC showed increased colony formation compared with 21% oxygen without NAC (P<0.03), showed increased resistance to mitomycin C compared with green fluorescent protein (GFP) vector-transduced controls (P<0.007), and increased survival. Thus, combining short transduction and reducing oxidative stress may enhance the viability and engraftment of gene-corrected cells in patients with FANCA. Gene Therapy (2010) 17, 1244-1252; doi:10.1038/gt.2010.62; published online 20 May 2010
C1 [Becker, P. S.; Zhao, X.; Chien, S.] Univ Washington, Div Hematol, Dept Med, Seattle, WA 98109 USA.
[Taylor, J. A.] Oregon Hlth & Sci Univ, Div Hematol Oncol, Dept Med, Portland, OR USA.
[Taylor, J. A.] Portland VA Med Ctr, Portland, OR USA.
[Trobridge, G. D.; Beard, B. C.; Adair, J.; Shimamura, A.; Kiem, H-P] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA.
[Trobridge, G. D.; Kiem, H-P] Univ Washington, Div Med Oncol, Dept Med, Seattle, WA 98109 USA.
[Kohn, D. B.] Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90024 USA.
[Kohn, D. B.] Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90024 USA.
[Wagner, J. E.] Univ Minnesota, Dept Pediat, Div Pediat Hematol Oncol, Minneapolis, MN 55455 USA.
[Shimamura, A.] Seattle Childrens Hosp, Dept Pediat, Div Pediat Hematol Oncol, Seattle, WA USA.
[Kiem, H-P] Univ Washington, Dept Pathol, Seattle, WA 98109 USA.
RP Becker, PS (reprint author), Univ Washington, Div Hematol, Dept Med, Campus Box 358056,815 Mercer St N415, Seattle, WA 98109 USA.
EM pbecker@u.washington.edu
RI Kohn, Donald/N-5085-2016
OI Kohn, Donald/0000-0003-1840-6087
FU NIH [HL085693, DK56465, DK47754]; National Institutes of Health
FX This work was supported by NIH Grants HL085693, DK56465 and DK47754 to
HPK. We thank Helen Crawford and Bonnie Larson for help with the
preparation of the article. HPK is a Molecular Medicine Investigator and
the recipient of the Jose Carreras/E. Donnall Thomas Endowed Chair for
Cancer Research. We received grant support from National Institutes of
Health.
NR 27
TC 15
Z9 15
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0969-7128
J9 GENE THER
JI Gene Ther.
PD OCT
PY 2010
VL 17
IS 10
BP 1244
EP 1252
DI 10.1038/gt.2010.62
PG 9
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Genetics & Heredity; Medicine, Research & Experimental
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Genetics & Heredity; Research & Experimental Medicine
GA 664GO
UT WOS:000282948600008
PM 20485382
ER
PT J
AU Chen, G
Buck, KJ
AF Chen, G.
Buck, K. J.
TI Rostroventral caudate putamen involvement in ethanol withdrawal is
influenced by a chromosome 4 locus
SO GENES BRAIN AND BEHAVIOR
LA English
DT Article
DE c-Fos; lesion; Mpdz; MUPP1 seizure; striatum
ID PDZ DOMAIN PROTEIN; C-FOS EXPRESSION; ACUTE ALCOHOL-WITHDRAWAL; BASAL
GANGLIA; STRIATOPALLIDAL NEURONS; INDUCED CONVULSIONS; NMDA RECEPTORS;
NERVOUS-SYSTEM; C57BL/6J MICE; NR2B SUBUNIT
AB Physiological dependence and associated withdrawal episodes are thought to constitute a motivational force that sustains alcohol use and abuse and may contribute to relapse in dependent individuals. Although no animal model duplicates alcoholism, models for specific factors, like withdrawal, are useful for identifying potential genetic and neural determinants of liability in humans. Previously, we identified a quantitative trait locus (QTL) and gene (Mpdz, which encodes the multi-PDZ domain protein) on chromosome 4 with a large effect on alcohol withdrawal in mice. Using congenic mice that confirm this QTL and c-Fos expression as a high-resolution marker of neuronal activation, we report that congenic mice show significantly less neuronal activity associated with alcohol withdrawal in the rostroventral caudate putamen (rvCP), but not other parts of the striatum, compared with background strain mice. Moreover, bilateral rvCP lesions significantly increase alcohol withdrawal severity. Using retrograde (fluorogold) and anterograde (Texas Red conjugated dextran amine) tract tracing, we found that similar to 25% of c-Fos immunoreactive rvCP neurons project to caudolateral substantia nigra pars reticulata (clSNr), which we previously found is crucially involved in withdrawal following acute and repeated alcohol exposure. Our results expand upon work suggesting that this QTL impacts alcohol withdrawal via basal ganglia circuitry associated with limbic function, and indicate that an rvCP-clSNr projection plays a critical role. Given the growing body of evidence that the syntenic region of human chromosome 9p and human MPDZ gene are associated with alcohol abuse, our results may facilitate research on alcohol dependence and associated withdrawal in clinical populations.
C1 [Buck, K. J.] Portland VA Med Ctr, Dept Behav Neurosci, Portland, OR 97239 USA.
Portland VA Med Ctr, Portland Alcohol Res Ctr, Portland, OR 97239 USA.
Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
RP Buck, KJ (reprint author), Portland VA Med Ctr, Dept Behav Neurosci, Portland, OR 97239 USA.
EM buckk@ohsu.edu
FU VA; [AA011114]; [AA10760]; [DA05228]
FX Supported by AA011114, AA10760, DA05228, and the VA. We are grateful to
Drs. Laura Kozell, Robert Hitzemann, Charles Meshul, John Belknap and
John Crabbe for helpful discussions of these experiments and their
comments on a draft of this manuscript.
NR 60
TC 6
Z9 6
U1 1
U2 2
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1601-1848
J9 GENES BRAIN BEHAV
JI Genes Brain Behav.
PD OCT
PY 2010
VL 9
IS 7
BP 768
EP 776
DI 10.1111/j.1601-183X.2010.00611.x
PG 9
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA 660IT
UT WOS:000282634300011
PM 20608999
ER
PT J
AU Silber, JH
Rosenbaum, PR
Brachet, TJ
Ross, RN
Bressler, LJ
Even-Shoshan, O
Lorch, SA
Volpp, KG
AF Silber, Jeffrey H.
Rosenbaum, Paul R.
Brachet, Tanguy J.
Ross, Richard N.
Bressler, Laura J.
Even-Shoshan, Orit
Lorch, Scott A.
Volpp, Kevin G.
TI The Hospital Compare Mortality Model and the Volume-Outcome Relationship
SO HEALTH SERVICES RESEARCH
LA English
DT Article
DE Hospital Compare; mortality; acute myocardial infarction; random effects
model
ID ACUTE MYOCARDIAL-INFARCTION; REPORT CARDS; HEALTH-CARE; QUALITY;
SURVIVAL
AB Objective
We ask whether Medicare's Hospital Compare random effects model correctly assesses acute myocardial infarction (AMI) hospital mortality rates when there is a volume-outcome relationship.
Data Sources/Study Setting
Medicare claims on 208,157 AMI patients admitted in 3,629 acute care hospitals throughout the United States.
Study Design
We compared average-adjusted mortality using logistic regression with average adjusted mortality based on the Hospital Compare random effects model. We then fit random effects models with the same patient variables as in Medicare's Hospital Compare mortality model but also included terms for hospital Medicare AMI volume and another model that additionally included other hospital characteristics.
Principal Findings
Hospital Compare's average adjusted mortality significantly underestimates average observed death rates in small volume hospitals. Placing hospital volume in the Hospital Compare model significantly improved predictions.
Conclusions
The Hospital Compare random effects model underestimates the typically poorer performance of low-volume hospitals. Placing hospital volume in the Hospital Compare model, and possibly other important hospital characteristics, appears indicated when using a random effects model to predict outcomes. Care must be taken to insure the proper method of reporting such models, especially if hospital characteristics are included in the random effects model.
C1 [Silber, Jeffrey H.; Brachet, Tanguy J.; Ross, Richard N.; Bressler, Laura J.; Even-Shoshan, Orit; Lorch, Scott A.] Childrens Hosp Philadelphia, Ctr Outcomes Res, Philadelphia, PA 19104 USA.
[Silber, Jeffrey H.; Brachet, Tanguy J.] Univ Penn, Sch Med, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA.
[Silber, Jeffrey H.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA.
[Silber, Jeffrey H.; Volpp, Kevin G.] Univ Penn, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19104 USA.
[Silber, Jeffrey H.; Rosenbaum, Paul R.; Brachet, Tanguy J.; Even-Shoshan, Orit; Lorch, Scott A.; Volpp, Kevin G.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Rosenbaum, Paul R.] Univ Penn, Wharton Sch, Dept Stat, Philadelphia, PA 19104 USA.
[Lorch, Scott A.] Childrens Hosp Philadelphia, Dept Pediat, Div Neonatol, Philadelphia, PA 19104 USA.
[Volpp, Kevin G.] Vet Adm Hosp, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
[Volpp, Kevin G.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA.
RP Silber, JH (reprint author), Childrens Hosp Philadelphia, Ctr Outcomes Res, 3535 Market St,Suite 1029, Philadelphia, PA 19104 USA.
EM silberj@wharton.upenn.edu
RI Rosenbaum, Paul/H-8687-2012
FU NHLBI [R01 HL082637, R01 HL094593]; NSF [0849370]
FX This work was supported by NHLBI grants R01 HL082637 and R01 HL094593
and NSF grant 0849370. Portions of this work were presented at the 2009
Academy Health Annual Meeting. We thank Traci Frank, A. A., for her
assistance with preparing this manuscript.
NR 33
TC 39
Z9 39
U1 1
U2 6
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0017-9124
J9 HEALTH SERV RES
JI Health Serv. Res.
PD OCT
PY 2010
VL 45
IS 5
BP 1148
EP 1167
DI 10.1111/j.1475-6773.2010.01130.x
PN 1
PG 20
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 648RU
UT WOS:000281712400002
PM 20579125
ER
PT J
AU Meterko, M
Wright, S
Lin, H
Lowy, E
Cleary, PD
AF Meterko, Mark
Wright, Steven
Lin, Hai
Lowy, Elliott
Cleary, Paul D.
TI Mortality among Patients with Acute Myocardial Infarction: The
Influences of Patient-Centered Care and Evidence-Based Medicine
SO HEALTH SERVICES RESEARCH
LA English
DT Article
DE Patient assessment; satisfaction; patient outcomes; functional status;
ADLs; IADLs; quality of care; patient safety (measurement)
ID MEDICARE MANAGED CARE; HEALTH-CARE; HOSPITAL-CARE; OUTCOMES; QUALITY;
SATISFACTION; ADHERENCE; CAHPS(R); PERFORMANCE; PHYSICIAN
AB Background
Recent studies have suggested that there is a positive impact of patient-centered care (PCC) on both the patient-physician relationship and subsequent patient health-related behaviors. One recent prospective study reported a significant relationship between the degree of PCC experienced by patients during their hospitalization for acute myocardial infarction (AMI) and their postdischarge cardiac symptoms. A limitation of this study, however, was a lack of information regarding the technical quality of the AMI care, which might have explained at least part of the differences in outcomes. The present study was undertaken to test the influence of both PCC and technical care quality on outcomes among AMI patients.
Methods
We analyzed data from a national sample of 1,858 veterans hospitalized for an initial AMI in a Department of Veterans Affairs medical center during fiscal years 2003 and 2004 for whom data had been compiled on evidence-based treatment and who had also completed a Picker questionnaire assessing perceptions of PCC. Cox proportional hazards models were used to estimate the relationship between PCC and survival 1-year postdischarge, controlling for technical quality of care, patient clinical condition and history, admission process characteristics, and patient sociodemographic characteristics. We hypothesized that better PCC would be associated with a lower probability of death 1-year postdischarge, even after controlling for patient characteristics and the technical quality of care.
Results
Better PCC was associated with a significantly but modestly lower hazard of death over the 1-year study period (hazard ratio 0.992, 95 percent confidence interval 0.986-0.999).
Conclusions
Providing PCC may result in important clinical benefits, in addition to meeting patient needs and expectations.
C1 [Meterko, Mark] VA Boston Healthcare Syst 152 M, HSR&D Ctr Org Leadership & Management Res, Boston, MA USA.
[Meterko, Mark] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA.
[Wright, Steven] VA Off Qual & Performance, Washington, DC USA.
[Lin, Hai] Women & Infants Hosp Rhode Isl, Brown Ctr Study Children Risk, Providence, RI 02908 USA.
[Lowy, Elliott] VA Puget Sound Healthcare Syst, HSR&D NW Ctr Excellence, Seattle, WA USA.
[Cleary, Paul D.] Yale Univ, Sch Med, Sch Publ Hlth, New Haven, CT 06520 USA.
RP Cleary, PD (reprint author), Yale Univ, Sch Med, Sch Publ Hlth, 60 Coll St,LEPH 210,POB 208034, New Haven, CT 06520 USA.
EM paul.cleary@yale.edu
FU Picker Institute
FX This research was supported by a grant from the Picker Institute.
Marjorie Nealon-Seibert, M.B.A., Survey Administrator at COLMR, assisted
with preparation and submission of the study for IRB review by the VA
Boston Healthcare System. There are no financial or other disclosures.
NR 46
TC 61
Z9 62
U1 5
U2 13
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0017-9124
J9 HEALTH SERV RES
JI Health Serv. Res.
PD OCT
PY 2010
VL 45
IS 5
BP 1188
EP 1204
DI 10.1111/j.1475-6773.2010.01138.x
PN 1
PG 17
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 648RU
UT WOS:000281712400004
PM 20662947
ER
PT J
AU Liu, CF
Chapko, M
Bryson, CL
Burgess, JF
Fortney, JC
Perkins, M
Sharp, ND
Maciejewski, ML
AF Liu, Chuan-Fen
Chapko, Michael
Bryson, Chris L.
Burgess, James F., Jr.
Fortney, John C.
Perkins, Mark
Sharp, Nancy D.
Maciejewski, Matthew L.
TI Use of Outpatient Care in Veterans Health Administration and Medicare
among Veterans Receiving Primary Care in Community-Based and Hospital
Outpatient Clinics
SO HEALTH SERVICES RESEARCH
LA English
DT Article
DE Access; demand; utilization of services; Medicare; VA health care
system; cohort analysis
ID PERFORMANCE-MEASURES; DUAL-USE; VA; AFFAIRS; SERVICES; QUALITY; ACCESS;
COVERAGE; SYSTEM
AB Objective
To examine differences in use of Veterans Health Administration (VA) and Medicare outpatient services by VA primary care patients.
Data Sources/Study Setting
VA administrative and Medicare claims data from 2001 to 2004.
Study Design
Retrospective cohort study of outpatient service use by 8,964 community-based and 6,556 hospital-based VA primary care patients.
Principal Findings
A significant proportion of VA patients used Medicare-reimbursed primary care (> 30 percent) and specialty care (> 60 percent), but not mental health care (3-4 percent). Community-based patients had 17 percent fewer VA primary care visits (p <.001), 9 percent more Medicare-reimbursed visits (p <.001), and 6 percent fewer total visits (p <.05) than hospital-based patients. Community-based patients had 22 percent fewer VA specialty care visits (p <.0001) and 21 percent more Medicare-reimbursed specialty care visits (p <.0001) than hospital-based patients, but no difference in total visits (p=.80).
Conclusions
Medicare-eligible VA primary care patients followed over 4 consecutive years used significant primary care and specialty care outside of VA. Community-based patients offset decreased VA use with increased service use paid by Medicare, suggesting that increasing access to VA primary care via community clinics may fragment veteran care in unintended ways. Coordination of care between VA and non-VA providers and health care systems is essential to improve the quality and continuity of care.
C1 [Liu, Chuan-Fen] VA Puget Sound Hlth Care Syst, HSR&D, Dept Vet Affairs, NW Ctr Outcomes Res Older Adults, Seattle, WA 98101 USA.
[Liu, Chuan-Fen; Chapko, Michael; Sharp, Nancy D.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Bryson, Chris L.] Univ Washington, Dept Med, Div Gen Internal Med, Seattle, WA 98195 USA.
[Burgess, James F., Jr.] Ctr Org Leadership & Management Res, Dept Vet Affairs, Boston, MA USA.
[Burgess, James F., Jr.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA.
[Fortney, John C.] S Cent Mental Hlth Illness Res & Educ & Clin Ctr, N Little Rock, AR USA.
[Fortney, John C.] Cent Arkansas Vet Healthcare Syst, HSR&D Ctr Mental Healthcare & Outcomes Res, N Little Rock, AR USA.
[Fortney, John C.] Univ Arkansas Med Sci, Dept Psychiat & Behav Sci, Div Hlth Serv Res, N Little Rock, AR USA.
[Maciejewski, Matthew L.] Vet Adm Med Ctr, Ctr Hlth Serv Res Primary Care, Dept Vet Affairs, Durham, NC 27705 USA.
[Maciejewski, Matthew L.] Duke Univ, Med Ctr, Dept Med, Div Gen Internal Med, Durham, NC 27710 USA.
RP Liu, CF (reprint author), VA Puget Sound Hlth Care Syst, HSR&D, Dept Vet Affairs, NW Ctr Outcomes Res Older Adults, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA.
EM chuan-fen.liu@va.gov
OI Burgess, James/0000-0002-6646-7071
FU Office of Research and Development, Health Services Research and
Development Service, Department of Veterans Affairs [IIR 04-292]
FX This work was supported by the Office of Research and Development,
Health Services Research and Development Service, Department of Veterans
Affairs, project number IIR 04-292. Drs. Liu, Chapko, Bryson, Sharp, and
Perkins are at the Northwest Center for Outcomes Research in Older
Adults at the Seattle VA. Dr. Burgess is at the Center for Organization,
Leadership & Management Research at the Boston VA. Dr. Fortney is at the
Center for Mental Healthcare and Outcomes Research at the Little Rock
VA. Dr. Maciejewski is at the Center for Health Services Research in
Primary Care at the Durham VA. The authors are grateful for helpful
comments from Will Manning. The views expressed herein are those of the
authors and do not necessarily represent the views of the Department of
Veterans Affairs and other affiliated institutions.
NR 31
TC 25
Z9 25
U1 1
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0017-9124
EI 1475-6773
J9 HEALTH SERV RES
JI Health Serv. Res.
PD OCT
PY 2010
VL 45
IS 5
BP 1268
EP 1286
DI 10.1111/j.1475-6773.2010.01123.x
PN 1
PG 19
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 648RU
UT WOS:000281712400008
PM 20831716
ER
PT J
AU Blosser, CD
Ayehu, G
Wu, S
Lomagro, RM
Malone, E
Brunelli, SM
Itkin, M
Golden, M
McCombs, P
Lipschutz, JH
AF Blosser, Christopher D.
Ayehu, Gashu
Wu, Sam
Lomagro, Ruth M.
Malone, Ellen
Brunelli, Steven M.
Itkin, Max
Golden, Michael
McCombs, Peter
Lipschutz, Joshua H.
TI High rate of fistula placement in a cohort of dialysis patients in a
single payer system
SO HEMODIALYSIS INTERNATIONAL
LA English
DT Article
DE Fistula; hemodialysis; health care economics
ID VEIN ARTERIOVENOUS-FISTULAS; VASCULAR ACCESS; HEMODIALYSIS-PATIENTS;
OUTCOMES; TRANSPOSITION; PATENCY; IMPACT; CARE
C1 [Blosser, Christopher D.; Ayehu, Gashu; Wu, Sam; Lipschutz, Joshua H.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
[Lomagro, Ruth M.; Lipschutz, Joshua H.] Vet Affairs Med Ctr, Dept Med, Philadelphia, PA USA.
[Malone, Ellen; Golden, Michael; McCombs, Peter] Vet Affairs Med Ctr, Dept Surg, Vasc Surg Sect, Philadelphia, PA USA.
[Brunelli, Steven M.] Harvard Univ, Sch Med, Dept Med, Brigham & Womens Hosp, Boston, MA USA.
[Itkin, Max] Vet Affairs Med Ctr, Dept Radiol, Intervent Radiol Sect, Philadelphia, PA USA.
RP Lipschutz, JH (reprint author), 431 Hill Pavilion,380 S Univ Ave, Philadelphia, PA 19104 USA.
EM jhlipsch@mail.med.upenn.edu
FU National Institutes of Health [DK069909, DK070980, K23DK079056];
Satellite Healthcare
FX The authors and this work were supported in part by the National
Institutes of Health (DK069909 and DK070980 to J.H.L.; K23DK079056 to
S.M.B.) and Satellite Healthcare (Norman S. Coplon Extramural Research
Grant to J.H.L).
NR 25
TC 1
Z9 1
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1492-7535
J9 HEMODIAL INT
JI Hemodial. Int.
PD OCT
PY 2010
VL 14
IS 4
BP 393
EP 397
DI 10.1111/j.1542-4758.2010.00479.x
PG 5
WC Urology & Nephrology
SC Urology & Nephrology
GA 667DY
UT WOS:000283174100009
PM 20812959
ER
PT J
AU Cusi, K
Lomonaco, R
Ortiz-Lopez, C
Webb, A
Orsak, B
Darland, CM
Finch, J
Kaminski-Graham, R
AF Cusi, Kenneth
Lomonaco, Romina
Ortiz-Lopez, Carolina
Webb, Amy
Orsak, Beverly
Darland, Celia M.
Finch, Joan
Kaminski-Graham, Rosemarie
TI ASSESSMENT OF ETHNIC AND METABOLIC FACTORS IN THE DEVELOPMENT OF NASH IN
A PREDOMINANTLY HISPANIC POPULATION: THE UNIVERSITY OF TEXAS AT SAN
ANTONIO NASH TRIAL
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 61st Annual Meeting of the
American-Association-for-the-Study-of-Liver-Diseases
CY OCT 29-NOV 02, 2010
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Cusi, Kenneth; Lomonaco, Romina; Ortiz-Lopez, Carolina; Orsak, Beverly] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Cusi, Kenneth; Lomonaco, Romina; Webb, Amy; Darland, Celia M.; Finch, Joan; Kaminski-Graham, Rosemarie] Vet Adm Med Ctr, Diabet Div, San Antonio, TX USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2010
VL 52
IS 4
SU S
MA 698
BP 653A
EP 654A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 740EY
UT WOS:000288775601017
ER
PT J
AU Louvet, A
Artru, F
Wartel, F
O'Grady, JG
Carithers, RL
Phillips, M
Mendenhall, CL
Naveau, S
Canva-Delcambre, V
Morgan, TR
Mathurin, P
AF Louvet, Alexandre
Artru, Florent
Wartel, Faustine
O'Grady, John G.
Carithers, Robert L.
Phillips, Martin
Mendenhall, Charles L.
Naveau, Sylvie
Canva-Delcambre, Valerie
Morgan, Timothy R.
Mathurin, Philippe
TI A RESPONSE-GUIDED THERAPY FOR A BETTER MANAGEMENT OF PATIENTS SEVERE
ALCOHOLIC HEPATITIS TREATED WITH CORTICOSTEROIDS
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 61st Annual Meeting of the
American-Association-for-the-Study-of-Liver-Diseases
CY OCT 29-NOV 02, 2010
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Louvet, Alexandre; Artru, Florent; Wartel, Faustine; Canva-Delcambre, Valerie; Mathurin, Philippe] Ctr Hosp Reg & Univ Lille, Hop Huriez, F-59037 Lille, France.
[O'Grady, John G.; Phillips, Martin] Kings Coll London, London WC2R 2LS, England.
[Mendenhall, Charles L.] Vet Affairs Med Ctr, Cincinnati, OH 45267 USA.
[Carithers, Robert L.] Vet Affairs Puget Sound Hlth Care Syst, Gastroenterol, Seattle, WA USA.
[Naveau, Sylvie] Hop Antoine Beclere, Clamart, France.
[Morgan, Timothy R.] Vet Affairs Long Beach Healthcare Syst, Gastroenterol Sect, Long Beach, CA USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2010
VL 52
IS 4
SU S
MA 1652
BP 1109A
EP 1109A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 740EY
UT WOS:000288775602272
ER
PT J
AU Chirinos, JA
Segers, P
AF Chirinos, Julio A.
Segers, Patrick
TI Noninvasive Evaluation of Left Ventricular Afterload Part 1: Pressure
and Flow Measurements and Basic Principles of Wave Conduction and
Reflection
SO HYPERTENSION
LA English
DT Article
DE afterload; noninvasive; input impedance; arterial load
ID MIDDLE-AGED MEN; ARTERIAL STIFFNESS; AUGMENTATION INDEX; INPUT
IMPEDANCE; PULSE; VELOCITY; QUANTIFICATION; AMPLIFICATION; HYPERTENSION;
VALIDATION
AB The mechanical load imposed by the systemic circulation to the left ventricle is an important determinant of normal and abnormal cardiovascular function. Left ventricular afterload is determined by complex time-varying phenomena, which affect pressure and flow patterns generated by the pumping ventricle and cannot be expressed as a single numeric measure or described in terms of pressure alone. Left ventricular afterload is best described in terms of pressure-flow relations. High-fidelity arterial applanation tonometry can be used to record time-resolved central pressure noninvasively, whereas contemporary noninvasive imaging techniques, such as Doppler echocardiography and phase-contrast MRI, allow for accurate assessments of aortic flow. Central pressure and flow can be analyzed using simplified biomechanical models to characterize various components of afterload, with great potential for mechanistic understanding of the role of central hemodynamics in cardiovascular disease and the effects of therapeutic interventions. In the first part of this tutorial, we review noninvasive techniques for central pressure and flow measurements and basic concepts of wave conduction and reflection as they relate to the interpretation of central pressure-flow relations. Conceptual descriptions of various models and methods are emphasized over mathematical ones. Our review is aimed at helping researchers and clinicians apply and interpret results obtained from analyses of left ventricular afterload in clinical and epidemiological settings. (Hypertension. 2010;56:555-562.)
C1 [Chirinos, Julio A.] Univ Penn, Dept Med, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
[Segers, Patrick] Univ Ghent, IBiTech, B-9000 Ghent, Belgium.
RP Chirinos, JA (reprint author), Room 8B-111,Univ & Woodland Ave, Philadelphia, PA 19104 USA.
EM julio.chirinos@uphs.upenn.edu
NR 23
TC 43
Z9 45
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0194-911X
J9 HYPERTENSION
JI Hypertension
PD OCT
PY 2010
VL 56
IS 4
BP 555
EP U30
DI 10.1161/HYPERTENSIONAHA.110.157321
PG 18
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 650VL
UT WOS:000281881400001
PM 20733089
ER
PT J
AU Chirinos, JA
Segers, P
AF Chirinos, Julio A.
Segers, Patrick
TI Noninvasive Evaluation of Left Ventricular Afterload Part 2: Arterial
Pressure-Flow and Pressure-Volume Relations in Humans
SO HYPERTENSION
LA English
DT Article
DE afterload; noninvasive; input impedance; arterial load
ID HEART-FAILURE; HYPERTENSION; WINDKESSEL; LOAD
AB The mechanical load imposed by the systemic circulation to the left ventricle is an important determinant of normal and abnormal cardiovascular function. Left ventricular afterload is determined by complex time-varying phenomena, which affect pressure and flow patterns generated by the pumping ventricle. Left ventricular afterload is best described in terms of pressure-flow relations, allowing for quantification of various components of load using simplified biomechanical models of the circulation, with great potential for mechanistic understanding of the role of central hemodynamics in cardiovascular disease and the effects of therapeutic interventions. In the second part of this tutorial, we review analytic methods used to characterize left ventricular afterload, including analyses of central arterial pressure-flow relations and windkessel modeling (pressure-volume relations). Conceptual descriptions of various models and methods are emphasized over mathematical ones. Our review is aimed at helping researchers and clinicians obtain and interpret results from analyses of left ventricular afterload in clinical and epidemiological settings. (Hypertension. 2010;56:563-570.)
C1 [Chirinos, Julio A.] Univ Penn, Dept Med, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
[Segers, Patrick] Univ Ghent, IBiTech, B-9000 Ghent, Belgium.
RP Chirinos, JA (reprint author), Room 8B-111,Univ & Woodland Ave, Philadelphia, PA 19104 USA.
EM julio.chirinos@uphs.upenn.edu
NR 24
TC 48
Z9 51
U1 2
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0194-911X
J9 HYPERTENSION
JI Hypertension
PD OCT
PY 2010
VL 56
IS 4
BP 563
EP 570
DI 10.1161/HYPERTENSIONAHA.110.157339
PG 8
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 650VL
UT WOS:000281881400002
PM 20733088
ER
PT J
AU Chirinos, JA
Townsend, R
AF Chirinos, Julio A.
Townsend, Raymond
TI Sodium, Potassium, and Target Organ Damage A Case for Central
Hemodynamics
SO HYPERTENSION
LA English
DT Editorial Material
ID ESSENTIAL-HYPERTENSION; RATS
C1 [Chirinos, Julio A.; Townsend, Raymond] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
[Chirinos, Julio A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Chirinos, JA (reprint author), Room 8B-111,Univ & Woodland Ave, Philadelphia, PA 19104 USA.
EM julio.chirinos@uphs.upenn.edu
NR 11
TC 1
Z9 2
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0194-911X
J9 HYPERTENSION
JI Hypertension
PD OCT
PY 2010
VL 56
IS 4
BP 578
EP 580
DI 10.1161/HYPERTENSIONAHA.110.159046
PG 3
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 650VL
UT WOS:000281881400006
PM 20733084
ER
PT J
AU Selby, JV
Lee, J
Swain, BE
Tavel, HM
Ho, PM
Margolis, KL
O'Connor, PJ
Fine, L
Schmittdiel, JA
Magid, DJ
AF Selby, Joe V.
Lee, Janelle
Swain, Bix E.
Tavel, Heather M.
Ho, P. Michael
Margolis, Karen L.
O'Connor, Patrick J.
Fine, Lawrence
Schmittdiel, Julie A.
Magid, David. J.
TI Trends in Time to Confirmation and Recognition of New-Onset
Hypertension, 2002-2006
SO HYPERTENSION
LA English
DT Article
DE hypertension; electronic health records; registries; early detection;
screening
ID AMBULATORY BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE; DIABETES-MELLITUS;
RISK; MANAGEMENT; CARE; VARIABILITY; POPULATION; ADULTS; TRIAL
AB Achieving full benefits of blood pressure control in populations requires prompt recognition of previously undetected hypertension. In 2003, the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure provided definitions of hypertension and recommended that single elevated readings be confirmed within 1 to 2 months. We sought to determine whether the time required to confirm and recognize (ie, diagnose and/or treat) new-onset hypertension decreased from 2002 to 2006 for adult members of 2 large integrated healthcare delivery systems, Kaiser Permanente Northern California and Colorado. Using electronically stored office blood pressure readings, physician diagnoses, and pharmacy prescriptions, we identified 200 587 patients with new-onset hypertension (2002-2006) marked by 2 consecutive elevated blood pressure readings in previously undiagnosed, untreated members. Mean confirmation intervals (time from the first to second consecutive elevated reading) declined steadily from 103 to 89 days during this period. For persons recognized within 12 months after confirmation, the mean interval to recognition declined from 78 to 61 days. However, only 33% of individuals were recognized within 12 months. One third were never recognized during observed follow-up. For these patients, most subsequent blood pressure recordings were not elevated. Higher initial blood pressure levels, history of previous cardiovascular disease, and older age were associated with shorter times to recognition. Times to confirmation and recognition of new-onset hypertension have become shorter in recent years, especially for patients with higher cardiovascular disease risk. Variability in office-based blood pressure readings suggests that further improvements in recognition and treatment may be achieved with more specific automated approaches to identifying hypertension. (Hypertension. 2010;56:605-611.)
C1 [Selby, Joe V.; Lee, Janelle; Swain, Bix E.; Schmittdiel, Julie A.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA.
[Tavel, Heather M.; Magid, David. J.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA.
[Ho, P. Michael] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Ho, P. Michael] Univ Colorado, Denver, CO 80202 USA.
[Margolis, Karen L.; O'Connor, Patrick J.] HealthPartners Res Fdn, Minneapolis, MN USA.
[Fine, Lawrence] NHLBI, NIH, Bethesda, MD 20892 USA.
RP Selby, JV (reprint author), Kaiser Permanente, Div Res, 2000 Broadway, Oakland, CA 94612 USA.
EM joe.selby@kp.org
FU National Heart, Lung, and Blood Institute [U19HL091179]; Office of
Research in Women's Health Building Interdisciplinary Careers
[K12HD052163]; Veterans' Affairs Research and Development [05-026-2]
FX This study was supported by the National Heart, Lung, and Blood
Institute (award No. U19HL091179). J.A.S. is supported by the Office of
Research in Women's Health Building Interdisciplinary Careers in Women's
Health K12 Career Development Award (K12HD052163). P.M.H. is supported
by a Veterans' Affairs Research and Development Career Development Award
(05-026-2).
NR 27
TC 21
Z9 21
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0194-911X
J9 HYPERTENSION
JI Hypertension
PD OCT
PY 2010
VL 56
IS 4
BP 605
EP 611
DI 10.1161/HYPERTENSIONAHA.110.153528
PG 7
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 650VL
UT WOS:000281881400011
PM 20733092
ER
PT J
AU Heliot, R
Ganguly, K
Jimenez, J
Carmena, JM
AF Heliot, Rodolphe
Ganguly, Karunesh
Jimenez, Jessica
Carmena, Jose M.
TI Learning in Closed-Loop Brain-Machine Interfaces: Modeling and
Experimental Validation
SO IEEE TRANSACTIONS ON SYSTEMS MAN AND CYBERNETICS PART B-CYBERNETICS
LA English
DT Article
DE Brain-machine interfaces (BMIs); internal model; macaque monkey; motor
learning
ID DIRECT CORTICAL CONTROL; PRIMATE MOTOR CORTEX; ARM MOVEMENTS; PROSTHETIC
DEVICES; INTERNAL-MODELS; TETRAPLEGIA; FEEDFORWARD; KINEMATICS;
DIRECTION; NETWORKS
AB Closed-loop operation of a brain-machine interface (BMI) relies on the subject's ability to learn an inverse transformation of the plant to be controlled. In this paper, we propose a model of the learning process that undergoes closed-loop BMI operation. We first explore the properties of the model and show that it is able to learn an inverse model of the controlled plant. Then, we compare the model predictions to actual experimental neural and behavioral data from nonhuman primates operating a BMI, which demonstrate high accordance of the model with the experimental data. Applying tools from control theory to this learning model will help in the design of a new generation of neural information decoders which will maximize learning speed for BMI users.
C1 [Heliot, Rodolphe; Carmena, Jose M.] Univ Calif Berkeley, Dept Elect Engn & Comp Sci, Program Cognit Sci, Berkeley, CA 94720 USA.
[Heliot, Rodolphe; Ganguly, Karunesh; Carmena, Jose M.] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA.
[Ganguly, Karunesh] San Francisco VA Med Ctr, Neurol & Rehabil Serv, San Francisco, CA 94121 USA.
[Ganguly, Karunesh] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.
RP Heliot, R (reprint author), Univ Calif Berkeley, Dept Elect Engn & Comp Sci, Program Cognit Sci, Berkeley, CA 94720 USA.
EM carmena@eecs.berkeley.edu
FU French "Delegation generale pour l'armement' [PDE 07C0067]; American
Heart Association; Graduate Assistance in Areas of National Need
Fellowship; Christopher and Dana Reeve Foundation
FX The work of R. Heliot was supported by the French "Delegation generale
pour l'armement' under Grant PDE 07C0067. The work of K. Ganguly was
supported by the American Heart Association. The work of J. Jimenez was
supported by the Graduate Assistance in Areas of National Need
Fellowship. The work of J. M. Carmena was supported by the Christopher
and Dana Reeve Foundation. This paper was recommended by Associate
Editor J. D. R. Millan.
NR 42
TC 26
Z9 26
U1 1
U2 6
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 1083-4419
J9 IEEE T SYST MAN CY B
JI IEEE Trans. Syst. Man Cybern. Part B-Cybern.
PD OCT
PY 2010
VL 40
IS 5
BP 1387
EP 1397
DI 10.1109/TSMCB.2009.2036931
PG 11
WC Automation & Control Systems; Computer Science, Artificial Intelligence;
Computer Science, Cybernetics
SC Automation & Control Systems; Computer Science
GA 668TI
UT WOS:000283292800014
PM 20007050
ER
PT J
AU Durazzo, TC
Meyerhoff, DJ
Nixon, SJ
AF Durazzo, Timothy C.
Meyerhoff, Dieter J.
Nixon, Sara Jo
TI Chronic Cigarette Smoking: Implications for Neurocognition and Brain
Neurobiology
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE chronic cigarette smoking; neurocognition; neurobiology; neuroimaging;
genetics
ID CEREBRAL-BLOOD-FLOW; MAGNETIC-RESONANCE SPECTROSCOPY; MIDDLE-AGED
ADULTS; BODY-MASS INDEX; MILD COGNITIVE IMPAIRMENT; WHITE-MATTER
LESIONS; YOUNG-WOMEN SMOKE; RISK TASK BART; NICOTINE DEPENDENCE;
CARDIOVASCULAR HEALTH
AB Compared to the substantial volume of research on the general health consequences associated with chronic smoking, little research has been specifically devoted to the investigation of its effects on human neurobiology and neurocognition. This review summarizes the peer-reviewed literature on the neurocognitive and neurobiological implications of chronic cigarette smoking in cohorts that were not seeking treatment for substance use or psychiatric disorders. Studies that specifically assessed the neurocognitive or neurobiological (with emphasis on computed tomography and magnetic resonance-based neuroimaging studies) consequences of chronic smoking are highlighted. Chronic cigarette smoking appears to be associated with deficiencies in executive functions, cognitive flexibility, general intellectual abilities, learning and/or memory processing speed, and working memory. Chronic smoking is related to global brain atrophy and to structural and biochemical abnormalities in anterior frontal regions, subcortical nuclei and commissural white matter. Chronic smoking may also be associated with an increased risk for various forms of neurodegenerative diseases. The existing literature is limited by inconsistent accounting for potentially confounding biomedical and psychiatric conditions, focus on cross-sectional studies with middle aged and older adults and the absence of studies concurrently assessing neurocognitive, neurobiological and genetic factors in the same cohort. Consequently, the mechanisms promoting the neurocognitive and neurobiological abnormalities reported in chronic smokers are unclear. Longitudinal studies are needed to determine if the smoking-related neurobiological and neurocognitive abnormalities increase over time and/or show recovery with sustained smoking cessation.
C1 [Durazzo, Timothy C.; Meyerhoff, Dieter J.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA.
[Durazzo, Timothy C.; Meyerhoff, Dieter J.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA 94121 USA.
[Nixon, Sara Jo] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA.
[Nixon, Sara Jo] Univ Florida, Dept Psychol, Gainesville, FL 32611 USA.
RP Durazzo, TC (reprint author), Univ Calif San Francisco, Dept Radiol & Biomed Imaging, 505 Parnassus Ave,M-391, San Francisco, CA 94143 USA.
EM timothy.durazzo@ucsf.edu; dieter.meyerhoff@ucsf.edu; sjnixon@ufl.edu
RI Nixon, Sara/L-1369-2014
OI Nixon, Sara/0000-0003-1179-2851
FU NIH [DA 024136, AA10788, DA 13677, U54 RR025208]
FX This material is the result of work supported by NIH DA 024136 (TCD),
AA10788 (DJM) and DA 13677 and U54 RR025208 (Nelson, PI; SJN,
Co-Investigator) with resources and the use of facilities at the San
Francisco Veterans Administration Medical Center, San Francisco, CA,
USA.
NR 195
TC 69
Z9 71
U1 2
U2 18
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD OCT
PY 2010
VL 7
IS 10
BP 3760
EP 3791
DI 10.3390/ijerph7103760
PG 32
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health
GA 672IO
UT WOS:000283576600011
PM 21139859
ER
PT J
AU Ford, JM
Roach, BJ
Miller, RM
Duncan, CC
Hoffman, RE
Mathalon, DH
AF Ford, Judith M.
Roach, Brian J.
Miller, Ryan M.
Duncan, Connie C.
Hoffman, Ralph E.
Mathalon, Daniel H.
TI When it's time for a change: Failures to track context in schizophrenia
SO INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY
LA English
DT Article
DE P300; Schizophrenia; Context
ID CONTINGENT NEGATIVE-VARIATION; EVENT-RELATED POTENTIALS; AUDITORY
EVOKED-RESPONSE; LATE POSITIVE WAVE; STIMULUS SEQUENCE; P300 AMPLITUDE;
MISMATCH NEGATIVITY; BRAIN POTENTIALS; SCALP TOPOGRAPHY; CNV
AB Introduction: Reduction of P300 event-related potential amplitude in schizophrenia is perhaps the most replicated biological reflection of the illness. P300 is typically elicited by infrequent deviant events that are imbedded in a series of identical frequent standard events. Deviants have features that explicitly distinguish them from standards, whereas standards can be distinguished from each other based on their local sequential probabilities within the stimulus series. The improbable occurrence of a standard should generate a P300, but only if the implicit local context generated by the recent stimulus history is processed.
Method: To assess the ability of schizophrenia patients to process this implicit contextual information, ERPs were elicited from 22 controls and 16 schizophrenia patients during an auditory oddball task containing infrequent target tones (15%) and novel distracter sounds (15%) imbedded pseudo-randomly in a series of standard tones (70%). Consecutively presented standards following deviant stimuli varied in sequential probability from p = 1.0 for the 1st standard to p = 0.16 for the 4th consecutive standard.
Results: Patients compared to controls demonstrated smaller P300 (P3a) to the fourth consecutive standard. However, in controls but not patients a contingent negative variation (CNV) was observed prior to the fourth standard, and an N2b/mismatch negativity (MMN) was observed following it.
Conclusions: These outcomes suggest that patients are deficient in using the implicit context established by recent stimulus history to anticipate that an otherwise standard stimulus was unlikely and its occurrence unexpected. (C) 2010 Published by Elsevier B.V.
C1 [Ford, Judith M.; Roach, Brian J.; Miller, Ryan M.; Mathalon, Daniel H.] San Francisco VA Med Ctr, Psychiat Serv, San Francisco, CA 94121 USA.
[Ford, Judith M.; Roach, Brian J.; Miller, Ryan M.; Mathalon, Daniel H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA.
[Duncan, Connie C.] Uniformed Serv Univ Hlth Sci, Dept Psychiat, Bethesda, MD 20814 USA.
[Hoffman, Ralph E.] Yale Univ, Dept Psychiat, Sch Med, New Haven, CT 06520 USA.
RP Ford, JM (reprint author), San Francisco VA Med Ctr, Psychiat Serv, 116D,4150 Clement St, San Francisco, CA 94121 USA.
EM judith.ford@ucsf.edu
OI Roach, Brian/0000-0002-3264-1465; Mathalon, Daniel/0000-0001-6090-4974
FU VA Schizophrenia Biological Research Center; Research Career Scientist;
VA Merit Review; NIMH; NARSAD; VA Career Award
FX This work was supported by the VA Schizophrenia Biological Research
Center (JMF), Research Career Scientist (JMF), VA Merit Review (JMF),
NIMH (JMF, DHM, REH), NARSAD (JMF, DHM, REH), VA Career Award (DHM).
NR 69
TC 19
Z9 19
U1 4
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-8760
J9 INT J PSYCHOPHYSIOL
JI Int. J. Psychophysiol.
PD OCT
PY 2010
VL 78
IS 1
SI SI
BP 3
EP 13
DI 10.1016/j.ijpsycho.2010.05.005
PG 11
WC Psychology, Biological; Neurosciences; Physiology; Psychology;
Psychology, Experimental
SC Psychology; Neurosciences & Neurology; Physiology
GA 657IR
UT WOS:000282406900002
PM 20580752
ER
PT J
AU Estrella, MM
Parekh, RS
Abraham, A
Astor, BC
Szczech, LA
Anastos, K
Dehovitz, JA
Merenstein, DJ
Pearce, CL
Tien, PC
Cohen, MH
Gange, SJ
AF Estrella, Michelle M.
Parekh, Rulan S.
Abraham, Alison
Astor, Brad C.
Szczech, Lynda A.
Anastos, Kathryn
Dehovitz, Jack A.
Merenstein, Daniel J.
Pearce, C. Leigh
Tien, Phyllis C.
Cohen, Mardge H.
Gange, Stephen J.
TI The Impact of Kidney Function at Highly Active Antiretroviral Therapy
Initiation on Mortality in HIV-Infected Women
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE kidney disease; mortality; HIV; WIHS; antiretroviral therapy
ID DISEASE; DEATH; OUTCOMES; LEVEL; RATES; RISK
AB Background: In the early highly active antiretroviral therapy (HAART) era, kidney dysfunction was strongly associated with death among HIV-infected individuals. We re-examined this association in the later HAART period to determine whether chronic kidney disease remains a predictor of death after HAART initiation.
Methods: To evaluate the effect of kidney function at the time of HAART initiation on time to all-cause mortality, we evaluated 1415 HIV-infected women initiating HAART in the Women's Interagency HIV Study. Multivariable proportional hazards models with survival times calculated from HAART initiation to death were constructed; participants were censored at the time of the last available visit or December 31, 2006.
Results: Chronic kidney disease (estimated glomerular filtration rate less than 60 mL/min/1.73 m(2)) at HAART initiation was associated with higher mortality risk adjusting for age, race, hepatitis C serostatus, AIDS history, and CD4(+) cell count (hazard ratio 2.23, 95% confidence interval: 1.45-3.43). Adjustment for hypertension and diabetes history attenuated this association (hazard ratio = 1.89, confidence interval: 0.94-3.80). Lower kidney function at HAART initiation was weakly associated with increased mortality risk in women with prior AIDS (hazard ratio = 1.09, confidence interval: 1.00-1.19, per 20% decrease in estimated glomerular filtration rate).
Conclusions: Kidney function at HAART initiation remains an independent predictor of death in HIV-infected individuals, especially in those with a history of AIDS. Our study emphasizes the necessity of monitoring kidney function in this population. Additional studies are needed to determine mechanisms underlying the increased mortality risk associated with chronic kidney disease in HIV-infected persons.
C1 [Estrella, Michelle M.] Johns Hopkins Sch Med, Dept Med, Div Nephrol, Baltimore, MD 21205 USA.
[Parekh, Rulan S.] Univ Toronto, Div Nephrol, Toronto, ON, Canada.
[Parekh, Rulan S.; Abraham, Alison; Astor, Brad C.; Gange, Stephen J.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Szczech, Lynda A.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
[Anastos, Kathryn] Montefiore Med Ctr, Dept Med, Washington, DC USA.
[Dehovitz, Jack A.] SUNY Hlth Sci Ctr, Sch Publ Hlth, Dept Prevent Med & Community Hlth, Washington, DC USA.
[Dehovitz, Jack A.] SUNY Hlth Sci Ctr, Sch Publ Hlth, Dept Med, Washington, DC USA.
[Merenstein, Daniel J.] Georgetown Univ, Med Ctr, Dept Family Med, Washington, DC 20007 USA.
[Pearce, C. Leigh] Univ So Calif, Norris Comprehens Canc Ctr, Dept Prevent Med, Keck Sch Med, San Francisco, CA USA.
[Tien, Phyllis C.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Tien, Phyllis C.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Cohen, Mardge H.] Stroger Hosp, Dept Med, Chicago, IL USA.
[Cohen, Mardge H.] Rush Univ, Chicago, IL 60612 USA.
RP Estrella, MM (reprint author), Johns Hopkins Sch Med, Dept Med, Div Nephrol, 1830 E Monument St,Suite 416, Baltimore, MD 21205 USA.
EM mestrel1@jhmi.edu
OI Gange, Stephen/0000-0001-7842-512X
FU [UO1-AI-35004]; [UO1-AI-31834]; [UO1-AI-34994]; [UO1-AI-34989];
[UO1-AI-34993]; [UO1-AI-42590]; [UO1-HD-32632]; [UL1 RR024131];
[1K23-DK-081317-01A1]; [5U01DK070657-03]; [1R01-DK-072367];
[R01-DK-07677001]; [R21-DK078218-01A1]; [R01-DK-080094-02]
FX The WIHS is funded by UO1-AI-35004, UO1-AI-31834, UO1-AI-34994,
UO1-AI-34989, UO1-AI-34993, UO1-AI-42590, UO1-HD-32632, and UL1
RR024131. Additional support came from 1K23-DK-081317-01A1 to MME,
5U01DK070657-03 and 1R01-DK-072367 to RSP, R01-DK-07677001 and
R21-DK078218-01A1 to BCA, and R01-DK-080094-02 to LAS.
NR 17
TC 25
Z9 27
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD OCT 1
PY 2010
VL 55
IS 2
BP 217
EP 220
DI 10.1097/QAI.0b013e3181e674f4
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 658QI
UT WOS:000282504100018
PM 20581688
ER
PT J
AU Ghotb, A
Noworolski, SM
Madden, E
Scherzer, R
Qayyum, A
Pannell, J
Ferrell, L
Peters, M
Tien, PC
AF Ghotb, Alireza
Noworolski, Susan M.
Madden, Erin
Scherzer, Rebecca
Qayyum, Aliya
Pannell, Jane
Ferrell, Linda
Peters, Marion
Tien, Phyllis C.
TI Adipose Tissue and Metabolic Factors Associated With Steatosis in
HIV/HCV Coinfection: Histology Versus Magnetic Resonance Spectroscopy
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE adipose tissue; HIV; HCV; insulin resistance; magnetic resonance
spectroscopy; steatosis
ID HEPATITIS-C-VIRUS; HIV-INFECTED PATIENTS; HCV GENOTYPE; LIVER;
PREVALENCE; FIBROSIS
AB Background: Hepatic steatosis is common in persons with HIV and hepatitis C virus (HCV); yet biopsy measurement of steatosis is prone to sampling error. We compared magnetic resonance spectroscopy (MRS) measurement of steatosis to histology in HIV/HCV-coinfected patients and explored the associated adipose tissue and metabolic factors.
Methods: Cross-sectional analysis of 42 HIV/HCV-coinfected men and women. Logistic regression analysis identified factors (MRI-measured visceral adipose tissue and abdominal subcutaneous adipose tissue and Homeostasis Model Assessment-estimated insulin resistance) associated with histologic steatosis (>= 5% of hepatocytes with fat) and MRS steatosis (>= 5% of hepatic fat).
Results: MRS steatosis was strongly associated with histologic steatosis, when measured continuously (odds ratio: 10.2 per doubling of MRS-measured hepatic fat; 95% confidence interval: 2.9 to 69.3) and dichotomously (Kappa coefficient = 0.52; P = 0.0007). Four of the 10 with MRS-measured steatosis did not have histologic steatosis; 3 of 9 with histologic steatosis did not have MRS-measured steatosis (67% sensitivity; 88% specificity). Associations of visceral adipose tissue and abdominal subcutaneous adipose tissue were associated with both histologic and MRS-measured steatosis. Insulin resistance was also associated with both.
Conclusions: When compared with histology, MRS was similarly associated with adipose tissue and metabolic factors. MRS is a useful noninvasive alternative to biopsy in HIV/HCV coinfection.
C1 [Tien, Phyllis C.] Univ Calif San Francisco, VAMC, Infect Dis Sect, Dept Med, San Francisco, CA 94121 USA.
[Scherzer, Rebecca; Tien, Phyllis C.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Ghotb, Alireza] Calif Pacific Med Ctr, Dept Med, San Francisco, CA USA.
[Noworolski, Susan M.; Qayyum, Aliya] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94121 USA.
[Madden, Erin] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94121 USA.
[Pannell, Jane] Univ Calif San Francisco, Dept Clin Pharm, San Francisco, CA 94121 USA.
[Ferrell, Linda] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94121 USA.
RP Tien, PC (reprint author), Univ Calif San Francisco, VAMC, Infect Dis Sect, Dept Med, 111W,4150 Clement St, San Francisco, CA 94121 USA.
EM ptien@ucsf.edu
FU UCSF Hellman Early Career Faculty Award; National Institute of Allergy
and Infectious Diseases [UO1-AI-35004, UO1-AI-31834, UO1-AI-34994,
UO1-AI-34989, UO1-AI-34993, UO1-AI-42590]; National Institute of Child
Health and Human Development [UO1-HD-32632]; National Cancer Institute;
National Institute on Drug Abuse; National Institute on Deafness and
Other Communication Disorders; National Center for Research Resources
[UL1 RR024131]; [K23 AI-66943]; [P01 HD-40543]; [UO1 AI-34989]; [M01
RR-00083]
FX Supported in part by grants K23 AI-66943, P01 HD-40543, UO1 AI-34989,
M01 RR-00083, and the UCSF Hellman Early Career Faculty Award.; The WIHS
is funded by the National Institute of Allergy and Infectious Diseases
(UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993,
and UO1-AI-42590) and by the National Institute of Child Health and
Human Development (UO1-HD-32632). The study is cofunded by the National
Cancer Institute, the National Institute on Drug Abuse, and the National
Institute on Deafness and Other Communication Disorders. Funding is also
provided by the National Center for Research Resources (UCSF-CTSI Grant
Number UL1 RR024131).
NR 15
TC 7
Z9 7
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD OCT 1
PY 2010
VL 55
IS 2
BP 228
EP 231
DI 10.1097/QAI.0b013e3181e1d963
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 658QI
UT WOS:000282504100021
PM 20512045
ER
PT J
AU Goodrich, DE
Lai, ZS
Lasky, E
Burghardt, AR
Kilbourne, AM
AF Goodrich, David E.
Lai, Zongshan
Lasky, Elaine
Burghardt, Amy R.
Kilbourne, Amy M.
TI Access to weight loss counseling services among patients with bipolar
disorder
SO JOURNAL OF AFFECTIVE DISORDERS
LA English
DT Article
DE Bipolar disorder; Weight loss; Physical activity; Nutritional
counseling; Atypical; Antipsychotics; Service access
ID CARDIOVASCULAR-DISEASE; PHYSICAL-ACTIVITY; UNITED-STATES; SCHIZOPHRENIA;
HEALTH; RISK; COMORBIDITY; OBESITY; CARE; INDIVIDUALS
AB Background: Cardiovascular disease is the leading cause of mortality in persons with bipolar disorder but little is known about utilization of services for risk reduction. We assessed determinants of access to weight counseling in a sample of patients with bipolar disorder.
Methods: Patients enrolled in the Continuous Improvement for Veterans in Care: Mood Disorders (CIVIC-MD), a prospective study conducted from July 2004-July 2006. Patient data were obtained from a baseline questionnaire and chart review.
Results: Out of 298 patients, 73% received some weight counseling, with utilization more likely for those with higher BMI (OR = 1.12, p<0.001) or prescribed a second generation antipsychotic (SGA) (OR = 1.80, p = 0.05). About 41% received 2 >= dietary consultations with consults more likely for those reporting illicit substance use (OR = 1.9, p<0.05) or SGA treatment (OR = 2.4, p<0.05). In approximately 25% of patients, increased BMI (OR = 1.06, p = 0.04) and SGA treatment (OR = 2.13, p = 0.04) were associated with greater likelihood of receiving >= 2 exercise consultations. Zero-inflated Poisson regression found SGA treatment was associated with more diet consultations (beta = 35, p<0.05) while SGA treatment (beta = 29, p<0.05) and women (beta = 76, p<0.001) were associated with more exercise consultations. Illicit substance use (beta = -0.36, p<0.05), binge drinking (beta = 32, p<0.05) and other ethnicity (beta = -0.57, p<0.05) were associated with fewer exercise consults.
Limitations: Single-site study and limited chart detail.
Conclusion: The majority of patients received some weight counseling, with obesity and SGA predicting service use over time. However, low utilization patterns underscore the need for research into determinants of long-term counseling utilization to improve patient health outcomes. Published by Elsevier B.V.
C1 [Goodrich, David E.; Kilbourne, Amy M.] VA Ann Arbor Hlth Serv Res & Dev Ctr Excellence, Ann Arbor, MI USA.
[Lasky, Elaine] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Lai, Zongshan; Burghardt, Amy R.; Kilbourne, Amy M.] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI 48109 USA.
RP Kilbourne, AM (reprint author), VA Ann Arbor HSR&D 11H,2215 Fuller Rd, Ann Arbor, MI 48105 USA.
EM amykilbo@umich.edu
OI Goodrich, David/0000-0003-3232-2189
FU Department of Veterans Affairs; Veterans Health Administration; Health
Services Research and Development Service [IIR 02-283-2, 02-283];
National Institutes of Health [R34 MH74509]
FX This research was supported by the Department of Veterans Affairs,
Veterans Health Administration, Health Services Research and Development
Service (IIR 02-283-2; A. Kilbourne, PI) and the National Institutes of
Health (R34 MH74509; A. Kilbourne, PI). The funding source had no role
in the design and conduct of the study; collection, management,
analysis, and interpretation of the data; and preparation, review, or
approval of the manuscript. The views expressed in this article are
those of the authors and do not necessarily represent the views of the
Department of Veterans Affairs.; This work was supported by the
Department of Veterans Affairs, Veterans Health Administration, Health
Services Research and Development Service (02-283) and the National
Institute of Mental Health (MH 74509).
NR 26
TC 7
Z9 7
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-0327
J9 J AFFECT DISORDERS
JI J. Affect. Disord.
PD OCT
PY 2010
VL 126
IS 1-2
BP 75
EP 79
DI 10.1016/j.jad.2010.02.138
PG 5
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 658KD
UT WOS:000282488000009
PM 20381155
ER
PT J
AU Black, HL
Priolo, C
Akinyemi, D
Gonzalez, R
Jackson, DS
Garcia, L
George, M
Apter, AJ
AF Black, Heather L.
Priolo, Chantel
Akinyemi, D'Jahna
Gonzalez, Rodalyn
Jackson, Danielle S.
Garcia, Laura
George, Maureen
Apter, Andrea J.
TI Clearing Clinical Barriers: Enhancing Social Support Using a Patient
Navigator for Asthma Care
SO JOURNAL OF ASTHMA
LA English
DT Article
DE Asthma; barriers; communication; control; patient navigator;
self-management
ID DISPARITIES; ADULTS; INTERVENTION; MANAGEMENT; ADHERENCE; NUMERACY;
OUTCOMES; QUALITY; SYSTEM; WOMEN
AB Background. Patients with moderate or severe asthma, particularly those who are minority or poor, often encounter significant personal, clinical practice, and health system barriers to accessing care. Objective. To explore the ideas of patients and providers for potentially feasible, individualized, cost-effective ways to reduce obstacles to care by providing social support using a patient advocate or navigator. Methods. The authors conducted four focus groups of adults with moderate or severe asthma. Participants were recruited from clinics serving low-income and minority urban neighborhoods. Data from these patient focus groups were shared with two additional focus groups, one of nurses and one of physicians. Researchers independently coded and agreed upon themes from all focus groups, which were categorized by types of social support: instrumental (physical aid), informational (educational), emotional (empathizing), validation (comparisons to others). Results. Patients and providers agreed that a patient navigator could help patients manage asthma by giving social support. Both groups found instrumental and informational support most important. However, patients desired more instrumental help whereas providers focused on informational support. Physicians stressed review of medical information whereas patients wanted information to complete administrative tasks. Providers and patients agreed that the patient navigator's role in asthma would need to address both short-term care of exacerbations and enhance long-term chronic self-management by working with practice personnel. Conclusions. Along with medical information, there is a need for providers to connect patients to instrumental support relevant to acute and long-term asthma-self-management.
C1 [Black, Heather L.; Priolo, Chantel; Akinyemi, D'Jahna; Gonzalez, Rodalyn; Jackson, Danielle S.; Garcia, Laura; Apter, Andrea J.] Univ Penn, Div Pulm Allergy & Crit Care Med, Sect Allergy & Immunol, Philadelphia, PA 19104 USA.
[George, Maureen] Univ Penn, Sch Nursing, Family & Community Hlth Div, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA.
RP Apter, AJ (reprint author), Hosp Univ Penn, 829 Gates Bldg,3600 Spruce St, Philadelphia, PA 19104 USA.
EM apter@mail.med.upenn.edu
FU [HL073932]; [HL088469]; [HL099612]; [K23AT003907]
FX This work is support by grants HL073932, HL088469, and HL099612 (A.
Apter); HL073932, HL099612 (C. Priolo, L. Garcia, R. Gonzalez, D.
Jackson); and K23AT003907 (M. George).
NR 33
TC 11
Z9 12
U1 0
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 0277-0903
J9 J ASTHMA
JI J. Asthma
PD OCT
PY 2010
VL 47
IS 8
BP 913
EP 919
DI 10.3109/02770903.2010.506681
PG 7
WC Allergy; Respiratory System
SC Allergy; Respiratory System
GA 658VB
UT WOS:000282516400012
PM 20846085
ER
PT J
AU Takahashi, TA
Maciejewski, ML
Bradley, K
AF Takahashi, Traci A.
Maciejewski, Matthew L.
Bradley, Katharine
TI US Hospitalizations and Costs for Illicit Drug Users with Soft Tissue
Infections
SO JOURNAL OF BEHAVIORAL HEALTH SERVICES & RESEARCH
LA English
DT Article
ID RESISTANT STAPHYLOCOCCUS-AUREUS; SAN-FRANCISCO; INJECTION; CARE;
EMERGENCY; ABSCESSES; ABUSE; SKIN; ACCIDENT
AB Skin and soft tissue infections (SSTIs) are common complications of illicit drug use. Studies at single, urban hospitals demonstrate high rates of emergency department visits and hospitalizations for these infections. This study sought to estimate nationwide and regional incidence and costs of hospitalizations for illicit drug users with SSTIs in the US. AHRQ's Nationwide Inpatient Sample was used to conduct a retrospective cross-sectional, time-series study. Hospitalizations of illicit drug users with SSTIs were identified using International Classification of Diseases, 9th Revision Clinical Modification codes. An estimated 106,126 hospitalizations for illicit drug users with SSTIs represented 0.07% of all US non-Federal hospitalizations from 1998 to 2001 and cost over 193 million dollars in 2001. Higher rates of hospitalization were found in the West, Northeast, and urban teaching hospitals. Hospitalization rates for illicit drug users with SSTIs vary significantly according to US region. Resources to reduce the incidence and severity of these infections should be targeted accordingly.
C1 [Takahashi, Traci A.; Bradley, Katharine] VA Puget Sound Hlth Care Syst, HSR&D, Seattle, WA 98108 USA.
[Maciejewski, Matthew L.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
[Bradley, Katharine] Univ Washington, Sch Med, Seattle, WA USA.
RP Takahashi, TA (reprint author), VA Puget Sound Hlth Care Syst, HSR&D, 1660 S ColumbianWay,S-111 PCC, Seattle, WA 98108 USA.
EM traci@u.washington.edu; matthew.maciejewski@va.gov;
katharine.bradley@va.gov
FU NIDA NIH HHS [R03DA14518]
NR 27
TC 9
Z9 9
U1 2
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1094-3412
J9 J BEHAV HEALTH SER R
JI J. Behav. Health Serv. Res.
PD OCT
PY 2010
VL 37
IS 4
BP 508
EP 518
DI 10.1007/s11414-009-9177-z
PG 11
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 652YA
UT WOS:000282047300008
PM 19381818
ER
PT J
AU Matlock, DD
Nowels, CT
Bekelman, DB
AF Matlock, Dan D.
Nowels, Carolyn T.
Bekelman, David B.
TI Patient Perspectives on Decision Making in Heart Failure
SO JOURNAL OF CARDIAC FAILURE
LA English
DT Article
DE Heart failure; patient-centered care; decision making; qualitative
ID CARE; DEPRESSION; LIFE; PARTICIPATION; INVOLVEMENT; PREFERENCES; QUALITY
AB Background: Patients with heart failure (HF) face an array of challenging decisions involving medications, devices, and transplants. The goal of this qualitative study was to describe patients' perceptions surrounding difficult decisions along with factors that influenced their decisions.
Methods and Results: We studied 22 patients with symptomatic HF from the University of Colorado Hospital using in-depth, semistructured interviews. We used descriptive theme analysis in an iterative process to analyze responses to the question: "Can you tell me about any important or difficult decisions you have had to make about your heart condition?" Two distinct decision-making styles emerged: active (55%) and passive (45%). Active decision makers identified interventions such as implantable cardioverter-defibrillators, medications, and transplants to be the most difficult decisions and weighed concerns for side effects, family, and quality of life. Passive decision makers generally did not identify a difficult decision and described factors such as trust in God, trust in the physician, and power of the physician as reasons for their passivity.
Conclusions: Patients with HF use active and passive decision styles in their approach to medical decision making. Future work should investigate communication techniques to assure that passive decision makers receive health care that is concordant with their values. (J Cardiac Fail 2010;16:823-826)
C1 [Matlock, Dan D.; Nowels, Carolyn T.; Bekelman, David B.] Univ Colorado Denver, Div Gen Internal Med, Acad Off 1, Sch Med, Aurora, CO 80045 USA.
[Matlock, Dan D.; Bekelman, David B.] Colorado Cardiovasc Outcomes Res Grp, Denver, CO USA.
[Bekelman, David B.] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Matlock, DD (reprint author), Univ Colorado Denver, Div Gen Internal Med, Acad Off 1, Sch Med, 12631 E 17th Ave,Campus Box B-180, Aurora, CO 80045 USA.
EM daniel.matlock@ucdenver.edu
FU University of Colorado Denver (UCD) Hartford/Jahnigen Center for
Excellence in Geriatric Medicine; UCD
FX This research was conducted while Dan Matlock, MD, was a Hartford
Geriatrics Health Outcomes Scholar. This research was funded by the
University of Colorado Denver (UCD) Hartford/Jahnigen Center for
Excellence in Geriatric Medicine and the UCD Mordecai Palliative Care
Grants Fund.
NR 19
TC 11
Z9 11
U1 3
U2 6
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 1071-9164
J9 J CARD FAIL
JI J. Card. Fail.
PD OCT
PY 2010
VL 16
IS 10
BP 823
EP 826
DI 10.1016/j.cardfail.2010.06.003
PG 4
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 664XO
UT WOS:000282997500004
PM 20932464
ER
PT J
AU Wijelath, E
Namekata, M
Murray, J
Furuyashiki, M
Zhang, SY
Coan, D
Wakao, M
Harris, RB
Suda, Y
Wang, LC
Sobel, M
AF Wijelath, Errol
Namekata, Mayumi
Murray, Jacqueline
Furuyashiki, Mai
Zhang, Siyuan
Coan, Daniel
Wakao, Masahiro
Harris, Robert B.
Suda, Yasuo
Wang, Lianchun
Sobel, Michael
TI Multiple Mechanisms for Exogenous Heparin Modulation of Vascular
Endothelial Growth Factor Activity
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE VEGF-A; VEGFR2; HEPARIN; ENDOTHELIAL CELL; Ndst
ID VEGF RECEPTOR; EXTRACELLULAR DOMAIN; BIOLOGICAL-ACTIVITY; BINDING
PEPTIDE; SUGAR CHIPS; SULFATE; CELLS; ANGIOGENESIS; NEUROPILIN-1;
MIGRATION
AB Heparin and heparin-like molecules are known to modulate the cellular responses to vascular endothelial growth factor-A (VEGF-A). In this study, we investigated the likely mechanisms for heparin's influence on the biological activity of VEGF-A. Previous studies have shown that exogenous heparin's effects on the biological activity of VEGF-A are many and varied, in part due to the endogenous cell-surface heparan sulfates. To circumvent this problem, we used mutant endothelial cells lacking cell-surface heparan sulfates. We showed that VEGF-induced cellular responses are dependent in part on the presence of the heparan sulfates, and that exogenous heparin significantly augments VEGF's cellular effects especially when endogenous heparan sulfates are absent. Exogenous heparin was also found to play a cross-bridging role between VEGF-A165 and putative heparin-binding sites within its cognate receptor, VEGFR2 when they were examined in isolation. The cross-bridging appears to be more dependent on molecular weight than on a specific heparin structure. This was confirmed by surface plasmon resonance binding studies using sugar chips immobilized with defined oligosaccharide structures, which showed that VEGF-A165 binds to a relatively broad range of sulfated glycosaminoglycan structures. Finally, studies of the far-UV circular dichroism spectra of VEGF-A165 showed that heparin can also modulate the conformation and secondary structure of the protein. J. Cell. Biochem. 111: 461-468, 2010. (C) 2010 Wiley-Liss, Inc.
C1 [Wijelath, Errol; Namekata, Mayumi; Murray, Jacqueline; Coan, Daniel; Sobel, Michael] VA Puget Sound Hlth Care Syst, Dept Surg, Div Vasc Surg, Seattle, WA 98108 USA.
[Wijelath, Errol; Namekata, Mayumi; Murray, Jacqueline; Coan, Daniel; Sobel, Michael] Univ Washington, Sch Med, Seattle, WA USA.
[Furuyashiki, Mai; Suda, Yasuo] SUDx Biotec Corp, Kobe, Hyogo, Japan.
[Zhang, Siyuan; Wang, Lianchun] Univ Georgia, Complex Carbohydrate Res Ctr, Dept Biochem & Mol Biol, Athens, GA 30602 USA.
[Wakao, Masahiro; Suda, Yasuo] Kagoshima Univ, Dept Nanostruct & Adv Mat, Grad Sch Sci & Engn, Kagoshima 890, Japan.
[Harris, Robert B.] Commonwealth Biotechnol Inc, Richmond, VA USA.
RP Wijelath, E (reprint author), VA Puget Sound Hlth Care Syst, Dept Surg, Div Vasc Surg, S151,1660 S Columbian Way, Seattle, WA 98108 USA.
EM errolw@u.washington.edu
FU NIH [RO1HL097182, P41RR005351]; Japan Science and Technology Agency
FX Grant sponsor: NIH; Grant numbers: RO1HL097182, P41RR005351; Grant
sponsor: Japan Science and Technology Agency.
NR 34
TC 12
Z9 13
U1 1
U2 7
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD OCT 1
PY 2010
VL 111
IS 2
BP 461
EP 468
DI 10.1002/jcb.22727
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 658HZ
UT WOS:000282482400022
PM 20524207
ER
PT J
AU Dey, N
Ghosh-Choudhury, N
Das, F
Li, XN
Venkatesan, B
Barnes, JL
Kasinath, BS
Choudhury, GG
AF Dey, Nirmalya
Ghosh-Choudhury, Nandini
Das, Falguni
Li, Xiaonan
Venkatesan, Balachandar
Barnes, Jeffrey L.
Kasinath, Balakuntalam S.
Choudhury, Goutam Ghosh
TI PRAS40 Acts as a Nodal Regulator of High Glucose-Induced TORC1
Activation in Glomerular Mesangial Cell Hypertrophy
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID RICH AKT-SUBSTRATE; MESSENGER-RNA TRANSLATION; GROWTH-FACTOR RECEPTOR;
TUMOR-SUPPRESSOR PTEN; INDUCED DNA-SYNTHESIS; 40 KDA PRAS40;
DIABETIC-NEPHROPATHY; MAMMALIAN TARGET; RENAL HYPERTROPHY;
PHOSPHATIDYLINOSITOL 3-KINASE
AB Diabetic nephropathy manifests aberrant activation of TORC1, which senses key signals to modulate protein synthesis and renal hypertrophy. PRAS40 has recently been identified as a raptor-interacting protein and is a component and a constitutive inhibitor of TORC1. The mechanism by which high glucose stimulates TORC1 activity is not known. PRAS40 was identified in the mesangial cells in renal glomeruli and in tubulointerstitium of rat kidney. Streptozotocin-induced diabetic renal hypertrophy was associated with phosphorylation of PRAS40 in the cortex and glomeruli. In vitro, high glucose concentration increased PRAS40 phosphorylation in a PI 3 kinase- and Akt-dependent manner, resulting in dissociation of raptor PRAS40 complex in mesangial cells. High glucose augmented the inactivating and activating phosphorylation of 4EBP-I and S6 kinase, respectively, with concomitant induction of protein synthesis and hypertrophy. Expression of TORC1-nonphosphorylatable mutant of 4EBP-I and dominant-negative S6 kinase significantly inhibited high glucose-induced protein synthesis and hypertrophy. PRAS40 knockdown mimicked the effect of high glucose on phosphorylation of 4EBP-I and S6 kinase, protein synthesis, and hypertrophy. To elucidate the role of PRAS40 phosphorylation, we used phosphorylation-deficient mutant of PRAS40, which in contrast to PRAS40 knockdown inhibited phosphorylation of 4EBP-I and S6 kinase, leading to reduced mesangial cell hypertrophy. Thus, our data identify high glucose-induced phosphorylation and inactivation of PRAS40 as a central node for mesangial cell hypertrophy in diabetic nephropathy. J. Cell. Physiol. 225: 27-41, 2010. (C) 2010 Wiley-Liss, Inc.
C1 [Dey, Nirmalya; Das, Falguni; Li, Xiaonan; Venkatesan, Balachandar; Barnes, Jeffrey L.; Kasinath, Balakuntalam S.; Choudhury, Goutam Ghosh] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Ghosh-Choudhury, Nandini; Barnes, Jeffrey L.; Kasinath, Balakuntalam S.; Choudhury, Goutam Ghosh] S Texas Vet Hlth Care Syst, VA Res, San Antonio, TX USA.
[Ghosh-Choudhury, Nandini] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[Choudhury, Goutam Ghosh] S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX USA.
RP Choudhury, GG (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Mail Code 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM choudhuryg@uthscsa.edu
FU NIH [ROI DK50190, ROI AR52425]; Juvenile Diabetes Research Foundation
[1-2008-185]; Department of Veterans Affairs; VA Merit Review; VA
Research Service; VA Research Service Merit Review
FX The authors thank Dr. L. Mahimainathan for his help in animal
experiments. The authors wish to acknowledge the University of Texas
Health Science Center FACS Core Facility for FACS analysis provided in
this article. This work was supported by NIH ROI DK50190, The Juvenile
Diabetes Research Foundation 1-2008-185, and VA Research Service Merit
Review grants to G.G.C., who is a recipient of Senior Research Career
Scientist Award from the Department of Veterans Affairs. N.G.C. is
supported by NIH ROI AR52425 and VA Merit Review grants. B.S.K. is
supported by grants from NIH, VA Research Service.
NR 87
TC 26
Z9 26
U1 0
U2 0
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0021-9541
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD OCT
PY 2010
VL 225
IS 1
BP 27
EP 41
DI 10.1002/jcp.22186
PG 15
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA 643KK
UT WOS:000281295100005
PM 20629086
ER
PT J
AU Brooks, AC
Comer, SD
Sullivan, MA
Bisaga, A
Carpenter, KM
Raby, WM
Yu, E
O'Brien, CP
Nunes, EV
AF Brooks, Adam C.
Comer, Sandra D.
Sullivan, Maria A.
Bisaga, Adam
Carpenter, Kenneth M.
Raby, Wilfrid M.
Yu, Elmer
O'Brien, Charles P.
Nunes, Edward V.
TI Long-Acting Injectable Versus Oral Naltrexone Maintenance Therapy With
Psychosocial Intervention for Heroin Dependence: A Quasi-Experiment
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Article
ID OPIOID DEPENDENCE; CONTINGENCY MANAGEMENT; EFFICACY; IMPLANTS; GUIDE
AB Objective: To conduct a quasi-experimental comparison of early clinical outcomes between injectable, sustained-release, depot naltrexone formulation versus oral naltrexone maintenance therapy in individuals with opiate dependence.
Method: Early retention in treatment and urine-confirmed opiate use in the first 8 weeks postdetoxification were compared between patients (diagnosed as opiate-dependent according to DSM-IV criteria) participating in 2 concurrently run randomized clinical trials of oral (n = 69; patients treated from September 1999 to May 2002) and long-acting injectable (n = 42; patients treated from November 2000 to June 2003) naltrexone maintenance therapy with psychosocial therapy.
Results: Long-acting injectable naltrexone produced significantly better outcome than oral naltrexone on days retained in treatment (F(1,106) = 6.49, P = .012) and for 1 measure of opiate use (F(1,106) = 5.26, P = .024); other measures were not significantly different, but differences were in the same direction. In subanalyses, there were interaction effects between baseline heroin use severity and type of treatment. In subanalyses, heroin users with more severe baseline use showed better retention with oral naltrexone maintenance therapy combined with intensive psychotherapy (behavioral naltrexone therapy) as compared to retention shown by severe heroin users treated with long-acting naltrexone injections combined with standard cognitive-behavioral therapy (chi(2)(1) = 9.31, P = .002); less severe heroin users evidenced better outcomes when treated with long-acting injectable naltrexone.
Conclusions: This quasi-experimental analysis provides tentative indications of superior outcomes for heroin-dependent patients treated with long-acting injectable naltrexone compared to oral naltrexone. The finding that heroin users with more severe baseline use achieved better outcomes with oral naltrexone is most probably attributable to the intensive nature of the psychosocial treatments provided and points to the opportunity for continued research in augmenting injectable naltrexone with psychosocial strategies to further improve outcome, especially in individuals with more severe use. The results should be considered exploratory given the quasi-experimental nature of the study. J Clin Psychiatry 2010;71(10): 1371-1378 (C) Copyright 2010 Physicians Postgraduate Press, Inc,
C1 [Brooks, Adam C.] Treatment Res Inst, Philadelphia, PA 19106 USA.
[Brooks, Adam C.; Comer, Sandra D.; Sullivan, Maria A.; Bisaga, Adam; Carpenter, Kenneth M.; Raby, Wilfrid M.; Nunes, Edward V.] New York State Psychiat Inst & Hosp, Div Subst Abuse, New York, NY 10032 USA.
[Comer, Sandra D.; Sullivan, Maria A.; Bisaga, Adam; Carpenter, Kenneth M.; Raby, Wilfrid M.; Nunes, Edward V.] Columbia Univ, Coll Phys & Surg, New York, NY USA.
[Yu, Elmer; O'Brien, Charles P.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Yu, Elmer; O'Brien, Charles P.] Philadelphia Vet Affairs Med Ctr, Dept Behav Hlth, Philadelphia, PA USA.
RP Brooks, AC (reprint author), Treatment Res Inst, 600 Publ Ledger Bldg,150 S Independence Mall W, Philadelphia, PA 19106 USA.
EM abrooks@tresearch.org
FU Schering-Plough; Grunenthal GmbH; Reckitt Benckiser; Johnson Johnson;
Alkermes; National Institute on Drug Abuse; [P50 DA09236]; [P60
DA05186]; [R01 DA10746]; [K02 DA00288]
FX Dr Corner has been a consultant to Purdue Pharma, Alpharma, King,
Inflexxion, Shire, BioDelivery Services, and Analgesics Research; has
received grant/research support from Schering-Plough, Grunenthal GmbH,
Reckitt Benckiser, and Johnson & Johnson; has received honoraria from
the Rehabilitation Institute of Chicago, Yale University, Wake Forest
University, and the University of Michigan at Ann Arbor; and has served
on the speakers or advisory boards of Alpharma and King. Dr Bisaga has
received a grant from Alkermes to conduct a study of depot naltrexone in
a clinical trial; Alkermes is providing the medication. Dr O'Brien has
an ongoing intermittent consulting relationship with Alkermes. Dr Nunes
served on the board of Alkermes/Cephalon until he resigned from that
position in November of 2007. Alkermes/Cephalon makes a comparable
product to Depotrex, the product used in this study. Drs Brooks,
Sullivan, Carpenter, Baby, and Yu have no conflicts to disclose that
could affect the reporting of this study.; The authors gratefully
acknowledge the support of the National Institute on Drug Abuse. Support
for original data collection was drawn from center grants P50 DA09236
and P60 DA05186, as well as R01 DA10746 and K02 DA00288 (Dr Nunes).
NR 23
TC 11
Z9 11
U1 1
U2 3
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 240008, MEMPHIS, TN 38124 USA
SN 0160-6689
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD OCT
PY 2010
VL 71
IS 10
BP 1371
EP 1378
DI 10.4088/JCP.09m05080ecr
PG 8
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 696LY
UT WOS:000285444100014
PM 20673549
ER
PT J
AU Long, JA
Field, S
Armstrong, K
Chang, VW
Metlay, JP
AF Long, Judith A.
Field, Sam
Armstrong, Katrina
Chang, Virginia W.
Metlay, Joshua P.
TI Social Capital and Glucose Control
SO JOURNAL OF COMMUNITY HEALTH
LA English
DT Article
DE Diabetes; Veterans; African Americans; Residence characteristics
ID CARDIOVASCULAR-DISEASE; RACIAL-DIFFERENCES; DIABETES-MELLITUS; GLYCEMIC
CONTROL; HEALTH; MORTALITY; DISPARITIES; POPULATION; COMMUNITIES;
POVERTY
AB There is a growing diabetes epidemic in the United States and if we are to halt its progress we need to better understand the social determinants of this disease and its control. Social capital, which has been associated with general health and mortality, may be one important mediator of glucose control. In this study we determine if neighborhood social capital is associated with glucose control, independent of individual factors. We performed a cross-sectional study of Black veterans with diabetes living in Philadelphia. We merged individual-level data from surveys and charts with six area-level social capital descriptors. Holding all other variables constant, patients who lived in neighborhoods that scored near the 5th percentile of working together to improve the neighborhood were estimated to have glycosylated hemoglobin (HbA1c) values that were at least one point above a conservative clinical definition of "diabetes control" (HbA1c a parts per thousand currency sign 8%). If these same patients were to live in neighborhoods in the 95th percentile, their expected HbA1c would be over A1/2 a point below the cut-off value 8%. No other measure of social capital was associated with HbA1c. In this study of black veterans with diabetes we observed that living in neighborhoods where people work together is associated with better glucose control.
C1 [Long, Judith A.; Chang, Virginia W.; Metlay, Joshua P.] Philadelphia Vet Affairs Ctr Hlth Equ Res & Promo, Philadelphia, PA 19104 USA.
[Long, Judith A.; Armstrong, Katrina; Chang, Virginia W.; Metlay, Joshua P.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Long, Judith A.; Armstrong, Katrina; Chang, Virginia W.; Metlay, Joshua P.] Univ Penn, Dept Med, Sch Med, Philadelphia, PA 19104 USA.
[Long, Judith A.] Univ Penn, Sch Med, Metab & Diabet Endocrinol Res Ctr, Philadelphia, PA 19104 USA.
[Field, Sam] Univ N Carolina, FPG Child Dev Inst, Chapel Hill, NC USA.
[Metlay, Joshua P.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
RP Long, JA (reprint author), Philadelphia Vet Affairs Ctr Hlth Equ Res & Promo, 1201 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM jalong@mail.med.upenn.edu
NR 41
TC 8
Z9 8
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0094-5145
J9 J COMMUN HEALTH
JI J. Community Health
PD OCT
PY 2010
VL 35
IS 5
BP 519
EP 526
DI 10.1007/s10900-010-9222-0
PG 8
WC Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 661DK
UT WOS:000282703000010
PM 20143139
ER
PT J
AU Onishi, Y
Hayashi, T
Sato, KK
Ogihara, T
Kuzuya, N
Anai, M
Tsukuda, K
Boyko, EJ
Fujimoto, WY
Kikuchi, M
AF Onishi, Yukiko
Hayashi, Tomoshige
Sato, Kyoko Kogawa
Ogihara, Takehide
Kuzuya, Nobuaki
Anai, Motonobu
Tsukuda, Katsunori
Boyko, Edward J.
Fujimoto, Wilfred Y.
Kikuchi, Masatoshi
TI Fasting tests of insulin secretion and sensitivity predict future
prediabetes in Japanese with normal glucose tolerance
SO JOURNAL OF DIABETES INVESTIGATION
LA English
DT Article
DE Glucose intolerance; Insulin resistance; Epidemiology
ID BETA-CELL FUNCTION; VISCERAL ADIPOSITY; DIABETES-MELLITUS;
PLASMA-GLUCOSE; RISK-FACTOR; PROGRESSION; PREVALENCE; PROJECTIONS;
POPULATION; AMERICANS
AB Aims/Introduction: Reduced insulin sensitivity and secretion are important in the pathogenesis of type 2 diabetes. Their relationships to prediabetes, impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) have been previously studied with the oral glucose tolerance test (OGTT). We investigated whether or not baseline measures of insulin secretion and sensitivity obtained from fasting blood specimens were related to the development of prediabetes and how these measures compared with those based on the OGTT.
Materials and Methods: In 152 Japanese subjects with normal glucose tolerance, we measured baseline plasma glucose and insulin after an overnight fast and during a 75 g OGTT, insulin resistance index (homeostasis model assessment [HOMA-IR]), and insulin secretion (insulinogenic index [30 min insulin - fasting insulin] divided by [30 min glucose - fasting glucose] or HOMA-beta).
Results: At a 5-6 year (mean 5.7 years) follow-up examination, we confirmed 36 cases of prediabetes. After adjusting for age, sex, family history of diabetes, body mass index, and 2-h plasma glucose, the odds ratio comparing the lowest tertile (<= 0.82) of insulinogenic index with the highest tertile (>= 1.43) was 6.98 (95% confidence interval, 1.96-24.85) and was 10.72 (2.08-55.3) comparing the lowest tertile (<= 76.3) of HOMA-beta with the highest tertile (>= 122.1), whereas the respective odds ratios of HOMA-IR were 3.74 (1.03-13.57) and 10.89 (1.93-61.41) comparing the highest tertile (>= 1.95) with the lowest tertile (<= 1.25).
Conclusions: Lower insulin secretion and sensitivity are independent risk factors for prediabetes. Clinically practical identification of those at risk for prediabetes is obtainable from HOMA-beta and HOMA-IR, both of which are measured in fasting state. (J Diabetes Invest, doi: 10.1111.j.2040-1124.2010.00041.x, 2010)
C1 [Onishi, Yukiko; Tsukuda, Katsunori; Kikuchi, Masatoshi] Asahi Life Fdn, Inst Adult Dis, Dept Diabet & Metab, Tokyo, Japan.
[Anai, Motonobu] Univ Tokyo, Adv Sci & Technol Res Ctr, Lab Syst Biol & Med, Tokyo, Japan.
[Hayashi, Tomoshige; Sato, Kyoko Kogawa] Osaka City Univ, Grad Sch Med, Dept Prevent Med & Environm Hlth, Osaka 558, Japan.
[Ogihara, Takehide] Hitachi Gen Hosp, Div Internal Med, Ibaraki, Japan.
[Kuzuya, Nobuaki] Yokohama Sakae Kyosai Hosp, Dept Endocrinol & Metab, Yokohama, Kanagawa, Japan.
[Hayashi, Tomoshige; Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA.
[Hayashi, Tomoshige; Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Epidemiol Res Informat Ctr, Seattle, WA USA.
[Boyko, Edward J.; Fujimoto, Wilfred Y.] Univ Washington, Dept Med, Seattle, WA USA.
RP Onishi, Y (reprint author), Asahi Life Fdn, Inst Adult Dis, Dept Diabet & Metab, Tokyo, Japan.
EM y-ohnishi@asahi-life.or.jp
RI Hayashi, Tomoshige/N-8508-2015
OI Boyko, Edward/0000-0002-3695-192X
NR 22
TC 5
Z9 5
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 2040-1116
J9 J DIABETES INVEST
JI J. Diabetes Investig.
PD OCT
PY 2010
VL 1
IS 5
BP 191
EP 195
DI 10.1111/j.2040-1124.2010.00041.x
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 755DN
UT WOS:000289907000006
PM 24843431
ER
PT J
AU Bilimoria, KY
Cohen, ME
Merkow, RP
Wang, X
Bentrem, DJ
Ingraham, AM
Richards, K
Hall, BL
Ko, CY
AF Bilimoria, Karl Y.
Cohen, Mark E.
Merkow, Ryan P.
Wang, Xue
Bentrem, David J.
Ingraham, Angela M.
Richards, Karen
Hall, Bruce L.
Ko, Clifford Y.
TI Comparison of Outlier Identification Methods in Hospital Surgical
Quality Improvement Programs
SO JOURNAL OF GASTROINTESTINAL SURGERY
LA English
DT Article
DE Surgery; Hospital; Quality; Morbidity; Mortality; Morbidity;
Complications; Deaths; National surgery quality improvement program;
Outlier
ID RISK-ADJUSTMENT; PATIENT SAFETY; HEALTH-CARE; OF-CARE; SURGERY;
PERFORMANCE
AB Surgeons and hospitals are being increasingly assessed by third parties regarding surgical quality and outcomes, and much of this information is reported publicly. Our objective was to compare various methods used to classify hospitals as outliers in established surgical quality assessment programs by applying each approach to a single data set.
Using American College of Surgeons National Surgical Quality Improvement Program data (7/2008-6/2009), hospital risk-adjusted 30-day morbidity and mortality were assessed for general surgery at 231 hospitals (cases = 217,630) and for colorectal surgery at 109 hospitals (cases = 17,251). The number of outliers (poor performers) identified using different methods and criteria were compared.
The overall morbidity was 10.3% for general surgery and 25.3% for colorectal surgery. The mortality was 1.6% for general surgery and 4.0% for colorectal surgery. Programs used different methods (logistic regression, hierarchical modeling, partitioning) and criteria (P < 0.01, P < 0.05, P < 0.10) to identify outliers. Depending on outlier identification methods and criteria employed, when each approach was applied to this single dataset, the number of outliers ranged from 7 to 57 hospitals for general surgery morbidity, 1 to 57 hospitals for general surgery mortality, 4 to 27 hospitals for colorectal morbidity, and 0 to 27 hospitals for colorectal mortality.
There was considerable variation in the number of outliers identified using different detection approaches. Quality programs seem to be utilizing outlier identification methods contrary to what might be expected, thus they should justify their methodology based on the intent of the program (i.e., quality improvement vs. reimbursement). Surgeons and hospitals should be aware of variability in methods used to assess their performance as these outlier designations will likely have referral and reimbursement consequences.
C1 [Bilimoria, Karl Y.; Cohen, Mark E.; Merkow, Ryan P.; Wang, Xue; Ingraham, Angela M.; Richards, Karen] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA.
[Bilimoria, Karl Y.; Bentrem, David J.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL 60611 USA.
[Bilimoria, Karl Y.] Univ Texas Houston, MD Anderson Canc Ctr, Div Surg Oncol, Houston, TX 77030 USA.
[Hall, Bruce L.] John Cochran Vet Affairs Med Ctr, Dept Surg, St Louis, MO USA.
[Hall, Bruce L.] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA.
[Hall, Bruce L.] St Louis & Barnes Jewish Hosp, St Louis, MO USA.
[Hall, Bruce L.] Washington Univ, Olin Business Sch, St Louis, MO 63110 USA.
[Hall, Bruce L.] Washington Univ, Ctr Hlth Policy, St Louis, MO 63110 USA.
[Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA.
RP Bilimoria, KY (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair St,22nd Floor, Chicago, IL 60611 USA.
EM kbilimoria@facs.org
NR 27
TC 10
Z9 10
U1 1
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1091-255X
J9 J GASTROINTEST SURG
JI J. Gastrointest. Surg.
PD OCT
PY 2010
VL 14
IS 10
BP 1600
EP 1606
DI 10.1007/s11605-010-1316-6
PG 7
WC Gastroenterology & Hepatology; Surgery
SC Gastroenterology & Hepatology; Surgery
GA 653OM
UT WOS:000282101500025
PM 20824379
ER
PT J
AU Bradley, KA
Williams, EC
AF Bradley, Katharine A.
Williams, Emily C.
TI What Can General Medical Providers Do for Hospitalized Patients with
Alcohol Dependence After Discharge?
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Editorial Material
ID RANDOMIZED-CONTROLLED-TRIAL; DOUBLE-BLIND; BRIEF INTERVENTION; USE
DISORDERS; DRINKING; OUTCOMES; CARE; INDIVIDUALS; TOPIRAMATE; SEEKING
C1 [Bradley, Katharine A.; Williams, Emily C.] Vet Affairs Puget Sound Hlth Care Syst, HSR&D, Seattle, WA 98101 USA.
[Bradley, Katharine A.] Vet Affairs Puget Sound Hlth Care Syst, Gen Med Serv, Seattle, WA 98101 USA.
[Bradley, Katharine A.; Williams, Emily C.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98101 USA.
[Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA USA.
RP Bradley, KA (reprint author), Vet Affairs Puget Sound Hlth Care Syst, HSR&D, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA.
EM Katharine.bradley@va.gov
NR 31
TC 2
Z9 2
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD OCT
PY 2010
VL 25
IS 10
BP 1000
EP 1002
DI 10.1007/s11606-010-1441-7
PG 3
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 652ZN
UT WOS:000282051400003
PM 20632122
ER
PT J
AU Vig, EK
Starks, H
Taylor, JS
Hopley, EK
Fryer-Edwards, K
AF Vig, Elizabeth K.
Starks, Helene
Taylor, Janelle S.
Hopley, Elizabeth K.
Fryer-Edwards, Kelly
TI Why Don't Patients Enroll in Hospice? Can We Do Anything About It?
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE hospice; decision making; terminally ill; terminal care
ID MENTAL STATUS QUESTIONNAIRE; OF-LIFE-CARE; TREATMENT PREFERENCES;
BARRIERS; END; DISCUSSIONS; ELIGIBILITY; PHYSICIANS; AMERICAN; SERVICES
AB United States hospice organizations aim to provide quality, patient-centered end-of-life care to patients in the last 6 months of life, yet some of these organizations observe that some hospice-eligible patients who are referred to hospice do not initially enroll.
Primary objective: To identify reasons that eligible patients do not enroll in hospice (phase 1). Secondary objective: To identify strategies used by hospice providers to address these reasons (phase 2).
Semi-structured interviews analyzed using content analysis.
In phase 1, we interviewed 30 patients and/or family members of patients who had a hospice admissions visit, but who did not enroll. In phase 2, we interviewed 19 hospice staff and national experts.
In phase 1, we asked participants to describe the patient's illness, the hospice referral, and why they had not enrolled. We performed a content analysis to characterize their reasons for not enrolling in hospice. In phase 2, we enrolled hospice admissions staff and hospice experts. We asked them to describe how they would respond to each reason (from phase 1) during an admissions visit with a potential new hospice patient. We identified key phrases, and summarized their recommendations.
Reasons that patients hadn't enrolled fell into three broad categories: patient/family perceptions (e.g., "not ready"), hospice specific issues (e.g., variable definitions of hospice-eligible patients), and systems issues (e.g., concerns about continuity of care). Hospice staff/experts had encountered each reason, and offered strategies at the individual and organizational level for responding.
In hopes of increasing hospice enrollment among hospice-eligible patients, non-hospice and hospice clinicians may want to adopt some of the strategies used by hospice staff/experts for talking about hospice with patients/families and may want to familiarize themselves with the differences between hospice organizations in their area. Hospices may want to reconsider their admission policies and procedures in light of patients' and families' perceptions and concerns.
C1 [Vig, Elizabeth K.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr & Extended Care, Seattle, WA 98108 USA.
[Vig, Elizabeth K.; Hopley, Elizabeth K.] Univ Washington, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA.
[Starks, Helene; Fryer-Edwards, Kelly] Univ Washington, Dept Bioeth & Humanities, Seattle, WA 98195 USA.
[Starks, Helene] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Taylor, Janelle S.] Univ Washington, Dept Anthropol, Seattle, WA 98195 USA.
RP Vig, EK (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Geriatr & Extended Care, 1660 S Columbian Way S-182 Eth, Seattle, WA 98108 USA.
EM vigster@u.washington.edu
FU National Institute on Aging [K23 AG19635]
FX This work was supported by the National Institute on Aging (K23
AG19635). This material was presented in part at the Annual Assembly of
the American Academy of Hospice and Palliative Medicine in New Orleans,
LA in January 2005, and at the Annual Meeting of the Society of General
Internal Medicine in Toronto, Ontario, Canada in April 2007.
NR 42
TC 23
Z9 23
U1 3
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD OCT
PY 2010
VL 25
IS 10
BP 1009
EP 1019
DI 10.1007/s11606-010-1423-9
PG 11
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 652ZN
UT WOS:000282051400005
PM 20535577
ER
PT J
AU Williams, BA
McGuire, J
Lindsay, RG
Baillargeon, J
Cenzer, IS
Lee, SJ
Kushel, M
AF Williams, Brie A.
McGuire, James
Lindsay, Rebecca G.
Baillargeon, Jacques
Cenzer, Irena Stijacic
Lee, Sei J.
Kushel, Margot
TI Coming Home: Health Status and Homelessness Risk of Older Pre-release
Prisoners
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE health status; homelessness risk; pre-release prisoners; older prisoners
ID FORMER INMATES; ADULTS; POPULATION; DEATH; CARE; SYSTEM; BOSTON; ILL
AB Older adults comprise an increasing proportion of the prison and homeless populations. While older age is associated with adverse post-release health events and incarceration is a risk factor for homelessness, the health status and homelessness risk of older pre-release prisoners are unknown. Moreover, most post-release services are geared towards veterans; it is unknown whether the needs of non-veterans differ from those of veterans.
To assess health status and risk of homelessness of older pre-release prisoners, and to compare veterans with non-veterans.
Cross-sectional study of 360 prisoners (a parts per thousand yen55 years of age) within 2 years of release from prison using data from the 2004 Survey of Inmates in State and Federal Correctional Facilities.
Veteran status, health status (based on self-report), and risk of homelessness (homelessness before arrest).
Mean age was 61 years; 93.8% were men and 56.5% were white. Nearly 40% were veterans, of whom 77.2% reported likely VA service eligibility. Veterans were more likely to be white and to have obtained a high school diploma or GED. Overall, 79.1% reported a medical condition and 13.6% reported a serious mental illness. There was little difference in health status between veterans and non-veterans. Although 1 in 12 prisoners reported a risk factor for homelessness, the risk factors did not differ according to veteran status.
Older pre-release prisoners had a high burden of medical and mental illness and were at risk for post-release homelessness regardless of veteran status. Reentry programs linking pre-release older prisoners to medical and psychiatric services and to homelessness prevention programs are needed for both veterans and non-veterans.
C1 [Williams, Brie A.; Cenzer, Irena Stijacic; Lee, Sei J.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94121 USA.
[Williams, Brie A.; Cenzer, Irena Stijacic; Lee, Sei J.] San Francisco VA Med Ctr, Hlth Serv Res & Dev Res Enhancement Award Program, San Francisco, CA USA.
[McGuire, James] Vet Hlth Adm, Healthcare Reentry Vet Program, Durham, NC USA.
[Lindsay, Rebecca G.] Univ Calif San Francisco, San Francisco Sch Med, San Francisco, CA 94121 USA.
[Lindsay, Rebecca G.] Univ Calif Berkeley, Berkeley, CA 94720 USA.
[Baillargeon, Jacques] Univ Texas Med Branch, Dept Prevent Med & Community Hlth, Galveston, TX USA.
[Baillargeon, Jacques] Univ Texas Med Branch, Div Epidemiol, Galveston, TX USA.
[Kushel, Margot] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA.
RP Williams, BA (reprint author), Univ Calif San Francisco, Div Geriatr, 4150 Clement St,Box 181-G, San Francisco, CA 94121 USA.
EM brie.williams@ucsf.edu; mkushel@medsfgh.ucsf.edu
FU Brookdale Leadership in Aging Fellowship; National Institute of Aging
[K23AG033102]; Hellman Family Award; UCSF
FX Brie Williams was supported in part by the Brookdale Leadership in Aging
Fellowship, the National Institute of Aging (K23AG033102), and the
Hellman Family Award. Rebecca Lindsay was supported by the UCSF Dean's
Summer Fellowship. Drs. Williams, McGuire, and Lee are employees of the
Department of Veterans Affairs. The opinions expressed in this
manuscript may not represent those of the VA.
NR 58
TC 23
Z9 23
U1 2
U2 19
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD OCT
PY 2010
VL 25
IS 10
BP 1038
EP 1044
DI 10.1007/s11606-010-1416-8
PG 7
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 652ZN
UT WOS:000282051400009
PM 20532651
ER
PT J
AU Lynch, CP
Gebregziabher, M
Echols, C
Gilbert, GE
Zhao, YM
Egede, LE
AF Lynch, Cheryl P.
Gebregziabher, Mulugeta
Echols, Carrae
Gilbert, Gregory E.
Zhao, Yumin
Egede, Leonard E.
TI Racial Disparities in All-Cause Mortality Among Veterans with Type 2
Diabetes
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE race; all-cause mortality; diabetes; veterans
ID HEALTH-CARE-SYSTEM; US ADULTS; CARDIOVASCULAR-DISEASE; ADMINISTRATIVE
DATA; MEN; METAANALYSIS; HEMOGLOBIN; MELLITUS; OUTCOMES; BLACKS
AB Racial differences in mortality among veterans with diabetes are less well characterized than those in the general population.
To examine racial differences in all-cause mortality in a large sample of veterans with diabetes.
A retrospective cohort.
Participants comprised 8,812 veterans with type 2 diabetes.
The main outcome measure was time to death. The main predictor was race/ethnicity. Other risk factors (or covariates) included age, gender, marital status, employment, glycosylated hemoglobin (HgbA1c), and several ICD-9 coded physical and mental health comorbidities.
Average follow-up was 4.5 years; 64% of veterans were non-Hispanic whites (NHW), 97% male, and 84% at least 50 years old. The overall mortality rate was 15% and was significantly lower for non-Hispanic blacks (NHB). Baseline HgbA1c values also differed for NHW (mean = 7.05) and NHB (mean = 7.65) (p < 0.001). In sequentially-built models NHB race was associated with a lower risk of mortality with HR ranging 0.80-0.92. After adjusting for all significant covariates, the risk of mortality remained lower for NHB (HR = 0.84, 95% CI: 0.75, 0.94). Increased mortality risk was associated with age, not being employed or retired, poor glycemic control, cancer, Coronary Heart Disease (CHD), and anxiety disorder; while a lower risk was associated with being female and ever being married.
The risk of death among NHB veterans with diabetes remained significantly lower than that of NHW after controlling for important confounding variables. Future studies in the VA need to examine detailed contributions of patient, provider and system-level factors on racial differences in mortality in adults with diabetes, especially if the findings of this study are replicated at other sites or using national VA data.
C1 [Egede, Leonard E.] Med Univ S Carolina, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA.
[Lynch, Cheryl P.; Zhao, Yumin; Egede, Leonard E.] Med Univ S Carolina, Div Gen Internal Med, Ctr Hlth Dispar Res, Charleston, SC 29425 USA.
[Gebregziabher, Mulugeta] Med Univ S Carolina, Div Biostat & Epidemiol, Charleston, SC 29425 USA.
RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Ralph H Johnson Vet Affairs Med Ctr, 135 Rutledge Ave,Room 280H,POB 250593, Charleston, SC 29425 USA.
EM Egedel@musc.edu
RI Gilbert, Gregory/C-7735-2016
OI Gilbert, Gregory/0000-0003-0879-5496; Gebregziabher,
Mulugeta/0000-0002-4826-481X
FU VA HSRD [REA 08-261]
FX This study represents work supported by the use of resources at the VA
HSR&D Funded Center for Disease Prevention and Health Interventions for
Diverse Populations (REA 08-261) in Charleston, SC.
NR 33
TC 8
Z9 8
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD OCT
PY 2010
VL 25
IS 10
BP 1051
EP 1056
DI 10.1007/s11606-010-1405-y
PG 6
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 652ZN
UT WOS:000282051400011
PM 20532659
ER
PT J
AU Bishop, TF
Federman, AD
Ross, JS
AF Bishop, Tara F.
Federman, Alex D.
Ross, Joseph S.
TI Laboratory Test Ordering at Physician Offices with and without On-Site
Laboratories
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE physician self-referral; reimbursement/incentive;
laboratories/economics; laboratories/utilization
ID REFERRING PHYSICIANS; OWNERSHIP; CHARGES; GROWTH; COSTS
AB Physician self-referral, ordering a test or procedure or referring to a facility in which a physician has a financial interest, has been associated with increased utilization of health care services.
To examine the association between on-site laboratories and laboratory test ordering among visits to group-practice physicians.
Cross-sectional study using data from the 2005 and 2006 National Ambulatory Medical Care Surveys.
Visits by adults to non-federally-funded, non-hospital-based group practices. Primary analyses focused on visits to physician owners; secondary analyses focused on visits to non-owners.
Ordering of five laboratory tests: complete blood count (CBC), electrolytes, glycoslyated hemoglobin A1c (HbA1c), cholesterol, and prostate-specific antigen (PSA).
There were 19,163 visits to group-practice owners with 51.9% to a practice with an on-site laboratory. Visits to primary care physicians were more likely to be to a practice with an on-site laboratory when compared with visits to specialists (64.4% vs. 34.0%, p < 0.001). Among visits to specialist group owners, all five tests were ordered more often if there was an on-site laboratory, even after accounting for patient and practice characteristics: CBC: adjusted odds ratio[OR] = 8.01, 95% Confidence Interval [CI], 5.00-12.82, p < 0.001; electrolytes: aOR = 3.51, 95% CI, 1.93-6.40, p < 0.001; HbA1c: aOR = 4.91, 95% CI, 1.75-13.78, p = 0.003; cholesterol: aOR = 3.32, 95% CI, 1.85-5.93, p < 0.001; and PSA: aOR = 3.84, 95% CI, 1.93-7.65, p < 0.001. This association was not found among visits to primary care physician owners and all practice non-owners (both primary care and specialists). The estimated excess spending on these five tests by specialist owners with on-site laboratories was $75 million per 100 million visits.
In a nationally representative sample of visits to physician-owned group practices, specialist owners with on-site laboratories were more likely to order five common laboratory tests, potentially resulting in millions in excess healthcare spending.
C1 [Bishop, Tara F.; Federman, Alex D.] Mt Sinai Sch Med, Div Gen Internal Med, New York, NY 10029 USA.
[Ross, Joseph S.] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY 10029 USA.
[Ross, Joseph S.] James J Peters Vet Adm Med Ctr, HSR&D Res Enhancement Award Program, Bronx, NY USA.
[Ross, Joseph S.] James J Peters Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA.
RP Bishop, TF (reprint author), Mt Sinai Sch Med, Div Gen Internal Med, 1 Gustave L Levy Pl,Box 1087, New York, NY 10029 USA.
EM taraf@alum.mit.edu
FU National Institute on Aging [K08 AG032886, K23 AG028955-01]; American
Federation of Aging Research
FX This project was not directly supported with external funds. Drs. Ross
and Federman are both currently supported by the National Institute on
Aging (K08 AG032886 and K23 AG028955-01, respectively) and by the
American Federation of Aging Research through the Paul B. Beeson Career
Development Award Program.
NR 23
TC 6
Z9 6
U1 1
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD OCT
PY 2010
VL 25
IS 10
BP 1057
EP 1063
DI 10.1007/s11606-010-1409-7
PG 7
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 652ZN
UT WOS:000282051400012
PM 20532656
ER
PT J
AU Henderson, MC
Dhaliwal, G
Jones, SR
Culbertson, C
Bowen, JL
AF Henderson, Mark C.
Dhaliwal, Gurpreet
Jones, Stephen R.
Culbertson, Charles
Bowen, Judith L.
TI RE: Doing What Comes Naturally (vol 25, pg 84, 2010)
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Correction
C1 [Henderson, Mark C.; Bowen, Judith L.] UC Davis Med Ctr, Dept Internal Med, Sacramento, CA USA.
[Dhaliwal, Gurpreet] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Dhaliwal, Gurpreet] San Francisco VA Med Ctr, San Francisco, CA USA.
[Jones, Stephen R.; Culbertson, Charles] Legacy Hlth Syst, Dept Internal Med, Portland, OR USA.
[Jones, Stephen R.; Culbertson, Charles] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
RP Henderson, MC (reprint author), UC Davis Med Ctr, Dept Internal Med, Sacramento, CA USA.
EM MCHenderson@ucdavis.edu
NR 1
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD OCT
PY 2010
VL 25
IS 10
BP 1138
EP 1138
DI 10.1007/s11606-010-1339-4
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 652ZN
UT WOS:000282051400028
ER
PT J
AU Trombetta, JM
Bradshaw, AD
AF Trombetta, Jessica M.
Bradshaw, Amy D.
TI SPARC/Osteonectin Functions to Maintain Homeostasis of the Collagenous
Extracellular Matrix in the Periodontal Ligament
SO JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
LA English
DT Article
DE SPARC; periodontal ligament; collagen; BM-40; osteonectin; extracellular
matrix; matricellular; periodontium; aging
ID ALVEOLAR BONE LOSS; MATRICELLULAR PROTEIN; SECRETED PROTEIN;
CELL-MATRIX; SPARC; FIBROBLASTS; DISEASE; TISSUES; FIBRILLOGENESIS;
REGENERATION
AB Expression of secreted protein acidic and rich in cysteine (SPARC)/osteonectin, a collagen-binding matricellular protein, is frequently associated with tissues with high rates of collagen turnover, such as bone. In the oral cavity, expression of SPARC/osteonectin has been localized to the periodontal ligament (PDL), a collagen-rich tissue with high rates of collagen turnover. The PDL is critical for tooth position within the alveolar bone and for absorbing forces generated by chewing. To characterize the function of SPARC/osteonectin in PDL, SPARC/osteonectin expression in murine PDL was evaluated by immunochemistry at 1, 4, 6, and >18 months. Highest levels of SPARC/osteonectin were detected at 1 and >18 months, with decreased levels associated with adult (4-6 months) PDL. To determine whether the absence of SPARC/osteonectin expression influenced cellular and fibrillar collagen content in PDL, PDL of SPARC-null mice was evaluated using histological stains and compared with that of wild-type (WT). Our results demonstrated decreased numbers of nuclei in PDL of SPARC-null mice at 1 month. In addition, decreased collagen volume fractions were found at 1 and >18 months and decreases in thick collagen fiber volume fraction were detected at 4, 6, and >18 months in SPARC-null PDL. The greatest differences in cell number and in collagen content between SPARC-null and WT PDL coincided with ages at which levels of SPARC/osteonectin expression were highest in WT PDL, at 1 and >18 months. These results support the hypothesis that SPARC/osteonectin is critical in the control of tissue collagen content and indicate that SPARC/osteonectin is necessary for PDL homeostasis. (J Histochem Cytochem 58:871-879, 2010)
C1 [Bradshaw, Amy D.] Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Craniofacial Biol, Charleston, SC 29425 USA.
[Trombetta, Jessica M.; Bradshaw, Amy D.] Med Univ S Carolina, Div Cardiol, Dept Med, Charleston, SC 29425 USA.
[Bradshaw, Amy D.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA.
RP Bradshaw, AD (reprint author), Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Craniofacial Biol, 114 Doughty St,Rm 223, Charleston, SC 29425 USA.
EM bradshad@musc.edu
RI Self, Casey/B-6871-2011
FU National Institutes of Health [T32 DE-017551, 2P20RR017696, HL-094517];
Veterans Administration
FX This work was supported by National Institutes of Health Grants T32
DE-017551 (to JMT), 2P20RR017696 (to ADB), and HL-094517 (to ADB) and by
a Veterans Administration Merit Award (to ADB).
NR 33
TC 18
Z9 19
U1 0
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0022-1554
J9 J HISTOCHEM CYTOCHEM
JI J. Histochem. Cytochem.
PD OCT
PY 2010
VL 58
IS 10
BP 871
EP 879
DI 10.1369/jhc.2010.956144
PG 9
WC Cell Biology
SC Cell Biology
GA 652BK
UT WOS:000281975100002
PM 20566756
ER
PT J
AU Crum-Cianflone, NF
Hullsiek, KH
Roediger, M
Ganesan, A
Patel, S
Landrum, ML
Weintrob, A
Agan, BK
Medina, S
Rahkola, J
Hale, BR
Janoff, EN
AF Crum-Cianflone, Nancy F.
Hullsiek, Katherine Huppler
Roediger, Mollie
Ganesan, Anuradha
Patel, Sugat
Landrum, Michael L.
Weintrob, Amy
Agan, Brian K.
Medina, Sheila
Rahkola, Jeremy
Hale, Braden R.
Janoff, Edward N.
CA Infect Dis Clinical Res Program HI
TI A Randomized Clinical Trial Comparing Revaccination with Pneumococcal
Conjugate Vaccine to Polysaccharide Vaccine among HIV-Infected Adults
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS-INFECTION; PROTECTIVE ANTIBODY-RESPONSES; CELL
TRANSPLANTATION; DOUBLE-BLIND; DISEASE; CHILDREN; IMMUNOGENICITY;
IMMUNIZATION; BACTEREMIA; TYPE-1
AB Background. The risk of pneumococcal disease persists, and antibody responses to revaccination with the 23-valent polysaccharide vaccine (PPV) are low among human immunodeficiency virus (HIV)-infected adults. We determined whether revaccination with the 7-valent pneumococcal conjugate vaccine (PCV) would enhance these responses.
Methods. In a randomized clinical trial, we compared the immunogenicity of revaccination with PCV (np) or PPV (n = 73) among HIV-infected adults (median CD4 cell count, 533 cells/mm(3)) who had been vaccinated with PPV 3-8 years earlier. HIV-uninfected adults (n = 25) without prior pneumococcal vaccination received 1 dose of PCV. A positive response was defined as a >= 2-fold increase (from baseline to day 60) in capsule-specific immunoglobulin G, with a postvaccination level >= 1000 ng/mL for at least 2 of the 4 serotypes.
Results. HIV-infected persons demonstrated a higher frequency of positive antibody responses to PCV than to PPV (57% vs 36%) (Pp. 004) and greater mean changes in the immunoglobulin G concentration from baseline to day 60 for serotypes 4, 9V, and 19F (P<.05, for all), but not for serotype 14. However, by day 180, both outcomes were similar. Responses to PCV were greater in frequency and magnitude for all serotypes in HIV-uninfected adults, compared with those in HIV-infected adults.
Conclusions. Among persons with HIV infection, revaccination with PCV was only transiently more immunogenic than PPV, and responses were inferior to those in HIV-uninfected subjects with primary vaccination. Pneumococcal vaccines with more robust and sustained immunogenicity are needed for HIV-infected adults.
C1 [Crum-Cianflone, Nancy F.] USN, San Diego Med Ctr, Clin Invest Dept KCA, Infect Dis Clin, San Diego, CA 92134 USA.
[Crum-Cianflone, Nancy F.; Hullsiek, Katherine Huppler; Roediger, Mollie; Ganesan, Anuradha; Landrum, Michael L.; Weintrob, Amy; Agan, Brian K.; Medina, Sheila; Hale, Braden R.] Uniformed Serv Univ Hlth Sci, Infect Dis Clin Res Program, Bethesda, MD 20814 USA.
[Ganesan, Anuradha] USN, Med Ctr, Infect Dis Clin, Bethesda, MD 20814 USA.
[Hullsiek, Katherine Huppler; Roediger, Mollie] Univ Minnesota, Div Biostat, Minneapolis, MN USA.
[Patel, Sugat] USN, Med Ctr Portsmouth, Infect Dis Clin, Portsmouth, VA USA.
[Landrum, Michael L.] San Antonio Mil Med Ctr, Infect Dis Serv, San Antonio, TX USA.
[Weintrob, Amy] Walter Reed Army Med Ctr, Infect Dis Clin, Washington, DC 20307 USA.
[Rahkola, Jeremy; Janoff, Edward N.] Univ Colorado, Div Infect Dis, Mucosal & Vaccine Res Program Colorado, Denver, CO 80202 USA.
[Janoff, Edward N.] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Crum-Cianflone, NF (reprint author), USN, San Diego Med Ctr, Clin Invest Dept KCA, Infect Dis Clin, 34800 Bob Wilson Dr,Ste 5, San Diego, CA 92134 USA.
EM nancy.crum@med.navy.mil; braden.hale@med.navy.mil
OI Polis, Michael/0000-0002-9151-2268; Agan, Brian/0000-0002-5114-1669
FU NIAID NIH HHS [Y01 AI005072, Y1-AI-5072]
NR 35
TC 42
Z9 44
U1 0
U2 1
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD OCT 1
PY 2010
VL 202
IS 7
BP 1114
EP 1125
DI 10.1086/656147
PG 12
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 651FR
UT WOS:000281912100016
PM 20795819
ER
PT J
AU Pang, YG
Greisler, HP
AF Pang, Yonggang
Greisler, Howard P.
TI Using a Type 1 Collagen-Based System to Understand Cell-Scaffold
Interactions and to Deliver Chimeric Collagen-Binding Growth Factors for
Vascular Tissue Engineering
SO JOURNAL OF INVESTIGATIVE MEDICINE
LA English
DT Article
DE type 1 collagen; growth factor; confocal microscopy; local delivery;
scaffold
ID SMOOTH-MUSCLE-CELLS; DRUG-DELIVERY; BLOOD-VESSEL; IN-VITRO; MIGRATION;
MATRIX; REORGANIZATION; CONSTRUCTION; BIOMATERIALS; VEHICLE
AB Vascular tissue engineering should provide more biocompatible and functional conduits than synthetic vascular grafts. Understanding cell-scaffold interactions and developing an efficient delivery system for growth factors and other biomolecules to control the signaling between the cells and the scaffold are fundamental issues in a wide range of tissue engineering research fields. Type 1 collagen is a natural scaffold extensively used in vascular tissue engineering and is a widely used vehicle in biomolecule delivery. In this article, we will discuss type 1 collagen as a vascular tissue engineering scaffold, describe strategies for elucidating the interaction between cells and type 1 collagen scaffolds using various imaging techniques, and summarize our work on the development of a chimeric collagen-binding growth factor-based local delivery system.
C1 [Pang, Yonggang; Greisler, Howard P.] Loyola Univ, Dept Surg, Med Ctr, Maywood, IL 60153 USA.
[Pang, Yonggang; Greisler, Howard P.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA.
[Pang, Yonggang] IIT, Dept Biomed Engn, Chicago, IL 60616 USA.
[Greisler, Howard P.] Loyola Univ, Med Ctr, Dept Cell Biol Neurobiol & Anat, Maywood, IL 60153 USA.
RP Greisler, HP (reprint author), Loyola Univ, Dept Surg, Med Ctr, 2160 S 1st Ave, Maywood, IL 60153 USA.
EM hgreisl@lumc.edu
RI Pang, Yonggang/B-2843-2011
FU NIH [R01-HL41272]; Department of Veteran's Affairs; Chicago Association
for Research and Education in Science; National Center for Research
Resources [R13 RR023236]
FX Supported by grants from the NIH R01-HL41272 (HPG), Department of
Veteran's Affairs (HPG), and Chicago Association for Research and
Education in Science (HPG). This symposium was supported in part by a
grant from the National Center for Research Resources (R13 RR023236).
NR 33
TC 6
Z9 11
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1081-5589
J9 J INVEST MED
JI J. Invest. Med.
PD OCT
PY 2010
VL 58
IS 7
BP 845
EP 848
PG 4
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA 653WD
UT WOS:000282127700010
PM 20683346
ER
PT J
AU Kaczorowski, DJ
Afrazi, A
Scott, MJ
Kwak, JH
Gill, R
Edmonds, RD
Liu, YJ
Fan, J
Billiar, TR
AF Kaczorowski, David J.
Afrazi, Amin
Scott, Melanie J.
Kwak, Joon H.
Gill, Roop
Edmonds, Rebecca D.
Liu, Yujian
Fan, Jie
Billiar, Timothy R.
TI Pivotal Advance: The pattern recognition receptor ligands
lipopolysaccharide and polyinosine-polycytidylic acid stimulate factor B
synthesis by the macrophage through distinct but overlapping mechanisms
SO JOURNAL OF LEUKOCYTE BIOLOGY
LA English
DT Article
DE Toll-like receptors; complement; inflammation
ID TOLL-LIKE RECEPTORS; INNATE IMMUNITY; ENDOTHELIAL-CELLS; MOUSE
MACROPHAGES; 3RD COMPONENT; EARLY EVENTS; IFN-GAMMA; TNF-ALPHA;
COMPLEMENT; PATHWAY
AB TLRs and complement are critical to the host response in sepsis, trauma, and ischemia/reperfusion. We hypothesize that TLR stimulation leads to synthesis and release of complement components by macrophages, an important source of extrahepatic complement. RAW264.7 macrophages or peritoneal macrophages from WT and TLR4-, TLR3-, TRIF-, or MyD88-deficient mice were cultured under standard conditions. In some experiments, cells were pretreated with inhibitors of MAPKs or a NF-kappa B inhibitor. Cells were stimulated with TLR ligands at known stimulatory concentrations. Intratracheal and i.p. injections were also performed in mice. RT-PCR, Western blotting, and immunocytochemistry were used for analysis. Using a RT-PCR-based panel, we demonstrate that of 18 complement components tested, factor B of the alternative pathway is the most robustly up-regulated complement component in macrophages in response to LPS. This up-regulation results in release of factor B into the media. Upregulation of factor B by LPS is dependent on TLR4, TRIF, JNK, and NF-kappa B. A screen of other TLR ligands demonstrated that stimulation with poly I: C (dsRNA analog) also results in up-regulation of factor B, which is dependent on JNK and NF-kappa B but independent of TLR3 and TRIF. Up-regulation of factor B is also observed after intratracheal and i.p. injection of LPS or poly I: C in vivo. PRR stimulation profoundly influences production and release of factor B by macrophages. Understanding the mechanisms of PRR-mediated complement production may lead to strategies aimed at preventing tissue damage in diverse settings, including sepsis, trauma, and ischemia/reperfusion. J. Leukoc. Biol. 88: 609-618; 2010.
C1 [Kaczorowski, David J.; Afrazi, Amin; Scott, Melanie J.; Kwak, Joon H.; Gill, Roop; Edmonds, Rebecca D.; Liu, Yujian; Fan, Jie; Billiar, Timothy R.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15213 USA.
[Liu, Yujian; Fan, Jie] Vet Affairs Pittsburgh Healthcare Syst, Surg Res, Pittsburgh, PA USA.
RP Billiar, TR (reprint author), Univ Pittsburgh, Presbyterian Univ Hosp, Dept Surg F1281, Med Ctr, POB 7533,200 Lothrop St, Pittsburgh, PA 15213 USA.
EM billiartr@upmc.edu
FU National Institutes of Health [P50-GM-53789, R01-HL-079669]; VA Merit
Award; American College of Surgeons
FX This work was supported by National Institutes of Health grant
P50-GM-53789 (T. R. B. and J.F.), National Institutes of Health grant
R01-HL-079669 (J. F.), and VA Merit Award (J. F.). D. J. K. and R. D. E.
are each recipients of American College of Surgeons Resident Research
Scholarships. We thank Meihua Bo, Hong Liao, and Danielle Reiser for
technical assistance.
NR 33
TC 14
Z9 14
U1 0
U2 3
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0741-5400
J9 J LEUKOCYTE BIOL
JI J. Leukoc. Biol.
PD OCT
PY 2010
VL 88
IS 4
BP 609
EP 618
DI 10.1189/jlb.0809588
PG 10
WC Cell Biology; Hematology; Immunology
SC Cell Biology; Hematology; Immunology
GA 692ZW
UT WOS:000285195400002
PM 20413727
ER
PT J
AU Hammad, SM
Pierce, JS
Soodavar, F
Smith, KJ
Al Gadban, MM
Rembiesa, B
Klein, RL
Hannun, YA
Bielawski, J
Bielawska, A
AF Hammad, Samar M.
Pierce, Jason S.
Soodavar, Farzan
Smith, Kent J.
Al Gadban, Mohammed M.
Rembiesa, Barbara
Klein, Richard L.
Hannun, Yusuf A.
Bielawski, Jacek
Bielawska, Alicja
TI Blood sphingolipidomics in healthy humans: impact of sample collection
methodology
SO JOURNAL OF LIPID RESEARCH
LA English
DT Article
DE sphingolipid metabolome; sphingomyelin; ceramide; sphingosine
ID TANDEM MASS-SPECTROMETRY; APOLIPOPROTEIN-A-I; SPHINGOSINE 1-PHOSPHATE;
DENSITY-LIPOPROTEIN; SIGNAL-TRANSDUCTION; SPHINGOSINE-1-PHOSPHATE;
CERAMIDE; PLASMA; METABOLISM; CELLS
AB We used a HPLC-MS/MS methodology for determination of a basic metabolomic profile (18:1,18:0 sphingoid backbone, C(14)-C(26) N-acyl part) of "normal" sphingolipid levels in human serum and plasma. Blood was collected from healthy males and nonpregnant females under fasting and nonfasting conditions with and without anticoagulants. Sphingolipids analyzed included sphingoid bases, sphingosine and dihydrosphingosine, their 1-phosphates (S1P and dhS1P), molecular species (C(n)-) of ceramide (Cer), sphingomyelin (SM), hexosylceramide (HexCer), lactosylceramide (LacCer), and Cer 1-phosphate (Cer1P). SM, LacCer, HexCer, Cer, and Cer1P constituted 87.7, 5.8, 3.4, 2.8, and 0.15% of total sphingolipids, respectively. The abundant circulating SM was C(16)-SM (64.0 mu M), and it increased with fasting (100 mu M). The abundant LacCer was C(16)-LacCer (10.0 mu M) and the abundant HexCer was C(24)-HexCer (2.5 mu M). The abundant Cer, C(24)-Cer (4.0 mu M), was not influenced by fasting; however, levels of C(16)-C(20) Cers were decreased in response to fasting. S1P levels were higher in serum than plasma (0.68 mu M vs. 0.32 mu M). We also determined levels of sphingoid bases and SM species in isolated lipoprotein classes. HDL(3) was the major carrier of S1P, dhS1P, and Sph, and LDL was the major carrier of Cer and dhSph. Per particle, VLDL contained the highest levels of SM, Cer, and S1P. HPLC-MS/MS should provide a tool for clinical testing of circulating bioactive sphingolipids in human blood.-Hammad, S. M., J. S. Pierce, F. Soodavar, K. J. Smith, M. M. Al Gadban, B. Rembiesa, R. L. Klein, Y. A. Hannun, J. Bielawski, and A. Bielawska. Blood sphingolipidomics in healthy humans:impact of sample collection methodology. J. Lipid Res. 2010. 51: 3074-3087.
C1 [Hammad, Samar M.; Soodavar, Farzan; Smith, Kent J.; Al Gadban, Mohammed M.] Med Univ S Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA.
[Pierce, Jason S.; Rembiesa, Barbara; Hannun, Yusuf A.; Bielawski, Jacek; Bielawska, Alicja] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
[Klein, Richard L.] Med Univ S Carolina, Div Endocrinol, Dept Med, Charleston, SC 29425 USA.
[Klein, Richard L.] Ralph H Johnson Vet Affairs Med Ctr, Dept Vet Affairs, Charleston, SC 29401 USA.
RP Hammad, SM (reprint author), Med Univ S Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA.
EM hammadsm@musc.edu
FU National Institutes of Health [HL-079274, R0-1HL079274-04S1];
Southeastern Clinical and Translational Research Institute; South
Carolina Center of Biomedical Research Excellence (COBRE) in Lipidomics
and Pathobiology; National Center for Research Resources (NCCR) [P20
RR17677, CO6RR018823]; Department of Veterans Affairs
FX This work was supported by National Institutes of Health Grants
HL-079274 and R0-1HL079274-04S1 (American Recovery and Reinvestment
Act), The Southeastern Clinical and Translational Research Institute to
S.M.H., the South Carolina Center of Biomedical Research Excellence
(COBRE) in Lipidomics and Pathobiology (P20 RR17677 from National Center
for Research Resources (NCCR) to S.M.H., Y.A.H., A.B., and J.B., the
Department of Veterans Affairs Merit Review Program to R.L.K., and NCRR
Grant CO6RR018823 for the facility. Its contents are solely the
responsibility of the authors and do not necessarily represent the
official views of the National Institutes of Health or other granting
agencies.
NR 56
TC 98
Z9 99
U1 4
U2 22
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0022-2275
J9 J LIPID RES
JI J. Lipid Res.
PD OCT
PY 2010
VL 51
IS 10
BP 3074
EP 3087
DI 10.1194/jlr.D008532
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 649GS
UT WOS:000281756800021
PM 20660127
ER
PT J
AU Walker, RH
Davies, G
Koch, RJ
Haack, AK
Moore, C
Meshul, CK
AF Walker, Ruth H.
Davies, Georgia
Koch, Rick J.
Haack, Andrew K.
Moore, Cynthia
Meshul, Charles K.
TI Effects of Zona Incerta Lesions on Striatal Neurochemistry and
Behavioral Asymmetry in 6-Hydroxydopamine-Lesioned Rats
SO JOURNAL OF NEUROSCIENCE RESEARCH
LA English
DT Article
DE microdialysis; 6-hydroxydopamine; glutamate; dopamine
ID DEEP BRAIN-STIMULATION; SUBTHALAMIC NUCLEUS LESIONS; HIGH-FREQUENCY
STIMULATION; ACTIVE ELECTRODE CONTACTS; MEDIAL FRONTAL-CORTEX;
PARKINSONS-DISEASE; BASAL GANGLIA; DOPAMINE NEUROTRANSMISSION;
NIGROSTRIATAL PATHWAY; 6-OHDA LESION
AB Analysis of optimal sites for neurosurgical interventions in patients with Parkinson's disease (PD) suggests that significant clinical benefits may be achieved by involvement of the zona incerta (ZI). Unilateral electrolytic ZI lesions were made in intact and ipsilaterally 6-hydroxydopamine (60HDA)-lesioned rats. Extracellular levels of glutamate, dopamine, and its metabolites in the ipsilateral striatum of awake rats were measured by using microdialysis, and tests of behavioral asymmetry were performed. In intact rats, ZI lesions had no effect on striatal extracellular glutamate or absolute levels of dopamine or metabolites, but dopamine metabolism decreased. After ZI lesions, contralateral forepaw use decreased in the forepaw adjusting steps test, but there was no change in response to vibrissa stimulation or cylinder exploration. There was no development of rotational asymmetry with amphetamine. In 60HDA-lesioned rats, striatal extracellular glutamate levels were elevated compared with controls. ZI lesions reduced the increased levels of glutamate back to normal values. ZI lesions reduced dopamine and homovanillic acid levels and showed a trend toward a decrease in dopamine metabolism. 60HDA-lesioned rats demonstrated the expected asymmetry of motor behaviors. After ZI lesions, ipsilateral turns following amphetamine injection were reduced, and there was a trend toward improved symmetry of forepaw use as determined with the forepaw adjusting steps test. There was no change in forepaw use with vibrissa stimulation or cylinder exploration. These data indicate that lesions of the ZI can affect striatal neurochemistry and motor behavioral asymmetry and suggest potential mechanisms by which ZI lesions may improve symptoms in PD. (C) 2010 Wiley-Liss, Inc.
C1 [Walker, Ruth H.; Davies, Georgia; Koch, Rick J.] James J Peters Vet Affairs Med Ctr, Dept Neurol, Bronx, NY 10468 USA.
[Walker, Ruth H.] Mt Sinai Sch Med, Dept Neurol, New York, NY USA.
[Haack, Andrew K.; Moore, Cynthia; Meshul, Charles K.] Oregon Hlth & Sci Univ, Vet Affairs Med Ctr, Neurocytol Lab, Res Serv, Portland, OR 97201 USA.
[Meshul, Charles K.] Oregon Hlth & Sci Univ, Dept Behav Neurosci & Pathol, Portland, OR 97201 USA.
RP Walker, RH (reprint author), James J Peters Vet Affairs Med Ctr, Dept Neurol 127, Bronx, NY 10468 USA.
EM ruth.walker@mssm.edu
FU U.S. Department of Veterans Affairs
FX Contract grant sponsor: U.S. Department of Veterans Affairs (to R.H.W.,
C.K.M.).
NR 52
TC 3
Z9 3
U1 0
U2 3
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0360-4012
J9 J NEUROSCI RES
JI J. Neurosci. Res.
PD OCT
PY 2010
VL 88
IS 13
BP 2964
EP 2975
DI 10.1002/jnr.22446
PG 12
WC Neurosciences
SC Neurosciences & Neurology
GA 642OK
UT WOS:000281225100019
PM 20544826
ER
PT J
AU Vo, NV
Sowa, GA
Kang, JD
Seidel, C
Studer, RK
AF Vo, Nam V.
Sowa, Gwendolyn A.
Kang, James D.
Seidel, Christopher
Studer, Rebecca K.
TI Prostaglandin E2 and Prostaglandin F2 alpha Differentially Modulate
Matrix Metabolism of Human Nucleus Pulposus Cells
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE nucleus pulposus cells; prostaglandins; PGE(2); PGF(2 alpha);
intervertebral disc matrix
ID INTERVERTEBRAL DISC DEGENERATION; NECROSIS-FACTOR-ALPHA; HUMAN ARTICULAR
CHONDROCYTES; IN-VITRO; NITRIC-OXIDE; EXPRESSION; CYCLOOXYGENASE-2;
ACTIVATION; HERNIATION; MEDIATORS
AB Prostaglandin (PG) actions on disc metabolism are unclear even though certain PGs are highly expressed by disc cells under inflammatory conditions and nonsteroidal anti-inflammatory drugs (NSAI Ds) are frequently used to block PG production to treat back pain. Hence this study aimed to (1) quantify gene expression of arachiclonic acid cascade components responsible for PG synthesis and (2) examine the effects of key PGs on disc matrix homeostasis Microarray analysis revealed that inflammatory stress increases expression of synthases and receptors for prostaglandin E2 (PGE(2)) and prostaglandin F2 alpha (PGF(2 alpha)), resulting in elevated PGE(2) and PGF(2 alpha) production in conditioned mocha of disc cells PGE(2) diminished disc cell proteoglycan synthesis, in a dose-dependent manner Semiquantitative RT-PGR revealed differential effects of PGE(2) and PGF(2 alpha) on disc cell expression of key matrix structural genes. aggrecan, versican, collagens type I and II PGE(2) and PGF(2 alpha) also decreased message for the anabolic factor, IGF-1 PGE2 decreased mRNA expression for the anti-catabolic factor TIMP-1 while PGF(2 alpha) increased mRNAs for catabolic factors MMP-1 and MMP-3 Thus, PGE(2) and PGF(2 alpha) may have an overall negative impact on disc matrix homeostasis, and the use of NSAIDs may impact disc metabolism is well as treat back pain (C) 2010 Orthopaedic Research Society Published by Wiley Periodicals, Inc J Orthop Res 28 1259-1266, 2010
C1 [Vo, Nam V.; Sowa, Gwendolyn A.; Kang, James D.; Studer, Rebecca K.] Univ Pittsburgh, Sch Med, Ferguson Lab Orthopaed Res, Pittsburgh, PA 15260 USA.
[Vo, Nam V.; Sowa, Gwendolyn A.; Kang, James D.; Studer, Rebecca K.] Univ Pittsburgh, Sch Med, Dept Orthopaed Surg, Pittsburgh, PA 15261 USA.
[Sowa, Gwendolyn A.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA 15261 USA.
[Studer, Rebecca K.] Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15261 USA.
[Seidel, Christopher] Stowers Inst Med Res, Kansas City, MO USA.
RP Vo, NV (reprint author), Univ Pittsburgh, Sch Med, Ferguson Lab Orthopaed Res, Pittsburgh, PA 15260 USA.
FU VA Rehabilitation Research and Development [B4-3894RA]; Pittsburgh
Foundation; Ferguson Laboratory
FX This work supported by VA Rehabilitation Research and Development Grant
B4-3894RA and the Albert B. Ferguson, Jr, MD Orthopaedic Fund of the
Pittsburgh Foundation. The work was approved by the IRB of the
University of Pittsburgh The authors gratefully acknowledge the
technical support of SuLan Huang, Elizabeth Christian, Geoffrey
Sirockman, and the staff of the Ferguson Laboratory
NR 40
TC 8
Z9 9
U1 0
U2 2
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0736-0266
J9 J ORTHOP RES
JI J. Orthop. Res.
PD OCT
PY 2010
VL 28
IS 10
BP 1259
EP 1266
DI 10.1002/joi.21157
PG 8
WC Orthopedics
SC Orthopedics
GA 647YQ
UT WOS:000281657200001
PM 20839316
ER
PT J
AU Rabow, MW
Pantilat, SZ
Kerr, K
Enguidanos, S
Ferrell, B
Goldstein, R
Pankratz, C
Picchi, T
Rosenfeld, KE
Stone, SC
AF Rabow, Michael W.
Pantilat, Steven Z.
Kerr, Kathleen
Enguidanos, Susan
Ferrell, Bruce
Goldstein, Rebecca
Pankratz, Charles
Picchi, Tina
Rosenfeld, Kenneth E.
Stone, Susan C.
TI The Intersection of Need and Opportunity: Assessing and Capitalizing on
Opportunities To Expand Hospital-Based Palliative Care Services
SO JOURNAL OF PALLIATIVE MEDICINE
LA English
DT Article
ID METRICS CONSENSUS RECOMMENDATIONS; UNITED-STATES; PROGRAMS; LIFE
AB Background: To develop and grow most effectively, palliative care programs must consider how best to align their mission with that of their institution. To do so, programs must identify their institutional mission and needs, what palliative care can do to address those needs given available resources, and how the palliative care team can measure and document its value. Such an approach encourages the palliative care team to think strategically and to see themselves and their service as a solution to issues and concerns within the institution. It also helps a palliative care team decide which, among many potential opportunities and possible initiatives, is the one most likely to be supported by the institution and have a recognized and significant impact.
Subjects and Methods: We present five case studies to demonstrate how successful programs identify and address institutional needs to create opportunities for palliative care program growth. These case studies can serve as models for other programs seeking to develop or expand their palliative care services.
C1 [Rabow, Michael W.; Pantilat, Steven Z.; Kerr, Kathleen] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
[Enguidanos, Susan] Univ So Calif, Leonard Davis Sch Gerontol, Los Angeles, CA USA.
[Ferrell, Bruce] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA.
[Goldstein, Rebecca] Downey Med Ctr Kaiser Downey, Dept Med, Downey, CA USA.
[Pankratz, Charles] St Johns Reg Med Ctr, Dept Med, Oxnard, CA USA.
[Pankratz, Charles] St Johns Pleasant Valley Hosp, Dept Med, Camarillo, CA USA.
[Picchi, Tina] St Johns Reg Med Ctr, Dept Spiritual Care, Oxnard, CA USA.
[Picchi, Tina] St Johns Pleasant Valley Hosp, Dept Spiritual Care, Camarillo, CA USA.
[Rosenfeld, Kenneth E.] VA Greater Angeles Hlth Syst, Dept Med, Los Angeles, CA USA.
[Stone, Susan C.] Univ So Calif, Dept Emergency Med, Los Angeles, CA USA.
RP Rabow, MW (reprint author), Univ Calif San Francisco, Dept Med, 1701 Divisadero St 500, San Francisco, CA 94143 USA.
EM mrabow@medicine.ucsf.edu
OI Enguidanos, Susan/0000-0002-5112-288X
FU Archstone Foundation Hospital-Based Palliative Care Service Innovation
Initiative
FX All authors have received support from the Archstone Foundation
Hospital-Based Palliative Care Service Innovation Initiative.
NR 13
TC 4
Z9 5
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-6218
J9 J PALLIAT MED
JI J. Palliat. Med.
PD OCT
PY 2010
VL 13
IS 10
BP 1205
EP 1210
DI 10.1089/jpm.2010.0112
PG 6
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 664IP
UT WOS:000282953900008
PM 20831435
ER
PT J
AU Raval, MV
Sturgeon, C
Bentrem, DJ
Elaraj, DM
Stewart, AK
Winchester, DJ
Ko, CY
Reynolds, M
AF Raval, Mehul V.
Sturgeon, Cord
Bentrem, David J.
Elaraj, Dina M.
Stewart, Andrew K.
Winchester, David J.
Ko, Clifford Y.
Reynolds, Marleta
TI Influence of lymph node metastases on survival in pediatric medullary
thyroid cancer
SO JOURNAL OF PEDIATRIC SURGERY
LA English
DT Article
DE Medullary thyroid cancer; Thyroid neoplasm; Pediatric surgery;
Pathology; Epidemiology; National cancer data base
ID MULTIPLE ENDOCRINE NEOPLASIA; STANDARDIZED SURGICAL APPROACH; 80
CONSECUTIVE PATIENTS; DATA-BASE REPORT; CLINICAL-CHARACTERISTICS;
CONTEMPORARY SERIES; PROGNOSTIC-FACTORS; RET PROTOONCOGENE; BIOCHEMICAL
CURE; UNITED-STATES
AB Purpose: Lymph node metastases (LNM) from medullary thyroid cancer (MTC) are common in adults and are a poor prognostic factor. Less is known about LNM in children, who often have hereditary forms of MTC. Guidelines recommend prophylactic thyroidectomy in early childhood, but randomized prospective trials are not feasible. We hypothesized that LNM is associated with poor prognosis in children.
Methods: Patients with MTC 21 years or younger from the National Cancer Data Base from 1985 to 2007 were studied. Multivariable logistic regression was used to identify factors associated with lymph node evaluation. Survival was estimated using the Kaplan-Meier method.
Results: Of 430 patients, 276 (64.2%) had nodal evaluation with LNM present in 121 (28.1%). Older patients, those with tumors larger than 2 cm, and those with involved margins were more likely to have LNM (all P < .05). Patients undergoing total thyroidectomy, those with involved margins, and older patients were more likely to undergo lymph node evaluation after controlling for patient, tumor, and hospital factors (all P < .05). Over time an increasing number of patients with MTC have undergone total thyroidectomy. Patients 16 to 21 years of age had lower 10-year overall survival compared to patients 0 to 15 years old (88.7% vs 98.1%, P = .005). Lymph node metastases were also associated with decreased 10-year overall survival (84.4% vs 100%, P < .001).
Conclusions: In pediatric MTC, LNM predict poorer overall survival. Adequate lymph node assessment can provide valuable prognostic information for the pediatric MTC patient. Lymph node assessment should be considered for older pediatric patients undergoing surgery for hereditary MTC or biopsy confirmed MTC. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Raval, Mehul V.; Stewart, Andrew K.; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Canc Programs, Chicago, IL 60611 USA.
[Raval, Mehul V.; Reynolds, Marleta] Childrens Mem Hosp, Div Pediat Surg, Chicago, IL 60614 USA.
[Raval, Mehul V.; Sturgeon, Cord; Bentrem, David J.; Elaraj, Dina M.] Northwestern Univ, Feinberg Sch Med, Div Gastrointestinal & Oncol Surg, Dept Surg, Chicago, IL 60611 USA.
[Bentrem, David J.] Jesse Brown VA Med Ctr, Chicago, IL 60612 USA.
[Winchester, David J.] NorthShore Univ HealthSyst, Dept Surg, Evanston, IL 60201 USA.
[Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90073 USA.
[Ko, Clifford Y.] VA Greater Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
RP Raval, MV (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, Canc Programs, Chicago, IL 60611 USA.
EM m-raval@md.northwestern.edu
OI Raval, Mehul/0000-0002-1527-2661
FU John Gray Research Fellowship; Daniel F and Ada L Rice Foundation;
Department of Veterans Affairs, Veterans Health Administration, Health
Services Research and Development Service; American College of Surgeons,
Commission on Cancer; American Cancer Society
FX MVR participates in the American College of Surgeons Clinical Scholars
in Residence Program and is supported by the John Gray Research
Fellowship and the Daniel F and Ada L Rice Foundation. DJB is supported
by a career development award from the Department of Veterans Affairs,
Veterans Health Administration, Health Services Research and Development
Service. The National Cancer Data Base is supported by the American
College of Surgeons, Commission on Cancer, and the American Cancer
Society.
NR 42
TC 9
Z9 9
U1 0
U2 4
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0022-3468
J9 J PEDIATR SURG
JI J. Pediatr. Surg.
PD OCT
PY 2010
VL 45
IS 10
BP 1947
EP 1954
DI 10.1016/j.jpedsurg.2010.06.013
PG 8
WC Pediatrics; Surgery
SC Pediatrics; Surgery
GA 656WC
UT WOS:000282370800010
PM 20920711
ER
PT J
AU Ross, JH
Hardy, DC
Schuyler, CA
Slate, EH
Mize, TW
Huang, Y
AF Ross, J. H.
Hardy, D. C.
Schuyler, C. A.
Slate, E. H.
Mize, T. W.
Huang, Y.
TI Expression of periodontal interleukin-6 protein is increased across
patients with neither periodontal disease nor diabetes, patients with
periodontal disease alone and patients with both diseases
SO JOURNAL OF PERIODONTAL RESEARCH
LA English
DT Article
DE periodontal diseases; diabetes mellitus; interleukin-6 (IL-6); gene
expression
ID MATRIX METALLOPROTEINASE-1 EXPRESSION; CARDIOVASCULAR-DISEASE; IL-6;
LIPOPOLYSACCHARIDE; INFLAMMATION; TISSUE; RISK; POLYMORPHISMS;
FIBROBLASTS; MELLITUS
AB Background and Objective:
Epidemiological studies have established that patients with diabetes have an increased prevalence and severity of periodontal disease. Interleukin (IL)-6, a multifunctional cytokine, plays a role in the tissue inflammation that characterizes periodontal disease. Our recent study has shown a trend of increase in periodontal IL-6 expression at the mRNA level across patients with neither periodontal disease nor diabetes, patients with periodontal disease alone and patients with both diseases. However, the periodontal IL-6 expression at the protein level in these patients has not been investigated.
Material and Methods:
Periodontal tissue specimens were collected from eight patients without periodontal disease and diabetes (group 1), from 17 patients with periodontal disease alone (group 2) and from 10 patients with both periodontal disease and diabetes (group 3). The frozen sections were prepared from these tissue specimens and IL-6 protein expression was detected and quantified.
Results:
The nonparametric Kruskal-Wallis test showed that the difference in IL-6 protein levels among the three groups was statistically significant (p = 0.035). Nonparametric analysis using the Jonckheere-Terpstra test showed a tendency of increase in periodontal IL-6 protein levels across group 1 to group 2 to group 3 (p = 0.006). Parametric analysis of variance (ANOVA) on IL-6 protein levels showed that neither age nor gender significantly affected the difference of IL-6 levels among the groups.
Conclusion:
Periodontal IL-6 expression at the protein level is increased across patients with neither periodontal disease nor diabetes, patients with periodontal disease alone and patients with both diseases.
C1 [Huang, Y.] Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29403 USA.
[Ross, J. H.; Hardy, D. C.; Mize, T. W.] Med Univ S Carolina, Div Periodont, Dept Stomatol, Coll Dent Med, Charleston, SC 29403 USA.
[Slate, E. H.] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29403 USA.
[Huang, Y.] Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Dept Med, Charleston, SC 29403 USA.
RP Huang, Y (reprint author), Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, 114 Doughty St, Charleston, SC 29403 USA.
EM huangyan@musc.edu
FU NIH [DE16353]; Department of Veterans Affairs; COBRE, NIH [P20RR017696]
FX This work was supported by NIH grant DE16353 and by a Merit Review Grant
from the Department of Veterans Affairs (to Y.H.). This work was also
partially supported by COBRE grant P20RR017696 from NIH.
NR 29
TC 11
Z9 12
U1 0
U2 5
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0022-3484
J9 J PERIODONTAL RES
JI J. Periodont. Res.
PD OCT
PY 2010
VL 45
IS 5
BP 688
EP 694
DI 10.1111/j.1600-0765.2010.01286.x
PG 7
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 641PR
UT WOS:000281141500013
PM 20682019
ER
PT J
AU Petri, M
Naqibuddin, M
Carson, KA
Wallace, DJ
Weisman, MH
Holliday, SL
Sampedro, M
Padilla, PA
Brey, RL
AF Petri, Michelle
Naqibuddin, Mohammad
Carson, Kathryn A.
Wallace, Daniel J.
Weisman, Michael H.
Holliday, Stephen L.
Sampedro, Margaret
Padilla, Patricia A.
Brey, Robin L.
TI Depression and Cognitive Impairment in Newly Diagnosed Systemic Lupus
Erythematosus
SO JOURNAL OF RHEUMATOLOGY
LA English
DT Article
DE SYSTEMIC LUPUS ERYTHEMATOSUS; DEPRESSION; AUTOMATED NEUROPSYCHOLOGICAL
ASSESSMENT METRICS
ID RATING-SCALE; DISEASE-ACTIVITY; PSYCHIATRIC-SYMPTOMS; REVISED CRITERIA;
FATIGUE; CLASSIFICATION; SCHIZOPHRENICS; ANTIBODIES; DISORDERS; MOOD
AB Objective. Cognitive impairment is present in 80% of patients with systemic lupus erythematosus (SLE) 10 years after diagnosis. The natural history of cognitive dysfunction in newly diagnosed SLE is unknown. We examined the association of depression and cognitive performance in newly diagnosed SLE.
Methods. A multicenter cohort of 111 patients newly diagnosed (within 9 months) with SLE underwent cognitive function testing using an automated battery [Automated Neuropsychological Assessment Metrics (ANAM)] with 9 subtests. Depression was measured using the Calgary Depression Scale (CDS).
Results. The patient cohort was 97.3% female, 55.9% white, 15.3% African American, 20.7% Hispanic, mean age 37.8 years, mean education 15.2 years. CDS score ranged from 0 to 18 (mean 5.0 +/- 4.6). CDS score did not differ by age, sex, ethnicity, or prednisone dose. Higher Krupp Fatigue Severity Scale scores and presence of fibromyalgia were significantly associated with higher CDS score (p < 0.001 p = 0.006, respectively). Depressed patients, defined by a CDS score > 6, had significantly poorer performance on 5 ANAM throughput measures: code substitution (p = 0.03), continuous performance (p = 0.02), matching-to-sample (p = 0.04), simple reaction time (p = 0.02), and the Sternberg memory test (p = 0.04). Adjusting for age, sex, ethnicity, education, and prednisone dose, a higher CDS score remained significantly associated with poorer performance on 3 measures, but the association was slightly attenuated for code substitution and matching-to-sample. Depression was not associated with mathematical or spatial processing.
Conclusion. Depression, a modifiable risk factor, is associated with significantly poorer function in several cognitive domains in patients newly diagnosed with SLE. Treatment of depression when the CDS score is greater than 6 may improve cognitive functioning and should be further studied. (First Release July 15 2010; J Rheumatol 2010;37:2032-8; doi:10.3899/jrheum.091366)
C1 [Petri, Michelle; Naqibuddin, Mohammad; Carson, Kathryn A.; Sampedro, Margaret] Johns Hopkins Univ, Baltimore, MD 21205 USA.
[Wallace, Daniel J.; Weisman, Michael H.] Univ Calif Los Angeles, David Geffen Sch Med, Cedars Sinai Med Ctr, Los Angeles, CA 90095 USA.
[Holliday, Stephen L.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Padilla, Patricia A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
RP Petri, M (reprint author), Johns Hopkins Univ, 1830 E Monument St,Suite 7500, Baltimore, MD 21205 USA.
EM mpetri@jhmi.edu
FU NIH [RO1 AR049125]; Johns Hopkins Institute for Clinical and
Translational Research [UL1 RR 025005]; University of Texas Health
Science Center at San Antonio Frederic C. Bartter General Clinical
Research Center [MO1-RR-01346]
FX The Brain CONECTIONS study is supported by NIH RO1 AR049125 and the
Johns Hopkins Institute for Clinical and Translational Research (K.
Carson is supported by UL1 RR 025005) and the University of Texas Health
Science Center at San Antonio Frederic C. Bartter General Clinical
Research Center (MOI-RR-01346).
NR 46
TC 35
Z9 37
U1 3
U2 8
PU J RHEUMATOL PUBL CO
PI TORONTO
PA 920 YONGE ST, SUITE 115, TORONTO, ONTARIO M4W 3C7, CANADA
SN 0315-162X
J9 J RHEUMATOL
JI J. Rheumatol.
PD OCT
PY 2010
VL 37
IS 10
BP 2032
EP 2038
DI 10.3899/jrheum.091366
PG 7
WC Rheumatology
SC Rheumatology
GA 663DY
UT WOS:000282864400010
PM 20634244
ER
PT J
AU Emmons, RR
Garber, CE
Cirnigliaro, CM
Moyer, JM
Kirshblum, SC
Galea, MD
Spungen, AM
Bauman, WA
AF Emmons, Racine R.
Garber, Carol Ewing
Cirnigliaro, Christopher M.
Moyer, Jeremy M.
Kirshblum, Steven C.
Galea, Marinella D.
Spungen, Ann M.
Bauman, William A.
TI The Influence of Visceral Fat on the Postprandial Lipemic Response in
Men with Paraplegia
SO JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION
LA English
DT Article
DE spinal cord injury; postprandial lipemia; triglyceride clearance;
abdominal adiposity
ID DENSITY-LIPOPROTEIN CHOLESTEROL; SPINAL-CORD-INJURY; METABOLIC SYNDROME;
ULTRASONOGRAPHY; ATHEROGENESIS; OBESITY; PLASMA
AB Background: Postprandial lipemia (PPL) is associated with vascular dysfunction and may be an etiologic factor in the progression of atherogenic cardiovascular disease.
Objective: In 10 men with paraplegia and 10 able-bodied men, the magnitude of the PPL responses and the relationship of abdominal adiposity and the PPL responses were determined.
Methods: Anthropometrics, dual energy x-ray absorptiometry, and abdominal ultrasonography were performed to determine visceral fat and total body fat. A fasting lipid profile was performed. A high-fat milkshake (1.3 g fat/kg body mass) was administered with serum collected at baseline and at 2, 4, and 6 hours after the test meal for subsequent measurement of triglyceride. The triglyceride response was determined by the area under the triglyceride curve.
Results: No significant differences were noted between the groups in fasting lipid values or in measures of visceral fat. Total body fat tended to be higher in men with paraplegia than in able-bodied men (34.9 +/- 10.0 vs. 27.3 +/- 6.7%, p = 0.07). No significant difference between the groups was observed in triglyceride response. In men with paraplegia, visceral fat was strongly associated with the triglyceride (r = 0.8, p = 0.005), fasting low-density lipoprotein (r = 0.66, p = 0.04), and triglyceride responses (r = 0.80, p = 0.005); a significant relationship was not found between fasting high-density lipoprotein and any measure of adiposity. In men with paraplegia, triglyceride response was positively related to all measures of abdominal adiposity.
Conclusion: Visceral abdominal fat was related to delayed triglyceride clearance after a fat load, which may contribute to coronary heart disease (CHD) risk and progression of vascular disease in men with paraplegia.
C1 [Emmons, Racine R.; Cirnigliaro, Christopher M.; Moyer, Jeremy M.; Galea, Marinella D.; Spungen, Ann M.; Bauman, William A.] US Dept Vet Affairs, Rehabil Res & Dev Ctr Excellence Med Consequences, James J Peters VA Med Ctr, Bronx, NY USA.
[Emmons, Racine R.; Garber, Carol Ewing] Columbia Univ Teachers Coll, New York, NY 10027 USA.
[Spungen, Ann M.; Bauman, William A.] Mt Sinai Sch Med, Dept Med, New York, NY USA.
[Spungen, Ann M.; Bauman, William A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA.
[Kirshblum, Steven C.] Kessler Inst Rehabil, W Orange, NJ USA.
[Kirshblum, Steven C.] Univ Med Sch New Jersey, Dept Phys Med & Rehabil, Newark, NJ USA.
RP Emmons, RR (reprint author), James J Peters VA Med Ctr, VA Ctr Excellence Med Consequences SCI, Room 1E-02,130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM racine.emmons@va.gov
OI Garber, Carol/0000-0002-1268-576X
FU Department of Veterans Affairs Rehabilitation Research and Development
Center of Excellence for the Medical Consequences of Spinal Cord Injury
[B4162C]
FX This work was supported by the Department of Veterans Affairs
Rehabilitation Research and Development Center of Excellence for the
Medical Consequences of Spinal Cord Injury (#B4162C).
NR 25
TC 8
Z9 8
U1 0
U2 2
PU AMER COLLEGE NUTRITION
PI CLEARWATER
PA 300 SOUTH DUNCAN AVENUE, STE 225, CLEARWATER, FL 33755 USA
SN 0731-5724
J9 J AM COLL NUTR
JI J. Am. Coll. Nutr.
PD OCT
PY 2010
VL 29
IS 5
BP 476
EP 481
PG 6
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 716YX
UT WOS:000287010500005
PM 21504974
ER
PT J
AU Hempton, TJ
Dominici, JT
AF Hempton, Timothy J.
Dominici, John T.
TI MORE ABOUT CROWN LENGTHENING Response
SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION
LA English
DT Letter
C1 [Hempton, Timothy J.] Tufts Univ, Sch Dent Med, Boston, MA 02111 USA.
[Dominici, John T.] Michael E DeBakey Vet Adm Med Ctr, Prosthodont Residency Programs, Houston, TX USA.
RP Hempton, TJ (reprint author), Tufts Univ, Sch Dent Med, Boston, MA 02111 USA.
NR 8
TC 0
Z9 0
U1 0
U2 0
PU AMER DENTAL ASSOC
PI CHICAGO
PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA
SN 0002-8177
J9 J AM DENT ASSOC
JI J. Am. Dent. Assoc.
PD OCT
PY 2010
VL 141
IS 10
BP 1184
EP 1185
PG 2
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 662XJ
UT WOS:000282847300009
ER
PT J
AU Duru, OK
Sarkisian, CA
Leng, M
Mangione, CM
AF Duru, O. Kenrik
Sarkisian, Catherine A.
Leng, Mei
Mangione, Carol M.
TI Sisters in Motion: A Randomized Controlled Trial of a Faith-Based
Physical Activity Intervention
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE physical activity; African Americans; randomized controlled trial
ID AMERICAN-HEART-ASSOCIATION; OLDER-ADULTS; CARDIOVASCULAR-DISEASE;
HEALTH-PROMOTION; PUBLIC-HEALTH; WOMEN; EXERCISE; OUTCOMES;
RECOMMENDATIONS; QUESTIONNAIRE
AB OBJECTIVES
To evaluate a faith-based intervention (Sisters in Motion) intended to increase walking in older, sedentary African-American women.
DESIGN
Randomized controlled trial using within-church randomization.
SETTING
Three Los Angeles churches.
PARTICIPANTS
Sixty-two African-American women aged 60 and older who reported being active less than 30 minutes three times per week and walked less than 35,000 steps per week as measured using a baseline pedometer reading.
INTERVENTION
Intervention participants received a multicomponent curriculum including scripture readings, prayer, goal-setting, a community resource guide, and walking competitions. Intervention and control participants both participated in physical activity sessions.
MEASUREMENTS
The primary outcome was change in weekly steps walked as measured using the pedometer. Secondary outcomes included change in systolic blood pressure (SBP). Outcomes were assessed at baseline and 6 months after the intervention.
RESULTS
Eighty-five percent of participants attended at least six of eight sessions. Intervention participants averaged 12,727 steps per week at baseline, compared with 13,089 steps in controls. Mean baseline SBP was 156 mmHg for intervention participants and 147 mmHg for controls (P=.10). At 6 months, intervention participants had increased their weekly steps by 9,883 on average, compared with an increase of 2,426 for controls (P=.02); SBP decreased on average by 12.5 mmHg in intervention participants and only 1.5 mmHg in controls (P=.007).
CONCLUSION
The Sisters in Motion intervention led to an increase in walking and a decrease in SBP at 6 months. This is the first randomized controlled trial of a faith-based physical activity program to increase physical activity in older African-American women and represents an attractive approach to stimulate lifestyle change in this population.
C1 [Duru, O. Kenrik; Leng, Mei; Mangione, Carol M.] Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Sarkisian, Catherine A.] Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, Div Geriatr, Los Angeles, CA 90095 USA.
RP Duru, OK (reprint author), Univ Calif Los Angeles, Div Gen Internal Med Hlth Serv Res, 911 Broxton Plaza, Los Angeles, CA 90095 USA.
EM kduru@mednet.ucla.edu
FU Institute for Health and Aging, University of California at San
Francisco; National Institutes on Aging [R01-AG024460]; University of
California at Los Angeles (UCLA); National Center on Minority Health and
Health Disparities [2P20MD000182]; UCLA Center for Health Improvement of
Minority Elderly/Resource Centers for Minority Aging Research; National
Institutes of Health (NIH); NIA [2P30AG021684, P30-AG028748]
FX The authors gratefully acknowledge the support and guidance of Dr. Anita
Stewart and Ms. Dawn Gillis at the Institute for Health and Aging,
University of California at San Francisco, who graciously shared their
experiences in developing a physical activity intervention for
translation in a community setting. The authors would also like to thank
the program participants in the Seniors in Motion for Health program in
San Francisco, sponsored by the Network for Elders.; This study was
funded by a diversity supplement awarded to Dr. Duru by the National
Institutes on Aging, to Grant R01-AG024460. Dr. Mangione was supported
by University of California at Los Angeles (UCLA)/Drew Project Export,
National Center on Minority Health and Health Disparities, 2P20MD000182.
Dr. Mangione also received support from the UCLA Center for Health
Improvement of Minority Elderly/Resource Centers for Minority Aging
Research, National Institutes of Health (NIH), NIA under Grant
2P30AG021684. Drs. Duru, Sarkisian, and Mangione received support from
the UCLA Older Americans Independence Center, NIH, NIA Grant
P30-AG028748. The content of this article does not necessarily represent
the official views of the NIA or the NIH.
NR 33
TC 43
Z9 44
U1 2
U2 10
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD OCT
PY 2010
VL 58
IS 10
BP 1863
EP 1869
DI 10.1111/j.1532-5415.2010.03082.x
PG 7
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 660ZP
UT WOS:000282690900005
PM 20929464
ER
PT J
AU Palmer, RF
Royall, DR
AF Palmer, Raymond F.
Royall, Donald R.
TI Missing Data? Plan on It!
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE missing data methods; statistical measurement; longitudinal aging
research
ID FREEDOM HOUSE; MODELS; GROWTH; ASSOCIATION; DECLINE; TIME
AB Longitudinal study designs are indispensable for investigating age-related functional change. There now are well-established methods for addressing missing data in longitudinal studies. Modern missing data methods not only minimize most problems associated with missing data (e.g., loss of power and biased parameter estimates), but also have valuable new applications such as research designs that use modern missing data methods to plan missing data purposefully. This article describes two state-of-the-art statistical methodologies for addressing missing data in longitudinal research: growth curve analysis and statistical measurement models. How the purposeful planning of missing data in research designs can reduce subject burden, improve data quality and statistical power, and manage costs is then described. J Am Geriatr Soc 58:S343-S348, 2010.
C1 [Palmer, Raymond F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, San Antonio, TX 78284 USA.
[Palmer, Raymond F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biostat & Epidemiol, San Antonio, TX 78284 USA.
[Royall, Donald R.] S Texas Vet Hlth Syst, Audie L Murphy Div, Geriatr Res Educ & Clin Ctr, Dept Family & Community Med, San Antonio, TX USA.
[Royall, Donald R.] S Texas Vet Hlth Syst, Audie L Murphy Div, Geriatr Res Educ & Clin Ctr, Dept Psychiat, San Antonio, TX USA.
[Royall, Donald R.] S Texas Vet Hlth Syst, Audie L Murphy Div, Geriatr Res Educ & Clin Ctr, Dept Med, San Antonio, TX USA.
[Royall, Donald R.] S Texas Vet Hlth Syst, Audie L Murphy Div, Geriatr Res Educ & Clin Ctr, Dept Pharmacol, San Antonio, TX USA.
RP Palmer, RF (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.
EM palmerr@uthscsa.edu
FU Robert Wood Johnson Foundation
FX This paper is based on a January 2009 conference on Longitudinal Studies
in Aging, Boca Raton, Florida, supported by a grant from the Robert Wood
Johnson Foundation.
NR 44
TC 23
Z9 24
U1 0
U2 12
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD OCT
PY 2010
VL 58
SU 2
BP S343
EP S348
DI 10.1111/j.1532-5415.2010.03053.x
PG 6
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 656YJ
UT WOS:000282376700014
PM 21029065
ER
PT J
AU Hanlon, JT
Perera, S
Sevick, MA
Rodriguez, KL
Jaffe, EJ
AF Hanlon, Joseph T.
Perera, Subashan
Sevick, Mary Ann
Rodriguez, Keri L.
Jaffe, Emily J.
TI Pain and Its Treatment in Older Nursing Home Hospice/Palliative Care
Residents
SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION
LA English
DT Article
DE Aged; nursing home; hospice; palliative care; analgesics
ID NONMALIGNANT PAIN; HOSPICE CARE; MANAGEMENT; ADULTS
AB Objectives: The objectives of this study were to determine the prevalence of pain, describe its treatment, and determine factors associated with any pain in older residents assigned to a hospice specialty unit bed or receiving services from a hospice/palliative care/end-of-life special program in US nursing homes.
Design: Cross-sectional study of data from the 2004 National Nursing Home Survey.
Setting: The setting was 1174 US nursing homes.
Participants: Participants were 303 sampled patients, 65 years or older, representing 33,413 individuals receiving hospice/palliative care.
Measurements: Facility staff was asked if, in the past 7 days, the resident had reported or shown evidence of pain. Medication use data were derived from medication administration records. Information about demographics and health status was derived from Minimum Data Set records.
Results: Cancer was the primary diagnosis in only 11.4% of residents. Overall 36.6% had any pain in the previous week. Among those with any pain, 86.4% received some analgesic; specifically, 65.5% received opioids, whereas 31.7% received acetaminophen. Those with any pain compared with those without pain had shorter lengths of stay in hospice/palliative care (mean 123 days versus 161 days, P < .01), were more likely to be incontinent of bowel (76.2%, versus 60.3%, P < 0.01) and bladder (84.5% versus 71.8%, P = 0.01).
Conclusions: Pain symptoms were present in more than one third of older nursing home hospice/palliative care residents despite the use of opioids in two thirds of those who had reported or shown evidence of any pain. Additional future studies are needed to improve the management of pain in older residents receiving hospice/palliative care in US nursing homes. (J Am Med Dir Assoc 2010; 11: 579-583)
C1 [Hanlon, Joseph T.; Perera, Subashan] Univ Pittsburgh, Dept Med, Div Geriatr Med, Sch Med, Pittsburgh, PA 15213 USA.
[Hanlon, Joseph T.] Univ Pittsburgh, Dept Pharm & Therapeut, Sch Pharm, Pittsburgh, PA 15213 USA.
[Hanlon, Joseph T.] Univ Pittsburgh, Dept Epidemiol, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA.
[Hanlon, Joseph T.; Sevick, Mary Ann; Rodriguez, Keri L.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA.
[Hanlon, Joseph T.; Sevick, Mary Ann; Rodriguez, Keri L.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Perera, Subashan] Univ Pittsburgh, Dept Biostat, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA.
[Sevick, Mary Ann; Rodriguez, Keri L.; Jaffe, Emily J.] Univ Pittsburgh, Div Gen Internal Med, Dept Med, Sch Med, Pittsburgh, PA 15213 USA.
[Sevick, Mary Ann] Univ Pittsburgh, Dept Behav & Community Hlth Sci, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA.
RP Hanlon, JT (reprint author), Univ Pittsburgh, Dept Med, Div Geriatr Med, Sch Med, Kaufman Med Bldg,Suite 500,3471 5th Ave, Pittsburgh, PA 15213 USA.
EM jth14@pitt.edu
RI Perera, Subashan/D-7603-2014
FU National Institute of Aging [R01AG027017, P30AG024827]; VA Health
Services Research grant [IIR-06-062]
FX This study was supported by National Institute of Aging grants
(R01AG027017; P30AG024827), and a VA Health Services Research grant
(IIR-06-062).
NR 21
TC 16
Z9 18
U1 1
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1525-8610
J9 J AM MED DIR ASSOC
JI J. Am. Med. Dir. Assoc.
PD OCT
PY 2010
VL 11
IS 8
BP 579
EP 583
DI 10.1016/j.jamda.2009.11.014
PG 5
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 669FO
UT WOS:000283333500007
PM 20889094
ER
PT J
AU Jonker, MA
Sano, Y
Hermsen, JL
Lan, JG
Kudsk, KA
AF Jonker, Mark A.
Sano, Yoshifumi
Hermsen, Joshua L.
Lan, Jinggang
Kudsk, Kenneth A.
TI Proinflammatory Cytokine Surge After Injury Stimulates an Airway
Immunoglobulin A Increase
SO JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE
LA English
DT Article; Proceedings Paper
CT Annual Meeting of the Surgical-Infection-Society
CY MAY09, 2009
CL Chicago, IL
SP Surg Infection Soc
DE Pro-inflammatory cytokines; Mucosal immunity; Airway; Injury; Kinetics;
Intraperitoneal
ID TUMOR-NECROSIS-FACTOR; VENTILATOR-ASSOCIATED PNEUMONIA; CRITICALLY-ILL
PATIENTS; EPITHELIAL-CELL LINE; FACTOR-KAPPA-B; NOSOCOMIAL PNEUMONIA;
FACTOR-ALPHA; SECRETORY COMPONENT; TRAUMA PATIENTS; MUCOSAL IMMUNITY
AB Background: Injury stimulates an innate airway IgA response in severely injured patients, which also occurs in mice. Tumor necrosis factor (TNF)-alpha and interleukin (IL)-1 beta stimulate the production of polymeric immunoglobulin receptor, the protein required to transport immunoglobulin A (IgA) to mucosal surfaces. Blockade of TNF-alpha and IL-1 beta eliminates the airway IgA response to injury. IL-6 stimulates differentiation of B cells into IgA-secreting plasma cells at mucosal sites. We investigated the local and systemic kinetics of TNF-alpha, IL-1 beta, and IL-6 after injury in mice. We also hypothesized that injection of exogenous TNF-alpha, IL-1 beta, and IL-6 would replicate the airway IgA response to injury.
Methods: Experiment 1: male Institute of Cancer Research mice were randomized to uninjured controls (n = 8) or to surgical stress with laparotomy and neck incisions, with killing at 1, 2, 3, 5, or 8 hours after injury (n = 8/group). Bronchoalveolar lavage (BAL) and serum levels of TNF-alpha, IL-1 beta, and IL-6 were analyzed by enzyme-linked immunosorbent assay. Experiment 2: male Institute of Cancer Research mice were randomized to uninjured controls (n = 6), injury (surgical stress that was similar to experiment 1 except the peritoneum was left intact, n = 6), or cytokine injection with intraperitoneal injection of recombinant TNF-alpha, IL-1 beta, and IL-6. Animals were killed at 2 hours after injury, and nasal airway lavage and BAL IgA were analyzed by enzyme-linked immunosorbent assay.
Results: Experiment 1: BAL TNF-alpha, IL-1 beta, and IL-6 levels increased in bimodal pattern after injury at 3 hours and 8 hours versus controls (p < 0.05). Serum IL-6 did not increase at 3 hours, but did show a significant increase by 5 hours versus control (p < 0.05). Serum levels of TNF-alpha and IL-1 beta did not change. Experiment 2: both Injury and combination TNF-alpha, IL-1 beta, and IL-6 cytokine injection significantly increased IgA levels in airway lavage (BAL + nasal airway lavage) compared with control (p < 0.01 for both).
Conclusions: Airway levels of TNF-alpha, IL-1 beta, and IL-6 increase in a bimodal pattern after injury with peaks at 3 hours and 8 hours, which do not correspond to serum changes. The peak at 8 hours is consistent with the known increase in airway IgA after injury. Intraperitoneal injection of a combination exogenous TNF-alpha, IL-1 beta, and IL-6 replicates the airway IgA increase after injury. This effect is not seen with individual cytokine injections.
C1 [Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI USA.
[Jonker, Mark A.; Sano, Yoshifumi; Hermsen, Joshua L.; Lan, Jinggang; Kudsk, Kenneth A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Madison, WI USA.
RP Kudsk, KA (reprint author), 600 Highland Ave,H4-736 CSC, Madison, WI 53792 USA.
EM kudsk@surgery.wisc.edu
FU NIGMS NIH HHS [R01 GM53439, R01 GM053439-03, R01 GM053439-06A1, R01
GM053439-13, R01 GM053439-04, R01 GM053439-11, R01 GM053439-10A2, R01
GM053439-05, R01 GM053439-09, R01 GM053439-07, R01 GM053439-12, R01
GM053439, R01 GM053439-02, R01 GM053439-08]
NR 51
TC 5
Z9 5
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0022-5282
J9 J TRAUMA
JI J. Trauma-Injury Infect. Crit. Care
PD OCT
PY 2010
VL 69
IS 4
BP 843
EP 848
DI 10.1097/TA.0b013e3181c45284
PG 6
WC Critical Care Medicine; Surgery
SC General & Internal Medicine; Surgery
GA 664KP
UT WOS:000282959100036
PM 20173656
ER
PT J
AU Kalantar, BS
Hipp, JA
Reitman, CA
Dreiangel, N
Ben-Galim, P
AF Kalantar, Babak S.
Hipp, John A.
Reitman, Charles A.
Dreiangel, Niv
Ben-Galim, Peleg
TI Diagnosis of Unstable Cervical Spine Injuries: Laboratory Support for
the Use of Axial Traction to Diagnose Cervical Spine Instability
SO JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE
LA English
DT Article
DE Cervical spine; Trauma; Instability; Diagnosis; Traction
ID COMPUTED-TOMOGRAPHY SCAN; BLUNT TRAUMA PATIENTS; INTERVERTEBRAL MOTION;
PLAIN RADIOGRAPHY; JACKSON TABLE; DISLOCATIONS; CLEARANCE; PATIENT;
SERIES; HEAD
AB Background: The ability to detect damage to the intervertebral structures is critical in the management of patients after blunt trauma. A practical and inexpensive method to identify severe structural damage not clearly seen on computed tomography would be of benefit. The objective of this study was to assess whether ligamentous injury in the subaxial cervical spine can be reliably detected by analysis of lateral radiographs taken with and without axial traction.
Methods: Twelve fresh, whole, postrigor-mortis cadavers were used for this study. Lateral cervical spine radiographs were obtained during the application of 0 N, 89 N, and 178 N of axial traction applied to the head. Progressive incremental sectioning of posterior structures was then performed at C4 C5 with traction imaging repeated after each intervention. Intervertebral distraction was analyzed using computer-assisted software.
Results: Almost imperceptible intervertebral separation was found when traction was applied to intact spines. In the subaxial cervical spine, the average posterior disc height consistently increased under traction in severely injured spines. The average disc height increase was 14% of the C4 upper endplate width, compared with an average of 2% in the noninjured spines. A change of more than 5% in posterior disc height under traction was above the 95% confidence interval for intact spines, with sensitivity of 83% and specificity of 80%. Applied force of 89 N (20 lb) was sufficient to demonstrate injury. The combination of assessing alignment and distraction under traction increased both the sensitivity and specificity to nearly 100%.
Conclusion: This study supports further clinical investigations to determine whether low-level axial traction may be a useful adjunct for detecting unstable subaxial cervical spine injuries in an acute setting.
C1 [Hipp, John A.] Baylor Coll Med, Dept Orthoped Surg, Houston, TX 77030 USA.
Michael E DeBakey Vet Adm Med Ctr, Spine Res Lab, Houston, TX USA.
RP Hipp, JA (reprint author), Baylor Coll Med, Dept Orthoped Surg, 6620 Main St,11th Floor, Houston, TX 77030 USA.
EM jhipp@bcm.edu
NR 34
TC 1
Z9 1
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0022-5282
J9 J TRAUMA
JI J. Trauma-Injury Infect. Crit. Care
PD OCT
PY 2010
VL 69
IS 4
BP 889
EP 895
DI 10.1097/TA.0b013e3181bbd660
PG 7
WC Critical Care Medicine; Surgery
SC General & Internal Medicine; Surgery
GA 664KP
UT WOS:000282959100047
PM 20130489
ER
PT J
AU Forbes, D
Creamer, M
Bisson, JI
Cohen, JA
Crow, BE
Foa, EB
Friedman, MJ
Keane, TM
Kudler, HS
Ursano, RJ
AF Forbes, David
Creamer, Mark
Bisson, Jonathan I.
Cohen, Judith A.
Crow, Bruce E.
Foa, Edna B.
Friedman, Mathew J.
Keane, Terence M.
Kudler, Harold S.
Ursano, Robert J.
TI A Guide to Guidelines for the Treatment of PTSD and Related Conditions
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
AB In recent years, several practice guidelines have appeared to inform clinical work in the assessment and treatment of posttraumatic stress disorder. Although there is a high level of consensus across these documents, there are also areas of apparent difference that may lead to confusion among those to whom the guidelines are targeted providers, consumers, ant/purchasers of mental health services for people affected by trauma. The authors have been responsible for developing guidelines across three continents (North America, Europe, and Australia). The aim of this article is to examine the various guidelines and to compare and contrast their methodologies and recommendations to aid clinicians in making decisions about their use.
C1 [Forbes, David; Creamer, Mark] Univ Melbourne, ACPMH, Melbourne, Vic 3002, Australia.
[Bisson, Jonathan I.] Cardiff Univ, Dept Psychol Med, Cardiff, S Glam, Wales.
[Cohen, Judith A.] Allegheny Gen Hosp, Dept Psychiat, Pittsburgh, PA 15212 USA.
[Cohen, Judith A.] Drexel Univ, Coll Med, Philadelphia, PA USA.
[Foa, Edna B.] Univ Penn, Dept Psychiat, Ctr Treatment & Study Anxiety, Philadelphia, PA 19104 USA.
[Friedman, Mathew J.] Dartmouth Med Sch, Dept Psychiat, Hanover, NH USA.
[Friedman, Mathew J.] Dartmouth Med Sch, Dept Pharmacol, Hanover, NH USA.
[Keane, Terence M.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02215 USA.
[Kudler, Harold S.] US Dept Vet Affairs, Mid Atlantic Mental Illness Res Educ & Clin Ctr, Washington, DC USA.
[Ursano, Robert J.] Uniformed Serv Univ Hlth Sci, Ctr Study Traumat Stress, Bethesda, MD USA.
RP Forbes, D (reprint author), Univ Melbourne, ACPMH, Level 1,340 Albert St, Melbourne, Vic 3002, Australia.
EM dforbes@unimelb.edu.au
RI turton, miranda/F-4682-2011
NR 14
TC 95
Z9 96
U1 4
U2 27
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0894-9867
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD OCT
PY 2010
VL 23
IS 5
BP 537
EP 552
DI 10.1002/jts.20565
PG 16
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 674PF
UT WOS:000283758900001
PM 20839310
ER
PT J
AU Calohan, J
Peterson, K
Peskind, ER
Raskind, MA
AF Calohan, Jess
Peterson, Kris
Peskind, Elaine R.
Raskind, Murray A.
TI Prazosin Treatment of Trauma Nightmares and Sleep Disturbance in
Soldiers Deployed in Iraq
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; COMBAT VETERANS; PTSD; SYMPTOMS; BRAIN
AB Trauma nightmares and sleep disturbance impair combat soldiers' functioning. The alpha-1 adrenoreceptor antagonist prazosin has been demonstrated effective for these symptoms in Vietnam veterans. Thirteen soldiers seeking relief from distressing trauma nightmares impairing military function in northern Iraq in 2006 received prazosin alone or in combination with other psychotropics. Mean prazosin dose was 4.1 (SD = 2.2) mg before bed. Six soldiers improved markedly and 3 moderately on the Clinical Global Impression of Change Ratings of distressing dreams decreased from an average of 7.0 (SD = 0.7) to 2.9 (SD = 3.0, p < .001) and those of disturbed sleep from 67 (SD = 0.9) to 3.7 (SD = 2.4, p < .001). Prazosin appears effective and well tolerated in the desert warfare environment.
RP Raskind, MA (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S116 6 E, Seattle, WA 98108 USA.
EM murray.raskind@va.gov
NR 10
TC 18
Z9 19
U1 0
U2 6
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0894-9867
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD OCT
PY 2010
VL 23
IS 5
BP 645
EP 648
DI 10.1002/jts.20570
PG 4
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 674PF
UT WOS:000283758900014
PM 20931662
ER
PT J
AU Churchill, BM
Bergman, J
Kristo, B
Gore, JL
AF Churchill, Bernard M.
Bergman, Jonathan
Kristo, Blaine
Gore, John L.
TI Improved Continence in Patients With Neurogenic Sphincteric Incompetence
With Combination Tubularized Posterior Urethroplasty and Fascial Wrap:
The Lengthening, Narrowing and Tightening Procedure
SO JOURNAL OF UROLOGY
LA English
DT Article
DE urethra; urinary bladder, neurogenic; meningomyelocele; urinary
incontinence; reconstructive surgical procedures
ID BLADDER NECK REPAIR; URINARY-INCONTINENCE; CHILDREN; 10-YEAR
AB Purpose: We evaluated the outcome in 19 patients who underwent bladder neck reconstruction by lengthening, narrowing and tightening the bladder neck with a combined tubularized posterior urethroplasty and circumferential fascial wrap.
Materials and Methods: We reviewed the records of all patients who underwent bladder neck lengthening, narrowing and tightening between April 1996 and November 2002. Preoperative urodynamic and radiographic data were available on all patients. The surgical technique involved retroperitoneal exposure of the bladder neck with a tubularized posterior urethroplasty over a urethral catheter. The reconstructed urethra was then circumferentially wrapped with a fitted piece of cadaveric fascia.
Results: Of the 19 patients 15 remain completely continent at a mean +/- SD followup of 35.5 +/- 29.1 months. Three patients underwent secondary reconstruction, including bladder neck ligation in all 3 and secondary enterocystoplasty in 2. No patient experienced difficult intermittent catheterization via the urethra postoperatively.
Conclusions: Bladder neck lengthening, narrowing and tightening is effective for managing neurogenic sphincteric incontinence. Outcomes are comparable with those of other reconstructive procedures.
C1 [Gore, John L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA.
Univ Calif Los Angeles, Robert Wood Johnson Clin Scholars Program, Los Angeles, CA 90095 USA.
Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Gore, JL (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Box 951738,CHS 66-124, Los Angeles, CA 90095 USA.
EM jgore@mednet.ucla.edu
OI Gore, John/0000-0002-2847-5062
NR 13
TC 5
Z9 5
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5347
J9 J UROLOGY
JI J. Urol.
PD OCT
PY 2010
VL 184
IS 4
SU 1
BP 1763
EP 1767
DI 10.1016/j.juro.2010.03.080
PG 5
WC Urology & Nephrology
SC Urology & Nephrology
GA 660DC
UT WOS:000282618600065
PM 20728163
ER
PT J
AU Marsh, L
AF Marsh, Laura
TI Treatment of Lewy-body dementias and psychopathology
SO LANCET NEUROLOGY
LA English
DT Editorial Material
ID PARKINSONS-DISEASE; BODIES; SYSTEM
C1 [Marsh, Laura] Baylor Coll Med, Dept Psychiat, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Marsh, Laura] Baylor Coll Med, Dept Neurol, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
RP Marsh, L (reprint author), Baylor Coll Med, Dept Psychiat, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
EM laura.marsh2@va.gov
NR 9
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1474-4422
J9 LANCET NEUROL
JI Lancet Neurol.
PD OCT
PY 2010
VL 9
IS 10
BP 943
EP 945
DI 10.1016/S1474-4422(10)70208-8
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA 672WC
UT WOS:000283616700003
PM 20729149
ER
PT J
AU Heinrich, MC
AF Heinrich, Michael C.
TI Imatinib treatment of metastatic GIST: don't stop (believing)
SO LANCET ONCOLOGY
LA English
DT Editorial Material
ID GASTROINTESTINAL STROMAL TUMORS; STEM-CELLS; LEUKEMIA
C1 Portland VA Med Ctr, Portland, OR USA.
[Heinrich, Michael C.] OHSU Knight Canc Inst, Portland, OR USA.
RP Heinrich, MC (reprint author), Portland VA Med Ctr, Portland, OR USA.
EM heinrich@ohsu.edu
NR 6
TC 6
Z9 7
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1470-2045
J9 LANCET ONCOL
JI Lancet Oncol.
PD OCT
PY 2010
VL 11
IS 10
BP 910
EP 911
DI 10.1016/S1470-2045(10)70225-4
PG 2
WC Oncology
SC Oncology
GA 667RE
UT WOS:000283210600004
PM 20864404
ER
PT J
AU Naugler, WE
Sonnenberg, A
AF Naugler, Willscott E.
Sonnenberg, Amnon
TI Survival and Cost-Effectiveness Analysis of Competing Strategies in the
Management of Small Hepatocellular Carcinoma
SO LIVER TRANSPLANTATION
LA English
DT Article
ID HEPATITIS-C VIRUS; RADIOFREQUENCY ABLATION; COMPUTED-TOMOGRAPHY;
NATURAL-HISTORY; GROWTH-RATE; COMPENSATED CIRRHOSIS; CLINICAL-TRIALS;
UNITED-STATES; LIVER-TUMORS; COMPLICATIONS
AB The aim of the present study is to compare the survival rates and cost-effectiveness of different treatment strategies for small (<2 cm) hepatocellular carcinoma (HCC). Markov chains are developed to model different management strategies for patients with compensated cirrhosis and small HCC. Probabilities of progression and survival and the likelihood of orthotopic liver transplantation are taken from the literature and incorporated into the models. As a starting population, 1000 patients are followed over a period of 10 years. Patients treated immediately with transarterial chemoembolization (TACE) or radiofrequency ablation (RFA) live as long as or longer than patients who are monitored expectantly with the intention of liver transplantation once the HCC has grown larger than 2 cm and a higher transplant priority score becomes available. With TACE, immediate treatment results in an average survival time of 4.269 years versus 4.324 years with the monitoring strategy. With RFA, immediate treatment results in an average survival time of 5.273 years versus 5.236 years with the monitoring strategy. In addition, the cost analysis shows that immediate treatment with either TACE or RFA is less expensive than monitoring. The better cost-effectiveness of immediate therapy versus the monitoring strategy remains robust and unaffected by variations of the assumptions built into the model. In conclusion, in patients with compensated cirrhosis and small HCC, a strategy of immediate treatment with either TACE or RFA prevails over a strategy of expectant monitoring with the intention of transplantation. Liver Transpl 16: 1186-1194, 2010. (C) 2010 AASLD.
C1 [Naugler, Willscott E.] Oregon Hlth & Sci Univ, Div Gastroenterol, Portland, OR 97239 USA.
Portland VA Med Ctr, Portland, OR USA.
RP Naugler, WE (reprint author), Oregon Hlth & Sci Univ, Div Gastroenterol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM nauglers@ohsu.edu
NR 39
TC 27
Z9 28
U1 0
U2 3
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD OCT
PY 2010
VL 16
IS 10
BP 1186
EP 1194
DI 10.1002/lt.22129
PG 9
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 665XH
UT WOS:000283070000009
PM 20879017
ER
PT J
AU Keith, RL
Karoor, V
Mozer, AB
Hudish, TM
Le, M
Miller, YE
AF Keith, Robert L.
Karoor, Vijaya
Mozer, Anthony B.
Hudish, Tyler M.
Le, Mysan
Miller, York E.
TI Chemoprevention of murine lung cancer by gefitinib in combination with
prostacyclin synthase overexpression
SO LUNG CANCER
LA English
DT Article
DE Chemoprevention; Lung cancer; Transgenic mice; Src; EGFR; Gefitinib;
Prostacyclin
ID GROWTH-FACTOR RECEPTOR; PULMONARY PROSTACYCLIN; TRANSGENIC MICE;
TUMOR-GROWTH; CELL-LINES; EXPRESSION; ADENOCARCINOMA; INHIBITION; SRC;
TUMORIGENESIS
AB Introduction: We hypothesized that the combination of the EGFR tyrosine kinase inhibitor (TKI) gefitinib with the powerful chemopreventive manipulation of lung-specific transgenic prostacyclin synthase (PGIS) overexpression on tumorigenesis in FVB/N mice would result in augmented chemoprevention.
Materials and methods: Wildtype and littermate PGIS overexpressors (OE) were given urethane, 1 mg/kg i.p. followed by thrice weekly i.p. injections of gefitinib, 50 mg/kg or 100 mg/kg, or vehicle. Pulmonary adenomas were enumerated and measured.
Results: Gefitinib at either 50 mg/kg or 100 mg/kg administered i.p. three times weekly was effective in inhibiting EGF induced EGFR tyrosine phosphorylation and downstream signaling. The PGIS overexpressors showed significant decreases in tumor multiplicity consistent with prior studies. Gefitinib had no effect on tumor multiplicity or volume in wildtype mice. Among the PGIS overexpressors, a significant reduction in tumor multiplicity was shown in the 50 mg/kg, but not the 100 mg/kg, gefitinib treatment group vs. vehicle control animals (1.13 +/- 0.29 vs. 2.29 +/- 0.32 tumors/mouse, p = 0.015). We examined the phosphorylation status in selected downstream effectors of EGFR (Erk, Akt, Src, PTEN). The major difference in the 50 mg/kg vs. 100 mg/kg group was an increase in p-Src in the PGIS OE mice receiving the higher dose.
Conclusion: We conclude that gefitinib alone has no chemopreventive efficacy in this model; it augmented the effect of PGIS overexpression at 50 mg/kg but not 100 mg/kg. Increased p-Src is correlated with loss of efficacy at the higher dose, suggesting the potential for combined EGFR and Src inhibition strategies in chemoprevention. (C) 2010 Published by Elsevier Ireland Ltd.
C1 [Keith, Robert L.; Mozer, Anthony B.; Hudish, Tyler M.; Le, Mysan; Miller, York E.] Vet Adm Med Ctr, Div Pulm Sci & Crit Care Med, Denver, CO 80220 USA.
[Keith, Robert L.; Karoor, Vijaya; Miller, York E.] Univ Colorado, Dept Med, Denver, CO 80262 USA.
RP Miller, YE (reprint author), Denver VA Med Ctr, Dept Med, 1055 Clermont St,Pulm 111A, Denver, CO 80220 USA.
EM york.miller@ucdenver.edu
FU Department of Veterans Affairs; NCI [P50 CA58187]
FX Supported by Department of Veterans Affairs Merit Review Grants (YEM and
RLK) and NCI P50 CA58187 (SPORE in Lung Cancer, YEM and RLK).
NR 26
TC 6
Z9 6
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0169-5002
J9 LUNG CANCER
JI Lung Cancer
PD OCT
PY 2010
VL 70
IS 1
BP 37
EP 42
DI 10.1016/j.lungcan.2010.01.004
PG 6
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA 658QE
UT WOS:000282503700006
PM 20116128
ER
PT J
AU Cedfeldt, AS
Bower, EA
English, C
Grady-Weliky, TA
Girard, DE
Choi, D
AF Cedfeldt, Andrea S.
Bower, Elizabeth A.
English, Clea
Grady-Weliky, Tana A.
Girard, Donald E.
Choi, Dongseok
TI Personal time off and residents' career satisfaction, attitudes and
emotions
SO MEDICAL EDUCATION
LA English
DT Article
ID INTERNAL-MEDICINE RESIDENTS; HEALTH-CARE; BURNOUT; PHYSICIANS; PROGRAMS;
STRESS; PREDICTORS; STUDENTS
AB OBJECTIVES Doctors who are satisfied with their careers have less stress and burnout and are less likely to make medical errors and more likely to provide a higher quality of patient care. In response to reports that residents experienced barriers to taking time off, Oregon Health and Science University designed a survey to evaluate residents' awareness of their programmes' policies for time off, their ability to find time for personal needs, and associations of both with career satisfaction, emotions and training experience.
METHODS All 675 residents in a large, urban, tertiary care academic medical centre located in the USA were invited to participate in a confidential, web-based, cross-sectional survey in 2008; 66% completed the survey. The survey instrument consisted of a variety of items including yes/no, multiple choice, Likert scale and narrative response types.
RESULTS Only 41% of respondents were aware of their programmes' policies regarding time off. Residents who reported awareness of a policy were more able to find time to take care of personal needs (odds ratio = 1.553, p = 0.026). These respondents reported more positive experiences and emotions, fewer negative experiences and emotions, higher levels of career satisfaction and relatively less perceived stress than those who were unaware of a time-off policy. In addition, these respondents reported, on average, fewer work and more sleep hours.
CONCLUSIONS Our results highlight the importance of ensuring mechanisms for residents to find time to fulfil personal needs in order to enhance resident well-being and career satisfaction. Ensuring resident awareness of time-off policies is one way to do this. Our study demonstrates that ensuring residents are able to find time for personal needs has significant consequences with respect to resident perceptions of well-being and may be an effective strategy to promote career satisfaction and prevent burnout.
C1 [Cedfeldt, Andrea S.; Girard, Donald E.] Oregon Hlth & Sci Univ, Div Grad Med Educ, Portland, OR 97239 USA.
[Cedfeldt, Andrea S.] Portland VA Med Ctr, Div Hosp & Specialty Med, Portland, OR USA.
[Bower, Elizabeth A.; Girard, Donald E.] Oregon Hlth & Sci Univ, Div Continuing Med Educ, Portland, OR 97239 USA.
[Bower, Elizabeth A.; Girard, Donald E.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA.
[English, Clea] Oregon Hlth & Sci Univ, Div Gen Internal Med & Geriatr, Portland, OR 97239 USA.
[Grady-Weliky, Tana A.] Oregon Hlth & Sci Univ, Off Educ & Student Affairs, Portland, OR 97239 USA.
[Grady-Weliky, Tana A.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA.
[Choi, Dongseok] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA.
RP Choi, D (reprint author), Oregon Hlth & Sci Univ, Div Grad Med Educ, 3181 SW Sam Jackson Pk Rd,CB669, Portland, OR 97239 USA.
EM choid@ohsu.edu
OI Bower, Elizabeth/0000-0001-5331-4378
NR 32
TC 9
Z9 9
U1 1
U2 6
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0308-0110
J9 MED EDUC
JI Med. Educ.
PD OCT
PY 2010
VL 44
IS 10
BP 977
EP 984
DI 10.1111/j.1365-2923.2010.03773.x
PG 8
WC Education, Scientific Disciplines; Health Care Sciences & Services
SC Education & Educational Research; Health Care Sciences & Services
GA 659BC
UT WOS:000282541000007
PM 20880367
ER
PT J
AU Jeffreys, MD
Leibowitz, RQ
Finley, E
Arar, N
AF Jeffreys, Matthew D.
Leibowitz, Ruth Q.
Finley, Erin
Arar, Nedal
TI Trauma Disclosure to Health Care Professionals by Veterans: Clinical
Implications
SO MILITARY MEDICINE
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; ADMINISTERED PTSD SCALE; HELP-SEEKING;
SEXUAL-ABUSE; DOMESTIC VIOLENCE; EMOTIONAL DISCLOSURE; CHILDHOOD RAPE;
PANDORA BOX; EXPERIENCES; WOMENS
AB Trauma disclosure is the initial step toward healing trauma-related distress. This study used qualitative methods to better understand factors facilitating and inhibiting change in the disclosure process. Fifty-six veterans were interviewed about their disclosure experiences between August 2004 and 2005. Emerging themes and barriers to disclosure from 23 of these interviews are reported in this article. Barriers to trauma disclosure included lack of trust in the provider, fears about the potential negative consequences of disclosure, and trauma avoidance. Providers perceived as caring and communicating at the same level as the participants facilitated disclosure, whereas providers perceived as uncaring or disinterested inhibited disclosure. Veterans reported both positive and negative reactions to initial disclosure, but nearly all agreed that disclosure was worthwhile over the long term. Improving patient provider communications and creating settings that facilitate trauma disclosure may improve healing after trauma.
C1 [Jeffreys, Matthew D.; Finley, Erin; Arar, Nedal] S Texas Vet Hlth Care Syst, Vet Evidence Based Res Disseminat & Implementat C, San Antonio, TX 78229 USA.
[Leibowitz, Ruth Q.] Salem Hosp Reg Rehabil Ctr, Salem, OR 97301 USA.
RP Jeffreys, MD (reprint author), S Texas Vet Hlth Care Syst, Vet Evidence Based Res Disseminat & Implementat C, 7400 Merton Minter, San Antonio, TX 78229 USA.
OI Finley, Erin/0000-0003-4497-7721
FU Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development
FX Dr. Leibowitz acknowledges Dr. Polly Hitchcock Noel for her mentorship.
The authors also acknowledge Drs. Dianne Dunn and John Casada for their
work in interviewing study participants. This material is based upon
work supported by the Department of Veterans Affairs, Veterans Health
Administration, Office of Research and Development (PI: Ruth Leibowitz,
PhD).
NR 57
TC 5
Z9 5
U1 1
U2 4
PU ASSOC MILITARY SURG US
PI BETHESDA
PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA
SN 0026-4075
J9 MIL MED
JI Milit. Med.
PD OCT
PY 2010
VL 175
IS 10
BP 719
EP 724
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 658CX
UT WOS:000282468500005
PM 20968260
ER
PT J
AU Freedy, JR
Magruder, KM
Mainous, AG
Frueh, BC
Geesey, ME
Camemolla, M
AF Freedy, John R.
Magruder, Kathryn M.
Mainous, Arch G.
Frueh, B. Chris
Geesey, Mark E.
Camemolla, Mark
TI Gender Differences in Traumatic Event Exposure and Mental Health Among
Veteran Primary Care Patients
SO MILITARY MEDICINE
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; AFFAIRS PRIMARY-CARE; NEUROPSYCHIATRIC
INTERVIEW MINI; ADMINISTERED PTSD SCALE; COLLABORATIVE CARE;
PSYCHOMETRIC PROPERTIES; PHYSICAL SYMPTOMS; MILITARY TRAUMA; WOMEN
VETERANS; WAR VETERANS
AB Objective: This study evaluated gender differences in lifetime traumatic events. PTSD, and depression among VA primary care patients. Method: Participants were 865 adults attending primary care at one of four VA health centers (n = 681 males, 184 females). Results: Mental health findings included: male PTSD 12.3% vs. female PTSD 9.2% (p > 0.05); male depression 15.9% vs. female depression 29.3% (p < 0.001). Men reported more war zone exposure (p < 0.001). Women reported more physical and sexual victimization (p < 0.001). Male logistic regression equations determined PTSD was associated with disability (OR = 3.42; 1.74-6.72, 95% CI) and war zone exposure (OR = 7.14; 3.82-13.30, 95% CI); depression was associated with war zone exposure (OR = 2.27; 1.40-3.68, 95% CI) and interpersonal violence (OR = 1.75; 1.10-2.79, 95% CI). Female PTSD was associated with sexual victimization (OR = 4.50; 1.20-16.80, 95% CI); depression was not predicted. Conclusions: We discuss findings in terms of the crucial need to improve identification and management of PTSD within VA primary care settings.
C1 [Freedy, John R.; Mainous, Arch G.; Geesey, Mark E.; Camemolla, Mark] Med Univ S Carolina, Dept Family Med, Charleston, SC 29425 USA.
[Magruder, Kathryn M.; Frueh, B. Chris] Ralph H Johnson VA Med Ctr, Mental Hlth Serv, Charleston, SC 29401 USA.
[Magruder, Kathryn M.; Frueh, B. Chris] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
RP Freedy, JR (reprint author), Med Univ S Carolina, Dept Family Med, 295 Calhoun St, Charleston, SC 29425 USA.
OI Mainous, Arch/0000-0002-2535-7685
FU Veterans Affairs Health Services Research and Development
FX This research was partially supported by a grant from the Veterans
Affairs Health Services Research and Development Program to Dr.
Magruder.
NR 78
TC 14
Z9 14
U1 1
U2 7
PU ASSOC MILITARY SURG US
PI BETHESDA
PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA
SN 0026-4075
EI 1930-613X
J9 MIL MED
JI Milit. Med.
PD OCT
PY 2010
VL 175
IS 10
BP 750
EP 758
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 658CX
UT WOS:000282468500010
PM 20968265
ER
PT J
AU Duarte, VM
Han, E
Veena, MS
Salvado, A
Suh, JD
Liang, LJ
Faull, KF
Srivatsan, ES
Wang, MB
AF Duarte, Victor M.
Han, Eugene
Veena, Mysore S.
Salvado, Amanda
Suh, Jeffrey D.
Liang, Li-Jung
Faull, Kym F.
Srivatsan, Eri S.
Wang, Marilene B.
TI Curcumin Enhances the Effect of Cisplatin in Suppression of Head and
Neck Squamous Cell Carcinoma via Inhibition of IKK beta Protein of the
NF kappa B Pathway
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID LIPOSOME-ENCAPSULATED CURCUMIN; CANCER-CELLS; IN-VITRO;
COLORECTAL-CANCER; GENE-EXPRESSION; GROWTH; APOPTOSIS; KINASE;
ANGIOGENESIS; CETUXIMAB
AB Previous experiments have shown that curcumin or cisplatin treatment suppresses growth of head and neck squamous cell carcinoma (HNSCC). To study the potential cooperative effect of both agents, two HNSCC cell lines were treated with curcumin or cisplatin alone or in combination. In vivo studies consisted of intravenous tail vein injection of liposomal curcumin, with intraperitoneal cisplatin, into nude mice growing xenograft HNSCC tumors. Introduction of curcumin and suboptimal concentrations of cisplatin showed a significant suppressive effect compared with treatment with either agent alone. Reduced expression of cyclin D1, I kappa B alpha, phospho-I kappa B alpha, and IKK beta occurred in cisplatin- and curcumin-treated cell lines. Confocal microscopy showed expression of IKK beta in the nucleus of the cell lines. Chromatin immunoprecipitation assay on DNA isolated from IKK beta immunoprecipitated samples showed PCR amplification of interleukin-8 promoter sequences, a binding site of NF kappa B, indicating an interaction between IKK beta and NF kappa B. Curcumin inhibited IKK beta in the cytoplasm and nucleus, leading to reduced NF kappa B activity, with no effect on phospho-AKT. In vivo studies showed significant growth inhibition of xenograft tumors treated with a combination of liposomal curcumin and cisplatin. The suppressive effect of curcumin was mediated through inhibition of cytoplasmic and nuclear IKK beta, resulting in inhibition of NF kappa B activity. Cisplatin treatment led to cellular senescence, indicating an effect mediated by p53 activation. The mechanisms of the two agents through different growth signaling pathways suggest potential for the clinical use of subtherapeutic doses of cisplatin in combination with curcumin, which will allow effective suppression of tumor growth while minimizing the toxic side effects of cisplatin. Mol Cancer Ther; 9(10); 2665-75. (C) 2010 AACR.
C1 [Duarte, Victor M.; Han, Eugene; Veena, Mysore S.; Salvado, Amanda; Suh, Jeffrey D.; Srivatsan, Eri S.; Wang, Marilene B.] VA Greater Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA.
[Duarte, Victor M.; Salvado, Amanda; Wang, Marilene B.] UCLA David Geffen Sch Med, Div Head & Neck Surg, Neuropsychiat Semel Inst, Los Angeles, CA 90095 USA.
[Liang, Li-Jung] UCLA David Geffen Sch Med, Dept Med, Neuropsychiat Semel Inst, Los Angeles, CA 90095 USA.
UCLA David Geffen Sch Med, Pasarow Mass Spectrometry Lab, Neuropsychiat Semel Inst, Los Angeles, CA 90095 USA.
RP Wang, MB (reprint author), UCLA David Geffen Sch Med, Div Head & Neck Surg, Neuropsychiat Semel Inst, 200 UCLA Med Plaza Suite 550, Los Angeles, CA 90095 USA.
EM mbwang@ucla.edu
FU VA Greater Los Angeles Healthcare; NIH [R21 CA116826-01]; Veterans
Administration (Washington, DC); West Los Angeles Surgical Education
Research Center; UCLA Academic Senate
FX VA Greater Los Angeles Healthcare, West Los Angeles Surgical Education
Research Center, and UCLA Academic Senate (M. B. Wang); NIH grant R21
CA116826-01 (M. B. Wang); and Veterans Administration (Washington, DC)
Merit grant (E. S. Srivatsan).
NR 31
TC 64
Z9 69
U1 1
U2 10
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD OCT
PY 2010
VL 9
IS 10
BP 2665
EP 2675
DI 10.1158/1535-7163.MCT-10-0064
PG 11
WC Oncology
SC Oncology
GA 661JS
UT WOS:000282724600003
PM 20937593
ER
PT J
AU Latif, R
Michalek, K
Davies, TF
AF Latif, Rauf
Michalek, Krzysztof
Davies, Terry F.
TI Subunit Interactions Influence TSHR Multimerization
SO MOLECULAR ENDOCRINOLOGY
LA English
DT Article
ID HUMAN THYROTROPIN RECEPTOR; EXTRACELLULAR DOMAIN; OLIGOMERIZATION;
ECTODOMAIN; CLEAVAGE; ACTIVATION; REVEALS; BINDING; SITES
AB The TSH receptor (TSHR) is the key molecule influencing thyroid growth and development and is an antigenic target in autoimmune thyroid disease. The TSHR exists in monomeric and multimeric forms, and it has been shown previously that multimeric complexes of the TSHR preferentially localize in lipid rafts. However, unlike other glycoprotein hormone receptors, the TSHR exists in several forms on the cell membrane due to intramolecular cleavage of its ectodomain, which causes the production of alpha- and beta-subunits of various lengths. After cleavage and reduction of disulfide bonds, alpha-subunits consisting of the receptor ectodomain may be lost from the cell surface by receptor shedding, leading to accumulation of excess beta-subunits within the membrane. Because cell surface expression of these various forms of the TSHR is critical to receptor signaling and autoimmune responses, we set out to model the influence of beta-subunits on full-length TSHRs. To study this interaction, we generated three truncated ectodomain beta-subunits linked to green fluorescent protein (named beta-316, -366, and -409) as examples of native cleaved forms of the TSHR. These constructs were transfected into human embryonic kidney 293 cells in the presence and absence of the full-length receptor. Whereas the beta-316 and beta-366 forms showed cell surface expression, the expression of beta-409 was primarily intracellular. Cotransfection of the beta-subunits with a full-length hemagglutinin-tagged wild-type (WT) receptor (HT-WT-TSHR) in both transient and stable systems caused a significant decrease in surface expression of the full-length WT receptors. This decrease was not seen with control plasmid consisting of a plasma membrane-targeted protein tagged to red fluorescent protein. To ascertain if this response was due to homointeraction of the truncated beta-constructs with the WT-TSHRs, we immunoprecipitated membranes prepared from the cotransfected cells using antihemagglutinin and then probed with anti-green fluorescent protein. These studies confirmed dimerization of the beta-subunits with the WT full-length receptor, and this interaction was further observed in vivo by fluorescence resonance energy transfer. We then studied the functional consequences of this interaction on TSHR signaling by examining G alpha s-mediated signals. The well-expressed truncated constructs, when coexpressed with full-length TSHR, did not alter constitutive cAMP levels, but there was a significant decrease in TSH-induced cAMP generation. Furthermore, we observed that truncated beta-316 and beta-366 had faster internalization rate, which may lead to a significant decrease in the expression of the full-length receptor on the cell surface, thus contributing to the decreased signaling response. However, the decrease in surface receptors may also be due to inhibition of newly formed receptors reaching the surface as result of receptor-receptor interaction. It is well known that under normal physiological conditions both cleaved and uncleaved TSHR forms coexist on the cell surface of normal thyrocytes. Our studies allow us to conclude, therefore, that multimerization of cleaved/truncated forms of the beta-subunits with the full-length TSHR has a profound influence on TSHR internalization and signaling. Hence, the degree of intramolecular cleavage must also modulate TSHR signaling. (Molecular Endocrinology 24: 2009-2018, 2010)
C1 [Latif, Rauf; Michalek, Krzysztof; Davies, Terry F.] James J Peters Vet Affairs Med Ctr, Mt Sinai Sch Med, Thyroid Res Unit, New York, NY 10468 USA.
[Michalek, Krzysztof] Univ Med Sci, Dept Endocrinol, PL-60355 Poznan, Poland.
RP Latif, R (reprint author), James J Peters Vet Affairs Med Ctr, Room 2F-30,130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM rauf.latif@mssm.edu
OI latif, rauf/0000-0002-4226-3728
FU Department of Endocrinology, University of Medical Sciences, Poznan,
Poland; National Institute of Diabetes and Kidney and Digestive Diseases
[DK069713]; Veterans Affairs [4535-05-074]; David Owen Segal Endowment
FX We thank Zhong Yao (VAMC) for technical assistance and Professor Jerzy
Sowinski (Department of Endocrinology, University of Medical Sciences,
Poznan, Poland) for advice and support.; This work was supported by:
National Institutes of Health Grant DK069713 from National Institute of
Diabetes and Kidney and Digestive Diseases, the Veterans Affairs Merit
Award program 4535-05-074 (to T. F. D.), and the David Owen Segal
Endowment (to K.M.).
NR 21
TC 7
Z9 7
U1 0
U2 0
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0888-8809
J9 MOL ENDOCRINOL
JI Mol. Endocrinol.
PD OCT 1
PY 2010
VL 24
IS 10
BP 2009
EP 2018
DI 10.1210/me.2010-0001
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 655AY
UT WOS:000282214700010
PM 20719860
ER
PT J
AU Seepersaud, R
Bensing, BA
Yen, YFT
Sullam, PM
AF Seepersaud, Ravin
Bensing, Barbara A.
Yen, Yihfen T.
Sullam, Paul M.
TI Asp3 mediates multiple protein-protein interactions within the accessory
Sec system of Streptococcus gordonii
SO MOLECULAR MICROBIOLOGY
LA English
DT Article
ID SURFACE GLYCOPROTEINS GSPB; MOLECULAR CHAPERONE SECB; TRANSLOCATION
CHANNEL; III SECRETION; IB-ALPHA; BINDING; EXPORT; MEMBRANE; HSA;
GLYCOSYLATION
AB P>Bacterial binding to human platelets is an important step in the pathogenesis of infective endocarditis. Streptococcus gordonii can mediate its platelet attachment through a cell wall glycoprotein termed GspB ('gordonii surface protein B'). GspB export is mediated by a seven-component accessory Sec system, containing two homologues of the general secretory pathway (SecA2 and SecY2) and five accessory Sec proteins (Asps1-5). Here we show that the Asps are required for optimal export of GspB independent of the glycosylation process. Furthermore, yeast two-hybrid screening of the accessory Sec system revealed interactions occurring between Asp3 and the other components of the system. Asp3 was shown to bind SecA2, Asp1, Asp2 and itself. Mutagenesis of Asp3 identified N- and C-terminal regions that are essential for GspB transport, and conserved residues within the C-terminal domain mediated Asp3 binding to other accessory Sec components. The loss of binding by Asp3 also resulted in an impaired ability of S. gordonii to secrete GspB. These studies indicate that Asp3 is a central element mediating multiple interactions among accessory Sec components that are essential for GspB transport to the cell surface.
C1 [Seepersaud, Ravin; Bensing, Barbara A.; Yen, Yihfen T.; Sullam, Paul M.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA.
RP Sullam, PM (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA.
EM paul.sullam@ucsf.edu
FU Department of Veterans Affairs, National Institutes of Health [R01
AI41513, R01 AI057433]
FX This study was supported by the Department of Veterans Affairs, the VA
Merit Review programme, and grants R01 AI41513 and R01 AI057433 from the
National Institutes of Health. We thank Jason McGovern for his help with
the YTH assay.
NR 42
TC 20
Z9 20
U1 1
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0950-382X
J9 MOL MICROBIOL
JI Mol. Microbiol.
PD OCT
PY 2010
VL 78
IS 2
BP 490
EP 505
DI 10.1111/j.1365-2958.2010.07346.x
PG 16
WC Biochemistry & Molecular Biology; Microbiology
SC Biochemistry & Molecular Biology; Microbiology
GA 663IN
UT WOS:000282876900017
PM 20807195
ER
PT J
AU Masters, SL
Dunne, A
Subramanian, SL
Hull, RL
Tannahill, GM
Sharp, FA
Becker, C
Franchi, L
Yoshihara, E
Chen, Z
Mullooly, N
Mielke, LA
Harris, J
Coll, RC
Mills, KHG
Mok, KH
Newsholme, P
Nunez, G
Yodoi, J
Kahn, SE
Lavelle, EC
O'Neill, LAJ
AF Masters, Seth L.
Dunne, Aisling
Subramanian, Shoba L.
Hull, Rebecca L.
Tannahill, Gillian M.
Sharp, Fiona A.
Becker, Christine
Franchi, Luigi
Yoshihara, Eiji
Chen, Zhe
Mullooly, Niamh
Mielke, Lisa A.
Harris, James
Coll, Rebecca C.
Mills, Kingston H. G.
Mok, K. Hun
Newsholme, Philip
Nunez, Gabriel
Yodoi, Junji
Kahn, Steven E.
Lavelle, Ed C.
O'Neill, Luke A. J.
TI Activation of the NLRP3 inflammasome by islet amyloid polypeptide
provides a mechanism for enhanced IL-1 beta in type 2 diabetes
SO NATURE IMMUNOLOGY
LA English
DT Article
ID HUMAN PANCREATIC-ISLETS; LOW-DENSITY-LIPOPROTEIN; BETA-CELL MASS; NALP3
INFLAMMASOME; INSULIN-RESISTANCE; TRANSGENIC MICE; MOUSE MODEL;
IN-VITRO; AMYLIN; MELLITUS
AB Interleukin 1 beta (IL-1 beta) is an important inflammatory mediator of type 2 diabetes. Here we show that oligomers of islet amyloid polypeptide (IAPP), a protein that forms amyloid deposits in the pancreas during type 2 diabetes, triggered the NLRP3 inflammasome and generated mature IL-1 beta. One therapy for type 2 diabetes, glyburide, suppressed IAPP-mediated IL-1 beta production in vitro. Processing of IL-1 beta initiated by IAPP first required priming, a process that involved glucose metabolism and was facilitated by minimally oxidized low-density lipoprotein. Finally, mice transgenic for human IAPP had more IL-1 beta in pancreatic islets, which localized together with amyloid and macrophages. Our findings identify previously unknown mechanisms in the pathogenesis of type 2 diabetes and treatment of pathology caused by IAPP.
C1 [Masters, Seth L.; Dunne, Aisling; Mielke, Lisa A.; Harris, James; Mills, Kingston H. G.; Lavelle, Ed C.; O'Neill, Luke A. J.] Trinity Coll Dublin, Sch Biochem & Immunol, Immunol Res Ctr, Dublin, Ireland.
[Masters, Seth L.; Tannahill, Gillian M.; Becker, Christine; Coll, Rebecca C.; O'Neill, Luke A. J.] Trinity Coll Dublin, Sch Biochem & Immunol, Inflammat Res Grp, Dublin, Ireland.
[Dunne, Aisling; Mielke, Lisa A.; Mills, Kingston H. G.] Trinity Coll Dublin, Sch Biochem & Immunol, Immune Regulat Res Grp, Dublin, Ireland.
[Subramanian, Shoba L.; Hull, Rebecca L.; Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA.
[Subramanian, Shoba L.; Hull, Rebecca L.; Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA.
[Sharp, Fiona A.; Harris, James; Lavelle, Ed C.] Trinity Coll Dublin, Adjuvant Res Grp, Sch Biochem & Immunol, Dublin, Ireland.
[Franchi, Luigi; Nunez, Gabriel] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.
[Franchi, Luigi; Nunez, Gabriel] Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
[Yoshihara, Eiji; Chen, Zhe; Yodoi, Junji] Kyoto Univ, Dept Biol Responses, Inst Virus Res, Kyoto 6068501, Japan.
[Mullooly, Niamh; Newsholme, Philip] Univ Coll Dublin, Sch Biomol & Biomed Sci, Conway Inst, Dublin 2, Ireland.
[Mok, K. Hun] Trinity Coll Dublin, Sch Biochem & Immunol, Prot Folding & Biomol NMR Spect Grp, Dublin, Ireland.
RP Masters, SL (reprint author), Trinity Coll Dublin, Sch Biochem & Immunol, Immunol Res Ctr, Dublin, Ireland.
EM smasters@tcd.ie
RI Chen, Zhe/F-6273-2010; Mok, K. Hun/C-2607-2009; Masters,
Seth/N-2886-2013; Coll, Rebecca/J-2124-2014
OI Chen, Zhe/0000-0003-3626-9848; Masters, Seth/0000-0003-4763-576X; Coll,
Rebecca/0000-0002-7359-6023; Newsholme, Philip/0000-0002-0500-6984;
Harris, James/0000-0002-5634-9637; Hull, Rebecca/0000-0001-9690-4087
FU National Health and Medical Research Council [516783]; Science
Foundation Ireland; United States Department of Veterans Affairs; US
National Institutes of Health [DK-75998, AI063331]; Crohn's and Colitis
Foundation
FX We thank A. Mori for assistance with Nlrp3-/- mice; J.
Tschopp (University of Lausanne) for Nlrp3-/- mice; and E.
Latz (University of Bonn) for YFP-ASC BMDMs. Supported by the National
Health and Medical Research Council (516783 to S.L.M.), Science
Foundation Ireland (for work at Trinity College Dublin), the United
States Department of Veterans Affairs (for work at the VA Puget Sound
Health Care System), the US National Institutes of Health (DK-75998 to
S.E.K. for work at VA Puget Sound Health Care System, and AI063331 for
work at the University of Michigan) and the Crohn's and Colitis
Foundation (L.F.).
NR 53
TC 474
Z9 489
U1 6
U2 72
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1529-2908
J9 NAT IMMUNOL
JI Nat. Immunol.
PD OCT
PY 2010
VL 11
IS 10
BP 897
EP U1501
DI 10.1038/ni.1935
PG 9
WC Immunology
SC Immunology
GA 651KP
UT WOS:000281926900008
PM 20835230
ER
PT J
AU Ray, NB
Durairaj, L
Chen, BB
McVerry, BJ
Ryan, AJ
Donahoe, M
Waltenbaugh, AK
O'Donnell, CP
Henderson, FC
Etscheidt, CA
Mccoy, DM
Agassandian, M
Hayes-Rowan, EC
Coon, TA
Butler, PL
Gakhar, L
Mathur, SN
Sieren, JC
Tyurina, YY
Kagan, VE
McLennan, G
Mallampalli, RK
AF Ray, Nancy B.
Durairaj, Lakshmi
Chen, Bill B.
McVerry, Bryan J.
Ryan, Alan J.
Donahoe, Michael
Waltenbaugh, Alisa K.
O'Donnell, Christopher P.
Henderson, Florita C.
Etscheidt, Christopher A.
Mccoy, Diann M.
Agassandian, Marianna
Hayes-Rowan, Emily C.
Coon, Tiffany A.
Butler, Phillip L.
Gakhar, Lokesh
Mathur, Satya N.
Sieren, Jessica C.
Tyurina, Yulia Y.
Kagan, Valerian E.
McLennan, Geoffrey
Mallampalli, Rama K.
TI Dynamic regulation of cardiolipin by the lipid pump Atp8b1 determines
the severity of lung injury in experimental pneumonia
SO NATURE MEDICINE
LA English
DT Article
ID CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; FAMILIAL INTRAHEPATIC
CHOLESTASIS; PULMONARY-EDEMA; PROTEIN-A; IN-VIVO; SURFACTANT; DISEASE;
GENE; PHOSPHOLIPIDS; PURIFICATION
AB Pneumonia remains the leading cause of death from infection in the US, yet fundamentally new conceptual models underlying its pathogenesis have not emerged. We show that humans and mice with bacterial pneumonia have markedly elevated amounts of cardiolipin, a rare, mitochondrial-specific phospholipid, in lung fluid and find that it potently disrupts surfactant function. Intratracheal cardiolipin administration in mice recapitulates the clinical phenotype of pneumonia, including impaired lung mechanics, modulation of cell survival and cytokine networks and lung consolidation. We have identified and characterized the activity of a unique cardiolipin transporter, the P-type ATPase transmembrane lipid pump Atp8b1, a mutant version of which is associated with severe pneumonia in humans and mice. Atp8b1 bound and internalized cardiolipin from extracellular fluid via a basic residue-enriched motif. Administration of a peptide encompassing the cardiolipin binding motif or Atp8b1 gene transfer in mice lessened bacteria-induced lung injury and improved survival. The results unveil a new paradigm whereby Atp8b1 is a cardiolipin importer whose capacity to remove cardiolipin from lung fluid is exceeded during inflammation or when Atp8b1 is defective. This discovery opens the door for new therapeutic strategies directed at modulating the abundance or molecular interactions of cardiolipin in pneumonia.
C1 [Chen, Bill B.; McVerry, Bryan J.; Donahoe, Michael; Waltenbaugh, Alisa K.; O'Donnell, Christopher P.; Hayes-Rowan, Emily C.; Coon, Tiffany A.; Mallampalli, Rama K.] Univ Pittsburgh, Dept Internal Med, Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15260 USA.
[Ray, Nancy B.; Durairaj, Lakshmi; Ryan, Alan J.; Henderson, Florita C.; Etscheidt, Christopher A.; Mccoy, Diann M.; Agassandian, Marianna; Mathur, Satya N.; Sieren, Jessica C.; McLennan, Geoffrey] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA.
[Butler, Phillip L.; Gakhar, Lokesh] Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA.
[Tyurina, Yulia Y.; Kagan, Valerian E.] Univ Pittsburgh, Dept Environm & Occupat Hlth, Ctr Free Radl & Antioxidant Hlth, Pittsburgh, PA USA.
[McLennan, Geoffrey] Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA.
[McLennan, Geoffrey] Univ Iowa, Dept Biomed Engn, Iowa City, IA 52242 USA.
[Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA USA.
RP Mallampalli, RK (reprint author), Univ Pittsburgh, Dept Internal Med, Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15260 USA.
EM mallampallirk@upmc.edu
RI Gakhar, Lokesh/F-2113-2010
FU US Department of Veterans Affairs; US National Institutes of Health [R01
HL068135, HL080229, HL081784, HL096376, HL097376, HL098174, HL70755,
HL094488, NIOSH OH008282, K23 HL075402, U01 HL102288]
FX We thank M. E. Anderson, M.J. Welsh, J. Zabner and M. Gladwin for
critical review of the manuscript and helpful suggestions. The
Atp8b1G308V/G308V 129S1/SvlmJ mutant mice14 were a generous
gift from L. Bull (University of California-San Francisco). Nontypable
H. influenza strain 12 bacteria were kindly provided by D. Look
(University of Iowa) 29. Antibodies to ATP8b1 were generous gifts from
D. Ortiz (Tufts University) 30 and M. Ananthanarayanan (Mount Sinai
School of Medicine) 31. This material is based upon work supported, in
part, by the US Department of Veterans Affairs, Veterans Health
Administration, Office of Research and Development, Biomedical
Laboratory Research and Development. This work was supported by a Merit
Review Award from the US Department of Veterans Affairs and US National
Institutes of Health R01 grants HL068135, HL080229, HL081784, HL096376,
HL097376 and HL098174 (to R. K. M.), HL70755, HL094488 and NIOSH
OH008282 (to V. E. K.) and K23 HL075402 and U01 HL102288 (to L. D.). The
contents do not represent the views of the Department of Veterans
Affairs or the US government.
NR 38
TC 67
Z9 70
U1 1
U2 12
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
J9 NAT MED
JI Nat. Med.
PD OCT
PY 2010
VL 16
IS 10
BP 1120
EP U1
DI 10.1038/nm.2213
PG 9
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
Medicine
GA 660LR
UT WOS:000282644800042
PM 20852622
ER
PT J
AU Menon, V
Katz, R
Mukamal, K
Kestenbaum, B
de Boer, IH
Siscovick, DS
Sarnak, MJ
Shlipak, MG
AF Menon, Vandana
Katz, Ronit
Mukamal, Kenneth
Kestenbaum, Bryan
de Boer, Ian H.
Siscovick, David S.
Sarnak, Mark J.
Shlipak, Michael G.
TI Alcohol consumption and kidney function decline in the elderly Alcohol
and Kidney Disease
SO NEPHROLOGY DIALYSIS TRANSPLANTATION
LA English
DT Article
DE alcohol; kidney disease; outcomes; progression
ID STAGE RENAL-DISEASE; GLOMERULAR-FILTRATION-RATE; CORONARY-HEART-DISEASE;
CARDIOVASCULAR HEALTH; OLDER-ADULTS; SERUM CREATININE; RISK-FACTORS;
METAANALYSIS; ASSOCIATION; DAMAGE
AB Methods. This prospective cohort study included 4343 subjects from the Cardiovascular Health Study, a longitudinal, community-based cohort of persons aged >= 65 from four US communities. We used previously defined categories based on weekly alcohol consumption: none, former, < 1 drink, 1-6 drinks, 7-13 drinks and >= 14 drinks. Cystatin C was measured at baseline, year 3 and year 7; eligible subjects had at least two measures. Estimated GFR(cys) was calculated from cystatin C. The primary outcome was rapid kidney function as an annual estimated GFR (eGFR(cys)) loss > 3 mL/min/1.73 m(2)/year.
Results. Eight percent of the cohort reported former alcohol use and 52% reported current alcohol consumption. During a mean follow-up of 5.6 years, 1075 (25%) participants had rapid kidney function decline. In adjusted logistic regression models, there was no association between alcohol use and kidney function decline (odds ratio, 95% confidence interval: none = reference; former = 1.18, 0.89-1.56; < 1 drink = 1.20, 0.99-1.47; 1-6 = 1.18, 0.95-1.45; 7-13 = 1.10, 0.80-1.53; > 14 = 0.89, 0.61-1.13). Results were similar with kidney function decline as a continuous outcome.
Conclusions. Our results suggest that moderate alcohol consumption has neither adverse nor beneficial effects on kidney function. Although clinicians will need to consider the potential deleterious effects associated with alcohol consumption, there does not appear to be a basis for recommending that older adults discontinue or initiate light to moderate alcohol consumption to protect against kidney disease.
C1 [Menon, Vandana; Sarnak, Mark J.] Tufts Med Ctr, Div Nephrol, Boston, MA USA.
[Katz, Ronit] Univ Washington, Dept Biostat, Collaborat Hlth Studies Coordinating Ctr, Seattle, WA 98195 USA.
[Mukamal, Kenneth] Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA.
[Siscovick, David S.] Univ Washington, Dept Med, Seattle, WA USA.
[Siscovick, David S.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Kestenbaum, Bryan; de Boer, Ian H.] Univ Washington, Div Nephrol, Seattle, WA 98195 USA.
[Shlipak, Michael G.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Shlipak, Michael G.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
RP Menon, V (reprint author), Tufts Med Ctr, Div Nephrol, Boston, MA USA.
EM vmenon@tuftsmedicalcenter.org
FU NIDDK [K23 DK067303, RO1 AG 027002]; American Heart Association;
National Heart, Lung and Blood Institute [N01-HC-85079, N01-HC-85086,
N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133,
U01 HL080295]; National Institute of Neurological Disorders and Stroke
FX This study was supported by grants NIDDK K23 DK067303 and RO1 AG 027002.
Dr Shlipak's work on this project was supported by RO1 DK066488-01 and
the American Heart Association Established Investigator Award. This
research was supported by N01-HC-85079 through N01-HC-85086,
N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133 and
U01 HL080295 from the National Heart, Lung and Blood Institute, with
additional contribution from the National Institute of Neurological
Disorders and Stroke. A full list of principal CHS investigators and
institutions can be found at http://www.chs-nhlbi.org/pi.htm.
NR 25
TC 16
Z9 16
U1 2
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0931-0509
J9 NEPHROL DIAL TRANSPL
JI Nephrol. Dial. Transplant.
PD OCT
PY 2010
VL 25
IS 10
BP 3301
EP 3307
DI 10.1093/ndt/gfq188
PG 7
WC Transplantation; Urology & Nephrology
SC Transplantation; Urology & Nephrology
GA 654ML
UT WOS:000282172300028
PM 20400446
ER
PT J
AU Zhang, JH
Fung, SJ
Xi, MC
Sampogna, S
Chase, MH
AF Zhang, Jian-Hua
Fung, Simon J.
Xi, Mingchu
Sampogna, Sharon
Chase, Michael H.
TI Apnea produces neuronal degeneration in the pons and medulla of guinea
pigs
SO NEUROBIOLOGY OF DISEASE
LA English
DT Article
DE Apnea; Single-stranded DNA; lmmunohistochemistry; Guinea pig; Brainstem
ID OBSTRUCTIVE SLEEP-APNEA; CHRONIC INTERMITTENT HYPOXIA; VENTRAL
RESPIRATORY GROUP; DEMONSTRATING CELL-DEATH; LATERAL TEGMENTAL FIELD;
RAT-BRAIN; DNA-DAMAGE; IN-VIVO; SUBNUCLEAR ORGANIZATION; CATECHOLAMINE
NEURONS
AB Obstructive sleep apnea and other sleep-related breathing disorders result in recurrent periods of oxygen deprivation (hypoxia), hypercapnia and an increase in the cellular production of reactive oxygen species (oxidative stress-related injury). Individuals with these disorders suffer from a variety of cellular abnormalities that result in cardiopulmonary dysfunctions, disturbances in sleep and other pathologies. In the present experiment, using an animal model of sleep apnea, we determined that the degeneration of neurons and glia, due to apoptosis, occurs in specific regions of the pons and medulla. Adult guinea pigs, which were divided into control (normoxic) and experimental (hypoxic) groups, were anesthetized with alpha-chloralose and immobilized with Flaxedil. Apnea (hypoxia) was induced by ventilatory arrest in order to desaturate the oxyhemoglobin to 75% SpO(2). A sequence of apnea, followed by ventilation with recovery to > 95% SpO(2), was repeated for a period of 3 h. At the end of the period of recurrent apnea, the animals were perfused and brain sections were immunostained with a mouse monoclonal antibody raised against single-stranded DNA (ssDNA). Apoptotic neurons and glia, which were not found in the control group of animals, were present in brainstem regions in hypoxic group of animals; these regions involved in the control of respiration (e.g., the parafacial respiratory group and the ventral respiratory group), cardiovascular functions (e.g., the nucleus ambiguus, the nucleus tractus solitarius and the dorsal motor nucleus of the vagus) as well as REM sleep (the nucleus pontis oralis) and wakefulness (e.g., the dorsal raphe and locus ceruleus). We suggest apoptotic neurons and glia in critical areas of the pons and medulla results in many of the comorbidities experienced by patients with sleep-disordered breathing pathologies. (c) 2010 Elsevier Inc. All rights reserved.
C1 [Zhang, Jian-Hua; Fung, Simon J.; Xi, Mingchu; Sampogna, Sharon; Chase, Michael H.] WebSci Int, Los Angeles, CA 90024 USA.
[Zhang, Jian-Hua; Fung, Simon J.; Xi, Mingchu; Chase, Michael H.] VA Greater Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Chase, Michael H.] Univ Calif Los Angeles, Dept Physiol, Sch Med, Los Angeles, CA 90025 USA.
RP Zhang, JH (reprint author), WebSci Int, 1251 Westwood Blvd, Los Angeles, CA 90024 USA.
EM jzhang@websciences.org
NR 69
TC 15
Z9 16
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0969-9961
J9 NEUROBIOL DIS
JI Neurobiol. Dis.
PD OCT
PY 2010
VL 40
IS 1
SI SI
BP 251
EP 264
DI 10.1016/j.nbd.2010.05.032
PG 14
WC Neurosciences
SC Neurosciences & Neurology
GA 645OY
UT WOS:000281473400030
PM 20554036
ER
PT J
AU Spreng, RN
Rosen, HJ
Strother, S
Chow, TW
Diehl-Schmid, J
Freedman, M
Graff-Radford, NR
Hodges, JR
Lipton, AM
Mendez, MF
Morelli, SA
Black, SE
Miller, BL
Levine, B
AF Spreng, R. Nathan
Rosen, Howard J.
Strother, Stephen
Chow, Tiffany W.
Diehl-Schmid, Janine
Freedman, Morris
Graff-Radford, Neill R.
Hodges, John R.
Lipton, Anne M.
Mendez, Mario F.
Morelli, Sylvia A.
Black, Sandra E.
Miller, Bruce L.
Levine, Brian
TI Occupation attributes relate to location of atrophy in frontotemporal
lobar degeneration
SO NEUROPSYCHOLOGIA
LA English
DT Article
DE Frontotemporal dementia; Laterality; Reserve
ID ALZHEIMERS-DISEASE; DEVELOPMENTAL DYSLEXIA; LIFETIME OCCUPATION;
PROGRESSIVE APHASIA; RESERVE HYPOTHESIS; COGNITIVE RESERVE; SEMANTIC
DEMENTIA; WORK GROUP; BRAIN; EDUCATION
AB Frontotemporal lobar degeneration (FTLD) often presents with asymmetric atrophy We assessed whether premorbid occupations in FTLD patients were associated with these hemispheric asymmetries In a multi-center chart review of 588 patients occupation information was related to location of tissue loss or dysfunction Patients with atrophy lateralized to the right had professions more dependent on verbal abilities than patients with left-lateralized or symmetrical atrophy In a subgroup of 96 well-characterized patients with quantified neuroimaging data the lateralization effect was localized to the temporal lobes and Included verbal and mathematical ability Patients whose professions placed high demands on language and mathematics had relatively preserved left temporal relative to right temporal volumes Thus occupation selection occurring in early adulthood is related to lateralized brain asymmetry in patients who develop FTLD decades later in the relatively deficient hemisphere The finding suggests that verbal and mathematical occupations may have been pursued due to developmental right-lateralized functional impairment that precedes the neurodegeneranve process Alternatively long-term engagement of activities associated with these occupations contributed to left-lateralized reserve right-lateralized dysfunction or both (C) 2010 Elsevier Ltd All rights reserved
C1 [Spreng, R. Nathan; Strother, Stephen; Chow, Tiffany W.; Levine, Brian] Baycrest Ctr Geriatr Care, Rotman Res Inst, Toronto, ON, Canada.
[Spreng, R. Nathan; Freedman, Morris; Black, Sandra E.; Levine, Brian] Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada.
[Rosen, Howard J.; Miller, Bruce L.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.
[Rosen, Howard J.; Miller, Bruce L.] UCSF Memory & Aging Ctr, San Francisco, CA USA.
[Chow, Tiffany W.; Freedman, Morris; Black, Sandra E.; Levine, Brian] Univ Toronto, Dept Med Neurol, Toronto, ON M5S 1A1, Canada.
[Chow, Tiffany W.] Univ Toronto, Dept Psychiat Geriatr Psychiat, Toronto, ON M5S 1A1, Canada.
[Diehl-Schmid, Janine] Tech Univ Munich, Dept Psychiat, Munich, Germany.
[Diehl-Schmid, Janine] Tech Univ Munich, Dept Psychotherapy, Munich, Germany.
[Freedman, Morris] Baycrest Ctr Geriatr Care, Div Neurol, Behav Neurol Program, Toronto, ON, Canada.
[Freedman, Morris] Mt Sinai Hosp, Dept Med, Div Neurol, Univ Hlth Network, Toronto, ON M5G 1X5, Canada.
[Graff-Radford, Neill R.] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA.
[Hodges, John R.] MRC, Cognit & Brain Sci Unit, Cambridge, England.
[Lipton, Anne M.] Presbyterian Med Ctr, Dept Neurol, Dallas, TX USA.
[Mendez, Mario F.] Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA.
[Mendez, Mario F.] Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
[Mendez, Mario F.] W Los Angeles VA Med Ctr, Los Angeles, CA USA.
[Morelli, Sylvia A.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA.
RP Spreng, RN (reprint author), Harvard Univ, Dept Psychol, 33 Kirkland St, Cambridge, MA 02138 USA.
RI Levine, Brian/G-4328-2010
OI Levine, Brian/0000-0003-4343-811X; Morelli, Sylvia/0000-0002-3353-678X;
Spreng, R. Nathan/0000-0003-1530-8916; Black,
Sandra/0000-0001-7093-8289; Strother, Stephen/0000-0002-3198-217X
FU Canadian Institutes of Health Research [MGP-62963]; National Institute
of Child Health and Human Development [HD42385-01]
FX This study was supported by Canadian Institutes of Health Research
(MGP-62963) and the National Institute of Child Health and Human
Development (HD42385-01) grants to B Levine The authors declare no
actual or potential conflicts of interest All appropriate approval and
procedures were followed concerning human subjects We thank Morris
Moscovitch for his involvement Pheth Sengdy Irina Nica and Namita Kumar
for their assistance and Karen Spreng for her contributions during the
course of this project
NR 54
TC 9
Z9 9
U1 1
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0028-3932
J9 NEUROPSYCHOLOGIA
JI Neuropsychologia
PD OCT
PY 2010
VL 48
IS 12
BP 3634
EP 3641
DI 10.1016/j.neuropsychologia.2010.08.020
PG 8
WC Behavioral Sciences; Neurosciences; Psychology, Experimental
SC Behavioral Sciences; Neurosciences & Neurology; Psychology
GA 677UM
UT WOS:000284017300030
PM 20800604
ER
PT J
AU Larson, PS
AF Larson, Paul S.
TI Minimally Invasive Surgery for Movement Disorders
SO NEUROSURGERY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Deep brain stimulation; Stereotactic surgery; Frameless deep brain
stimulation; Interventional MRI; Gene transfer
ID PHASE-I TRIAL; SUBTHALAMIC NUCLEUS; PARKINSONS-DISEASE; OPEN-LABEL;
BRAIN; TOLERABILITY; SAFETY
AB Movement disorders surgery, particularly deep brain stimulation (DBS), is already a minimally invasive procedure However new innovations in the delivery devices for DBS electrodes, new methods for target localization, and alternatives to implanted hardware are all strategies that can make movement disorders surgery less invasive Frameless DBS techniques can increase patient comfort and shorten operative time Interventional magnetic resonance imaging can further reduce operative time, and allows DBS placement to be done with a patient asleep and usually with a single brain penetration Finally, gene transfer eliminates the need for implanted hardware or batteries and simplifies postoperative care
C1 [Larson, Paul S.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
[Larson, Paul S.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
RP Larson, PS (reprint author), Univ Calif San Francisco, Dept Neurol Surg, 505 Parnassus Ave,Box 0112, San Francisco, CA 94143 USA.
FU Medtronic Inc; Surgivision Inc; Ceregene Inc; Genzyme Inc
FX This article describes work that was supported by research grants and
support to the author from Medtronic Inc Surgivision Inc Ceregene Inc
and Genzyme Inc
NR 11
TC 4
Z9 4
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1042-3680
J9 NEUROSURG CLIN N AM
JI Neurosurg. Clin. N. Am.
PD OCT
PY 2010
VL 21
IS 4
BP 691
EP +
DI 10.1016/j.nec.2010.07.012
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 681DO
UT WOS:000284291800011
PM 20947036
ER
PT J
AU Yenari, MA
Kauppinen, TM
Swanson, RA
AF Yenari, Midori A.
Kauppinen, Tiina M.
Swanson, Raymond A.
TI Microglial Activation in Stroke: Therapeutic Targets
SO NEUROTHERAPEUTICS
LA English
DT Review
DE NF-kappa B; AP-1; PARP-1; minocycline; inflammation; ischemia; TREM2
ID FOCAL CEREBRAL-ISCHEMIA; NF-KAPPA-B; NITRIC-OXIDE SYNTHASE; METABOTROPIC
GLUTAMATE RECEPTORS; TRANSIENT FOREBRAIN ISCHEMIA;
TUMOR-NECROSIS-FACTOR; BLOOD-BRAIN-BARRIER; HEAT-SHOCK-PROTEIN;
POLY(ADP-RIBOSE) POLYMERASE INHIBITOR; INDUCED NEURONAL DEATH
AB Microglial activation is an early response to brain ischemia and many other stressors. Microglia continuously monitor and respond to changes in brain homeostasis and to specific signaling molecules expressed or released by neighboring cells. These signaling molecules, including ATP, glutamate, cytokines, prostaglandins, zinc, reactive oxygen species, and HSP60, may induce microglial proliferation and migration to the sites of injury. They also induce a nonspecific innate immune response that may exacerbate acute ischemic injury. This innate immune response includes release of reactive oxygen species, cytokines, and proteases. Microglial activation requires hours to days to fully develop, and thus presents a target for therapeutic intervention with a much longer window of opportunity than acute neuroprotection. Effective agents are now available for blocking both microglial receptor activation and the microglia effector responses that drive the inflammatory response after stroke. Effective agents are also available for targeting the signal transduction mechanisms linking these events. However, the innate immune response can have beneficial as well deleterious effects on outcome after stoke, and a challenge will be to find ways to selectively suppress the deleterious effects of microglial activation after stroke without compromising neurovascular repair and remodeling.
C1 San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA.
RP Swanson, RA (reprint author), VAMC, 4150 Clement St, San Francisco, CA 94121 USA.
EM raymond.swanson@ucsf.edu
OI Swanson, Raymond/0000-0002-3664-5359; Kauppinen,
Tiina/0000-0001-7219-9862
FU Department of Veterans Affairs; Department of Defense [W81XH-05-2-0094,
DAMD17-03-1-0532]; National Institutes of Health [NS14543, NS40516];
American Heart Association [0835222N]
FX This work was supported by the Department of Veterans Affairs (R.A.S.,
M.A.Y.), the Department of Defense (W81XH-05-2-0094, R.A.S.;
DAMD17-03-1-0532, M.A.Y.), the National Institutes of Health (NS14543,
R.A.S.; NS40516, M.A.Y.), and the American Heart Association (0835222N,
T.M.K.).
NR 232
TC 123
Z9 127
U1 2
U2 39
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1933-7213
J9 NEUROTHERAPEUTICS
JI Neurotherapeutics
PD OCT
PY 2010
VL 7
IS 4
BP 378
EP 391
PG 14
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 654VG
UT WOS:000282198500005
PM 20880502
ER
PT J
AU Thompson, LR
Boudreau, R
Newman, AB
Hannon, MJ
Chu, CR
Nevitt, MC
Kwoh, CK
AF Thompson, L. R.
Boudreau, R.
Newman, A. B.
Hannon, M. J.
Chu, C. R.
Nevitt, M. C.
Kwoh, C. Kent
CA OAI Investigators
TI The association of osteoarthritis risk factors with localized, regional
and diffuse knee pain
SO OSTEOARTHRITIS AND CARTILAGE
LA English
DT Article
DE Knee osteoarthritis; Pain localization; Risk factors; Knee pain
ID NUTRITION EXAMINATION SURVEY; NATIONAL-HEALTH; PERCEPTION; EPIDEMIOLOGY;
LOCATION; GENDER
AB Objective: To identify determinants of different patterns of knee pain with a focus on risk factors for knee osteoarthritis (OA).
Design: The Knee Pain Map is an interviewer-administered assessment that asks subjects to characterize their knee pain as localized, regional, or diffuse. A total of 2677 participants from the Osteoarthritis Initiative were studied. We used multinomial logistic regression to examine the relationship between risk factors for OA and knee pain patterns. We examined the bivariate and multivariate relationships of knee pain pattern with age, body mass index (BMI), sex, race, family history of total joint replacement, knee injury, knee surgery, and hand OA.
Results: We compared 2462 knees with pain to 1805 knees without pain. In the bivariate analysis, age, sex, BMI, injury, surgery, and hand OR were associated with at least one pain pattern. In the multivariate model, all of these variables remained significantly associated with at least one pattern. When compared to knees without pain, higher BMI, injury, and surgery were associated with all patterns. BMI had its strongest association with diffuse pain. Older age was less likely to be associated with localized pain while female sex was associated with regional pain.
Conclusions: We have shown that specific OA risk factors are associated with different knee pain patterns. Better understanding of the relationship between OA risk factors and knee pain patterns may help to characterize the heterogeneous subsets of knee OA. Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.
C1 [Thompson, L. R.; Newman, A. B.; Hannon, M. J.; Chu, C. R.; Kwoh, C. Kent] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA.
[Boudreau, R.; Newman, A. B.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA.
[Nevitt, M. C.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Kwoh, C. Kent] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
RP Kwoh, CK (reprint author), S702 BSTWR,200 Lothrop St, Pittsburgh, PA 15261 USA.
EM kwoh@pitt.edu
RI Newman, Anne/C-6408-2013
OI Newman, Anne/0000-0002-0106-1150; Boudreau, Robert/0000-0003-0162-5187
FU National Institutes of Health [N01-AR-2-2258, N01-AR-2-2259,
N01-AR-2-2260, N01AR-2-2261, N01-AR-2-2262]; Department of Health and
Human Services; Merck Research Laboratories; Novartis Pharmaceuticals
Corporation, GlaxoSmithKline; Pfizer, Inc.; Foundation for the National
Institutes of Health; National Institute of Aging (NIA) [AG 021885];
University of Pittsburgh
FX The OAI is a public private partnership which comprised five contracts
(N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01AR-2-2261;
N01-AR-2-2262) funded by the National Institutes of Health, a branch of
the Department of Health and Human Services, and conducted by the OAI
Study Investigators. Private funding partners include Merck Research
Laboratories; Novartis Pharmaceuticals Corporation, GlaxoSmithKline; and
Pfizer, Inc. Private sector funding for the OAI is managed by the
Foundation for the National Institutes of Health. This manuscript has
received the approval of the OAI Publications Committee based on a
review of its scientific content and data interpretation.; This study
was also supported by the National Institute of Aging (NIA) Ruth L
Kirschstein National Research Service Award Institutional Research
Training Grant AG 021885, and the University of Pittsburgh, School of
Medicine Clinical Scientist Training Program.
NR 24
TC 14
Z9 14
U1 1
U2 3
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 1063-4584
J9 OSTEOARTHR CARTILAGE
JI Osteoarthritis Cartilage
PD OCT
PY 2010
VL 18
IS 10
BP 1244
EP 1249
DI 10.1016/j.joca.2010.05.014
PG 6
WC Orthopedics; Rheumatology
SC Orthopedics; Rheumatology
GA 670UK
UT WOS:000283452600002
PM 20633678
ER
PT J
AU Bethel-Brown, CS
Zhang, HY
Fowler, SC
Chertoff, ME
Watson, GS
Stanford, JA
AF Bethel-Brown, Crystal S.
Zhang, Hongyu
Fowler, Stephen C.
Chertoff, Mark E.
Watson, G. Stennis
Stanford, John A.
TI Within-session analysis of amphetamine-elicited rotation behavior
reveals differences between young adult and middle-aged F344/BN rats
with partial unilateral striatal dopamine depletion
SO PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
LA English
DT Article
DE Parkinson's disease; Animal models; Behavioral assay; Basal ganglia;
Rotation; Striatum; Amphetamine
ID PARKINSONS-DISEASE; BASAL GANGLIA; PROGRESSIVE DEGENERATION;
NIGROSTRIATAL PATHWAY; MOVEMENT INITIATION; FISCHER-344 RATS; PARTIAL
LESIONS; 6-OHDA LESIONS; ANIMAL-MODEL; TIME-COURSE
AB Preclinical modeling of Parkinson's disease using 6-hydroxydopamine (6-OHDA) has been valuable in developing and testing therapeutic strategies. Recent efforts have focused on modeling early stages of disease by infusing 6-OHDA into the striatum. The partial DA depletion that follows intrastriatal 6-OHDA is more variable than the near-complete depletion following medial forebrain bundle infusion, and behavioral screening assays are not as well characterized in the partial lesion model. We compared relationships between amphetamine-elicited rotation behavior and DA depletion following intrastriatal 6-OHDA (12.5 mu g) in 6 month vs. 18 month F344/BN rats, at 2-weeks and 6-weeks post-lesion. We compared the total number of rotations with within-session (bin-by-bin) parameters of rotation behavior as indicators of DA depletion. Striatal DA depletion was greater in the young adult than in the middle-aged rats at 2 weeks but not at 6 weeks post-lesion. The total number of rotations for the whole session and striatal DA depletion did not differ between the two age groups. Regression analysis revealed a greater relationship between within-session parameters of rotation behavior and DA depletion in the middle-aged group than in the young adult group. These results have implications for estimating DA depletion in preclinical studies using rats of different ages. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Stanford, John A.] Univ Kansas, Med Ctr, Dept Physiol, Landon Ctr Aging, Kansas City, KS 66160 USA.
[Bethel-Brown, Crystal S.; Zhang, Hongyu] Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA.
[Chertoff, Mark E.] Univ Kansas, Med Ctr, Dept Speech & Hearing, Kansas City, KS 66160 USA.
[Fowler, Stephen C.; Chertoff, Mark E.; Stanford, John A.] Univ Kansas, Med Ctr, Kansas Intellectual & Dev Disabil Res Ctr, Kansas City, KS 66160 USA.
[Fowler, Stephen C.] Univ Kansas, Dept Pharmacol & Toxicol, Lawrence, KS 66045 USA.
[Fowler, Stephen C.] Univ Kansas, Schiefelbusch Inst Life Span Studies, Lawrence, KS 66045 USA.
[Watson, G. Stennis] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98108 USA.
[Watson, G. Stennis] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr GRECC, Seattle, WA 98108 USA.
RP Stanford, JA (reprint author), Univ Kansas, Med Ctr, Dept Physiol, Landon Ctr Aging, Mailstop 3051,3901 Rainbow Blvd, Kansas City, KS 66160 USA.
EM jstanford@kumc.edu
FU NIH [AG023549, AG026491, MH43429, AG23640]; Smith Intellectual and
Developmental Disabilities Research Center [HD02528]; Lied Endowed Basic
Science Research Grant
FX This study was supported by NIH grants AG023549 (JAS), AG026491 (JAS),
MH43429 (SCF), AG23640 (GSW), the Smith Intellectual and Developmental
Disabilities Research Center (HD02528), and a Lied Endowed Basic Science
Research Grant (JAS).
NR 42
TC 7
Z9 7
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0091-3057
J9 PHARMACOL BIOCHEM BE
JI Pharmacol. Biochem. Behav.
PD OCT
PY 2010
VL 96
IS 4
BP 423
EP 428
DI 10.1016/j.pbb.2010.06.014
PG 6
WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy
SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy
GA 653TT
UT WOS:000282120500007
PM 20600242
ER
PT J
AU Collinger, JL
Impink, BG
Ozawa, H
Boninger, ML
AF Collinger, Jennifer L.
Impink, Bradley G.
Ozawa, Haishin
Boninger, Michael L.
TI Effect of an Intense Wheelchair Propulsion Task on Quantitative
Ultrasound of Shoulder Tendons
SO PM&R
LA English
DT Article
AB Objective: To investigate acute ultrasound changes of biceps and supraspinatus tendon appearance after an intense wheelchair propulsion task, and how these changes relate to demographic and biomechanical risk factors.
Design: A survey.
Setting: Research laboratory and research space at the National Veterans Wheelchair Games.
Participants: A convenience sample of 60 manual wheelchair users were recruited through research registries and rehabilitation clinics as well as from participants at the 2007 and 2008 National Veterans Wheelchair Games. The subjects were between 18 and 65 years of age at least 1 year after injury and did not have progressive disabilities.
Main Outcome Measures: Quantitative ultrasound (QUS) measures of biceps and supraspinatus tendon appearance, stroke frequency, resultant force, tendinopathy score, and duration of wheelchair use.
Results: Biceps tendon appearance after an intense propulsion task was significantly related to chronic biceps tendinopathy, duration of wheelchair use, stroke frequency, and resultant force. The subjects with a higher stroke frequency or resultant force tended to have a brighter, more organized tendon appearance compared with the prepropulsion imaging session (baseline). The subjects with tendinopathy or a longer duration of wheelchair use were more likely to have a darker, diffuse tendon appearance immediately after the propulsion task. Supraspinatus tendon appearance after propulsion was only significantly predicted by baseline QUS measures.
Conclusions: QUS has proven to be sensitive to risk factors for tendon pathology. Future studies can apply grayscale-based QUS to study the development and prevention of repetitive strain injuries, particularly on an individual basis. PM R 2010;2:920-925
C1 [Collinger, Jennifer L.; Impink, Bradley G.; Ozawa, Haishin; Boninger, Michael L.] Dept Vet Affairs, Human Engn Res Labs, Pittsburgh, PA USA.
[Boninger, Michael L.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15206 USA.
[Collinger, Jennifer L.; Ozawa, Haishin; Boninger, Michael L.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA.
[Collinger, Jennifer L.; Impink, Bradley G.; Boninger, Michael L.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA.
RP Boninger, ML (reprint author), Dept Vet Affairs, Human Engn Res Labs, Pittsburgh, PA USA.
EM boninger@pitt.edu
OI Boninger, Michael/0000-0001-6966-919X
FU Office of Research and Development, Rehabilitation Research &
Development Service, Department of Veterans Affairs [B3142C]; National
Institute of Health [R21HD054529]; National Institute on Disability and
Rehabilitation Research Rehabilitation Engineering Research Center on
Spinal Cord Injury [H133E070024]; National Science Foundation Graduate
Research Fellowship
FX This material is the result of work supported with resources and the use
of facilities at the Human Engineering Research Laboratories, VA
Pittsburgh Healthcare System. This study was supported by the Office of
Research and Development, Rehabilitation Research & Development Service,
Department of Veterans Affairs, Grant B3142C, the National Institute of
Health, Grant R21HD054529, the National Institute on Disability and
Rehabilitation Research Rehabilitation Engineering Research Center on
Spinal Cord Injury, Grant H133E070024, and a National Science Foundation
Graduate Research Fellowship. The contents of this paper do not
represent the views of the Department of Veterans Affairs or the United
States Government.
NR 18
TC 10
Z9 10
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1934-1482
J9 PM&R
JI PM&R
PD OCT
PY 2010
VL 2
IS 10
BP 920
EP 925
DI 10.1016/j.pmrj.2010.06.007
PG 6
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA V23SE
UT WOS:000208361700007
PM 20970761
ER
PT J
AU Harris, AHS
Bradley, KA
Bowe, T
Henderson, P
Moos, R
AF Harris, Alex H. S.
Bradley, Katharine A.
Bowe, Thomas
Henderson, Patricia
Moos, Rudolf
TI Associations Between AUDIT-C and Mortality Vary by Age and Sex
SO POPULATION HEALTH MANAGEMENT
LA English
DT Article
ID ALCOHOL SCREENING SCORES; IDENTIFICATION TEST AUDIT; ALL-CAUSE
MORTALITY; USE DISORDERS; GENERAL-POPULATION; RISK DRINKING;
CONSUMPTION; QUESTIONNAIRES; WOMEN; COMORBIDITY
AB We sought to determine the sex-and age-specific risk of mortality associated with scores on the 3-item Alcohol Use Disorder Identification Test-Consumption (AUDIT-C) questionnaire using data from a national sample of Veterans Health Administration (VHA) patients. Men (N = 215,924) and women (N = 9168) who completed the AUDIT-C in a patient survey were followed for 24 months. AUDIT-C categories (0, 1-4, 5-8, 9-12) were evaluated as predictors of mortality in logistic regression models, adjusted for age, race, education, marital status, smoking, depression, and comorbidities. For women, AUDIT-C scores of 9-12 were associated with a significantly increased risk of death compared to the AUDIT-C 1-4 group (odds ratio [OR] 7.09; 95% confidence interval [CI] = 2.67, 18.82). For men overall, AUDIT-C scores of 5-8 and 9-12 were associated with increased risk of death compared to the AUDIT-C 1-4 group (OR 1.13, 95% CI = 1.05, 1.21, and OR 1.63, 95% CI = 1.45, 1.84, respectively) but these associations varied by age. These results provide sex-and age-tailored risk information that clinicians can use in evidence-based conversations with patients about the health-related risks of their alcohol consumption. This study adds to the growing literature establishing the AUDIT-C as a scaled marker of alcohol-related risk or "vital sign" that might facilitate the detection and management of alcohol-related risks and problems. (Population Health Management 2010;13:263-268)
C1 [Harris, Alex H. S.; Bowe, Thomas; Henderson, Patricia; Moos, Rudolf] Stanford Univ, Sch Med, VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA 94025 USA.
[Bradley, Katharine A.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Bradley, Katharine A.] Univ Washington, Sch Med, Seattle, WA USA.
[Bradley, Katharine A.] Puget Sound HC Syst, Seattle, WA USA.
RP Harris, AHS (reprint author), Stanford Univ, Sch Med, VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, 795 Willow Rd, Menlo Pk, CA 94025 USA.
EM Alexander.Harris2@va.gov
FU National Institute of Alcohol and Alcoholism [R03 AA016793-01]; VA
Office of Quality and Performance
FX This work was made possible through a grant from the National Institute
of Alcohol and Alcoholism (R03 AA016793-01) and support from the VA
Office of Quality and Performance. The views presented in this paper do
not necessarily represent the views of the Department of Veterans
Affairs.
NR 33
TC 19
Z9 19
U1 0
U2 2
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1942-7891
J9 POPUL HEALTH MANAG
JI Popul. Health Manag.
PD OCT
PY 2010
VL 13
IS 5
BP 263
EP 268
DI 10.1089/pop.2009.0060
PG 6
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 658BJ
UT WOS:000282463400005
PM 20879907
ER
PT J
AU Stetler, RA
Gan, Y
Zhang, WT
Liou, AK
Gao, YQ
Cao, GD
Chen, J
AF Stetler, R. Anne
Gan, Yu
Zhang, Wenting
Liou, Anthony K.
Gao, Yanqin
Cao, Guodong
Chen, Jun
TI Heat shock proteins: Cellular and molecular mechanisms in the central
nervous system
SO PROGRESS IN NEUROBIOLOGY
LA English
DT Review
DE Heat shock protein; Synaptic transmission; Protein degradation; Cell
death; Cerebral ischemia; Parkinson's disease; Huntington's disease;
Alzheimer's disease; Prion; Charcot-Marie-Tooth
ID CHAPERONE-MEDIATED AUTOPHAGY; FOCAL CEREBRAL-ISCHEMIA;
ENDOPLASMIC-RETICULUM STRESS; CYSTEINE-STRING PROTEIN; ALPHA-SYNUCLEIN
AGGREGATION; CLATHRIN-COATED VESICLES; N-TERMINAL KINASE; INHIBITS
HUNTINGTIN AGGREGATION; HUMAN NEUROMUSCULAR DISORDERS;
UBIQUITIN-PROTEASOME PATHWAY
AB Emerging evidence indicates that heat shock proteins (HSPs) are critical regulators in normal neural physiological function as well as in cell stress responses. The functions of HSPs represent an enormous and diverse range of cellular activities, far beyond the originally identified roles in protein folding and chaperoning. HSPs are now understood to be involved in processes such as synaptic transmission, autophagy, ER stress response, protein kinase and cell death signaling. In addition, manipulation of HSPs has robust effects on the fate of cells in neurological injury and disease states. The ongoing exploration of multiple HSP superfamilies has underscored the pluripotent nature of HSPs in the cellular context, and has demanded the recent revamping of the nomenclature referring to these families to reflect a re-organization based on structure and function. In keeping with this re-organization, we first discuss the HSP superfamilies in terms of protein structure, regulation, expression and distribution in the brain. We then explore major cellular functions of HSPs that are relevant to neural physiological states, and from there we discuss known and proposed HSP impacts on major neurological disease states. This review article presents a three-part discussion on the array of HSP families relevant to neuronal tissue, their cellular functions, and the exploration of therapeutic targets of these proteins in the context of neurological diseases. Published by Elsevier Ltd.
C1 [Stetler, R. Anne] Univ Pittsburgh, Sch Med, Dept Neurol, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA.
[Stetler, R. Anne; Cao, Guodong; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA 15261 USA.
[Stetler, R. Anne; Gan, Yu; Zhang, Wenting; Gao, Yanqin; Cao, Guodong; Chen, Jun] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China.
RP Stetler, RA (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA.
EM stetlerra@upmc.edu; chenj2@upmc.edu
RI Gao, Yanqin/I-6790-2016
OI Gao, Yanqin/0000-0002-4915-9819
FU American Heart Association [09POST22006065]; National Institutes of
Health [NS36736, NS43802, NS45048]; VA Merit Review Grant; Chinese
National Science Foundation [30870794, 30670642]
FX We thank Armando Signore for the artwork, Carol Culver and Sulaiman
Hassan for editorial assistance, and Pat Strickler for secretarial
support. This work was supported by funds from the American Heart
Association (09POST22006065 to R.A.S.), the National Institutes of
Health (NS36736, NS43802 and NS45048 to J.C.), the VA Merit Review Grant
(to J.C.) and the Chinese National Science Foundation (30870794,
30670642 to Y.G.).
NR 322
TC 85
Z9 89
U1 2
U2 39
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0301-0082
J9 PROG NEUROBIOL
JI Prog. Neurobiol.
PD OCT
PY 2010
VL 92
IS 2
BP 184
EP 211
DI 10.1016/j.pneurobio.2010.05.002
PG 28
WC Neurosciences
SC Neurosciences & Neurology
GA 661LG
UT WOS:000282729200005
PM 20685377
ER
PT J
AU McCarthy, JF
Valenstein, M
Zivin, K
Zeber, JE
Kilbourne, AM
AF McCarthy, John F.
Valenstein, Marcia
Zivin, Kara
Zeber, John E.
Kilbourne, Amy M.
TI Access-Related Measures and Out-of-System Utilization Among Veterans
With Bipolar Disorder
SO PSYCHIATRIC SERVICES
LA English
DT Article
ID SERIOUS MENTAL-ILLNESS; HEALTH-CARE; MEDICAL-CARE; VA; SATISFACTION;
SERVICES; BARRIERS
AB Objective: This study examined associations between access-related measures and out-of-system health services utilization (general medicine and mental health services) among patients with bipolar disorder at a U.S. Department of Veterans Affairs (VA) medical center. Methods: VA patients (N=391) with bipolar disorder answered questions about health services access (non-VA insurance coverage, travel distance to their VA facility, service-connected disability status, and difficulty receiving needed mental health care) and out-of-system services utilization. Multivariable Tobit regression was used to evaluate associations between access measures and propensity to receive out-of-system services. Results: More than half the veterans (56%) reported some non-VA utilization. Out-of-system utilization was more likely among patients who were married, younger, homeless, with private insurance, without service-connected disabilities, and who reported access difficulties. Conclusions: Out-of-system utilization was associated with multiple measures of access and indicators specific to VA and non-VA providers. Enhancing health system access for patients with bipolar disorder may reduce out-of-system utilization, potentially enhancing continuity of care. (Psychiatric Services 61: 1035-1038, 2010)
C1 [McCarthy, John F.] US Dept Vet Affairs, Natl Serious Mental Illness Treatment Resource &, Ann Arbor, MI 48113 USA.
Ctr Clin Management Res, Ann Arbor, MI 48113 USA.
RP McCarthy, JF (reprint author), US Dept Vet Affairs, Natl Serious Mental Illness Treatment Resource &, POB 130170, Ann Arbor, MI 48113 USA.
EM john.mccarthy2@va.gov
FU VA [IIR 02-283]
FX This study was supported by VA grant IIR 02-283.
NR 14
TC 3
Z9 3
U1 0
U2 4
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD OCT
PY 2010
VL 61
IS 10
BP 1035
EP 1038
PG 4
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 657WB
UT WOS:000282448500018
PM 20889645
ER
PT J
AU Zhang, XY
Xiu, MH
Chen, DC
Yang, FD
Wu, GY
Lu, L
Kosten, TA
Kosten, TR
AF Zhang, Xiang Yang
Xiu, Mei Hong
Chen, Da Chun
Yang, Fu De
Wu, Gui Ying
Lu, Lin
Kosten, Therese A.
Kosten, Thomas R.
TI Nicotine dependence and serum BDNF levels in male patients with
schizophrenia
SO PSYCHOPHARMACOLOGY
LA English
DT Article
DE Schizophrenia; Smoking; Nicotine; Brain-derived neurotrophic factor;
Neurotrophin
ID NEUROTROPHIC FACTOR BDNF; FACTOR MESSENGER-RNA; LONG-TERM TREATMENT;
RAT-BRAIN; EXPERIMENTAL PARKINSONISM; STRIATAL INCREASE; BIPOLAR
DISORDER; DECREASED LEVELS; KNOCKOUT MICE; SMOKING
AB Schizophrenia is associated with a significantly high prevalence of smoking. Upregulation of neurotrophins by nicotine is well established. Accumulating evidence shows that brain-derived neurotrophic factor (BDNF) may be involved in the pathophysiology of schizophrenia. The purposes of this study were to compare BDNF levels in smokers to nonsmokers with schizophrenia and examine the association between BDNF levels and psychopathological symptoms.
Serum BDNF levels were measured in 139 male inpatients with DSM-IV schizophrenia: 102 smokers and 37 nonsmokers. Symptoms were assessed with the Positive and Negative Syndrome Scale (PANSS).
The positive PANSS symptoms were lower in smokers than in nonsmokers, while the negative symptoms were lower in those who smoked more cigarettes. BDNF levels were significantly higher in smokers than in nonsmokers (p < 0.05). Higher BDNF levels correlated with fewer negative symptoms and with smoking more cigarettes.
The fewer positive symptoms in smokers and fewer negative symptoms in those who smoked more cigarettes may be associated with nicotine-induced upregulation of BDNF.
C1 [Zhang, Xiang Yang; Kosten, Thomas R.] VA Med Ctr, Houston, TX 77030 USA.
[Zhang, Xiang Yang; Xiu, Mei Hong; Chen, Da Chun; Yang, Fu De] Beijing HuiLongGuan Hosp, Ctr Biol Psychiat, Beijing 100096, Peoples R China.
[Lu, Lin] Peking Univ, Natl Inst Drug Dependence, Beijing 100083, Peoples R China.
[Zhang, Xiang Yang; Wu, Gui Ying; Kosten, Therese A.; Kosten, Thomas R.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
RP Zhang, XY (reprint author), VA Med Ctr, Res Bldg 109,Room 130,2002 Holcombe Blvd, Houston, TX 77030 USA.
EM xyzhang@bcm.edu; kosten@bcm.edu
FU Stanley Medical Research Institute [03T-459, 05T-726]; Department of
Veterans Affairs; US National Institute of Health [K05-DA0454,
P50-DA18827, U01-MH79639]; VISN 16, Mental Illness Research, Education
and Clinical Center (MIRECC)
FX This study was funded by the Stanley Medical Research Institute (03T-459
and 05T-726) and the Department of Veterans Affairs, VISN 16, Mental
Illness Research, Education and Clinical Center (MIRECC), US National
Institute of Health K05-DA0454, P50-DA18827, and U01-MH79639.
NR 63
TC 14
Z9 16
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0033-3158
J9 PSYCHOPHARMACOLOGY
JI Psychopharmacology
PD OCT
PY 2010
VL 212
IS 3
BP 301
EP 307
DI 10.1007/s00213-010-1956-y
PG 7
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 662RD
UT WOS:000282828100002
PM 20661552
ER
PT J
AU Yehuda, R
Flory, JD
Pratchett, LC
Buxbaum, J
Ising, M
Holsboer, F
AF Yehuda, Rachel
Flory, Janine D.
Pratchett, Laura C.
Buxbaum, Joseph
Ising, Marcus
Holsboer, Florian
TI Putative biological mechanisms for the association between early life
adversity and the subsequent development of PTSD
SO PSYCHOPHARMACOLOGY
LA English
DT Article
DE PTSD; Early life stress; Cortisol; Gene x environment interaction; Gene
expression; Epigenetics; Glucocorticoid receptor
ID POSTTRAUMATIC-STRESS-DISORDER; CHILDHOOD SEXUAL-ABUSE; PERIPHERAL
MONONUCLEAR LEUKOCYTES; PITUITARY-ADRENAL RESPONSES; NATIONAL
COMORBIDITY SURVEY; DEXAMETHASONE-SUPPRESSION; GLUCOCORTICOID-RECEPTOR;
DNA METHYLATION; HOLOCAUST SURVIVORS; MATERNAL-BEHAVIOR
AB Early Life Stress (ELS) increases risk for both adult traumatization and posttraumatic stress disorder (PTSD). Adult PTSD may also reflect a continuation of a response to an earlier exposure to adversity. Given similarities between neuroendocrine aspects of PTSD and ELS, such as in reduced cortisol signaling and glucocorticoid receptor (GR) responsiveness, some aspects of the biology of PTSD may reflect biological correlates of risk.
This paper will examine how empirical findings regarding the biological basis of ELS can inform our understanding of the neuroendocrinology of PTSD. This paper will also propose a hypothetical model to guide future research that integrates genetic, epigenetic, neuroendocrine, and psychological observations to understand the contribution of ELS neurobiology to PTSD.
Recent genetic findings demonstrate heritable aspects of at least some of these cortisol-related disturbances. Furthermore, ELS may produce at least some of the PTSD-associated changes in glucocorticoid responsiveness through epigenetic mechanisms such as developmental programming. These, then, may contribute to enduring changes in stress responsiveness as well as enhanced risk for adult exposure and PTSD.
Molecular mechanisms associated with gene x environment interactions or GR programming are essential in explaining current observations in the neuroendocrinology of PTSD that have been difficult to understand through the lens of contemporary stress theory.
C1 [Yehuda, Rachel; Flory, Janine D.; Pratchett, Laura C.] James J Peters Vet Affairs Med Ctr, Dept Psychiat, Bronx, NY USA.
[Yehuda, Rachel; Buxbaum, Joseph] Mt Sinai Sch Med, Dept Psychiat & Neurobiol, New York, NY USA.
[Flory, Janine D.] CUNY, Queens Coll, Dept Psychol, New York, NY USA.
[Flory, Janine D.] CUNY, Grad Ctr, New York, NY USA.
[Ising, Marcus; Holsboer, Florian] Max Planck Inst Psychiat, D-80804 Munich, Germany.
RP Yehuda, R (reprint author), James J Peters Vet Affairs Med Ctr, Dept Psychiat, 526 OOMH,130 W Kingsbridge Rd, Bronx, NY USA.
EM rachel.yehuda@va.gov
OI Buxbaum, Joseph/0000-0001-8898-8313
FU NIMH [MH088101, DOD PT073577, 10164894]
FX This work was supported by the following funding: NIMH MH088101, DOD
PT073577 and 10164894, and VA Merit Review to RY. We thank Dr. Linda M.
Bierer for her careful reading of this manuscript and thoughtful
suggestions.
NR 130
TC 80
Z9 83
U1 9
U2 39
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0033-3158
J9 PSYCHOPHARMACOLOGY
JI Psychopharmacology
PD OCT
PY 2010
VL 212
IS 3
BP 405
EP 417
DI 10.1007/s00213-010-1969-6
PG 13
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 662RD
UT WOS:000282828100011
PM 20706708
ER
PT J
AU Boockvar, KS
Livote, EE
Goldstein, N
Nebeker, JR
Siu, A
Fried, T
AF Boockvar, K. S.
Livote, E. E.
Goldstein, N.
Nebeker, J. R.
Siu, A.
Fried, T.
TI Electronic health records and adverse drug events after patient transfer
SO QUALITY & SAFETY IN HEALTH CARE
LA English
DT Article
ID MEDICATION RECONCILIATION; SYSTEM; CARE; DISCREPANCIES; SAFETY
AB Background Our objective was to examine the frequencies of medication error and adverse drug events (ADEs) at the time of patient transfer in a system with an electronic health record (EHR) as compared with a system without an ERR. It was hypothesised that the frequencies of these events would be lower in the EHR system because of better information exchange across sites of care.
Methods 469 patients transferred between seven nursing homes and three hospitals in New York and Connecticut between 1999 and 2005 were followed retrospectively. Two groups of patients were compared: OS Veterans Affairs (VA) patients, with an EHR, and non-VA patients, without an EHR, on the following measures: (1) medication prescribing discrepancies at nursing home/hospital transfer, (2) high-risk medication discrepancies and (3) ADEs caused by medication discrepancies according to structured medical record review by pairs of physician and pharmacist raters.
Results The overall incidence of ADEs caused by medication discrepancies was 0.20 per hospitalisation episode. After controlling for demographic and clinical covariates, there were no significant differences between VA and non-VA groups in medication discrepancies (mean difference 0.02; 95% CI -0.81 to 0.85), high-risk medication discrepancies ( 0.18; 95%CI -0.22 to 0.58) or occurrence of an ADEs caused by a medication discrepancy (OR 0.96; 95% CI 0.18 to 5.01).
Conclusions There was no difference, with and without an EHR, in the occurrence of medication discrepancies or ADEs caused by medication discrepancies at the time of transfer between sites of care. Reducing such problems may require specialised computer tools to facilitate medication review.
C1 [Boockvar, K. S.; Livote, E. E.; Goldstein, N.; Siu, A.] James J Peters VA Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY 10468 USA.
[Boockvar, K. S.; Goldstein, N.; Siu, A.] Mt Sinai Sch Med, Dept Geriatr, New York, NY USA.
[Boockvar, K. S.; Goldstein, N.; Siu, A.] Mt Sinai Sch Med, Dept Palliat Med, New York, NY USA.
[Boockvar, K. S.] Jewish Home Lifecare, New York, NY USA.
[Nebeker, J. R.] VA Geriatr Res Educ & Clin Ctr, Salt Lake City, UT USA.
[Fried, T.] Yale Univ, Sch Med, New Haven, CT USA.
[Fried, T.] VA Connecticut Healthcare Syst, Clin Epidemiol Res Ctr, West Haven, CT USA.
RP Boockvar, KS (reprint author), James J Peters VA Med Ctr, Geriatr Res Educ & Clin Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM kenneth.boockvar@mssm.edu
OI Boockvar, Kenneth/0000-0003-1165-5558
FU VA Health Services Research and Development Service; Now York State
Department of Health; Mount Sinai Practice Improvement Cluster; NIH
[5K23AG025933-04]
FX Financial support was provided by the VA Health Services Research and
Development Service, the Now York State Department of Health and the
Mount Sinai Practice Improvement Cluster. Dr. Goldstein was supported by
5K23AG025933-04 from NIH.
NR 24
TC 8
Z9 10
U1 2
U2 6
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1475-3898
J9 QUAL SAF HEALTH CARE
JI Qual. Saf. Health Care
PD OCT
PY 2010
VL 19
IS 5
AR e16
DI 10.1136/qshc.2009.033050
PG 5
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 690UB
UT WOS:000285032700036
PM 20724395
ER
PT J
AU Singh, H
Petersen, LA
Daci, K
Collins, C
Khan, M
El-Serag, HB
AF Singh, Hardeep
Petersen, Laura A.
Daci, Kuang
Collins, Clyde
Khan, Myrna
El-Serag, Hashem B.
TI Reducing referral delays in colorectal cancer diagnosis: is it about how
you ask?
SO QUALITY & SAFETY IN HEALTH CARE
LA English
DT Article
ID OCCULT BLOOD-TEST; SCREENING COLONOSCOPY; MALPRACTICE CLAIMS; FOLLOW-UP;
COMMUNICATION; QUALITY; CONSULTATIONS; DETERMINANTS; SURVIVAL; IMPROVE
AB Objectives Delays in colorectal cancer (CRC) diagnosis related to colonoscopy referrals are not well studied. The authors tested whether certain details of information transmitted through computerised provider order entry (CPOE)-based referrals affected timeliness of diagnostic colonoscopy for patients with newly diagnosed CRC.
Methods The authors studied a 6-year cohort of all newly diagnosed patients with CRC at a large tertiary care Veterans Affairs hospital and its affiliated multispecialty clinics. Referring providers included primary care clinicians, resident trainees and other specialists. From the colonoscopy referral preceding CRC diagnosis, the authors determined request date, type and frequency of diagnostic clues provided (symptoms, signs, test results), notation of in and documented evidence of verbal contact between referring provider and consultant to expedite referral. The authors compared distributions of proportions of diagnostic clues between patients with a lag of >60 and <= 60 day, and examined predictors of lag time.
Results Of 367 electronic referrals identified with a median lag of 57 days, 178 (48.5%) had a lag of >60 days. Referrals associated with longer lag times included those with 'positive faecal occult blood test' (92 days, p<0.0001), 'haematochesia' (75 days, p=0.02), 'history of polyps' (221 days, p=0.0006) and when 'screening' (vs specific symptoms) was given as the reason for diagnostic colonoscopy (203 days, p=0.002). Independent predictors of shorter wait times included three diagnostic clues, notation of urgency and documentation of verbal contact.
Conclusions Attention to certain details of diagnostic information provided to consultants through CPOE-based referrals may help reduce delays in CRC diagnosis.
C1 [Singh, Hardeep; Petersen, Laura A.; Khan, Myrna] Michael E DeBakey VA Med Ctr, Houston VA HSR&D Ctr Excellence, Houston, TX USA.
[Singh, Hardeep; Petersen, Laura A.; Khan, Myrna] Michael E DeBakey VA Med Ctr, Ctr Inquiry Improve Outpatient Safety Effect Elec, Houston, TX USA.
[Singh, Hardeep; Petersen, Laura A.; Khan, Myrna] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA.
[El-Serag, Hashem B.] Michael E DeBakey VA Med Ctr, Sect Gastroenterol & Hepatol, Houston, TX USA.
[El-Serag, Hashem B.] Baylor Coll Med, Dept Med, Houston VA HSR&D Ctr Excellence, Houston, TX 77030 USA.
RP Singh, H (reprint author), VA Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM hardeeps@bcm.tmc.edu
FU NIH [K23, K23CA125585]; VA National Center of Patient Safely; Houston VA
HSR&D Center of Excellence [HFP90-020]
FX The study was supported by an NIH K23 career development award
(K23CA125585) to HS. the VA National Center of Patient Safely, and in
part the Houston VA HSR&D Center of Excellence (HFP90-020).
NR 30
TC 17
Z9 17
U1 0
U2 1
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1475-3898
J9 QUAL SAF HEALTH CARE
JI Qual. Saf. Health Care
PD OCT
PY 2010
VL 19
IS 5
AR e27
DI 10.1136/qshc.2009.033712
PG 6
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 690UB
UT WOS:000285032700047
PM 20584706
ER
PT J
AU Anzueto, A
Miravitlles, M
AF Anzueto, Antonio
Miravitlles, Marc
TI Short-course fluoroquinolone therapy in exacerbations of chronic
bronchitis and COPD
SO RESPIRATORY MEDICINE
LA English
DT Review
DE Chronic bronchitis; COPD; AECB; Fluoroquinolones; Duration of therapy;
Short-course therapy
ID OBSTRUCTIVE PULMONARY-DISEASE; ACUTE BACTERIAL EXACERBATION; LONG-TERM
OUTCOMES; ANTIBIOTIC-TREATMENT; 5-DAY MOXIFLOXACIN; DOUBLE-BLIND;
ANTIMICROBIAL TREATMENT; PSEUDOMONAS-AERUGINOSA; ORAL LEVOFLOXACIN;
LUNG-FUNCTION
AB Acute exacerbations of chronic bronchitis (AECB) and chronic obstructive pulmonary disease (COPD) are associated with significant healthcare costs and contribute to the progress of the disease. Although a number of factors may trigger these episodes, between 40% and 60% are bacterial in nature. Antimicrobial therapy can be effective in treating exacerbations, leading to improved peak expiratory flow rates, fewer hospitalizations, lower relapse rates, and greater clinical success. Evidence suggests that short-course antimicrobial therapy can be as effective as standard duration therapy (>7 days) in treating exacerbations. Randomized trials have shown that clinical and bacteriological success rates are comparable with both 5-day and standard antibiotic courses. Furthermore, 5-day fluoroquinolone therapy is associated with faster recovery, fewer relapses, prolonged duration between episodes, and less hospitalization when compared with standard therapy. Both moxifloxacin and gemifloxacin have received FDA-approval for 5-day therapy in AECB. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, Dept Med, San Antonio, TX 78229 USA.
[Miravitlles, Marc] Hosp Clin Barcelona, IDIBAPS, Fudacio Clin, Barcelona 08036, Catalonia, Spain.
RP Anzueto, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, Dept Med, 111E,7400 Merton Minter Blvd, San Antonio, TX 78229 USA.
EM anzueto@uthscsa.edu
OI Miravitlles, Marc/0000-0002-9850-9520
FU Schering-Plough Corporation
FX The authors would like to acknowledge the editorial assistance of Dr.
Ching-Ling Chen in the preparation of this manuscript. Support for this
assistance was provided by Schering-Plough Corporation. The authors
accept full responsibility for the contents of this manuscript.
NR 49
TC 7
Z9 9
U1 0
U2 4
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
J9 RESP MED
JI Respir. Med.
PD OCT
PY 2010
VL 104
IS 10
BP 1396
EP 1403
DI 10.1016/j.rmed.2010.05.018
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA 655JW
UT WOS:000282247300002
PM 20580215
ER
PT J
AU Gomez, M
Church, LWP
Judson, MA
AF Gomez, Mario
Church, L. W. Preston
Judson, Marc A.
TI Tuberculous mediastinal lymphadenitis that evolved into pulmonary
tuberculosis following transbronchial needle aspiration
SO RESPIROLOGY
LA English
DT Article
DE bronchoscopy; lymphadenitis; transbronchial needle aspiration;
tuberculosis
ID LYMPHADENOPATHY; ADULTS
AB This case report describes a patient with multi-drug-resistant mediastinal lymph node tuberculosis that evolved to smear-positive pulmonary tuberculosis following transbronchial needle aspiration. This is the first report of this complication, and bronchoscopists should be vigilant for its occurrence.
C1 [Gomez, Mario; Judson, Marc A.] Med Univ S Carolina, Div Pulm Crit Care Allergy & Sleep Med, Charleston, SC 29425 USA.
[Church, L. W. Preston] Ralph H Johnson VA Med Ctr, Div Infect Dis, Charleston, SC USA.
RP Gomez, M (reprint author), Med Univ S Carolina, Div Pulm Crit Care Allergy & Sleep Med, 96 Jonathan Lucas St,Suite 812 CSB,POB 250630, Charleston, SC 29425 USA.
EM mariogomezdel@gmail.com
OI Judson, Marc/0000-0002-4663-7985
FU Centocor; Gilead; Celegene; Merck
FX Drs Gomez and Church do not have any conflict of interest to declare. Dr
Judson is a consultant to Lilly and Centocor. He is on the speaker's
bureau for Bohringer-Ingelheim. He has received grants from Centocor,
Gilead, Celegene and Merck.
NR 10
TC 1
Z9 3
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1323-7799
J9 RESPIROLOGY
JI Respirology
PD OCT
PY 2010
VL 15
IS 7
BP 1140
EP 1141
PG 2
WC Respiratory System
SC Respiratory System
GA 655DZ
UT WOS:000282225400018
PM 20573061
ER
PT J
AU Chakraborty, BH
Steinhauer, SR
AF Chakraborty, Beatrice H.
Steinhauer, Stuart R.
TI Reporting of minority participation rates and racial differences in
schizophrenia and psychophysiological research: Improving but still not
adequate
SO SCHIZOPHRENIA RESEARCH
LA English
DT Letter
C1 [Chakraborty, Beatrice H.] VA Pittsburgh Healthcare Syst, Biometr Res Program, Pittsburgh, PA 15206 USA.
Univ Pittsburgh, Western Psychiat Inst & Clin, Sch Med, Pittsburgh, PA 15213 USA.
RP Chakraborty, BH (reprint author), VA Pittsburgh Healthcare Syst, Biometr Res Program, 7180 Highland Dr,151R, Pittsburgh, PA 15206 USA.
EM Bec27@pitt.edu; Sthauer@pitt.edu
FU NCRR NIH HHS [RR024153]; NIMH NIH HHS [MH55762, R01 MH055762]
NR 4
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD OCT
PY 2010
VL 123
IS 1
BP 90
EP 91
DI 10.1016/j.schres.2010.06.006
PG 2
WC Psychiatry
SC Psychiatry
GA 665IR
UT WOS:000283029100015
PM 20837319
ER
PT J
AU Snelgrove, RJ
Jackson, PL
Hardison, MT
Noerager, BD
Kinloch, A
Gaggar, A
Shastry, S
Rowe, SM
Shim, YM
Hussell, T
Blalock, JE
AF Snelgrove, Robert J.
Jackson, Patricia L.
Hardison, Matthew T.
Noerager, Brett D.
Kinloch, Andrew
Gaggar, Amit
Shastry, Suresh
Rowe, Steven M.
Shim, Yun M.
Hussell, Tracy
Blalock, J. Edwin
TI A Critical Role for LTA(4)H in Limiting Chronic Pulmonary Neutrophilic
Inflammation
SO SCIENCE
LA English
DT Article
ID LEUKOTRIENE A(4) HYDROLASE; CYSTIC-FIBROSIS; ENZYME; CHEMOATTRACTANT;
PEPTIDASE; AMINOPEPTIDASE; ARGININE; DISEASE; CELLS; COPD
AB Leukotriene A(4) hydrolase (LTA(4)H) is a proinflammatory enzyme that generates the inflammatory mediator leukotriene B-4 (LTB4). LTA(4)H also possesses aminopeptidase activity with unknown substrate and physiological importance; we identified the neutrophil chemoattractant proline-glycine-proline (PGP) as this physiological substrate. PGP is a biomarker for chronic obstructive pulmonary disease (COPD) and is implicated in neutrophil persistence in the lung. In acute neutrophil-driven inflammation, PGP was degraded by LTA(4)H, which facilitated the resolution of inflammation. In contrast, cigarette smoke, a major risk factor for the development of COPD, selectively inhibited LTA(4)H aminopeptidase activity, which led to the accumulation of PGP and neutrophils. These studies imply that therapeutic strategies inhibiting LTA(4)H to prevent LTB4 generation may not reduce neutrophil recruitment because of elevated levels of PGP.
C1 [Snelgrove, Robert J.; Jackson, Patricia L.; Hardison, Matthew T.; Gaggar, Amit; Shastry, Suresh; Rowe, Steven M.; Blalock, J. Edwin] Univ Alabama, Dept Med, Lung Hlth Ctr, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA.
[Snelgrove, Robert J.; Hussell, Tracy] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Leukocyte Biol Sect, London SW7 2AZ, England.
[Noerager, Brett D.] Univ Montevallo, Dept Biol Chem & Math, Montevallo, AL 35115 USA.
[Kinloch, Andrew] Univ London Imperial Coll Sci Technol & Med, Kennedy Inst Rheumatol, London W6 8LH, England.
[Gaggar, Amit; Rowe, Steven M.; Blalock, J. Edwin] Univ Alabama, Gregory Fleming James Cyst Fibrosis Ctr, Birmingham, AL 35294 USA.
[Gaggar, Amit] Birmingham VA Med Ctr, Birmingham, AL 35294 USA.
[Rowe, Steven M.] Univ Alabama, Dept Pediat, Birmingham, AL 35294 USA.
[Shim, Yun M.] Univ Virginia, Dept Med, Div Pulm & Crit Care Med, Charlottesville, VA 22908 USA.
RP Snelgrove, RJ (reprint author), Univ Alabama, Dept Med, Lung Hlth Ctr, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA.
EM rjs198@imperial.ac.uk
RI Hussell, Tracy/O-4630-2014; Kinloch, Anthony/F-6042-2011
OI Hussell, Tracy/0000-0001-7186-6141; Kinloch, Anthony/0000-0002-8752-7184
FU Wellcome Trust [082727/Z/07/Z]; National Heart, Lung, and Blood
Institute [HL07783, HL090999, HL087824, HL102371-A1, K08HL091127];
Cystic Fibrosis Foundation [GAGGAR07]; National Institute of Diabetes
and Digestive and Kidney Diseases [1K23DK075788, 1R03DK084110-01];
Flight Attendant Medical Research Institute; Medical Research Council
[P171/03/C1/048]; NIH [RR19231, P30CA13148, P50 AT00477, U54CA100949,
P30AR050948, P30 DK079337]
FX This project was supported by grants from the Wellcome Trust
(082727/Z/07/Z to R.J.S.), the National Heart, Lung, and Blood Institute
(HL07783, HL090999, and HL087824 to J.E.B. and HL102371-A1 to A. G.),
the Cystic Fibrosis Foundation (GAGGAR07 to A. G.), the National
Institute of Diabetes and Digestive and Kidney Diseases (1K23DK075788
and 1R03DK084110-01 to S. M. R.), the Flight Attendant Medical Research
Institute (Young Clinical Scientist Award to Y.M.S.) and the National
Heart, Lung, and Blood Institute (K08HL091127 to Y.M.S.), and the
Medical Research Council (P171/03/C1/048 to T. H.). The Univ. of Alabama
Birmingham (UAB) Lung Health Center Pulmonary Proteomics Laboratory is
funded through the NIH (by grants RR19231, P30CA13148, P50 AT00477,
U54CA100949, P30AR050948, and P30 DK079337). We thank R. Moore and L.
Wilson of the UAB Targeted Metabolomics and Proteomics Laboratory for
their technical assistance with mass spectrometry, D. Muccio of the UAB
Chemistry Department for the use of his fast protein liquid
chromatography system, G. Xia for technical assistance, and D. Saliba of
the Kennedy Institute of Rheumatology, Imperial College London, for his
technical assistance in the generation of murine LTA4H. The
content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Heart, Lung,
and Blood Institute or the NIH.
NR 30
TC 106
Z9 110
U1 1
U2 15
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD OCT 1
PY 2010
VL 330
IS 6000
BP 90
EP 94
DI 10.1126/science.1190594
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 656KW
UT WOS:000282334500042
PM 20813919
ER
PT J
AU Zhang, WT
Hu, XM
Yang, W
Gao, YQ
Chen, J
AF Zhang, Wenting
Hu, Xiaoming
Yang, Wei
Gao, Yanqin
Chen, Jun
TI Omega-3 Polyunsaturated Fatty Acid Supplementation Confers Long-Term
Neuroprotection Against Neonatal Hypoxic-Ischemic Brain Injury Through
Anti-Inflammatory Actions
SO STROKE
LA English
DT Article
DE hypoxia/ischemia; inflammation; polyunsaturated fatty acids
ID CEREBRAL-ISCHEMIA; ACTIVATION; PROTECTS
AB Background and Purpose-Current available therapies for neonatal hypoxia/ischemia (H/I) brain injury are rather limited. Here, we investigated the effect of omega-3 polyunsaturated fatty acids on brain damage and long-term neurological function after H/I in neonates.
Methods-Female rats were treated with or without an omega-3 polyunsaturated fatty acids-enriched diet from the second day of pregnancy until 14 days after parturition. Seven-day-old neonates were subjected to H/I and euthanized 5 weeks later for evaluation of tissue loss. Neurological impairment was assessed progressively for 5 weeks after H/I by grid walking, foot fault, and Morris water maze. Activation of microglia and production of inflammatory mediators were examined up to 7 days after H/I.
Results-Omega-3 polyunsaturated fatty acid supplementation significantly reduced brain damage and improved long-term neurological outcomes up to 5 weeks after neonatal H/I injury. Omega-3 polyunsaturated fatty acids exerted an anti-inflammatory effect in microglia both in an in vivo model of H/I and in in vitro microglial cultures subjected to inflammatory stimuli by inhibiting NF-kappa B activation and subsequent release of inflammatory mediators.
Conclusions-Our results suggest that omega-3 polyunsaturated fatty acids confer potent neuroprotection against neonatal H/I brain injury through, at least partially, suppressing a microglial-mediated inflammatory response. (Stroke. 2010;41:2341-2347.)
C1 [Zhang, Wenting; Hu, Xiaoming; Gao, Yanqin; Chen, Jun] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA.
[Zhang, Wenting; Hu, Xiaoming; Gao, Yanqin; Chen, Jun] Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA.
[Zhang, Wenting; Yang, Wei; Gao, Yanqin; Chen, Jun] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200433, Peoples R China.
[Zhang, Wenting; Yang, Wei; Gao, Yanqin; Chen, Jun] Fudan Univ, Inst Brain Sci, Shanghai 200433, Peoples R China.
[Hu, Xiaoming; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
RP Chen, J (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA.
EM yqgao@shmu.edu.cn; chenj2@upmc.edu
RI Gao, Yanqin/I-6790-2016
OI Gao, Yanqin/0000-0002-4915-9819
FU National Institutes of Health [NS45048, NS056118, NS036736]; Chinese
Natural Science Foundation [30870794]; Shanghai Science & Technology
Bureau [08410703000]; Chinese Ministry of Science Technology; American
Heart Association [10POST4150028]
FX This project was supported by National Institutes of Health grants
NS45048, NS056118, and NS036736 (to J.C); Chinese Natural Science
Foundation grant (30870794) and International Collaboration grant
(08410703000) from Shanghai Science & Technology Bureau (to Y.G and
J.C); and Special Research Funds from Chinese Ministry of Science &
Technology to State Key laboratories. X.H. is supported by a fellowship
award from the American Heart Association (10POST4150028).
NR 20
TC 57
Z9 60
U1 2
U2 15
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0039-2499
J9 STROKE
JI Stroke
PD OCT
PY 2010
VL 41
IS 10
BP 2341
EP 2347
DI 10.1161/STROKEAHA.110.586081
PG 7
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 655CY
UT WOS:000282221700048
PM 20705927
ER
PT J
AU Wortzel, HS
Gutierrez, PM
Homaifar, BY
Breshears, RE
Harwood, JE
AF Wortzel, Hal S.
Gutierrez, Peter M.
Homaifar, Beeta Y.
Breshears, Ryan E.
Harwood, Jeri E.
TI Surrogate Endpoints in Suicide Research
SO SUICIDE AND LIFE-THREATENING BEHAVIOR
LA English
DT Article
ID TOWER-OF-BABEL; REVISED NOMENCLATURE; DECISION-MAKING; CLINICAL-TRIALS;
BEHAVIORS; LETHALITY; ATTEMPTERS; FAMILIES; GENETICS
AB Surrogate endpoints frequently substitute for rare outcomes in research. The ability to learn about completed suicides by investigating more readily available and proximate outcomes, such as suicide attempts, has obvious appeal. However, concerns with surrogates from the statistical science perspective exist, and mounting evidence from psychometric, neurochemical, genetic, and neuroimaging studies suggests that surrogates may be particularly problematic in suicide research. The need for greater phenotypic refinement of suicide-related behaviors, development of and adherence to a shared suicide nomenclature, and conservative interpretation of investigational results that are limited to the precise population and suicide-related behavior under examination are discussed.
C1 [Wortzel, Hal S.; Gutierrez, Peter M.; Homaifar, Beeta Y.; Breshears, Ryan E.] Denver VA Med Ctr, VISN MIRECC 19, Denver, CO USA.
[Wortzel, Hal S.; Gutierrez, Peter M.; Homaifar, Beeta Y.; Breshears, Ryan E.] Univ Colorado, Denver Sch Med, Dept Psychiat, Boulder, CO 80309 USA.
[Harwood, Jeri E.] Univ Colorado, Denver Sch Med, Dept Pediat, Boulder, CO 80309 USA.
RP Wortzel, HS (reprint author), Denver Vet Hosp, VISN MIRECC 19, 1055 Clermont St,Room 4E130, Denver, CO 80220 USA.
EM hal.wortzel@ucdenver.edu
OI Gutierrez, Peter/0000-0001-8981-8404
NR 25
TC 3
Z9 3
U1 0
U2 0
PU GUILFORD PUBLICATIONS INC
PI NEW YORK
PA 72 SPRING STREET, NEW YORK, NY 10012 USA
SN 0363-0234
J9 SUICIDE LIFE-THREAT
JI Suicide Life-Threat. Behav.
PD OCT
PY 2010
VL 40
IS 5
BP 500
EP 505
PG 6
WC Psychiatry; Psychology, Multidisciplinary
SC Psychiatry; Psychology
GA 670GM
UT WOS:000283409200008
PM 21034212
ER
PT J
AU Ingraham, AM
Cohen, ME
Bilimoria, KY
Pritts, TA
Ko, CY
Esposito, TJ
AF Ingraham, Angela M.
Cohen, Mark E.
Bilimoria, Karl Y.
Pritts, Timothy A.
Ko, Clifford Y.
Esposito, Thomas J.
TI Comparison of outcomes after laparoscopic versus open appendectomy for
acute appendicitis at 222 ACS NSQIP hospitals
SO SURGERY
LA English
DT Article; Proceedings Paper
CT 67th Annual Meeting of the Central-Surgical-Association
CY MAR 10-13, 2010
CL Chicago, IL
SP Cent Surg Assoc
ID PROSPECTIVE RANDOMIZED-TRIAL; CONVENTIONAL APPENDECTOMY; COMPLICATED
APPENDICITIS; PERFORATED APPENDICITIS; CLINICAL-TRIAL; SURGICAL CARE;
BLINDED TRIAL; METAANALYSIS; STANDARD; SURGERY
AB Background. The benefit of laparoscopic (LA) versus open (OA) appendectomy, particularly for complicated appendicitis, remains unclear Our objectives were to assess 30-day outcomes after LA versus OA for acute appendicitis and complicated appendicitis, determine the incidence of specific outcomes after appendectomy, and examine factors influencing the utilization and duration of the operative approach with multi-institutional clinical data.
Methods. Using the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) database (2005-2008), patients were identified who underwent emergency appendectomy for acute appendicitis at 222 participating hospitals. Regression models, which included propensity scare adjustment to minimize the influence of treatment selection bias, were constructed. Models assessed the association between surgical approach (LA vs OA) and risk-adjusted overall morbidity, surgical site infliction (SSI), serious morbidity, and serious morbidity/mortality, as well as individual complications in patients with acute appendicitis and complicated appendicitis. The relationships between operative approach, operative duration, and extended duration of stay with hospital academic affiliation were also examined.
Results. Of 32,683 patients, 24,969 (76.4%) underwent LA and 7,714 (23.6%) underwent OA. Patients who underwent OA were significantly older with more comorbidities compared with those who underwent LA. Patients treated with LA were less likely to experience an overall morbidity (4.5% vs 8.8%; odds ratio [OR], 0.60; 95% confidence interval [CI], 0.54-0.68) or a SSI (3.3% vs 6.7%; OR, 0.57; 95% CI, 0.50-0.65) but not a serious morbidity (2.6% vs 4.2%; OR, 0.86; 95% CI, 0.74-1.01) or a serious morbidity/mortality (2.6% vs 4.3%; OR, 0.87; 95% CI, 0.74-1.01) compared with those who underwent OA. All patients treated with LA were significantly less likely to develop individual infectious complications except for organ. space SSI. Among patients with complicated appendicitis, organ space SSI was significantly more common after laparoscopic appendectomy (6.3% vs 4.8%; OR, 1.35; 95% CI, 1.05-1.73). For all patients with acute appendicitis, those treated at academic-affiliated versus community hospitals were equally likely to undergo LA versus OA (77.0% vs 77.3%; P = .58). Operative duration at academic centers was significantly longer for both LA and OA (LA, 47 vs 38 minutes [P < .0001]; OA, 49 vs 44 minutes [P < .0001]). Median duration of stay after LA was I day at both academic-affiliated and community hospitals.
Conclusion. Within ACS NSQIP hospitals, LA is associated with lower overall morbidity in selected patients. However patients with complicated appendicitis may have a greater risk of organ space SSI after LA. Academic affiliation does not seem to influence the operative approach. However; LA is associated with similar durations of stay but slightly putter operative times than OA at academic versus community hospitals. (Surgery 2010;148:625-37.)
C1 [Ingraham, Angela M.; Cohen, Mark E.; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA.
[Ingraham, Angela M.; Pritts, Timothy A.] Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH 45267 USA.
[Bilimoria, Karl Y.; Esposito, Thomas J.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL 60611 USA.
[Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA.
VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Esposito, Thomas J.] Loyola Univ Chicago, Stritch Sch Med, Dept Surg, Maywood, IL USA.
RP Ingraham, AM (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair St,Floor 22NE, Chicago, IL 60611 USA.
EM aingraham@facs.org
NR 78
TC 88
Z9 94
U1 3
U2 7
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-6060
J9 SURGERY
JI Surgery
PD OCT
PY 2010
VL 148
IS 4
BP 625
EP 635
DI 10.1016/j.surg.2010.07.025
PG 11
WC Surgery
SC Surgery
GA 654WJ
UT WOS:000282201500004
PM 20797745
ER
PT J
AU Lin, R
Hogen, V
Cannon, S
Marion, KM
Fenton, MS
Hershman, JM
AF Lin, Rose
Hogen, Victor
Cannon, Sophie
Marion, Kenneth M.
Fenton, Mike S.
Hershman, Jerome M.
TI Stability of Recombinant Human Thyrotropin Potency Based on Bioassay in
FRTL-5 Cells
SO THYROID
LA English
DT Article
ID DIFFERENTIATED THYROID-CANCER; MULTINODULAR GOITERS; RADIOIODINE
TREATMENT; NODULAR GOITER; SINGLE; REDUCTION; THERAPY
AB Background: Recombinant human thyrotropin (rhTSH; Thyrogen (R)) is approved for use in a 0.9mg dose/day for 2 consecutive days for diagnosis and treatment of differentiated thyroid cancer. It is recommended that it be injected immediately after reconstitution in the distilled water diluent supplied by the manufacturer. However, Thyrogen has been used off-label in doses less than the standard 0.9mg dose for stimulation of radioiodine uptake in the treatment of multinodular goiter. To determine whether the biologic activity of Thyrogen can be preserved after dilution, we designed experiments to assess the biologic stability of Thyrogen under different durations and temperatures of storage.
Methods: rhTSH was diluted in 1% bovine serum albumin in phosphate-buffered saline to a concentration of 0.9mg/mL and further diluted to 0.1mg/mL. Aliquots of 0.5mL were stored at room temperature, 4 degrees 8C, -11 degrees C, and -60 degrees C for various lengths of time. In addition, rhTSH aliquots were also subjected to incubation for 1 hour at 50 degrees C and to 10 cycles of freezing in dry ice alternating with thawing at 37 degrees C. Bioassays were performed in FRTL-5 cells. rhTSH was added to the media at a final concentration of either 5 ng/mL or 20 ng/mL, and the cells were then incubated for 48 hours. Potency was assessed by measurement of (125)I-iodide uptake in comparison to cells treated with perchlorate to block iodide uptake. Samples were immunoassayed at day 185 of storage.
Results: Samples stored at 4 degrees C, -11 degrees C, -60 degrees C, and room temperature retained activity after storage periods of up to 204 days. Samples subjected to 10 freeze-thaw cycles or heated to 50 degrees C for 1 hour retained full biologic activity. Immunoassay at day 185 showed no difference in immunoactivity in relation to the storage condition.
Conclusion: rhTSH kept at 4 degrees C, -11 degrees C, -60 degrees C, and room temperature maintained good biologic potency for more than 6 months of storage when tested in vitro, indicating that the biologic activity is very stable. However, altered sialylation occurring during storage could have altered the half-life of rhTSH. Nevertheless, the data provide reassurance that storage in the cold for a few months does not result in significant loss of biologic activity.
C1 [Hershman, Jerome M.] W Los Angeles Vet Affairs Med Ctr, Endocrinol & Diabet Div, Los Angeles, CA 90073 USA.
Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA.
RP Hershman, JM (reprint author), W Los Angeles Vet Affairs Med Ctr, Endocrinol & Diabet Div, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM jhershmn@ucla.edu
OI Cannon, Sophie M/0000-0003-1643-6944
FU VA; UCLA
FX This work was supported by VA and UCLA Medical Research Funds. The
authors are grateful to Eduardo De Guia for performing the immunoassays
and to Armen Okunyan for assistance with cell culture.
NR 13
TC 6
Z9 8
U1 0
U2 4
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1050-7256
J9 THYROID
JI Thyroid
PD OCT
PY 2010
VL 20
IS 10
BP 1139
EP 1143
DI 10.1089/thy.2009.0408
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 656UL
UT WOS:000282363700012
PM 20615135
ER
PT J
AU Dasgupta, SK
Argaiz, ER
Mercado, JEC
Maul, HOE
Garza, J
Enriquez, AB
Abdel-Monem, H
Prakasam, A
Andreeff, M
Thiagarajan, P
AF Dasgupta, Swapan Kumar
Argaiz, Eduardo Rios
Mercado, Jose Emmanel Chedid
Maul, Hector Omar Elizondo
Garza, Jorge
Enriquez, Ana Bety
Abdel-Monem, Hanan
Prakasam, Anthony
Andreeff, Michael
Thiagarajan, Perumal
TI Platelet senescence and phosphatidylserine exposure
SO TRANSFUSION
LA English
DT Article
ID PERMEABILITY TRANSITION PORE; PROTEIN-KINASE; EXPRESSION; MEMBRANE;
MITOCHONDRIA; BINDING; CELLS
AB BACKGROUND:
The exposure of phosphatidylserine occurs during platelet (PLT) activation and during in vitro storage. Phosphatidylserine exposure also occurs during apoptosis after the release of mitochondrial cytochrome c. We have examined the role of cytochrome c release, mitochondrial membrane potential (Delta Psi m), and cyclophilin D (CypD) in phosphatidylserine exposure due to activation and storage.
STUDY DESIGN AND METHODS:
The exposure of phosphatidylserine and the loss of Delta Psi m were determined in a flow cytometer using fluorescein isothiocyanate-lactadherin and JC-1, a lipophilic cationic reporter dye. The role of CypD was determined with cyclosporin A and CypD-deficient murine PLTs. Cytochrome c-induced caspase-3 and Rho-associated kinase I (ROCK1) activation were determined by immunoblotting and using their inhibitors.
RESULTS:
Collagen- and thrombin-induced exposure of phosphatidylserine was accompanied by a decrease in Delta Psi m. Cyclosporin A inhibited the phosphatidylserine exposure and the loss of Delta Psi m. CypD-/- mice had decreased loss of Delta Psi m and impaired phosphatidylserine exposure. Collagen and thrombin did not induce the release of cytochrome c nor the activation of caspase-3 and ROCK1. In contrast, in PLTs stored for more than 5 days, the phosphatidylserine exposure was associated with cytochrome c-induced caspase-3 and ROCK1 activation. ABT737, a BH3 mimetic that induces mitochondrial pathway of apoptosis, induced cytochrome c release and activation of caspase-3 and ROCK1 and phosphatidylserine exposure independent of CypD.
CONCLUSION:
These results show that in stored PLTs cytochrome c release and the subsequent activation of caspase-3 and ROCK1 mediate phosphatidylserine exposure and it is distinct from activation-induced phosphatidylserine exposure.
C1 Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Pathol, Houston, TX 77030 USA.
Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA.
Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA.
RP Thiagarajan, P (reprint author), Michael E DeBakey VA Med Ctr, Mail Stop 113,2002 Holcombe Blvd, Houston, TX 77030 USA.
EM perumalt@bcm.tmc.edu
OI Thiagarajan, Perumal/0000-0003-2186-7036
FU Veterans Affairs Research Service; National Institutes of Health
[T-32HL072754]
FX Supported by grants from the Veterans Affairs Research Service and by a
training grant from National Institutes of Health (T-32HL072754).
NR 31
TC 25
Z9 25
U1 0
U2 5
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0041-1132
J9 TRANSFUSION
JI Transfusion
PD OCT
PY 2010
VL 50
IS 10
BP 2167
EP 2175
DI 10.1111/j.1537-2995.2010.02676.x
PG 9
WC Hematology
SC Hematology
GA 661AF
UT WOS:000282693500014
PM 20456701
ER
PT J
AU Forsberg, CW
Goldberg, J
Sporleder, J
Smith, NL
AF Forsberg, Christopher W.
Goldberg, Jack
Sporleder, Jennifer
Smith, Nicholas L.
TI Determining Zygosity in the Vietnam Era Twin Registry: An Update
SO TWIN RESEARCH AND HUMAN GENETICS
LA English
DT Article
DE Questionnaire Zygosity Determination; Vietnam Era Twin Registry; Twin
Study
ID QUESTIONNAIRE
AB Our work assessed the accuracy of the original zygosity classification in the Vietnam Era Twin (VET) Registry using new information from DNA markers on a subset of participants. We then constructed an updated zygosity classification algorithm. The VET Registry includes 7,375 male-male twin pairs who served in the military during the Vietnam era. During the mid-1980s 4,774 twin pairs completed a zygosity questionnaire of 20 items. Additionally, military record information, including blood group, was available. Items from the zygosity questionnaire and blood group were used in the original zygosity classification. Between 1990-2009 DNA was obtained from 612 twin pairs and concordance between co-twins was used to classify zygosity. Next logistic regression was used to construct predicted probabilities of zygosity using items from the zygosity questionnaire with this subsample. All twins were reclassified according to the new zygosity prediction model and compared with the original zygosity assignment. The original and new predicted probabilities of zygosity were highly correlated (r = 0.962) and concordance for the classification of zygosity was similarly high (kappa = 0.936). Errors in the original zygosity assignment were primarily due to monozygotic twins that were misclassified as dizygotic based on military record blood group data. Removing the military record blood group data markedly improved the accuracy of the original classification. Zygosity assignment based on a zygosity questionnaire was highly predictive of DNA-based zygosity. Augmentation of such a zygosity classification from administrative data, military records, or other records, should be done with caution.
C1 [Forsberg, Christopher W.; Goldberg, Jack; Sporleder, Jennifer; Smith, Nicholas L.] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Dept Vet Affairs Off Res & Dev, Vietnam Era Twin Registry, Seattle, WA 98101 USA.
[Goldberg, Jack; Smith, Nicholas L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Smith, Nicholas L.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA.
RP Forsberg, CW (reprint author), VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Dept Vet Affairs Off Res & Dev, Vietnam Era Twin Registry, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA.
EM Christopher.Forsberg@va.gov
FU United States Department of Veterans Affairs
FX The United States Department of Veterans Affairs has provided financial
support for the development and maintenance of the Vietnam Era Twin
(VET) Registry. The views expressed in this article are those of the
authors and do not necessarily represent the views of the Department of
Veterans Affairs. Numerous organizations have provided invaluable
assistance in the conduct of this study, including: Department of
Defense; National Personnel Records Cente; National Archives and Records
Administration; the Internal Revenue Service; National Institutes et
Health; National Opinion Research Center; National Research Council,
National Academy of Sciences; the Institute for Survey Research, Temple
University. Most importantly, the authors gratefully acknowledge the
continued cooperation and participation of the members of the VET
Registry and their families. Without their contribution this research
would not have been possible.
NR 10
TC 11
Z9 12
U1 0
U2 0
PU AUSTRALIAN ACAD PRESS
PI BOWEN HILLS
PA 32 JEAYS ST, BOWEN HILLS, QLD 4006, AUSTRALIA
SN 1832-4274
J9 TWIN RES HUM GENET
JI Twin Res. Hum. Genet.
PD OCT
PY 2010
VL 13
IS 5
BP 461
EP 464
PG 4
WC Genetics & Heredity; Obstetrics & Gynecology
SC Genetics & Heredity; Obstetrics & Gynecology
GA 664YX
UT WOS:000283001300008
PM 20874468
ER
PT J
AU Xiao, YH
Isaacs, SN
AF Xiao, Yuhong
Isaacs, Stuart N.
TI Therapeutic Vaccines and Antibodies for Treatment of Orthopoxvirus
Infections
SO VIRUSES-BASEL
LA English
DT Review
DE orthopoxvirus; variola virus; vaccinia virus; monkeypox virus;
post-exposure vaccination; Dryvax; Lister; modified vaccinia Ankara
(MVA); vaccinia immune globulin (VIG); monoclonal antibodies
ID ANTIVACCINIAL GAMMA-GLOBULIN; NEUTRALIZING MONOCLONAL-ANTIBODIES;
SECONDARY POXVIRUS INFECTION; IMMUNE GLOBULIN; SMALLPOX VACCINATION;
PROGRESSIVE VACCINIA; VIRUS-INFECTION; PROTECTIVE ANTIBODIES; ECZEMA
VACCINATUM; IN-VITRO
AB Despite the eradication of smallpox several decades ago, variola and monkeypox viruses still have the potential to become significant threats to public health. The current licensed live vaccinia virus-based smallpox vaccine is extremely effective as a prophylactic vaccine to prevent orthopoxvirus infections, but because of safety issues, it is no longer given as a routine vaccine to the general population. In the event of serious human orthopoxvirus infections, it is important to have treatments available for individual patients as well as their close contacts. The smallpox vaccine and vaccinia immune globulin (VIG) were used in the past as therapeutics for patients exposed to smallpox. VIG was also used in patients who were at high risk of developing complications from smallpox vaccination. Thus post-exposure vaccination and VIG treatments may again become important therapeutic modalities. This paper summarizes some of the historic use of the smallpox vaccine and immunoglobulins in the post-exposure setting in humans and reviews in detail the newer animal studies that address the use of therapeutic vaccines and immunoglobulins in orthopoxvirus infections as well as the development of new therapeutic monoclonal antibodies.
C1 [Xiao, Yuhong; Isaacs, Stuart N.] Univ Penn, Sch Med, Div Infect Dis, Philadelphia, PA 19104 USA.
[Isaacs, Stuart N.] Philadelphia Vet Affairs Med Ctr, Infect Dis Sect, Philadelphia, PA 19104 USA.
RP Isaacs, SN (reprint author), Univ Penn, Sch Med, Div Infect Dis, Philadelphia, PA 19104 USA.
EM yuhong2@mail.med.upenn.edu; isaacs@mail.med.upenn.edu
FU National Institute of Allergy and Infectious Disease (Middle Atlantic
Regional Center of Excellence in Biodefense and Emerging Infectious
Diseases) [U01-AI077913, U01-AI066333, U54-AI057168]
FX We thank Matt Cohen for critical reading of the manuscript. S.N.I. is
supported in part by Public Health Service grants U01-AI077913,
U01-AI066333, and U54-AI057168 (Middle Atlantic Regional Center of
Excellence in Biodefense and Emerging Infectious Diseases) from the
National Institute of Allergy and Infectious Disease. The views
expressed in this article are those of the authors and do not
necessarily reflect the position or policy of the University of
Pennsylvania, the Department of Veterans Affairs or the United States
government.
NR 79
TC 4
Z9 5
U1 0
U2 0
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD OCT
PY 2010
VL 2
IS 10
BP 2381
EP 2403
DI 10.3390/v2102381
PG 23
WC Virology
SC Virology
GA 684VQ
UT WOS:000284581900011
PM 21197387
ER
PT J
AU DeKosky, ST
Ikonomovic, MD
Gandy, S
AF DeKosky, Steven T.
Ikonomovic, Milos D.
Gandy, Sam
TI Traumatic Brain Injury -- Football, Warfare, and Long-Term Effects.
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
C1 [DeKosky, Steven T.] Univ Virginia, Sch Med, Dept Neurol, Charlottesville, VA 22908 USA.
[Ikonomovic, Milos D.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA.
[Ikonomovic, Milos D.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15261 USA.
[Ikonomovic, Milos D.] VA Pittsburgh Healthcare Syst, Geriatr Res Edu & Clin Ctr, Pittsburgh, PA USA.
[Gandy, Sam] Mt Sinai Sch Med, Dept Neurol, New York, NY USA.
[Gandy, Sam] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
[Gandy, Sam] Mt Sinai Sch Med, Alzheimers Dis Res Ctr, New York, NY USA.
[Gandy, Sam] James J Peters VA Med Ctr, New York, NY USA.
RP DeKosky, ST (reprint author), Univ Virginia, Sch Med, Dept Neurol, Charlottesville, VA 22908 USA.
FU NIA NIH HHS [P01 AG010491, P01 AG010491-14]
NR 5
TC 123
Z9 125
U1 1
U2 13
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD SEP 30
PY 2010
VL 363
IS 14
BP 1293
EP 1296
DI 10.1056/NEJMp1007051
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA 655TD
UT WOS:000282271500001
PM 20879875
ER
PT J
AU Townsend, JD
Eberhart, NK
Bookheimer, SY
Eisenberger, NI
Foland-Ross, LC
Cook, IA
Sugar, CA
Altshuler, LL
AF Townsend, Jennifer D.
Eberhart, Nicole K.
Bookheimer, Susan Y.
Eisenberger, Naomi I.
Foland-Ross, Lara C.
Cook, Ian A.
Sugar, Catherine A.
Altshuler, Lori L.
TI fMRI activation in the amygdala and the orbitofrontal cortex in
unmedicated subjects with major depressive disorder
SO PSYCHIATRY RESEARCH-NEUROIMAGING
LA English
DT Article
DE Amygdala; DLPFC; Emotion; Major depressive disorder
ID FUNCTIONAL MAGNETIC-RESONANCE; MOOD REGULATING CIRCUIT; UNIPOLAR
DEPRESSION; FACIAL EXPRESSIONS; ANTIDEPRESSANT TREATMENT;
COGNITIVE-CONTROL; NEURAL RESPONSES; BRAIN IMAGES; RISK-FACTORS;
CONNECTIVITY
AB Although amygdala and frontal lobe functional abnormalities have been reported in patients with mood disorders, the literature regarding major depressive disorder (MDD) is inconsistent. Likely confounds include heterogeneity of patient samples, medication status, and analytic approach. This study evaluated the amygdala and frontal lobe activation in unmedicated MDD patients. Fifteen MDD patients and 15 matched healthy controls were scanned using fMRI during the performance of an emotional face task known to robustly activate the amygdala and prefrontal cortex (PFC). Whole-brain and region of interest analyses were performed, and correlations between clinical features and activation were examined. Significant amygdala and lateral PFC activation were seen within patient and control groups. In a between-group comparison, patients showed significantly reduced activation in the insula, temporal and occipital cortices. In MDD, the presence of anxiety symptoms was associated with decreased orbitofrontal activation. We found robust activation in both the MOD and control groups in fronto-limbic regions with no significant between-group differences using either analytic approach. The current study replicates previous research on unmedicated subjects showing no significant differences in amygdala function in depressed vs. control subjects with respect to simple tasks involving emotion observation. (c) 2010 Elsevier Ireland Ltd. All rights reserved.
C1 [Townsend, Jennifer D.; Bookheimer, Susan Y.; Cook, Ian A.; Altshuler, Lori L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Townsend, Jennifer D.; Bookheimer, Susan Y.; Cook, Ian A.; Altshuler, Lori L.] Semel Inst Neurosci & Human Behav, Los Angeles, CA USA.
[Eberhart, Nicole K.] RAND Corp, Santa Monica, CA USA.
[Eisenberger, Naomi I.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA.
[Foland-Ross, Lara C.] Univ Calif Los Angeles, Sch Med, Dept Neurol, Lab NeuroImaging, Los Angeles, CA 90024 USA.
[Sugar, Catherine A.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA.
[Altshuler, Lori L.] VA Greater Los Angeles Healthcare Syst, Dept Psychiat, W Los Angeles Healthcare Ctr, Los Angeles, CA USA.
RP Altshuler, LL (reprint author), 300 UCLA Med Plaza,Suite 1544,Box 696824, Los Angeles, CA 90095 USA.
EM laltshuler@mednet.ucla.edu
FU Stein Oppenheimer Foundation; National Center for Research Resources
(NCRR) [RR12169, RR13642, RR00865]; National Institutes of Health (NIH)
FX We are grateful for funding from the Stein Oppenheimer Foundation which
supported this research. For generous support the authors also wish to
thank the Brain Mapping Medical Research Organization, Brain Mapping
Support Foundation, Pierson-Lovelace Foundation, the Ahmanson
Foundation, the William M. and Linda R. Dietel Philanthropic Fund at the
Northern Piedmont Community Foundation, the Tamkin Foundation, the
Jennifer Jones-Simon Foundation, the Capital Group Companies Charitable
Foundation, the Robson Family and the Northstar Fund. The project
described was supported by Grant Numbers RR12169, RR13642 and RR00865
from the National Center for Research Resources (NCRR), a component of
the National Institutes of Health (NIH); its contents are solely the
responsibility of the authors and do not necessarily represent the
official views of NCR or NIH. Cyberonics, Eli Lilly and Company, Forest
laboratories, Janssen, Neuronetics, Scale Venture Partners, and the U.S.
Department of Justice; and has been a member of the speakers bureau for
Bristol-Myers Squibb, CME LLC, Medical Education Speakers Network,
Pfizer, and Wyeth. Dr. Cook is not a shareholder in any pharmaceutical
or medical device company; his patents are assigned to the University of
California. In the past 5 years, Dr. Altshuler has received grant
support from Abbott Laboratories; honoraria from Abbott Laboratories,
Forest Laboratories and GlaxoS-mithldine; has served on advisory boards
for Abbott Laboratories and Forest Laboratories; and has been a member
of the speakers bureau for Forest Laboratories and GlaxoSmithKline. Dr.
Altshuler is not a shareholder in any pharmaceutical or medical device
company. The remaining authors have no conflicts of interest to declare.
NR 71
TC 50
Z9 50
U1 3
U2 14
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0925-4927
J9 PSYCHIAT RES-NEUROIM
JI Psychiatry Res. Neuroimaging
PD SEP 30
PY 2010
VL 183
IS 3
BP 209
EP 217
DI 10.1016/j.pscychresns.2010.06.001
PG 9
WC Clinical Neurology; Neuroimaging; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 654BJ
UT WOS:000282142800005
PM 20708906
ER
PT J
AU Brody, AL
London, ED
Olmstead, RE
Allen-Martinez, Z
Shulenberger, S
Costello, MR
Abrams, AL
Scheibal, D
Farahi, J
Shoptaw, S
Mandelkern, MA
AF Brody, Arthur L.
London, Edythe D.
Olmstead, Richard E.
Allen-Martinez, Zoe
Shulenberger, Stephanie
Costello, Matthew R.
Abrams, Anna L.
Scheibal, David
Farahi, Judah
Shoptaw, Steven
Mandelkern, Mark A.
TI Smoking-induced change in intrasynaptic dopamine concentration: Effect
of treatment for Tobacco Dependence
SO PSYCHIATRY RESEARCH-NEUROIMAGING
LA English
DT Article
DE Tobacco Dependence; (11)C-raclopride; Positron emission tomography;
Dopamine; Ventral striatum; Cigarette craving
ID POSITRON-EMISSION-TOMOGRAPHY; SUSTAINED-RELEASE BUPROPION; SYNAPSE
IN-VIVO; NUCLEUS-ACCUMBENS; CONTINUOUS-INFUSION; NICOTINE PATCH;
HUMAN-BRAIN; RACLOPRIDE BINDING; EXTRACELLULAR DOPAMINE; C-11
RACLOPRIDE
AB The aim of this study was to determine whether standard treatments for Tobacco Dependence affect smoking-induced changes in intrasynaptic dopamine (DA) concentration. Forty-three otherwise healthy adult cigarette smokers (10 to 40 cigarettes per day) were treated with either practical group counseling (PGC) psychotherapy (n = 14), bupropion HCl (n = 14), or matching pill placebo (n = 15) (random assignment) for 8 weeks. Before and after treatment, each subject underwent a bolus-plus-continuous-infusion (11)C-raclopride positron emission tomography (PET) scanning session, during which he or she smoked a regular cigarette. The PET scanning outcome measure of interest was percent change in smoking-induced 11C-raclopride binding potential (BP(ND)) in the ventral caudate/nucleus accumbens (VCD/NAc), as an indirect measure of DA release. Although the entire study sample had a smaller mean smoking-induced reduction in VCD/NAc BP(ND) after treatment (compared to before treatment), this change was highly correlated with smaller total cigarette puff volumes (and not other treatment variables). These data indicate that smoking-induced DA release is dose-dependent, and is not significantly affected by reductions in daily smoking levels or treatment type. Published by Elsevier Ireland Ltd.
C1 [Brody, Arthur L.; London, Edythe D.; Allen-Martinez, Zoe; Costello, Matthew R.; Abrams, Anna L.; Scheibal, David] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90095 USA.
[Brody, Arthur L.; Olmstead, Richard E.; Allen-Martinez, Zoe; Shulenberger, Stephanie; Costello, Matthew R.; Abrams, Anna L.; Scheibal, David; Farahi, Judah; Mandelkern, Mark A.] Greater Los Angeles VA Healthcare Syst, Dept Nucl Med, Los Angeles, CA USA.
[Brody, Arthur L.; London, Edythe D.; Shoptaw, Steven] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA.
[London, Edythe D.] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA.
[Shoptaw, Steven] Univ Calif Los Angeles, Dept Family Med, Los Angeles, CA 90095 USA.
[Mandelkern, Mark A.] Univ Calif Irvine, Dept Phys, Irvine, CA 92717 USA.
RP Brody, AL (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, 300 UCLA Med Plaza,Suite 2200, Los Angeles, CA 90095 USA.
EM abrody@ucla.edu
FU Tobacco-Related Disease Research Program [11RT-0024, 16RT-0098];
National Institute on Drug Abuse [R01 DA15059, DA20872]; Veterans
Affairs Type I Merit Review Award; Office of National Drug Control
Policy [DABT63-00-C-1003]
FX Supported by the Tobacco-Related Disease Research Program (A.L.B.
[11RT-0024 and 16RT-0098]), the National Institute on Drug Abuse (A.L.B.
[R01 DA15059 and DA20872]), a Veterans Affairs Type I Merit Review Award
(A.L.B.), and the Office of National Drug Control Policy (E.D.L
[DABT63-00-C-1003]). The authors thank Josephine Ribe and Michael Clark
for their technical support in performing positron emission tomography
and magnetic resonance imaging scans, respectively.
NR 73
TC 15
Z9 15
U1 1
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0925-4927
J9 PSYCHIAT RES-NEUROIM
JI Psychiatry Res. Neuroimaging
PD SEP 30
PY 2010
VL 183
IS 3
BP 218
EP 224
DI 10.1016/j.pscychresns.2009.06.004
PG 7
WC Clinical Neurology; Neuroimaging; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 654BJ
UT WOS:000282142800006
PM 20682457
ER
PT J
AU Hajcak, G
Anderson, BS
Arana, A
Borckardt, J
Takacs, I
George, MS
Nahas, Z
AF Hajcak, G.
Anderson, B. S.
Arana, A.
Borckardt, J.
Takacs, I.
George, M. S.
Nahas, Z.
TI DORSOLATERAL PREFRONTAL CORTEX STIMULATION MODULATES ELECTROCORTICAL
MEASURES OF VISUAL ATTENTION: EVIDENCE FROM DIRECT BILATERAL EPIDURAL
CORTICAL STIMULATION IN TREATMENT-RESISTANT MOOD DISORDER
SO NEUROSCIENCE
LA English
DT Article
DE brain stimulation; attention; IAPS; late positive potential
ID EMOTIONAL PICTURES; MOTIVATED ATTENTION; AROUSING PICTURES; BRAIN
POTENTIALS; NEURAL RESPONSE; ORGANIZATION; ASSOCIATION; PERCEPTION;
AMYGDALA; FACILITATION
AB Electrocortical activity is increasingly being used to study emotion regulation and the impact of cognitive control on neural response to visual stimuli. In the current study, we used direct epidural cortical stimulation (EpCS) to examine regional specificity of PFC stimulation on the parietally-maximal late positive potential (LPP), an event-related potential (ERP) biomarker of visual attention to salient stimuli. Five patients with treatment-resistant mood disorders were stereotactically implanted with stimulating paddles over frontopolar (FP) and dorsolateral (DL) prefrontal cortex bilaterally. On their first day of activation, patients underwent sham-controlled EpCS coupled with 64-channel electroencephalograph (EEG) recordings and passive viewing of aversive and neutral images. In addition to sham, patients had either FP or DL prefrontal cortex stimulated at 2 or 4 V while they viewed neutral and aversive pictures. As expected during the sham condition, LPP was larger for aversive compared to neutral stimuli (F(1,4)=232.07, P<.001). Stimulation of DL compared to FP prefrontal cortex resulted in a reduction of the LPP (F(1,4)=8.15, P=.048). These data provide additional and unique support to the role of the DL prefrontal cortex in regulating measures of neural activity that have been linked to emotional arousal and attention. Future studies with EpCS can help directly map out various prefrontal functions in treatment-resistant mood disorder. (C) 2010 IBRO. Published by Elsevier Ltd. All rights reserved.
C1 [Hajcak, G.] SUNY Stony Brook, Dept Psychol, Stony Brook, NY 11794 USA.
[Anderson, B. S.; Arana, A.; Borckardt, J.; George, M. S.; Nahas, Z.] Med Univ S Carolina, Mood Disorders Program, Charleston, SC 29425 USA.
[Anderson, B. S.; Arana, A.; Borckardt, J.; George, M. S.; Nahas, Z.] Med Univ S Carolina, Dept Psychiat, Brain Stimulat Lab, Charleston, SC 29425 USA.
[Borckardt, J.; George, M. S.; Nahas, Z.] Med Univ S Carolina, CAIR, Charleston, SC 29425 USA.
[Borckardt, J.; Takacs, I.; George, M. S.; Nahas, Z.] Med Univ S Carolina, Dept Physiol & Neurosci, Charleston, SC 29425 USA.
[Takacs, I.] Med Univ S Carolina, Dept Neurosurg, Charleston, SC 29425 USA.
[George, M. S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Nahas, Z (reprint author), SUNY Stony Brook, Dept Psychol, Stony Brook, NY 11794 USA.
EM nahasz@musc.edu
FU National Alliance of Research for Depression and Schizophrenia (NARSAD);
Mood Disorders Program; Brain Stimulation Laboratory; General Clinical
Research Center (GCRC); Center for Advanced Imaging Research (CAIR) at
the Medical University of South Carolina
FX Study funded primarily by a National Alliance of Research for Depression
and Schizophrenia (NARSAD) Independent Investigator Award to ZN. Study
was also made possible with general funds from the Mood Disorders
Program, the Brain Stimulation Laboratory, the General Clinical Research
Center (GCRC), the Center for Advanced Imaging Research (CAIR) at the
Medical University of South Carolina. Medtronic Inc. (Minneapolis,
Minnesota) donated the devices but was otherwise not involved in the
study, particularly data acquisition, analysis, or drafting this
manuscript. The authors would like to thank Mark Rise (Medtronic Inc.)
for technical assistance in stimulation set ups.
NR 59
TC 19
Z9 20
U1 6
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
J9 NEUROSCIENCE
JI Neuroscience
PD SEP 29
PY 2010
VL 170
IS 1
BP 281
EP 288
DI 10.1016/j.neuroscience.2010.04.069
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA 645OX
UT WOS:000281473300029
PM 20451585
ER
PT J
AU Salinthone, S
Yadav, V
Schillace, RV
Bourdette, DN
Carr, DW
AF Salinthone, Sonemany
Yadav, Vijayshree
Schillace, Robynn V.
Bourdette, Dennis N.
Carr, Daniel W.
TI Lipoic Acid Attenuates Inflammation via cAMP and Protein Kinase A
Signaling
SO PLOS ONE
LA English
DT Article
ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; T-CELL MIGRATION;
CENTRAL-NERVOUS-SYSTEM; NECROSIS-FACTOR-ALPHA; MULTIPLE-SCLEROSIS;
CYCLIC-AMP; DIABETIC POLYNEUROPATHY; CERAMIDE-1-PHOSPHATE ANALOG;
INHIBITS EXPRESSION; DIAGNOSTIC-CRITERIA
AB Background: Abnormal regulation of the inflammatory response is an important component of diseases such as diabetes, Alzheimer's disease and multiple sclerosis (MS). Lipoic acid (LA) has been shown to have antioxidant and anti-inflammatory properties and is being pursued as a therapy for these diseases. We first reported that LA stimulates cAMP production via activation of G-protein coupled receptors and adenylyl cyclases. LA also suppressed NK cell activation and cytotoxicity. In this study we present evidence supporting the hypothesis that the anti-inflammatory properties of LA are mediated by the cAMP/PKA signaling cascade. Additionally, we show that LA oral administration elevates cAMP levels in MS subjects.
Methodology/Principal Findings: We determined the effects of LA on IL-6, IL-17 and IL-10 secretion using ELISAs. Treatment with 50 mg/ml and 100 mg/ml LA significantly reduced IL-6 levels by 19 and 34%, respectively, in T cell enriched PBMCs. IL-17 levels were also reduced by 35 and 50%, respectively. Though not significant, LA appeared to have a biphasic effect on IL-10 production. Thymidine incorporation studies showed LA inhibited T cell proliferation by 90%. T-cell activation was reduced by 50% as measured by IL-2 secretion. Western blot analysis showed that LA treatment increased phosphorylation of Lck, a downstream effector of protein kinase A. Pretreatment with a peptide inhibitor of PKA, PKI, blocked LA inhibition of IL-2 and IFN gamma production, indicating that PKA mediates these responses. Oral administration of 1200 mg LA to MS subjects resulted in increased cAMP levels in PBMCs four hours after ingestion. Average cAMP levels in 20 subjects were 43% higher than baseline.
Conclusions/Significance: Oral administration of LA in vivo resulted in significant increases in cAMP concentration. The anti-inflammatory effects of LA are mediated in part by the cAMP/PKA signaling cascade. These novel findings enhance our understanding of the mechanisms of action of LA.
C1 [Salinthone, Sonemany; Yadav, Vijayshree; Schillace, Robynn V.; Bourdette, Dennis N.; Carr, Daniel W.] Portland VA Med Ctr, Portland, OR USA.
[Salinthone, Sonemany; Yadav, Vijayshree; Schillace, Robynn V.; Bourdette, Dennis N.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA.
[Carr, Daniel W.] Oregon Hlth & Sci Univ, Dept Endocrinol, Portland, OR 97201 USA.
RP Salinthone, S (reprint author), Portland VA Med Ctr, Portland, OR USA.
EM carrd@ohsu.edu
FU Department of Veterans Affairs Biomedical Laboratory Research &
Development Service; Collins Medical Trust; National Multiple Sclerosis
Society [CA1055A]; Laura Fund for Innovation in Multiple Sclerosis
Research and Nancy Davis Center Without Walls; National Center of
Complementary and Alternative Medicine [K23 AT003258]; Oregon Clinical
and Translational Research Institute (OCTRI); National Center for
Research Resources, National Institutes of Health (NIH), NIH Roadmap for
Medical Research [UL1RR024140]
FX This research was supported by the Department of Veterans Affairs
Biomedical Laboratory Research & Development Service (D.B and D.C), the
Collins Medical Trust (S.S), National Multiple Sclerosis Society
(CA1055A, D.B), the Laura Fund for Innovation in Multiple Sclerosis
Research and Nancy Davis Center Without Walls (D.B), the National Center
of Complementary and Alternative Medicine (K23 AT003258, D.B), Oregon
Clinical and Translational Research Institute (OCTRI, V.Y)), National
Center for Research Resources (UL1RR024140, V.Y.), components of the
National Institutes of Health (NIH), and NIH Roadmap for Medical
Research (V.Y). The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
NR 68
TC 20
Z9 24
U1 3
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 28
PY 2010
VL 5
IS 9
AR e13058
DI 10.1371/journal.pone.0013058
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 654ZQ
UT WOS:000282210700025
ER
PT J
AU Menconi, F
Osman, R
Monti, MC
Greenberg, DA
Concepcion, ES
Tomer, Y
AF Menconi, Francesca
Osman, Roman
Monti, Maria C.
Greenberg, David A.
Concepcion, Erlinda S.
Tomer, Yaron
TI Shared molecular amino acid signature in the HLA-DR peptide binding
pocket predisposes to both autoimmune diabetes and thyroiditis
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE autoimmunity; gene; structure
ID JOINT GENETIC SUSCEPTIBILITY; POLYGLANDULAR SYNDROMES; GRAVES-DISEASE;
MELLITUS; FAMILIES; CHILDREN; COMMON; EPIDEMIOLOGY; ASSOCIATION;
ADOLESCENTS
AB There is strong genetic association between type 1A diabetes (T1D) and autoimmune thyroid disease (AITD). T1D and AITD frequently occur together in the same individual, a condition classified as a variant of the autoimmune polyglandular syndrome type 3 (APS3). Because T1D and AITD are individually strongly associated with different HLA class II sequences, we asked which HLA class II pocket sequence and structure confer joint susceptibility to both T1D and AITD in the same individual (APS3v). We sequenced the HLA-DR gene in 105 APS3v patients and 153 controls, and identified a pocket amino acid signature, DR beta-Tyr-26, DR beta-Leu-67, DR beta-Lys-71, and DR beta-Arg-74, that was strongly associated with APS3v (P = 5.4 x 10(-14), odds ratio = 8.38). Logistic regression analysis demonstrated that DR beta-Leu-67 (P = 9.4 x 10(-13)) and DR beta-Arg-74 (P = 1.21 x 10(-13)) gave strong independent effects on disease susceptibility. Structural modeling studies demonstrated that pocket 4 was critical for the development of T1D+AITD; all disease-associated amino acids were linked to areas of the pocket that interact directly with the peptide and, therefore, influence peptide binding. The disease-susceptible HLA-DR pocket was more positively charged (Lys-71, Arg-74) compared with the protective pocket (Ala-71, Gln-74). We conclude that a specific pocket amino acid signature confers joint susceptibility to T1D+AITD in the same individual by causing significant structural changes in the MHC II peptide binding pocket and influencing peptide binding and presentation. Moreover, Arg-74 is a major amino acid position for the development of several autoimmune diseases. These findings suggest that blocking the critical Arg-74 pocket might offer a method for treating certain autoimmune conditions.
C1 [Menconi, Francesca; Concepcion, Erlinda S.; Tomer, Yaron] Mt Sinai Sch Med, Div Endocrinol, Dept Med, New York, NY 10029 USA.
[Osman, Roman] Mt Sinai Sch Med, Dept Struct & Chem Biol, New York, NY 10029 USA.
[Monti, Maria C.] Univ Pavia, Dept Appl Hlth Sci, I-27100 Pavia, Italy.
[Greenberg, David A.] Columbia Univ, Div Stat Genet, New York, NY 10032 USA.
[Tomer, Yaron] James J Peters Vet Adm Med Ctr, Bronx, NY 10468 USA.
RP Tomer, Y (reprint author), Mt Sinai Sch Med, Div Endocrinol, Dept Med, New York, NY 10029 USA.
EM yaron.tomer@mssm.edu
OI Monti, Maria Cristina/0000-0003-1586-527X
FU National Institutes of Health [DK61659, DK067555, DK073681, MH48858,
NS27941]
FX This work was supported in part by Grants DK61659, DK067555, and
DK073681 (to Y.T.) and MH48858 and NS27941 (to D.A.G.) from the National
Institutes of Health.
NR 33
TC 32
Z9 33
U1 0
U2 3
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD SEP 28
PY 2010
VL 107
IS 39
BP 16899
EP 16903
DI 10.1073/pnas.1009511107
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 655AA
UT WOS:000282211700032
PM 20837527
ER
PT J
AU Spinale, FG
Mukherjee, R
Zavadzkas, JA
Koval, CN
Bouges, S
Stroud, RE
Dobrucki, LW
Sinusas, AJ
AF Spinale, Francis G.
Mukherjee, Rupak
Zavadzkas, Juozas A.
Koval, Christine N.
Bouges, Shenikqua
Stroud, Robert E.
Dobrucki, Lawrence W.
Sinusas, Albert J.
TI Cardiac Restricted Overexpression of Membrane Type-1 Matrix
Metalloproteinase Causes Adverse Myocardial Remodeling following
Myocardial Infarction
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID LEFT-VENTRICULAR FUNCTION; TGF-BETA; HEART-FAILURE; 1-MATRIX
METALLOPROTEINASE; ACTIVATION; MICE; INHIBITION;
MATRIX-METALLOPROTEINASE-9; TRANSCRIPTION; FIBROBLASTS
AB The membrane type-1 matrix metalloproteinase (MT1MMP) is a unique member of the MMP family, but induction patterns and consequences of MT1-MMP overexpression (MT1-MMPexp), in a left ventricular (LV) remodeling process such as myocardial infarction (MI), have not been explored. MT1-MMP promoter activity (murine luciferase reporter) increased 20-fold at 3 days and 50-fold at 14 days post-MI. MI was then induced in mice with cardiac restricted MT1-MMPexp (n = 58) and wild type (WT, n = 60). Post-MI survival was reduced (67% versus 46%, p < 0.05), and LV ejection fraction was lower in the post-MI MT1-MMPexp mice compared with WT (41 +/- 2 versus 32 +/- 2%, p < 0.05). In the post-MI MT1-MMPexp mice, LV myocardial MMP activity, as assessed by radiotracer uptake, and MT1-MMP-specific proteolytic activity using a specific fluorogenic assay were both increased by 2-fold. LV collagen content was increased by nearly 2-fold in the post-MI MT1-MMPexp compared with WT. Using a validated fluorogenic construct, it was discovered that MT1-MMP proteolytically processed the pro-fibrotic molecule, latency-associated transforming growth factor-1 binding protein (LTBP-1), and MT1-MMP-specific LTBP-1 proteolytic activity was increased by 4-fold in the post-MIMT1-MMPexp group. Early and persistent MT1-MMP promoter activity occurred post-MI, and increased myocardial MT1-MMP levels resulted in poor survival, worsening of LV function, and significant fibrosis. A molecular mechanism for the adverse LV matrix remodeling with MT1-MMP induction is increased processing of pro-fibrotic signaling molecules. Thus, a proteolytically diverse portfolio exists for MT1-MMP within the myocardium and likely plays a mechanistic role in adverse LV remodeling.
C1 [Spinale, Francis G.; Mukherjee, Rupak; Zavadzkas, Juozas A.; Koval, Christine N.; Bouges, Shenikqua; Stroud, Robert E.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Spinale, Francis G.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA.
[Dobrucki, Lawrence W.; Sinusas, Albert J.] Yale Univ, Sch Med New Haven, New Haven, CT 06510 USA.
RP Sinusas, AJ (reprint author), Room 625,770 MUSC Complex,114 Doughty St, Charleston, SC 29425 USA.
EM wilburnm@musc.edu
OI Dobrucki, Wawrzyniec/0000-0002-6807-217X
FU National Institutes of Health [HL057952, HL059165, HL078825]; Veterans
Affairs Health Administration
FX This work was supported, in whole or in part, by National Institutes of
Health Grants HL057952, HL059165, and HL078825. This work was also
supported by a Merit Award from the Veterans Affairs Health
Administration.
NR 30
TC 34
Z9 34
U1 0
U2 1
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD SEP 24
PY 2010
VL 285
IS 39
BP 30316
EP 30327
DI 10.1074/jbc.M110.158196
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 652EK
UT WOS:000281984300067
PM 20643648
ER
PT J
AU Hays, LE
Keeble, WW
Yates, JE
Rathbun, RK
Koretsky, T
Olson, SB
Sun, ZJ
Clapp, DW
Bagby, GC
AF Hays, Laura E.
Keeble, Winifred W.
Yates, Jane E.
Rathbun, R. K.
Koretsky, Tara
Olson, Susan B.
Sun, Zejin
Clapp, D. Wade
Bagby, Grover C., Jr.
TI Human FANCC is hypomorphic in murine Fancc-deficient cells
SO BLOOD
LA English
DT Article
ID C GENE; REPOPULATING ABILITY; STEM-CELLS; ANEMIA; EXPRESSION; MICE;
INTERFERON; INACTIVATION; INSTABILITY; VECTORS
AB Fancc suppresses cross-linker-induced genotoxicity, modulates growth-inhibitory cytokine responses, and modulates endotoxin responses. Although loss of the latter function is known to account for endotoxin-induced marrow failure in murine Fancc (mFancc)-deficient mice, some argue that cytokine and endotoxin hypersensitivities devolve simply from genomic instability. Seeking to resolve this question, we planned to ectopically express instructive human FANCC(hFANCC) mutants in murine Fancc-deficient hematopoietic stem cells. To first assure that hFANCC cDNA was competent in murine cells, we compared hFANCC and mFancc in complementation assays for cross-linking agent hypersensitivity and endotoxin hypersensitivity. We found that mFancc complemented murine Fancc-deficient cells in both assays, but that hFANCC fully suppressed only endotoxin hypersensitivity, not cross-linking agent hypersensitivity. These results support the notions that Fancc is multifunctional and that structural prerequisites for its genoprotective functions differ from those required to constrain endotoxin responses known to lead to marrow failure in Fancc-deficient mice. (Blood. 2010;116(12):2057-2060)
C1 [Hays, Laura E.; Keeble, Winifred W.; Yates, Jane E.; Rathbun, R. K.; Koretsky, Tara; Bagby, Grover C., Jr.] Portland VA Med Ctr, Portland, OR 97239 USA.
[Hays, Laura E.; Keeble, Winifred W.; Yates, Jane E.; Rathbun, R. K.; Koretsky, Tara; Olson, Susan B.; Bagby, Grover C., Jr.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
[Hays, Laura E.; Bagby, Grover C., Jr.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA.
[Olson, Susan B.; Bagby, Grover C., Jr.] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA.
[Sun, Zejin; Clapp, D. Wade] Indiana Univ Sch Med, Indianapolis, IN USA.
RP Hays, LE (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd,R&D-2, Portland, OR 97239 USA.
EM haysl@ohsu.edu
FU Fanconi Anemia Research Fund; Knight Cancer Institute at Oregon Health &
Science University; Veterans Association; National Institutes of
Health/National Heart, Lung, and Blood Institute [5P01-HL48546];
National Institutes of Health/ National Cancer Institute
[1-R01-CA138237-01]
FX This work was supported by Fanconi Anemia Research Fund (L.E.H.), the
Knight Cancer Institute at Oregon Health & Science University, Veterans
Association Merit Review (G.C.B.), National Institutes of
Health/National Heart, Lung, and Blood Institute (5P01-HL48546; G.C.B.,
S.B.O.), and National Institutes of Health/ National Cancer Institute
(1-R01-CA138237-01; D.W.C., G.C.B.).
NR 20
TC 6
Z9 6
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD SEP 23
PY 2010
VL 116
IS 12
BP 2057
EP 2060
DI 10.1182/blood-2010-02-266411
PG 4
WC Hematology
SC Hematology
GA 653ZG
UT WOS:000282137300012
PM 20554974
ER
PT J
AU De Gasperi, R
Sosa, MAG
Dracheva, S
Elder, GA
AF De Gasperi, Rita
Sosa, Miguel A. Gama
Dracheva, Stella
Elder, Gregory A.
TI Presenilin-1 regulates induction of hypoxia inducible factor-1 alpha:
altered activation by a mutation associated with familial Alzheimer's
disease
SO MOLECULAR NEURODEGENERATION
LA English
DT Article
ID AMYLOID PRECURSOR PROTEIN; GROWTH-FACTOR-I; PROMOTES
TAU-PHOSPHORYLATION; GENE-EXPRESSION; SIGNALING PATHWAYS;
GAMMA-SECRETASE; INSULIN-RESISTANCE; TYROSINE KINASE; TRANSGENIC MICE;
TALKING POINT
AB Background: Mutations in presenilin-1 (Psen1) cause familial Alzheimer's disease (FAD). Both hypoxia and ischemia have been implicated in the pathological cascade that leads to amyloid deposition in AD. Here we investigated whether Psen1 might regulate hypoxic responses by modulating induction of the transcription factor hypoxia inducible factor 1-alpha (HIF-1 alpha).
Results: In fibroblasts that lack Psen1 induction of HIF-1 alpha was impaired in response to the hypoxia mimetic cobalt chloride, as well as was induction by insulin and calcium chelation. Reintroduction of human Psen1 using a lentiviral vector partially rescued the responsiveness of Psen1(-/-) fibroblasts to cobalt chloride induction. HIF-1 alpha induction did not require Psen1's associated gamma-secretase activity. In addition, the failure of insulin to induce HIF-1 alpha was not explicable on the basis of failed activation of the phosphatidylinositol 3-kinase (PI3K/Akt) pathway which activated normally in Psen1(-/-) fibroblasts. Rather we found that basal levels of HIF-1 alpha were lower in Psen1(-/-) fibroblasts and that the basis for lower constitutive levels of HIF-1 alpha was best explained by accelerated HIF-1 alpha degradation. We further found that Psen1 and HIF-1 alpha physically interact suggesting that Psen1 may protect HIF-1 alpha from degradation through the proteasome. In fibroblasts harboring the M146V Psen1 FAD mutation on a mouse Psen1 null background, metabolic induction of HIF-1 alpha by insulin was impaired but not hypoxic induction by cobalt chloride. Unlike Psen1(-/-) fibroblasts, basal levels of HIF-1 alpha were normal in FAD mutant fibroblasts but activation of the insulin-receptor pathway was impaired. Interestingly, in Psen1(-/-) primary neuronal cultures HIF-1 alpha was induced normally in response to cobalt chloride but insulin induction of HIF-1 alpha was impaired even though activation of the PI3K/Akt pathway by insulin proceeded normally in Psen1(-/-) neuronal cultures. Basal levels of HIF-1 alpha were not significantly different in Psen1(-/-) neurons and HIF-1 alpha levels were normal in Psen1(-/-) embryos.
Conclusions: Collectively these studies show that Psen1 regulates induction of HIF-1 alpha although they indicate that cell type specific differences exist in the effect of Psen1 on induction. They also show that the M146V Psen1 FAD mutation impairs metabolic induction of HIF-1 alpha, an observation that may have pathophysiological significance for AD.
C1 [Elder, Gregory A.] Vet Adm Med Ctr, James J Peters Dept, Neurol Serv, Bronx, NY 10468 USA.
[De Gasperi, Rita; Sosa, Miguel A. Gama; Dracheva, Stella; Elder, Gregory A.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
[Elder, Gregory A.] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA.
RP Elder, GA (reprint author), Vet Adm Med Ctr, James J Peters Dept, Neurol Serv, Bronx, NY 10468 USA.
EM gregory.elder@mssm.edu
FU Department of Veterans Affairs [5I01BX000342-02]; National Institute on
Aging [AG20139, AG02219, AG05138, AG029361]; Alzheimer's Association
[IIRG-07-57318]
FX This work was supported by a Merit Award from the Department of Veterans
Affairs (5I01BX000342-02) and grants from the National Institute on
Aging (AG20139, AG02219, AG05138, and AG029361), and the Alzheimer's
Association (IIRG-07-57318). We thank Drs. Paul Mathews and Nikolaos
Robakis for gifts of antibodies, Dr. Nikolaos Robakis for gift of
Psen-/- fibroblasts and Ms. Gissel Perez for expert technical
assistance. Dr. Vahram Haroutunian is thanked for critical reading of
the manuscript.
NR 89
TC 13
Z9 13
U1 1
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1750-1326
J9 MOL NEURODEGENER
JI Mol. Neurodegener.
PD SEP 23
PY 2010
VL 5
AR 38
DI 10.1186/1750-1326-5-38
PG 20
WC Neurosciences
SC Neurosciences & Neurology
GA 664QR
UT WOS:000282977900001
PM 20863403
ER
PT J
AU Anzueto, A
AF Anzueto, Antonio
TI Endobronchial Valves to Reduce Lung Hyperinflation
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
ID COPD; SURGERY
C1 [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Anzueto, Antonio] S Texas Vet Hlth Care Ctr, San Antonio, TX USA.
RP Anzueto, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
NR 9
TC 1
Z9 1
U1 0
U2 1
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD SEP 23
PY 2010
VL 363
IS 13
BP 1280
EP 1281
DI 10.1056/NEJMe1008256
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 652ZA
UT WOS:000282050000015
PM 20860512
ER
PT J
AU Azadani, AN
Jaussaud, N
Ge, L
Chitsaz, S
Chuter, TAM
Tseng, EE
AF Azadani, Ali N.
Jaussaud, Nicolas
Ge, Liang
Chitsaz, Sam
Chuter, Timothy A. M.
Tseng, Elaine E.
TI Impact of Orientation and Size Matched Transcatheter Aortic Valves on
Valve-in-Valve Hemodynamics
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Meeting Abstract
CT 22nd Annual Transcatheter Cardiovascular Therapeutics (TCT) Symposium
CY SEP 21-25, 2010
CL Washington, DC
SP Cardiovascular Res Fdn
C1 UCSF Med Ctr, San Francisco, CA USA.
San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
EI 1558-3597
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD SEP 21
PY 2010
VL 56
IS 13
SU S
MA TCT-132
BP B31
EP B31
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA V45NV
UT WOS:000209824200133
ER
PT J
AU Siderowf, A
Xie, SX
Hurtig, H
Weintraub, D
Duda, J
Chen-Plotkin, A
Shaw, M
Van Deerlin, V
Trojanowski, JQ
Clark, C
AF Siderowf, A.
Xie, S. X.
Hurtig, H.
Weintraub, D.
Duda, J.
Chen-Plotkin, A.
Shaw, L. M.
Van Deerlin, V.
Trojanowski, J. Q.
Clark, C.
TI CSF amyloid beta 1-42 predicts cognitive decline in Parkinson disease
SO NEUROLOGY
LA English
DT Article
ID CEREBROSPINAL-FLUID TAU; ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; LEWY
BODIES; FOLLOW-UP; DEMENTIA; BIOMARKERS; DIAGNOSIS; GENOTYPE; PLASMA
AB Objective: Cognitive decline associated with Parkinson disease (PD) is common and highly disabling. Biomarkers that help identify patients at risk for cognitive decline would be useful additions to the clinical management of the disease.
Methods: A total of 45 patients with PD were enrolled in this prospective cohort study and had at least 1 yearly longitudinal follow-up evaluation. CSF was collected at baseline and cognition was assessed at baseline and follow-up visits using the Mattis Dementia Rating Scale (DRS-2). CSF was tested for amyloid beta 1-42 (A beta(1-42)), p-tau(181p), and total tau levels using the Luminex xMAP platform. Mixed linear models were used to test for associations between baseline CSF biomarker levels and change in cognition over time.
Results: Lower baseline CSF A beta(1-42) was associated with more rapid cognitive decline. Subjects with CSF A beta(1-42) levels <= 192 pg/mL declined an average of 5.85 (95% confidence interval 2.11-9.58, p = 0.002) points per year more rapidly on the DRS-2 than subjects above that cutoff, after adjustment for age, disease duration, and baseline cognitive status. CSF total tau and p-tau(181p) levels were not significantly associated with cognitive decline. Conclusions: Reduced CSF A beta(1-42) was an independent predictor of cognitive decline in patients with PD. This observation is consistent with previous research showing that Alzheimer disease pathology contributes to cognitive impairment in PD. This biomarker may provide clinically useful prognostic information, particularly if combined with other risk factors for cognitive impairment in PD. Neurology (R) 2010;75:1055-1061
C1 [Siderowf, A.; Hurtig, H.; Weintraub, D.; Chen-Plotkin, A.; Clark, C.] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19107 USA.
[Siderowf, A.; Xie, S. X.; Hurtig, H.; Weintraub, D.; Duda, J.; Chen-Plotkin, A.; Van Deerlin, V.; Trojanowski, J. Q.] Univ Penn, Sch Med, Morris K Udall Ctr Excellence Parkinsons Dis Res, Philadelphia, PA 19107 USA.
[Xie, S. X.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19107 USA.
[Weintraub, D.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19107 USA.
[Shaw, L. M.; Van Deerlin, V.; Trojanowski, J. Q.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19107 USA.
[Siderowf, A.; Shaw, L. M.; Trojanowski, J. Q.] Univ Penn, Sch Med, Inst Aging, Philadelphia, PA 19107 USA.
[Weintraub, D.; Duda, J.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Siderowf, A (reprint author), Univ Penn, Sch Med, Dept Neurol, 330 S 9th St,2nd Floor, Philadelphia, PA 19107 USA.
EM andrew.siderowf@uphs.upenn.edu
FU NINDS [NS-053488, SAP4100027296]; Department of Health of the
Commonwealth of Pennsylvania; NIH (NINDS) [NINDS U10 NS0444451, NINDS
P50 NS053488, NINDS R43NS0636071, NINDS R01NS065087, NINDS P50
NS053488-01, NINDS U10 NS044451-023]; US Department of Defense;
Department of Health, Commonwealth of Pennsylvania; NIH/NINDS
[NS053488]; Michael J. Fox Foundation for Parkinson's Research; Teva
Pharmaceutical Industries Ltd.; Boehringer Ingelheim; Bayer Schering
Pharma; Kyowa Hakko Kirin Pharma, Inc.; PRA International; Novartis;
Glaxo-SmithKline; Avid Radiopharmaceuticals, Inc.; St Jude Medical;
Amarin Corporation; Prestwick Pharmaceutical, Inc.; HP Therapeutics
Foundation, Inc.; Cephalon, Inc.; NIH [NS053488, K23 MH067894, K08
AG033101, AG024904, 1RC 2AG-036535, NIA P01 AG 09215-20, NIA P30 AG
10124-18, NIA PO1 AG 17586-10, NIA 1PO1 AG-19724-07, NIA 1 UO1 AG
024904-05, NINDS P50 NS053488-02, NIA UO1 AG029213-01, RC2NS069368,
RC1AG035427, NIA P30AG036468]; Penn Center for Excellence in Research on
Neurodegenerative Diseases (CERND); Department of Veterans Affairs;
Department of Veterans Affairs, NIH [RO1 NS41265-01, RO1 NS44266];
Michael J. Fox Foundation; Samueli Foundation; Burroughs Wellcome Fund;
Pfizer Inc.; Applied Pharmacokinetics and Pharmacodynamics: Principles
of Therapeutic Drug Monitoring; Molecular Pathology in Clinical
Practice; Marian S. Ware Alzheimer Program
FX Supported by a Morris K. Udall Parkinson's Disease Research Center of
Excellence grant from NINDS (NS-053488) and by SAP4100027296, a health
research grant awarded by the Department of Health of the Commonwealth
of Pennsylvania from the Tobacco Master Settlement Agreement under Act
2001-77.; Dr. Siderowf serves on a scientific advisory board for and has
received speaker honoraria from Teva Pharmaceutical Industries Ltd.;
serves/has served as a consultant to Supernus Pharmaceuticals, Inc.,
Teva Pharmaceutical Industries Ltd., Merck Serono, and Schering-Plough
Corp.; receives research support from the NIH (NINDS U10 NS0444451 [site
PI], NINDS P50 NS053488 [Co-I], NINDS R43NS0636071 [Co-I], and NINDS
R01NS065087 [Co-I]), the US Department of Defense, and the Department of
Health, Commonwealth of Pennsylvania; and has served as a consultant on
manganese litigation. Dr. Xie receives research support from the
NIH/NINDS (NS053488 [coinvestigator and core director]). Dr. Hurtig
served on a grant review panel for the Michael J. Fox Foundation for
Parkinson's Research; serves on the editorial board of Parkinsonism and
Related Disorders; serves as Movement Disorders Section Editor for
UpToDate; has received speaker honoraria from Teva Pharmaceutical
Industries Ltd.; receives research support from Teva Pharmaceutical
Industries Ltd., Boehringer Ingelheim, Bayer Schering Pharma, Kyowa
Hakko Kirin Pharma, Inc., PRA International, Novartis, Glaxo-SmithKline,
Avid Radiopharmaceuticals, Inc., St Jude Medical, Amarin Corporation,
Prestwick Pharmaceutical, Inc., HP Therapeutics Foundation, Inc.,
Cephalon, Inc., NIH (NINDS P50 NS053488-01 [core leader and PI] and
NINDS U10 NS044451-023 [site PI]); and holds stock in Teva
Pharmaceutical Industries Ltd. Dr. Weintraub has served on a scientific
advisory board for Boehringer Ingelheim; serves on the editorial board
of Movement Disorders; has received honoraria from Boehringer Ingelheim,
ACADIA Pharmaceuticals Inc., GE Healthcare, Novartis, Osmotica
Pharmaceutical Corp., BrainCells Inc., Merck Serono, Sanofi-Aventis,
Johnson & Johnson, Solvay Pharmaceuticals, Inc., and Pfizer Inc.; and
receives research support from Boehringer Ingelheim, the NIH (K23
MH067894 [PI]), the Penn Center for Excellence in Research on
Neurodegenerative Diseases (CERND), and the Michael J. Fox Foundation
for Parkinson's Research. Dr. Duda served on a grant review panel for
the Michael J. Fox Foundation for Parkinson's Research; serves/has
served on a scientific advisory boards for Boehringer Ingelheim, the
Lewy Body Dementia Association, and the Lewy Body Society; has received
honoraria for interviews for articles in the PD Monitor and Commentary,
a publication supported by an educational grant from Teva Pharmaceutical
Industries Ltd.; receives research support from the Department of
Veterans Affairs (Biomedical Laboratory Research and Development Service
Merit Award [PI], Cooperative Studies Program 468 [site PI]), the NIH
(RO1 NS41265-01 [Co-I], RO1 NS44266 [Co-I]), the Michael J. Fox
Foundation, the Department of Health, Commonwealth of Pennsylvania, and
the Samueli Foundation; and holds stock in C. R. Bard, Inc., Celgene,
Clarient, and Johnson & Johnson. Dr. Chen-Plotkin receives research
support from the Burroughs Wellcome Fund and the NIH (K08 AG033101
[PI]). Dr. Shaw has served on a scientific advisory board for
Bristol-Myers Squibb; has received funding for travel and speaker
honoraria from Pfizer Inc.; ; serves on the editorial board of
Therapeutic Drug Monitoring; may potentially receive revenue for patent
pending re: O-methylated rapamycin derivatives for alleviation and
inhibition of lymphoproliferative disorders, licensed by the University
of Pennsylvania to Novartis; receives royalties from publication of
Applied Pharmacokinetics and Pharmacodynamics: Principles of Therapeutic
Drug Monitoring (Wolters Kluwer/ippincott Williams & Wilkins, 2005);
receives research support from the NIH (AG024904 [Co-PI Biomarker Core
Laboratory] and 1RC 2AG-036535 (ARRA) [PI Biomarker Core Laboratory]);
and receives board of directors' compensation and holds stock options in
Saladax Biomedical. Dr. Van Deerlin serves on the editorial board of
Molecular Diagnosis and Therapy; has a patent pending re: Compositions
and methods for the treatment of frontotemporal lobar degeneration with
TDP-43 inclusions; receives royalties from the publication of Molecular
Pathology in Clinical Practice (Springer, 2007); and receives research
support from the NIH (NS053488 [Neuropathology and Genetics Core, Core
Co-Leader] and AG010124 [Neuropathology Core, Co-I]). Dr. Trojanowski
has received funding for travel and honoraria from Takeda Pharmaceutical
Company Ltd.; has received speaker honoraria from Pfizer Inc.; serves as
an Associate Editor of Alzheimer's & Dementia; may accrue revenue on
patents re: Modified avidin-biotin technique, Method of stabilizing
microtubules to treat Alzheimer's disease, Method of detecting
abnormally phosphorylated tau, Method of screening for Alzheimer's
disease or disease associated with the accumulation of paired helical
filaments, Compositions and methods for producing and using homogeneous
neuronal cell transplants, Rat comprising straight filaments in its
brain, Compositions and methods for producing and using homogeneous
neuronal cell transplants to treat neurodegenerative disorders and brain
and spinal cord injuries, Diagnostic methods for Alzheimer's disease by
detection of multiple MRNAs, Methods and compositions for determining
lipid peroxidation levels in oxidant stress syndromes and diseases,
Compositions and methods for producing and using homogenous neuronal
cell transplants, Method of identifying, diagnosing and treating
alpha-synuclein positive neurodegenerative disorders, Mutation-specific
functional impairments in distinct tau isoforms of hereditary
frontotemporal dementia and parkinsonism linked to chromosome-17:
genotype predicts phenotype, Microtubule stabilizing therapies for
neurodegenerative disorders, and Treatment of Alzheimer's and related
diseases with an antibody; and receives research support from the NIH
(NIA P01 AG 09215-20 [PI], NIA P30 AG 10124-18 [PI], NIA PO1 AG 17586-10
[Project 4 Leader], NIA 1PO1 AG-19724-07 [Core C Leader], NIA 1 UO1 AG
024904-05 [Co-PI Biomarker Core Laboratory], NINDS P50 NS053488-02 [PI],
NIA UO1 AG029213-01 (Co-I); RC2NS069368 (PI), RC1AG035427 (PI), and NIA
P30AG036468 [PI]) and the Marian S. Ware Alzheimer Program. Dr. Clark
serves as Medical Director of and holds stock options in Avid
Radiopharmaceuticals, Inc.; has served on scientific advisory boards for
Elan Corporation and Wyeth; and receives research support from the
Department of Health, Commonwealth of Pennsylvania.
NR 36
TC 138
Z9 140
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD SEP 21
PY 2010
VL 75
IS 12
BP 1055
EP 1061
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 658EZ
UT WOS:000282474500006
PM 20720189
ER
PT J
AU Aarsland, D
Bronnick, K
Williams-Gray, C
Weintraub, D
Marder, K
Kulisevsky, J
Burn, D
Barone, P
Pagonabarraga, J
Allcock, L
Santangelo, G
Foltynie, T
Janvin, C
Larsen, JP
Barker, RA
Emre, M
AF Aarsland, D.
Bronnick, K.
Williams-Gray, C.
Weintraub, D.
Marder, K.
Kulisevsky, J.
Burn, D.
Barone, P.
Pagonabarraga, J.
Allcock, L.
Santangelo, G.
Foltynie, T.
Janvin, C.
Larsen, J. P.
Barker, R. A.
Emre, M.
TI Mild cognitive impairment in Parkinson disease A multicenter pooled
analysis
SO NEUROLOGY
LA English
DT Article
ID ORTHOSTATIC HYPOTENSION; DIAGNOSTIC-CRITERIA; NORWEGIAN PARKWEST;
CLINICAL-DIAGNOSIS; EXECUTIVE FUNCTION; RATING-SCALE; DEMENTIA; COHORT;
RECOMMENDATIONS; INCIDENT
AB Background: In studies of mild cognitive impairment (MCI) in Parkinson disease (PD), patients without dementia have reported variable prevalences and profiles of MCI, likely to be due to methodologic differences between the studies.
Objective: The objective of this study was to determine frequency and the profile of MCI in a large, multicenter cohort of well-defined patients with PD using a standardized analytic method and a common definition of MCI.
Methods: A total of 1,346 patients with PD from 8 different cohorts were included. Standardized analysis of verbal memory, visuospatial, and attentional/executive abilities was performed. Subjects were classified as having MCI if their age-and education-corrected z score on one or more cognitive domains was at least 1.5 standard deviations below the mean of either control subjects or normative data.
Results: A total of 25.8% of subjects (95% confidence interval [CI] 23.5-28.2) were classified as having MCI. Memory impairment was most common (13.3%; 11.6-15.3), followed by visuospatial (11.0%; 9.4-13.0) and attention/executive ability impairment (10.1%; 8.6-11.9). Regarding cognitive profiles, 11.3% (9.7-13.1) were classified as nonamnestic single-domain MCI, 8.9% (7.0-9.9) as amnestic single-domain, 4.8% (3.8-6.1) as amnestic multiple-domain, and 1.3% (0.9-2.1) as nonamnestic multiple-domain MCI. Having MCI was associated with older age at assessment and at disease onset, male gender, depression, more severe motor symptoms, and advanced disease stage.
Conclusions: MCI is common in patients with PD without dementia, affecting a range of cognitive domains, including memory, visual-spatial, and attention/executive abilities. Future studies of patients with PD with MCI need to determine risk factors for ongoing cognitive decline and assess interventions at a predementia stage. Neurology (R) 2010;75:1062-1069
C1 [Aarsland, D.; Janvin, C.] Stavanger Univ Hosp, Div Psychiat, N-4068 Stavanger, Norway.
[Bronnick, K.; Larsen, J. P.] Stavanger Univ Hosp, Norwegian Ctr Movement Disorders, N-4068 Stavanger, Norway.
[Aarsland, D.] Akershus Univ Hosp, Div Mental Hlth Serv, Oslo, Norway.
Univ Oslo, Oslo, Norway.
[Williams-Gray, C.; Barker, R. A.] Univ Cambridge, Dept Clin Neurosci, Ctr Brain Repair, Cambridge, England.
[Weintraub, D.] Univ Penn, Dept Psychiat & Neurol, Philadelphia, PA 19104 USA.
Philadelphia Vet Affairs Med Ctr, Parkinsons Dis & Mental Illness Res Educ & Clin C, Philadelphia, PA USA.
[Marder, K.] Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA.
[Kulisevsky, J.; Pagonabarraga, J.] Autonomous Univ Barcelona, St Pau Hosp, Dept Neurol, Movement Disorders Unit, Barcelona, Spain.
CIBERNED Ctr Invest Biomed Red Enfermedades Neuro, Barcelona, Spain.
[Burn, D.; Allcock, L.] Newcastle Univ, Inst Ageing & Hlth, Newcastle Upon Tyne, Tyne & Wear, England.
[Barone, P.; Santangelo, G.] ICD Hermitage Capodimonte, Dept Neurol Sci, Naples, Italy.
[Foltynie, T.] UCL, Inst Neurol, Sobell Dept Motor Neurosci & Movement Disorders, London WC1E 6BT, England.
[Emre, M.] Istanbul Univ, Istanbul Fac Med, Dept Neurol, Behav Neurol & Movement Disorders Unit, Istanbul, Turkey.
RP Aarsland, D (reprint author), Stavanger Univ Hosp, Div Psychiat, POB 8100, N-4068 Stavanger, Norway.
EM daarsland@gmail.com
OI Santangelo, Gabriella/0000-0002-7728-852X; Bronnick,
Kolbjorn/0000-0002-9156-1633; Aarsland, Dag/0000-0001-6314-216X
FU Merck Serono; Lundbeck Inc.; Novartis; GE Healthcare; GlaxoSmithKline;
Solvay Pharmaceuticals, Inc; Parkinson's Disease Society; Patrick
Berthoud Trust; Boehringer Ingelheim; ACADIA Pharmaceuticals; Osmotica
Pharmaceutical Corp.; BrainCells Inc.; Sanofi-Aventis; Johnson Johnson;
Solvay Pharmaceuticals, Inc.; NIH [NIMH K23 MH067894, NINDS P50
NS053488-01, NIA RO1AG031348, NINDS R01NS065087, NS36630, 1UL1
RR024156-01, PO412196-G]; Michael J. Fox Foundation for Parkinson's
Research; University of Pennsylvania; Amarin Corporation; Boehringer
Ingelheim NeuroSearch; Parkinson Disease Foundation; Huntington's
Disease Society of America; Parkinson Study Group; Instituto de Salud
Carlos III, Spain; Wellcome Trust; NIHR Health Technology Assessment
Programme; Michael J Fox Foundation; UCB; MDS Nordion; Orion
Corporation; Brain Research Trust; Parkinson's Appeal; Western Norway
Health Trust; Norwegian Research Counsel; Norwegian Parkinson's disease
Association; Neuroscience at a Glance (Blackwell Publishing); UK Medical
Research Council; NIHR; Parkinson Hastalydy (Gunes Tip Kitapevi);
Dementia in Parkinson's Disease (Oxford University Press); Eli Lilly and
Company
FX Supported by an unrestricted grant from Merck Serono.; Dr. Aarsland
serves on scientific advisory boards for Lundbeck Inc. and Merck Serono;
has received funding for travel and speaker honoraria from Lundbeck
Inc., Novartis, GE Healthcare, and GlaxoSmithKline; serves on the
editorial boards of International Psychogeriatrics, Movement Disorders,
and the Journal of Neurology, Neurosurgery, and Psychiatry; and receives
research support from Lundbeck Inc. and Merck Serono. Dr. Bronnick has
received funding for travel and speaker honoraria from Solvay
Pharmaceuticals, Inc. Dr. Williams-Gray has received research support
from the Parkinson's Disease Society and the Patrick Berthoud Trust. Dr.
Weintraub has served on scientific advisory boards for Boehringer
Ingelheim, ACADIA Pharmaceuticals, Novartis, Osmotica Pharmaceutical
Corp., BrainCells Inc., Merck Serono, Sanofi-Aventis, GE Healthcare,
Johnson & Johnson, and Solvay Pharmaceuticals, Inc.; serves on the
editorial board of Movement Disorders; has received speaker honoraria
from Boehringer Ingelheim and Pfizer Inc.; has received/receives
research support from Boehringer Ingelheim, the NIH (NIMH K23 MH067894
[PI], NINDS P50 NS053488-01 [coinvestigator], NIA RO1AG031348 [site PI],
and NINDS R01NS065087 [coinvestigator]), and the Michael J. Fox
Foundation for Parkinson's Research; and receives payments from the
University of Pennsylvania for licensing of Questionnaire for
Impulsive-Compulsive Disorders in Parkinson's Disease. Dr. Marder serves
on the editorial board of Neurology (R) and receives research support
from Amarin Corporation, Boehringer Ingelheim NeuroSearch, the NIH
(NS36630 [PI], 1UL1 RR024156-01 [Director PCIR], PO412196-G
[coinvestigator], and PO412196-G [coinvestigator]), the Parkinson
Disease Foundation, the Huntington's Disease Society of America, and the
Parkinson Study Group. Dr. Kulisevsky has served on scientific advisory
boards for Merck Serono and Servier; has received honoraria from Merck
Serono, Novartis, Lundbeck Inc., and Schwartz Biomedical, LLC.; serves
as an Associate Editor for Revista de Neurologia; and receives research
support from Lundbeck Inc. and Instituto de Salud Carlos III, Spain. Dr.
Burn serves on scientific advisory boards for Teva Pharmaceutical
Industries Ltd. and Merck Serono; serves as a consultant for Archimedes,
Inc.; serves as an Associate Editor for the Movement Disorder Journal;
has received speaker honoraria from Teva Pharmaceutical Industries
Ltd./Lundbeck Inc., Orion Corporation, Boehringer Ingelheim,
GlaxoSmithKline, Novartis, and UCB; and has received research support
from the Wellcome Trust, the NIHR Health Technology Assessment
Programme, the Michael J Fox Foundation, and the Parkinson's Disease
Society. Dr. Barone serves on scientific advisory boards for and has
received funding for travel and speaker honoraria from Boehringer
Ingelheim, Merck Serono, Novartis, UCB, and Lundbeck Inc.; serves as an
Associate Editor for the Journal of Neurodegenerative Disorders and
Parkinson's Europe; and receives research support from Boehringer
Ingelheim, Merck Serono, Novartis, UCB, Lundbeck Inc., and Solvay
Pharmaceuticals, Inc. Dr. Pagonabarraga has served on a scientific
advisory board for Novartis and has received honoraria from Boehringer
Ingelheim, Novartis, Janssen, Lundbeck Inc., GlaxoSmithKline, and
Schwartz Biomedical, LLC. Dr. Allcock holds stock in the C/N Group, Inc.
Dr. Santangelo reports no disclosures. Dr. Foltynie has served on a
scientific advisory board for Solvay Pharmaceuticals, Inc.; has received
funding for travel or speaker honoraria from Teva Pharmaceutical
Industries Ltd.; ,MDS Nordion, GlaxoSmithKline, and Orion Corporation;
and has received research support from the Parkinson's Disease Society,
Brain Research Trust, and Parkinson's Appeal. Dr. Janvin reports no
disclosures. Dr. Larsen has served on scientific advisory boards for
Lundbeck Inc. and GlaxoSmithKline; has received speaker honoraria from
GlaxoSmithKline; and receives research support from the Western Norway
Health Trust, the Norwegian Research Counsel, and the Norwegian
Parkinson's disease Association. Dr. Barker serves on scientific
advisory boards for and has received speaker honoraria from Teva
Pharmaceutical Industries Ltd. and Lundbeck Inc.; serves as
co-editor-in-Chief for the Journal of Neurology and ACNR and on the
editorial board of Synapse, Cell Transplantation and Regenerative
Medicine; receives royalties from the publication of Neuroscience at a
Glance (Blackwell Publishing, 1999); and receives research support from
the Parkinson's Disease Society, Wellcome Trust, the UK Medical Research
Council, and NIHR Biomedical research award to Addenbrooke's University
Hospital. Dr. Emre serves on scientific advisory boards for Merck
Serono, Novartis, Schering-Plough Corp., Teva Pharmaceutical Industries
Ltd./Lundbeck Inc., Orion Corporation, Noscira, and AC Immune SA; has
received funding for travel from Lundbeck Inc.; serves on the editorial
board of Practical Neurology; receives royalties from the publication of
Parkinson Hastalydy (Gunes Tip Kitapevi, 2009) and Dementia in
Parkinson's Disease (Oxford University Press, 2010); has received
speaker honoraria from Novartis, Lundbeck Inc., Orion Corporation,
Pfizer Inc., and Boehringer Ingelheim; and receives/has received
research support from Novartis, Lundbeck Inc., and Eli Lilly and
Company.
NR 32
TC 242
Z9 252
U1 3
U2 28
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD SEP 21
PY 2010
VL 75
IS 12
BP 1062
EP 1069
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA 658EZ
UT WOS:000282474500007
PM 20855849
ER
PT J
AU Lee, SH
Jung, SY
Park, HA
Kang, HB
Kim, J
Choo, DJ
Handforth, A
Lee, JY
AF Lee, So Hyung
Jung, Soo Yeon
Park, Hang Ah
Kang, Han Byul
Kim, Jungahn
Choo, Dong Joon
Handforth, Adrian
Lee, Jae Yeol
TI Multi-Functional 3,4-Dihydroquinazoline Derivative as T-Type Calcium
Channel Blocker: Pharmacokinetics and Anti-Tremor Activity
SO BULLETIN OF THE KOREAN CHEMICAL SOCIETY
LA English
DT Article
DE 3,4-Dihydroquinazoline; T-type calcium channel blocker; Pharmacokinetic
parameters; Anti-tremor activity
ID HUMAN CANCER-CELLS; CA2+ CHANNELS; DISCOVERY; MIBEFRADIL; PHARMACOLOGY;
INHIBITION; GROWTH; POTENT
C1 [Lee, So Hyung; Jung, Soo Yeon; Park, Hang Ah; Kang, Han Byul; Kim, Jungahn; Choo, Dong Joon; Lee, Jae Yeol] Kyung Hee Univ, Coll Sci, Res Inst Basic Sci, Seoul 130701, South Korea.
[Lee, So Hyung; Jung, Soo Yeon; Park, Hang Ah; Kang, Han Byul; Kim, Jungahn; Choo, Dong Joon; Lee, Jae Yeol] Kyung Hee Univ, Coll Sci, Dept Chem, Seoul 130701, South Korea.
[Handforth, Adrian] Vet Affairs Greater Los Angeles Healthcare Syst, Neurol Serv, Los Angeles, CA USA.
RP Lee, JY (reprint author), Kyung Hee Univ, Coll Sci, Res Inst Basic Sci, Seoul 130701, South Korea.
EM ljy@khu.ac.kr
OI Lee, Jae Yeol/0000-0001-6622-6692
NR 24
TC 1
Z9 1
U1 0
U2 1
PU KOREAN CHEMICAL SOC
PI SEOUL
PA 635-4 YEOGSAM-DONG, KANGNAM-GU, SEOUL 135-703, SOUTH KOREA
SN 0253-2964
J9 B KOREAN CHEM SOC
JI Bull. Korean Chem. Soc.
PD SEP 20
PY 2010
VL 31
IS 9
BP 2451
EP 2452
DI 10.5012/bkcs.2010.31.9.2451
PG 2
WC Chemistry, Multidisciplinary
SC Chemistry
GA 676XV
UT WOS:000283953600003
ER
PT J
AU Mao, ZH
Sun, W
Xu, RJ
Novgorodov, S
Szulc, ZM
Bielawski, J
Obeid, LM
Mao, CG
AF Mao, Zhehao
Sun, Wei
Xu, Ruijuan
Novgorodov, Sergei
Szulc, Zdzislaw M.
Bielawski, Jacek
Obeid, Lina M.
Mao, Cungui
TI Alkaline Ceramidase 2 (ACER2) and Its Product Dihydrosphingosine Mediate
the Cytotoxicity of N-(4-Hydroxyphenyl)retinamide in Tumor Cells
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID PERFORMANCE LIQUID-CHROMATOGRAPHY; FENRETINIDE-INDUCED APOPTOSIS; HUMAN
NEUROBLASTOMA-CELLS; LONG-CHAIN CERAMIDES; COLON-CANCER CELLS;
DIHYDROCERAMIDE DESATURASE; PROSTATE-CANCER; INDUCTION; SPHINGOSINE;
CARCINOMA
AB Increased generation of dihydrosphingosine (DHS), a bioactive sphingolipid, has been implicated in the cytotoxicity of the synthetic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) in tumor cells. However, how 4-HPR increases DHS remains unclear. Here we demonstrate that 4-HPR increases the expression of ACER2, which catalyzes the hydrolysis of dihydroceramides to generate DHS, and that ACER2 up-regulation plays a key role in mediating the 4-HPR-induced generation of DHS as well as the cytotoxicity of 4-HPR in tumor cells. Treatment with 4-HPR induced the accumulation of dihydroceramides (DHCs) in tumor cells by inhibiting dihydroceramide desaturase (DES) activity, which catalyzes the conversion of DHCs to ceramides. Treatment with 4-HPR also increased ACER2 expression through a retinoic acid receptor-independent and caspase-dependent manner. Overexpression of ACER2 augmented the 4-HPR-induced generation of DHS as well as 4-HPR cytotoxicity, and 4-HPR-induced death in tumor cells, whereas knocking down ACER2 had the opposite effects. ACER2 overexpression, along with treatment with GT11, another DES inhibitor, markedly increased cellular DHS, leading to tumor cell death, whereas ACER2 overexpression or GT11 treatment alone failed to do so, suggesting that both ACER2 up-regulation and DES inhibition are necessary and sufficient to mediate 4-HPR-induced DHS accumulation, cytotoxicity, and death in tumor cells. Taken together, these results suggest that up-regulation of the ACER2/DHS pathway mediates the cytotoxicity of 4-HPR in tumor cells and that up-regulating or activating ACER2 may improve the anti-cancer activity of 4-HRR and other DHC-inducing agents.
C1 [Obeid, Lina M.] Med Univ S Carolina, Dept Med, Div Gen Internal Med, Charleston, SC 29425 USA.
[Szulc, Zdzislaw M.; Bielawski, Jacek; Obeid, Lina M.; Mao, Cungui] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
[Obeid, Lina M.; Mao, Cungui] Ralph H Johnson Vet Adm Hosp, Charleston, SC 29425 USA.
RP Obeid, LM (reprint author), Med Univ S Carolina, Dept Med, Div Gen Internal Med, 114 Doughty St,POB 250779, Charleston, SC 29425 USA.
EM maoc@musc.edu
FU National Institutes of Health [R01CA104834, P20RR017677]; Veterans
Affairs
FX This work was supported, in whole or in part, by National Institutes of
Health Grants R01CA104834 (to C. M.) and P20RR017677 (to L. M. O.). This
work was also supported by a Veterans Affairs merit award (to L. M. O.).
NR 48
TC 23
Z9 24
U1 0
U2 4
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD SEP 17
PY 2010
VL 285
IS 38
BP 29078
EP 29090
DI 10.1074/jbc.M110.105296
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 649BC
UT WOS:000281740100009
PM 20628055
ER
PT J
AU Adeyemo, MA
Spiegel, BMR
Chang, L
AF Adeyemo, M. A.
Spiegel, B. M. R.
Chang, L.
TI Meta-analysis: do irritable bowel syndrome symptoms vary between men and
women?
SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS
LA English
DT Review
ID FUNCTIONAL GASTROINTESTINAL DISORDERS; HEALTH-CARE SEEKING;
GENDER-RELATED DIFFERENCES; ROME-II CRITERIA; QUALITY-OF-LIFE;
MENSTRUAL-CYCLE; COLONIC TRANSIT; RISK-FACTORS; POSTMENOPAUSAL WOMEN;
MANNING CRITERIA
AB P>Background
Studies suggest that sex and gender-related differences exist in irritable bowel syndrome (IBS), but data is often conflicting.
Aim
To evaluate gender differences and the effect of menstrual cycle and menopausal status on IBS symptoms.
Methods
We performed a systematic review of MEDLINE to search for studies comparing IBS symptoms between gender, menstrual cycle phases and menopausal states in IBS and/or healthy individuals. We performed meta-analyses to compare the relative risk (RR) of individual IBS symptoms between men and women.
Results
Twenty-two studies measured gender differences in IBS symptoms. Women were more likely to report abdominal pain (RR = 1.12, 95% CI: 1.02, 1.22) and constipation-related symptoms (RR = 1.12, 95% CI: 1.02, 1.23) than men (all P < 0.05). However, men with IBS were more likely to report diarrhoea-related symptoms than women with IBS (RR = 0.84, 95% CI: 0.75, 0.94, P < 0.05). A systematic review of 13 studies demonstrated that both IBS and healthy women reported increased IBS symptoms during menses vs. other phases. There were insufficient data to determine the effect of menopause and hormone supplementation on IBS symptoms.
Conclusions
In the general and IBS populations, gender differences in IBS symptoms exist, although these differences are modest. Studies suggest that female sex hormones influence the severity of IBS symptoms, but more studies are needed.
C1 [Adeyemo, M. A.; Chang, L.] Ctr Neurobiol Stress, Los Angeles, CA 90095 USA.
[Spiegel, B. M. R.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Div Digest Dis, Los Angeles, CA 90024 USA.
[Spiegel, B. M. R.] Univ Calif Los Angeles, VA Ctr Outcomes Res & Educ CORE, Los Angeles, CA 90073 USA.
RP Chang, L (reprint author), Ctr Neurobiol Stress, CHS 47-122,10833 Le Conte Ave, Los Angeles, CA 90095 USA.
EM linchang@ucla.edu
FU Takeda; Rose; Prometheus; Amgen; Shire; Novartis; NIH [P50 DK64539, R24
AT002681]
FX Declaration of personal interests: The authors thank Melissa Alberto and
Teresa Olivas for their assistance in the preparation of the work.
Mopelola Adeyemo has nothing to declare. Brennan Spiegel has served as a
consultant for Prometheus Laboratories, Astra-Zeneca, TAP, Takeda,
Ironwood, and Novartis. He has received research funding from Takeda,
Rose, Prometheus, Amgen, Shire, and Novartis. Lin Chang has served as a
consultant for Prometheus Laboratories, Takeda, Forest, Albireo, McNeil,
Rose Pharma, GlaxoSmithKline, Salix, Ocera and Movetis. She has received
research funding from Takeda, Rose and Prometheus. Declaration of
funding interests: This study was funded by NIH Grants Nos P50 DK64539
and R24 AT002681.
NR 109
TC 58
Z9 62
U1 2
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0269-2813
EI 1365-2036
J9 ALIMENT PHARM THER
JI Aliment. Pharmacol. Ther.
PD SEP 15
PY 2010
VL 32
IS 6
BP 738
EP 755
DI 10.1111/j.1365-2036.2010.04409.x
PG 18
WC Gastroenterology & Hepatology; Pharmacology & Pharmacy
SC Gastroenterology & Hepatology; Pharmacology & Pharmacy
GA 639JX
UT WOS:000280972200004
PM 20662786
ER
PT J
AU Gastaldelli, A
Harrison, S
Belfort-Aguiar, R
Hardies, J
Balas, B
Schenker, S
Cusi, K
AF Gastaldelli, A.
Harrison, S.
Belfort-Aguiar, R.
Hardies, J.
Balas, B.
Schenker, S.
Cusi, K.
TI Pioglitazone in the treatment of NASH: the role of adiponectin
SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
ID HEPATIC INSULIN-RESISTANCE; ACTIVATED PROTEIN-KINASE; PLACEBO-CONTROLLED
TRIAL; FATTY LIVER-DISEASE; NONALCOHOLIC STEATOHEPATITIS;
DIABETES-MELLITUS; FIBROSIS; GLUCOSE; MICE; METABOLISM
AB P>Background
Plasma adiponectin is decreased in NASH patients and the mechanism(s) for histological improvement during thiazolidinedione treatment remain(s) poorly understood.
Aim
To evaluate the relationship between changes in plasma adiponectin following pioglitazone treatment and metabolic/histological improvement.
Methods
We measured in 47 NASH patients and 20 controls: (i) fasting glucose, insulin, FFA and adiponectin concentrations; (ii) hepatic fat content by magnetic resonance spectroscopy; and (iii) peripheral/hepatic insulin sensitivity (by double-tracer oral glucose tolerance test). Patients were then treated with pioglitazone (45 mg/day) or placebo and all measurements were repeated after 6 months.
Results
Patients with NASH had decreased plasma adiponectin levels independent of the presence of obesity. Pioglitazone increased 2.3-fold plasma adiponectin and improved insulin resistance, glucose tolerance and glucose clearance, steatosis and necroinflammation (all P < 0.01-0.001 vs. placebo). In the pioglitazone group, plasma adiponectin was significantly associated (r = 0.52, P = 0.0001) with hepatic insulin sensitivity and with the change in both variables (r = 0.44, P = 0.03). Increase in adiponectin concentration was related also to histological improvement, in particular, to hepatic steatosis (r = -0.46, P = 0006) and necroinflammation (r = -0.56, P < 0.0001) but importantly also to fibrosis (r = -0.29, P = 0.03).
Conclusions
Adiponectin exerts an important metabolic role at the level of the liver, and its increase during pioglitazone treatment is critical to reverse insulin resistance and improve liver histology in NASH patients.
C1 [Gastaldelli, A.; Belfort-Aguiar, R.; Balas, B.; Cusi, K.] Univ Texas Hlth Sci Ctr San Antonio, Div Diabet, San Antonio, TX 78284 USA.
[Gastaldelli, A.] CNR, Natl Res Council, Inst Clin Physiol, I-00185 Rome, Italy.
[Harrison, S.] Brooke Army Med Ctr, Div Gastroenterol, San Antonio, TX USA.
[Hardies, J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med & Radiol, San Antonio, TX 78284 USA.
[Schenker, S.] Univ Texas Hlth Sci Ctr San Antonio, Div Gastroenterol, San Antonio, TX 78284 USA.
[Cusi, K.] Brooke Army Med Ctr, Div Diabet, Audie L Murphy Vet Adm Med Ctr, San Antonio, TX USA.
RP Cusi, K (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Diabet, Room 3-380S,7703 Floyd Curl Dr, San Antonio, TX 78284 USA.
EM cusi@uthscsa.edu
RI Hardies, Lou /F-2102-2010; Gastaldelli, Amalia/H-3319-2014
OI Gastaldelli, Amalia/0000-0003-2594-1651
FU Veterans Affairs Medical Research Fund; National Center for Research
Resources [UL 1RR025767]; Italian National Research Council; Takeda
Pharmaceuticals
FX The authors thank the study volunteers, the nursing staff, and the
nutrition and laboratory staff for their assistance in performing the
described studies. Declaration of personal interests: Gastaldelli A,
Harrison S, Belfort R, Hardies J, Balas B, Schenker S and Cusi K have no
conflicts of interest. Declaration of funding interests: The project
described (and Cusi K) was supported by the Veterans Affairs Medical
Research Fund and by Award Number UL 1RR025767 from the National Center
for Research Resources. The content is solely the responsibility of the
authors and does not necessarily represent the official views of the
National Center for Research Resources of the National Institutes of
Health. A. G. was supported by the Italian National Research Council.
Partial support was received for the original study from Takeda
Pharmaceuticals.
NR 29
TC 47
Z9 52
U1 3
U2 7
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0269-2813
J9 ALIMENT PHARM THER
JI Aliment. Pharmacol. Ther.
PD SEP 15
PY 2010
VL 32
IS 6
BP 769
EP 775
DI 10.1111/j.1365-2036.2010.04405.x
PG 7
WC Gastroenterology & Hepatology; Pharmacology & Pharmacy
SC Gastroenterology & Hepatology; Pharmacology & Pharmacy
GA 639JX
UT WOS:000280972200007
PM 20662773
ER
PT J
AU Horberg, MA
Aberg, JA
Cheever, LW
Renner, P
Kaleba, EO
Asch, SM
AF Horberg, Michael A.
Aberg, Judith A.
Cheever, Laura W.
Renner, Philip
Kaleba, Erin O'Brien
Asch, Steven M.
TI Development of National and Multiagency HIV Care Quality Measures
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTIOUS-DISEASES-SOCIETY; IMMUNIZATION
PRACTICES ACIP; PNEUMOCYSTIS-CARINII-PNEUMONIA; UNITED-STATES; MEDICINE
ASSOCIATION; ADVISORY-COMMITTEE; OPPORTUNISTIC INFECTIONS; PNEUMOCOCCAL
DISEASE; RISK-FACTORS
AB Background. Human immunodeficiency virus (HIV) is now a complex, chronic disease requiring high quality care. Demonstration of quality HIV care requires uniform, aligned HIV care quality measurement.
Methods. In September 2007, the National Committee for Quality Assurance, under contract with the Health Resources and Services Administration, the Physician Consortium for Performance Improvement of the American Medical Association, and HIV Medicine Association of the Infectious Disease Society of America jointly sponsored and convened an expert panel as a HIV/AIDS Work Group to draft national HIV/AIDS performance measures for individual patient-level and system-level quality improvement.
Results. A total of 17 measures were developed to assess processes and outcomes of HIV/AIDS care for patients established in care, defined as having at least 2 visits in a 12-month period; thus, measures of HIV screening, testing, linkage, and access to care were not included. As a set, the measures assess a wide range of care, including patient retention, screening and prophylaxis for opportunistic infections, immunization, and initiation and monitoring of potent antiretroviral therapy. Since development, the HIV/AIDS measures' specifications have been fully determined and are being beta tested, and a majority have been endorsed by the National Quality Forum and have been adopted and implemented by the sponsoring organizations.
Conclusions. HIV care quality measurement should be assessed with greater uniformity. The measures presented offer opportunities for such alignment.
C1 [Horberg, Michael A.] Kaiser Permanente, HIV AIDS, HIV Interreg Initiat, Oakland, CA 94612 USA.
[Asch, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA.
[Asch, Steven M.] RAND Corp, Los Angeles, CA USA.
[Aberg, Judith A.] NYU, Sch Med, Dept Med, New York, NY USA.
[Cheever, Laura W.] US Hlth Resources & Serv Adm, HIV AIDS Bur, Rockville, MD 20857 USA.
[Renner, Philip] Natl Comm Qual Assurance, Washington, DC USA.
[Kaleba, Erin O'Brien] Alliance Chicago Community Hlth Serv, Chicago, IL USA.
RP Horberg, MA (reprint author), Kaiser Permanente, HIV AIDS, HIV Interreg Initiat, 2000 Broadway, Oakland, CA 94612 USA.
EM michael.horberg@kp.org
FU National Committee for Quality Assurance; Physician Consortium for
Performance Improvement of the American Medical Association; HIV
Medicine Association of the Infectious Diseases Society of America;
Health Resources and Services Administration
FX Financial support. National Committee for Quality Assurance, the
Physician Consortium for Performance Improvement of the American Medical
Association, the HIV Medicine Association of the Infectious Diseases
Society of America, and the Health Resources and Services
Administration.
NR 48
TC 39
Z9 39
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD SEP 15
PY 2010
VL 51
IS 6
BP 732
EP 738
DI 10.1086/655893
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 641QA
UT WOS:000281143400015
PM 20715924
ER
PT J
AU Margolis, M
Kaiser, L
Christie, J
AF Margolis, Mitchell
Kaiser, Larry
Christie, Jason
TI Patient Decisions to Undergo Surgery for Early-Stage Lung Cancer
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
ID RACIAL-DIFFERENCES; BELIEF
C1 [Margolis, Mitchell] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Kaiser, Larry] Univ Texas Houston Hlth Sci Ctr, Houston, TX USA.
[Christie, Jason] Univ Penn, Philadelphia, PA 19104 USA.
RP Margolis, M (reprint author), Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
EM mitchell.margolis@va.gov
NR 5
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD SEP 15
PY 2010
VL 304
IS 11
BP 1165
EP 1165
DI 10.1001/jama.2010.1311
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 649LF
UT WOS:000281770600002
PM 20841526
ER
PT J
AU Boulware, DR
Bonham, SC
Meya, DB
Wiesner, DL
Park, GS
Kambugu, A
Janoff, EN
Bohjanen, PR
AF Boulware, David R.
Bonham, Shulamith C.
Meya, David B.
Wiesner, Darin L.
Park, Gregory S.
Kambugu, Andrew
Janoff, Edward N.
Bohjanen, Paul R.
TI Paucity of Initial Cerebrospinal Fluid Inflammation in Cryptococcal
Meningitis Is Associated with Subsequent Immune Reconstitution
Inflammatory Syndrome
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID ACTIVE ANTIRETROVIRAL THERAPY; COLONY-STIMULATING FACTOR; T-CELLS;
NEOFORMANS INFECTION; DENDRITIC CELLS; CASE-DEFINITION; EARLY MORTALITY;
AMPHOTERICIN-B; IFN-GAMMA; ACTIVATION
AB Background. Cryptococcal meningitis (CM)-related immune reconstitution inflammatory syndrome (IRIS) complicates antiretroviral therapy (ART) in 20%-40% of ART-naive persons with AIDS and prior CM. Pathogenesis is unknown.
Methods. We compared initial cerebrospinal fluid (CSF) cultures, inflammatory markers, and cytokine profiles in ART-naive patients with AIDS who did or did not subsequently develop IRIS after starting ART. We also compared results obtained at IRIS events or CM relapse.
Results. Of 85 subjects with CM, 33 (39%) developed CM-related IRIS and 5 (6%) developed culture-positive CM relapse. At CM diagnosis, subjects subsequently developing IRIS had less inflammation, with decreased CSF leukocytes, protein, interferon-gamma, interleukin-6, interleukin-8, and tumor necrosis factor-alpha, compared with subjects not developing IRIS (P<.05, for each). Initial CSF white blood cell counts <= 25 cells/mu L and protein levels <= 50 mg/dL were associated with development of IRIS (odds ratio, 7.2 [95% confidence interval, 2.7-18.7]; P<.001). Compared with baseline levels, we identified CSF elevations of interferon-gamma, tumor necrosis factor-alpha, granulocyte colony-stimulating factor, vascular-endothelial growth factor, and eotaxin (CCL11) (P<.05, for each) at the time of IRIS but minimal inflammatory changes in those with CM relapse.
Conclusions. Patients who subsequently develop CM-related IRIS exhibit less initial CSF inflammation at the time of CM diagnosis, compared with those who do not develop IRIS. The inflammatory CSF cytokine profiles observed at time of IRIS can distinguish IRIS from CM relapse.
C1 [Boulware, David R.; Bonham, Shulamith C.; Meya, David B.; Kambugu, Andrew; Bohjanen, Paul R.] Univ Minnesota, Dept Med, Div Infect Dis & Int Med, Minneapolis, MN 55455 USA.
[Boulware, David R.; Bonham, Shulamith C.; Wiesner, Darin L.; Park, Gregory S.; Bohjanen, Paul R.] Univ Minnesota, Ctr Infect Dis & Microbiol Translat Res, Minneapolis, MN 55455 USA.
[Wiesner, Darin L.; Bohjanen, Paul R.] Univ Minnesota, Dept Microbiol, Minneapolis, MN 55455 USA.
[Meya, David B.; Kambugu, Andrew] Makerere Univ, Infect Dis Inst, Kampala, Uganda.
[Janoff, Edward N.] Univ Colorado, Denver Sch Med, Denver Vet Affairs Med Ctr, Mucosal & Vaccine Res Program Colorado,Div Infect, Denver, CO 80202 USA.
RP Boulware, DR (reprint author), MMC 250,420 Delaware St SE, Minneapolis, MN 55455 USA.
EM boulw001@umn.edu
RI Boulware, David/B-5516-2011; Boulware, David/I-4533-2013; Bohjanen,
Paul/B-2329-2015
OI Bohjanen, Paul/0000-0002-2772-3597; Meya, David/0000-0002-4138-240X;
Boulware, David/0000-0002-4715-0060
FU NCRR NIH HHS [K12 RR023247, K12 RR023247-04, K12RR023247-04]; NIAID NIH
HHS [L30 AI066779, K23 AI073192, K23 AI073192-01A2, K23AI073192-01A2,
L30 AI066779-03, L30AI066779, R03 AI078750, R03 AI078750-02,
R03AI078750-01, T32 AI055433, T32 AI055433-05, T32AI055433-05]
NR 45
TC 82
Z9 83
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD SEP 15
PY 2010
VL 202
IS 6
BP 962
EP 970
DI 10.1086/655785
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 640YV
UT WOS:000281091200019
PM 20677939
ER
PT J
AU Chen, DH
Raskind, WH
Parson, WW
Sonnen, JA
Vu, T
Zheng, YL
Matsushita, M
Wolff, J
Lipe, H
Bird, TD
AF Chen, Dong-Hui
Raskind, Wendy H.
Parson, William W.
Sonnen, Joshua A.
Vu, Tiffany
Zheng, YunLin
Matsushita, Mark
Wolff, John
Lipe, Hillary
Bird, Thomas D.
TI A novel mutation in FHL1 in a family with X-linked scapuloperoneal
myopathy: Phenotypic spectrum and structural study of FHL1 mutations
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE X-linked myopathy; Scapuloperoneal; FHL1; Neurogenetics; Muscular
dystrophy; Genetic diagnosis
ID REDUCING BODY MYOPATHY; ELECTROSTATIC ENERGIES; BINDING PROTEIN; GENE;
DOMINANT
AB An X-linked myopathy was recently associated with mutations in the four-and-a-half-LIM domains 1 (FHL1) gene. We identified a family with late onset, slowly progressive weakness of scapuloperoneal muscles in three brothers and their mother. A novel missense mutation in the LIM2 domain of FHL1 (W122C) co-segregated with disease in the family. The phenotype was less severe than that in other reported families. Muscle biopsy revealed myopathic changes with FHL1 inclusions that were ubiquitin- and desmin-positive. This mutation provides additional evidence for X-linked myopathy caused by a narrow spectrum of mutations in FHL1, mostly in the LIM2 domain. Molecular dynamics (MD) simulations of the newly identified mutation and five previously published missense mutations in the LIM2 domain revealed no major distortions of the protein structure or disruption of zinc binding. There were, however, increases in the nonpolar, solvent-accessible surface area in one or both of two clusters of residues, suggesting that the mutant proteins have a variably increased propensity to aggregate. Review of the literature shows a wide range of phenotypes associated with mutations in FHL1. However, recognizing the typical scapuloperoneal phenotype and X-linked inheritance pattern will help clinicians arrive at the correct diagnosis. Published by Elsevier B.V.
C1 [Chen, Dong-Hui; Lipe, Hillary; Bird, Thomas D.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA.
[Raskind, Wendy H.; Vu, Tiffany; Zheng, YunLin; Matsushita, Mark; Wolff, John; Bird, Thomas D.] Univ Washington, Dept Med, Seattle, WA USA.
[Raskind, Wendy H.; Bird, Thomas D.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Parson, William W.] Univ Washington, Dept Biochem, Seattle, WA 98195 USA.
[Sonnen, Joshua A.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
[Wolff, John; Lipe, Hillary; Bird, Thomas D.] Vet Affairs Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA.
[Raskind, Wendy H.] Vet Affairs Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA.
RP Bird, TD (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S-182 GRECC, Seattle, WA 98108 USA.
EM tomnroz@uw.edu
RI Sonnen, 37382016/H-3738-2016
OI Sonnen, 37382016/0000-0001-9267-8705
FU Veterans Affairs; National Institutes of Health [NS069719]; National
Science Foundation [MCB-0641640]
FX This research was supported by the Veterans Affairs Medical Research
funds (TDB, HL, WHR, and JW), National Institutes of Health grant
NS069719 (WHR), and National Science Foundation grant MCB-0641640 (WWP).
Randy Small, Department of Pathology, University of Washington, provided
technical assistance for the histopathology studies.
NR 24
TC 27
Z9 27
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD SEP 15
PY 2010
VL 296
IS 1-2
BP 22
EP 29
DI 10.1016/j.jns.2010.06.017
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 643CY
UT WOS:000281272300004
PM 20633900
ER
PT J
AU Marsh, L
AF Marsh, L.
TI Depression and Cognitive Dysfunction in PD: What is the Relationship?
SO MOVEMENT DISORDERS
LA English
DT Meeting Abstract
C1 [Marsh, L.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0885-3185
J9 MOVEMENT DISORD
JI Mov. Disord.
PD SEP 15
PY 2010
VL 25
SU 3
BP S588
EP S588
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA 655WO
UT WOS:000282286300074
ER
PT J
AU Marsh, L
AF Marsh, L.
TI Neuropsychiatric Issues in Advancing PD: Clinical Spectrum and Resulting
QOL Implications
SO MOVEMENT DISORDERS
LA English
DT Meeting Abstract
C1 [Marsh, L.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0885-3185
J9 MOVEMENT DISORD
JI Mov. Disord.
PD SEP 15
PY 2010
VL 25
SU 3
BP S570
EP S570
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA 655WO
UT WOS:000282286300007
ER
PT J
AU Pan, C
Hwang, H
Zhang, J
Hancock, A
Shi, M
Chung, K
Leverenz, J
Zabetian, C
Peskind, E
Jankovic, J
Quinn, J
Galasko, D
Zhang, J
AF Pan, C.
Hwang, H.
Zhang, J.
Hancock, A.
Shi, M.
Chung, K.
Leverenz, J.
Zabetian, C.
Peskind, E.
Jankovic, J.
Quinn, J.
Galasko, D.
Zhang, J.
TI Identification of Plasma Glycoproteins Unique to Diagnosis and
Correlated with Severity of Parkinson's Disease
SO MOVEMENT DISORDERS
LA English
DT Meeting Abstract
C1 [Pan, C.; Hwang, H.; Zhang, J.; Hancock, A.; Shi, M.; Zhang, J.] Univ Washington, Seattle, WA 98195 USA.
[Chung, K.] Portland VA Med Ctr, Portland, OR USA.
[Jankovic, J.] Baylor Coll Med, Houston, TX 77030 USA.
[Quinn, J.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Galasko, D.] Univ Calif San Diego, La Jolla, CA 92093 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0885-3185
J9 MOVEMENT DISORD
JI Mov. Disord.
PD SEP 15
PY 2010
VL 25
SU 3
BP S663
EP S663
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA 655WO
UT WOS:000282286300321
ER
PT J
AU Schmidt, PN
Okun, MS
Siderowf, A
Nutt, JG
O'Conner, GT
Bloem, BR
Olmstead, EM
Guttman, M
Simuni, T
Cheng, E
Parashos, S
Marsh, L
Malaty, IA
Giladi, N
Wu, S
Oberdorf, J
AF Schmidt, P. N.
Okun, M. S.
Siderowf, A.
Nutt, J. G.
O'Conner, G. T.
Bloem, B. R.
Olmstead, E. M.
Guttman, M.
Simuni, T.
Cheng, E.
Parashos, S.
Marsh, L.
Malaty, I. A.
Giladi, N.
Wu, S.
Oberdorf, J.
TI Are Results from PD Trials Generalizable? The NPF Database Reveals a
Mismatch Between Typical Clinic Populations and Subjects in PD Trials
SO MOVEMENT DISORDERS
LA English
DT Meeting Abstract
C1 [Okun, M. S.; Malaty, I. A.; Wu, S.] Univ Florida, Gainesville, FL 32611 USA.
[Siderowf, A.] Univ Penn, Philadelphia, PA 19104 USA.
[Nutt, J. G.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[O'Conner, G. T.; Olmstead, E. M.] Dartmouth Med Sch, Hanover, NH USA.
[Bloem, B. R.] Radboud Univ Nijmegen, Nijmegen, Netherlands.
[Guttman, M.] Univ Toronto, Toronto, ON M5S 1A1, Canada.
[Simuni, T.] Northwestern Univ, Evanston, IL 60208 USA.
[Cheng, E.] W Los Angeles VA Med Ctr, Los Angeles, CA USA.
[Giladi, N.] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel.
RI Bloem, Bastiaan/E-3812-2010; Bloem, B.R./H-8013-2014
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0885-3185
J9 MOVEMENT DISORD
JI Mov. Disord.
PD SEP 15
PY 2010
VL 25
SU 3
BP S640
EP S640
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA 655WO
UT WOS:000282286300252
ER
PT J
AU Watson, GS
Thomas, S
Zabetian, CP
Gerton, BK
Kim, HM
Samii, A
Schantz, A
Leverenz, JB
AF Watson, G. S.
Thomas, S.
Zabetian, C. P.
Gerton, B. K.
Kim, H. M.
Samii, A.
Schantz, A.
Leverenz, J. B.
TI How Well Can Screening Instruments Discriminate Among PD Patients with
Normal Cognition, Mild Impairments, and Dementia?
SO MOVEMENT DISORDERS
LA English
DT Meeting Abstract
C1 [Watson, G. S.; Samii, A.; Schantz, A.] Univ Washington, VA Puget Sound HCS, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0885-3185
J9 MOVEMENT DISORD
JI Mov. Disord.
PD SEP 15
PY 2010
VL 25
SU 3
BP S692
EP S692
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA 655WO
UT WOS:000282286300407
ER
PT J
AU Holt, SK
Kwon, EM
Koopmeiners, JS
Lin, DW
Feng, ZD
Ostrander, EA
Peters, U
Stanford, JL
AF Holt, Sarah K.
Kwon, Erika M.
Koopmeiners, Joseph S.
Lin, Daniel W.
Feng, Ziding
Ostrander, Elaine A.
Peters, Ulrike
Stanford, Janet L.
TI Vitamin D Pathway Gene Variants and Prostate Cancer Prognosis
SO PROSTATE
LA English
DT Article
DE vitamin D receptor; 1-alpha-hydroxylase; 24-hydroxylase; prostatic
neoplasms; outcomes
ID D-RECEPTOR GENE; RADICAL PROSTATECTOMY; 25-HYDROXYVITAMIN
D-1-ALPHA-HYDROXYLASE; UNITED-STATES; COLON-CANCER; RISK; POLYMORPHISMS;
ASSOCIATION; EXPRESSION; DIAGNOSIS
AB BACKGROUND. Observational studies linking vitamin D deficiency with increased prostate cancer (PCa) mortality and the pleiotropic anticancer effects of vitamin D in malignant prostate cell lines have initiated trials examining potential therapeutic benefits of vitamin D metabolites. There have been some successes but efforts have been hindered by risk of inducing hypercalcemia. A limited number of studies have investigated associations between variants in vitamin D pathway genes with aggressive forms of PCa. Increased understanding of relevant germline genetic variation with disease outcome could aid in the development of vitamin-D-based therapies.
METHODS. We undertook a comprehensive analysis of 48 tagging single-nucleotide polymorphisms (tagSNPs) in genes encoding for vitamin D receptor (VDR), vitamin D activating enzyme 1-alpha-hydroxylase (CYP27B1), and deactivating enzyme 24-hydroxylase (CYP24A1) in a cohort of 1,294 Caucasian cases with an average of 8 years of follow-up. Disease recurrence/progression and PCa-specific mortality risks were estimated using adjusted Cox proportional hazards regression.
RESULTS. There were 139 cases with recurrence/progression events and 57 cases who died of PCa. Significantly altered risks of recurrence/progression were observed in relation to genotype for two VDR tagSNPs (rs6823 and rs2071358) and two CYP24A1 tagSNPs (rs927650 and rs2762939). Three VDR tagSNPs (rs3782905, rs7299460, and rs11168314), one CYP27B1 tagSNP (rs3782130), and five CYP24A1 tagSNPs (rs3787557, rs4809960, rs2296241, rs2585428, and rs6022999) significantly altered risks of PCa death.
CONCLUSIONS. Genetic variations in vitamin D pathway genes were found to alter both risk of recurrence/progression and PCa-specific mortality. Prostate 70: 1448-1460, 2010. (C) 2010 Wiley-Liss, Inc.
C1 [Holt, Sarah K.; Koopmeiners, Joseph S.; Feng, Ziding; Peters, Ulrike; Stanford, Janet L.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA.
[Kwon, Erika M.; Ostrander, Elaine A.] NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA.
[Kwon, Erika M.] Johns Hopkins Univ, Sch Med, Program Human Genet & Mol Biol, Baltimore, MD USA.
[Lin, Daniel W.] Univ Washington, Dept Urol, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
[Feng, Ziding] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Peters, Ulrike; Stanford, Janet L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
RP Holt, SK (reprint author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Mailstop M4-A402,POB 19024, Seattle, WA 98109 USA.
EM skholt@fhcrc.org
OI Ostrander, Elaine/0000-0001-6075-9738
FU National Cancer Institute [RO1-CA056678, RO1-CA092579, RO1-CA082664,
P50-CA097186]
FX Grant sponsor: National Cancer Institute; Grant numbers: RO-CA056678,
RO1-CA092579, RO1-CA082664, P50-CA097186.; This work was supported by
grants RO1-CA056678, RO1-CA092579, RO1-CA082664, and P50-CA097186 from
the National Cancer Institute; additional support was provided by the
Fred Hutchinson Cancer Research Center, the Intramural Program of the
National Human Genome Research Institute, and the Prostate Cancer
Foundation Young Investigator Award Grant.
NR 50
TC 41
Z9 41
U1 0
U2 4
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0270-4137
J9 PROSTATE
JI Prostate
PD SEP 15
PY 2010
VL 70
IS 13
BP 1448
EP 1460
DI 10.1002/pros.21180
PG 13
WC Endocrinology & Metabolism; Urology & Nephrology
SC Endocrinology & Metabolism; Urology & Nephrology
GA 646LM
UT WOS:000281542100009
PM 20687218
ER
PT J
AU Teerlink, JR
AF Teerlink, John R.
TI Ivabradine in heart failure-no paradigm SHIFT ... yet
SO LANCET
LA English
DT Editorial Material
ID CARDIAC-INSUFFICIENCY BISOPROLOL; PLACEBO-CONTROLLED TRIAL; RATE
REDUCTION; RANDOMIZED-TRIAL; I-F; CARVEDILOL; DISEASE; DYSFUNCTION;
METOPROLOL; CIBIS
C1 [Teerlink, John R.] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA.
[Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
RP Teerlink, JR (reprint author), Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA.
EM john.teerlink@ucsf.edu
RI Teerlink, John/D-2986-2012
NR 19
TC 25
Z9 27
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD SEP 11
PY 2010
VL 376
IS 9744
BP 847
EP 849
DI 10.1016/S0140-6736(10)61314-1
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 653DW
UT WOS:000282069100004
PM 20801501
ER
PT J
AU Goebel, M
Stengel, A
Wang, LX
Coskun, T
Alsina-Fernandez, J
Rivier, J
Tache, Y
AF Goebel, Miriam
Stengel, Andreas
Wang, Lixin
Coskun, Tamer
Alsina-Fernandez, Jorge
Rivier, Jean
Tache, Yvette
TI Pattern of Fos expression in the brain induced by selective activation
of somatostatin receptor 2 in rats
SO BRAIN RESEARCH
LA English
DT Article
DE Somatostatin receptor; Brain; Oxytocin; Vasopressin
ID GENE-RELATED PEPTIDE; TRIGEMINAL SUBNUCLEUS CAUDALIS; LATERAL
PARABRACHIAL NUCLEUS; NERVOUS-SYSTEM REGULATION; ARCUATE NUCLEUS;
NEUROPEPTIDE-Y; GROWTH-HORMONE; IN-VITRO; C-FOS; SPINAL-CORD
AB Central activation of somatostatin (sst) receptors by oligosomatostatin analogs inhibits growth hormone and stress-related rise in catecholamine plasma levels while stimulating grooming, feeding behaviors, gastric transit and acid secretion, which can be mimicked by selective sst(2) receptor agonist. To evaluate the pattern of neuronal activation induced by peptide sst receptor agonists, we assessed Fos-expression in rat brain after intracerebroventricular (icv) injection of a newly developed selective sst(2) agonist compared to the oligosomatostatin ODT8-SST, a pan-sst(1-5) agonist. Ninety min after injection of vehicle (10 mu l) or previously established maximal orexigenic dose of peptides (1 mu g = 1 nmol/rat), brains were assessed for Fos-immunohistochemistry and doublelabeling. Food and water were removed after injection. The sst(2) agonist and ODT8-SST induced a similar Fos distribution pattern except in the arcuate nucleus where only the sst(2) agonist increased Fos. Compared to ODT8-SST, the sst(2) agonist induced higher Fos-expression by 3.7-times in the basolateral amygdaloid nucleus, 1.2-times in the supraoptic nucleus (SON), 1.6-times in the magnocellular paraventricular hypothalamic nucleus (mPVN), 4.1-times in the external lateral parabrachial nucleus, and 2.6-times in both the inferior olivary nucleus and superficial layer of the caudal spinal trigeminal nucleus. Doublelabeling in the hypothalamus showed that ODT8-SST activates 36% of oxytocin, 63% of vasopressin and 79% of sst(2) immunoreactive neurons in the mPVN and 28%, 55% and 25% in the SON, respectively. Selective activation of sst(2) receptor results in a more robust neuronal activation than the pan-sst(1-5) agonist in various brain regions that may have relevance in sst(2) mediated alterations of behavioral, autonomic and endocrine functions. Published by Elsevier B.V.
C1 [Tache, Yvette] VA Greater Los Angeles Healthcare Syst, Ctr Neurobiol Stress, Los Angeles, CA 90073 USA.
[Goebel, Miriam; Stengel, Andreas; Wang, Lixin; Tache, Yvette] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis,Dept Med, CURE Digest Dis Res Ctr,Ctr Neurobiol Stress, Los Angeles, CA 90095 USA.
[Coskun, Tamer; Alsina-Fernandez, Jorge] Eli Lilly & Co, Biotechnol Discovery Res, Indianapolis, IN 46285 USA.
[Rivier, Jean] Salk Inst Biol Studies, Peptide Biol Labs, La Jolla, CA USA.
RP Tache, Y (reprint author), VA Greater Los Angeles Healthcare Syst, Ctr Neurobiol Stress, CURE Bldg 115,Room 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM ytache@mednet.ucla.edu
FU German Research Foundation [GO 1718/1-1, STE 1765/1-1]; VA Research
Career Scientist Award; NIH, Center [R01 DK- 33061, DK-41301]
FX This work was supported by German Research Foundation fellowship grants
GO 1718/1-1 (M.G.) and STE 1765/1-1 (AS.), the VA Research Career
Scientist Award (Y.T.), the NIH R01 DK- 33061 (Y.T.) and Center grant
DK-41301 (Animal Core, Y.T.). J.R. is the Dr. Frederik Paulsen Chair in
Neurosciences Professor. We are grateful to Mrs. Honghui Liang for her
excellent technical support and Ms. Eugenia Hu for reviewing the
manuscript.
NR 109
TC 12
Z9 13
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
J9 BRAIN RES
JI Brain Res.
PD SEP 10
PY 2010
VL 1351
BP 150
EP 164
DI 10.1016/j.brainres.2010.07.024
PG 15
WC Neurosciences
SC Neurosciences & Neurology
GA 653UD
UT WOS:000282121500015
PM 20637739
ER
PT J
AU Burgess, SJ
Kelly, JX
Shomloo, S
Wittlin, S
Brun, R
Liebmann, K
Peyton, DH
AF Burgess, Steven J.
Kelly, Jane X.
Shomloo, Shawheen
Wittlin, Sergio
Brun, Reto
Liebmann, Katherine
Peyton, David H.
TI Synthesis, Structure-Activity Relationship, and Mode-of-Action Studies
of Antimalarial Reversed Chloroquine Compounds
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID BETA-HEMATIN FORMATION; PLASMODIUM-FALCIPARUM CHLOROQUINE; MALARIA
PARASITES; QUINOLINE ANTIMALARIALS; RESISTANCE TRANSPORTER; DRUG
RESISTANCE; IN-VITRO; MECHANISM; ASSAY; INHIBITION
AB We have previously shown that a "reversed chloroquine (RCQ)" molecule, composed of a chloroquine-like moiety and a resistance reversal-like moiety, can overcome chloroquine resistance in P. falciparum (Burgess, S. J.; Selzer; A.; Kelly, J. X.; Smilkstein, M. J.; Riscoe, M. K.; Peyton, D. H. J. Med. Chem. 2006, 49, 5623. Andrews, S.; Burgess, S. J.; Skaalrud, D.; Kelly, J. X.; Peyton, D. H. J. Med. Chem. 2010, 53, 916). Here, we present an investigation into the structure-activity relationship of the RCQ structures, resulting in an orally active molecule with good in vitro and in vivo antimalarial activity. We also present evidence of the mode of action, indicating that the RCQ molecules inhibit hemozoin formation in the parasite's digestive vacuole in a manner similar to that of chloroquine.
C1 [Burgess, Steven J.; Kelly, Jane X.; Shomloo, Shawheen; Liebmann, Katherine; Peyton, David H.] Portland State Univ, Dept Chem, Portland, OR 97207 USA.
[Burgess, Steven J.; Shomloo, Shawheen; Peyton, David H.] DesignMedix Inc, Portland, OR 97201 USA.
[Kelly, Jane X.] Portland VA Med Ctr, Portland, OR 97239 USA.
[Wittlin, Sergio; Brun, Reto] Swiss Trop & Publ Hlth Inst, Basel, Switzerland.
[Wittlin, Sergio; Brun, Reto] Univ Basel, Basel, Switzerland.
RP Peyton, DH (reprint author), Portland State Univ, Dept Chem, POB 751, Portland, OR 97207 USA.
EM peytond@pdx.edu
FU The Medical Research Foundation of Oregon [0530]; National Institutes of
Health [AI067837, AI072923]; Murdock Charitable Trust
FX The authors thank the following for supporting this research: The
Medical Research Foundation of Oregon (Grant 0530) and the National
Institutes of Health (Grants ) to D.H.P., as well as the Murdock
Charitable Trust for a grant for the NMR instruments. The authors also
thank Westin Morrill for his help in preparing this manuscript.
NR 43
TC 30
Z9 30
U1 1
U2 6
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD SEP 9
PY 2010
VL 53
IS 17
BP 6477
EP 6489
DI 10.1021/jm1006484
PG 13
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 644TM
UT WOS:000281404200020
PM 20684562
ER
PT J
AU Marso, SP
House, JA
Rumsfeld, JS
AF Marso, Steven P.
House, John A.
Rumsfeld, John S.
TI Bleeding Avoidance Strategies and Percutaneous Coronary Intervention
Reply
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
ID VASCULAR CLOSURE DEVICES; CATHETERIZATION
C1 [Marso, Steven P.; House, John A.] St Lukes Mid Amer Heart Inst, Kansas City, MO USA.
[Rumsfeld, John S.] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Marso, SP (reprint author), St Lukes Mid Amer Heart Inst, Kansas City, MO USA.
EM smarso@saint-lukes.org
NR 3
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD SEP 8
PY 2010
VL 304
IS 10
BP 1068
EP 1069
DI 10.1001/jama.2010.1256
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 646RM
UT WOS:000281559800013
ER
PT J
AU Werner, RM
AF Werner, Rachel M.
TI Does Pay-for-Performance Steal From the Poor and Give to the Rich?
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Editorial Material
ID QUALITY-OF-CARE; HOSPITAL FINANCIAL CONDITION
C1 [Werner, Rachel M.] Univ Penn, Philadelphia, PA 19104 USA.
[Werner, Rachel M.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
RP Werner, RM (reprint author), Univ Penn, 1230 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM rwerner@upenn.edu
NR 12
TC 6
Z9 6
U1 1
U2 1
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD SEP 7
PY 2010
VL 153
IS 5
BP 340
EP 341
DI 10.7326/0003-4819-153-5-201009070-00010
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 647GF
UT WOS:000281605500009
PM 20820044
ER
PT J
AU Hoen, PW
Whooley, MA
Martens, EJ
Na, B
van Melle, JP
de Jonge, P
AF Hoen, Petra W.
Whooley, Mary A.
Martens, Elisabeth J.
Na, Beeya
van Melle, Joost P.
de Jonge, Peter
TI Differential Associations Between Specific Depressive Symptoms and
Cardiovascular Prognosis in Patients With Stable Coronary Heart Disease
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE depression; stable coronary heart disease and prognosis
ID POSTMYOCARDIAL INFARCTION DEPRESSION; ACUTE MYOCARDIAL-INFARCTION;
QUALITY-OF-LIFE; RATE-VARIABILITY; BLOOD-INSTITUTE; NATIONAL-HEART;
ARTERY-DISEASE; RISK-FACTOR; MORTALITY; METAANALYSIS
AB Objectives The purpose of this research was to evaluate the relationship between cognitive and somatic depressive symptoms and cardiovascular prognosis.
Background Depression in patients with stable coronary heart disease (CHD) is associated with poor cardiac prognosis. Whether certain depressive symptoms are more cardiotoxic than others is unknown.
Methods In the Heart and Soul Study, 1,019 patients with stable CHD were assessed using the Patient Health Questionnaire to determine the presence of the 9 depressive symptoms included in the Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition. The mean age of the patients was 67 years, and 82% were men. A comparison was made on a new cardiovascular event (myocardial infarction, stroke, transient ischemic attack, or congestive heart failure) or death (mean follow-up duration 6.1 +/- 2.0 years) on the basis of cognitive and somatic sum scores and for patients with or without each of those specific depressive symptoms. Demographic characteristics, cardiac risk factors, and cardiac medications were controlled for.
Results After adjustment for demographic data and cardiac risk factors, each somatic symptom was associated with 14% greater risk for events (hazard ratio [HR]: 1.14; 95% confidence interval [CI]: 1.05 to 1.24; p = 0.002). Fatigue (HR: 1.34; 95% CI: 1.07 to 1.67; p = 0.01), appetite problems (HR: 1.46; 95% CI: 1.12 to 1.91; p = 0.005), and sleeping difficulties (HR: 1.26; 95% CI: 1.00 to 1.58; p = 0.05) were most strongly predictive of cardiovascular events. In contrast, cognitive symptoms (HR: 1.08; 95% CI: 0.99 to 1.17; p = 0.09) were not significantly associated with cardiovascular events.
Conclusions In patients with stable CHD, somatic symptoms of depression were more strongly predictive of cardiovascular events than cognitive symptoms, although the CIs surrounding these estimates had substantial overlap. These findings are highly consistent with those of previous studies. Further research is needed to understand the pathophysiological processes by which somatic depressive symptoms contribute to prognosis in patients with CHD. (J Am Coll Cardiol 2010;56:838-44) (C) 2010 by the American College of Cardiology Foundation
C1 [Hoen, Petra W.] Univ Groningen, Univ Med Ctr Groningen, Interdisciplinary Ctr Psychiat Epidemiol, Dept Psychiat, NL-9713 GZ Groningen, Netherlands.
[van Melle, Joost P.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, NL-9713 GZ Groningen, Netherlands.
[Martens, Elisabeth J.; de Jonge, Peter] Tilburg Univ, Dept Med Psychol, NL-5000 LE Tilburg, Netherlands.
[Whooley, Mary A.; Na, Beeya] San Francisco VA Med Ctr, San Francisco, CA USA.
[Whooley, Mary A.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
RP Hoen, PW (reprint author), Univ Groningen, Univ Med Ctr Groningen, Interdisciplinary Ctr Psychiat Epidemiol, Dept Psychiat, CC72,Hanzepl 1, NL-9713 GZ Groningen, Netherlands.
EM p.w.hoen@med.umcg.nl
RI de Jonge, peter/L-6395-2013
OI de Jonge, peter/0000-0002-0866-6929
FU U.S. Department of Veterans Affairs; U.S. Department of Veterans Affairs
Health Services Research and Development Service; National Heart, Lung,
and Blood Institute [R01 HL079235]; American Federation for Aging
Research; Robert Wood Johnson Foundation; Ischemia Research and
Education Foundation; Nancy Kirwan Heart Research Fund; Dutch Medical
Research Council [016.086.397]
FX The Heart and Soul Study was supported by the U.S. Department of
Veterans Affairs Epidemiology Merit Review Program; the U.S. Department
of Veterans Affairs Health Services Research and Development Service;
grant R01 HL079235 from the National Heart, Lung, and Blood Institute;
the Paul Beeson Scholars Program of the American Federation for Aging
Research; the Generalist Physician Faculty Scholars Program of the
Robert Wood Johnson Foundation; the Ischemia Research and Education
Foundation; and the Nancy Kirwan Heart Research Fund. The funding
organizations had no role in the design and conduct of the study; the
collection, management, analysis, and interpretation of the data; or the
preparation, review, or approval of the manuscript. Dr. de Jonge was
supported by VIDI grant 016.086.397 from the Dutch Medical Research
Council. All other authors have reported that they have no relationships
to disclose.
NR 38
TC 62
Z9 62
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD SEP 7
PY 2010
VL 56
IS 11
BP 838
EP 844
DI 10.1016/j.jacc.2010.03.080
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 645IT
UT WOS:000281448500003
PM 20813281
ER
PT J
AU Furlong, CE
Suzuki, SM
Stevens, RC
Marsillach, J
Richter, RJ
Jarvik, GP
Checkoway, H
Samii, A
Costa, LG
Griffith, A
Roberts, JW
Yearout, D
Zabetian, CP
AF Furlong, C. E.
Suzuki, S. M.
Stevens, R. C.
Marsillach, J.
Richter, R. J.
Jarvik, G. P.
Checkoway, H.
Samii, A.
Costa, L. G.
Griffith, A.
Roberts, J. W.
Yearout, D.
Zabetian, C. P.
TI Human PON1, a biomarker of risk of disease and exposure
SO CHEMICO-BIOLOGICAL INTERACTIONS
LA English
DT Article; Proceedings Paper
CT 10th International Meeting on Cholinesterases
CY SEP 20-25, 2009
CL Sibenik, CROATIA
SP Inst Med Res & Occupat Hlth, Croatian Soc Biochem & Mole Biol, Croatian Acad Sci & Arts
DE Paraoxonase 1; Parkinson disease; Organophosphate; Therapy for OP
poisoning; Chlorpyrifos/chlorpyrifos oxon; Diazinon/diazoxon
ID HUMAN-SERUM PARAOXONASE; CORONARY-HEART-DISEASE; APOLIPOPROTEIN-A-I;
PARKINSONS-DISEASE; GENE POLYMORPHISMS; CARDIOVASCULAR-DISEASE; Q192R
POLYMORPHISM; CHLORPYRIFOS-OXON; VASCULAR-DISEASE; MOLECULAR-BASIS
AB Human paraoxonase 1 (PON1) is a high-density lipoprotein (HDL)-associated serum enzyme that exhibits a broad substrate specificity. In addition to protecting against exposure to some organophosphorus (OP) pesticides by hydrolyzing their toxic oxon metabolites. PON1 is important in protecting against vascular disease by metabolizing oxidized lipids. Recently, PON1 has also been shown to play a role in inactivating the quorum sensing factor N-(3-oxododecanoyl)-L-homoserine lactone (3OC12-HSL) of Pseudomonas aeruginosa. Native, untagged engineered recombinant human PON1 (rHuPON1) expressed in Escherichia coli and purified by conventional column chromatographic purification is stable, active, and capable of protecting PON1 knockout mice (PON1(-/-)) from exposure to high levels of the OP compound diazoxon. The bacterially derived rHuPON1 can be produced in large quantities and lacks the glycosylation of eukaryotic systems that can produce immunogenic complications when inappropriately glycosylated recombinant proteins are used as therapeutics. Previous studies have shown that the determination of PON1 status, which reveals both PON1(192) functional genotype and serum enzyme activity level, is required for a meaningful evaluation of PON1's role in risk of disease or exposure. We have developed a new two-substrate assay/analysis protocol that provides PON1 status without use of toxic OP substrates, allowing for use of this protocol in non-specialized laboratories. Factors were also determined for inter-converting rates of hydrolysis of different substrates. PON1 status also plays an important role in revealing changes in HDL-associated PON1 activities in male patients with Parkinson disease (PD). Immunolocalization studies of PONs 1, 2 and 3 in nearly all mouse tissues suggest that the functions of PONs 1 and 3 extend beyond the plasma and the HDL particle. (C) 2010 Published by Elsevier Ireland Ltd.
C1 [Furlong, C. E.; Suzuki, S. M.; Stevens, R. C.; Marsillach, J.; Richter, R. J.; Jarvik, G. P.] Univ Washington, Dept Med, Div Med Genet, Seattle, WA 98195 USA.
[Furlong, C. E.; Suzuki, S. M.; Stevens, R. C.; Marsillach, J.; Richter, R. J.; Jarvik, G. P.] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA.
[Checkoway, H.; Costa, L. G.] Univ Washington, Dept Environm & Occupat Hlth Sci, Seattle, WA 98195 USA.
[Checkoway, H.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Samii, A.; Yearout, D.; Zabetian, C. P.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA.
[Samii, A.; Yearout, D.; Zabetian, C. P.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Costa, L. G.] Univ Parma, Dept Human Anat Pharmacol & Forens Sci, I-43100 Parma, Italy.
[Griffith, A.] Evergreen Hosp Med Ctr, Kirkland, WA USA.
[Roberts, J. W.] Virginia Mason Med Ctr, Seattle, WA 98101 USA.
RP Furlong, CE (reprint author), Univ Washington, Dept Med, Div Med Genet, Box 357720, Seattle, WA 98195 USA.
EM clem@u.washington.edu
RI Jarvik, Gail/N-6476-2014; Marsillach, Judit/I-1329-2015
OI Jarvik, Gail/0000-0002-6710-8708; Marsillach, Judit/0000-0002-3061-6266;
Zabetian, Cyrus/0000-0002-7739-4306
FU NHLBI NIH HHS [HL67406, R01 HL067406, R01 HL067406-07]; NIEHS NIH HHS
[ES04696, ES07033, ES09601, ES09883, P01 ES009601, P01 ES009601-10, P30
ES007033, P30 ES007033-14S1, P42 ES004696, P42 ES004696-23, P42
ES004696-235868, R01 ES009883, R01 ES009883-09A1]; NINDS NIH HHS [P50
NS062684, P50 NS062684-01A16218, R01 NS065070, R01 NS065070-01A1, R01
NS065070-02, R01 NS065070-03]
NR 77
TC 44
Z9 46
U1 2
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0009-2797
J9 CHEM-BIOL INTERACT
JI Chem.-Biol. Interact.
PD SEP 6
PY 2010
VL 187
IS 1-3
SI SI
BP 355
EP 361
DI 10.1016/j.cbi.2010.03.033
PG 7
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA 641EW
UT WOS:000281108600065
PM 20338154
ER
PT J
AU Pham, SV
Pham, PCT
Pham, PMT
Miller, JM
Pham, PTT
Pham, PAT
AF Pham, Son V.
Pham, Phuong-Chi T.
Pham, Phuong-Mai T.
Miller, Jeffrey M.
Pham, Phuong-Thu T.
Pham, Phuong-Anh T.
TI Antithrombotic strategies in patients undergoing percutaneous coronary
intervention for acute coronary syndrome
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Review
DE acute coronary syndrome; percutaneous coronary intervention; aspirin;
clopidogrel; glycoprotein IIb/IIIa inhibitors; bivalirudin
AB In patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), both periprocedural acute myocardial infarction and bleeding complications have been shown to be associated with early and late mortality. Current standard antithrombotic therapy after coronary stent implantation consists of lifelong aspirin and clopidogrel for a variable period depending in part on the stent type. Despite its well-established efficacy in reducing cardiac-related death, myocardial infarction, and stroke, dual antiplatelet therapy with aspirin and clopidogrel is not without shortcomings. While clopidogrel may be of little beneficial effect if administered immediately prior to PCI and may even increase major bleeding risk if coronary artery bypass grafting is anticipated, early discontinuation of the drug may result in insufficient antiplatelet coverage with thrombotic complications. Optimal and rapid inhibition of platelet activity to suppress ischemic and thrombotic events while minimizing bleeding complications is an important therapeutic goal in the management of patients undergoing percutaneous coronary intervention. In this article we present an overview of the literature on clinical trials evaluating the different aspects of antithrombotic therapy in patients undergoing PCI and discuss the emerging role of these agents in the contemporary era of early invasive coronary intervention. Clinical trial acronyms and their full names are provided in Table 1.
C1 [Pham, Phuong-Thu T.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Nephrol Div,Kidney & Pancreas Transplant Program, Los Angeles, CA 90095 USA.
[Pham, Phuong-Anh T.] Mercy Gen Hosp, Inst Heart & Vasc, Dept Cardiol, Sacramento, CA USA.
[Pham, Son V.] Bay Pines VA Med Ctr, Dept Cardiol, Bay Pines, FL USA.
[Pham, Phuong-Chi T.] Univ Calif Los Angeles, Olive View Med Ctr, Dept Med, Div Nephrol, Los Angeles, CA 90095 USA.
[Miller, Jeffrey M.] Univ Calif Los Angeles, Olive View Med Ctr, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA.
[Pham, Phuong-Mai T.] Greater Los Angeles VA Med Ctr, Dept Med, Los Angeles, CA USA.
RP Pham, PTT (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Nephrol Div,Kidney & Pancreas Transplant Program, Los Angeles, CA 90095 USA.
EM ppham@mednet.ucla.edu
NR 53
TC 1
Z9 3
U1 0
U2 3
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PD SEP 6
PY 2010
VL 4
BP 203
EP 220
DI 10.2147/DDDT.S12056
PG 18
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA V20YU
UT WOS:000208176100001
PM 20856846
ER
PT J
AU Won, JS
Im, YB
Kim, J
Singh, AK
Singh, I
AF Won, Je-Seong
Im, Yeong-Bin
Kim, Jinsu
Singh, Avtar K.
Singh, Inderjit
TI Involvement of AMP-activated-protein-kinase (AMPK) in neuronal
amyloidogenesis
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE AMPK; Amyloid-beta; Amyloid precursor protein; Cholesterol; Lipid rafts;
Sphingomyelin
ID LIPID RAFTS; DISEASE; APP; CHOLESTEROL; GENERATION; OBESITY
AB AMP-activated-protein-kinase (AMPK) is a key sensor and regulator of cellular and whole-body energy metabolism and plays a key role in regulation of lipid metabolism. Since lipid metabolism has been implicated in neuronal amyloid-beta (A beta) homeostasis and onset of Alzheimer's disease, we investigated the involvement of AMPK in neuronal lipid metabolism and A beta production. We observed in cultured rat cortical neurons that AD production was significantly reduced when the neurons were stimulated with AMPK activator, 5-aminoimidazole-4-carboxamide-1-D-ribofuranoside (AICAR), but increased when AMPK alpha 2 was knocked out, thus indicating the role of AMPK in amyloidogenesis. Although the detailed mechanisms by which AMPK regulates A beta generation is not well understood, AMPK-mediated alterations in cholesterol and sphingomyelin homeostasis and in turn the altered distribution of A beta precursor-protein (APP) in cholesterol and sphingomyelin rich membrane lipid rafts participate in A beta generation. Taken together, this is the first report on the role of AMPK in regulation of neuronal amyloidogenesis. (C) 2010 Published by Elsevier Inc.
C1 [Won, Je-Seong; Im, Yeong-Bin; Kim, Jinsu; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Charles P Darby Children Res Inst, Charleston, SC 29425 USA.
[Won, Je-Seong] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA.
[Singh, Avtar K.] Ralph H Johnson Vet Adm Med Ctr, Dept Pathol & Lab Med, Charleston, SC USA.
RP Singh, I (reprint author), Med Univ S Carolina, Dept Pediat, Charles P Darby Children Res Inst, 504D,173 Ashley Ave, Charleston, SC 29425 USA.
EM singhi@musc.edu
FU National Institute of Health [NS-22576, NS-34741, NS-37766, AG-25307,
RR018823, RR015455]
FX We thank Ms. Joyce Bryan for laboratory assistance and Ms. Chara
Williams for secretarial assistance. This study was supported in part by
grants from National Institute of Health (NS-22576, NS-34741, NS-37766,
AG-25307, RR018823 and RR015455). We would like to thank Dr. Benoit
Viollet in INSERM U567 for providing AMP-K alpha 2 knockout mice.
NR 18
TC 33
Z9 38
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 3
PY 2010
VL 399
IS 4
BP 487
EP 491
DI 10.1016/j.bbrc.2010.07.081
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 650HQ
UT WOS:000281840200005
PM 20659426
ER
PT J
AU Bendlin, BB
Newman, LM
Ries, ML
Puglielli, L
Carlsson, CM
Sager, MA
Rowley, HA
Gallagher, CL
Willette, AA
Alexander, AL
Asthana, S
Johnson, SC
AF Bendlin, Barbara B.
Newman, Lisa M.
Ries, Michele L.
Puglielli, Luigi
Carlsson, Cynthia M.
Sager, Mark A.
Rowley, Howard A.
Gallagher, Catherine L.
Willette, Auriel A.
Alexander, Andrew L.
Asthana, Sanjay
Johnson, Sterling C.
TI NSAIDs may protect against age-related brain atrophy
SO FRONTIERS IN AGING NEUROSCIENCE
LA English
DT Article
DE Alzheimer's disease; aging; risk factors; volumetric MRI; NSAIDs
ID RANDOMIZED CONTROLLED-TRIAL; NONSTEROIDAL ANTIINFLAMMATORY DRUGS;
ALZHEIMER-TYPE PATHOLOGY; BETA-AMYLOID BURDEN; COGNITIVE DECLINE;
CHRONIC NEUROINFLAMMATION; APOLIPOPROTEIN-E; TRANSGENIC MICE; GENETIC
RISK; DISEASE PROGRESSION
AB The use of non-steroidal anti-inflammatory drugs (NSAIDs) in humans is associated with brain differences including decreased number of activated microglia. In animals, NSAIDs are associated with reduced microglia, decreased amyloid burden, and neuronal preservation. Several studies suggest NSAIDs protect brain regions affected in the earliest stages of AD, including hippocampal and parahippocampal regions. In this cross-sectional study, we examined the protective effect of NSAID use on gray matter volume in a group of middle-aged and older NSAID users (n = 25) compared to non-user controls (n = 50). All participants underwent neuropsychological testing and T1-weighted magnetic resonance imaging. Non-user controls showed smaller volume in portions of the left hippocampus compared to NSAID users. Age-related loss of volume differed between groups, with controls showing greater medial temporal lobe volume loss with age compared to NSAID users. These results should be considered preliminary, but support previous reports that NSAIDs may modulate age-related loss of brain volume.
C1 [Bendlin, Barbara B.; Newman, Lisa M.; Ries, Michele L.; Puglielli, Luigi; Carlsson, Cynthia M.; Sager, Mark A.; Gallagher, Catherine L.; Asthana, Sanjay; Johnson, Sterling C.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA.
[Bendlin, Barbara B.; Newman, Lisa M.; Ries, Michele L.; Puglielli, Luigi; Carlsson, Cynthia M.; Sager, Mark A.; Rowley, Howard A.; Gallagher, Catherine L.; Willette, Auriel A.; Asthana, Sanjay; Johnson, Sterling C.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Wisconsin Alzheimers Dis Res Ctr, Madison, WI USA.
[Willette, Auriel A.] Univ Wisconsin, Dept Psychol, Harlow Primate Lab, Madison, WI 53706 USA.
[Alexander, Andrew L.] Univ Wisconsin, Dept Med Phys, Sch Med & Publ Hlth, Madison, WI 53706 USA.
[Alexander, Andrew L.] Univ Wisconsin, Dept Psychiat, Sch Med & Publ Hlth, Madison, WI 53706 USA.
[Alexander, Andrew L.] Waisman Lab Brain Imaging & Behav, Madison, WI USA.
RP Bendlin, BB (reprint author), Vet Adm Hosp, Geriatr Res Educ & Clin Ctr, 2500 Overlook Terrace, Madison, WI 53705 USA.
EM bbb@medicine.wisc.edu
OI Bendlin, Barbara/0000-0002-0580-9875
FU National Institutes of Health [AG021155, MH62015, R01 AG27161, P50
AG033514]; Merit Review Grant from the Department of Veterans Affairs
FX This work was supported by the National Institutes of Health (AG021155
to Sterling C. Johnson, MH62015 to Andrew L. Alexander, and R01 AG27161
to Mark A. Sager, and P50 AG033514); a Merit Review Grant from the
Department of Veterans Affairs (to Sterling C. Johnson), and by the
facilities and resources at the William S. Middleton Memorial Veterans
Hospital (GRECC manuscript number 2010-15). The authors gratefully
acknowledge the assistance of Brent Thiel, Britta Jabbar, Michele
Fitzgerald, Erik Kastman, Amy Hawley, and Sandra Harding at the
University of Wisconsin-Madison for their roles in data collection and
technical assistance. In addition, we would like to acknowledge the kind
support of researchers and staff at the Waisman Center, University of
Wisconsin-Madison, where MR imaging took place. Finally, we extend
thanks to our volunteers who participated in this research.
NR 62
TC 3
Z9 3
U1 0
U2 6
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1663-4365
J9 FRONT AGING NEUROSCI
JI Front. Aging Neurosci.
PD SEP 3
PY 2010
VL 2
AR 35
DI 10.3389/fnagi.2010.00035
PG 8
WC Geriatrics & Gerontology; Neurosciences
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA V26QS
UT WOS:000208560700001
ER
PT J
AU Follett, K
Weaver, F
Stern, M
AF Follett, Kenneth
Weaver, Frances
Stern, Matthew
TI Deep-Brain Stimulation for Parkinson's Disease REPLY
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter
C1 [Follett, Kenneth] Iowa City Vet Affairs Med Ctr, Iowa City, IA USA.
[Weaver, Frances] Hines Vet Affairs Hosp, Hines, IL USA.
[Stern, Matthew] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Follett, K (reprint author), Iowa City Vet Affairs Med Ctr, Iowa City, IA USA.
EM frances.weaver@va.gov
NR 1
TC 0
Z9 0
U1 0
U2 0
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD SEP 2
PY 2010
VL 363
IS 10
BP 988
EP 988
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 645GW
UT WOS:000281441500018
ER
PT J
AU Al Gadban, MM
Smith, KJ
Soodavar, F
Piansay, C
Chassereau, C
Twal, WO
Klein, RL
Virella, G
Lopes-Virella, MF
Hammad, SM
AF Al Gadban, Mohammed M.
Smith, Kent J.
Soodavar, Farzan
Piansay, Christabelle
Chassereau, Charlyne
Twal, Waleed O.
Klein, Richard L.
Virella, Gabriel
Lopes-Virella, Maria F.
Hammad, Samar M.
TI Differential Trafficking of Oxidized LDL and Oxidized LDL Immune
Complexes in Macrophages: Impact on Oxidative Stress
SO PLOS ONE
LA English
DT Article
ID LOW-DENSITY-LIPOPROTEIN; MONOCYTE-DERIVED MACROPHAGES; SCAVENGER
RECEPTORS; ANTIPHOSPHOLIPID SYNDROME; HEAT-SHOCK; CELLS;
ATHEROSCLEROSIS; ANTIBODIES; OXLDL; ATHEROGENESIS
AB Background: Oxidized low-density lipoproteins (oxLDL) and oxLDL-containing immune complexes (oxLDL-IC) contribute to formation of lipid-laden macrophages (foam cells). It has been shown that oxLDL-IC are considerably more efficient than oxLDL in induction of foam cell formation, inflammatory cytokines secretion, and cell survival promotion. Whereas oxLDL is taken up by several scavenger receptors, oxLDL-IC are predominantly internalized through the FCc receptor I (FCc RI). This study examined differences in intracellular trafficking of lipid and apolipoprotein moieties of oxLDL and oxLDL-IC and the impact on oxidative stress.
Methodology/Findings: Fluorescently labeled lipid and protein moieties of oxLDL co-localized within endosomal and lysosomal compartments in U937 human monocytic cells. In contrast, the lipid moiety of oxLDL-IC was detected in the endosomal compartment, whereas its apolipoprotein moiety advanced to the lysosomal compartment. Cells treated with oxLDL-IC prior to oxLDL demonstrated co-localization of internalized lipid moieties from both oxLDL and oxLDL-IC in the endosomal compartment. This sequential treatment likely inhibited oxLDL lipid moieties from trafficking to the lysosomal compartment. In RAW 264.7 macrophages, oxLDL-IC but not oxLDL induced GFP-tagged heat shock protein 70 (HSP70) and HSP70B', which co-localized with the lipid moiety of oxLDL-IC in the endosomal compartment. This suggests that HSP70 family members might prevent the degradation of the internalized lipid moiety of oxLDL-IC by delaying its advancement to the lysosome. The data also showed that mitochondrial membrane potential was decreased and generation of reactive oxygen and nitrogen species was increased in U937 cell treated with oxLDL compared to oxLDL-IC.
Conclusions/Significance: Findings suggest that lipid and apolipoprotein moieties of oxLDL-IC traffic to separate cellular compartments, and that HSP70/70B' might sequester the lipid moiety of oxLDL-IC in the endosomal compartment. This mechanism could ultimately influence macrophage function and survival. Furthermore, oxLDL-IC might regulate the intracellular trafficking of free oxLDL possibly through the induction of HSP70/70B'.
C1 [Al Gadban, Mohammed M.; Smith, Kent J.; Soodavar, Farzan; Twal, Waleed O.; Hammad, Samar M.] Med Univ S Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA.
[Piansay, Christabelle] Med Univ S Carolina, Summer Undergrad Res Program, Coll Grad Studies, Charleston, SC 29425 USA.
[Chassereau, Charlyne; Klein, Richard L.; Lopes-Virella, Maria F.] Med Univ S Carolina, Dept Med, Div Endocrinol, Charleston, SC 29425 USA.
[Klein, Richard L.; Lopes-Virella, Maria F.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC USA.
[Virella, Gabriel] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA.
RP Al Gadban, MM (reprint author), Med Univ S Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA.
EM hammadsm@musc.edu
FU National Institutes of Health (NIH) [HL079274]; NIH (ARRA) [R01
HL079274-04S1]; NCRR [P20 RR17677]; NIH [P01 HL55782, R01 DK081352, R01
DK081352-02S1]; Department of Veterans Affairs
FX This work was supported by the National Institutes of Health (NIH) grant
HL079274, NIH (ARRA) grant R01 HL079274-04S1, and the South Carolina
COBRE in Lipidomics and Pathobiology (P20 RR17677 from NCRR) to SMH, and
NIH grants P01 HL55782, R01 DK081352 and R01 DK081352-02S1 (ARRA) to
MLV, and funding from the Department of Veterans Affairs to MLV and RLK.
The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 53
TC 9
Z9 9
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 2
PY 2010
VL 5
IS 9
AR e12534
DI 10.1371/journal.pone.0012534
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 645RB
UT WOS:000281480900017
ER
PT J
AU Levy, C
Pointer, L
AF Levy, Cari
Pointer, Lauren
TI Identifying Hospice Eligible Nursing Home Residents
SO JOURNAL OF PALLIATIVE CARE
LA English
DT Meeting Abstract
C1 [Levy, Cari; Pointer, Lauren] Denver Vet Affairs Med Ctr, Denver, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU CENTRE RECHERCHE INSTITUT UNIV GERIATRIE MONTREAL
PI MONTREAL
PA 4565 CHEMIN QUEEN MARY, MONTREAL, QUEBEC H3W 1W5, CANADA
SN 0825-8597
J9 J PALLIAT CARE
JI J. Palliative Care
PD FAL
PY 2010
VL 26
IS 3
BP 244
EP 244
PG 1
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 802BE
UT WOS:000293483500148
ER
PT J
AU Bersohn, M
Shapiro, S
Miller, DP
Turner, MP
Traiger, G
Frost, AE
AF Bersohn, M.
Shapiro, S.
Miller, D. P.
Turner, M. P.
Traiger, G.
Frost, A. E.
TI Prognostic value of heart rate and systemic systolic blood pressure in
pulmonary arterial hypertension in the REVEAL registry
SO EUROPEAN HEART JOURNAL
LA English
DT Meeting Abstract
CT ESC Congress
CY AUG 28-SEP 01, 2010
CL Stockholm, SWEDEN
C1 [Bersohn, M.; Shapiro, S.; Traiger, G.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare, Los Angeles, CA USA.
[Miller, D. P.; Turner, M. P.] ICON Clin Res, San Francisco, CA USA.
[Frost, A. E.] Baylor Coll Med, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
J9 EUR HEART J
JI Eur. Heart J.
PD SEP
PY 2010
VL 31
SU 1
BP 756
EP 756
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 646ID
UT WOS:000281531905083
ER
PT J
AU Shah, A
Lam, CS
Cheng, S
Verma, A
Oparil, S
Pitt, B
Zile, MR
Aurigemma, GP
Solomon, SD
AF Shah, A.
Lam, C. S.
Cheng, S.
Verma, A.
Oparil, S.
Pitt, B.
Zile, M. R.
Aurigemma, G. P.
Solomon, S. D.
TI Albuminuria is associated with increased systolic ventricular-arterial
stiffness in asymptomatic hypertensive subjects with diastolic
dysfunction
SO EUROPEAN HEART JOURNAL
LA English
DT Meeting Abstract
CT ESC Congress
CY AUG 28-SEP 01, 2010
CL Stockholm, SWEDEN
C1 [Shah, A.; Lam, C. S.; Cheng, S.; Verma, A.; Solomon, S. D.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Oparil, S.] Univ Alabama, Birmingham, AL USA.
[Pitt, B.] Univ Michigan, Sch Med, Ann Arbor, MI USA.
[Zile, M. R.] Med Univ S Carolina, Charleston, SC USA.
[Zile, M. R.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
[Aurigemma, G. P.] Univ Massachusetts, Worcester, MA 01605 USA.
RI Solomon, Scott/I-5789-2013
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
J9 EUR HEART J
JI Eur. Heart J.
PD SEP
PY 2010
VL 31
SU 1
BP 911
EP 911
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 646ID
UT WOS:000281531906135
ER
PT J
AU Crenshaw, K
Curry, W
Salanitro, AH
Safford, MM
Houston, TK
Allison, JJ
Estrada, CA
AF Crenshaw, Katie
Curry, William
Salanitro, Amanda H.
Safford, Monika M.
Houston, Thomas K.
Allison, Jeroan J.
Estrada, Carlos A.
TI Is Physician Engagement With Web-Based CME Associated With Patients'
Baseline Hemoglobin A1c Levels? The Rural Diabetes Online Care Study
SO ACADEMIC MEDICINE
LA English
DT Article
ID CONTINUING MEDICAL-EDUCATION; RANDOMIZED CONTROLLED-TRIAL; ACHIEVABLE
BENCHMARKS; POISSON REGRESSION; SPACED EDUCATION; COUNT DATA; FEEDBACK;
STUDENTS; QUALITY; HEALTH
AB Purpose
To investigate the association between physician participants' levels of engagement in a Web-based educational intervention and their patients' baseline diabetes measures.
Method
The authors conducted a randomized trial of online CME activities designed to improve diabetes care provided by family, general, and internal medicine physicians in rural areas of 11 southeastern states between September 2006 and July 2008. Using incidence rate ratios derived from negative binomial models, the relationship between physicians' engagement with the study Web site and baseline proportion of their patients having controlled diabetes (hemoglobin A1c <= 7%) was explored.
Results
One hundred thirty-three participants (intervention = 64; control = 69) provided information for 1,637 patients with diabetes. In the intervention group, physicians in practices in the worst quartiles of A1c control were least engaged with the study Web site in nearly all dimensions. Total number of pages viewed decreased as quartile of A1c control worsened (137, 73, 68, 57; P = .007); similarly, for a given 10% increase in proportion of patients with controlled A1c, participants viewed 1.13 times more pages (95% CI: 1.02-1.26, P = .02). In the control group, engagement was neither correlated with A1c control nor different across quartiles of A1c control.
Conclusions
Engagement in Web-based interventions is measurable and has important implications for research and education. Because physicians of patients with the greatest need for improvement in A1c control may not use online educational resources as intensely as others, other strategies may be necessary to engage these physicians in professional development activities.
C1 [Crenshaw, Katie] Univ Alabama, Div Continuing Med Educ, Birmingham, AL 35294 USA.
[Curry, William; Salanitro, Amanda H.; Estrada, Carlos A.] Univ Alabama, Div Gen Internal Med, Birmingham, AL 35294 USA.
[Salanitro, Amanda H.; Estrada, Carlos A.] Birmingham Vet Affairs Med Ctr, Vet Affairs Natl Qual Scholars Program, Birmingham, AL USA.
[Safford, Monika M.] Univ Alabama, Div Prevent Med, Birmingham, AL 35294 USA.
[Houston, Thomas K.] Bedford VAMC, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA.
[Houston, Thomas K.] Univ Massachusetts, Sch Med, Div Hlth Informat & Implementat Sci, Worcester, MA USA.
[Allison, Jeroan J.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA.
[Estrada, Carlos A.] Birmingham Vet Affairs Med Ctr, Deep S Ctr Effectiveness, REAP Ctr Surg Med Acute Care Res & Transit, Birmingham, AL USA.
RP Crenshaw, K (reprint author), Univ Alabama, Div Continuing Med Educ, 1670 Univ Blvd,VH Box 603, Birmingham, AL 35294 USA.
EM kcrenshaw@uab.edu
RI Houston, Thomas/F-2469-2013
OI Allison, Jeroan/0000-0003-4472-2112
FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
[5R18DK065001]; Veterans Affairs Quality Scholars fellowship
FX This study was funded by the National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK) 5R18DK065001 to Dr. Allison. Dr.
Salanitro was supported by a Veterans Affairs Quality Scholars
fellowship. The National Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK) had no role in the design and conduct of the study; in
the collection, management, analysis, and interpretation of the data; or
in the preparation, review, or approval of the manuscript.
NR 32
TC 8
Z9 8
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-2446
J9 ACAD MED
JI Acad. Med.
PD SEP
PY 2010
VL 85
IS 9
BP 1511
EP 1517
DI 10.1097/ACM.0b013e3181eac036
PG 7
WC Education, Scientific Disciplines; Health Care Sciences & Services
SC Education & Educational Research; Health Care Sciences & Services
GA 647IH
UT WOS:000281611300025
PM 20736679
ER
PT J
AU Gadomski, A
Wissow, LS
Slade, E
Jenkins, P
AF Gadomski, Anne
Wissow, Lawrence S.
Slade, Eric
Jenkins, Paul
TI Training Clinicians in Mental Health Communication Skills: Impact on
Primary Care Utilization
SO ACADEMIC PEDIATRICS
LA English
DT Article
DE child mental health; primary care utilization; Strengths and
Difficulties Questionnaire
ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; PEDIATRIC PRIMARY-CARE;
DIFFICULTIES QUESTIONNAIRE; PSYCHOMETRIC PROPERTIES;
PSYCHIATRIC-DISORDERS; MEDICAL-CARE; CHILDREN; STRENGTHS; PHYSICIANS;
SERVICES
AB OBJECTIVE: Although it is known that children with mental health problems utilize primary care services more than most other children, it is unknown how addressing mental health problems in primary care affects children's subsequent services utilization. This study measures primary care utilization in the context of a randomized trial of a communication skills training program for primary care clinicians that had a positive impact on child mental health outcomes.
METHODS: From 2002 to 2005, 48 pediatric primary care clinicians at 13 sites in rural upstate New York, urban Maryland, and Washington, DC, were randomized to in-office training or to a control group. Consecutive primary care patients between the ages of 5 and 16 years were screened for mental health problems, as indicated by a possible or probable score on the Strengths and Difficulties Questionnaire (SDQ). For 397 screened children, primary care visits during the next 6 months were identified using chart review and administrative databases. Using generalized estimating equation regression to account for clustering at the clinician level, primary care utilization was compared by study group and SDQ status.
RESULTS: The number of primary care visits to the trained clinicians did not differ significantly from those made to control clinicians (2.5 for both groups; P =.63). Children with possible or probable SDQ scores made, on average, 0.38 or 0.65 more visits on a per child basis, respectively, during the 6-month follow-up period than SDQ unlikely children (P =.0002).
CONCLUSIONS: Seeing a trained clinician did not increase subsequent primary care utilization. However, primary care utilization was greater among children with mental health problems as measured by the SDQ. Addressing children's mental health in primary care does not increase the primary care visit burden. Research on overall health services utilization is needed.
C1 [Gadomski, Anne; Jenkins, Paul] Bassett Healthcare, Res Inst, Ctr Comp, Cooperstown, NY 13326 USA.
[Wissow, Lawrence S.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Slade, Eric] US Dept Vet Affairs, Mental Illness Res & Educ Clin Ctr VISN5, Baltimore, MD USA.
RP Gadomski, A (reprint author), Bassett Healthcare, Res Inst, Ctr Comp, 1 Atwell Rd, Cooperstown, NY 13326 USA.
EM anne.gadomski@bassett.org
FU National Institute of Mental Health [R01-MH62469]
FX We thank the families, clinicians, and research assistants who took part
in the study. The study was funded by grant R01-MH62469 to Dr Lawrence
S. Wissow by the National Institute of Mental Health.
NR 37
TC 3
Z9 3
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1876-2859
J9 ACAD PEDIATR
JI Acad. Pediatr.
PD SEP-OCT
PY 2010
VL 10
IS 5
BP 346
EP 352
PG 7
WC Pediatrics
SC Pediatrics
GA 653PS
UT WOS:000282109700012
PM 20685190
ER
PT J
AU Jakupcak, M
Tull, MT
McDermott, MJ
Kaysen, D
Hunt, S
Simpson, T
AF Jakupcak, Matthew
Tull, Matthew T.
McDermott, Michael J.
Kaysen, Debra
Hunt, Stephen
Simpson, Tracy
TI PTSD symptom clusters in relationship to alcohol misuse among Iraq and
Afghanistan war veterans seeking post-deployment VA health care
SO ADDICTIVE BEHAVIORS
LA English
DT Article
DE Iraq and Afghanistan War Veterans; Alcohol misuse; PTSD; Depression
ID POSTTRAUMATIC-STRESS-DISORDER; CONFIRMATORY FACTOR-ANALYSIS; DUTY
MILITARY PERSONNEL; SUBSTANCE-ABUSE; COMBAT VETERANS; DRINKING;
DIMENSIONALITY; SOLDIERS; BEHAVIOR; TRENDS
AB Demographic factors, characteristics of military service, PTSD, and depression were examined as predictors of alcohol misuse in Iraq and Afghanistan War Veterans (N = 287) presenting for post-deployment Veteran Affairs (VA) health care. Results indicated that alcohol misuse was more common among younger male Veterans who served in the Army or Marine Corps. Accounting for demographic factors and characteristics of service, Veterans who screened positive for PTSD or depression were two times more likely to report alcohol misuse relative to Veterans who did not screen positive for these disorders. The examination of specific PTSD symptom clusters suggested that emotional numbing symptoms were most strongly associated with alcohol misuse. The implications for interventions for alcohol misuse in returning Veterans are discussed. Published by Elsevier Ltd.
C1 [Jakupcak, Matthew; Simpson, Tracy] VA Puget Sound Hlth Care Syst, MIRECC, Seattle, WA 98108 USA.
[Jakupcak, Matthew; Kaysen, Debra; Simpson, Tracy] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Tull, Matthew T.] Univ Mississippi, Med Ctr, Dept Psychiat & Human Behav, Jackson, MS 39216 USA.
[McDermott, Michael J.] Univ Mississippi, Dept Psychol, Oxford, MS USA.
RP Jakupcak, M (reprint author), VA Puget Sound Hlth Care Syst, MIRECC, S-116,1660 S Columbian Way, Seattle, WA 98108 USA.
EM matthew.jakupcak@va.gov
FU VA Puget Sound Health Care System, Seattle, Washington
FX This material is the result of work supported by resources from the VA
Puget Sound Health Care System, Seattle, Washington.
NR 31
TC 79
Z9 79
U1 2
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4603
J9 ADDICT BEHAV
JI Addict. Behav.
PD SEP
PY 2010
VL 35
IS 9
BP 840
EP 843
DI 10.1016/j.addbeh.2010.03.023
PG 4
WC Psychology, Clinical; Substance Abuse
SC Psychology; Substance Abuse
GA 627HL
UT WOS:000280030000006
PM 20471180
ER
PT J
AU Lee, HY
Tong, YP
Xing, S
Cooke, CE
AF Lee, Helen Y.
Tong, Yvette P.
Xing, Shan
Cooke, Catherine E.
TI Total costs and atrial fibrillation ablation success or failure in
medicare-aged patients in the United States
SO ADVANCES IN THERAPY
LA English
DT Article
DE aspirin; cardiovascular disease; medication therapy management; women
ID RANDOMIZED CONTROLLED-TRIALS; SERVICES TASK-FORCE; LOW-DOSE ASPIRIN;
PRIMARY PREVENTION; CARDIOVASCULAR-DISEASE; COLLABORATIVE METAANALYSIS;
SECONDARY PREVENTION; RISK; WOMEN; CARE
AB Introduction: Cardiovascular disease is the largest single cause of death among women in the US. The American Heart Association guidelines recommend aspirin use in women >= 65 years of age if blood pressure is controlled and the benefits of cardiovascular risk reduction likely outweigh the risk of bleeding. The objective of this study is to determine the prevalence of aspirin use in elderly women and factors associated with use. Methods: This retrospective study evaluated aspirin use in women aged >= 65 years based on cardiovascular and gastrointestinal bleeding risk using a medication therapy management database within a large mid-Atlantic managed care organization. Logistic regression was used to analyze patient-related variables associated with aspirin use. Variables included clinical coronary heart disease (CHD), number of CHD risk factors, diabetes diagnosis, number of chronic medications and presence of contraindications to aspirin. Results: Aspirin use was reported in 50% of patients: 68.0% in the secondary prevention group and 46.3% in the primary prevention group. The percentage of patients using aspirin or with relative aspirin contraindications increased to 84% for the secondary prevention group and 65.9% for the primary prevention group. Patients with clinical CHD and those with diabetes and without clinical CHD were 5.88 (P=0.008) and 7.54 (P=0.012) times more likely to utilize aspirin, respectively, than patients with only one CHD risk factor of age. Patients with relative contraindications to aspirin were less likely to use aspirin (P<0.001). Conclusion: The high use of aspirin in patients at higher CHD risk supports national recommendations. Clinical practitioners need to carefully assess the value of aspirin in patients at low CHD risk and those 80 years of age and beyond where evidence of benefit should be weighed against risk.
C1 [Cooke, Catherine E.] PosiHealth Inc, Ellicott City, MD 21043 USA.
[Lee, Helen Y.] CareFirst BlueCross BlueShield, Baltimore, MD USA.
[Tong, Yvette P.] Denver VA Med Ctr, Denver, CO USA.
[Xing, Shan] Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA.
RP Cooke, CE (reprint author), PosiHealth Inc, 5106 Bonnie Branch Rd, Ellicott City, MD 21043 USA.
EM cCooke@PosiHealth.com
NR 24
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0741-238X
J9 ADV THER
JI Adv. Ther.
PD SEP
PY 2010
VL 27
IS 9
BP 613
EP 622
DI 10.1007/s12325-010-0060-3
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 642UP
UT WOS:000281246600004
PM 20607467
ER
PT J
AU Bendlin, BB
Ries, ML
Canu, E
Sodhi, A
Lazar, M
Alexander, AL
Carlsson, CM
Sager, MA
Asthana, S
Johnson, SC
AF Bendlin, Barbara B.
Ries, Michele L.
Canu, Elisa
Sodhi, Aparna
Lazar, Mariana
Alexander, Andrew L.
Carlsson, Cynthia M.
Sager, Mark A.
Asthana, Sanjay
Johnson, Sterling C.
TI White matter is altered with parental family history of Alzheimer's
disease
SO ALZHEIMERS & DEMENTIA
LA English
DT Article
DE Alzheimer's disease; Family history; APOE epsilon 4;; Diffusion tensor
imaging; MRI; White matter
ID MILD COGNITIVE IMPAIRMENT; APOLIPOPROTEIN-E EPSILON-4; BRAIN
GLUCOSE-METABOLISM; DIFFUSION-TENSOR MRI; MYELIN BREAKDOWN;
NEUROPSYCHOLOGICAL ASSESSMENT; FRONTOTEMPORAL DEMENTIA; POSTERIOR
CINGULATE; RECOGNITION MEMORY; CORPUS-CALLOSUM
AB Background: Brain alterations in structure and function have been identified in people with risk factors for sporadic type Alzheimer's disease (AD), suggesting that alterations can be detected decades before AD diagnosis. Although the effect of apolipoprotein E (APOE) epsilon 4 on the brain is well-studied, less is known about the effect of family history of AD. We examined the main effects of family history and APOE epsilon 4 on brain integrity, in addition to assessing possible additive effects of these two risk factors.
Methods: Diffusion tensor imaging was performed in 136 middle-aged asymptomatic participants stratified on family history and APOE epsilon 4. Mean diffusivity and fractional anisotropy (FA) were entered in factorial analyses to test the effect of AD risk on microstructural brain integrity. We performed a post hoc analysis of the three principal diffusivities (lambda 1, lambda 2, lambda 3) to provide potential additional insight on underlying tissue differences.
Results: Parental family history of AD was associated with lower FA in regions of the brain known to be affected by AD, including cingulum, corpus callosum, tapetum, uncinate fasciculus, hippocampus, and adjacent white matter. Contrary to previous reports, there was no main effect of APOE epsilon 4; however, there was an additive effect of family history and APOE epsilon 4 in which family history positive participants who were also APOE epsilon 4 carriers had the lowest FA compared with the other groups.
Conclusions: The data indicate that unknown risk factors contained in family history are associated with changes in microstructural brain integrity in areas of the brain known to be affected by AD. Importantly, the results provide further evidence that AD pathology might be detected before cognitive changes, perhaps decades before disease onset. (c) 2010 The Alzheimer's Association. All rights reserved.
C1 [Bendlin, Barbara B.; Canu, Elisa; Sodhi, Aparna; Carlsson, Cynthia M.; Sager, Mark A.; Asthana, Sanjay; Johnson, Sterling C.] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI USA.
[Bendlin, Barbara B.; Ries, Michele L.; Canu, Elisa; Sodhi, Aparna; Carlsson, Cynthia M.; Sager, Mark A.; Asthana, Sanjay; Johnson, Sterling C.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA.
[Lazar, Mariana] NYU, Sch Med, Dept Radiol, New York, NY USA.
[Alexander, Andrew L.] Univ Wisconsin, Dept Med Phys, Sch Med & Publ Hlth, Madison, WI 53706 USA.
[Alexander, Andrew L.] Univ Wisconsin, Dept Psychiat, Sch Med & Publ Hlth, Madison, WI 53706 USA.
[Alexander, Andrew L.] Waisman Lab Brain Imaging & Behav, Madison, WI USA.
RP Johnson, SC (reprint author), William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI USA.
EM scj@medicine.wisc.edu
RI ; Canu, Elisa/K-1423-2016
OI Lazar, Mariana/0000-0001-9285-8124; Bendlin,
Barbara/0000-0002-0580-9875; Canu, Elisa/0000-0001-5804-3378
FU National Institutes of Health [AG021155, MH62015, R01 AG27161];
Department of Veterans Affairs
FX The authors gratefully acknowledge the assistance of Donald McLaren,
Brent Thiel, Britta Jabbar, Michele Fitzgerald, and Erik Kastman. In
addition, we would like to acknowledge the support of researchers and
staff at the Waisman Center, University of Wisconsin-Madison, where MR
imaging took place. Finally, we thank our volunteers for their
participation in this research. This work was supported by the National
Institutes of Health (AG021155 to S.C.J., MH62015 to A.L.A., and R01
AG27161 to M.A.S); a Merit Review Grant from the Department of Veterans
Affairs (to S.C.J.), and by the facilities and resources at the William
S. Middleton Memorial Veterans Hospital (GRECC manuscript number
2009-09).
NR 89
TC 43
Z9 46
U1 1
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1552-5260
J9 ALZHEIMERS DEMENT
JI Alzheimers. Dement.
PD SEP
PY 2010
VL 6
IS 5
BP 394
EP 403
DI 10.1016/j.jalz.2009.11.003
PG 10
WC Clinical Neurology
SC Neurosciences & Neurology
GA 654HF
UT WOS:000282158400004
PM 20713315
ER
PT J
AU Iles-Shih, L
Collins, JF
Holub, JL
Lieberman, DA
AF Iles-Shih, LuLu
Collins, Judy F.
Holub, Jennifer L.
Lieberman, David A.
TI Prevalence of Significant Neoplasia in FOBT-Positive Patients on
Warfarin Compared With Those Not on Warfarin
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
ID FECAL OCCULT BLOOD; LOW-DOSE ASPIRIN; ACUTE GASTROINTESTINAL HEMORRHAGE;
AMERICAN-CANCER-SOCIETY; COLORECTAL-CANCER; ANTICOAGULANT-THERAPY;
ATRIAL-FIBRILLATION; TASK-FORCE; SURVEILLANCE; POLYPS
AB OBJECTIVES: The fecal occult blood test (FOBT) is widely used for colorectal cancer screening. However, the impact of warfarin use on FOBT sensitivity and specificity remains unclear. This study compares the relative risk of neoplasia in FOBT-positive patients stratified by warfarin use.
METHODS: The Clinical Outcomes Research Initiative database was used to identify patients with positive FOBT as the only indication for colonoscopy during 2005-2006. Patients were categorized on the basis of documented warfarin status within a 30-day period before FOBT. We compared the demographics and prevalence of significant colon findings (defined as polyp > 9 mm or suspected malignant tumor) among the two groups. After adjusting for confounding variables, logistic regression was used to estimate the odds ratio of significant findings in warfarin-positive vs. warfarin-negative patients.
RESULTS: Of 10,266 patients with positive FOBT, 372 used warfarin, 9,265 did not use warfarin, and 629 were excluded because of missing warfarin status. Warfarin-positive patients were more likely male (65 vs. 50%; P < 0.0001), Caucasian (88 vs. 80%; P < 0.0001), and veterans (53 vs. 33%; P < 0.0001). The prevalence of a significant finding was greater in the warfarin group, 16 vs. 11.4% (P < 0.01). After adjusting for age and sex, the relative risk of significant colon findings among warfarin-positive patients was not significantly different from warfarin-negative patients (odds ratio 1.1, 95% confidence interval: 0.81-1.44).
CONCLUSIONS: No increased risk for significant colonic findings among FOBT-positive patients according to warfarin use was identified. These findings suggest that continuing warfarin before FOBT will not affect the positive predictive value of this screening test.
C1 [Iles-Shih, LuLu; Collins, Judy F.; Holub, Jennifer L.; Lieberman, David A.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Collins, Judy F.; Lieberman, David A.] Portland VA Med Ctr, Portland, OR USA.
RP Collins, JF (reprint author), VAMC, Dept Internal Med, Div Gastroenterol, P3-GI ,3710 SW Vet Hosp Rd, Portland, OR 97239 USA.
EM collinsj@ohsu.edu
FU NIDDK NIH HHS [R33 DK061778, U01 DK057132]
NR 33
TC 11
Z9 12
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD SEP
PY 2010
VL 105
IS 9
BP 2030
EP 2034
DI 10.1038/ajg.2010.264
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 646SM
UT WOS:000281563100018
PM 20683445
ER
PT J
AU Jutabha, R
Jensen, DM
Chavalitdhamrong, D
AF Jutabha, Rome
Jensen, Dennis M.
Chavalitdhamrong, Disaya
TI Hepatitis B Vaccine Administered by Intradermal Route in Patients With
Celiac Disease Unresponsive to the Intramuscular Vaccination Schedule: A
Pilot Study Response
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Letter
ID LIGATION
C1 [Jutabha, Rome] Univ Calif Los Angeles, CURE Digest Dis Res Ctr, Los Angeles, CA 90024 USA.
[Jutabha, Rome; Jensen, Dennis M.; Chavalitdhamrong, Disaya] Univ Calif Los Angeles, David Geffen Sch Med, Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA 90095 USA.
RP Jutabha, R (reprint author), Univ Calif Los Angeles, CURE Digest Dis Res Ctr, Los Angeles, CA 90024 USA.
EM rjutabha@mednet.ucla.edu
NR 2
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD SEP
PY 2010
VL 105
IS 9
BP 2119
EP 2119
DI 10.1038/ajg.2010.176
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 646SM
UT WOS:000281563100041
PM 20818369
ER
PT J
AU Kasckow, J
Fellows, I
Golshan, S
Solorzano, E
Meeks, T
Zisook, S
AF Kasckow, John
Fellows, Ian
Golshan, Shahrokh
Solorzano, Ellen
Meeks, Thomas
Zisook, Sidney
TI Treatment of Subsyndromal Depressive Symptoms in Middle-Age and Older
Patients With Schizophrenia: Effect of Age on Response
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE Schizophrenia; age differences; citalopram; depression; psychopathology;
quality of life
ID SCALE
AB Objective: The authors hypothesized that age would moderate the response of patients with schizophrenia and subsyndromal depression (SSD) treated citalopram with depressive symptoms and other outcomes. Also, older patients would exhibit more side effects with citalopram. Methods: Participants of 40 years or older had schizophrenia or schizoaffective disorder with SSD. Patients randomly received flexible dosing of citalopram or placebo augmentation of their antipsychotic medication. Linear regression determined whether age had any moderating effect on depressive symptoms, global psychopathology, negative symptoms, mental functioning, and quality of life. Age-related side effects were examined. Results: There were no significant drug group by age interaction in depressive or psychotic symptoms, mental Short Form-12, or quality of life scores. Similarly, there were few age-related side effect differences. Conclusion: Symptoms in younger and older patients with schizophrenia and SSD treated with citalopram seem to respond similarly. Adverse events do not seem to differ with age. (Am J Geriatr Psychiatry 2010; 18:853-857)
C1 [Kasckow, John] VA Pittsburgh Hlth Care Syst, MIRECC & Behav Hlth Serv, Pittsburgh, PA 15206 USA.
[Kasckow, John] Univ Pittsburgh, Western Psychiat Inst & Clin, Med Ctr, Pittsburgh, PA 15213 USA.
[Fellows, Ian; Golshan, Shahrokh; Solorzano, Ellen; Meeks, Thomas; Zisook, Sidney] Univ Calif San Diego, VA San Diego Hlth Care Syst, Dept Psychiat, San Diego, CA 92103 USA.
RP Kasckow, J (reprint author), VA Pittsburgh Hlth Care Syst, MIRECC & Behav Hlth Serv, 7180 Highland Dr, Pittsburgh, PA 15206 USA.
EM kasckowjw@upmc.edu
FU Cincinnati VA Medical Center; University of Cincinnati College Of
Medicine; VISN 4; VISN 22 MIRECC; University of California, San Diego,
CA.; Center for Community-based Research in Older People with Psychoses;
Aspect Medical; PamLab; Forest; Astra Zeneca; Bristol Meyers Squibb;
Pfizer; Johnson and Johnson; Solvay; Eli Lilly; [MH6398]
FX The authors thank the Cincinnati VA Medical Center and the University of
Cincinnati College Of Medicine for their support.; This work was
supported by MH6398 (to SZ, JWK), the VISN 4 and VISN 22 MIRECC, and the
University of California, San Diego, CA., Center for Community-based
Research in Older People with Psychoses. Research support from Aspect
Medical and PamLab and speaker's honoraria from Forest Pharmaceuticals,
Inc. and GlaxoSmithKline (to SZ). Grant support as well as honoraria for
speaking and consultation from Forest, Astra Zeneca, Bristol Meyers
Squibb, Pfizer, Johnson and Johnson, Solvay and Eli Lilly (to JK).
NR 10
TC 5
Z9 6
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD SEP
PY 2010
VL 18
IS 9
BP 853
EP 857
DI 10.1097/JGP.0b013e3181dba12f
PG 5
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 647HV
UT WOS:000281610000010
PM 20808103
ER
PT J
AU Fromme, EK
Smith, AK
Hughes, MT
Brokaw, FC
Rosenfeld, KE
Arnold, RM
AF Fromme, Erik K.
Smith, Alexander K.
Hughes, Mark T.
Brokaw, Frances C.
Rosenfeld, Kenneth E.
Arnold, Robert M.
TI Update in Palliative Medicine
SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE
LA English
DT Editorial Material
ID CARE CONSULTATION; CANCER; DEPRESSION; OUTCOMES; PAIN
C1 [Fromme, Erik K.] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97239 USA.
[Smith, Alexander K.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.
[Hughes, Mark T.] Johns Hopkins Univ, Sch Med, Div Gen Internal Med, Baltimore, MD USA.
[Brokaw, Frances C.] Dartmouth Hitchcock Med Ctr, Div Gen Internal Med, Lebanon, NH 03766 USA.
[Rosenfeld, Kenneth E.] VA Greater Los Angeles Healthcare Syst, Div Gen Med, Palliat Care Sect, Los Angeles, CA USA.
[Arnold, Robert M.] Univ Pittsburgh, Div Gen Internal Med, Sect Palliat Care & Med Eth, Pittsburgh, PA USA.
RP Fromme, EK (reprint author), Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, L586,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM frommee@ohsu.edu
FU NCI NIH HHS [K07CA109511]
NR 16
TC 1
Z9 1
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1049-9091
J9 AM J HOSP PALLIAT ME
JI Am. J. Hosp. Palliat. Med.
PD SEP
PY 2010
VL 27
IS 6
BP 420
EP 427
DI 10.1177/1049909110370745
PG 8
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 636DD
UT WOS:000280707500010
PM 20555038
ER
PT J
AU Grota, PG
Stone, PW
Jordan, S
Pogorzelska, M
Larson, E
AF Grota, Patti G.
Stone, Patricia W.
Jordan, Sarah
Pogorzelska, Monika
Larson, Elaine
TI Electronic surveillance systems in infection prevention: Organizational
support, program characteristics, and user satisfaction
SO AMERICAN JOURNAL OF INFECTION CONTROL
LA English
DT Article
DE Surveillance; infection prevention programs; organizational support
ID CARE-ASSOCIATED INFECTIONS; AUTOMATED SURVEILLANCE; HEALTH; TECHNOLOGY;
EPIDEMIOLOGY
AB Background: The use of electronic surveillance systems (ESSs) is gradually increasing in infection prevention and control programs. Little is known about the characteristics of hospitals that have a ESS, user satisfaction with ESSs, and organizational support for implementation of ESSs.
Methods: A total of 350 acute care hospitals in California were invited to participate in a Web-based survey; 207 hospitals (59%) agreed to participate. The survey included a description of infection prevention and control department staff, where and how they spent their time, a measure of organizational support for infection prevention and control, and reported experience with ESSs.
Results: Only 23% (44/192) of responding infection prevention and control departments had an ESS. No statistically significant difference was seen in how and where infection preventionists (IPs) who used an ESS and those who did not spend their time. The 2 significant predictors of whether an ESS was present were score on the Organizational Support Scale (odds ratio [OR], 1.10; 95% confidence interval [CI], 1.02-1.18) and hospital bed size (OR, 1.004; 95% CI, 1.00-1.007). Organizational support also was positively correlated with IP satisfaction with the ESS, as measured on the Computer Usability Scale (P = .02).
Conclusion: Despite evidence that such systems may improve efficiency of data collection and potentially improve patient outcomes, ESSs remain relatively uncommon in infection prevention and control programs. Based on our findings, organizational support appears to be a major predictor of the presence, use, and satisfaction with ESSs in infection prevention and control programs. Key Words: Surveillance; infection prevention programs; organizational support.
C1 [Stone, Patricia W.; Jordan, Sarah; Pogorzelska, Monika; Larson, Elaine] Columbia Univ, Sch Nursing, New York, NY 10035 USA.
[Grota, Patti G.] Univ Texas Hlth Sci Ctr San Antonio, Infect Prevent Adm, S Texas Vet Healthcare Syst, San Antonio, TX 78229 USA.
RP Larson, E (reprint author), Columbia Univ, Sch Nursing, 617 W 168th St, New York, NY 10035 USA.
EM ell23@columbia.edu
FU Blue Shield of California Foundation [BSCAFND 2490932]
FX The authors thank all of the participating California hospitals. This
study was funded by the Blue Shield of California Foundation (Grant
BSCAFND 2490932) and conducted in collaboration with APIC.
NR 23
TC 15
Z9 16
U1 1
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-6553
J9 AM J INFECT CONTROL
JI Am. J. Infect. Control
PD SEP
PY 2010
VL 38
IS 7
SI SI
BP 509
EP 514
DI 10.1016/j.ajic.2009.10.007
PG 6
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 641SK
UT WOS:000281149800002
PM 20176411
ER
PT J
AU Sambamoorthi, U
Bean-Mayberry, B
Findley, PA
Yano, EM
Banerjea, R
AF Sambamoorthi, Usha
Bean-Mayberry, Bevanne
Findley, Patricia A.
Yano, Elizabeth M.
Banerjea, Ranjana
TI Organization of Care and Diagnosed Depression Among Women Veterans
SO AMERICAN JOURNAL OF MANAGED CARE
LA English
DT Article
ID AFFAIRS PRIMARY-CARE; MENTAL-HEALTH-CARE; MEDICAL HOME; CLINICS;
DISORDERS; ILLNESS; MANAGEMENT; INNOVATION; DELIVERY; QUALITY
AB Objective: To analyze the association between the organizational features of integration of physical and mental healthcare in women's health clinics and the diagnosis of depression among women veterans with or at risk for cardiovascular conditions (ie, diabetes mellitus, heart disease, or hypertension).
Study Design: Retrospective and observational secondary data analyses.
Methods: We studied 27,972 women veterans from 118 facilities with diagnosed cardiovascular conditions in fiscal year 2001 (FY2001) using merged Medicare claims and Veterans Health Administration (VHA) data merged with the 1999 VHA Survey of Primary Care Practices and the 2001 VHA Survey of Women Veterans Health Programs and Practices. The dependent variable was a binary indicator for diagnosed depression during FY2001 at the individual level. We used a multilevel logistic regression model to control for clustering of women veterans within facilities. Individual-level independent variables included demographics, socioeconomic characteristics, and chronic physical conditions.
Results: Overall, 27% of women veterans using the VHA were diagnosed as having depression in FY2001. Across facilities, rates of diagnosed depression varied from 13% to 41%. After controlling for individual-level and facility-level independent variables, women veterans who were served in separate women's health clinics with integrated physical and mental healthcare were more likely to have diagnosed depression. The adjusted odds ratio was 1.12 (95% confidence interval, 1.01-1.25).
Conclusions: Existing women-specific VHA organizational features with integration of primary care and mental health seem effective in diagnosing depression. Emerging patient-centered medical home models may facilitate diagnosis and treatment of mental health issues among women with complex chronic conditions. (Am J Manag Care. 2010; 16(9): 657-665)
C1 [Findley, Patricia A.] Rutgers State Univ, Sch Social Work, New Brunswick, NJ 08901 USA.
[Sambamoorthi, Usha] W Virginia Univ, Dept Pharmaceut Syst & Policy, Morgantown, WV 26506 USA.
[Sambamoorthi, Usha; Findley, Patricia A.; Banerjea, Ranjana] Dept Vet Affairs New Jersey Hlth Care Syst, HSR&D Ctr Healthcare Knowledge Management, E Orange, NJ USA.
[Sambamoorthi, Usha] Morehouse Sch Med, Dept Community Hlth & Prevent Med, Atlanta, GA 30310 USA.
[Bean-Mayberry, Bevanne; Yano, Elizabeth M.] VA Greater Los Angeles Healthcare Syst, HSR&D Ctr Excellence, Sepulveda, CA USA.
[Bean-Mayberry, Bevanne] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA.
[Yano, Elizabeth M.] Univ Calif Los Angeles, Dept Hlth Serv, Los Angeles, CA USA.
RP Findley, PA (reprint author), Rutgers State Univ, Sch Social Work, 536 George St, New Brunswick, NJ 08901 USA.
EM pfindley@ssw.rutgers.edu
OI Sambamoorthi, Usha/0000-0001-8311-1360
FU Department of Veterans Affairs-Health Services Research and Development
Service [IAE-05-255, IIR-05-016]
FX This research was supported by grants IAE-05-255, IIR-05-016, and the
Diabetes Epidemiology Cohort II from the Department of Veterans
Affairs-Health Services Research and Development Service.
NR 35
TC 6
Z9 6
U1 1
U2 5
PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC
PI PLAINSBORO
PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA
SN 1088-0224
J9 AM J MANAG CARE
JI Am. J. Manag. Care
PD SEP
PY 2010
VL 16
IS 9
BP 657
EP 665
PG 9
WC Health Care Sciences & Services; Health Policy & Services; Medicine,
General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 660EA
UT WOS:000282621400003
PM 20873953
ER
PT J
AU Singh, JA
Sloan, JA
Atherton, PJ
Smith, T
Hack, TF
Huschka, MM
Rummans, TA
Clark, MM
Diekmann, B
Degner, LF
AF Singh, Jasvinder A.
Sloan, Jeff A.
Atherton, Pamela J.
Smith, Tenbroeck
Hack, Thomas F.
Huschka, Mashele M.
Rummans, Teresa A.
Clark, Matthew M.
Diekmann, Brent
Degner, Lesley F.
TI Preferred Roles in Treatment Decision Making Among Patients With Cancer:
A Pooled Analysis of Studies Using the Control Preferences Scale
SO AMERICAN JOURNAL OF MANAGED CARE
LA English
DT Article
ID BREAST-CANCER; URINARY-INCONTINENCE; CONTROLLED-TRIAL; UNITED-STATES;
TREATMENT CONSULTATIONS; PROVIDING AUDIOTAPES; INVOLVEMENT; WOMEN; CARE;
PARTICIPATION
AB Objectives: To collect normative data, assess differences between demographic groups, and indirectly compare US and Canadian medical systems relative to patient expectations of involvement in cancer treatment decision making.
Study Design: Meta-analysis.
Methods: Individual patient data were compiled across 6 clinical studies among 3491 patients with cancer who completed the 2-item Control Preferences Scale indicating the roles they preferred versus actually experienced in treatment decision making.
Results: The roles in treatment decision making that patients preferred were 26% active, 49% collaborative, and 25% passive. The roles that patients reported actually experiencing were 30% active, 34% collaborative, and 36% passive. Roughly 61% of patients reported having their preferred role; only 6% experienced extreme discordance between their preferred versus actual roles. More men than women (66% vs 60%, P = .001) and more US patients than Canadian patients (84% vs 54%, P < .001) reported concordance between their preferred versus actual roles. More Canadian patients than US patients preferred and actually experienced (42% vs 18%, P < .001) passive roles. More women than men reported taking a passive role (40% vs 24%, P < .001). Older patients preferred and were more likely than younger patients to assume a passive role.
Conclusions: Roughly half of the studied patients with cancer indicated that they preferred to have a collaborative relationship with physicians. Although most patients had the decision-making role they preferred, about 40% experienced discordance. This highlights the need for incorporation of individualized patient communication styles into treatment plans. (Am J Manag Care. 2010; 16(9): 688--696)
C1 [Singh, Jasvinder A.; Sloan, Jeff A.; Atherton, Pamela J.; Huschka, Mashele M.; Rummans, Teresa A.; Clark, Matthew M.; Diekmann, Brent] Mayo Clin, Rochester, MN USA.
[Singh, Jasvinder A.] Birmingham VA Med Ctr, Birmingham, AL USA.
[Singh, Jasvinder A.] Univ Alabama, Birmingham, AL USA.
[Smith, Tenbroeck] Amer Canc Soc, Atlanta, GA 30329 USA.
[Hack, Thomas F.; Degner, Lesley F.] Univ Manitoba, Winnipeg, MB, Canada.
[Hack, Thomas F.; Degner, Lesley F.] St Boniface Gen Hosp, Res Ctr, Winnipeg, MB R2H 2A6, Canada.
RP Singh, JA (reprint author), Minneapolis Vet Affairs Ctr, 1 Vet Dr 111R, Minneapolis, MN 55417 USA.
EM jasvinder.md@gmail.com
RI Hack, Thomas/C-5174-2012
OI Hack, Thomas/0000-0002-6913-8732; singh, jasvinder/0000-0003-3485-0006
FU National Institutes of Health [1 KL2 RR024151-01]
FX Supported by clinical and translational science award 1 KL2 RR024151-01
from the National Institutes of Health (to the Mayo Clinic Center for
Clinical and Translational Research).
NR 42
TC 50
Z9 54
U1 3
U2 12
PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC
PI PLAINSBORO
PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA
SN 1088-0224
J9 AM J MANAG CARE
JI Am. J. Manag. Care
PD SEP
PY 2010
VL 16
IS 9
BP 688
EP 696
PG 9
WC Health Care Sciences & Services; Health Policy & Services; Medicine,
General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 660EA
UT WOS:000282621400006
PM 20873956
ER
PT J
AU Borrero, S
Moore, CG
Creinin, MD
Ibrahim, SA
AF Borrero, Sonya
Moore, Charity G.
Creinin, Mitchell D.
Ibrahim, Said A.
TI Low Rates of Vasectomy Among Minorities: A Result of Differential
Receipt of Counseling?
SO AMERICAN JOURNAL OF MENS HEALTH
LA English
DT Article
DE sterilization; vasectomy; disparities; health services; contraception
ID HEALTH-SERVICES; UNITED-STATES; YOUNG MEN; STERILIZATION
AB Male sterilization is a highly effective contraceptive method that is underused especially among minorities. This analysis examined the association between race/ethnicity and receipt of sterilization counseling. This study used data collected by the 2002 National Survey of Family Growth. The analysis included men 15 to 44 years old who had not undergone sterilization. The outcome was receipt of sterilization counseling in the 12 months prior to interview, and the primary predictor was race/ethnicity. Sociodemographic characteristics, history of fathering an unintended birth, intention for more children, and access to health care were examined as confounders. Sixty-one (1.7%) men reported receiving sterilization counseling. Although counseling was reported more commonly by Black and Hispanic men compared with White men, the rates were not significantly different (odds ratio [OR] = 2.4, 95% confidence interval [CI] = 0.8-7.1 and OR = 1.9, 95% CI = 0.9-4.1, respectively). In this nationally representative sample of men aged 15 to 44 years, there were exceedingly low rates of sterilization counseling for all men regardless of race/ethnicity.
C1 [Borrero, Sonya; Moore, Charity G.; Ibrahim, Said A.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA.
[Borrero, Sonya; Ibrahim, Said A.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Creinin, Mitchell D.] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Biol, Pittsburgh, PA USA.
[Creinin, Mitchell D.] Magee Womens Res Inst, Pittsburgh, PA USA.
[Creinin, Mitchell D.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA.
RP Borrero, S (reprint author), Univ Pittsburgh, Sch Med, Div Gen Internal Med, 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA.
EM borrerosp@upmc.edu
OI Moore, Charity/0000-0002-0060-0124
FU NCATS NIH HHS [KL2 TR000146]; NCRR NIH HHS [1KL2 RR02415403, KL2
RR024154, KL2 RR024154-016500]
NR 19
TC 4
Z9 4
U1 0
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1557-9883
J9 AM J MENS HEALTH
JI Am. J. Mens Health
PD SEP
PY 2010
VL 4
IS 3
BP 243
EP 249
DI 10.1177/1557988309337619
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 638WY
UT WOS:000280930400008
PM 19706674
ER
PT J
AU Baker, AM
Haeri, S
Klein, RL
Boggess, K
AF Baker, Arthur M.
Haeri, Sina
Klein, Richard L.
Boggess, Klim
TI Association of midgestation paraoxonase 1 activity and pregnancies
complicated by preterm birth
SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
LA English
DT Article; Proceedings Paper
CT 30th Annual Meeting of the Society-for-Maternal-Fetal-Medicine
CY FEB 01-06, 2010
CL Chicago, IL
SP Soc Maternal Fetal Med, Univ Texas Med Branch, Dept Obstetrics & Gynecology
DE oxidative stress; paraoxonase 1; preterm birth
ID DEPENDENT DIABETES-MELLITUS; CORONARY HEART-DISEASE;
CARDIOVASCULAR-DISEASE; DELIVERY; RISK; POLYMORPHISMS; LIPOPROTEINS;
MORTALITY; COHORT
AB OBJECTIVE: The objective of the study was to determine whether an association exists between low paraoxonase 1 activity and dyslipidemia at midgestation and preterm birth.
STUDY DESIGN: We conducted a case-control study of 30 women with preterm birth and 90 women with uncomplicated term deliveries. Maternal serum collected at 15-20 weeks was used to measure lipid concentrations and paraoxonase 1 activity using 2 substrates: paraoxon and phenylacetate (arylesterase activity).
RESULTS: The groups did not differ with respect to maternal demographics. Paraoxonase 1 activity (paraoxon) was significantly lower in women delivering preterm compared with controls (12.9 +/- 6.1 vs 16.6 +/- 7.7 dA/min; P = .02). Arylesterase activity and serum lipid concentrations were similar between women with preterm birth and controls.
CONCLUSION: Midgestation paraoxonase 1 activity is lower in women who later experience spontaneous preterm birth compared with women who have term deliveries. Prospective studies are needed to determine the significance of paraoxonase 1 in the pathogenesis of preterm birth.
C1 [Baker, Arthur M.; Haeri, Sina; Boggess, Klim] Univ N Carolina, Dept Obstet & Gynecol, Div Maternal Fetal Med, Chapel Hill, NC 27599 USA.
[Klein, Richard L.] Med Univ S Carolina, Dept Med, Div Endocrinol Metab & Med Genet, Charleston, SC 29425 USA.
[Klein, Richard L.] Vet Affairs Med Ctr, Res Serv, Ralph H Johnson Dept, Charleston, SC 29403 USA.
RP Baker, AM (reprint author), Univ N Carolina, Dept Obstet & Gynecol, Div Maternal Fetal Med, 3010 Old Clin Bldg,CB 7516, Chapel Hill, NC 27599 USA.
EM abaker2@med.unc.edu
NR 24
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9378
J9 AM J OBSTET GYNECOL
JI Am. J. Obstet. Gynecol.
PD SEP
PY 2010
VL 203
IS 3
AR 246.e1
DI 10.1016/j.ajog.2010.04.048
PG 4
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 647FH
UT WOS:000281602700025
PM 20541733
ER
PT J
AU Cowart, LA
AF Cowart, L. Ashley
TI A novel role for sphingolipid metabolism in oxidant-mediated skeletal
muscle fatigue. Focus on "Sphingomyelinase stimulates oxidant signaling
to weaken skeletal muscle and promote fatigue"
SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
LA English
DT Article
ID PROTEIN-KINASE-C; NEUTRAL SPHINGOMYELINASES; SPHINGOSINE INHIBITION;
HUMAN-PLATELETS; CERAMIDE; DIFFERENTIATION; APOPTOSIS; EXERCISE; BASES
C1 [Cowart, L. Ashley] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
[Cowart, L. Ashley] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
RP Cowart, LA (reprint author), Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
EM cowartl@musc.edu
NR 26
TC 2
Z9 2
U1 0
U2 2
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6143
J9 AM J PHYSIOL-CELL PH
JI Am. J. Physiol.-Cell Physiol.
PD SEP
PY 2010
VL 299
IS 3
BP C549
EP C551
DI 10.1152/ajpcell.00236.2010
PG 3
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA 644OR
UT WOS:000281389100002
PM 20573998
ER
PT J
AU Ceppa, E
Cattaruzza, F
Lyo, V
Amadesi, S
Pelayo, JC
Poole, DP
Vaksman, N
Liedtke, W
Cohen, DM
Grady, EF
Bunnett, NW
Kirkwood, KS
AF Ceppa, Eugene
Cattaruzza, Fiore
Lyo, Victoria
Amadesi, Silvia
Pelayo, Juan-Carlos
Poole, Daniel P.
Vaksman, Natalya
Liedtke, Wolfgang
Cohen, David M.
Grady, Eileen F.
Bunnett, Nigel W.
Kirkwood, Kimberly S.
TI Transient receptor potential ion channels V4 and A1 contribute to
pancreatitis pain in mice
SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
LA English
DT Article
DE neurogenic inflammation; TRP channels
ID INDUCED NEUROGENIC INFLAMMATION; GENE-RELATED PEPTIDE; CAPSAICIN
RECEPTOR; SENSORY NEURONS; ACTIVATED RECEPTOR-2; TRPV4 CHANNELS; RAT
PANCREAS; MOUSE MODEL; TRPA1; HYPERALGESIA
AB Ceppa E, Cattaruzza F, Lyo V, Amadesi S, Pelayo J, Poole DP, Vaksman N, Liedtke W, Cohen DM, Grady EF, Bunnett NW, Kirkwood KS. Transient receptor potential ion channels V4 and A1 contribute to pancreatitis pain in mice. Am J Physiol Gastrointest Liver Physiol 299: G556-G571, 2010. First published June 10, 2010; doi: 10.1152/ajpgi.00433.2009.-The mechanisms of pancreatic pain, a cardinal symptom of pancreatitis, are unknown. Proinflammatory agents that activate transient receptor potential (TRP) channels in nociceptive neurons can cause neurogenic inflammation and pain. We report a major role for TRPV4, which detects osmotic pressure and arachidonic acid metabolites, and TRPA1, which responds to 4-hydroxynonenal and cyclopentenone prostaglandins, in pancreatic inflammation and pain in mice. Immunoreactive TRPV4 and TRPA1 were detected in pancreatic nerve fibers and in dorsal root ganglia neurons innervating the pancreas, which were identified by retrograde tracing. Agonists of TRPV4 and TRPA1 increased intracellular Ca2+ concentration ([Ca2+](i)) in these neurons in culture, and neurons also responded to the TRPV1 agonist capsaicin and are thus nociceptors. Intraductal injection of TRPV4 and TRPA1 agonists increased c-Fos expression in spinal neurons, indicative of nociceptor activation, and intraductal TRPA1 agonists also caused pancreatic inflammation. The effects of TRPV4 and TRPA1 agonists on [Ca2+](i), pain and inflammation were markedly diminished or abolished in trpv4 and trpa1 knockout mice. The secretagogue cerulein induced pancreatitis, c-Fos expression in spinal neurons, and pain behavior in wild-type mice. Deletion of trpv4 or trpa1 suppressed c-Fos expression and pain behavior, and deletion of trpa1 attenuated pancreatitis. Thus TRPV4 and TRPA1 contribute to pancreatic pain, and TRPA1 also mediates pancreatic inflammation. Our results provide new information about the contributions of TRPV4 and TRPA1 to inflammatory pain and suggest that channel antagonists are an effective therapy for pancreatitis, when multiple proinflammatory agents are generated that can activate and sensitize these channels.
C1 [Ceppa, Eugene; Cattaruzza, Fiore; Lyo, Victoria; Amadesi, Silvia; Pelayo, Juan-Carlos; Poole, Daniel P.; Vaksman, Natalya; Grady, Eileen F.; Bunnett, Nigel W.; Kirkwood, Kimberly S.] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA.
[Bunnett, Nigel W.] Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA.
[Liedtke, Wolfgang] Duke Univ Med Ctr, Dept Med & Neurobiol, Durham, NC USA.
[Cohen, David M.] Portland VA Med Ctr, Portland, OR USA.
RP Bunnett, NW (reprint author), Univ Calif San Francisco, Dept Surg, 513 Parnassus Ave,Rm S1268, San Francisco, CA 94143 USA.
EM nigel.bunnett@ucsf.edu
RI Liedtke, Wolfgang/G-4633-2011
FU National Institute of Diabetes and Digestive and Kidney Diseases
[DK46285, DK57840, DK43207, DK39957, T32 DK07573]; Crohn's and Colitis
Foundation [1730]
FX This research was supported by National Institute of Diabetes and
Digestive and Kidney Diseases Grants DK46285 (K. S. Kirkwood, N. W.
Bunnett), DK57840 (N. W. Bunnett), DK43207 (N. W. Bunnett), DK39957 (N.
W. Bunnett), and T32 DK07573 (E. Ceppa, N. W. Bunnett), and Crohn's and
Colitis Foundation 1730 (E. F. Grady).
NR 57
TC 44
Z9 45
U1 1
U2 8
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193-1857
EI 1522-1547
J9 AM J PHYSIOL-GASTR L
JI Am. J. Physiol.-Gastroint. Liver Physiol.
PD SEP
PY 2010
VL 299
IS 3
BP G556
EP G571
DI 10.1152/ajpgi.00433.2009
PG 16
WC Gastroenterology & Hepatology; Physiology
SC Gastroenterology & Hepatology; Physiology
GA 644MV
UT WOS:000281382600002
PM 20539005
ER
PT J
AU Cheng, F
McLaughlin, PJ
Banks, WA
Zagon, IS
AF Cheng, Fan
McLaughlin, Patricia J.
Banks, William A.
Zagon, Ian S.
TI Internalization of the opioid growth factor, [Met(5)]-enkephalin, is
dependent on clathrin-mediated endocytosis for downregulation of cell
proliferation
SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE
PHYSIOLOGY
LA English
DT Article
DE human mesenchymal stem cells; active transport; DNA synthase;
nucleocytoplasmic transport; siRNA
ID FACTOR RECEPTOR OGFR; AXIS; PEPTIDES; BIOLOGY; CANCER; LOCALIZATION;
CAVEOLIN-1; BRAIN; HEAD
AB Cheng F, McLaughlin PJ, Banks WA, Zagon IS. Internalization of the opioid growth factor, [Met(5)]-enkephalin, is dependent on clathrin-mediated endocytosis for downregulation of cell proliferation. Am J Physiol Regul Integr Comp Physiol 299: R774-R785, 2010. First published June 30, 2010; doi:10.1152/ajpregu.00318.2010.-The opioid growth factor (OGF; [Met(5)]-enkephalin), a constitutively expressed and tonically active inhibitory peptide, interacts with the OGF receptor (OGFr) to form an endogenous growth-regulating pathway in homeostasis. Amplification of OGF-OGFr interfacing in animal and clinical studies depresses development, neoplasia, angiogenesis, and immunity. Disruption of the OGF-OGFr axis accelerates cell proliferation and has been particularly important in wound repair. To investigate how OGF enters cells, OGF was labeled with 5,6-tetramethylrhodamine OGF (RhoOGF) to study its uptake in live cells. African green monkey kidney cells (COS-7) incubated with RhoOGF exhibited a temperature-dependent course of entry, being internalized at 37 C but not at 4 C. RhoOGF was detected in the cytoplasm 15 min after initial exposure, observed in both cytoplasm and nucleus within 30 min, and remained in the cells for as long as 5 h. A 100-fold excess of OGF or the opioid antagonist naltrexone, but not other opioid ligands (some selective for classic opioid receptors), markedly reduced entry of RhoOGF into cells. RhoOGF was functional because DNA synthesis in cells incubated with RhoOGF (10(-5) to 10(-8) M) was decreased 24-36%, and was comparable to cells treated with unlabeled OGF (reductions of 26-39%). OGF internalization was dependent on clathrin-mediated endocytosis, with addition of clathrin siRNA diminishing the uptake of RhoOGF and upregulating DNA synthesis. RhoOGF clathrin-mediated endocytosis was unrelated to endosomal or Golgi pathways. Taken together, these results suggest that OGF enters cells by active transport in a saturable manner that requires clathrin-mediated endocytosis.
C1 [Cheng, Fan; McLaughlin, Patricia J.; Zagon, Ian S.] Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Neural & Behav Sci, Hershey, PA 17033 USA.
[Banks, William A.] Univ Washington, Sch Med, Ctr Geriatr Res Educ & Clin, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
[Banks, William A.] Univ Washington, Sch Med, Dept Internal Med, Div Gerontol & Geriatr Med, Seattle, WA USA.
RP Zagon, IS (reprint author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Neural & Behav Sci, H109,500 Univ Dr,Rm C3729, Hershey, PA 17033 USA.
EM isz1@psu.edu
FU Paul K. and Anna E. Shockey Family Foundation; Zagon/Kostel families;
Veterans Affairs Merit Review
FX This study was supported, in part, by the Paul K. and Anna E. Shockey
Family Foundation and the Zagon/Kostel families and a Veterans Affairs
Merit Review (to W. A. Banks).
NR 31
TC 8
Z9 8
U1 1
U2 3
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6119
J9 AM J PHYSIOL-REG I
JI Am. J. Physiol.-Regul. Integr. Comp. Physiol.
PD SEP
PY 2010
VL 299
IS 3
BP R774
EP R785
DI 10.1152/ajpregu.00318.2010
PG 12
WC Physiology
SC Physiology
GA 646KA
UT WOS:000281537500007
PM 20592180
ER
PT J
AU Martinez, CO
McHale, MJ
Wells, JT
Ochoa, O
Michalek, JE
McManus, LM
Shireman, PK
AF Martinez, Carlo O.
McHale, Matthew J.
Wells, Jason T.
Ochoa, Oscar
Michalek, Joel E.
McManus, Linda M.
Shireman, Paula K.
TI Regulation of skeletal muscle regeneration by CCR2-activating chemokines
is directly related to macrophage recruitment
SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE
PHYSIOLOGY
LA English
DT Article
DE monocyte/macrophage; angiogenesis; CC chemokine receptor 2; MCP-1/CCL2;
MCP-5/CCL12
ID STEM-CELLS; IN-VIVO; ALTERED INFLAMMATION; CC-CHEMOKINE; BONE-MARROW;
CCR2-/-MICE; EXPRESSION; MCP-1; ACTIVATION; MONOCYTES
AB Martinez CO, McHale MJ, Wells JT, Ochoa O, Michalek JE, McManus LM, Shireman PK. Regulation of skeletal muscle regeneration by CCR2-activating chemokines is directly related to macrophage recruitment. Am J Physiol Regul Integr Comp Physiol 299: R832-R842, 2010. First published July 14, 2010; doi:10.1152/ajpregu.00797.2009.-Muscle regeneration requires CC chemokine receptor 2 (CCR2) expression on bone marrow-derived cells; macrophages are a prominent CCR2-expressing cell in this process. CCR2-/- mice have severe impairments in angiogenesis, macrophage recruitment, and skeletal muscle regeneration following cardiotoxin (CTX)-induced injury. However, multiple chemokines activate CCR2, including monocyte chemotactic proteins (MCP)-1, -3, and -5. We hypothesized that MCP-1 is the chemokine ligand that mediates the impairments present in CCR2-/- mice. We examined muscle regeneration, capillary density, and cellular recruitment in MCP-1-/- and CCR2-/- mice following injury. Muscle regeneration and adipocyte accumulation, but not capillary density, were significantly impaired in MCP-1-/- compared with wild-type (WT) mice; however, muscle regeneration and adipocyte accumulation impairments were not as severe as observed in CCR2-/- mice. Although tissue levels of MCP-5 were elevated in MCP-1-/- mice compared with WT, the administration of MCP-5 neutralizing antibody did not alter muscle regeneration in MCP-1-/- mice. While neutrophil accumulation after injury was similar in all three mouse strains, macrophage recruitment was highest in WT mice, intermediate in MCP-1-/- mice, and severely impaired in CCR2-/- mice. In conclusion, while the absence of MCP-1 resulted in impaired macrophage recruitment and muscle regeneration, MCP-1-/- mice exhibit an intermediate phenotype compared with CCR2-/- mice. Intermediate macrophage recruitment in MCP-1-/- mice was associated with similar capillary density to WT, suggesting that fewer macrophages may be needed to restore angiogenesis vs. muscle regeneration. Finally, other chemokines, in addition to MCP-1 and MCP-5, may activate CCR2-dependent regenerative processes resulting in an intermediate phenotype in MCP-1-/- mice.
C1 [Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Div Vasc Surg, Dept Surg, San Antonio, TX 78229 USA.
[Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Michalek, Joel E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA.
[McManus, Linda M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[McManus, Linda M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Periodont, San Antonio, TX 78229 USA.
[McManus, Linda M.; Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
[Shireman, Paula K.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Shireman, PK (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Vasc Surg, Dept Surg, 7703 Floyd Curl Dr MSC 7741, San Antonio, TX 78229 USA.
EM shireman@uthscsa.edu
FU Veterans Administration; National Heart, Lung, and Blood Institute
[HL-070158, HL-074236]; University of Texas Health Science Center San
Antonio; National Cancer Institute, Cancer Therapy & Research Center
[P30-CA-054174]
FX This work was supported, in part, by a Veterans Administration Merit
Review grant and the National Heart, Lung, and Blood Institute Grants
HL-070158 and HL-074236. Data was generated in the Core Flow Cytometry
Facility, which is supported by the University of Texas Health Science
Center San Antonio and National Cancer Institute Grant P30-CA-054174
(Cancer Therapy & Research Center).
NR 38
TC 46
Z9 47
U1 0
U2 3
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6119
J9 AM J PHYSIOL-REG I
JI Am. J. Physiol.-Regul. Integr. Comp. Physiol.
PD SEP
PY 2010
VL 299
IS 3
BP R832
EP R842
DI 10.1152/ajpregu.00797.2009
PG 11
WC Physiology
SC Physiology
GA 646KA
UT WOS:000281537500013
PM 20631294
ER
PT J
AU Melhorn, SJ
Krause, EG
Scott, KA
Mooney, MR
Johnson, JD
Woods, SC
Sakai, RR
AF Melhorn, Susan J.
Krause, Eric G.
Scott, Karen A.
Mooney, Marie R.
Johnson, Jeffrey D.
Woods, Stephen C.
Sakai, Randall R.
TI Meal patterns and hypothalamic NPY expression during chronic social
stress and recovery
SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE
PHYSIOLOGY
LA English
DT Article
DE adiposity; meal size; body composition; food intake
ID CORTICOTROPIN-RELEASING HORMONE; VISIBLE BURROW SYSTEM;
PITUITARY-ADRENAL AXIS; FOOD-INTAKE; BODY-WEIGHT; GENE-EXPRESSION;
NEUROPEPTIDE-Y; EATING BEHAVIOR; FEMALE RATS; SUBORDINATION STRESS
AB Melhorn SJ, Krause EG, Scott KA, Mooney MR, Johnson JD, Woods SC, Sakai RR. Meal patterns and hypothalamic NPY expression during chronic social stress and recovery. Am J Physiol Regul Integr Comp Physiol 299: R813-R822, 2010. First published July 7, 2010; doi:10.1152/ajpregu.00820.2009.-In the present study, we examined meal patterns during and after exposure to the visible burrow system (VBS), a rodent model of chronic social stress, to determine how the microstructure of food intake relates to the metabolic consequences of social subordination. Male Long-Evans rats were housed in mixed-sex VBS colonies (4 male, 2 female) for 2 wk, during which time a dominance hierarchy formed [1 dominant male (DOM) and 3 subordinate males (SUB)], and then male rats were individually housed for a 3-wk recovery period. Controls were individually housed with females during the 2-wk VBS period and had no changes in ingestive behavior compared with a habituation period. During the hierarchy-formation phase of VBS housing, DOM and SUB had a reduced meal frequency, whereas SUB also had a reduced meal size. However, during the hierarchy-maintenance phase of VBS housing, DOM meal patterns did not differ from controls, whereas SUB continued to display a reduced food intake via less frequent meals. During recovery, DOM had comparable meal patterns to controls, whereas SUB had an increased meal size. Hypothalamic neuropeptide Y (NPY) mRNA levels were not different between these groups during the experimental period. Together, the results suggest that exposure to chronic social stress alters ingestive behavior both acutely and in the long term, which may influence the metabolic changes that accompany bouts of stress and recovery; however, these differences in meal patterns do not appear to be mediated by hypothalamic NPY.
C1 [Melhorn, Susan J.; Krause, Eric G.; Scott, Karen A.; Woods, Stephen C.; Sakai, Randall R.] Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH USA.
[Melhorn, Susan J.; Scott, Karen A.] Univ Cincinnati, Coll Med, Program Neurosci, Cincinnati, OH USA.
[Mooney, Marie R.; Johnson, Jeffrey D.] Univ Cincinnati, Coll Med, Dept Biomed Engn, Cincinnati, OH USA.
RP Melhorn, SJ (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,151 Metab, Seattle, WA 98108 USA.
EM smelhorn@u.washington.edu
FU National Institute of Diabetes, Digestive and Kidney Diseases [RO1
DK066596-06]
FX These studies were supported by the National Institute of Diabetes,
Digestive and Kidney Diseases Grant RO1 DK066596-06 (to R. R. Sakai).
NR 57
TC 21
Z9 22
U1 0
U2 2
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6119
J9 AM J PHYSIOL-REG I
JI Am. J. Physiol.-Regul. Integr. Comp. Physiol.
PD SEP
PY 2010
VL 299
IS 3
BP R813
EP R822
DI 10.1152/ajpregu.00820.2009
PG 10
WC Physiology
SC Physiology
GA 646KA
UT WOS:000281537500011
PM 20610828
ER
PT J
AU Coviello, DM
Cornish, JW
Lynch, KG
Alterman, AI
O'Brien, CP
AF Coviello, Donna M.
Cornish, James W.
Lynch, Kevin G.
Alterman, Arthur I.
O'Brien, Charles P.
TI A Randomized Trial of Oral Naltrexone for Treating Opioid-Dependent
Offenders
SO AMERICAN JOURNAL ON ADDICTIONS
LA English
DT Article
ID HEALTH-CARE PROFESSIONALS; ADDICTION SEVERITY INDEX;
CLINICAL-EXPERIENCE; HEROIN-ADDICTION; FOLLOW-UP; NARCOTIC-ANTAGONIST;
MATCHING ALCOHOLICS; METHADONE PATIENTS; MAINTENANCE; PHARMACOTHERAPY
AB Offenders with a history of opioid dependence are a particularly difficult group to treat. A large proportion of offenders typically relapse shortly after release from prison, commit drug-related crimes, and then are arrested and eventually re-incarcerated. Previous research demonstrated that oral naltrexone was effective in reducing opioid use and preventing recidivism among offenders under federal supervision. The 111 opioid-dependent offenders in this study were under various levels of supervision that included county and federal probation/parole, a treatment court, an alternative disposition program, and an intermediate punishment program. Subjects were randomly assigned to receive 6 months of either 300 mg per week of oral naltrexone plus standard psychosocial treatment as usual (n = 56) or standard psychosocial treatment as usual (TAU) without naltrexone (n = 55). While the TAU subjects who remained in treatment used more opioids than the naltrexone subjects who remained, the high dropout rate for both groups made it difficult to assess the effectiveness of naltrexone. The study provides limited support for the use of oral naltrexone for offenders who are not closely monitored by the criminal justice system. (Am J Addict 2010;00:1-11).
C1 [Coviello, Donna M.; Cornish, James W.; Lynch, Kevin G.; Alterman, Arthur I.; O'Brien, Charles P.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Cornish, James W.; O'Brien, Charles P.] Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
RP Coviello, DM (reprint author), Treatment Res Ctr, 3440 Market St,Suite 370, Philadelphia, PA 19104 USA.
EM coviello_d@mail.trc.upenn.edu
FU NIDA NIH HHS [R01 DA012268, R01 DA012268-01A2, R01-DA-012268]
NR 47
TC 20
Z9 20
U1 2
U2 4
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1055-0496
J9 AM J ADDICTION
JI Am. J. Addict.
PD SEP-OCT
PY 2010
VL 19
IS 5
BP 422
EP 432
DI 10.1111/j.1521-0391.2010.00070.x
PG 11
WC Substance Abuse
SC Substance Abuse
GA 640NT
UT WOS:000281059000006
PM 20716305
ER
PT J
AU Chakravorty, S
Kuna, ST
Zaharakis, N
O'Brien, CP
Kampman, KM
Oslin, D
AF Chakravorty, Subhajit
Kuna, Samuel T.
Zaharakis, Nikola
O'Brien, Charles P.
Kampman, Kyle M.
Oslin, David
TI Covariates of Craving in Actively Drinking Alcoholics
SO AMERICAN JOURNAL ON ADDICTIONS
LA English
DT Article
ID INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; PSYCHOMETRIC PROPERTIES;
SOCIAL SUPPORT; NICOTINE DEPENDENCE; DOPAMINE SYNTHESIS; CUE REACTIVITY;
MOOD STATES; DSM-IV; RELAPSE; NALTREXONE
AB The goal of this cross-sectional study was to assess the relationship of alcohol craving with biopsychosocial and addiction factors that are clinically pertinent to alcoholism treatment. Alcohol craving was assessed in 315 treatment-seeking, alcohol dependent subjects using the Penn Alcohol Craving Scale questionnaire. Standard validated questionnaires were used to evaluate a variety of biological, addiction, psychological, psychiatric, and social factors. Individual covariates of craving included age, race, problematic consequences of drinking, heavy drinking, motivation for change, mood disturbance, sleep problems, and social supports. In a multivariate analysis (R2 = .34), alcohol craving was positively associated with mood disturbance, heavy drinking, readiness for change, and negatively associated with age. The results from this study suggest that alcohol craving is a complex phenomenon influenced by multiple factors. (Am J Addict 2010;00:1-8).
C1 [Chakravorty, Subhajit; O'Brien, Charles P.; Oslin, David] Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Vet Integrated Serv Network, Philadelphia, PA 19104 USA.
[Chakravorty, Subhajit; Kuna, Samuel T.] Univ Penn, Ctr Sleep & Resp Neurobiol, Philadelphia, PA 19104 USA.
[Chakravorty, Subhajit; O'Brien, Charles P.; Kampman, Kyle M.; Oslin, David] Univ Penn, Treatment Res Ctr, Ctr Study Addict, Philadelphia, PA 19104 USA.
[Kuna, Samuel T.] Philadelphia VA Med Ctr, Pulm Crit Care & Sleep Sect, Philadelphia, PA 19104 USA.
[Zaharakis, Nikola] Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23284 USA.
[Oslin, David] Univ Penn, Sect Geriatr Psychiat, Philadelphia, PA 19104 USA.
RP Chakravorty, S (reprint author), Philadelphia VA Med Ctr, MIRECC VISN 4, Univ & Woodland Ave, Philadelphia, PA 19104 USA.
EM Subhajit.Chakravorty@uphs.upenn.edu
FU NIAAA NIH HHS [5R01AA014851, R01 AA014851, R01 AA014851-01, R01
AA014851-02, R01 AA014851-03, R01 AA014851-04, R01 AA014851-05]
NR 62
TC 14
Z9 18
U1 6
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1055-0496
EI 1521-0391
J9 AM J ADDICTION
JI Am. J. Addict.
PD SEP-OCT
PY 2010
VL 19
IS 5
BP 450
EP 457
DI 10.1111/j.1521-0391.2010.00067.x
PG 8
WC Substance Abuse
SC Substance Abuse
GA 640NT
UT WOS:000281059000009
PM 20716308
ER
PT J
AU Badgett, RG
Lawrence, VA
Cohn, SL
AF Badgett, Robert G.
Lawrence, Valerie A.
Cohn, Steven L.
TI Variations in Pharmacology of beta-Blockers May Contribute to
Heterogeneous Results in Trials of Perioperative beta-Blockade
SO ANESTHESIOLOGY
LA English
DT Article
ID RANDOMIZED-CONTROLLED-TRIAL; HIGH-RISK PATIENTS; NONCARDIAC SURGERY;
MYOCARDIAL-INFARCTION; RECEPTOR GENOTYPE; MULTICENTER TRIAL;
VASCULAR-SURGERY; HEART-FAILURE; METOPROLOL; MORTALITY
AB Background: Randomized controlled trials and meta-analyses provide conflicting guidance on the role of beta-adrenergic receptor blockers (beta-blockers) in reducing perioperative complications. We hypothesize that variability in trial results may be due in part to heterogeneous properties of beta-blockers. First, we propose that the extent of beta-blocker metabolism by cytochrome P-450 and the time available to titrate the dosage before surgery (titration time) may interact; dependence on P-450 may be most harmful when titration time is short. Second, beta-blockers vary in their selectivity for the beta-1 receptor and reduced selectivity may contribute to cerebral ischemia.
Methods: We used meta-analysis and meta-regression of existing trials to explore the role of these pharmacological properties.
Results: We found that both of these pharmacological factors are significantly associated with reduced efficacy of beta-blockers.
Conclusions: Pharmacological properties of beta-blockers may contribute to heterogeneous trial results. Many trials have used metoprolol, which is extensively metabolized by cytochrome P450 and is less selective for the beta-1 receptor. For these two reasons, the efficacy of metoprolol to prevent perioperative cardiac complications should be compared with the efficacy of other beta-blockers.
C1 [Badgett, Robert G.; Lawrence, Valerie A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Badgett, Robert G.; Lawrence, Valerie A.] Audie L Murphy Mem Vet Affairs Hosp, San Antonio, TX USA.
[Cohn, Steven L.] SUNY Hlth Sci Ctr, Dept Med, Brooklyn, NY 11203 USA.
RP Badgett, RG (reprint author), Univ Kansas, Sch Med Wichita, Dept Med, 1010 N Kansas St, Wichita, KS 67214 USA.
EM rbadgett@kumc.edu
OI Badgett, Robert/0000-0003-2888-3303
NR 44
TC 29
Z9 31
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-3022
J9 ANESTHESIOLOGY
JI Anesthesiology
PD SEP
PY 2010
VL 113
IS 3
BP 585
EP 592
DI 10.1097/ALN.0b013e3181e73eea
PG 8
WC Anesthesiology
SC Anesthesiology
GA 642WL
UT WOS:000281251600012
PM 20693881
ER
PT J
AU Isaacson, BM
Stinstra, JG
MacLeod, RS
Pasquina, PF
Bloebaum, RD
AF Isaacson, Brad M.
Stinstra, Jeroen G.
MacLeod, Rob S.
Pasquina, Paul F.
Bloebaum, Roy D.
TI Developing a Quantitative Measurement System for Assessing Heterotopic
Ossification and Monitoring the Bioelectric Metrics from Electrically
Induced Osseointegration in the Residual Limb of Service Members
SO ANNALS OF BIOMEDICAL ENGINEERING
LA English
DT Article
DE Electrical stimulation; Finite element analysis; Heterotopic
ossification; Osseointegration; Residual limb; Service members
ID TOTAL HIP-ARTHROPLASTY; HEAD-INJURED ADULTS; BONE-FORMATION; TRAUMATIC
AMPUTEE; RISK-FACTORS; STIMULATION; FRACTURES; FIELD; FIBROBLASTS;
PROSTHESES
AB Poor prosthetic fit is often the result of heterotopic ossification (HO), a frequent problem following blast injuries for returning service members. Osseointegration technology offers an advantage for individuals with significant HO and poor socket tolerance by using direct skeletal attachment of a prosthesis to the distal residual limb, but remains limited due to prolonged post-operative rehabilitation regimens. Therefore, electrical stimulation has been proposed as a catalyst for expediting skeletal attachment and the bioelectric effects of HO were evaluated using finite element analysis in 11 servicemen with transfemoral amputations. Retrospective computed tomography (CT) scans provided accurate reconstructions, and volume conductor models demonstrated the variability in residual limb anatomy and necessity for patient-specific modeling to characterize electrical field variance if patients were to undergo a theoretical osseointegration of a prosthesis. In this investigation, the volume of HO was statistically significant when selecting the optimal potential difference for enhanced skeletal fixation, since higher HO volumes required increased voltages at the periprosthetic bone (p = 0.024, r = 0.670). Results from Spearman's rho correlations also indicated that the age of the subject and volume of HO were statistically significant and inversely proportional, in which younger service members had a higher frequency of HO (p = 0.041, r = -0.622). This study demonstrates that the volume of HO and age may affect the voltage threshold necessary to improve current osseointegration procedures.
C1 [Isaacson, Brad M.; Bloebaum, Roy D.] US Dept Vet Affairs, Bone & Joint Res Lab, Salt Lake City, UT 84148 USA.
[Pasquina, Paul F.] Walter Reed Army Med Ctr, Dept Orthopaed & Rehabil, Washington, DC 20307 USA.
[Isaacson, Brad M.; MacLeod, Rob S.; Bloebaum, Roy D.] Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA.
[Bloebaum, Roy D.] Univ Utah, Dept Orthopaed, Salt Lake City, UT USA.
[Bloebaum, Roy D.] Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA.
[Stinstra, Jeroen G.; MacLeod, Rob S.] Univ Utah, Sci Comp & Imagining Inst, Salt Lake City, UT USA.
RP Bloebaum, RD (reprint author), US Dept Vet Affairs, Bone & Joint Res Lab 151F, Salt Lake City, UT 84148 USA.
EM roy.bloebaum@hsc.utah.edu
FU Veterans Affairs Office of Research and Development, Rehabilitation R&D
Service, DVA SLC Health Care System, Salt Lake City, UT; Albert &
Margaret Hofmann Chair and the Department of Orthopaedics, University of
Utah School of Medicine, Salt Lake City, UT; Technology
Commercialization Office, University of Utah, Salt Lake City, UT
FX Gratitude is expressed to Gregory Stoddard for assistance and
interpretation of statistical analysis, Darrell Swenson for support with
image visualizations, and Gwenevere Shaw and Sharon Weeks for support
with manuscript preparation. Grant & Financial Support: This material is
based on study supported by the Veterans Affairs Office of Research and
Development, Rehabilitation R&D Service, DVA SLC Health Care System,
Salt Lake City, UT; the Albert & Margaret Hofmann Chair and the
Department of Orthopaedics, University of Utah School of Medicine, Salt
Lake City, UT; the Technology Commercialization Office, University of
Utah, Salt Lake City, UT. Technical support for the simulations was
provided by the Center for Integrative Biomedical Computing of
Scientific Computing and Imaging Institute, and was made possible in
part by software from the NIH/NCRR Center for Integrative Biomedical
Computing, P41-RR12553-07.
NR 56
TC 7
Z9 7
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0090-6964
J9 ANN BIOMED ENG
JI Ann. Biomed. Eng.
PD SEP
PY 2010
VL 38
IS 9
BP 2968
EP 2978
DI 10.1007/s10439-010-0050-2
PG 11
WC Engineering, Biomedical
SC Engineering
GA 634PB
UT WOS:000280594300016
PM 20458630
ER
PT J
AU Edwardsen, EA
Dichter, ME
Horwitz, SH
Cerulli, C
AF Edwardsen, E. A.
Dichter, M. E.
Horwitz, S. H.
Cerulli, C.
TI Instructional Curriculum Improves Medical Staff Understanding of the
Importance for Routine Inquiry About Partner Violence and Appropriate
Service Referral
SO ANNALS OF EMERGENCY MEDICINE
LA English
DT Meeting Abstract
CT Conference on American-College-of-Emergency-Physicians-Research-Forum
CY SEP 28-29, 2010
CL Las Vegas, NV
SP Amer Coll Emergency Phys Res Forum
C1 Univ Rochester, Rochester, NY USA.
Philadelphia VA Med Ctr, Philadelphia, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-0644
J9 ANN EMERG MED
JI Ann. Emerg. Med.
PD SEP
PY 2010
VL 56
IS 3
SU S
BP S39
EP S40
PG 2
WC Emergency Medicine
SC Emergency Medicine
GA 645FY
UT WOS:000281438000119
ER
PT J
AU Hsia, RY
Asch, SM
Weiss, RE
Zingmond, DS
Liang, L
McCreath, H
Sun, BC
AF Hsia, R. Y.
Asch, S. M.
Weiss, R. E.
Zingmond, D. S.
Liang, L.
McCreath, H.
Sun, B. C.
TI County and Hospital Determinants of Ambulance Diversion
SO ANNALS OF EMERGENCY MEDICINE
LA English
DT Meeting Abstract
CT Conference on American-College-of-Emergency-Physicians-Research-Forum
CY SEP 28-29, 2010
CL Las Vegas, NV
SP Amer Coll Emergency Phys Res Forum
C1 Univ Calif San Francisco, San Francisco, CA 94143 USA.
Univ Calif Los Angeles, Los Angeles, CA USA.
Greater Los Angeles VA Hlth Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-0644
J9 ANN EMERG MED
JI Ann. Emerg. Med.
PD SEP
PY 2010
VL 56
IS 3
SU S
BP S93
EP S93
PG 1
WC Emergency Medicine
SC Emergency Medicine
GA 645FY
UT WOS:000281438000283
ER
PT J
AU Parchman, ML
Zeber, JE
Palmer, RF
AF Parchman, Michael L.
Zeber, John E.
Palmer, Raymond F.
TI Participatory Decision Making, Patient Activation, Medication Adherence,
and Intermediate Clinical Outcomes in Type 2 Diabetes: A STARNet Study
SO ANNALS OF FAMILY MEDICINE
LA English
DT Article
DE Patient-centered care; physician-patient relations; diabetes mellitus,
type 2
ID SELF-MANAGEMENT; PRIMARY-CARE; PHYSICIAN; COMMUNICATION; INERTIA;
HEMOGLOBIN; PREDICTORS; ALLIANCE; MELLITUS; QUALITY
AB PURPOSE Participatory decision making (PDM) is associated with improved diabetes control. We examine a causal model linking PDM to improved clinical outcomes that included patient activation and medication adherence.
METHODS This observational study was conducted in 5 family physician offices. Diabetic patients were recruited by mail and by completing a study interest card at the conclusion of their office visit. Two survey questionnaires, administered 12 months apart, elicited patients' ratings of their physician's PDM style at baseline and their level of activation and medication adherence both at baseline and at follow-up. Measures of glycated hemoglobin (hemoglobin A(1c)), systolic blood pressure, and low-density lipoprotein (LDL) cholesterol were abstracted from the medical record starting 12 months before the baseline survey to 12 months after the follow-up survey. A path analysis using a structural equation model was used to test hypotheses.
RESULTS We mailed questionnaires to 236 participants; 166 (70%) returned the baseline questionnaire, and 141 (80%) returned the follow-up questionnaire. Hemoglobin A(1c) levels, systolic blood pressure, and LDL cholesterol values all declined significantly, and patient activation and medication adherence improved. PDM at baseline was associated with patient activation at follow-up. Patient activation at follow-up was associated with medication adherence at follow-up, and medication adherence at follow-up was associated with change in hemoglobin A(1c) levels and LDL cholesterol values but not with systolic blood pressure.
CONCLUSIONS Participatory decision making during primary care encounters by patients with type 2 diabetes resulted in improvements in hemoglobin A(1c) levels and LDL cholesterol values by improving patient activation, which in turn improved medication adherence.
C1 [Parchman, Michael L.; Zeber, John E.] S Texas Vet Hlth Care Syst, VERDICT Hlth Serv Res Program, San Antonio, TX 78229 USA.
[Parchman, Michael L.; Palmer, Raymond F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, San Antonio, TX 78229 USA.
[Zeber, John E.] Scott & White Healthcare, Ctr Appl Hlth Res, Temple, TX USA.
[Zeber, John E.] Cent Texan Vet Hlth Care Syst, Temple, TX USA.
RP Parchman, ML (reprint author), S Texas Vet Hlth Care Syst, VERDICT 11C6, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.
EM parchman@uthscsa.edu
OI Parchman, Michael/0000-0001-7129-2889
FU National Institutes of Health, National Institute for Diabetes,
Digestive and Kidney Disorders [DK067300-02]; Department of Veterans
Affairs, Veterans Health Administration, Health Services Research and
Development Service
FX This research was supported by the National Institutes of Health,
National Institute for Diabetes, Digestive and Kidney Disorders
(DK067300-02); and the Department of Veterans Affairs, Veterans Health
Administration, Health Services Research and Development Service.
NR 40
TC 73
Z9 75
U1 3
U2 19
PU ANNALS FAMILY MEDICINE
PI LEAWOOD
PA 11400 TOMAHAWK CREEK PARKWAY, LEAWOOD, KS 66211-2672 USA
SN 1544-1709
J9 ANN FAM MED
JI Ann. Fam. Med.
PD SEP-OCT
PY 2010
VL 8
IS 5
BP 410
EP 417
DI 10.1370/afm.1161
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 662JT
UT WOS:000282804300005
PM 20843882
ER
PT J
AU Tyler, KL
AF Tyler, Kenneth L.
TI Progressive Multifocal Leukoencephalopathy: Can We Reduce Risk in
Patients Receiving Biological Immunomodulatory Therapies?
SO ANNALS OF NEUROLOGY
LA English
DT Editorial Material
ID JC VIRUS-DNA; MULTIPLE-SCLEROSIS; NATALIZUMAB; BRAIN; INFECTION;
PROTEINS; LATENCY
C1 [Tyler, Kenneth L.] Univ Colorado, Sch Med, Dept Neurol, Denver, CO 80202 USA.
[Tyler, Kenneth L.] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Tyler, KL (reprint author), Univ Colorado, Sch Med, Dept Neurol, Denver, CO 80202 USA.
OI Tyler, Kenneth/0000-0003-3294-5888
NR 20
TC 21
Z9 21
U1 0
U2 1
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0364-5134
J9 ANN NEUROL
JI Ann. Neurol.
PD SEP
PY 2010
VL 68
IS 3
BP 271
EP 274
DI 10.1002/ana.22185
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 644ZX
UT WOS:000281421800004
PM 20818784
ER
PT J
AU Wasif, N
Ko, CY
Farrell, J
Wainberg, Z
Hines, OJ
Reber, H
Tomlinson, JS
AF Wasif, Nabil
Ko, Clifford Y.
Farrell, James
Wainberg, Zev
Hines, Oscar J.
Reber, Howard
Tomlinson, James S.
TI Impact of Tumor Grade on Prognosis in Pancreatic Cancer: Should We
Include Grade in AJCC Staging?
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Article
ID SINGLE-INSTITUTION EXPERIENCE; LONG-TERM SURVIVAL; DUCTAL
ADENOCARCINOMA; RESECTION; DATABASE; CHEMOTHERAPY; VALIDATION; NOMOGRAM;
TRIAL
AB Background. AJCC staging of pancreatic cancer (PAC) is used to determine prognosis, yet survival within each stage shows wide variation and remains unpredictable. We hypothesized that tumor grade might be responsible for some of this variation and that the addition of grade to current AJCC staging would provide improved prognostication.
Methods. The Surveillance, Epidemiology, and End Results (SEER) database (1991-2005) was used to identify 8082 patients with resected PAC. The impact of grade on overall and stage-specific survival was assessed using Cox regression analysis. Variables in the model were age, sex, tumor size, lymph node status, and tumor grade.
Results. For each AJCC stage, survival was significantly worse for high-grade versus low-grade tumors. On multivariate analysis, high tumor grade was an independent predictor of survival for the entire cohort (hazard ratio [HR] 1.40, 95% confidence interval [95% CI] 1.31-1.48) as well as for stage I (HR 1.28, 95% CI 1.07-1.54), stage IIA (HR 1.43, 95% CI 1.26-1.61), stage IIB (HR 1.38, 95% CI 1.27-1.50), stage III (HR 1.28, 95% CI 1.02-1.59), and stage IV (HR 1.58, 95% CI 1.21-2.05) patients. The addition of grade to staging results in a statistically significant survival discrimination between all stages.
Conclusions. Tumor grade is an important prognostic variable of survival in PAC. We propose a novel staging system incorporating grade into current AJCC staging for pancreas cancer. The improved prognostication is more reflective of tumor biology and may impact therapy decisions and stratification of future clinical trials.
C1 [Ko, Clifford Y.; Hines, Oscar J.; Reber, Howard; Tomlinson, James S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA.
[Wasif, Nabil] St Johns Hlth Ctr, John Wayne Canc Inst, Santa Monica, CA USA.
[Ko, Clifford Y.; Tomlinson, James S.] Greater Los Angeles VA Healthcare Syst, Dept Surg, Los Angeles, CA USA.
[Farrell, James] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA.
[Wainberg, Zev] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol, Los Angeles, CA 90095 USA.
RP Tomlinson, JS (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA.
EM james.tomlinson@va.gov
FU Gonda (Goldschmied) Research Laboratories of the John Wayne Cancer
Institute at Saint John's Health Center; QVC; Fashion Footwear
Association of New York Charitable Foundation (New York, NY); Margie and
Robert E. Petersen Foundation (Los Angeles, CA); Los Angeles, CA;
Associates for Breast and Prostate Cancer Studies (Santa Monica, CA);
Family of Robert Novick (Los Angeles, CA); Ruth and Martin H. Weil Fund
(Los Angeles, CA); Wrather Family Foundation (Los Alamos, CA)
FX Supported by grants from the Gonda (Goldschmied) Research Laboratories
of the John Wayne Cancer Institute at Saint John's Health Center.
Supported by funding from QVC and the Fashion Footwear Association of
New York Charitable Foundation (New York, NY), the Margie and Robert E.
Petersen Foundation (Los Angeles, CA), Mrs. Lois Rosen (Los Angeles,
CA), and the Associates for Breast and Prostate Cancer Studies (Santa
Monica, CA). Supported by funding from the Family of Robert Novick (Los
Angeles, CA), Ruth and Martin H. Weil Fund (Los Angeles, CA), and the
Wrather Family Foundation (Los Alamos, CA).
NR 28
TC 46
Z9 46
U1 1
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD SEP
PY 2010
VL 17
IS 9
BP 2312
EP 2320
DI 10.1245/s10434-010-1071-7
PG 9
WC Oncology; Surgery
SC Oncology; Surgery
GA 650OJ
UT WOS:000281858600009
PM 20422460
ER
PT J
AU Wecht, JM
Rosado-Rivera, D
Handrakis, JP
Radulovic, M
Bauman, WA
AF Wecht, Jill M.
Rosado-Rivera, Dwindally
Handrakis, John P.
Radulovic, Miroslav
Bauman, William A.
TI Effects of Midodrine Hydrochloride on Blood Pressure and Cerebral Blood
Flow During Orthostasis in Persons With Chronic Tetraplegia
SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
LA English
DT Article; Proceedings Paper
CT Congress of Spinal Cord Medicine and Rehabilitation
CY SEP 24, 2009
CL Dallas, TX
DE Hypotension, orthostatic; Midodrine; Rehabilitation; Spinal cord
injuries; Tilt-table test
ID SPINAL-CORD-INJURY; COGNITIVE PERFORMANCE; TRANSCRANIAL DOPPLER;
ESSENTIAL HYPOTENSION; DOUBLE-BLIND; MEN; EJACULATION; PLACEBO;
STIMULATION; ENHANCEMENT
AB Wecht JM, Rosado-Rivera D, Handrakis JP, Radulovic M. Bauman WA. Effects of midodrine hydrochloride on blood pressure and cerebral blood flow during orthostasis in persons with chronic tetraplegia. Arch Phys Med Rehabil 2010;91:1429-35.
Objective: To determine the mean arterial pressure (MAP) and middle cerebral artery mean blood flow velocity (MFV) responses to 5 and 10mg midodrine during head-up tilt (HUT) in persons with tetraplegia.
Design: Prospective dose-response trial.
Setting: James J. Peters Veterans Administration Medical Center.
Participants: Persons (N=10) with chronic tetraplegia (duration of injury = 23 +/- 11y).
Intervention: A dose titration study was performed over 3 testing days: control (no drug), 5mg midodrine (5mg), or 10mg midodrine (10mg) during 30 minutes of baseline (predrug/no drug), 30 minutes of supine rest postdrug/no drug, 15 minutes of progressive HUT (5 minutes at 15 degrees, 25 degrees, 35 degrees), and 45 minutes of 45 degrees HUT.
Main Outcome Measures: MAP and MFV response to midodrine supine and during HUT.
Results: Ten milligrams of midodrine significantly increased MAP while supine and during the HUT maneuver. Of note, the mean increase in MAP during HUT with 10mg was a result of a robust effect in 2 persons, with minimal change in the remaining 8 study subjects. The reduction in cerebral MFV during HUT was attenuated with 10mg.
Conclusions: These findings suggest that midodrine 10mg may be efficacious for treatment of hypotension and orthostatic hypotension in select persons with tetraplegia. Although midodrine is routinely prescribed to treat orthostatic hypotension, the results of our work suggests limited efficacy of this agent, but additional studies in a larger sample of subjects with spinal cord injury should be performed.
C1 [Wecht, Jill M.] James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Bronx, NY 10468 USA.
[Wecht, Jill M.; Rosado-Rivera, Dwindally; Handrakis, John P.; Radulovic, Miroslav; Bauman, William A.] Mt Sinai Sch Med, Ctr Excellence, New York, NY USA.
[Wecht, Jill M.; Radulovic, Miroslav; Bauman, William A.] Mt Sinai Sch Med, Med Serv, New York, NY USA.
[Wecht, Jill M.; Radulovic, Miroslav; Bauman, William A.] NYIT, Dept Med, Old Westbury, NY USA.
[Wecht, Jill M.; Radulovic, Miroslav; Bauman, William A.] NYIT, Dept Rehabil Med, Old Westbury, NY USA.
[Handrakis, John P.] NYIT, Sch Hlth Profess, Old Westbury, NY USA.
RP Wecht, JM (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Room 1E-02,130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM JM.WECHT@VA.GOV
NR 43
TC 14
Z9 14
U1 0
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0003-9993
J9 ARCH PHYS MED REHAB
JI Arch. Phys. Med. Rehabil.
PD SEP
PY 2010
VL 91
IS 9
BP 1429
EP 1435
DI 10.1016/j.apmr.2010.06.017
PG 7
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 651IM
UT WOS:000281921400018
PM 20801263
ER
PT J
AU Ingraham, AM
Cohen, ME
Bilimoria, KY
Ko, CY
Hall, BL
Russell, TR
Nathens, AB
AF Ingraham, Angela M.
Cohen, Mark E.
Bilimoria, Karl Y.
Ko, Clifford Y.
Hall, Bruce L.
Russell, Thomas R.
Nathens, Avery B.
TI Effect of Delay to Operation on Outcomes in Adults With Acute
Appendicitis
SO ARCHIVES OF SURGERY
LA English
DT Article
ID SURGICAL CARE; APPENDECTOMY; SURGERY; QUALITY; TRIAL; NIGHT; NSQIP; RISK
AB Objective: To examine the effect of delay from surgical admission to induction of anesthesia on outcomes after appendectomy for acute appendicitis in adults.
Design: Retrospective cohort study with the principal exposure being time to operation. Regression models yielded probabilities of outcomes adjusted for patient and operative risk factors.
Setting: Data were submitted to the American College of Surgeons National Surgical Quality Improvement Program database from January 1, 2005, through December 31, 2008.
Patients: Patients with acute appendicitis who underwent an appendectomy.
Main Outcome Measures: Thirty-day overall morbidity and serious morbidity/mortality.
Results: Of 32 782 patients, 24 647 (75.2%) underwent operations within 6 hours of surgical admission, 4934(15.1%) underwent operations more than 6 through 12 hours, and 3201 (9.8%) underwent operations more than 12 hours after surgical admission. Differences in operative duration (51, 50, and 55 minutes, respectively; P<.001) were statistically significant but not clinically meaningful. The length of postoperative stay (2.2 days for the >12-hour group vs 1.8 days for the remaining groups; P<.001) was statistically significant but not clinically meaningful. No significant differences were found in adjusted overall morbidity (5.5%, 5.4%, and 6.1%, respectively; P=.33) or serious morbidity/mortality (3.0%, 3.6%, and 3.0%, respectively; P=.17). Duration from surgical admission to induction of anesthesia was not predictive in regression models for overall morbidity or serious morbidity/mortality.
Conclusions: In this retrospective study, delay of appendectomy for acute appendicitis in adults does not appear to adversely affect 30-day outcomes. This information can guide the use of potentially limited operative and professional resources allocated for emergency care.
C1 [Ingraham, Angela M.; Cohen, Mark E.; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA.
[Bilimoria, Karl Y.] Northwestern Univ, Dept Surg, Feinberg Sch Med, Chicago, IL 60611 USA.
[Ingraham, Angela M.] Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH 45267 USA.
[Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA.
[Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Hall, Bruce L.] Washington Univ, Sch Med, Dept Surg, John Cochran Vet Affairs Med Ctr, St Louis, MO 63110 USA.
[Hall, Bruce L.] Barnes Jewish Hosp, St Louis, MO 63110 USA.
[Hall, Bruce L.] Washington Univ, Ctr Hlth Policy, St Louis, MO 63110 USA.
[Hall, Bruce L.] Washington Univ, Olin Business Sch, St Louis, MO 63110 USA.
[Russell, Thomas R.] Univ Calif San Francisco, Div Surg, San Francisco, CA 94143 USA.
[Nathens, Avery B.] St Michaels Hosp, Div Surg & Trauma, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada.
RP Ingraham, AM (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair St,Floor 22NE, Chicago, IL 60611 USA.
EM aingraham@facs.org
FU American College of Surgeons; Northwestern University; Canada Research
Chair in Systems of Trauma Care; Center for Health Policy, Washington
University in St Louis
FX Dr Ingraham is supported by the Clinical Scholar in Residence Program at
the American College of Surgeons. Dr Bilimoria is supported by a
Priority Grant from Northwestern University. Dr Nathens is supported by
a Canada Research Chair in Systems of Trauma Care. Dr Hall is supported
by the Center for Health Policy, Washington University in St Louis.
NR 23
TC 47
Z9 49
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0004-0010
J9 ARCH SURG-CHICAGO
JI Arch. Surg.
PD SEP
PY 2010
VL 145
IS 9
BP 886
EP 892
PG 7
WC Surgery
SC Surgery
GA 649JH
UT WOS:000281764400020
PM 20855760
ER
EF